In	O
addition	O
,	O
we	O
examined	O
in	O
cell	O
culture	O
experiments	O
the	O
effect	O
some	O
of	O
these	O
mutations	O
have	O
on	O
the	O
induction	O
of	O
ER	O
stress	O
and	O
the	O
UPR	O
pathway	O
[	O
18	O
]	O
.	O

Second	O
,	O
the	O
mutation	O
was	O
not	O
found	O
in	O
100	O
ethnically	O
-	O
matched	O
healthy	O
controls	O
or	O
any	O
other	O
public	O
database	O
,	O
including	O
the	O
one	O
from	O
the	O
1000	O
Genomes	O
Project	O
.	O

AO	O
has	O
a	O
transverse	O
resolution	O
of	O
approximately	O
1	O
.	O
6	O
mu	O
m	O
compared	O
to	O
commercial	O
OCT	O
systems	O
with	O
a	O
resolution	O
of	O
approximately	O
15	O
mu	O
m	O
.	O

No	O
Pendred	B-DISEASE
syndrome	I-DISEASE
was	O
diagnosed	O
.	O

(	O
J	O
)	O
The	O
arrows	O
indicate	O
that	O
the	O
Thr165	O
and	O
Met946	O
residues	O
are	O
evolutionary	O
highly	O
conserved	O
among	O
multiple	O
species	O
.	O

"	O
GG	O
-	O
G	O
is	O
a	O
recipient	O
of	O
a	O
fellowship	O
from	O
the	O
Spanish	O
Ministry	O
of	O
Education	O
(	O
REF	O
:	O
AP2008	O
-	O
02760	O
)	O
.	O

Further	O
improvements	O
in	O
sequencing	O
technology	O
together	O
with	O
the	O
identification	O
of	O
novel	O
RP	B-DISEASE
genes	O
will	O
undoubtedly	O
boost	O
the	O
success	O
rate	O
of	O
NGS	O
-	O
based	O
diagnostic	O
approaches	O
in	O
RP	B-DISEASE
in	O
near	O
future	O
.	O

Consanguineous	O
family	O
.	O

Following	O
our	O
variant	O
filtering	O
as	O
described	O
in	O
the	O
Methods	O
,	O
we	O
retained	O
341	O
variants	O
as	O
potentially	O
deleterious	O
alleles	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
of	O
a	O
new	O
deafness	B-DISEASE
gene	O
,	O
which	O
encodes	O
an	O
ELMO	O
/	O
CED	O
12	O
domain	O
containing	O
protein	O
,	O
ELMOD3	B-GENE
.	O

The	O
error	O
rates	O
of	O
a	O
base	O
position	O
on	O
each	O
strand	O
were	O
calculated	O
from	O
50	O
control	O
samples	O
.	O

The	O
former	O
,	O
c	B-VARIANT
.	I-VARIANT
2626_2627delGA	I-VARIANT
in	O
exon	O
15	O
(	O
Figure	O
1F	O
)	O
,	O
was	O
identified	O
in	O
patient	O
TCS	B-DISEASE
8	O
and	O
causes	O
the	O
formation	O
of	O
a	O
stop	O
codon	O
two	O
aminoacids	O
later	O
.	O

The	O
remaining	O
approximately	O
5	O
%	O
of	O
the	O
poorly	O
covered	O
regions	O
(	O
<	O
10	O
reads	O
)	O
were	O
in	O
extremely	O
high	O
GC	O
-	O
rich	O
regions	O
.	O

gz	O
output	O
files	O
.	O

49	O
,	O
50	O
To	O
further	O
assess	O
CIB2	B-GENE
function	O
,	O
we	O
measured	O
phototransduction	O
activity	O
with	O
electroretinograms	O
(	O
ERGs	O
)	O
following	O
dCib2	O
RNAi	O
-	O
knockdown	O
.	O

MAT	O
and	O
GVC	O
performed	O
the	O
linkage	O
studies	O
.	O

Genotypes	O
for	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
and	O
short	O
indels	O
were	O
called	O
using	O
a	O
Bayesian	O
approach	O
implemented	O
in	O
most	O
probable	O
genotype	O
(	O
5	O
)	O
and	O
filtered	O
using	O
a	O
score	O
threshold	O
of	O
10	O
and	O
a	O
score	O
/	O
depth	O
ratio	O
threshold	O
of	O
0	O
.	O
5	O
.	O

The	O
CIB2	B-GENE
gene	O
lies	O
distal	O
to	O
the	O
critical	O
intervals	O
for	O
USH1H	B-GENE
locus	O
defined	O
by	O
linkage	O
analysis	O
in	O
family	O
PKDF125	O
.	O
(	O
ref	O
2	O
)	O
As	O
expected	O
,	O
no	O
mutations	O
in	O
exons	O
of	O
CIB2	B-GENE
were	O
found	O
in	O
affected	O
members	O
of	O
family	O
PKDF125	O
.	O

This	O
genetic	O
heterogeneity	O
is	O
emphasized	O
by	O
the	O
number	O
of	O
sequence	O
variations	O
observed	O
in	O
both	O
the	O
patient	O
and	O
general	O
population	O
.	O

This	O
chip	O
was	O
designed	O
to	O
capture	O
the	O
coding	O
sequences	O
with	O
at	O
least	O
100	O
base	O
pairs	O
(	O
bps	O
)	O
of	O
flanking	O
intronic	O
sequences	O
,	O
and	O
5	O
'	O
-	O
and	O
3	O
'	O
-	O
untranslated	O
regions	O
(	O
UTR	O
)	O
of	O
179	O
genes	O
associated	O
with	O
HRDs	O
and	O
10	O
candidate	O
genes	O
including	O
all	O
USH	O
-	O
related	O
genes	O
.	O

6a	O
,	O
b	O
)	O
;	O
however	O
,	O
both	O
patients	O
exhibited	O
hyperintense	O
signal	O
abnormalities	O
with	O
muscle	B-DISEASE
atrophy	I-DISEASE
in	O
the	O
calf	O
(	O
Fig	O
.	O

We	O
found	O
variant	O
p	B-VARIANT
.	I-VARIANT
R882S	I-VARIANT
in	O
a	O
sporadic	O
Spanish	O
USH2	B-DISEASE
patient	O
together	O
with	O
the	O
variant	O
p	B-VARIANT
.	I-VARIANT
S648Y	I-VARIANT
.	O

Thus	O
,	O
if	O
this	O
mutant	O
transcript	O
was	O
translated	O
,	O
the	O
new	O
protein	O
would	O
be	O
of	O
2950	O
amino	O
acids	O
in	O
length	O
,	O
p	B-VARIANT
.	I-VARIANT
S2909AfsX43	I-VARIANT
.	O

2	O
)	O
.	O

Based	O
on	O
these	O
findings	O
,	O
the	O
hearing	B-DISEASE
dysfunction	I-DISEASE
found	O
in	O
OPA1	B-GENE
patients	O
could	O
be	O
considered	O
essentially	O
as	O
a	O
neural	O
rather	O
than	O
a	O
receptor	O
disorder	O
and	O
thus	O
qualified	O
as	O
'	O
post	B-DISEASE
-	I-DISEASE
synaptic	I-DISEASE
auditory	I-DISEASE
neuropathy	I-DISEASE
'	O
(	O
Starr	O
et	O
al	O
.	O

OA	B-DISEASE
was	O
diagnosed	O
at	O
the	O
age	O
of	O
14	O
years	O
.	O

The	O
relatively	O
high	O
prevalence	O
of	O
DOA	O
+	O
phenotypes	O
among	O
patients	O
with	O
OPA1	B-GENE
mutations	O
in	O
the	O
North	O
of	O
England	O
prompted	O
us	O
to	O
extend	O
our	O
original	O
study	O
to	O
other	O
diagnostic	O
and	O
research	O
centres	O
with	O
an	O
interest	O
in	O
neuro	B-DISEASE
-	I-DISEASE
ophthalmological	I-DISEASE
disorders	I-DISEASE
.	O

PhyloP	O
(	O
http	O
:	O
/	O
/	O
hgdownload	O
.	O
cse	O
.	O
ucsc	O
.	O
edu	O
/	O
goldenPath	O
/	O
hg18	O
/	O
phyloP44way	O
/	O
)	O
,	O
Sorting	O
Intolerant	O
from	O
Tolerant	O
(	O
SIFT	O
;	O
http	O
:	O
/	O
/	O
sift	O
.	O
jcvi	O
.	O
org	O
/	O
)	O
,	O
Polymorphism	O
Phenotyping	O
(	O
PolyPhen2	O
;	O
http	O
:	O
/	O
/	O
genetics	O
.	O
bwh	O
.	O
harvard	O
.	O
edu	O
/	O
pph2	O
/	O
)	O
,	O
LRT	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
genetics	O
.	O
wustl	O
.	O
edu	O
/	O
jflab	O
/	O
lrt_query	O
.	O
html	O
)	O
,	O
MutationTaster	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
mutationtaster	O
.	O
org	O
/	O
)	O
,	O
and	O
GERP	O
+	O
+	O
(	O
http	O
:	O
/	O
/	O
mendel	O
.	O
stanford	O
.	O
edu	O
/	O
SidowLab	O
/	O
downloads	O
/	O
gerp	O
/	O
index	O
.	O
html	O
)	O
.	O

"	O
From	O
this	O
,	O
the	O
average	O
coverage	O
across	O
all	O
the	O
regions	O
was	O
calculated	O
for	O
each	O
sample	O
(	O
Supp	O
.	O

Although	O
it	O
appeared	O
that	O
p	B-VARIANT
.	I-VARIANT
D87Y	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
S93R	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
G222V	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R409C	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
L506R	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
C662Y	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
A664V	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
R776G	I-VARIANT
all	O
reached	O
the	O
plasma	O
membrane	O
,	O
their	O
expression	O
levels	O
were	O
reduced	O
when	O
compared	O
to	O
normal	O
pendrin	O
.	O

Scale	O
bar	O
represents	O
10	O
u	O
m	O
.	O

Alleles	O
of	O
microsatellite	O
markers	O
are	O
represented	O
by	O
numbers	O
indicating	O
different	O
repeat	O
lengths	O
.	O

DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
using	O
standard	O
procedures	O
[	O
Miller	O
et	O
al	O
.	O
,	O
1988	O
]	O
.	O

The	O
detailed	O
clinical	O
information	O
was	O
listed	O
in	O
Table	O
1	O
.	O

None	O
of	O
the	O
12	O
individuals	O
from	O
our	O
DFNA67	B-DISEASE
family	O
who	O
carried	O
the	O
p	B-VARIANT
.	I-VARIANT
Ser96	I-VARIANT
*	I-VARIANT
SLC17A9	B-GENE
mutation	O
had	O
any	O
skin	O
abnormalities	O
.	O

Exon	O
capture	O
and	O
enrichment	O
was	O
performed	O
(	O
Illumina	O
TruSeq	O
Exome	O
)	O
in	O
solution	O
and	O
libraries	O
were	O
sequenced	O
as	O
100	O
bp	O
paired	O
end	O
reads	O
on	O
an	O
Illumina	O
HiSeq	O
2000	O
instrument	O
.	O

[	O
12	O
]	O
documented	O
the	O
evolution	O
of	O
multiple	O
small	O
macular	B-DISEASE
holes	I-DISEASE
into	O
a	O
large	O
macular	B-DISEASE
hole	I-DISEASE
in	O
a	O
male	O
AS	B-DISEASE
patient	O
.	O

ND	O
:	O
No	O
data	O
.	O

*	O
in	O
vitro	O
functional	O
characterisation	O
performed	O
.	O

All	O
primers	O
had	O
a	O
tailed	O
sequence	O
added	O
for	O
automated	O
Sanger	O
sequencing	O
.	O

Sequences	O
from	O
patients	O
and	O
the	O
OPA1	B-GENE
reference	O
sequence	O
(	O
NM_015560	O
.	O
1	O
)	O
were	O
compared	O
using	O
SeqMan	O
II	O
software	O
(	O
Lasergene	O
8	O
.	O
0	O
,	O
DNASTAR	O
,	O
Madison	O
,	O
WI	O
)	O
.	O

We	O
identified	O
three	O
rare	O
,	O
high	O
-	O
quality	O
CNVs	O
(	O
one	O
deletion	O
and	O
two	O
duplications	O
)	O
under	O
de	O
novo	O
,	O
inherited	O
recessive	O
or	O
X	O
linked	O
models	O
(	O
Table	O
1	O
and	O
Supplementary	O
Material	O
,	O
Table	O
S4	O
and	O
Supplementary	O
Material	O
,	O
Fig	O
.	O

This	O
selection	O
process	O
takes	O
place	O
in	O
the	O
endoplasmic	O
reticulum	O
,	O
where	O
the	O
three	O
alpha	O
-	O
chains	O
fold	O
to	O
form	O
the	O
protomer	O
,	O
which	O
subsequently	O
undergoes	O
a	O
series	O
of	O
post	O
-	O
translational	O
modifications	O
before	O
secretion	O
to	O
the	O
GBM	O
[	O
9	O
]	O
.	O

Exon	O
27	O
is	O
not	O
deleted	O
in	O
1598	O
and	O
1602	O
.	O

Language	O
was	O
developed	O
after	O
4	O
months	O
of	O
CI	O
use	O
(	O
Scores	O
of	O
IT	O
-	O
MAIS	O
:	O
9	O
/	O
40	O
>	O
23	O
/	O
40	O
)	O
.	O

(	O
We	O
considered	O
the	O
following	O
predictions	O
as	O
pathogenic	O
:	O
Polyphen2	O
,	O
probably	O
damaging	O
;	O
SIFT	O
,	O
damaging	O
;	O
PROVEA	O
,	O
deleterious	O
;	O
Mutation	O
Assessor	O
,	O
medium	O
/	O
high	O
functional	O
impact	O
)	O
.	O

The	O
mutation	O
resulted	O
in	O
a	O
premature	O
stop	O
codon	O
.	O

Closed	O
symbol	O
represents	O
affected	O
patient	O
and	O
open	O
symbol	O
indicates	O
unaffected	O
subject	O
.	O

[	O
29	O
]	O
reported	O
that	O
in	O
murine	O
XLAS	B-DISEASE
,	O
favorable	O
X	O
-	O
inactivation	O
improved	O
survival	O
of	O
female	O
carriers	O
.	O

The	O
earliest	O
detectable	O
response	O
has	O
a	O
peak	O
latency	O
of	O
approximately	O
30	O
ms	O
post	O
stimulus	O
.	O

The	O
c	B-VARIANT
.	I-VARIANT
2299delG	I-VARIANT
was	O
the	O
most	O
common	O
mutation	O
with	O
an	O
allele	O
frequency	O
of	O
14	O
-	O
50	O
%	O
in	O
patients	O
from	O
Europe	O
and	O
North	O
America	O
[	O
6	O
,	O
11	O
-	O
13	O
,	O
15	O
-	O
19	O
]	O
.	O

Click	O
here	O
for	O
file	O
We	O
thank	O
the	O
patients	O
and	O
their	O
families	O
for	O
participation	O
in	O
the	O
study	O
.	O

M	O
.	O
L	O
.	O
-	O
A	O
.	O

Sequence	O
conservation	O
around	O
the	O
p	B-VARIANT
.	I-VARIANT
L54P	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
A123D	I-VARIANT
changes	O
.	O

Several	O
proteins	O
have	O
been	O
identified	O
to	O
interact	O
with	O
myosin	B-GENE
VIIA	I-GENE
.	O

The	O
onset	O
of	O
hearing	B-DISEASE
impairment	I-DISEASE
was	O
categorized	O
as	O
prelingual	O
/	O
early	O
(	O
<	O
=	O
6	O
years	O
)	O
and	O
late	O
(	O
>	O
6	O
years	O
)	O
.	O

Similar	O
case	O
reports	O
have	O
been	O
described	O
previously	O
[	O
8	O
]	O
,	O
[	O
12	O
]	O
,	O
[	O
14	O
]	O
.	O

For	O
example	O
,	O
setting	O
a	O
minimum	O
coverage	O
of	O
30	O
x	O
,	O
only	O
50	O
%	O
of	O
the	O
USH	B-DISEASE
sequences	O
are	O
available	O
for	O
analysis	O
.	O

More	O
than	O
50	O
%	O
of	O
prelingual	O
deafness	B-DISEASE
is	O
estimated	O
to	O
have	O
a	O
genetic	O
etiology	O
,	O
of	O
which	O
about	O
70	O
%	O
is	O
nonsyndromic	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
NSHL	B-DISEASE
)	O
.	O

5	O
B	O
)	O
.	O

Unfortunately	O
,	O
exact	O
audiological	O
data	O
(	O
pure	O
tone	O
thresholds	O
)	O
from	O
Hungarian	O
patients	O
were	O
not	O
available	O
as	O
only	O
severity	O
and	O
age	O
of	O
onset	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
were	O
noted	O
in	O
the	O
accessible	O
clinical	O
files	O
.	O

The	O
proband	O
(	O
III	O
:	O
5	O
)	O
was	O
a	O
47	O
-	O
year	O
-	O
old	O
female	O
who	O
experienced	O
night	B-DISEASE
blindness	I-DISEASE
at	O
the	O
age	O
of	O
23	O
years	O
as	O
her	O
initial	O
symptoms	O
of	O
RP	B-DISEASE
,	O
which	O
was	O
followed	O
by	O
progressive	O
loss	B-DISEASE
of	I-DISEASE
visual	I-DISEASE
acuity	I-DISEASE
.	O

It	O
has	O
been	O
reported	O
that	O
TFIIIB	O
assembled	O
with	O
certain	O
deletion	O
mutants	O
of	O
its	O
BRF1	B-GENE
and	O
BDP1	B-GENE
subunits	O
is	O
competent	O
in	O
pol	O
III	O
recruitment	O
[	O
21	O
]	O
but	O
the	O
resulting	O
preinitiation	O
complex	O
does	O
not	O
open	O
the	O
promoter	O
.	O

Combining	O
these	O
observations	O
with	O
our	O
observations	O
,	O
we	O
suggest	O
the	O
possibility	O
that	O
the	O
dark	O
regions	O
observed	O
in	O
the	O
en	O
face	O
AO	O
images	O
of	O
our	O
ADOA	B-DISEASE
patients	O
are	O
areas	O
of	O
degenerated	O
horizontal	O
,	O
bipolar	O
,	O
and	O
amacrine	O
cells	O
in	O
the	O
INL	O
caused	O
by	O
retrograde	B-DISEASE
transsynaptic	I-DISEASE
degeneration	I-DISEASE
.	O

Hearing	B-DISEASE
loss	I-DISEASE
was	O
evaluated	O
using	O
pure	O
-	O
tone	O
audiometry	O
(	O
PTA	O
)	O
classified	O
by	O
a	O
pure	O
-	O
tone	O
average	O
over	O
500	O
,	O
1000	O
,	O
2000	O
and	O
4000	O
Hz	O
in	O
the	O
better	O
hearing	O
ears	O
.	O

Despite	O
the	O
overall	O
low	O
prevalence	O
of	O
USH1C	B-GENE
in	O
most	O
populations	O
,	O
c	B-VARIANT
.	I-VARIANT
238	I-VARIANT
-	I-VARIANT
239insC	I-VARIANT
has	O
been	O
found	O
in	O
14	O
%	O
and	O
12	O
.	O
5	O
%	O
of	O
USH1	B-DISEASE
patients	O
in	O
the	O
UK	O
and	O
Germany	O
,	O
respectively	O
,	O
which	O
may	O
be	O
due	O
to	O
founder	O
effects	O
[	O
15	O
,	O
18	O
]	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
ML	O
LJ	O
RK	O
JL	O
DW	O
.	O

William	O
B	O
.	O

The	O
obtained	O
sequences	O
were	O
compared	O
with	O
the	O
consensus	O
sequence	O
NM_015404	O
.	O

Acceptor	O
and	O
donor	O
splice	O
site	O
mutations	O
were	O
analyzed	O
with	O
a	O
maximum	O
-	O
entropy	O
model	O
and	O
filtered	O
for	O
their	O
putative	O
effect	O
on	O
splicing	O
.	O

The	O
transfected	O
BHK	O
-	O
21	O
cells	O
were	O
immunostained	O
with	O
HA	O
antibody	O
(	O
red	O
)	O
showing	O
the	O
localization	O
of	O
WT	O
CLRN1	O
-	O
HA	O
(	O
E	O
)	O
,	O
the	O
novel	O
sequence	O
alteration	O
p	B-VARIANT
.	I-VARIANT
L54P	I-VARIANT
mutated	O
CLRN1	O
-	O
HA	O
(	O
B	O
)	O
and	O
the	O
known	O
disease	O
-	O
causing	O
p	B-VARIANT
.	I-VARIANT
N48K	I-VARIANT
mutated	O
CLRN1	O
-	O
HA	O
(	O
H	O
)	O
.	O

They	O
found	O
no	O
evidence	O
for	O
an	O
association	O
between	O
mutations	O
of	O
KCNJ10	B-GENE
or	O
FOXI1	B-GENE
with	O
SLC26A4	B-GENE
mutations	O
in	O
the	O
pathogenesis	O
of	O
EVA	B-DISEASE
or	O
Pendred	B-DISEASE
syndrome	I-DISEASE
[	O
32	O
]	O
.	O

Consequently	O
,	O
no	O
nucleotide	O
variants	O
were	O
detected	O
(	O
Fig	O
.	O

By	O
contrast	O
,	O
HL	B-DISEASE
was	O
non	O
-	O
fluctuating	O
and	O
several	O
individuals	O
manifested	O
an	O
earlier	O
onset	O
age	O
(	O
the	O
youngest	O
was	O
10	O
years	O
old	O
)	O
in	O
our	O
family	O
.	O

The	O
onset	O
of	O
RP	B-DISEASE
when	O
she	O
was	O
9	O
years	O
old	O
included	O
night	O
blindness	B-DISEASE
and	O
peripheral	O
visual	O
loss	O
.	O

This	O
spectrum	O
included	O
unaffected	O
carrier	O
,	O
seemingly	O
IHH	B-DISEASE
,	O
isolated	O
KS	B-DISEASE
,	O
and	O
KS	B-DISEASE
with	O
additional	O
features	O
(	O
including	O
anomalies	O
of	O
digits	O
falling	O
out	O
of	O
the	O
definition	O
of	O
ectrodactyly	B-DISEASE
,	O
or	O
mild	O
expression	O
of	O
HPE	B-DISEASE
,	O
such	O
as	O
corpus	B-DISEASE
callosum	I-DISEASE
agenesis	I-DISEASE
or	O
central	O
incisor	O
)	O
,	O
and	O
septo	O
-	O
optic	O
-	O
like	O
dysplasia	O
.	O

Microinjection	O
was	O
performed	O
at	O
the	O
one	O
-	O
to	O
two	O
-	O
cell	O
stage	O
using	O
a	O
microinjection	O
system	O
consisting	O
of	O
a	O
SZX9	O
stereomicroscope	O
(	O
Olympus	O
,	O
Tokyo	O
,	O
Japan	O
)	O
and	O
an	O
IM300	O
Microinjector	O
(	O
Narishige	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

Most	O
targets	O
show	O
a	O
coverage	O
of	O
20	O
-	O
30	O
x	O
.	O

(	O
TIF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Despite	O
the	O
absence	O
of	O
genetic	O
information	O
from	O
other	O
family	O
members	O
that	O
could	O
help	O
excluding	O
nonpathogenic	O
DNA	O
variants	O
,	O
we	O
could	O
detect	O
causative	O
mutations	O
in	O
a	O
variety	O
of	O
genes	O
known	O
to	O
represent	O
a	O
wide	O
spectrum	O
of	O
clinical	O
phenotypes	O
in	O
83	O
%	O
of	O
the	O
patients	O
analyzed	O
.	O

The	O
dotted	O
curve	O
represents	O
presbyacusis	B-DISEASE
and	O
was	O
previously	O
established	O
for	O
patients	O
with	O
presbyacusis	B-DISEASE
.	O

Krawitz	O
(	O
KR	O
3985	O
/	O
1	O
-	O
1	O
)	O
,	O
and	O
to	O
S	O
.	O

T15LM007093	O
)	O
.	O

USH	B-DISEASE
is	O
clinically	O
and	O
genetically	O
heterogeneous	O
and	O
is	O
the	O
most	O
common	O
form	O
of	O
deaf	B-DISEASE
-	I-DISEASE
blindness	I-DISEASE
of	O
genetic	O
origin	O
,	O
representing	O
50	O
%	O
of	O
cases	O
[	O
1	O
]	O
.	O

The	O
youngest	O
brother	O
was	O
11	O
years	O
old	O
.	O

Both	O
exhibited	O
normal	O
temporal	O
bone	O
imaging	O
results	O
.	O

(	O
B	O
)	O
This	O
example	O
shows	O
a	O
heterozygous	O
deletion	O
of	O
the	O
exon	O
20	O
of	O
the	O
OTOA	B-GENE
gene	O
.	O

Variant	O
reads	O
were	O
51	O
%	O
and	O
48	O
%	O
of	O
total	O
reads	O
,	O
suggesting	O
heterozygosity	O
for	O
both	O
alleles	O
.	O

The	O
inheritance	O
pattern	O
of	O
the	O
four	O
families	O
was	O
autosomal	O
dominant	O
.	O

At	O
the	O
time	O
of	O
referral	O
,	O
he	O
had	O
an	O
occipito	O
-	O
frontal	O
circumference	O
of	O
48	O
.	O
5	O
cm	O
(	O
-	O
2	O
.	O
8	O
SD	O
)	O
,	O
hypertelorism	B-DISEASE
and	O
severe	O
exorbitism	B-DISEASE
.	O

Image	O
analysis	O
and	O
base	O
calling	O
were	O
performed	O
using	O
the	O
Illumina	O
Real	O
-	O
Time	O
Analysis	O
Pipeline	O
version	O
1	O
.	O
14	O
with	O
default	O
parameters	O
.	O

The	O
genetic	O
etiology	O
of	O
LQTS	B-DISEASE
in	O
Denmark	O
is	O
similar	O
to	O
that	O
found	O
in	O
other	O
populations	O
.	O

Abbreviations	O
:	O
N	O
/	O
A	O
represents	O
data	O
not	O
available	O
;	O
the	O
asterisk	O
indicates	O
that	O
the	O
allele	O
frequency	O
referred	O
to	O
patients	O
.	O

,	O
1996	O
;	O
Fujikawa	O
and	O
Starr	O
,	O
2000	O
;	O
Sinha	O
et	O
al	O
.	O

In	O
implanted	O
patients	O
,	O
aided	O
thresholds	O
were	O
measured	O
(	O
Interacoustic	O
AC30	O
Audiometer	O
connected	O
to	O
a	O
Pioneer	O
A	O
103	O
amplifier	O
,	O
JBL	O
TLX130	O
loudspeakers	O
)	O
with	O
subjects	O
wearing	O
their	O
sound	O
processor	O
on	O
user	O
settings	O
.	O

Variations	O
found	O
in	O
the	O
sequencing	O
were	O
confirmed	O
with	O
the	O
restriction	O
endonucleases	O
Taq	O
a	O
I	O
,	O
MslI	O
,	O
and	O
EcoRV	O
(	O
New	O
England	O
Biolabs	O
,	O
Ipswich	O
MA	O
)	O
,	O
which	O
were	O
used	O
with	O
all	O
available	O
family	O
members	O
and	O
100	O
normal	O
controls	O
.	O

Thereafter	O
,	O
latencies	O
increased	O
until	O
animals	O
became	O
completely	O
resistant	O
at	O
6	O
weeks	O
of	O
age	O
(	O
180	O
s	O
,	O
n	O
=	O
15	O
)	O
.	O

One	O
of	O
the	O
homozygous	O
intervals	O
shared	O
among	O
these	O
three	O
individuals	O
included	O
a	O
known	O
RP	B-DISEASE
-	O
causative	O
gene	O
(	O
nuclear	O
receptor	O
subfamily	O
2	O
,	O
group	O
E	O
,	O
member	O
3	O
;	O
NR2E3	B-GENE
)	O
;	O
however	O
,	O
screening	O
of	O
all	O
coding	O
exons	O
was	O
negative	O
for	O
mutations	O
.	O

Thyroid	O
hormone	O
assays	O
showed	O
that	O
total	O
T3	O
was	O
slightly	O
elevated	O
in	O
two	O
patients	O
(	O
Patient	O
3	O
and	O
Patient	O
19	O
)	O
,	O
but	O
this	O
abnormity	O
had	O
no	O
clinical	O
value	O
when	O
evaluated	O
by	O
endocrinologist	O
from	O
Chinese	O
PLA	O
General	O
Hospital	O
.	O

Considering	O
the	O
clinical	O
reports	O
so	O
far	O
described	O
,	O
it	O
is	O
now	O
possible	O
to	O
outline	O
some	O
conclusions	O
:	O
i	O
)	O
PEO1	B-GENE
mutations	O
are	O
more	O
frequent	O
in	O
adult	O
-	O
onset	O
cases	O
than	O
in	O
paediatric	O
subjects	O
;	O
ii	O
)	O
the	O
most	O
common	O
clinical	O
features	O
are	O
PEO	B-DISEASE
and	O
ptosis	B-DISEASE
,	O
whilst	O
syndromic	O
features	O
and	O
central	O
nervous	O
system	O
involvement	O
are	O
less	O
frequent	O
than	O
in	O
other	O
genetic	O
backgrounds	O
,	O
such	O
as	O
in	O
POLG1	B-GENE
-	O
mutated	O
patients	O
;	O
iii	O
)	O
clinical	O
onset	O
of	O
patients	O
with	O
PEO1	B-GENE
dominant	O
mutations	O
is	O
often	O
before	O
the	O
fifth	O
decade	O
(	O
two	O
thirds	O
of	O
the	O
reported	O
cases	O
)	O
;	O
iv	O
)	O
histochemical	O
analysis	O
of	O
muscle	O
biopsy	O
confirms	O
the	O
presence	O
of	O
COX	O
-	O
deficient	O
fibres	O
in	O
most	O
but	O
not	O
all	O
the	O
patients	O
;	O
v	O
)	O
detection	O
of	O
mtDNA	O
-	O
deleted	O
molecules	O
in	O
muscle	O
tissue	O
is	O
often	O
,	O
but	O
not	O
always	O
,	O
observed	O
.	O

As	O
part	O
of	O
a	O
preoperative	O
selection	O
procedure	O
for	O
cochlear	B-DISEASE
implantation	I-DISEASE
,	O
the	O
proband	O
also	O
underwent	O
electronystagmography	O
,	O
computed	O
tomography	O
(	O
CT	O
)	O
,	O
and	O
auditory	O
steady	O
-	O
state	O
response	O
(	O
ASSR	O
)	O
testing	O
.	O

Sequences	O
of	O
the	O
amplicons	O
were	O
determined	O
with	O
BigDye	O
Terminator	O
cycle	O
sequencing	O
kit	O
v3	O
.	O
1	O
and	O
an	O
ABI3130	O
Genetic	O
Analyzer	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
.	O

The	O
indentified	O
nucleotide	O
change	O
was	O
not	O
found	O
in	O
335	O
Turkish	O
controls	O
via	O
Sanger	O
sequencing	O
.	O

Eight	O
small	O
families	O
with	O
autosomal	O
dominant	O
,	O
non	O
-	O
syndromic	O
,	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
were	O
selected	O
,	O
and	O
80	O
target	O
genes	O
associated	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
were	O
screened	O
using	O
target	O
capture	O
and	O
massively	O
parallel	O
sequencing	O
methods	O
.	O

Cataracts	O
were	O
present	O
in	O
two	O
patients	O
(	O
RP	O
-	O
614	O
and	O
RP	O
-	O
1520	O
)	O
.	O

Traditionally	O
,	O
Sanger	O
sequencing	O
was	O
used	O
to	O
identify	O
the	O
mutations	O
responsible	O
of	O
the	O
disease	O
[	O
25	O
,	O
50	O
]	O
.	O

Multi	O
-	O
species	O
alignment	O
of	O
amino	O
acids	O
encoded	O
by	O
exon	O
20	O
of	O
TECTA	B-GENE
across	O
different	O
vertebrates	O
.	O

Patients	O
were	O
considered	O
to	O
be	O
diazoxide	O
responsive	O
if	O
satisfactory	O
glycemic	O
control	O
was	O
achieved	O
with	O
doses	O
of	O
oral	O
diazoxide	O
not	O
exceeding	O
20	O
mg	O
/	O
kg	O
per	O
day	O
and	O
were	O
considered	O
to	O
be	O
in	O
remission	O
if	O
good	O
glycemic	O
control	O
was	O
maintain	O
without	O
further	O
medical	O
or	O
surgical	O
therapy	O
.	O

In	O
four	O
of	O
the	O
patients	O
,	O
these	O
variants	O
occurred	O
together	O
with	O
a	O
definitely	O
pathogenic	O
mutation	O
.	O

In	O
an	O
attempt	O
to	O
identify	O
the	O
altered	O
gene	O
,	O
we	O
first	O
performed	O
a	O
genetic	O
linkage	O
analysis	O
of	O
fluorescent	O
dye	O
-	O
labeled	O
polymorphic	O
microsatellite	O
markers	O
covering	O
all	O
known	O
loci	O
for	O
USH	B-DISEASE
.	O

For	O
the	O
flash	O
VEP	O
,	O
the	O
most	O
robust	O
components	O
are	O
the	O
negative	O
peak	O
N2	O
and	O
positive	O
peak	O
P2	O
peaks	O
.	O

Then	O
adapters	O
were	O
ligated	O
to	O
both	O
ends	O
of	O
the	O
fragments	O
.	O

Audiograms	O
of	O
the	O
affected	O
siblings	O
showed	O
that	O
the	O
hearing	B-DISEASE
loss	I-DISEASE
was	O
bilateral	O
and	O
severe	O
to	O
profound	O
(	O
Figure	O
1	O
B	O
)	O
.	O

The	O
box	O
labeled	O
with	O
different	O
color	O
indicates	O
different	O
mutation	O
in	O
each	O
pedigree	O
.	O

developed	O
and	O
ran	O
the	O
analysis	O
pipeline	O
for	O
NextGen	O
sequence	O
data	O
and	O
Illumina	O
Omni2	O
.	O
5	O
data	O
and	O
reviewed	O
and	O
edited	O
the	O
manuscript	O
.	O

In	O
order	O
to	O
examine	O
the	O
relation	O
between	O
the	O
variations	O
in	O
genes	O
coding	O
for	O
TJ	O
proteins	O
and	O
genetic	O
causes	O
of	O
ADNSHL	B-DISEASE
and	O
ARNSHL	B-DISEASE
in	O
the	O
Korean	O
population	O
,	O
we	O
selected	O
the	O
TJP2	B-GENE
and	O
CLDN14	B-GENE
genes	O
,	O
and	O
screened	O
all	O
their	O
exons	O
and	O
exon	O
-	O
intron	O
boundaries	O
.	O

This	O
study	O
systematically	O
reviewed	O
GSDs	B-DISEASE
as	O
defined	O
in	O
"	O
Nosology	O
and	O
Classification	O
of	O
genetic	B-DISEASE
skeletal	I-DISEASE
disorders	I-DISEASE
(	O
2010	O
version	O
)	O
"	O
using	O
Chinese	O
biomedical	O
literature	O
published	O
over	O
the	O
past	O
34	O
years	O
from	O
1978	O
to	O
2012	O
.	O

During	O
the	O
third	O
year	O
of	O
beta	O
-	O
blocker	O
treatment	O
,	O
she	O
experienced	O
another	O
syncopal	B-DISEASE
episode	I-DISEASE
,	O
evoked	O
by	O
exercise	O
.	O

NR	O
=	O
Not	O
reported	O
,	O
NA	O
=	O
Not	O
available	O
,	O
Leiden	O
Open	O
Variation	O
Database	O
(	O
LOVD	O
)	O
54	O
key	O
:	O
Numbers	O
indicate	O
number	O
of	O
LOVD	O
reports	O
.	O

In	O
order	O
to	O
identify	O
positions	O
where	O
the	O
bases	O
in	O
a	O
read	O
differed	O
from	O
those	O
in	O
the	O
reference	O
sequence	O
,	O
each	O
read	O
was	O
aligned	O
to	O
its	O
reference	O
sequence	O
with	O
the	O
dpAlign	O
module	O
in	O
the	O
BioPerl	O
package	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
bioperl	O
.	O
org	O
/	O
)	O
.	O

Here	O
we	O
report	O
on	O
the	O
genetic	O
analysis	O
of	O
a	O
consanguineous	O
family	O
from	O
the	O
south	O
Indian	O
state	O
of	O
Karnataka	O
with	O
members	O
affected	O
with	O
two	O
disorders	O
:	O
Waardenburg	B-DISEASE
syndrome	I-DISEASE
and	O
Duchenne	B-DISEASE
muscular	I-DISEASE
dystrophy	I-DISEASE
.	O

MYH9	B-GENE
variants	O
:	O
nucleotide	O
cDNA	O
changes	O
and	O
corresponding	O
protein	O
alterations	O
GenBank	O
Accession	O
Number	O
of	O
the	O
relevant	O
wild	O
-	O
type	O
MYH9	B-GENE
gene	O
sequence	O
:	O
NM_002473	O
.	O
4	O
.	O

(	O
A	O
)	O
DNA	O
sequence	O
analysis	O
.	O

Due	O
to	O
the	O
highly	O
heterogenous	O
nature	O
of	O
HRD	B-DISEASE
,	O
such	O
an	O
elevated	O
frequency	O
of	O
unaffected	O
carriers	O
has	O
a	O
limited	O
influence	O
on	O
the	O
likelihood	O
of	O
generating	O
affected	O
offspring	O
,	O
since	O
the	O
chance	O
of	O
two	O
unrelated	O
parents	O
carrying	O
each	O
a	O
heterozygous	O
mutation	O
in	O
the	O
same	O
gene	O
remains	O
low	O
.	O

The	O
aim	O
of	O
the	O
present	O
work	O
was	O
the	O
mutation	O
screening	O
of	O
the	O
USH1C	B-GENE
gene	O
in	O
a	O
cohort	O
of	O
33	O
Usher	B-DISEASE
syndrome	I-DISEASE
patients	O
,	O
to	O
identify	O
the	O
genetic	O
cause	O
of	O
the	O
disease	O
and	O
to	O
determine	O
the	O
relative	O
involvement	O
of	O
this	O
gene	O
in	O
USH1	B-DISEASE
pathogenesis	O
in	O
the	O
Spanish	O
population	O
.	O

In	O
another	O
three	O
families	O
(	O
6	O
.	O
4	O
%	O
)	O
we	O
suspect	O
involvement	O
of	O
USH1	B-DISEASE
genes	O
based	O
on	O
haplotype	O
analysis	O
(	O
family	O
168	O
shown	O
in	O
supplemental	O
figure	O
1	O
,	O
and	O
families	O
104	O
,	O
206	O
)	O
.	O

Moreover	O
,	O
Subject	O
1	O
had	O
a	O
positive	O
history	O
of	O
exposure	O
to	O
occupational	O
noise	O
and	O
showed	O
a	O
typical	O
audiometric	O
profile	O
of	O
noise	O
-	O
induced	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Temperature	B-DISEASE
-	I-DISEASE
sensitive	I-DISEASE
auditory	I-DISEASE
neuropathy	I-DISEASE
(	O
TS	B-DISEASE
-	I-DISEASE
AN	I-DISEASE
)	O
was	O
first	O
reported	O
in	O
1998	O
[	O
27	O
]	O
,	O
and	O
the	O
responsible	O
heterozygous	O
mutation	O
of	O
the	O
OTOF	B-GENE
gene	O
,	O
p	O
.	O
I515T	O
,	O
was	O
first	O
found	O
in	O
two	O
affected	O
children	O
and	O
their	O
father	O
[	O
23	O
]	O
,	O
but	O
no	O
available	O
information	O
on	O
their	O
maternal	O
mutation	O
was	O
in	O
the	O
study	O
.	O

It	O
appears	O
then	O
that	O
the	O
presence	O
of	O
giant	O
platelets	O
per	O
se	O
is	O
not	O
a	O
risk	O
factor	O
for	O
bleeding	B-DISEASE
in	O
MYH9	B-DISEASE
-	I-DISEASE
RD	I-DISEASE
.	O

Typical	O
yields	O
of	O
preparations	O
from	O
10	O
x	O
10	O
cm	O
plates	O
were	O
~	O
600	O
u	O
g	O
of	O
GST	O
-	O
ELMOD3	B-GENE
or	O
mutant	O
and	O
~	O
6	O
mg	O
of	O
GST	O
.	O

(	O
B	O
)	O
Number	O
of	O
bleeders	O
for	O
each	O
affected	O
exon	O
and	O
intron	O
.	O

Functional	O
studies	O
included	O
cellular	O
patch	O
clamp	O
,	O
confocal	O
microscopy	O
,	O
and	O
immunoblotting	O
.	O

Six	O
consecutive	O
cases	O
of	O
ADOA	B-DISEASE
patients	O
from	O
4	O
families	O
who	O
visited	O
Nippon	O
Medical	O
School	O
Chiba	O
Hokusoh	O
Hospital	O
from	O
December	O
2010	O
through	O
April	O
2013	O
were	O
studied	O
.	O

We	O
selected	O
15	O
SNVs	O
that	O
co	O
-	O
segregated	O
with	O
NSHL	B-DISEASE
in	O
the	O
family	O
,	O
which	O
were	O
located	O
in	O
six	O
linkage	O
candidate	O
loci	O
.	O

A	O
copy	O
of	O
the	O
written	O
consent	O
is	O
available	O
for	O
review	O
by	O
the	O
Editor	O
of	O
this	O
journal	O
.	O

S1K	O
)	O
.	O

The	O
biggest	O
transcript	O
of	O
MYO7A	B-GENE
consists	O
of	O
49	O
exons	O
and	O
encodes	O
a	O
2	O
,	O
215	O
amino	O
acid	O
unconventional	O
myosin	O
named	O
myosin	B-GENE
VIIA	I-GENE
.	O

Disease	O
in	O
11	O
patients	O
explained	O
by	O
mutations	O
outside	O
ABCA4	B-GENE
Patients	O
who	O
were	O
clinically	O
examined	O
following	O
the	O
molecular	O
diagnosis	O
are	O
in	O
bold	O
.	O

2	O
B	O
)	O
.	O

Genomic	O
DNA	O
sample	O
was	O
randomly	O
fragmented	O
by	O
Covaris	O
;	O
the	O
size	O
of	O
the	O
library	O
fragments	O
was	O
distributed	O
mainly	O
between	O
250	O
and	O
300	O
bp	O
.	O

In	O
six	O
families	O
,	O
hearing	B-DISEASE
loss	I-DISEASE
was	O
not	O
linked	O
to	O
any	O
known	O
hearing	O
-	O
related	O
gene	O
.	O

The	O
sequence	O
and	O
orientation	O
of	O
the	O
luciferase	O
reporter	O
were	O
verified	O
by	O
DNA	O
sequencing	O
.	O

This	O
residue	O
is	O
exposed	O
on	O
the	O
protein	O
surface	O
(	O
exposed	O
surface	O
area	O
of	O
122	O
A	O
2	O
)	O
.	O

Ocular	O
contents	O
are	O
not	O
discernible	O
posterior	O
to	O
calcification	O
.	O

We	O
aimed	O
to	O
approach	O
RD	B-DISEASE
genetic	O
diagnosis	O
using	O
all	O
the	O
available	O
genetic	O
information	O
to	O
prioritize	O
candidates	O
for	O
mutational	O
screening	O
,	O
and	O
then	O
restrict	O
the	O
number	O
of	O
cases	O
to	O
be	O
analyzed	O
by	O
massive	O
sequencing	O
.	O

Because	O
the	O
SureSelect	O
TGE	O
technology	O
tends	O
to	O
avoid	O
placing	O
baits	O
over	O
repeat	O
elements	O
,	O
target	O
regions	O
with	O
low	O
bait	O
density	O
should	O
have	O
higher	O
densities	O
of	O
repeat	O
elements	O
.	O

Expression	O
of	O
the	O
mutant	O
KCNQ1	B-GENE
did	O
not	O
significantly	O
change	O
current	O
density	O
of	O
activation	O
and	O
the	O
current	O
density	O
at	O
+	O
70	O
mV	O
(	O
Figure	O
3	O
)	O
.	O

The	O
geographic	O
distribution	O
and	O
the	O
proportion	O
of	O
patients	O
carrying	O
two	O
SLC26A4	B-GENE
mutant	O
alleles	O
in	O
each	O
region	O
are	O
shown	O
in	O
Figure	O
S1	O
.	O

These	O
changes	O
result	O
in	O
the	O
substitution	O
of	O
a	O
larger	O
residue	O
for	O
a	O
conserved	O
amino	O
acid	O
,	O
predicted	O
to	O
result	O
in	O
the	O
destabilization	O
of	O
the	O
protein	O
.	O

Similarly	O
,	O
mutating	O
threonine	O
to	O
leucine	O
in	O
the	O
linker	O
was	O
shown	O
to	O
reduce	O
DNA	O
binding	O
[	O
34	O
]	O
.	O

(	O
DOC	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

All	O
deaf	B-DISEASE
probands	O
(	O
n	O
=	O
190	O
)	O
were	O
pre	O
-	O
screened	O
against	O
common	O
deafness	B-DISEASE
genes	O
GJB2	B-GENE
,	O
SLC26A4	B-GENE
and	O
MT	B-GENE
-	I-GENE
RNR1	I-GENE
by	O
PCR	O
amplification	O
and	O
bidirectional	O
sequencing	O
as	O
previously	O
described	O
[	O
4	O
-	O
6	O
]	O
.	O

A	O
total	O
of	O
23	O
pathogenic	O
mutations	O
were	O
identified	O
.	O

We	O
show	O
that	O
massively	O
parallel	O
targeted	O
sequencing	O
of	O
19	O
genes	O
provides	O
a	O
new	O
and	O
reliable	O
strategy	O
for	O
molecular	O
diagnosis	O
of	O
Usher	B-DISEASE
syndrome	I-DISEASE
(	O
USH	B-DISEASE
)	O
and	O
nonsyndromic	B-DISEASE
deafness	I-DISEASE
,	O
particularly	O
appropriate	O
for	O
these	O
disorders	O
characterized	O
by	O
a	O
high	O
clinical	O
and	O
genetic	O
heterogeneity	O
and	O
a	O
complex	O
structure	O
of	O
several	O
of	O
the	O
genes	O
involved	O
.	O

The	O
proband	O
is	O
homozygous	O
for	O
MYO15A	B-GENE
c	B-VARIANT
.	I-VARIANT
4240G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
E1414K	I-VARIANT
)	O
,	O
a	O
novel	O
mutation	O
predicted	O
to	O
be	O
damaging	O
by	O
Polyphen2	O
and	O
SIFT	O
(	O
Tables	O
2	O
and	O
3	O
)	O
.	O

Remarkably	O
,	O
the	O
c	B-VARIANT
.	I-VARIANT
1155dupC	I-VARIANT
mutation	O
was	O
observed	O
in	O
homozygosis	O
in	O
12	O
patients	O
from	O
9	O
families	O
(	O
cases	O
2	O
.	O
1	O
,	O
3	O
.	O
1	O
,	O
3	O
.	O
2	O
,	O
4	O
.	O
1	O
,	O
6	O
.	O
1	O
,	O
7	O
.	O
1	O
,	O
7	O
.	O
2	O
,	O
8	O
.	O
1	O
,	O
10	O
.	O
1	O
,	O
10	O
.	O
2	O
,	O
12	O
.	O
1	O
and	O
13	O
.	O
1	O
)	O
.	O

Patients	O
were	O
considered	O
as	O
USH3	B-DISEASE
when	O
their	O
hearing	B-DISEASE
impairment	I-DISEASE
had	O
been	O
detected	O
in	O
adulthood	O
and	O
showed	O
clear	O
progressiveness	O
.	O

Universal	O
primer	O
sequences	O
5	O
-	O
ACACTGACGACATGGTTCTACA	O
-	O
[	O
target	O
-	O
specific	O
forward	O
]	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
TACGGTAGCAGAGACTTGGTCT	O
-	O
[	O
target	O
-	O
specific	O
reverse	O
]	O
-	O
3	O
'	O
were	O
added	O
at	O
the	O
5	O
'	O
end	O
to	O
all	O
target	O
-	O
specific	O
forward	O
and	O
reverse	O
primers	O
,	O
respectively	O
.	O

Confocal	O
microscopy	O
and	O
immunoblotting	O
were	O
used	O
to	O
assess	O
the	O
functional	O
impact	O
of	O
the	O
mutations	O
.	O

(	O
2012	O
)	O
compared	O
the	O
effectiveness	O
of	O
exome	O
sequencing	O
compared	O
to	O
long	O
PCR	O
-	O
based	O
methods	O
that	O
both	O
include	O
the	O
exons	O
of	O
the	O
above	O
named	O
nine	O
Usher	B-DISEASE
genes	O
and	O
showed	O
that	O
the	O
coverage	O
of	O
long	O
PCR	O
-	O
based	O
approach	O
is	O
currently	O
still	O
superior	O
to	O
standard	O
human	O
all	O
exon	O
kits	O
.	O

Moreover	O
,	O
the	O
p	B-VARIANT
.	I-VARIANT
S243X	I-VARIANT
and	O
in	O
fact	O
all	O
of	O
the	O
mutations	O
reported	O
to	O
date	O
,	O
apart	O
from	O
D458V	B-VARIANT
,	O
are	O
predicted	O
to	O
result	O
in	O
premature	B-DISEASE
termination	I-DISEASE
codons	I-DISEASE
(	O
PTCs	B-DISEASE
)	O
,	O
causing	O
aberrant	O
mRNAs	O
that	O
encode	O
truncated	O
proteins	O
.	O

Paired	O
end	O
adaptor	O
oligonucleotides	O
from	O
Illumina	O
were	O
ligated	O
on	O
repaired	O
A	O
-	O
tailed	O
fragments	O
that	O
were	O
purified	O
and	O
enriched	O
by	O
six	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
cycles	O
.	O

Diagrammatic	O
representation	O
of	O
the	O
OPA1	B-GENE
gene	O
with	O
the	O
location	O
of	O
mutations	O
resulting	O
in	O
DOA	O
+	O
syndromes	O
.	O

The	O
remaining	O
variants	O
were	O
not	O
found	O
to	O
affect	O
any	O
ESE	O
site	O
.	O

Each	O
genomic	O
DNA	O
sample	O
was	O
captured	O
using	O
Agilent	O
SureSelectXT	O
Human	O
All	O
Exon	O
V5	O
technology	O
(	O
Agilent	O
Technologies	O
,	O
Santa	O
Clara	O
,	O
California	O
,	O
USA	O
)	O
and	O
enriched	O
libraries	O
were	O
sequenced	O
using	O
the	O
HiSeq	O
2000	O
platform	O
(	O
Illumina	O
,	O
San	O
Diego	O
,	O
California	O
,	O
USA	O
)	O
.	O

The	O
frequency	O
of	O
carrier	O
rate	O
of	O
in	O
our	O
region	O
is	O
1	O
/	O
75	O
(	O
1	O
.	O
33	O
%	O
)	O
,	O
not	O
significantly	O
different	O
from	O
that	O
of	O
the	O
deaf	O
population	O
.	O

These	O
individuals	O
had	O
no	O
known	O
history	O
of	O
aminoglycoside	O
exposure	O
.	O

Next	O
,	O
we	O
applied	O
targeted	O
resequencing	O
of	O
known	O
204	O
deafness	B-DISEASE
-	O
related	O
genes	O
(	O
TRS	O
-	O
204	O
)	O
for	O
those	O
without	O
a	O
potential	O
pathogenic	O
variant	O
in	O
candidate	O
genes	O
or	O
the	O
GJB2	B-GENE
mutation	O
.	O

1	O
,	O
2	O
Subsequently	O
,	O
we	O
identified	O
52	O
additional	O
DFNB48	B-DISEASE
families	O
(	O
Supplementary	O
Figs	O
.	O

Charcot	B-DISEASE
-	I-DISEASE
Marie	I-DISEASE
-	I-DISEASE
Tooth	I-DISEASE
disease	I-DISEASE
-	I-DISEASE
5	I-DISEASE
(	O
CMTX5	B-DISEASE
,	O
MIM	O
311070	O
[	O
1	O
,	O
2	O
]	O
)	O
,	O
Arts	B-DISEASE
syndrome	I-DISEASE
(	O
MIM	O
301835	O
[	O
3	O
,	O
4	O
]	O
)	O
and	O
X	B-DISEASE
-	I-DISEASE
linked	I-DISEASE
nonsyndromic	I-DISEASE
sensorineural	I-DISEASE
deafness	I-DISEASE
(	O
DFN2	B-DISEASE
;	O
MIM	O
304500	O
[	O
5	O
]	O
)	O
present	O
three	O
clinically	O
distinct	O
but	O
genetically	O
allelic	O
disorders	O
,	O
caused	O
by	O
reduced	O
phosphoribosylpyrophosphate	O
synthetase	O
1	O
(	O
PRS1	O
)	O
activity	O
due	O
to	O
PRPS1	B-GENE
mutations	O
[	O
6	O
]	O
.	O

These	O
53	O
probands	O
included	O
12	O
in	O
whom	O
the	O
candidate	O
gene	O
approach	O
failed	O
and	O
41	O
GJB2	B-GENE
(	O
-	O
)	O
probands	O
without	O
any	O
phenotypic	O
marker	O
(	O
Figure	O
1	O
)	O
.	O

Consistent	O
with	O
our	O
previous	O
results	O
[	O
8	O
]	O
,	O
partial	O
mislocalization	O
of	O
the	O
p	B-VARIANT
.	I-VARIANT
P69H	I-VARIANT
ILDR1	B-GENE
mutant	O
in	O
this	O
study	O
led	O
to	O
the	O
incomplete	O
recruitment	O
of	O
tricellulin	B-GENE
to	O
TCs	O
in	O
LSR	B-GENE
knockdown	O
epithelial	O
cells	O
.	O

Products	O
were	O
separated	O
electrophoretically	O
and	O
the	O
signals	O
captured	O
by	O
a	O
CCD	O
camera	O
.	O

DNA	O
was	O
extracted	O
by	O
a	O
standard	O
protocol	O
using	O
phenol	O
-	O
chloroform	O
.	O

Therefore	O
,	O
this	O
variant	O
is	O
characterized	O
by	O
complete	O
penetrance	O
and	O
significantly	O
variable	O
expressivity	O
.	O

With	O
the	O
progresses	O
on	O
next	O
-	O
generation	O
sequencing	O
(	O
NGS	O
)	O
and	O
bioinformatics	O
,	O
it	O
has	O
been	O
demonstrated	O
to	O
have	O
higher	O
efficiency	O
but	O
lower	O
cost	O
comparing	O
with	O
previous	O
methods	O
[	O
4	O
]	O
.	O

There	O
is	O
segmental	B-DISEASE
glomerular	I-DISEASE
sclerosis	I-DISEASE
in	O
the	O
hilar	O
region	O
with	O
moderate	O
interstitial	B-DISEASE
fibrosis	I-DISEASE
,	O
clusters	O
of	O
foam	O
cells	O
in	O
the	O
interstitium	O
,	O
and	O
tubular	O
atrophy	O
.	O

It	O
involves	O
more	O
than	O
100	O
different	O
genes	O
with	O
autosomal	O
dominant	O
(	O
DFNA	B-DISEASE
)	O
,	O
autosomal	O
recessive	O
(	O
DFNB	B-DISEASE
)	O
,	O
X	O
-	O
linked	O
(	O
DFN	B-DISEASE
)	O
,	O
and	O
maternal	O
inheritance	O
[	O
4	O
]	O
;	O
autosomal	O
recessive	O
is	O
the	O
most	O
common	O
.	O

PCR	O
reactions	O
were	O
performed	O
in	O
a	O
50	O
-	O
mu	O
L	O
volume	O
containing	O
100	O
-	O
500	O
ng	O
DNA	O
,	O
0	O
.	O
2	O
mu	O
M	O
of	O
each	O
forward	O
and	O
reverse	O
primer	O
,	O
200	O
mu	O
M	O
dNTPs	O
,	O
1	O
x	O
PCR	O
buffer	O
(	O
10	O
mM	O
Tris	O
-	O
HCl	O
pH	O
8	O
.	O
3	O
,	O
50	O
mM	O
KCl	O
,	O
2	O
.	O
5	O
mM	O
MgCl	O
2	O
)	O
,	O
and	O
0	O
.	O
5	O
U	O
of	O
Ampli	O
Taq	O
Gold	O
(	O
tm	O
)	O
DNA	O
Polymerase	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Quantitative	O
-	O
PCR	O
and	O
Western	O
blotting	O
showed	O
that	O
OPA1	B-GENE
mRNA	O
and	O
its	O
protein	O
expression	O
have	O
no	O
obvious	O
difference	O
between	O
patient	O
skin	O
fibroblast	O
and	O
control	O
.	O

However	O
,	O
validation	O
of	O
any	O
genotype	O
-	O
phenotype	O
correlation	O
must	O
await	O
detailed	O
functional	O
analysis	O
of	O
mutations	O
on	O
a	O
cellular	O
and	O
molecular	O
level	O
.	O

All	O
experiments	O
were	O
then	O
set	O
up	O
using	O
the	O
robot	O
BioMEK	O
2000	O
(	O
Beckman	O
)	O
.	O

S2	O
B	O
)	O
.	O

Four	O
possible	O
constellations	O
of	O
the	O
5	O
'	O
polymorphisms	O
were	O
identified	O
in	O
the	O
patient	O
collective	O
.	O

Yet	O
,	O
we	O
formulated	O
several	O
hypothesis	O
to	O
account	O
for	O
the	O
intra	O
-	O
familial	O
phenotypic	O
variability	O
:	O
i	O
)	O
since	O
different	O
EDNRB	B-GENE
transcripts	O
are	O
expressed	O
concomitantly	O
(	O
at	O
least	O
in	O
the	O
still	O
developing	O
newborn	O
'	O
s	O
gut	O
[	O
31	O
]	O
the	O
phenotype	O
manifestation	O
could	O
depend	O
on	O
the	O
relative	O
expression	O
amounts	O
of	O
the	O
mutated	O
EDNRB	B-GENE
isoforms	O
(	O
benign	O
/	O
damaging	O
)	O
at	O
a	O
given	O
time	O
point	O
during	O
the	O
embryonic	O
stages	O
,	O
provided	O
that	O
all	O
isoforms	O
play	O
a	O
similar	O
role	O
on	O
neural	O
crest	O
cell	O
development	O
-	O
enteric	O
neurons	O
/	O
skin	O
melanocytes	O
-	O
;	O
ii	O
)	O
in	O
carriers	O
,	O
in	O
spite	O
of	O
having	O
the	O
initiation	O
codon	O
(	O
M1V	B-VARIANT
)	O
mutated	O
in	O
isoform	O
1	O
and	O
2	O
,	O
the	O
protein	O
is	O
translated	O
using	O
an	O
alternative	O
translation	O
start	O
site	O
and	O
the	O
resulting	O
protein	O
,	O
although	O
shorter	O
,	O
still	O
is	O
functional	O
[	O
32	O
]	O
;	O
iii	O
)	O
while	O
the	O
amount	O
of	O
protein	O
expressed	O
from	O
the	O
wild	O
-	O
type	O
EDNRB	B-GENE
allele	O
is	O
sufficient	O
to	O
maintain	O
proper	O
signalling	O
in	O
healthy	O
carriers	O
,	O
it	O
does	O
not	O
reach	O
the	O
necessary	O
threshold	O
for	O
signalling	O
in	O
affected	O
individuals	O
;	O
and	O
/	O
or	O
iv	O
)	O
differential	O
allelic	O
expression	O
(	O
or	O
imprinting	O
)	O
between	O
carriers	O
and	O
affected	O
individuals	O
exists	O
.	O

We	O
have	O
found	O
MME	B-DISEASE
in	O
the	O
INL	O
of	O
the	O
ADOA	B-DISEASE
patients	O
,	O
but	O
it	O
is	O
important	O
to	O
note	O
that	O
only	O
in	O
two	O
patients	O
.	O

A	O
schematic	O
diagram	O
of	O
the	O
human	O
otoferlin	O
structure	O
with	O
all	O
pathogenic	O
mutations	O
of	O
this	O
work	O
illustrated	O
(	O
shown	O
by	O
arrows	O
)	O
[	O
9	O
,	O
20	O
]	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
WS	O
-	O
j	O
LP	O
-	O
F	O
WJ	O
-	O
l	O
.	O

In	O
US	O
population	O
,	O
mutations	O
in	O
SLC26A4	B-GENE
account	O
for	O
about	O
one	O
third	O
of	O
the	O
nonsyndromic	O
EVA	B-DISEASE
patients	O
[	O
15	O
]	O
.	O

(	O
g	O
)	O
Analysis	O
of	O
dCib2	O
RNAi	O
retinas	O
by	O
water	O
immersion	O
(	O
top	O
two	O
panel	O
sets	O
)	O
or	O
thin	O
plastic	O
sections	O
(	O
bottom	O
panel	O
set	O
)	O
reveal	O
little	O
to	O
no	O
differences	O
from	O
controls	O
when	O
raised	O
in	O
12hr	O
:	O
12hr	O
light	O
:	O
dark	O
cycles	O
(	O
not	O
shown	O
)	O
or	O
in	O
complete	O
darkness	O
.	O

DNA	O
samples	O
from	O
individuals	O
III	O
:	O
3	O
,	O
IV	O
:	O
2	O
,	O
and	O
IV	O
:	O
3	O
were	O
subjected	O
to	O
WES	O
(	O
Figure	O
1	O
A	O
)	O
.	O

In	O
ten	O
of	O
the	O
11	O
families	O
,	O
the	O
original	O
clinical	O
diagnosis	O
/	O
description	O
was	O
clarified	O
after	O
WES	O
analysis	O
(	O
Table	O
1	O
)	O
.	O

Silver	O
,	O
and	O
M	O
.	O

C	O
:	O
35	O
-	O
year	O
-	O
old	O
USH3	B-DISEASE
patient	O
with	O
homozygous	O
p	B-VARIANT
.	I-VARIANT
A123D	I-VARIANT
mutation	O
and	O
VA	O
of	O
20	O
/	O
25	O
.	O

We	O
also	O
thank	O
Maria	O
Vurchio	O
(	O
CNR	O
-	O
ITB	O
)	O
for	O
technical	O
and	O
administrative	O
support	O
.	O
Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

3	O
The	O
list	O
of	O
causative	O
genes	O
includes	O
OTOF	B-GENE
,	O
PJVK	B-GENE
,	O
DIAPH3	B-GENE
and	O
mtDNA	B-GENE
(	O
m	B-VARIANT
.	I-VARIANT
1095T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
)	O
in	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
ANSD	I-DISEASE
and	O
PMP22	B-GENE
,	O
MPZ	B-GENE
,	O
TMEM126A	B-GENE
and	O
DDDP	B-GENE
in	O
syndromic	B-DISEASE
ANSD	I-DISEASE
,	O
although	O
other	O
genetic	O
aetiologies	O
await	O
discovery	O
.	O

While	O
historically	O
a	O
COL4A5	B-GENE
mutation	O
has	O
been	O
identified	O
in	O
90	O
%	O
of	O
XLAS	B-DISEASE
[	O
4	O
]	O
,	O
in	O
suspected	O
autosomal	O
disease	O
the	O
detection	O
rate	O
of	O
detection	O
of	O
COL4A3	B-GENE
/	O
COL4A4	B-GENE
mutations	O
has	O
been	O
reported	O
as	O
low	O
as	O
20	O
%	O
[	O
5	O
]	O
.	O

The	O
two	O
patients	O
from	O
family	O
USH01	O
met	O
the	O
diagnostic	O
criteria	O
for	O
USH	B-DISEASE
type	I-DISEASE
2	I-DISEASE
.	O

There	O
was	O
no	O
significant	O
family	O
history	O
(	O
Supplementary	O
Note	O
)	O
.	O

CNVs	O
were	O
found	O
in	O
4	O
.	O
8	O
%	O
of	O
42	O
patients	O
with	O
QTc	O
duration	O
>	O
=	O
480	O
ms	O
and	O
/	O
or	O
a	O
Schwartz	O
score	O
>	O
=	O
4	O
who	O
were	O
negative	O
for	O
mutations	O
in	O
12	O
of	O
the	O
LQTS	O
-	O
associated	O
genes	O
[	O
40	O
]	O
.	O

Bidirectional	O
sequencing	O
was	O
performed	O
using	O
BigDye	O
v3	O
.	O
1	O
chemistry	O
and	O
ABI3130	O
(	O
AppliedBiosystems	O
)	O
.	O

In	O
aggregate	O
,	O
our	O
data	O
show	O
that	O
HOMER2	B-GENE
is	O
required	O
for	O
normal	O
hearing	O
.	O

12	O
Variant	O
annotation	O
was	O
done	O
with	O
SNPeff	O
and	O
depth	O
of	O
coverage	O
was	O
computed	O
using	O
BEDtools	O
coveragebed	O
13	O
and	O
in	O
-	O
house	O
perl	O
and	O
R	O
scripts	O
,	O
over	O
all	O
coding	O
exons	O
from	O
Ensembl	O
release	O
66	O
.	O

This	O
image	O
is	O
F	O
-	O
actin	O
-	O
activated	O
ATPase	O
activity	O
of	O
WT	O
and	O
p	B-VARIANT
.	I-VARIANT
R205Q	I-VARIANT
.	O

Run	O
-	O
to	O
-	O
run	O
variations	O
in	O
the	O
error	O
occurrence	O
(	O
>	O
1	O
%	O
frequency	O
)	O
a	O
The	O
number	O
of	O
positions	O
where	O
the	O
error	O
rates	O
in	O
each	O
category	O
were	O
commonly	O
>	O
1	O
%	O
for	O
both	O
strands	O
in	O
two	O
independent	O
runs	O
.	O

We	O
could	O
thus	O
confirm	O
that	O
the	O
second	O
most	O
common	O
PEX1	B-GENE
allele	O
,	O
2097_2098insT	B-VARIANT
,	O
is	O
coupled	O
to	O
the	O
c	B-VARIANT
.	I-VARIANT
-	I-VARIANT
137	I-VARIANT
T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
c	B-VARIANT
.	I-VARIANT
-	I-VARIANT
53	I-VARIANT
C	I-VARIANT
>	I-VARIANT
G	I-VARIANT
constellation	O
and	O
probably	O
evolved	O
on	O
the	O
basis	O
of	O
this	O
allele	O
(	O
Table	O
2	O
)	O
.	O

This	O
hypothesis	O
is	O
supported	O
by	O
the	O
observation	O
that	O
Clrn1	B-GENE
knockout	O
mouse	O
F	O
-	O
actin	O
-	O
rich	O
hair	O
cell	O
stereocilia	O
are	O
disorganized	O
[	O
28	O
,	O
30	O
]	O
.	O

Sample	O
-	O
level	O
quality	O
control	O
was	O
performed	O
with	O
PLINK	O
(	O
11	O
)	O
and	O
included	O
checks	O
for	O
sample	O
contamination	O
and	O
verification	O
of	O
pedigree	O
structure	O
and	O
sex	O
.	O

Flow	O
cytometry	O
showed	O
normal	O
expression	O
of	O
the	O
glycoproteins	O
Ib	O
-	O
IX	O
-	O
V	O
,	O
IIb	O
-	O
IIIa	O
,	O
and	O
Ia	O
-	O
IIa	O
on	O
the	O
platelet	O
surface	O
;	O
in	O
vitro	O
aggregation	O
studies	O
were	O
not	O
performed	O
because	O
of	O
the	O
low	O
platelet	O
count	O
.	O

This	O
novel	O
mutation	O
is	O
expected	O
to	O
lead	O
to	O
a	O
frameshift	O
and	O
premature	O
termination	O
of	O
translation	O
after	O
insertion	O
of	O
four	O
irrelevant	O
amino	O
acids	O
,	O
starting	O
at	O
position	O
769	O
of	O
the	O
myosin	B-GENE
VIIA	I-GENE
protein	O
(	O
p	O
.	O
N769	O
fs	O
X4	O
)	O
.	O

Each	O
molecule	O
of	O
CNGA1	B-GENE
protein	O
has	O
at	O
least	O
three	O
functional	O
domains	O
as	O
described	O
in	O
the	O
UniProtKB	O
(	O
acc	O
.	O

Our	O
determination	O
of	O
a	O
variant	O
as	O
pathogenic	O
,	O
is	O
therefore	O
stringent	O
.	O

Given	O
these	O
in	O
vivo	O
findings	O
,	O
it	O
is	O
also	O
possible	O
that	O
the	O
mutation	O
within	O
ILDR1	B-GENE
may	O
lead	O
to	O
deafness	B-DISEASE
via	O
a	O
different	O
mechanism	O
unrelated	O
to	O
failed	O
tricellulin	B-GENE
recruitment	O
at	O
TCs	O
,	O
or	O
through	O
a	O
combination	O
of	O
these	O
mechanisms	O
.	O

Both	O
mutations	O
affect	O
the	O
highly	O
preserved	O
residues	O
(	O
Figure	O
2	O
)	O
.	O

The	O
high	O
density	O
8x60K	O
array	O
covers	O
known	O
STGD	B-DISEASE
genes	O
and	O
genes	O
associated	O
with	O
age	B-DISEASE
-	I-DISEASE
related	I-DISEASE
macular	I-DISEASE
dystrophy	I-DISEASE
.	O

To	O
determine	O
the	O
severity	O
of	O
HI	B-DISEASE
,	O
air	O
conduction	O
testing	O
was	O
performed	O
using	O
a	O
portable	O
audiometer	O
.	O

On	O
this	O
basis	O
,	O
TRIC	B-GENE
,	O
LHFPL5	B-GENE
,	O
and	O
TMC1	B-GENE
were	O
selected	O
to	O
be	O
directly	O
sequenced	O
from	O
the	O
genomic	O
DNA	O
of	O
all	O
members	O
in	O
the	O
particular	O
family	O
that	O
affected	O
patients	O
were	O
homozygous	O
for	O
the	O
interval	O
containing	O
the	O
applicable	O
gene	O
.	O

This	O
mutation	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
aminoglycoside	O
injection	O
and	O
found	O
in	O
3	O
%	O
of	O
the	O
patients	O
who	O
visited	O
the	O
outpatient	O
clinic	O
[	O
17	O
]	O
,	O
[	O
18	O
]	O
.	O

Evenness	O
of	O
coverage	O
was	O
calculated	O
for	O
all	O
samples	O
according	O
to	O
Mokry	O
et	O
al	O
.	O

For	O
cryosections	O
,	O
ears	O
were	O
fixed	O
,	O
equilibrated	O
in	O
a	O
graded	O
series	O
of	O
sucrose	O
in	O
PBS	O
,	O
transferred	O
to	O
a	O
2	O
:	O
1	O
mixture	O
of	O
20	O
%	O
Sucrose	O
in	O
PBS	O
:	O
OCT	O
Medium	O
(	O
Saukra	O
)	O
,	O
frozen	O
over	O
dry	O
ice	O
and	O
ethanol	O
,	O
and	O
sectioned	O
at	O
12	O
mu	O
m	O
.	O

Mutation	O
screening	O
was	O
performed	O
by	O
direct	O
DNA	O
sequence	O
analysis	O
.	O

Several	O
members	O
of	O
the	O
ELMO	O
family	O
have	O
been	O
shown	O
to	O
regulate	O
a	O
subset	O
of	O
GTPases	O
within	O
the	O
Ras	O
superfamily	O
.	O

Regina	O
Rodrigo	O
has	O
a	O
Contrato	O
-	O
Investigador	O
SNS	O
Miguel	O
Servet	O
(	O
CP09	O
/	O
118	O
)	O
from	O
Instituto	O
de	O
Salud	O
Carlos	O
III	O
,	O
Ministerio	O
de	O
Ciencia	O
e	O
Innovaci	O
o	O
n	O
.	O

Porin	O
is	O
used	O
as	O
a	O
loading	O
control	O
.	O

Among	O
160	O
patients	O
,	O
8	O
(	O
5	O
.	O
0	O
%	O
)	O
had	O
this	O
mutation	O
,	O
confirming	O
it	O
is	O
indeed	O
a	O
recurrent	O
mutation	O
in	O
Japanese	O
.	O

One	O
USH1	B-DISEASE
and	O
two	O
USH2	B-DISEASE
patients	O
were	O
heterozygotes	O
for	O
mutations	O
in	O
two	O
or	O
three	O
USH	B-DISEASE
genes	O
,	O
suggesting	O
a	O
possible	O
digenic	O
/	O
oligogenic	O
inheritance	O
of	O
the	O
syndrome	O
.	O

The	O
parents	O
were	O
not	O
relatives	O
,	O
originated	O
from	O
distant	O
geographic	O
areas	O
of	O
the	O
country	O
,	O
and	O
each	O
of	O
them	O
was	O
a	O
heterozygous	O
carrier	O
for	O
a	O
different	O
WFS1	B-GENE
mutation	O
.	O

Denatured	O
samples	O
were	O
electrophoresed	O
on	O
a	O
16	O
%	O
nondenaturing	O
polyacrylamide	O
gel	O
,	O
with	O
an	O
acrylamide	O
:	O
bisacrylamide	O
ratio	O
of	O
49	O
:	O
1	O
,	O
for	O
12	O
-	O
16	O
h	O
at	O
300	O
v	O
and	O
4	O
deg	O
C	O
,	O
before	O
gels	O
were	O
silver	O
-	O
stained	O
and	O
analyzed	O
.	O

We	O
also	O
excluded	O
another	O
responsible	O
gene	O
(	O
PJVK	B-GENE
)	O
,	O
because	O
no	O
mutations	O
in	O
this	O
gene	O
were	O
found	O
.	O

Subject	O
'	O
s	O
identification	O
numbers	O
shown	O
in	O
this	O
report	O
are	O
based	O
on	O
their	O
numbers	O
in	O
the	O
registry	O
and	O
are	O
therefore	O
not	O
necessarily	O
consecutive	O
.	O

Importantly	O
,	O
such	O
mechanism	O
has	O
already	O
been	O
described	O
in	O
HSCR	B-DISEASE
[	O
17	O
]	O
,	O
[	O
18	O
]	O
.	O

She	O
also	O
underwent	O
standard	O
endocrinology	O
examination	O
and	O
found	O
to	O
have	O
normal	O
thyroid	O
hormone	O
.	O

GeneMapper	O
v4	O
.	O
0	O
software	O
(	O
Applied	O
Biosystems	O
,	O
Forster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
was	O
used	O
to	O
analyze	O
genotypes	O
for	O
each	O
marker	O
.	O

2A	O
)	O
,	O
result	O
in	O
an	O
isoleucine	O
to	O
lysine	O
substitution	O
(	O
p	B-VARIANT
.	I-VARIANT
I411K	I-VARIANT
)	O
.	O

In	O
order	O
to	O
maintain	O
the	O
accuracy	O
of	O
NGS	O
while	O
reducing	O
cost	O
,	O
capture	O
protocols	O
have	O
been	O
developed	O
that	O
enrich	O
for	O
DNA	O
of	O
interest	O
,	O
allowing	O
targeted	O
sequencing	O
.	O

In	O
addition	O
,	O
we	O
found	O
three	O
polymorphic	O
changes	O
in	O
both	O
heterozygosis	O
or	O
homozygosis	O
:	O
(	O
c	B-VARIANT
.	I-VARIANT
5	I-VARIANT
T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
;	O
p	B-VARIANT
.	I-VARIANT
Val2Ala	I-VARIANT
)	O
in	O
exon	O
3	O
in	O
7	O
patients	O
(	O
14	O
.	O
1	O
,	O
15	O
.	O
1	O
,	O
16	O
.	O
2	O
,	O
17	O
.	O
1	O
,	O
18	O
.	O
1	O
,	O
19	O
.	O
1	O
and	O
20	O
.	O
1	O
)	O
,	O
c	B-VARIANT
.	I-VARIANT
1662C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
;	O
p	B-VARIANT
.	I-VARIANT
Phe554Phe	I-VARIANT
in	O
exon	O
16	O
in	O
three	O
patients	O
(	O
16	O
.	O
1	O
,	O
16	O
.	O
2	O
and	O
19	O
.	O
1	O
)	O
and	O
c	B-VARIANT
.	I-VARIANT
1812	I-VARIANT
T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
;	O
p	B-VARIANT
.	I-VARIANT
His604His	I-VARIANT
in	O
exon	O
17	O
in	O
8	O
patients	O
(	O
14	O
.	O
1	O
,	O
15	O
.	O
1	O
,	O
16	O
.	O
1	O
,	O
16	O
.	O
2	O
,	O
17	O
.	O
1	O
,	O
18	O
.	O
1	O
,	O
19	O
.	O
1	O
and	O
20	O
.	O
1	O
)	O
.	O

Fortunately	O
,	O
the	O
mother	O
demonstrated	O
a	O
good	O
cardio	O
-	O
respiratory	O
response	O
despite	O
her	O
severe	O
dwarfism	B-DISEASE
and	O
skeletal	B-DISEASE
abnormalities	I-DISEASE
.	O

2011	O
;	O
Garcia	O
-	O
Garcia	O
et	O
al	O
.	O

According	O
to	O
previous	O
reports	O
,	O
the	O
overall	O
prevalence	O
of	O
USH	B-DISEASE
ranges	O
from	O
3	O
.	O
2	O
per	O
100	O
,	O
000	O
to	O
6	O
.	O
2	O
per	O
100	O
,	O
000	O
individuals	O
[	O
2	O
]	O
.	O

Transient	O
expression	O
in	O
COS7	O
cells	O
of	O
WT	O
-	O
GATA3	B-GENE
cDNA	O
stimulated	O
transcriptional	O
activity	O
of	O
the	O
GATA	O
-	O
response	O
element	O
-	O
containing	O
reporter	O
gene	O
estimated	O
using	O
luciferase	O
activity	O
.	O

Diabetologists	O
,	O
as	O
well	O
as	O
adult	O
and	O
pediatric	O
endocrinologists	O
,	O
pediatricians	O
and	O
ophthalmologists	O
,	O
are	O
likely	O
to	O
have	O
the	O
first	O
opportunity	O
to	O
recognize	O
WFS	B-DISEASE
after	O
the	O
diagnosis	O
of	O
an	O
initial	O
manifestation	O
,	O
and	O
school	O
health	O
screening	O
programs	O
may	O
also	O
provide	O
an	O
opportunity	O
to	O
identify	O
vision	B-DISEASE
defects	I-DISEASE
,	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
and	O
abnormal	O
urinalysis	O
results	O
.	O

-	I-VARIANT
22	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
/	O
c	B-VARIANT
.	I-VARIANT
35delG	I-VARIANT
heterozygotes	O
of	O
family	O
S1599	O
.	O

To	O
date	O
over	O
80	O
genes	O
have	O
been	O
causally	O
implicated	O
in	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
NSHL	B-DISEASE
;	O
Hereditary	B-DISEASE
Hearing	I-DISEASE
Loss	I-DISEASE
Homepage	O
)	O
.	O

Figure	O
4	O
shows	O
the	O
normal	O
and	O
mutated	O
sequences	O
.	O

Expanded	O
screening	O
in	O
large	O
cohorts	O
revealed	O
that	O
mutations	O
in	O
three	O
genes	O
,	O
GJB2	B-GENE
,	O
SLC26A4	B-GENE
and	O
MT	B-GENE
-	I-GENE
RNR1	I-GENE
,	O
were	O
commonly	O
found	O
in	O
deaf	B-DISEASE
patients	O
.	O

(	O
D	O
)	O
Dimeric	O
representation	O
of	O
Entamoeba	O
histolytica	O
AsnRS	O
(	O
PDB	O
:	O
3M4Q	O
)	O
using	O
PyMol	O
molecular	O
graphics	O
system	O
.	O

The	O
sequences	O
were	O
mapped	O
and	O
quality	O
-	O
checked	O
with	O
the	O
programs	O
BWA	O
,	O
Novoalign	O
,	O
Picard	O
,	O
and	O
GATK	O
using	O
the	O
human	O
reference	O
sequence	O
hg19	O
/	O
GRCh37	O
.	O

Mice	O
with	O
missense	O
mutation	O
in	O
the	O
ZP	O
domain	O
of	O
Tecta	B-GENE
(	O
Tecta	B-GENE
Y1870C	B-VARIANT
/	O
+	O
,	O
Tecta	B-GENE
L1820F	B-VARIANT
,	O
G18724D	B-VARIANT
/	O
+	O
and	O
Tecta	B-GENE
C1837G	B-VARIANT
/	O
+	O
)	O
display	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
mild	O
-	O
frequency	O
range	O
,	O
phenocopying	O
the	O
clinical	O
observation	O
with	O
affected	O
patients	O
[	O
17	O
,	O
19	O
]	O
.	O

Two	O
(	O
A	O
and	O
B	O
)	O
of	O
11	O
families	O
had	O
causative	O
MYO15A	B-GENE
mutation	O
[	O
18	O
]	O
.	O

Detailed	O
ophthalmologic	O
examinations	O
and	O
optical	O
coherence	O
tomography	O
were	O
performed	O
in	O
the	O
patient	O
and	O
her	O
family	O
members	O
.	O

Italics	O
indicate	O
age	O
in	O
years	O
.	O

7	O
B	O
-	O
scan	O
of	O
individual	O
III	O
:	O
1	O
of	O
family	O
PKDF740	O
revealed	O
severe	O
microphthalmia	B-DISEASE
with	O
retinal	B-DISEASE
dysplasia	I-DISEASE
and	O
disorganization	B-DISEASE
of	I-DISEASE
intraocular	I-DISEASE
contents	I-DISEASE
in	O
the	O
right	O
eye	O
.	O

F	O
:	O
Dystopia	B-DISEASE
canthorum	I-DISEASE
(	O
W	O
index	O
:	O
2	O
.	O
19	O
)	O
,	O
brilliant	O
blue	O
iris	O
,	O
and	O
broad	O
nasal	O
root	O
were	O
present	O
in	O
a	O
10	O
-	O
year	O
old	O
girl	O
(	O
IV	O
:	O
5	O
)	O
.	O

The	O
ages	O
at	O
onset	O
of	O
diabetes	B-DISEASE
mellitus	I-DISEASE
and	O
/	O
or	O
optic	B-DISEASE
atrophy	I-DISEASE
were	O
not	O
associated	O
with	O
the	O
presence	O
or	O
the	O
absence	O
of	O
WFS1	B-GENE
mutations	O
in	O
our	O
patients	O
(	O
Table	O
3	O
)	O
.	O

The	O
identified	O
mutation	O
is	O
therefore	O
likely	O
to	O
have	O
a	O
structural	O
role	O
and	O
destabilize	O
the	O
protein	O
fold	O
.	O

Algorithm	O
followed	O
for	O
the	O
genetic	O
analysis	O
.	O

All	O
subjects	O
were	O
screened	O
first	O
for	O
mutations	O
of	O
GJB2	B-GENE
and	O
SLC26A4	B-GENE
,	O
which	O
have	O
a	O
predominant	O
presence	O
in	O
genetic	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

The	O
m	B-VARIANT
.	I-VARIANT
1555A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
mutation	O
in	O
the	O
mitochondrial	B-GENE
12SrRNA	I-GENE
gene	O
,	O
which	O
was	O
found	O
in	O
5	O
4	O
subjects	O
,	O
was	O
mainly	O
found	O
in	O
those	O
with	O
older	O
onset	O
age	O
.	O

Non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	I-DISEASE
NSHL	B-DISEASE
)	I-DISEASE
mimics	I-DISEASE
are	O
syndromic	B-DISEASE
forms	I-DISEASE
of	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
that	O
present	O
as	O
NSHL	B-DISEASE
early	O
in	O
life	O
with	O
syndromic	O
features	O
developing	O
later	O
.	O

Subjects	O
with	O
auditory	B-DISEASE
neuropathy	I-DISEASE
were	O
tested	O
for	O
OTOF	B-GENE
mutations	O
,	O
which	O
are	O
associated	O
with	O
auditory	B-DISEASE
neuropathy	I-DISEASE
[	O
12	O
]	O
,	O
and	O
subjects	O
with	O
OTOF	B-GENE
mutations	O
were	O
excluded	O
.	O

Western	O
blotting	O
analysis	O
of	O
protein	O
expression	O
extracted	O
from	O
the	O
patient	O
and	O
control	O
fibroblasts	O
showed	O
the	O
same	O
level	O
of	O
OPA1	B-GENE
protein	O
expression	O
(	O
Fig	O
.	O

The	O
clinical	O
diagnosis	O
of	O
these	O
disorders	O
is	O
complicated	O
by	O
extensive	O
phenotypic	O
and	O
genetic	O
heterogeneity	O
,	O
with	O
at	O
least	O
450	O
disorders	O
associated	O
with	O
more	O
than	O
300	O
genes	O
.	O

1	O
;	O
Table	O
S3	O
)	O
.	O

The	O
segregation	O
analysis	O
confirmed	O
that	O
the	O
deletion	O
and	O
the	O
nonsense	O
mutation	O
were	O
in	O
cis	O
and	O
the	O
missense	O
variant	O
was	O
in	O
the	O
other	O
allele	O
and	O
cosegregated	O
with	O
the	O
disease	O
.	O

2012CB316504	O
and	O
2012CB316503	O
to	O
XG	O
Zhang	O
and	O
MQ	O
Zhang	O
)	O
,	O
and	O
Hong	O
Kong	O
RGC	O
General	O
Research	O
Fund	O
(	O
463811	O
)	O
to	O
KW	O
Choy	O
.	O

The	O
appearance	O
of	O
the	O
fundus	O
in	O
two	O
patients	O
with	O
non	O
-	O
syndromic	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
(	O
RP	B-DISEASE
)	O
or	O
Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
II	I-DISEASE
(	O
USH2	B-DISEASE
)	O
.	O

DNA	O
from	O
blood	O
lymphocytes	O
was	O
isolated	O
from	O
the	O
12	O
subjects	O
,	O
while	O
DNA	O
from	O
III	O
-	O
2	O
was	O
obtained	O
with	O
a	O
buccal	O
swab	O
.	O

However	O
,	O
two	O
probands	O
with	O
an	O
FGFR1	B-GENE
defect	O
did	O
also	O
harbor	O
novel	O
variants	O
in	O
NELF	B-GENE
(	O
G94S	B-VARIANT
and	O
T505M	B-VARIANT
)	O
,	O
but	O
given	O
that	O
the	O
incidence	O
of	O
KS	B-DISEASE
in	O
Finland	O
was	O
1	O
in	O
48	O
000	O
and	O
these	O
variants	O
were	O
also	O
present	O
in	O
6	O
%	O
and	O
1	O
%	O
of	O
the	O
controls	O
,	O
it	O
is	O
apparent	O
that	O
these	O
variants	O
are	O
not	O
causing	O
congenital	O
HH	B-DISEASE
.	O

G	O
,	O
H	O
:	O
OCT	O
of	O
RE	O
and	O
LE	O
,	O
respectively	O
,	O
of	O
individual	O
II	O
:	O
3	O
demonstrates	O
normal	O
retinal	O
thickness	O
.	O

After	O
this	O
,	O
validation	O
of	O
the	O
pooled	O
libraries	O
was	O
performed	O
by	O
quantifying	O
and	O
verifying	O
the	O
size	O
of	O
the	O
enriched	O
fragments	O
.	O

c	B-VARIANT
.	I-VARIANT
5856G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
K1952K	I-VARIANT
,	O
MYO7A	B-GENE
)	O
.	O

Table	O
3	O
Major	O
clinical	O
features	O
observed	O
in	O
DOA	O
+	O
patients	O
CI	O
=	O
confidence	O
interval	O
.	O

The	O
amino	O
acid	O
alignment	O
of	O
the	O
13	O
human	O
myosin	O
heavy	O
chains	O
of	O
class	O
II	O
showed	O
conservation	O
of	O
valine	O
34	O
in	O
all	O
but	O
one	O
(	O
MYH10	B-GENE
)	O
protein	O
(	O
Fig	O
.	O

The	O
mtDNA	B-GENE
12S	I-GENE
rRNA	I-GENE
1555A	B-VARIANT
>	I-VARIANT
G	I-VARIANT
homoplasmic	O
mutation	O
.	O

All	O
primers	O
were	O
checked	O
for	O
absence	O
of	O
SNPs	O
to	O
avoid	O
problems	O
with	O
allelic	O
dropout	O
.	O

Clarin	O
1	O
is	O
a	O
four	O
-	O
transmembrane	O
protein	O
expressed	O
in	O
the	O
hair	O
cells	O
of	O
the	O
organ	O
of	O
Corti	O
and	O
in	O
the	O
neural	O
retina	O
[	O
9	O
,	O
10	O
]	O
.	O

The	O
22	O
,	O
591	O
variants	O
identified	O
in	O
the	O
patient	O
were	O
annotated	O
with	O
SeattleSeq	O
SNP	O
annotation	O
(	O
http	O
:	O
/	O
/	O
snp	O
.	O
gs	O
.	O
washington	O
.	O
edu	O
/	O
SeattleSeqAnnotation131	O
/	O
)	O
.	O

Of	O
the	O
12	O
families	O
,	O
three	O
had	O
a	O
family	O
history	O
of	O
optic	B-DISEASE
neuropathy	I-DISEASE
while	O
nine	O
were	O
sporadic	O
cases	O
.	O

MNCVs	O
of	O
the	O
median	O
,	O
ulnar	O
,	O
peroneal	O
,	O
and	O
tibial	O
nerves	O
were	O
all	O
decreased	O
.	O

Clinical	O
studies	O
of	O
USH3	B-DISEASE
patients	O
have	O
failed	O
to	O
determine	O
any	O
clear	O
-	O
cut	O
genotype	O
-	O
phenotype	O
correlations	O
while	O
broad	O
intrafamilial	O
and	O
mutational	O
variety	O
in	O
the	O
onset	O
,	O
progression	O
,	O
and	O
severity	O
of	O
symptoms	O
are	O
reported	O
among	O
the	O
largest	O
patient	O
groups	O
,	O
Ashkenazi	O
Jews	O
[	O
11	O
,	O
32	O
]	O
,	O
and	O
Finns	O
[	O
7	O
,	O
9	O
,	O
10	O
]	O
.	O

In	O
conclusion	O
,	O
we	O
identified	O
3	O
novel	O
possible	O
pathogenic	O
variants	O
and	O
1	O
known	O
probable	O
pathogenic	O
mutation	O
of	O
the	O
OTOF	B-GENE
gene	O
in	O
76	O
Chinese	O
ANSD	B-DISEASE
patients	O
.	O

Investigation	O
of	O
its	O
effects	O
on	O
GJB2	B-GENE
expression	O
provided	O
a	O
likely	O
explanation	O
of	O
the	O
molecular	O
mechanism	O
underlying	O
this	O
mild	O
DFNB1	B-GENE
phenotype	O
.	O

OPA1	B-GENE
positive	O
families	O
included	O
in	O
this	O
study	O
were	O
identified	O
from	O
the	O
following	O
groups	O
.	O

Whole	O
-	O
cell	O
patch	O
clamps	O
were	O
recorded	O
with	O
an	O
EPC	O
-	O
10	O
patch	O
clamp	O
amplifier	O
(	O
HEKA	O
Electronik	O
,	O
Lambrecht	O
,	O
Germany	O
)	O
.	O

There	O
is	O
growing	O
evidence	O
suggesting	O
that	O
these	O
proteins	O
form	O
a	O
network	O
,	O
which	O
is	O
critical	O
for	O
the	O
development	O
and	O
maintenance	O
of	O
the	O
sensorineural	O
cells	O
in	O
the	O
inner	O
ear	O
and	O
the	O
retina	O
[	O
3	O
,	O
4	O
,	O
24	O
-	O
28	O
]	O
.	O

The	O
chromatograms	O
were	O
read	O
using	O
SeqMan	O
software	O
(	O
DNAStar	O
;	O
Madison	O
,	O
WI	O
)	O
.	O

The	O
disease	O
symptoms	O
of	O
his	O
younger	O
brother	O
were	O
a	O
bit	O
severer	O
.	O

Targeted	O
assays	O
for	O
gene	O
panels	O
ranging	O
from	O
two	O
to	O
105	O
genes	O
have	O
been	O
developed	O
for	O
polycystic	B-DISEASE
kidney	I-DISEASE
disease	I-DISEASE
[	O
5	O
]	O
,	O
Bardet	B-DISEASE
-	I-DISEASE
Biedl	I-DISEASE
/	I-DISEASE
Alstr	I-DISEASE
o	I-DISEASE
m	I-DISEASE
syndrome	I-DISEASE
[	O
6	O
]	O
and	O
retinal	B-DISEASE
disease	I-DISEASE
[	O
7	O
]	O
.	O

The	O
DFNB88	B-GENE
locus	O
partially	O
overlaps	O
with	O
the	O
dominant	O
deafness	B-DISEASE
locus	O
DFNA43	B-GENE
(	O
Figure	O
1C	O
)	O
[	O
18	O
]	O
.	O

Both	O
variants	O
were	O
detected	O
with	O
a	O
relative	O
frequency	O
of	O
0	O
.	O
5	O
and	O
are	O
predicted	O
to	O
be	O
possibly	O
damaging	O
(	O
Table	O
4	O
)	O
.	O

Waardenburg	B-DISEASE
syndrome	I-DISEASE
(	O
WS	B-DISEASE
)	O
is	O
an	O
auditory	B-DISEASE
-	I-DISEASE
pigmentary	I-DISEASE
syndrome	I-DISEASE
that	O
occurs	O
with	O
a	O
frequency	O
of	O
1	O
in	O
40	O
000	O
.	O

Moreover	O
,	O
such	O
evaluation	O
and	O
genetic	O
consultation	O
to	O
family	O
members	O
may	O
be	O
crucial	O
since	O
more	O
severe	O
phenotypes	O
might	O
be	O
induced	O
by	O
toxic	O
materials	O
,	O
such	O
as	O
alcohol	O
,	O
smoking	O
,	O
and	O
some	O
drugs	O
,	O
as	O
seen	O
in	O
two	O
patients	O
who	O
had	O
taken	O
medicine	O
for	O
tuberculosis	O
in	O
this	O
study	O
.	O

Abbreviations	O
:	O
N	O
represents	O
The	O
Netherlands	O
,	O
S	O
represents	O
Spain	O
,	O
G	O
represents	O
Germany	O
,	O
H	O
represents	O
Hungary	O
,	O
C	O
represents	O
Canada	O
,	O
R	O
represents	O
Russia	O
,	O
T	O
represents	O
Turkey	O
,	O
A	O
represents	O
Arabia	O
)	O
,	O
E	O
represents	O
Egypt	O
,	O
LC	O
represents	O
Low	O
complexity	O
protein	O
domain	O
.	O

Because	O
of	O
the	O
elevated	O
genetic	O
and	O
allelic	O
heterogeneity	O
displayed	O
by	O
hereditary	O
retinal	O
degenerations	O
,	O
molecular	O
diagnoses	O
are	O
in	O
general	O
a	O
rather	O
complicated	O
task	O
.	O

We	O
identified	O
type	O
III	O
repeat	O
region	O
COMP	B-GENE
mutations	O
in	O
27	O
of	O
the	O
28	O
patients	O
with	O
PSACH	B-DISEASE
(	O
>	O
96	O
%	O
;	O
Table	O
1	O
;	O
Fig	O
.	O

1	O
)	O
.	O

KCNE1	B-GENE
-	O
WT	O
(	O
A	O
)	O
and	O
KCNE1	B-GENE
-	O
G60D	B-VARIANT
(	O
B	O
)	O
channel	O
subunits	O
co	O
-	O
expressed	O
with	O
K	B-GENE
V	I-GENE
7	I-GENE
.	I-GENE
1	I-GENE
in	O
CHO	O
cells	O
.	O

Data	O
obtained	O
from	O
the	O
test	O
sample	O
were	O
used	O
to	O
evaluate	O
the	O
quality	O
of	O
raw	O
data	O
.	O

2A	O
)	O
,	O
was	O
a	O
single	O
nucleotide	O
substitution	O
of	O
a	O
cytosine	O
for	O
an	O
adenine	O
at	O
nucleotide	O
position	O
863	O
(	O
c	B-VARIANT
.	I-VARIANT
863C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
in	O
exon	O
11	O
.	O

Figure	O
S2	O
.	O

Screening	O
for	O
GJB2	B-GENE
,	O
SLC26A4	B-GENE
,	O
and	O
12S	B-GENE
rRNA	I-GENE
should	O
be	O
considered	O
the	O
first	O
step	O
in	O
genetic	O
testing	O
of	O
deaf	O
Chinese	O
patients	O
.	O

OPA1	B-GENE
screening	O
was	O
performed	O
on	O
probands	O
with	O
a	O
clinical	O
diagnosis	O
of	O
DOA	B-DISEASE
where	O
previous	O
investigations	O
had	O
excluded	O
other	O
compressive	O
,	O
inflammatory	O
and	O
infiltrative	O
causes	O
for	O
their	O
bilateral	O
optic	B-DISEASE
atrophy	I-DISEASE
.	O

Both	O
parents	O
are	O
heterozygotes	O
and	O
an	O
unaffected	O
sister	O
carries	O
wild	O
type	O
alleles	O
.	O

The	O
longitudinal	O
threshold	O
data	O
of	O
individual	O
E10	O
covered	O
approximately	O
36	O
years	O
(	O
from	O
age	O
9	O
to	O
45	O
years	O
)	O
.	O

Combined	O
direct	O
sequence	O
and	O
invader	O
screening	O
enhanced	O
the	O
diagnostic	O
rate	O
but	O
not	O
the	O
mutation	O
detection	O
rate	O
.	O

Our	O
study	O
provides	O
much	O
-	O
needed	O
information	O
regarding	O
deafness	B-DISEASE
molecular	O
epidemiology	O
of	O
the	O
Yunnan	O
province	O
,	O
providing	O
a	O
rationale	O
for	O
deafness	B-DISEASE
gene	O
diagnosis	O
in	O
Yunnan	O
province	O
.	O

Patient	O
consent	O
:	O
Obtained	O
.	O

1c	O
)	O
and	O
was	O
predicted	O
to	O
be	O
damaging	O
,	O
according	O
to	O
in	O
silico	O
analyses	O
using	O
SIFT	O
,	O
PolyPhen	O
-	O
2	O
,	O
and	O
MUpro	O
(	O
Table	O
2	O
)	O
.	O

c	O
DC	O
:	O
Disease	O
causing	O
.	O

Congenital	B-DISEASE
anomalies	I-DISEASE
of	I-DISEASE
kidney	I-DISEASE
and	I-DISEASE
urinary	I-DISEASE
tract	I-DISEASE
(	O
CAKUT	B-DISEASE
)	O
are	O
observed	O
in	O
3	O
-	O
6	O
per	O
1	O
,	O
000	O
live	O
births	O
and	O
account	O
for	O
40	O
-	O
50	O
%	O
of	O
the	O
etiology	O
of	O
chronic	B-DISEASE
kidney	I-DISEASE
disease	I-DISEASE
(	O
CKD	B-DISEASE
)	O
in	O
children	O
worldwide	O
1	O
,	O
2	O
.	O

PCR	O
amplified	O
fragments	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
TMC1	B-GENE
exon	O
8	O
,	O
along	O
with	O
flanking	O
intronic	O
sequences	O
were	O
generated	O
with	O
the	O
following	O
primers	O
,	O
5	O
'	O
-	O
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCtgggtcctaatgttgactgc	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
GGGGACCACTTTGTACAAGAAAGCTGGGTCggatttagaaaatcaatatcaggg	O
-	O
3	O
'	O
,	O
that	O
contain	O
the	O
attB1	O
and	O
attB2	O
sites	O
necessary	O
for	O
Gateway	O
cloning	O
.	O

MBG	O
and	O
AMD	O
designed	O
the	O
study	O
and	O
chose	O
the	O
patient	O
cohort	O
.	O

The	O
10	O
most	O
frequently	O
reported	O
GSDs	B-DISEASE
were	O
Marfan	B-DISEASE
syndrome	I-DISEASE
,	O
osteogenesis	B-DISEASE
imperfecta	I-DISEASE
,	O
fibrous	B-DISEASE
dysplasia	I-DISEASE
,	O
mucopolysaccharidosis	B-DISEASE
,	O
multiple	B-DISEASE
cartilaginous	I-DISEASE
exostoses	I-DISEASE
,	O
neurofibromatosis	B-DISEASE
type	I-DISEASE
1	I-DISEASE
(	O
NF1	B-DISEASE
)	O
,	O
osteopetrosis	B-DISEASE
,	O
achondroplasia	B-DISEASE
,	O
enchondromatosis	B-DISEASE
(	O
Ollier	B-DISEASE
)	O
,	O
and	O
osteopoikilosis	B-DISEASE
,	O
accounting	O
for	O
76	O
.	O
5	O
%	O
of	O
cases	O
(	O
12	O
,	O
312	O
cases	O
)	O
.	O

In	O
our	O
study	O
,	O
the	O
variant	O
was	O
always	O
associated	O
in	O
cis	O
with	O
a	O
pathogenic	O
variant	O
(	O
a	O
splicing	O
variant	O
in	O
two	O
patients	O
and	O
a	O
nonsense	O
variant	O
in	O
one	O
patient	O
)	O
,	O
and	O
therefore	O
,	O
the	O
variant	O
'	O
s	O
pathogenicity	O
is	O
questionable	O
.	O

Membrane	O
localization	O
of	O
variant	O
KCNQ1	B-GENE
.	O

and	O
T	O
.	O
B	O
.	O
F	O
.	O

All	O
patients	O
were	O
from	O
the	O
general	O
Brazilian	O
population	O
,	O
a	O
multiethnic	O
and	O
highly	O
admixed	O
population	O
with	O
a	O
heterogeneous	O
genetic	O
profile	O
.	O

Importantly	O
,	O
linkage	O
analysis	O
with	O
a	O
relatively	O
small	O
number	O
of	O
markers	O
still	O
provides	O
useful	O
information	O
.	O

Twenty	O
-	O
eight	O
out	O
of	O
47	O
(	O
59	O
.	O
6	O
%	O
)	O
mutated	O
alleles	O
were	O
predicted	O
to	O
code	O
for	O
prematurely	O
truncated	O
proteins	O
,	O
17	O
(	O
36	O
.	O
2	O
%	O
)	O
were	O
missense	O
mutation	O
,	O
and	O
two	O
were	O
in	O
-	O
frame	O
deletions	O
.	O

However	O
,	O
we	O
did	O
not	O
detect	O
other	O
pathologic	O
allelic	O
variants	O
reported	O
previously	O
,	O
not	O
even	O
the	O
most	O
frequently	O
reported	O
mutations	O
,	O
p	B-VARIANT
.	I-VARIANT
Q829X	I-VARIANT
in	O
Spanish	O
patients	O
and	O
p	B-VARIANT
.	I-VARIANT
E1700Q	I-VARIANT
in	O
the	O
Taiwanese	O
subjects	O
,	O
who	O
are	O
closer	O
genetically	O
to	O
our	O
patients	O
[	O
34	O
]	O
.	O

Missense	O
mutations	O
are	O
the	O
most	O
frequent	O
form	O
of	O
mutation	O
in	O
the	O
LQTS	B-DISEASE
genes	O
,	O
accounting	O
for	O
about	O
65	O
-	O
73	O
%	O
of	O
the	O
mutations	O
in	O
the	O
large	O
LQTS	B-DISEASE
population	O
surveys	O
.	O

Sequence	O
chromatograms	O
were	O
compared	O
with	O
the	O
Genbank	O
OPA1	B-GENE
reference	O
sequence	O
(	O
Accession	O
number	O
AB011139	O
)	O
and	O
all	O
genetic	O
variants	O
were	O
confirmed	O
by	O
reverse	O
sequencing	O
.	O

This	O
mutation	O
introduces	O
a	O
positively	O
charged	O
residue	O
within	O
the	O
consensus	O
motif	O
for	O
the	O
iron	O
sulfur	O
binding	O
site	O
(	O
pfam10589	O
)	O
which	O
is	O
highly	O
conserved	O
across	O
eukaryotic	O
species	O
.	O

Our	O
data	O
offer	O
novel	O
insights	O
into	O
gene	O
pathways	O
essential	O
for	O
normal	O
auditory	O
function	O
and	O
the	O
maintenance	O
of	O
cochlear	O
hair	O
cells	O
.	O

This	O
study	O
was	O
performed	O
according	O
to	O
the	O
protocol	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
the	O
Chinese	O
PLA	O
General	O
Hospital	O
.	O

The	O
parents	O
are	O
first	O
cousins	O
.	O

Total	O
RNA	O
was	O
isolated	O
from	O
the	O
cells	O
using	O
the	O
RNeasy	O
Mini	O
Kit	O
(	O
Qiagen	O
)	O
and	O
reverse	O
transcribed	O
using	O
1	O
mu	O
g	O
of	O
total	O
RNA	O
from	O
cells	O
with	O
Oligo	O
-	O
dT	O
primer	O
.	O

The	O
lack	O
of	O
retinal	B-DISEASE
degeneration	I-DISEASE
in	O
both	O
parents	O
of	O
the	O
index	O
patient	O
and	O
LCA	B-DISEASE
in	O
her	O
brother	O
who	O
also	O
carried	O
both	O
mutations	O
strongly	O
indicate	O
that	O
both	O
CRX	B-GENE
mutations	O
identified	O
here	O
represent	O
recessive	O
loss	O
-	O
of	O
-	O
function	O
alleles	O
,	O
confirming	O
the	O
previous	O
assumption	O
that	O
recessive	O
LCA	B-DISEASE
may	O
result	O
from	O
biallelic	O
CRX	B-GENE
mutations	O
.	O

This	O
step	O
remains	O
to	O
be	O
automated	O
.	O

Experiments	O
were	O
repeated	O
at	O
least	O
three	O
times	O
.	O

We	O
also	O
recruited	O
100	O
healthy	O
matched	O
controls	O
from	O
the	O
same	O
ethnic	O
background	O
.	O

Such	O
degree	O
of	O
conservation	O
for	O
a	O
non	O
-	O
translated	O
base	O
suggests	O
that	O
this	O
5	O
'	O
UTR	O
guanine	O
may	O
be	O
critical	O
for	O
the	O
binding	O
of	O
regulatory	O
proteins	O
,	O
and	O
any	O
disruption	O
of	O
this	O
process	O
would	O
destabilise	O
the	O
mRNA	O
and	O
/	O
or	O
affect	O
translation	O
efficiency	O
.	O

To	O
date	O
,	O
nine	O
causative	O
genes	O
have	O
been	O
identified	O
.	O

For	O
two	O
of	O
the	O
four	O
patients	O
,	O
the	O
genetic	O
diagnoses	O
informed	O
specific	O
pharmacotherapies	O
.	O

All	O
PCR	O
-	O
duplicate	O
reads	O
were	O
removed	O
using	O
Picard	O
-	O
Tools	O
Version	O
:	O
1	O
.	O
65	O
(	O
http	O
:	O
/	O
/	O
picard	O
.	O
sourceforge	O
.	O
net	O
/	O
)	O
.	O

Mutations	O
in	O
MYO7A	B-GENE
gene	O
have	O
long	O
been	O
implicated	O
in	O
the	O
disease	O
etiology	O
of	O
USH	B-DISEASE
type	I-DISEASE
1	I-DISEASE
.	O

Ohta	O
YY	O
.	O

Among	O
621	O
probands	O
who	O
participated	O
in	O
a	O
genetic	O
study	O
at	O
our	O
institutes	O
from	O
November	O
2008	O
to	O
June	O
2012	O
(	O
the	O
first	O
subject	O
group	O
)	O
,	O
72	O
subjects	O
were	O
selected	O
for	O
CDH23	B-GENE
mutation	O
analysis	O
based	O
on	O
these	O
criteria	O
.	O

Computed	O
tomography	O
(	O
CT	O
)	O
of	O
the	O
temporal	O
bone	O
was	O
performed	O
in	O
the	O
index	O
patient	O
.	O

PCR	O
reaction	O
was	O
performed	O
in	O
20	O
mu	O
l	O
volumes	O
containing	O
80	O
ng	O
genomic	O
DNA	O
.	O

These	O
motifs	O
are	O
involved	O
in	O
binding	O
of	O
calcium	O
ions	O
for	O
the	O
interdomain	O
rigidification	O
of	O
the	O
cadherin	O
repeat	O
domains	O
.	O

Immunostaining	O
and	O
internalization	O
was	O
performed	O
essentially	O
as	O
previously	O
described	O
[	O
38	O
]	O
.	O

Most	O
of	O
those	O
genes	O
were	O
originally	O
identified	O
through	O
the	O
linkage	O
analysis	O
of	O
single	O
or	O
multiple	O
deaf	B-DISEASE
families	O
.	O

Molecular	O
analysis	O
of	O
HLA	O
-	O
DR	O
and	O
HLA	O
-	O
DQ	O
regions	O
revealed	O
0	O
heterodimers	O
for	O
type	B-DISEASE
1	I-DISEASE
DM	I-DISEASE
susceptibility	O
.	O

S4	O
)	O
.	O

Screening	O
for	O
gene	O
mutations	O
in	O
CDH23	B-GENE
,	O
which	O
has	O
many	O
exons	O
,	O
has	O
lagged	O
even	O
though	O
it	O
is	O
likely	O
to	O
be	O
an	O
important	O
cause	O
for	O
hearing	B-DISEASE
loss	I-DISEASE
patients	O
.	O

Physical	O
examinations	O
ruled	O
out	O
the	O
probability	O
of	O
syndromic	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

The	O
LNS	O
domains	O
are	O
usually	O
Ca	O
2	O
+	O
mediated	O
receptors	O
[	O
34	O
]	O
.	O

Fifteen	O
variants	O
were	O
considered	O
to	O
have	O
uncertain	O
pathogenicity	O
(	O
Table	O
1	O
)	O
.	O

Missense	O
/	O
non	O
-	O
sense	O
mutations	O
in	O
genes	O
encoding	O
the	O
CREB	B-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
(	O
CREBBP	B-GENE
)	O
or	O
the	O
E1A	B-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
(	O
EP300	B-GENE
)	O
are	O
the	O
most	O
common	O
,	O
although	O
micro	O
-	O
deletions	O
in	O
chromosome	O
16p13	O
.	O
3	O
and	O
other	O
rare	O
mutations	O
have	O
also	O
been	O
reported	O
as	O
genetic	O
causes	O
of	O
this	O
condition	O
[	O
8	O
,	O
10	O
,	O
11	O
,	O
12	O
,	O
13	O
,	O
14	O
,	O
15	O
]	O
.	O

The	O
diagnosis	O
of	O
ANSD	B-DISEASE
was	O
based	O
on	O
recognised	O
criteria	O
(	O
Guidelines	O
Development	O
Conference	O
at	O
NHS	O
2008	O
,	O
Como	O
,	O
Italy	O
)	O
.	O

She	O
presented	O
a	O
typical	O
phenotype	O
of	O
Fechtner	O
syndrome	O
,	O
as	O
observed	O
in	O
patients	O
with	O
mutations	O
in	O
exon	O
22	O
and	O
/	O
or	O
31	O
.	O

The	O
paternal	O
lineage	O
carried	O
a	O
heterozygous	O
p	B-VARIANT
.	I-VARIANT
Ser373TrpfsX10	I-VARIANT
only	O
,	O
while	O
the	O
maternal	O
lineage	O
carried	O
a	O
heterozygous	O
p	B-VARIANT
.	I-VARIANT
Val440AlafsX26	I-VARIANT
.	O

The	O
ERG	O
(	O
LKC	O
Technologies	O
,	O
Inc	O
.	O
,	O
Gaithersburg	O
,	O
MD	O
)	O
was	O
flat	O
in	O
all	O
three	O
affected	O
individuals	O
.	O

Together	O
with	O
the	O
results	O
of	O
this	O
study	O
,	O
it	O
is	O
likely	O
that	O
MYO7A	B-GENE
p	B-VARIANT
.	I-VARIANT
T381M	I-VARIANT
is	O
associated	O
with	O
ADNSHL	B-DISEASE
.	O

Most	O
cases	O
of	O
RSTS	B-DISEASE
occur	O
sporadically	O
and	O
are	O
caused	O
by	O
de	O
novo	O
mutations	O
.	O

The	O
shape	O
and	O
function	O
of	O
thyroid	O
were	O
confirmed	O
to	O
be	O
normal	O
by	O
thyroid	O
ultrasound	O
scan	O
and	O
thyroid	O
hormone	O
assays	O
in	O
19	O
of	O
the	O
20	O
patients	O
with	O
EVA	B-DISEASE
or	O
other	O
inner	B-DISEASE
ear	I-DISEASE
malformation	I-DISEASE
except	O
one	O
who	O
had	O
cystoid	O
change	O
in	O
the	O
right	O
side	O
of	O
thyroid	O
.	O

S1	O
)	O
,	O
with	O
a	O
mutation	O
rate	O
of	O
1	O
.	O
53	O
%	O
(	O
2	O
/	O
131	O
)	O
;	O
the	O
KCNJ10	B-GENE
c	B-VARIANT
.	I-VARIANT
1042C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
mutation	O
was	O
not	O
found	O
.	O

To	O
determine	O
the	O
cause	O
of	O
exon	O
10	O
skipping	O
,	O
we	O
performed	O
Sanger	O
sequencing	O
of	O
exon	O
10	O
and	O
the	O
flanking	O
intronic	O
regions	O
(	O
an	O
area	O
of	O
previous	O
poor	O
high	O
throughput	O
sequence	O
coverage	O
)	O
.	O

This	O
problem	O
highlights	O
a	O
limitation	O
of	O
exome	O
-	O
based	O
analyses	O
.	O

E	O
.	O

B	O
,	O
F	O
)	O
Fundus	O
auto	O
-	O
fluorescence	O
images	O
show	O
an	O
incomplete	O
rim	O
of	O
hyper	O
-	O
fluorescence	O
in	O
the	O
right	O
macular	O
area	O
and	O
a	O
complete	O
hyper	O
-	O
fluorescent	O
ring	O
in	O
left	O
macula	O
.	O

We	O
demonstrated	O
that	O
adult	O
leucocytes	O
and	O
mesenchymal	O
cells	O
from	O
TCS	B-DISEASE
patients	O
present	O
significantly	O
reduced	O
levels	O
of	O
TCOF1	B-GENE
.	O

In	O
individual	O
II	O
.	O
1	O
,	O
the	O
hearing	B-DISEASE
loss	I-DISEASE
progressed	O
slowly	O
to	O
a	O
loss	O
of	O
110	O
dB	O
at	O
12	O
years	O
of	O
age	O
and	O
individual	O
II	O
.	O
3	O
,	O
who	O
is	O
now	O
14	O
years	O
old	O
,	O
has	O
a	O
stable	O
hearing	B-DISEASE
loss	I-DISEASE
of	O
90	O
dB	O
HL	O
(	O
Fig	O
.	O

1B	O
)	O
and	O
it	O
fully	O
cosegregated	O
with	O
the	O
phenotype	O
in	O
the	O
two	O
families	O
(	O
Fig	O
.	O

Synofzik	O
received	O
honoraria	O
from	O
Actelion	O
Pharmaceuticals	O
Ltd	O
.	O

Nevertheless	O
,	O
considering	O
the	O
specificity	O
of	O
cells	O
where	O
the	O
PJVK	B-GENE
gene	O
functioned	O
[	O
11	O
]	O
,	O
the	O
mutation	O
spectra	O
in	O
ANSD	B-DISEASE
patients	O
should	O
be	O
monitored	O
continuously	O
.	O

The	O
OS	O
shows	O
an	O
atrophic	B-DISEASE
maculopathy	I-DISEASE
sparing	O
the	O
inferior	O
half	O
of	O
fovea	O
.	O

RNA	O
was	O
reverse	O
transcribed	O
,	O
and	O
cDNAs	O
were	O
used	O
as	O
templates	O
for	O
PCR	O
amplification	O
using	O
the	O
forward	O
and	O
reverse	O
primers	O
within	O
the	O
cassette	O
'	O
s	O
upstream	O
(	O
UE	O
,	O
4	O
.	O
1R	O
exon	O
13	O
)	O
and	O
downstream	O
(	O
DE	O
,	O
4	O
.	O
1R	O
exon	O
17	O
)	O
exons	O
,	O
as	O
previously	O
described	O
[	O
21	O
]	O
.	O

2006	O
)	O
.	O

2	O
.	O
0	O
)	O
.	O

We	O
also	O
evaluated	O
the	O
effect	O
of	O
cleavage	O
of	O
the	O
GST	O
fusion	O
tag	O
by	O
TEV	O
protease	O
on	O
ELMOD3	B-GENE
activity	O
;	O
no	O
changes	O
in	O
activity	O
in	O
the	O
Arl2	O
GAP	O
assay	O
were	O
observed	O
compared	O
to	O
un	O
-	O
cleaved	O
proteins	O
(	O
data	O
not	O
shown	O
)	O
.	O

All	O
identified	O
genetic	O
variants	O
entered	O
a	O
systematic	O
data	O
analysis	O
pipeline	O
that	O
included	O
Sanger	O
sequencing	O
validation	O
,	O
segregation	O
analysis	O
,	O
and	O
a	O
bioinformatic	O
prediction	O
of	O
pathogenicity	O
.	O

Thigh	O
and	O
lower	O
leg	O
(	O
calf	O
)	O
muscle	O
imaging	O
was	O
performed	O
in	O
axial	O
[	O
field	O
of	O
view	O
(	O
FOV	O
)	O
=	O
24	O
-	O
32	O
cm	O
;	O
slice	O
thickness	O
=	O
6	O
mm	O
;	O
slice	O
gap	O
=	O
0	O
.	O
5	O
-	O
1	O
.	O
0	O
mm	O
]	O
and	O
coronal	O
planes	O
(	O
FOV	O
=	O
38	O
-	O
40	O
cm	O
;	O
slice	O
thickness	O
=	O
4	O
-	O
5	O
mm	O
;	O
slice	O
gap	O
=	O
0	O
.	O
5	O
-	O
1	O
.	O
0	O
mm	O
)	O
.	O

and	O
R	O
.	O
H	O
.	O
H	O
.	O
S	O
.	O

Of	O
93	O
previously	O
found	O
GJB2	B-GENE
and	O
SLC26A4	B-GENE
mutations	O
,	O
we	O
confirmed	O
87	O
(	O
93	O
.	O
5	O
%	O
)	O
of	O
them	O
(	O
Table	O
S3	O
)	O
.	O

Following	O
the	O
description	O
of	O
the	O
X	B-DISEASE
-	I-DISEASE
linked	I-DISEASE
form	I-DISEASE
of	I-DISEASE
AS	I-DISEASE
(	O
XLAS	B-DISEASE
)	O
in	O
the	O
early	O
1990	O
'	O
s	O
[	O
12	O
]	O
,	O
[	O
13	O
]	O
the	O
rarer	O
ARAS	B-DISEASE
was	O
also	O
described	O
and	O
explained	O
by	O
homozygous	O
or	O
compound	O
heterozygous	O
mutations	O
in	O
either	O
the	O
COL4A3	B-GENE
or	O
COL4A4	B-GENE
genes	O
[	O
14	O
]	O
,	O
[	O
15	O
]	O
.	O

The	O
remaining	O
fetuses	O
are	O
sporadic	O
cases	O
,	O
and	O
none	O
of	O
the	O
parents	O
had	O
phenotypic	O
abnormalities	O
that	O
were	O
likely	O
to	O
be	O
related	O
to	O
that	O
of	O
the	O
fetuses	O
.	O

,	O
2008	O
)	O
.	O

B	O
:	O
Protein	O
alignment	O
showing	O
conservation	O
of	O
residues	O
myosin	O
VIIaG25	O
and	O
C154	O
across	O
nine	O
species	O
.	O

An	O
intriguing	O
observation	O
was	O
a	O
positive	O
correlation	O
between	O
a	O
high	O
mean	O
HbA	O
1c	O
and	O
the	O
number	O
of	O
neurodegenerative	O
and	O
endocrine	O
symptoms	O
that	O
occurred	O
after	O
the	O
onset	O
of	O
WSD	B-DISEASE
.	O

Previous	O
studies	O
have	O
found	O
that	O
digenic	O
inheritance	O
of	O
NSHI	B-DISEASE
is	O
caused	O
by	O
mutations	O
in	O
the	O
GJB2	B-GENE
and	O
GJB3	B-GENE
genes	O
[	O
26	O
]	O
.	O

Amplification	O
of	O
cDNA	O
from	O
individuals	O
heterozygous	O
for	O
either	O
the	O
FGFR2	B-GENE
c	B-VARIANT
.	I-VARIANT
1083A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
or	O
the	O
c	B-VARIANT
.	I-VARIANT
1083A	I-VARIANT
>	I-VARIANT
T	I-VARIANT
variants	O
demonstrated	O
the	O
presence	O
of	O
two	O
additional	O
bands	O
,	O
not	O
present	O
in	O
the	O
wild	O
type	O
control	O
,	O
at	O
approximately	O
430	O
bp	O
and	O
330	O
bp	O
(	O
Figure	O
2	O
B	O
)	O
.	O

Indeed	O
,	O
Stover	O
et	O
al	O
demonstrated	O
that	O
young	O
adult	O
patients	O
with	O
ATP6V0A4	B-GENE
mutations	O
could	O
develop	O
mild	O
SNHL	B-DISEASE
in	O
the	O
long	O
term	O
[	O
9	O
]	O
.	O

This	O
variant	O
involves	O
a	O
transition	O
from	O
a	O
guanine	O
to	O
an	O
adenine	O
nucleotide	O
at	O
position	O
2081	O
,	O
which	O
causes	O
a	O
glycine	O
to	O
glutamic	O
acid	O
substitution	O
at	O
amino	O
acid	O
position	O
694	O
(	O
p	B-VARIANT
.	I-VARIANT
G694E	I-VARIANT
)	O
.	O

We	O
also	O
applied	O
Fisher	O
'	O
s	O
exact	O
test	O
for	O
the	O
LOD	O
score	O
per	O
exon	O
to	O
detect	O
co	O
-	O
segregated	O
regions	O
of	O
CNVs	O
,	O
but	O
there	O
were	O
no	O
peaks	O
with	O
values	O
reaching	O
significance	O
.	O

Cochlear	O
potentials	O
recorded	O
from	O
OPA1	B-GENE
-	O
M	O
patients	O
were	O
compared	O
to	O
ECochG	O
data	O
previously	O
collected	O
from	O
children	O
tested	O
for	O
presumed	O
cochlear	B-DISEASE
deafness	I-DISEASE
.	O

Fetal	O
auxological	O
measurements	O
showing	O
the	O
shortening	O
of	O
the	O
femur	O
beginning	O
with	O
the	O
15th	O
the	O
week	O
of	O
gestation	O
.	O

The	O
Usher	B-DISEASE
syndrome	I-DISEASE
probands	O
disclosed	O
are	O
currently	O
younger	O
than	O
the	O
age	O
of	O
onset	O
for	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
,	O
which	O
is	O
why	O
we	O
do	O
not	O
currently	O
consider	O
these	O
individuals	O
as	O
syndromic	O
.	O

Approximately	O
one	O
week	O
after	O
initiation	O
of	O
the	O
selection	O
procedure	O
,	O
non	O
-	O
transfected	O
cells	O
were	O
dead	O
and	O
several	O
positive	O
clones	O
were	O
harvested	O
after	O
an	O
additional	O
week	O
of	O
the	O
selection	O
.	O

Variants	O
present	O
in	O
affected	O
individuals	O
but	O
not	O
in	O
healthy	O
individuals	O
of	O
the	O
family	O
or	O
in	O
the	O
control	O
local	O
population	O
were	O
ranked	O
based	O
on	O
the	O
analysis	O
of	O
the	O
interactome	O
to	O
generate	O
a	O
list	O
of	O
candidate	O
genes	O
.	O

Six	O
of	O
the	O
14	O
newly	O
identified	O
mutations	O
were	O
in	O
genes	O
that	O
had	O
not	O
been	O
tested	O
previously	O
because	O
extrapancreatic	O
features	O
characteristic	O
of	O
the	O
genetic	O
subtype	O
were	O
not	O
present	O
(	O
e	O
.	O
g	O
.	O

In	O
all	O
seven	O
biopsies	O
there	O
was	O
FSGS	B-DISEASE
,	O
in	O
keeping	O
with	O
our	O
previous	O
findings	O
which	O
showed	O
that	O
FSGS	B-DISEASE
can	O
be	O
the	O
prevailing	O
feature	O
,	O
occasionally	O
resulting	O
in	O
misdiagnosis	O
[	O
6	O
]	O
,	O
[	O
21	O
]	O
,	O
[	O
43	O
]	O
.	O

For	O
the	O
c	B-VARIANT
.	I-VARIANT
3742G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
mutation	O
,	O
a	O
454	O
bp	O
DNA	O
fragment	O
was	O
amplified	O
(	O
forward	O
:	O
5	O
'	O
-	O
CGG	O
CTG	O
CCC	O
TCA	O
AAA	O
TCC	O
ACA	O
T	O
-	O
3	O
'	O
;	O
reverse	O
:	O
5	O
'	O
-	O
TGG	O
CAG	O
GTA	O
AAG	O
GCA	O
TTG	O
AGA	O
CA	O
-	O
3	O
'	O
)	O
and	O
cut	O
into	O
172	O
bp	O
and	O
282	O
bp	O
with	O
BstXI	O
(	O
New	O
England	O
BioLabs	O
Inc	O
.	O
,	O
Beverly	O
,	O
MA	O
)	O
at	O
37	O
deg	O
C	O
for	O
4	O
h	O
.	O

and	O
Sh	O
.	O
R	O
.	O

[	O
11	O
]	O
.	O

We	O
compared	O
the	O
phenotypes	O
of	O
the	O
families	O
by	O
focusing	O
on	O
the	O
mutation	O
data	O
.	O

A	O
gene	O
with	O
two	O
or	O
more	O
non	O
-	O
synonymous	O
de	O
novo	O
hits	O
across	O
a	O
panel	O
of	O
trios	O
might	O
suggest	O
strong	O
candidacy	O
.	O

Additional	O
file	O
2	O
describes	O
all	O
identified	O
rare	O
variants	O
in	O
the	O
Swedish	O
cohort	O
with	O
a	O
frequency	O
less	O
than	O
5	O
%	O
,	O
as	O
well	O
as	O
all	O
missense	O
substitutions	O
,	O
all	O
of	O
which	O
were	O
classified	O
as	O
normal	O
genetic	O
variants	O
.	O

Haplotype	O
reconstruction	O
(	O
Figure	O
S	O
3	O
)	O
clearly	O
showed	O
the	O
transmission	O
of	O
the	O
-	B-VARIANT
248G	I-VARIANT
/	I-VARIANT
A	I-VARIANT
EDN3	B-GENE
variant	O
in	O
the	O
pedigree	O
from	O
the	O
unaffected	O
father	O
(	O
I	O
-	O
1	O
)	O
.	O

Patient	O
2	O
,	O
2	O
years	O
.	O

Hence	O
,	O
p	B-VARIANT
.	I-VARIANT
Glu1750	I-VARIANT
*	I-VARIANT
very	O
likely	O
presents	O
a	O
pathogenic	O
recessive	O
allele	O
,	O
an	O
interpretation	O
that	O
is	O
compatible	O
with	O
the	O
homozygous	O
mutation	O
p	B-VARIANT
.	I-VARIANT
Asn1760Cysfs	I-VARIANT
*	I-VARIANT
46	I-VARIANT
segregating	O
with	O
arRP	B-DISEASE
in	O
another	O
consanguineous	O
arRP	B-DISEASE
family	O
from	O
our	O
cohort	O
(	O
patient	O
28	O
)	O
,	O
refining	O
the	O
"	O
critical	O
position	O
"	O
to	O
p	O
.	O
1760	O
-	O
p	O
.	O
1816	O
.	O

Data	O
from	O
OMIM	O
,	O
DDG2P	O
,	O
BioGPS	O
,	O
NHGRI	O
GWAS	O
catalog	O
,	O
IKMC	O
,	O
ZFIN	O
and	O
PubMed	O
were	O
used	O
,	O
where	O
available	O
.	O

Four	O
conserved	O
T	O
-	O
half	O
sites	O
"	O
ATTTCACACCT	O
"	O
were	O
oriented	O
head	O
to	O
tail	O
,	O
synthesised	O
and	O
subcloned	O
into	O
the	O
KpnI	O
-	O
HindIII	O
sites	O
in	O
the	O
pGL4	O
.	O
25	O
[	O
luc2CP	O
/	O
minP	O
]	O
plasmid	O
.	O

This	O
alteration	O
would	O
lead	O
to	O
an	O
amino	O
acid	O
change	O
from	O
a	O
neutral	O
glycine	O
to	O
an	O
alkaline	O
arginine	O
at	O
residue	O
4763	O
(	O
p	B-VARIANT
.	I-VARIANT
G4763R	I-VARIANT
)	O
of	O
usherin	B-GENE
,	O
thus	O
changing	O
the	O
theoretical	O
isoelectric	O
point	O
from	O
6	O
.	O
40	O
to	O
6	O
.	O
42	O
.	O

In	O
silico	O
prediction	O
of	O
the	O
identified	O
variants	O
was	O
performed	O
using	O
online	O
prediction	O
tools	O
.	O

The	O
decreased	O
levels	O
of	O
mt	B-GENE
-	I-GENE
tRNA	I-GENE
Asn	I-GENE
may	O
be	O
suggestive	O
either	O
of	O
a	O
regulatory	O
role	O
of	O
NARS2	B-GENE
in	O
the	O
expression	O
of	O
its	O
cognate	O
tRNA	O
or	O
of	O
a	O
decrease	O
in	O
stability	O
of	O
the	O
tRNA	O
by	O
poor	O
interaction	O
with	O
the	O
mutant	O
NARS2	B-GENE
[	O
43	O
]	O
.	O

S1	O
)	O
.	O

Pupils	O
were	O
mydriatic	O
with	O
decreased	O
light	O
reflex	O
.	O

Namshin	O
Kim	O
,	O
Hee	O
Jeong	O
Yoo	O
and	O
Ki	O
Young	O
Lee	O
conceived	O
and	O
designed	O
the	O
experiments	O
.	O

When	O
analyzed	O
base	O
-	O
by	O
-	O
base	O
,	O
all	O
samples	O
showed	O
a	O
coverage	O
distribution	O
that	O
reflected	O
high	O
coverage	O
across	O
all	O
nucleotides	O
,	O
with	O
a	O
peak	O
in	O
the	O
center	O
of	O
the	O
sequenced	O
region	O
(	O
S1	O
Fig	O
)	O
.	O

Bovine	O
beta	O
-	O
actin	O
actin	O
has	O
a	O
99	O
%	O
identity	O
with	O
human	O
gamma	O
-	O
actin	O
.	O

Associated	O
symptoms	O
:	O
N	O
+	O
D	O
(	O
n	O
=	O
9	O
;	O
23	O
.	O
68	O
%	O
)	O
,	O
N	O
+	O
D	O
+	O
Ca	O
(	O
n	O
=	O
1	O
;	O
2	O
.	O
63	O
%	O
)	O
.	O

The	O
pedigree	O
contains	O
two	O
affected	O
male	O
siblings	O
(	O
1D	O
)	O
.	O

A	O
full	O
-	O
shaded	O
icon	O
denotes	O
ESRD	B-DISEASE
;	O
individuals	O
with	O
microscopic	B-DISEASE
hematuria	I-DISEASE
and	O
proteinuria	B-DISEASE
but	O
with	O
normal	O
renal	O
function	O
are	O
indicated	O
with	O
a	O
half	O
-	O
shaded	O
icon	O
;	O
individual	O
with	O
unknown	O
phenotype	O
is	O
indicated	O
in	O
gray	O
.	O

The	O
overall	O
results	O
of	O
this	O
study	O
are	O
highly	O
suggestive	O
that	O
underlying	O
molecular	O
basis	O
of	O
autosomal	O
recessive	O
non	O
-	O
syndromic	O
deafness	B-DISEASE
in	O
Saudi	O
Arabia	O
is	O
very	O
genetically	O
heterogeneous	O
.	O

For	O
the	O
second	O
screening	O
,	O
probes	O
of	O
these	O
26	O
mutations	O
selected	O
in	O
the	O
first	O
screening	O
was	O
applied	O
for	O
a	O
custom	O
TaqMan	O
(	O
r	O
)	O
SNP	O
Genotyping	O
Assays	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
[	O
19	O
]	O
.	O

In	O
fact	O
,	O
in	O
pedigree	O
E5	O
,	O
three	O
pathogenic	O
alleles	O
were	O
identified	O
in	O
two	O
generations	O
.	O

The	O
control	O
group	O
consisted	O
of	O
200	O
healthy	O
volunteers	O
showed	O
no	O
abnormalities	O
on	O
physical	O
,	O
neurological	O
and	O
radiological	O
examinations	O
.	O

Wolff	O
et	O
al	O
.	O

Immunoreactivity	O
was	O
visualized	O
using	O
Amersham	O
ECL	O
Western	O
blotting	O
detection	O
reagents	O
(	O
GE	O
Healthcare	O
Limited	O
,	O
Buckinghamshire	O
,	O
UK	O
)	O
.	O

Co	O
-	O
localization	O
of	O
EGFP	O
expression	O
and	O
the	O
di	O
-	O
8	O
-	O
ANEPPS	O
dye	O
in	O
the	O
membrane	O
would	O
suggest	O
proper	O
membrane	O
targeting	O
of	O
the	O
proteins	O
.	O

Several	O
novel	O
and	O
previously	O
known	O
COL4A	O
mutations	O
in	O
AS	B-DISEASE
,	O
APOL1	B-GENE
G2	O
deletion	O
variants	O
in	O
some	O
FSGS	B-DISEASE
patients	O
and	O
new	O
coexisting	O
gene	O
mutations	O
in	O
proteinuria	B-DISEASE
related	O
genes	O
(	O
LAMA5	B-GENE
)	O
were	O
identified	O
.	O

parents	O
were	O
heterozygous	O
carriers	O
for	O
the	O
mutation	O
and	O
unaffected	O
siblings	O
were	O
either	O
heterozygous	O
carriers	O
or	O
wild	O
-	O
type	O
normal	O
.	O

STGD	B-DISEASE
in	O
48	O
patients	O
(	O
55	O
%	O
)	O
was	O
explained	O
by	O
recessive	O
ABCA4	B-GENE
mutations	O
(	O
supplemental	O
table	O
S2	O
)	O
.	O

No	O
likely	O
pathogenic	O
CNVs	O
were	O
identified	O
.	O

2	O
B	O
)	O
.	O

Deaf	O
patients	O
received	O
routine	O
physical	O
and	O
otorhinolaryngoloical	O
examination	O
,	O
as	O
well	O
as	O
pure	O
tone	O
audiometry	O
.	O

Malfunctioning	O
of	O
cGMP	O
-	O
PDE	O
results	O
in	O
elevated	O
cGMP	O
concentrations	O
,	O
which	O
may	O
lead	O
to	O
an	O
excessive	O
energy	O
load	O
on	O
rod	O
photoreceptors	O
,	O
resulting	O
in	O
degeneration	O
[	O
20	O
]	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
HY	O
SI	O
SN	O
SU	O
.	O

Briefly	O
,	O
for	O
every	O
3	O
u	O
g	O
DNA	O
,	O
we	O
diluted	O
the	O
genomic	O
DNA	O
and	O
,	O
using	O
a	O
Covaris	O
station	O
,	O
sheered	O
the	O
genomic	O
DNA	O
to	O
150	O
base	O
pair	O
fragments	O
.	O

Indeed	O
,	O
there	O
were	O
only	O
two	O
mutation	O
negative	O
patients	O
in	O
which	O
a	O
diagnosis	O
of	O
suspected	O
mild	O
MED	B-DISEASE
was	O
agreed	O
upon	O
by	O
the	O
panel	O
prior	O
to	O
screening	O
(	O
Supp	O
.	O

No	O
audiogram	O
is	O
available	O
for	O
SR	O
-	O
106	O
,	O
only	O
ABR	O
data	O
.	O

Notably	O
,	O
we	O
found	O
a	O
mutation	O
in	O
the	O
exon	O
7	O
that	O
causes	O
the	O
complete	O
loss	O
of	O
the	O
second	O
SH2	O
domain	O
that	O
may	O
be	O
deleterious	O
to	O
the	O
protein	O
function	O
(	O
Table	O
3	O
)	O
.	O

We	O
have	O
identified	O
64	O
different	O
mutations	O
in	O
70	O
Danish	O
LQTS	B-DISEASE
families	O
referred	O
for	O
five	O
-	O
gene	O
screening	O
.	O

We	O
detected	O
a	O
similar	O
mutation	O
as	O
reported	O
in	O
a	O
study	O
about	O
ANSD	B-DISEASE
patients	O
east	O
China	O
[	O
21	O
]	O
.	O

The	O
panel	O
'	O
s	O
success	O
in	O
predicting	O
a	O
COL9	O
mutation	O
was	O
not	O
repeated	O
with	O
MED	B-DISEASE
resulting	O
from	O
MATN3	B-GENE
mutations	O
and	O
in	O
most	O
cases	O
the	O
panel	O
could	O
not	O
decide	O
between	O
COMP	B-GENE
or	O
MATN3	B-GENE
as	O
the	O
causative	O
gene	O
prior	O
to	O
screening	O
(	O
although	O
the	O
COL9	O
genes	O
were	O
never	O
considered	O
as	O
candidates	O
)	O
.	O

To	O
date	O
,	O
little	O
is	O
known	O
about	O
Wolfram	B-DISEASE
syndrome	I-DISEASE
-	O
related	O
diabetes	B-DISEASE
(	O
WSD	B-DISEASE
)	O
features	O
compared	O
with	O
autoimmune	O
type	B-DISEASE
1	I-DISEASE
diabetes	I-DISEASE
(	O
10	O
)	O
,	O
and	O
the	O
contribution	O
of	O
glycemic	O
control	O
to	O
the	O
observed	O
decline	O
in	O
neurologic	O
and	O
endocrine	O
function	O
remains	O
undefined	O
.	O

We	O
considered	O
only	O
enrichment	O
probes	O
overlapping	O
known	O
Usher	B-DISEASE
genes	O
.	O

A	O
correlation	O
was	O
found	O
between	O
the	O
number	O
of	O
Wolfram	B-DISEASE
syndrome	I-DISEASE
symptoms	O
and	O
the	O
patient	O
'	O
s	O
mean	O
HbA	O
1c	O
during	O
childhood	O
and	O
adolescence	O
.	O

The	O
c	B-VARIANT
.	I-VARIANT
2708_2711del	I-VARIANT
mutation	O
in	O
exon	O
27	O
was	O
present	O
in	O
approximately	O
27	O
%	O
of	O
families	O
in	O
previous	O
studies	O
.	O

The	O
PCR	O
products	O
were	O
checked	O
by	O
electrophoresis	O
in	O
a	O
2	O
%	O
agarose	O
gel	O
and	O
by	O
direct	O
sequencing	O
.	O

WS	B-DISEASE
is	O
classified	O
into	O
four	O
major	O
types	O
depending	O
on	O
the	O
presence	O
or	O
absence	O
of	O
dystopia	B-DISEASE
canthorum	I-DISEASE
and	O
additional	O
symptoms	O
[	O
1	O
,	O
5	O
-	O
8	O
]	O
.	O

This	O
translates	O
to	O
~	O
88	O
%	O
(	O
14	O
/	O
16	O
)	O
of	O
the	O
patients	O
having	O
been	O
directly	O
ascertained	O
for	O
such	O
hot	O
zone	O
de	O
novo	O
mutations	O
among	O
essential	O
genes	O
(	O
Figure	O
1	O
and	O
Supplementary	O
Table	O
S7	O
online	O
)	O
,	O
and	O
it	O
strongly	O
suggests	O
that	O
in	O
the	O
majority	O
of	O
the	O
patients	O
with	O
such	O
a	O
mutation	O
,	O
the	O
mutation	O
is	O
causing	O
or	O
contributing	O
to	O
the	O
disorder	O
.	O

Every	O
case	O
was	O
then	O
reviewed	O
and	O
discussed	O
by	O
the	O
ESDN	O
panel	O
members	O
.	O

DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
lymphocytes	O
using	O
a	O
standard	O
salting	O
-	O
out	O
method	O
.	O

On	O
the	O
other	O
hand	O
,	O
family	O
20NCE	O
,	O
with	O
an	O
unassigned	O
mendelian	O
pattern	O
,	O
cosegregated	O
with	O
X	O
-	O
linked	O
markers	O
,	O
which	O
prompted	O
to	O
focus	O
on	O
the	O
X	O
-	O
linked	O
candidates	O
.	O

This	O
variant	O
consists	O
of	O
the	O
insertion	O
of	O
a	O
cytosine	O
between	O
positions	O
c	O
.	O
1304	O
and	O
c	O
.	O
1305	O
of	O
the	O
PCDH15	B-GENE
gene	O
,	O
leading	O
to	O
a	O
frameshift	O
causing	O
a	O
truncated	O
protein	O
in	O
the	O
EC4	O
domain	O
.	O

TJs	O
prevent	O
the	O
passage	O
of	O
some	O
solutes	O
through	O
the	O
paracellular	O
pathway	O
of	O
adjacent	O
epithelial	O
cells	O
[	O
1	O
,	O
2	O
]	O
.	O

XC	O
and	O
GX	O
contributed	O
to	O
revisions	O
of	O
the	O
manuscript	O
.	O

The	O
thermal	O
cycling	O
profile	O
consisted	O
of	O
an	O
initial	O
denaturation	O
step	O
at	O
98	O
deg	O
C	O
for	O
20	O
s	O
,	O
followed	O
by	O
20	O
cycles	O
of	O
10	O
s	O
denaturation	O
at	O
98	O
deg	O
C	O
,	O
15	O
s	O
of	O
annealing	O
at	O
60	O
deg	O
C	O
,	O
and	O
a	O
40	O
s	O
extension	O
at	O
68	O
deg	O
C	O
.	O

Therefore	O
,	O
in	O
this	O
study	O
,	O
we	O
have	O
conducted	O
genetic	O
analysis	O
using	O
MPS	O
-	O
based	O
genetic	O
screening	O
to	O
find	O
mutations	O
in	O
nine	O
causative	O
USH	B-DISEASE
genes	O
(	O
except	O
CIB2	B-GENE
)	O
in	O
Japanese	O
USH1	B-DISEASE
patients	O
.	O

Haplotype	O
analysis	O
using	O
microsatellite	O
markers	O
from	O
each	O
of	O
the	O
eight	O
known	O
WS	B-DISEASE
loci	O
suggested	O
linkage	O
of	O
the	O
family	O
to	O
the	O
WS4B	O
locus	O
on	O
chromosome	O
20q13	O
.	O
2	O
-	O
q13	O
.	O
3	O
(	O
Figure	O
1	O
and	O
Table	O
1	O
)	O
,	O
indicating	O
that	O
WS	B-DISEASE
is	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
EDN3	B-GENE
gene	O
.	O

The	O
prevalence	O
of	O
WSD	B-DISEASE
among	O
children	O
and	O
adolescents	O
aged	O
<	O
21	O
years	O
with	O
diabetes	B-DISEASE
is	O
33	O
/	O
24	O
,	O
000	O
(	O
~	O
1	O
:	O
730	O
)	O
.	O

Primers	O
were	O
designed	O
using	O
Primer3	O
software	O
(	O
URL	O
:	O
http	O
:	O
/	O
/	O
www	O
.	O
bioinformatics	O
.	O
nl	O
/	O
cgi	O
-	O
bin	O
/	O
primer3plus	O
/	O
primer3plus	O
.	O
cgi	O
/	O
;	O
[	O
14	O
]	O
)	O
.	O

For	O
each	O
mutation	O
,	O
the	O
data	O
obtained	O
in	O
the	O
presence	O
and	O
absence	O
of	O
ASC	O
are	O
shown	O
.	O

While	O
male	O
patients	O
are	O
more	O
severe	O
than	O
females	O
with	O
70	O
%	O
of	O
affected	O
males	O
developing	O
into	O
ESRD	B-DISEASE
before	O
the	O
age	O
of	O
30	O
years	O
(	O
juvenile	O
form	O
)	O
,	O
the	O
remaining	O
30	O
%	O
are	O
progressing	O
toward	O
ESRD	B-DISEASE
after	O
the	O
age	O
of	O
30	O
years	O
(	O
rare	O
adult	O
form	O
)	O
[	O
18	O
]	O
.	O

Histological	O
diagnosis	O
is	O
challenging	O
as	O
features	O
may	O
be	O
non	O
-	O
specific	O
,	O
particularly	O
early	O
in	O
the	O
disease	O
course	O
and	O
in	O
females	O
with	O
X	O
-	O
linked	O
disease	O
.	O

(	O
b	O
)	O
POLR1C	B-GENE
mutations	O
in	O
patients	O
with	O
leukodystrophy	B-DISEASE
affect	O
amino	O
acids	O
that	O
are	O
conserved	O
through	O
species	O
.	O

The	O
exclusion	O
of	O
any	O
pathogenic	O
variation	O
in	O
these	O
regions	O
together	O
with	O
the	O
finding	O
of	O
a	O
predicted	O
stop	O
-	O
loss	O
mutation	O
in	O
BDP1	B-GENE
supports	O
the	O
involvement	O
of	O
the	O
BDP1	B-GENE
gene	O
mutation	O
in	O
the	O
hearing	B-DISEASE
loss	I-DISEASE
phenotype	O
.	O

In	O
other	O
words	O
,	O
the	O
same	O
mutation	O
may	O
lead	O
to	O
a	O
considerably	O
different	O
phenotype	O
in	O
two	O
distinct	O
families	O
as	O
each	O
individual	O
is	O
born	O
with	O
a	O
unique	O
complement	O
of	O
modifier	O
genes	O
[	O
18	O
]	O
.	O

Day	O
(	O
Department	O
of	O
Molecular	O
Genetics	O
,	O
Royal	O
Devon	O
&	O
Exeter	O
NHS	O
Foundation	O
Trust	O
,	O
Exeter	O
,	O
UK	O
)	O
is	O
much	O
appreciated	O
.	O

Of	O
these	O
316	O
were	O
families	O
with	O
two	O
affected	O
sibs	O
,	O
54	O
with	O
three	O
affected	O
sibs	O
and	O
4	O
with	O
four	O
or	O
more	O
affected	O
sibs	O
.	O

The	O
fragment	O
was	O
sequenced	O
from	O
forward	O
and	O
reverse	O
directions	O
.	O

We	O
found	O
two	O
possibly	O
pathogenic	O
de	O
novo	O
missense	O
variants	O
in	O
F6	O
,	O
a	O
female	O
fetus	O
with	O
abdominal	B-DISEASE
situs	I-DISEASE
inversus	I-DISEASE
,	O
cardiac	B-DISEASE
malposition	I-DISEASE
of	I-DISEASE
the	I-DISEASE
great	I-DISEASE
arteries	I-DISEASE
and	O
multiple	B-DISEASE
ventricular	I-DISEASE
septal	I-DISEASE
defects	I-DISEASE
.	O

As	O
reported	O
in	O
previous	O
studies	O
,	O
air	O
-	O
bone	O
gap	O
caused	O
by	O
the	O
third	O
window	O
effect	O
cannot	O
be	O
improved	O
by	O
middle	O
ear	O
explorations	O
[	O
27	O
]	O
,	O
[	O
28	O
]	O
.	O

Examination	O
showed	O
restricted	O
movement	O
of	O
the	O
hips	O
bilaterally	O
;	O
radiography	O
confirmed	O
femoral	O
head	O
collapse	O
and	O
subluxation	O
.	O

The	O
authors	O
declare	O
no	O
conflicts	O
of	O
interest	O
.	O
Treacher	B-DISEASE
Collins	I-DISEASE
syndrome	I-DISEASE
(	O
TCS	B-DISEASE
)	O
is	O
an	O
autosomal	O
dominant	O
craniofacial	B-DISEASE
disorder	I-DISEASE
caused	O
by	O
frameshift	O
deletions	O
or	O
duplications	O
in	O
the	O
TCOF1	B-GENE
gene	O
.	O

Table	O
S1	O
:	O
22	O
/	O
30	O
[	O
80	O
%	O
]	O
)	O
,	O
with	O
the	O
remainder	O
being	O
PSACH	B-DISEASE
(	O
1	O
)	O
,	O
DTD	B-DISEASE
(	O
2	O
)	O
,	O
SED	B-DISEASE
(	O
3	O
)	O
,	O
or	O
unknown	O
(	O
2	O
)	O
.	O

It	O
will	O
be	O
interesting	O
to	O
see	O
if	O
this	O
clustering	O
will	O
resist	O
the	O
addition	O
of	O
new	O
Hartsfield	O
mutations	O
.	O

Distribution	O
of	O
the	O
number	O
of	O
individuals	O
with	O
a	O
variant	O
per	O
gene	O
for	O
(	O
A	O
)	O
all	O
variants	O
(	O
B	O
)	O
rare	O
variants	O
.	O

We	O
sequenced	O
735	O
of	O
the	O
831	O
coding	O
exons	O
in	O
BLSW	O
genomic	O
DNA	O
and	O
identified	O
one	O
nucleotide	O
substitution	O
,	O
which	O
was	O
a	O
guanine	O
to	O
adenine	O
transition	O
in	O
exon	O
2	O
of	O
the	O
Gipc3	B-GENE
gene	O
(	O
c	B-VARIANT
.	I-VARIANT
343G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
;	I-VARIANT
Fig	O
.	O

Delmaghani	O
et	O
al	O
.	O

Furthermore	O
,	O
refined	O
mapping	O
and	O
haplotype	O
analyses	O
using	O
additional	O
PKDF406	O
family	O
members	O
excluded	O
the	O
MYO7A	B-GENE
gene	O
from	O
the	O
linkage	O
interval	O
on	O
chromosome	O
11q13	O
.	O
4	O
-	O
q14	O
.	O
1	O
.	O

DPG	O
is	O
supported	O
by	O
an	O
MRC	O
Clinician	O
Scientist	O
Fellowship	O
and	O
the	O
Rosetrees	O
Trust	O
.	O
To	O
describe	O
the	O
diabetes	B-DISEASE
phenotype	O
in	O
Wolfram	B-DISEASE
syndrome	I-DISEASE
compared	O
with	O
type	B-DISEASE
1	I-DISEASE
diabetes	I-DISEASE
,	O
to	O
investigate	O
the	O
effect	O
of	O
glycemic	O
control	O
on	O
the	O
neurodegenerative	O
process	O
,	O
and	O
to	O
assess	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
.	O

Parents	O
of	O
patients	O
were	O
offered	O
enrolment	O
in	O
this	O
study	O
,	O
where	O
appropriate	O
,	O
to	O
clarify	O
their	O
children	O
'	O
s	O
genetic	O
test	O
results	O
.	O

Some	O
of	O
these	O
families	O
showed	O
clear	O
evidence	O
of	O
linkage	O
to	O
the	O
DFNB1	O
locus	O
,	O
which	O
contains	O
two	O
genes	O
,	O
GJB2	B-GENE
and	O
GJB6	B-GENE
[	O
3	O
,	O
14	O
]	O
.	O

This	O
site	O
has	O
no	O
mutations	O
reported	O
in	O
COSMIC	O
,	O
HGMD	O
,	O
or	O
ClinVar	O
,	O
is	O
predicted	O
to	O
be	O
benign	O
by	O
PolyPhen	O
,	O
and	O
is	O
of	O
unknown	O
function	O
.	O

In	O
each	O
recording	O
the	O
horizontal	O
dashed	O
line	O
refers	O
to	O
baseline	O
.	O

Quality	O
control	O
,	O
alignment	O
to	O
the	O
human	O
reference	O
genome	O
(	O
hg19	O
,	O
GRCh37	O
build	O
)	O
,	O
and	O
variant	O
calling	O
were	O
performed	O
in	O
October	O
2013	O
using	O
the	O
Whole	O
-	O
Exome	O
sequencing	O
Pipeline	O
web	O
tool	O
9	O
.	O

6	O
)	O
.	O

Figure	O
2	O
Reprocessed	O
electron	O
micrographs	O
of	O
the	O
renal	O
biopsy	O
from	O
patient	O
III	O
-	O
1	O
of	O
family	O
1	O
.	O

The	O
remaining	O
2	O
index	O
patients	O
from	O
families	O
RP	B-DISEASE
-	O
0886	O
and	O
RP	B-DISEASE
-	O
0461	O
were	O
not	O
identified	O
with	O
pathogenic	O
RD	B-DISEASE
mutations	O
.	O

Performed	O
the	O
experiments	O
:	O
KYL	O
ARK	O
SK	O
MYK	O
DK	O
MF	O
.	O

(	O
A	O
)	O
Pedigree	O
of	O
a	O
Korean	O
family	O
with	O
autosomal	O
dominant	O
inheritance	O
(	O
upper	O
panel	O
)	O
.	O

BWA	O
[	O
11	O
]	O
was	O
used	O
to	O
align	O
sequence	O
reads	O
to	O
the	O
human	O
reference	O
genome	O
(	O
hg19	O
)	O
and	O
variants	O
were	O
called	O
using	O
the	O
GATK	O
software	O
package	O
[	O
12	O
]	O
,	O
[	O
13	O
]	O
.	O

The	O
sequences	O
were	O
aligned	O
and	O
read	O
with	O
Sequencher	O
(	O
r	O
)	O
4	O
.	O
9	O
software	O
(	O
Gene	O
Codes	O
Corporation	O
,	O
Ann	O
Arbor	O
,	O
MI	O
,	O
USA	O
)	O
.	O

HEK	O
-	O
293T	O
cells	O
were	O
grown	O
on	O
10cm	O
plates	O
to	O
60	O
%	O
confluence	O
and	O
cotransfected	O
with	O
a	O
packaging	O
plasmid	O
(	O
pCMV	O
-	O
delta	O
8	O
.	O
91	O
)	O
,	O
a	O
pseudotyping	O
plasmid	O
(	O
pMD2	O
-	O
VSVg	O
)	O
and	O
either	O
NUBPL	O
-	O
V5	O
-	O
pDest	O
or	O
FOXRED1	O
-	O
V5	O
-	O
pDest	O
.	O

We	O
also	O
observed	O
that	O
the	O
mutant	O
allele	O
is	O
usually	O
less	O
abundant	O
than	O
the	O
wild	O
type	O
one	O
in	O
mesenchymal	O
cells	O
.	O

Sequencing	O
of	O
the	O
complete	O
CDS	O
of	O
the	O
SOX10	B-GENE
gene	O
did	O
not	O
reveal	O
any	O
damaging	O
variant	O
that	O
could	O
have	O
explained	O
the	O
phenotype	O
.	O

In	O
contrast	O
,	O
the	O
mutants	O
GATA3	B-GENE
and	O
G289R	B-VARIANT
showed	O
significantly	O
less	O
potential	O
to	O
activate	O
transcription	O
of	O
the	O
reporter	O
gene	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
PD	O
XG	O
.	O

Similarly	O
,	O
USH1C	B-GENE
,	O
which	O
is	O
known	O
to	O
interact	O
with	O
CDH23	B-GENE
,	O
was	O
analyzed	O
in	O
the	O
three	O
families	O
carrying	O
heterozygous	O
changes	O
in	O
CDH23	B-GENE
(	O
Table	O
2D	O
)	O
.	O

All	O
these	O
findings	O
point	O
to	O
disruption	O
of	O
auditory	O
nerve	O
discharge	O
with	O
preservation	O
of	O
outer	O
hair	O
cell	O
function	O
consistent	O
with	O
the	O
occurrence	O
of	O
auditory	B-DISEASE
neuropathy	I-DISEASE
(	O
Starr	O
et	O
al	O
.	O

Additionally	O
,	O
we	O
found	O
another	O
patient	O
bearing	O
both	O
sequence	O
and	O
CNV	O
mutations	O
in	O
the	O
same	O
gene	O
,	O
which	O
could	O
unmask	O
the	O
heterozygous	O
effects	O
of	O
a	O
GJB3	B-GENE
point	O
mutation	O
and	O
harm	O
gene	O
function	O
.	O

Gallentine	O
,	O
Dr	O
.	O

The	O
37	O
amino	O
acids	O
encoded	O
by	O
exon	O
5b	O
are	O
identical	O
in	O
all	O
higher	O
vertebrates	O
and	O
only	O
two	O
substitutions	O
have	O
so	O
far	O
been	O
reported	O
,	O
both	O
non	O
-	O
synonymous	O
.	O

An	O
echocardiogram	O
was	O
normal	O
,	O
and	O
there	O
was	O
no	O
evidence	O
of	O
migraine	B-DISEASE
,	O
seizure	B-DISEASE
,	O
or	O
psychiatric	B-DISEASE
symptoms	I-DISEASE
.	O

Conservation	O
analysis	O
of	O
COL4A5	B-GENE
p	O
.	O
Pro167	O
amino	O
acid	O
residue	O
.	O

JR	O
,	O
HVDV	O
and	O
SDK	O
performed	O
the	O
practical	O
work	O
.	O

Biallelic	O
,	O
monoallelic	O
,	O
and	O
no	O
SLC26A4	B-GENE
mutations	O
were	O
detected	O
in	O
92	O
patients	O
(	O
63	O
.	O
9	O
%	O
)	O
,	O
nine	O
patients	O
(	O
6	O
.	O
3	O
%	O
)	O
,	O
and	O
43	O
patients	O
(	O
29	O
.	O
9	O
%	O
)	O
,	O
respectively	O
.	O

Clinical	O
features	O
include	O
progressive	B-DISEASE
night	I-DISEASE
blindness	I-DISEASE
,	O
constriction	O
and	O
gradual	O
loss	B-DISEASE
of	I-DISEASE
the	I-DISEASE
peripheral	I-DISEASE
visual	I-DISEASE
field	I-DISEASE
,	O
and	O
eventual	O
loss	B-DISEASE
of	I-DISEASE
visual	I-DISEASE
acuity	I-DISEASE
.	O

We	O
filtered	O
candidate	O
SNPs	O
with	O
the	O
following	O
criterion	O
:	O
SNP	O
quality	O
>	O
=	O
20	O
,	O
sequencing	O
depth	O
>	O
=	O
4	O
,	O
the	O
estimated	O
copy	O
number	O
<	O
=	O
2	O
,	O
and	O
the	O
distance	O
between	O
two	O
SNPs	O
>	O
5	O
(	O
the	O
quality	O
score	O
is	O
a	O
Phred	O
score	O
,	O
generated	O
by	O
the	O
program	O
SOAPsnp1	O
.	O
03	O
,	O
and	O
quality	O
score	O
20	O
represents	O
99	O
%	O
accuracy	O
of	O
a	O
base	O
call	O
)	O
[	O
6	O
]	O
.	O

Informed	O
consent	O
was	O
obtained	O
from	O
all	O
these	O
patients	O
,	O
and	O
this	O
study	O
followed	O
the	O
tenets	O
of	O
the	O
Declaration	O
of	O
Helsinki	O
.	O

M	O
/	O
M	O
,	O
homozygous	O
mutation	O
;	O
M	O
/	O
m	O
compound	O
heterozygous	O
mutations	O
.	O

JT	O
participated	O
in	O
the	O
study	O
design	O
and	O
the	O
molecular	O
genetic	O
analyses	O
,	O
and	O
drafted	O
the	O
manuscript	O
.	O

Amino	O
acids	O
identical	O
in	O
at	O
least	O
seven	O
of	O
the	O
nine	O
protein	O
sequences	O
are	O
in	O
bold	O
type	O
.	O

The	O
c	B-VARIANT
.	I-VARIANT
3742G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
mutation	O
was	O
predicted	O
to	O
cause	O
a	O
glutamic	O
acid	O
to	O
lysine	O
change	O
at	O
codon	O
1248	O
.	O

GS	O
FLX	O
DNA	O
Libraries	O
were	O
made	O
following	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

In	O
some	O
cases	O
such	O
information	O
may	O
lead	O
to	O
improvements	O
in	O
therapy	O
or	O
direct	O
patients	O
towards	O
trials	O
for	O
new	O
potential	O
therapies	O
.	O

Mutations	O
in	O
the	O
different	O
domains	O
in	O
the	O
MYH14	B-GENE
might	O
lead	O
to	O
different	O
audiogram	O
configurations	O
.	O

Ten	O
novel	O
candidate	O
disease	O
causing	O
mutations	O
outside	O
of	O
ABCA4	B-GENE
were	O
observed	O
(	O
table	O
1	O
)	O
.	O

In	O
this	O
work	O
we	O
have	O
described	O
the	O
clinical	O
and	O
molecular	O
features	O
of	O
four	O
Mexican	O
siblings	O
who	O
have	O
WS	B-DISEASE
.	O

This	O
genetic	O
heterogeneity	O
has	O
made	O
clinical	O
application	O
difficult	O
,	O
in	O
spite	O
of	O
the	O
considerable	O
advances	O
in	O
discovery	O
of	O
deafness	B-DISEASE
genes	O
.	O

For	O
the	O
final	O
WES	O
report	O
the	O
VARIANT	O
[	O
26	O
]	O
annotation	O
tool	O
provided	O
the	O
putative	O
functional	O
consequence	O
,	O
as	O
well	O
as	O
other	O
additional	O
relevant	O
information	O
of	O
the	O
identified	O
variants	O
for	O
the	O
final	O
candidate	O
gene	O
selection	O
.	O

The	O
second	O
mutation	O
results	O
in	O
an	O
amino	O
acid	O
substitution	O
in	O
the	O
CDH23	B-GENE
gene	O
and	O
was	O
found	O
in	O
50	O
out	O
of	O
96	O
reads	O
.	O

The	O
data	O
were	O
subsequently	O
compared	O
with	O
the	O
wild	O
-	O
type	O
OTOF	B-GENE
(	O
NG_009937	O
.	O
1	O
,	O
NM_194248	O
.	O
2	O
)	O
and	O
PJVK	B-GENE
(	O
NG_0012186	O
.	O
1	O
,	O
NM_001042702	O
.	O
3	O
)	O
sequences	O
,	O
and	O
a	O
panel	O
of	O
105	O
controls	O
verified	O
it	O
.	O

The	O
allele	O
frequency	O
of	O
all	O
mutations	O
in	O
the	O
GJB2	B-GENE
gene	O
in	O
NSHI	B-DISEASE
patients	O
varied	O
from	O
4	O
.	O
0	O
%	O
in	O
Guangxi	O
to	O
30	O
.	O
4	O
%	O
in	O
Jiangsu	O
(	O
Table	O
2	O
)	O
.	O

The	O
novel	O
BSND	B-GENE
(	O
MIM_606412	O
)	O
missense	O
mutation	O
c	B-VARIANT
.	I-VARIANT
97G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Val33Leu	I-VARIANT
)	O
in	O
family	O
7DF	O
(	O
Figure	O
1	O
)	O
was	O
predicted	O
to	O
be	O
deleterious	O
by	O
SIFT	O
and	O
Polyphen2	O
(	O
Table	O
2	O
)	O
and	O
Val33	O
is	O
conserved	O
across	O
species	O
(	O
Figure	O
S1C	O
)	O
.	O

Click	O
here	O
for	O
file	O
Clinical	O
findings	O
from	O
families	O
with	O
c	B-VARIANT
.	I-VARIANT
983A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
2708_2711delTTAG	I-VARIANT
mutations	O
.	O

Heterozygous	O
mutations	O
in	O
known	O
deafness	B-DISEASE
genes	O
in	O
affected	O
families	O
and	O
hearing	O
individuals	O
.	O

The	O
sequencing	O
results	O
were	O
compared	O
to	O
the	O
NCBI	O
Reference	O
Sequence	O
(	O
NG_008072	O
.	O
1	O
)	O
.	O

This	O
process	O
were	O
performed	O
using	O
an	O
Ion	O
OneTouch	O
(	O
tm	O
)	O
ES	O
system	O
(	O
Life	O
Technologies	O
)	O
.	O

Details	O
of	O
the	O
14	O
Markers	O
used	O
for	O
fine	O
mapping	O
.	O

A	O
standard	O
control	O
MO	O
(	O
5	O
'	O
-	O
CCTCTTACCTCAGTTACAATTTATA	O
-	O
3	O
'	O
)	O
was	O
used	O
for	O
injection	O
of	O
negative	O
controls	O
along	O
with	O
p53	O
MO	O
.	O

To	O
identify	O
the	O
disease	O
-	O
causing	O
mutation	O
(	O
s	O
)	O
in	O
a	O
Chinese	O
family	O
with	O
autosomal	O
recessive	O
Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
1	I-DISEASE
(	O
USH1	B-DISEASE
)	O
.	O

The	O
patient	O
carrying	O
mutation	O
G25V	B-VARIANT
had	O
no	O
family	O
history	O
of	O
arrhythmia	B-DISEASE
.	O

In	O
Campbell	O
'	O
s	O
research	O
[	O
35	O
]	O
,	O
57	O
%	O
of	O
patients	O
from	O
the	O
US	O
with	O
Mondini	O
(	O
EVA	B-DISEASE
with	O
MD	B-DISEASE
)	O
from	O
simplex	O
families	O
carried	O
SLC26A4	B-GENE
mutations	O
,	O
and	O
he	O
considered	O
that	O
SLC26A4	B-GENE
mutations	O
were	O
present	O
mostly	O
in	O
patients	O
with	O
EVA	B-DISEASE
plus	O
MD	B-DISEASE
.	O

One	O
affected	O
male	O
was	O
in	O
the	O
family	O
(	O
3D	O
)	O
.	O

The	O
genotypes	O
of	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
were	O
called	O
using	O
Affymetrix	O
GCOS	O
1	O
.	O
4	O
software	O
,	O
which	O
generated	O
an	O
overall	O
average	O
SNP	O
call	O
rate	O
of	O
97	O
%	O
.	O

Segregation	O
analysis	O
of	O
Optic	B-GENE
Atrophy	I-GENE
1	I-GENE
mutations	O
in	O
three	O
families	O
with	O
dominant	B-DISEASE
optic	I-DISEASE
atrophy	I-DISEASE
.	O

Data	O
are	O
represented	O
as	O
the	O
mean	O
+	O
-	O
SEM	O
.	O

Novel	O
p	B-VARIANT
.	I-VARIANT
I411K	I-VARIANT
mutation	O
identified	O
in	O
JSNY	O
-	O
023	O
family	O
.	O

a	O
Monozygotic	O
twins	O
.	O

His	O
26	O
-	O
year	O
-	O
old	O
sister	O
also	O
had	O
evidence	O
of	O
mild	O
optic	O
nerve	O
involvement	O
(	O
6	O
/	O
9	O
,	O
both	O
eyes	O
)	O
but	O
her	O
neurological	O
examination	O
was	O
otherwise	O
normal	O
.	O

For	O
deglycosylation	O
analysis	O
,	O
5	O
mu	O
g	O
of	O
protein	O
(	O
Protein	O
Quantification	O
kit	O
-	O
Rapid	O
(	O
Sigma	O
-	O
Aldrich	O
Chemie	O
GmbH	O
,	O
Buchs	O
,	O
Switzerland	O
)	O
)	O
was	O
subjected	O
to	O
PNGasef	O
and	O
EndoH	O
f	O
digestion	O
according	O
to	O
manufacturer	O
'	O
s	O
recommendations	O
(	O
New	O
England	O
Biolabs	O
,	O
Ipswich	O
,	O
MA	O
)	O
.	O

Comprehensive	O
genetic	O
testing	O
was	O
completed	O
on	O
1119	O
sequentially	O
accrued	O
and	O
unrelated	O
patients	O
.	O

Amino	O
acids	O
conserved	O
in	O
evolution	O
are	O
marked	O
in	O
bold	O
,	O
and	O
mutations	O
are	O
marked	O
with	O
red	O
.	O

In	O
vitro	O
analyses	O
confirmed	O
that	O
the	O
WT	O
transcript	O
contained	O
the	O
correct	O
exon	O
(	O
band	O
A	O
)	O
but	O
the	O
c	B-VARIANT
.	I-VARIANT
1342_1343delAG	I-VARIANT
construction	O
generated	O
several	O
bands	O
.	O

SIFT	O
and	O
Polyphen2	O
were	O
used	O
as	O
a	O
first	O
-	O
pass	O
filter	O
to	O
predict	O
how	O
the	O
identified	O
amino	O
acid	O
substitutions	O
would	O
affect	O
protein	O
function	O
taking	O
into	O
account	O
sequence	O
homology	O
and	O
the	O
physical	O
properties	O
of	O
amino	O
acids	O
.	O

As	O
for	O
the	O
family	O
SH41	O
,	O
p	B-VARIANT
.	I-VARIANT
A2T	I-VARIANT
variant	O
of	O
the	O
OTOR	B-GENE
gene	O
(	O
Accession	O
No	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
a	O
novel	O
COL2A1	B-GENE
mutation	O
(	O
c	B-VARIANT
.	I-VARIANT
1744G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Gly582Ser	I-VARIANT
)	O
)	O
from	O
the	O
chromosome	O
12q13	O
region	O
within	O
one	O
Japanese	O
family	O
.	O

M	O
.	O

The	O
inheritance	O
pattern	O
in	O
these	O
three	O
families	O
was	O
autosomal	O
recessive	O
(	O
Figure	O
1	O
)	O
.	O

(	O
Fig	O
.	O

Aatif	O
M	O
.	O

Coverage	O
distributions	O
for	O
different	O
enrichment	O
kits	O
in	O
the	O
selected	O
nine	O
known	O
Usher	B-DISEASE
genes	O
.	O

Nucleotide	O
numbering	O
reflects	O
cDNA	O
numbering	O
with	O
+	O
1	O
corresponding	O
to	O
the	O
A	O
of	O
the	O
ATG	O
translation	O
initiation	O
codon	O
in	O
the	O
reference	O
sequence	O
,	O
according	O
to	O
the	O
journal	O
guidelines	O
(	O
www	O
.	O
hgvs	O
.	O
org	O
/	O
mutnomen	O
)	O
.	O

The	O
three	O
members	O
had	O
normal	O
cognitive	O
function	O
and	O
no	O
anomalous	O
-	O
looking	O
features	O
.	O

Therefore	O
,	O
there	O
could	O
be	O
enough	O
space	O
for	O
the	O
side	O
chain	O
of	O
the	O
threonine	O
at	O
this	O
position	O
(	O
Fig	O
.	O

This	O
pipeline	O
would	O
also	O
be	O
efficient	O
to	O
detect	O
somatic	O
mosaicism	O
in	O
mutation	O
-	O
negative	O
patients	O
with	O
other	O
diseases	O
,	O
including	O
cancer	O
.	O

Non	O
-	O
pathogenic	O
variants	O
of	O
OTOF	B-GENE
gene	O
identified	O
in	O
this	O
study	O
.	O

"	O
The	O
Finnish	O
founder	O
mutation	O
,	O
Finmajor	O
,	O
is	O
the	O
nonsense	O
mutation	O
c	B-VARIANT
.	I-VARIANT
528T	I-VARIANT
>	I-VARIANT
G	I-VARIANT
at	O
codon	O
176	O
(	O
p	B-VARIANT
.	I-VARIANT
Y176X	I-VARIANT
)	O
,	O
and	O
is	O
responsible	O
for	O
94	O
%	O
of	O
the	O
patients	O
with	O
USH3	B-DISEASE
studied	O
[	O
18	O
]	O
.	O

It	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
Eye	O
Hospital	O
,	O
Wenzhou	O
Medical	O
University	O
.	O

The	O
relative	O
rates	O
of	O
'	O
functional	O
'	O
(	O
missense	O
,	O
nonsense	O
,	O
CSS	O
and	O
read	O
-	O
through	O
)	O
versus	O
silent	O
changes	O
did	O
not	O
deviate	O
from	O
expectation	O
(	O
Table	O
2	O
)	O
.	O

(	O
e	O
)	O
TMC1	B-GENE
c	B-VARIANT
.	I-VARIANT
1714G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
D572N	I-VARIANT
)	O
missense	O
mutation	O
in	O
the	O
JSNY	O
-	O
053	O
family	O
.	O

Three	O
hundred	O
and	O
seven	O
patients	O
had	O
two	O
confirmed	O
pathogenic	O
mutations	O
,	O
including	O
178	O
homozygotes	O
and	O
129	O
compound	O
heterozygotes	O
.	O

The	O
schematic	O
shows	O
p	B-VARIANT
.	I-VARIANT
S288X	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
Q393X	I-VARIANT
mutations	O
,	O
which	O
make	O
truncated	O
proteins	O
at	O
each	O
position	O
.	O

We	O
additionally	O
filtered	O
variants	O
that	O
occurred	O
exclusively	O
in	O
non	O
-	O
coding	O
RNA	O
genes	O
,	O
those	O
that	O
affected	O
only	O
predicted	O
,	O
hypothetical	O
,	O
or	O
olfactory	O
genes	O
,	O
those	O
that	O
had	O
a	O
frequency	O
>	O
1	O
%	O
in	O
the	O
Caucasian	O
population	O
in	O
the	O
NHLBI	O
GO	O
exomes	O
sequence	O
data	O
,	O
those	O
exclusively	O
within	O
a	O
transcript	O
annotated	O
as	O
a	O
pseudogene	O
or	O
processed	O
pseudogene	O
based	O
on	O
Ensembl	O
release	O
(	O
64	O
)	O
annotation	O
downloaded	O
via	O
Biomart	O
,	O
and	O
lastly	O
those	O
that	O
were	O
reported	O
as	O
a	O
validated	O
somatic	O
mutation	O
in	O
the	O
same	O
sample	O
.	O

We	O
did	O
not	O
find	O
the	O
presence	O
of	O
the	O
above	O
-	O
mentioned	O
p	B-VARIANT
.	I-VARIANT
Asp2006Tyr	I-VARIANT
mutation	O
in	O
the	O
TECTA	B-GENE
gene	O
(	O
data	O
not	O
shown	O
)	O
,	O
demonstrating	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
of	O
the	O
mutation	O
in	O
TECTA	B-GENE
gene	O
with	O
the	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
the	O
Mongolian	O
family	O
.	O

Mutations	O
in	O
OPA1	B-GENE
account	O
for	O
the	O
majority	O
(	O
60	O
%	O
-	O
70	O
%	O
)	O
of	O
patients	O
with	O
DOA	B-DISEASE
[	O
19	O
]	O
.	O

Rare	O
variants	O
are	O
thought	O
to	O
contribute	O
significantly	O
to	O
the	O
etiology	O
of	O
common	O
disease	O
[	O
32	O
]	O
,	O
and	O
strategies	O
for	O
prioritizing	O
disease	O
variants	O
from	O
WGS	O
often	O
include	O
a	O
frequency	O
filter	O
to	O
exclude	O
common	O
variants	O
.	O

Notably	O
,	O
two	O
novel	O
mutations	O
of	O
USH1G	B-GENE
were	O
recently	O
reported	O
in	O
individuals	O
with	O
atypical	O
Usher	B-DISEASE
syndrome	I-DISEASE
(	O
p	B-VARIANT
.	I-VARIANT
D458V	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
163_164	I-VARIANT
+	I-VARIANT
13del15	I-VARIANT
)	O
.	O

Several	O
recent	O
studies	O
have	O
also	O
performed	O
NGS	O
based	O
genetic	O
diagnosis	O
of	O
STGD	B-DISEASE
patients	O
10	O
,	O
31	O
-	O
33	O
.	O

These	O
primers	O
led	O
to	O
an	O
892	O
-	O
bp	O
PCR	O
product	O
.	O

Immunofluorescence	O
analysis	O
for	O
myosin	B-GENE
-	I-GENE
9	I-GENE
localization	O
in	O
neutrophils	O
was	O
performed	O
on	O
peripheral	O
blood	O
smears	O
using	O
the	O
NMG2	O
mouse	O
monoclonal	O
antibody	O
.	O

None	O
declared	O
.	O

Mutations	O
in	O
MYO15A	B-GENE
are	O
responsible	O
for	O
the	O
DFNB3	B-DISEASE
form	O
of	O
deafness	B-DISEASE
[	O
13	O
]	O
.	O

Comparison	O
between	O
the	O
MYO7A	B-GENE
group	O
and	O
CDH23	B-GENE
group	O
,	O
MYO7A	B-GENE
and	O
Control	O
group	O
and	O
CDH23	B-GENE
group	O
and	O
Control	O
group	O
.	O

These	O
factors	O
impinge	O
on	O
pancreatic	O
beta	O
-	O
cells	O
resulting	O
in	O
ER	B-DISEASE
stress	I-DISEASE
,	O
oxidative	B-DISEASE
stress	I-DISEASE
,	O
impaired	B-DISEASE
signal	I-DISEASE
transduction	I-DISEASE
,	O
and	O
mitochondrial	B-DISEASE
dysfunction	I-DISEASE
,	O
all	O
combining	O
to	O
result	O
in	O
beta	B-DISEASE
-	I-DISEASE
cell	I-DISEASE
apoptosis	I-DISEASE
and	O
diabetes	B-DISEASE
[	O
10	O
-	O
13	O
]	O
.	O

The	O
mutation	O
G60D	B-VARIANT
resides	O
in	O
the	O
transmembrane	O
segment	O
(	O
TMS	O
)	O
of	O
KCNE1	B-GENE
in	O
close	O
proximity	O
of	O
residues	O
57	O
-	O
59	O
(	O
"	O
the	O
gating	O
triplet	O
"	O
)	O
that	O
are	O
critical	O
for	O
the	O
modulation	O
of	O
K	B-GENE
V	I-GENE
7	I-GENE
.	I-GENE
1	I-GENE
channels	O
[	O
28	O
]	O
.	O

The	O
mutation	O
(	O
arrow	O
)	O
was	O
present	O
in	O
all	O
65	O
reads	O
covering	O
this	O
region	O
of	O
the	O
gene	O
and	O
therefore	O
appeared	O
homozygous	O
.	O

Although	O
not	O
satisfying	O
the	O
criteria	O
for	O
pathogenicity	O
,	O
this	O
variant	O
is	O
an	O
excellent	O
candidate	O
for	O
further	O
studies	O
as	O
to	O
its	O
clinical	O
impact	O
.	O

Syndromic	O
patient	O
95	O
was	O
tested	O
by	O
array	O
CGH	O
using	O
the	O
Agilent	O
4x180K	O
(	O
Agilent	O
Technologies	O
,	O
Santa	O
Clara	O
,	O
CA	O
)	O
platform	O
.	O

3h	O
)	O
staining	O
.	O

This	O
mutation	O
results	O
in	O
decreased	O
protease	O
activity	O
,	O
which	O
may	O
explain	O
its	O
underlying	O
molecular	O
etiology	O
for	O
deafness	B-DISEASE
.	O

Paciorkowski	O
,	O
M	O
.	O
D	O
.	O

These	O
findings	O
highlight	O
the	O
clinical	O
range	O
of	O
collagen	B-DISEASE
IV	I-DISEASE
-	I-DISEASE
related	I-DISEASE
nephropathies	I-DISEASE
and	O
resolved	O
diagnostic	O
confusion	O
arising	O
from	O
atypical	O
or	O
incomplete	O
clinical	O
/	O
histological	O
findings	O
,	O
allowing	O
appropriate	O
counselling	O
and	O
treatment	O
advice	O
to	O
be	O
given	O
.	O

The	O
13	O
patients	O
with	O
the	O
common	O
sequence	O
at	O
positions	O
c	O
.	O
-	O
137	O
and	O
c	O
.	O
-	O
53	O
and	O
the	O
11	O
patients	O
with	O
the	O
two	O
heterozygous	O
5	O
'	O
polymorphisms	O
distributed	O
equally	O
in	O
relation	O
to	O
the	O
p	B-VARIANT
.	I-VARIANT
Gly843Asp	I-VARIANT
mutation	O
.	O

The	O
alpha	O
-	O
tectorin	O
protein	O
,	O
which	O
is	O
encoded	O
by	O
the	O
TECTA	B-GENE
gene	O
,	O
is	O
one	O
of	O
the	O
major	O
components	O
of	O
the	O
tectorial	O
membrane	O
in	O
the	O
inner	O
ear	O
.	O

Temporal	O
bone	O
CT	O
scans	O
of	O
males	O
with	O
POU3F4	B-GENE
mutations	O
show	O
inner	B-DISEASE
ear	I-DISEASE
anomalies	I-DISEASE
.	O

The	O
replacement	O
of	O
Gly	O
by	O
Arg	O
may	O
induce	O
a	O
new	O
secondary	O
structure	O
that	O
includes	O
Leu1831	O
,	O
Val1832	O
,	O
and	O
Val1833	O
.	O

As	O
there	O
is	O
a	O
recombination	O
event	O
in	O
this	O
patient	O
for	O
marker	O
D11S1349	O
,	O
both	O
alleles	O
are	O
shown	O
.	O

An	O
additional	O
seven	O
are	O
among	O
genes	O
with	O
an	O
existing	O
OMIM	O
or	O
PubMed	O
disease	O
association	O
with	O
a	O
less	O
consistent	O
clinical	O
phenotypic	O
overlap	O
(	O
DCTN1	B-GENE
,	O
BIN1	B-GENE
,	O
GRIN1	B-GENE
,	O
GRIN2B	B-GENE
,	O
COL4A1	B-GENE
,	O
MYO5A	B-GENE
,	O
and	O
HUWE1	B-GENE
)	O
.	O

The	O
large	O
genomic	O
rearrangement	O
in	O
PCDH15	B-GENE
previously	O
reported	O
by	O
Le	O
Guedard	O
et	O
al	O
.	O

The	O
mitochondrion	O
was	O
labeled	O
using	O
the	O
MitoTracker	O
probe	O
.	O

B	O
:	O
c	B-VARIANT
.	I-VARIANT
8232G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
created	O
a	O
new	O
HpyCH4V	O
restriction	O
site	O
that	O
co	O
-	O
segregated	O
with	O
the	O
affected	O
individuals	O
and	O
the	O
carriers	O
(	O
88	O
bp	O
,	O
186	O
bp	O
,	O
218	O
bp	O
,	O
and	O
274	O
bp	O
)	O
,	O
but	O
not	O
with	O
unaffected	O
individuals	O
and	O
normal	O
controls	O
(	O
218	O
bp	O
,	O
274	O
bp	O
)	O
.	O

Therefore	O
,	O
the	O
present	O
results	O
provide	O
useful	O
information	O
for	O
clinical	O
application	O
of	O
mutant	O
gene	O
detection	O
in	O
patients	O
with	O
deafness	B-DISEASE
.	O

In	O
Asian	O
population	O
,	O
more	O
than	O
80	O
%	O
of	O
nonsyndromic	O
patients	O
with	O
EVA	B-DISEASE
harbored	O
mutations	O
in	O
SLC26A4	B-GENE
[	O
19	O
,	O
27	O
,	O
29	O
,	O
30	O
]	O
.	O

Retinitis	B-DISEASE
pigmentosa	I-DISEASE
(	O
RP	B-DISEASE
)	O
and	O
Leber	B-DISEASE
congenital	I-DISEASE
amaurosis	I-DISEASE
(	O
LCA	B-DISEASE
)	O
are	O
major	O
causes	O
of	O
blindness	B-DISEASE
.	O

Due	O
to	O
the	O
large	O
number	O
and	O
presumably	O
low	O
mutation	O
frequencies	O
of	O
those	O
genes	O
,	O
it	O
would	O
be	O
highly	O
expensive	O
and	O
time	O
-	O
consuming	O
to	O
address	O
this	O
issue	O
by	O
the	O
conventional	O
gene	O
-	O
by	O
-	O
gene	O
Sanger	O
sequencing	O
.	O

del	O
Castillo	O
,	O
personal	O
communication	O
]	O
.	O

Neither	O
c	B-VARIANT
.	I-VARIANT
161T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
nor	O
c	B-VARIANT
.	I-VARIANT
368C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
were	O
found	O
from	O
the	O
90	O
CEPH	O
control	O
samples	O
nor	O
the	O
19	O
Finnish	O
patients	O
we	O
sequenced	O
.	O

Additionally	O
,	O
one	O
patient	O
with	O
a	O
clinical	O
diagnosis	O
of	O
Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
1	I-DISEASE
carrying	O
three	O
apparently	O
homozygous	O
VUS	O
in	O
CDH23	B-GENE
had	O
bilateral	O
malformation	B-DISEASE
of	I-DISEASE
the	I-DISEASE
semicircular	I-DISEASE
canals	I-DISEASE
.	O

A	O
total	O
of	O
thirty	O
-	O
eight	O
fresh	O
nasal	O
samples	O
were	O
obtained	O
from	O
eight	O
USH1	B-DISEASE
patients	O
,	O
five	O
patients	O
with	O
mutations	O
in	O
MYO7A	B-GENE
gene	O
and	O
three	O
patients	O
with	O
mutations	O
in	O
the	O
CDH23	B-GENE
gene	O
,	O
and	O
thirty	O
control	O
subjects	O
.	O

Of	O
the	O
21	O
other	O
sequence	O
variations	O
observed	O
,	O
four	O
were	O
previously	O
reported	O
as	O
recessive	O
mutations	O
(	O
R32H	B-VARIANT
,	O
S19T	B-VARIANT
,	O
N206S	B-VARIANT
,	O
R184P	B-VARIANT
)	O
,	O
five	O
are	O
known	O
non	O
pathogenic	O
variants	O
(	O
V27I	B-VARIANT
,	O
F83L	B-VARIANT
,	O
E114G	B-VARIANT
,	O
V153I	B-VARIANT
,	O
G160S	B-VARIANT
)	O
,	O
three	O
of	O
them	O
are	O
silent	O
(	O
D159D	B-VARIANT
,	O
Q7Q	B-VARIANT
,	O
T26T	B-VARIANT
)	O
,	O
six	O
have	O
unknown	O
consequences	O
(	O
-	B-VARIANT
34T	I-VARIANT
>	I-VARIANT
G	I-VARIANT
,	O
IVS1	B-VARIANT
-	I-VARIANT
12C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
,	O
IVS1	B-VARIANT
-	I-VARIANT
7G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
G4D	B-VARIANT
,	O
H67R	B-VARIANT
,	O
Y68C	B-VARIANT
)	O
and	O
three	O
are	O
still	O
controversial	O
(	O
M34T	B-VARIANT
,	O
V37I	B-VARIANT
,	O
R127H	B-VARIANT
and	O
see	O
below	O
)	O
.	O

The	O
entire	O
custom	O
design	O
was	O
481	O
targets	O
with	O
a	O
total	O
size	O
of	O
132	O
.	O
763	O
Kb	O
.	O

WFS	B-DISEASE
is	O
a	O
rare	O
monogenic	O
disorder	O
characterized	O
by	O
ER	O
stress	O
in	O
cell	O
lines	O
[	O
4	O
,	O
6	O
,	O
27	O
]	O
and	O
in	O
animal	O
models	O
[	O
4	O
,	O
5	O
,	O
7	O
]	O
with	O
multiple	O
clinical	O
manifestations	O
.	O

Wild	O
type	O
(	O
WT	O
)	O
human	O
NARS2	B-GENE
cDNA	O
(	O
clone	O
#	O
Z7860	O
)	O
was	O
obtained	O
from	O
GeneCopoeia	O
and	O
subcloned	O
into	O
pEGFP	O
-	O
N2	O
vector	O
(	O
Clontech	O
)	O
using	O
InFusion	O
cloning	O
(	O
Clontech	O
)	O
.	O

(	O
2001	O
)	O
in	O
an	O
acquired	O
LQTS	B-DISEASE
cohort	O
.	O

Here	O
,	O
we	O
sought	O
to	O
determine	O
the	O
molecular	O
basis	O
of	O
Perrault	B-DISEASE
syndrome	I-DISEASE
in	O
one	O
non	O
-	O
consanguineous	O
Italian	O
family	O
by	O
whole	O
-	O
exome	O
sequencing	O
(	O
WES	O
)	O
.	O

As	O
a	O
result	O
,	O
two	O
clearly	O
pathogenic	O
,	O
novel	O
mutations	O
were	O
identified	O
in	O
the	O
USH1C	B-GENE
gene	O
.	O

We	O
sincerely	O
thank	O
all	O
the	O
family	O
members	O
for	O
their	O
participation	O
and	O
cooperation	O
in	O
this	O
study	O
.	O

Following	O
such	O
findings	O
,	O
these	O
patients	O
were	O
re	O
-	O
evaluated	O
clinically	O
,	O
and	O
confirmed	O
to	O
have	O
achromatopsia	B-DISEASE
and	O
choroideremia	B-DISEASE
.	O

Both	O
wild	O
type	O
and	O
mutant	O
DSPP	B-GENE
alleles	O
(	O
1933bp	O
containing	O
whole	O
exon3	O
-	O
intron3	O
-	O
exon4	O
and	O
partial	O
intron	O
2	O
and	O
intron	O
4	O
)	O
were	O
amplified	O
and	O
cloned	O
into	O
splicing	O
vector	O
pLRT	O
to	O
construct	O
the	O
recombinant	O
plasmids	O
.	O

For	O
sample	O
D	O
,	O
only	O
a	O
null	O
mutation	O
in	O
PRPF31	B-GENE
was	O
identified	O
as	O
consistent	O
with	O
the	O
diagnosis	O
of	O
RP	B-DISEASE
.	O

[	O
7	O
]	O
identified	O
51	O
additional	O
exons	O
at	O
the	O
3	O
'	O
end	O
of	O
USH2A	B-GENE
.	O

Results	O
from	O
a	O
recent	O
meta	O
-	O
analysis	O
of	O
GWAS	O
studies	O
suggest	O
that	O
this	O
variant	O
is	O
associated	O
either	O
with	O
slightly	O
higher	O
risk	O
of	O
breast	B-DISEASE
cancer	I-DISEASE
or	O
is	O
in	O
linkage	O
disequilibrium	O
with	O
higher	O
risk	O
variant	O
(	O
s	O
)	O
[	O
52	O
]	O
.	O

So	O
,	O
it	O
is	O
impossible	O
to	O
detect	O
a	O
mutation	O
in	O
a	O
region	O
which	O
is	O
not	O
covered	O
using	O
this	O
system	O
(	O
Case	O
#	O
9	O
:	O
c	B-VARIANT
.	I-VARIANT
5821	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
)	O
.	O

Mutations	O
in	O
FOXI1	B-GENE
,	O
13	O
a	O
modulatory	O
gene	O
of	O
SLC26A4	B-GENE
,	O
were	O
not	O
found	O
in	O
our	O
series	O
of	O
patients	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
coverage	O
over	O
the	O
exonic	O
regions	O
of	O
the	O
55	O
NSHL	B-DISEASE
genes	O
was	O
slightly	O
higher	O
than	O
the	O
overall	O
targets	O
for	O
III	O
-	O
4	O
,	O
but	O
similar	O
or	O
slightly	O
lower	O
than	O
the	O
overall	O
targets	O
for	O
III	O
-	O
13	O
(	O
Table	O
5	O
)	O
.	O

Finally	O
,	O
one	O
case	O
originally	O
from	O
the	O
group	O
of	O
11	O
samples	O
(	O
subgroup	O
3	O
,	O
S1	O
Table	O
)	O
,	O
that	O
was	O
initially	O
thought	O
to	O
have	O
a	O
phenotype	O
with	O
no	O
known	O
gene	O
at	O
the	O
time	O
,	O
was	O
re	O
-	O
evaluated	O
and	O
determined	O
to	O
be	O
Townes	B-DISEASE
-	I-DISEASE
Brock	I-DISEASE
syndrome	I-DISEASE
.	O

Some	O
authors	O
also	O
recognize	O
an	O
autosomal	B-DISEASE
dominant	I-DISEASE
form	I-DISEASE
of	I-DISEASE
AS	I-DISEASE
,	O
caused	O
by	O
heterozygous	O
COL4A3	B-GENE
/	I-GENE
A4	I-GENE
mutations	O
and	O
Alport	O
-	O
like	O
ultrastructural	O
histology	O
[	O
7	O
]	O
,	O
[	O
17	O
]	O
.	O

The	O
ClinVar	O
database	O
version	O
2013	O
-	O
8	O
[	O
28	O
]	O
,	O
an	O
archive	O
of	O
relationships	O
between	O
variations	O
found	O
in	O
patient	O
samples	O
and	O
phenotypes	O
,	O
was	O
consulted	O
for	O
reports	O
of	O
clinical	O
significance	O
.	O

In	O
the	O
11th	O
family	O
,	O
we	O
identified	O
a	O
de	O
novo	O
dominant	O
mutation	O
in	O
SYNGAP1	B-GENE
causing	O
intellectual	B-DISEASE
disability	I-DISEASE
(	O
MIM	O
#	O
612621	O
)	O
[	O
Berryer	O
et	O
al	O
.	O
,	O
2013	O
]	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Thus	O
far	O
,	O
TMPRSS3	B-GENE
:	O
207delC	B-VARIANT
is	O
the	O
most	O
commonly	O
reported	O
deafness	B-DISEASE
mutation	O
for	O
this	O
gene	O
.	O

Naoto	O
Hato	O
and	O
Kiyofumi	O
Gyo	O
(	O
Ehime	O
University	O
)	O
,	O
Drs	O
.	O

Each	O
captured	O
pool	O
was	O
sequenced	O
using	O
single	O
-	O
end	O
80	O
bp	O
reads	O
on	O
an	O
Illumina	O
GAIIx	O
Sequencer	O
(	O
Illumina	O
Inc	O
.	O
,	O
Little	O
Chesterford	O
,	O
UK	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Functional	O
tests	O
of	O
mutated	O
pendrin	O
allelic	O
variants	O
found	O
in	O
patients	O
with	O
Pendred	B-DISEASE
syndrome	I-DISEASE
or	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
EVA	I-DISEASE
revealed	O
that	O
the	O
pathology	O
is	O
linked	O
to	O
a	O
reduction	O
or	O
a	O
loss	O
of	O
function	O
in	O
the	O
ion	O
transport	O
activity	O
of	O
pendrin	O
[	O
34	O
]	O
,	O
[	O
35	O
]	O
.	O

screened	O
15	O
ARNSHL	B-DISEASE
genes	O
in	O
1	O
positive	O
control	O
and	O
3	O
ARNSHL	B-DISEASE
families	O
with	O
MPS	O
and	O
identified	O
a	O
pathogenic	O
mutation	O
in	O
2	O
ARNSHL	B-DISEASE
families	O
of	O
Iranian	O
ancestry	O
[	O
51	O
]	O
.	O

This	O
mutation	O
could	O
not	O
be	O
confirmed	O
with	O
Sanger	O
sequencing	O
(	O
see	O
Table	O
4	O
)	O
.	O

Extracted	O
DNA	O
was	O
then	O
amplified	O
by	O
ligation	O
-	O
mediated	O
PCR	O
(	O
LM	O
-	O
PCR	O
)	O
,	O
purified	O
,	O
and	O
hybridized	O
to	O
the	O
NimblegenSeqCap	O
EZ	O
Library	O
for	O
enrichment	O
;	O
non	O
-	O
hybridized	O
fragments	O
were	O
then	O
washed	O
out	O
.	O

Furthermore	O
,	O
we	O
sequenced	O
the	O
transcripts	O
of	O
OPA1	B-GENE
from	O
the	O
patient	O
skin	O
fibroblasts	O
and	O
found	O
there	O
is	O
six	O
-	O
nucleotide	O
deletion	O
(	O
c	B-VARIANT
.	I-VARIANT
2984	I-VARIANT
-	I-VARIANT
c	I-VARIANT
.	I-VARIANT
2989	I-VARIANT
,	I-VARIANT
AGAAAG	I-VARIANT
)	O
.	O

The	O
site	O
of	O
one	O
of	O
the	O
mutant	O
residues	O
,	O
p	O
.	O
Glu638	O
,	O
is	O
highly	O
conserved	O
across	O
eukaryotes	O
,	O
from	O
yeast	O
to	O
humans	O
.	O

It	O
would	O
not	O
have	O
been	O
possible	O
to	O
ascertain	O
this	O
without	O
whole	O
-	O
exome	O
sequencing	O
.	O

Two	O
missense	O
variants	O
,	O
p	B-VARIANT
.	I-VARIANT
N174S	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
R1273S	I-VARIANT
,	O
were	O
detected	O
in	O
very	O
low	O
frequency	O
(	O
see	O
Appendix	O
2	O
)	O
.	O

Provenance	O
and	O
peer	O
review	O
:	O
Not	O
commissioned	O
;	O
externally	O
peer	O
reviewed	O
.	O

The	O
genetic	O
spectrum	O
of	O
arNSHL	B-DISEASE
in	O
Chinese	O
patients	O
mainly	O
includes	O
mutations	O
in	O
GJB2	B-GENE
,	O
SLC26A4	B-GENE
,	O
MYO7A	B-GENE
,	O
POU3F4	B-GENE
,	O
USH2A	B-GENE
and	O
TMC1	B-GENE
.	O

SD	O
-	O
OCT	O
(	O
Carl	O
Zeiss	O
Meditec	O
)	O
images	O
were	O
obtained	O
from	O
all	O
of	O
the	O
patients	O
.	O

,	O
2005	O
)	O
;	O
CN	O
-	O
2	O
:	O
(	O
Ke	O
et	O
al	O
.	O

The	O
normalization	O
steps	O
were	O
automated	O
using	O
the	O
Packard	O
Multiprobe	O
II	O
HT	O
EX	O
.	O

All	O
images	O
are	O
projection	O
of	O
confocal	O
optical	O
sections	O
stack	O
.	O

After	O
fixation	O
,	O
BHK	O
-	O
21	O
cells	O
were	O
permeabilized	O
for	O
20	O
min	O
with	O
0	O
.	O
2	O
%	O
saponin	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
in	O
phosphate	O
buffered	O
saline	O
(	O
PBS	O
;	O
137	O
mM	O
NaCl	O
,	O
2	O
.	O
7	O
mM	O
KCl	O
,	O
10	O
mM	O
Na	O
2	O
HPO	O
4	O
,	O
and	O
1	O
.	O
5	O
mM	O
KH	O
2	O
PO	O
4	O
in	O
distilled	O
water	O
,	O
pH	O
7	O
.	O
4	O
)	O
containing	O
0	O
.	O
5	O
%	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
;	O
Sigma	O
-	O
Aldrich	O
)	O
.	O

In	O
addition	O
,	O
concerning	O
pathogenecity	O
of	O
mutations	O
identified	O
,	O
functional	O
analysis	O
will	O
be	O
necessary	O
to	O
draw	O
the	O
final	O
conclusion	O
in	O
the	O
future	O
.	O

Brownstein	O
et	O
al	O
.	O

We	O
found	O
three	O
T123N	B-VARIANT
alleles	O
in	O
our	O
control	O
subjects	O
but	O
none	O
in	O
the	O
patient	O
group	O
.	O

The	O
activation	O
was	O
significantly	O
faster	O
for	O
the	O
mutated	O
channels	O
as	O
compared	O
with	O
wild	O
-	O
type	O
channels	O
(	O
Figure	O
2E	O
,	O
Additional	O
file	O
1	O
:	O
Figure	O
S2	O
)	O
.	O

The	O
COL4A3	B-GENE
mutation	O
in	O
Family	O
DUK6696	O
is	O
most	O
likely	O
disease	O
causing	O
.	O

We	O
performed	O
whole	O
exome	O
sequencing	O
on	O
an	O
autosomal	O
recessive	O
IOSCA	B-DISEASE
family	O
with	O
sensorimotor	B-DISEASE
polyneuropathy	I-DISEASE
and	O
myopathy	B-DISEASE
to	O
identify	O
mutations	O
causally	O
associated	O
with	O
disease	O
onset	O
(	O
Fig	O
.	O

These	O
two	O
missense	O
variants	O
are	O
probably	O
benign	O
.	O

The	O
ERG	O
wave	O
amplitudes	O
of	O
patient	O
II	O
:	O
4	O
were	O
undetectable	O
from	O
the	O
baseline	O
.	O

c	O
However	O
,	O
a	O
follow	O
-	O
up	O
brain	O
MRI	O
3	O
years	O
later	O
revealed	O
bilateral	O
middle	O
cerebellar	O
peduncle	O
lesions	O
(	O
arrows	O
)	O
.	O

Located	O
on	O
11q13	O
.	O
5	O
,	O
the	O
MYO7A	B-GENE
gene	O
yields	O
a	O
transcript	O
of	O
7	O
.	O
46	O
Kb	O
encompassing	O
49	O
exons	O
.	O

The	O
heterozygous	O
deletion	O
of	O
exon	O
1	O
in	O
patient	O
57	O
was	O
detected	O
by	O
quantitative	O
analysis	O
of	O
NGS	O
data	O
.	O

Haplotype	O
analysis	O
of	O
STR	O
-	O
markers	O
flanking	O
TMC1	B-GENE
showed	O
compatibility	O
with	O
genetic	O
linkage	O
for	O
family	O
11DF	O
.	O

8	O
However	O
,	O
the	O
remaining	O
clinically	O
diagnosed	O
CINCA	B-DISEASE
/	O
NOMID	B-DISEASE
patients	O
(	O
~	O
40	O
%	O
)	O
show	O
no	O
heterozygous	O
germline	O
NLRP3	B-GENE
mutation	O
based	O
on	O
conventional	O
DNA	O
sequencing	O
-	O
based	O
genetic	O
analyses	O
(	O
mutation	O
-	O
negative	O
patients	O
)	O
.	O

Five	O
micrograms	O
of	O
whole	O
-	O
blood	O
genomic	O
DNA	O
from	O
the	O
affected	O
proband	O
and	O
his	O
parents	O
were	O
sent	O
to	O
the	O
University	O
of	O
Washington	O
Genome	O
Sciences	O
Genomic	O
Resource	O
Center	O
for	O
exome	O
capture	O
and	O
sequencing	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
institutional	O
review	O
board	O
of	O
the	O
First	O
Affiliated	O
Hospital	O
,	O
Sun	O
Yat	O
-	O
sen	O
University	O
.	O

All	O
subjects	O
but	O
one	O
had	O
diabetes	B-DISEASE
mellitus	I-DISEASE
and	O
all	O
diabetic	B-DISEASE
subjects	O
were	O
taking	O
insulin	O
either	O
by	O
multiple	O
daily	O
injections	O
(	O
Lantus	O
and	O
a	O
rapid	O
-	O
acting	O
insulin	O
analog	O
)	O
or	O
by	O
insulin	O
pump	O
.	O

First	O
,	O
variants	O
frequency	O
>	O
.	O
5	O
%	O
in	O
the	O
1	O
000	O
genomes	O
project	O
builds	O
2010	O
&	O
2011	O
16	O
,	O
NHLBI	O
GO	O
Exome	O
Sequencing	O
Project	O
(	O
ESP	O
)	O
cohort	O
17	O
,	O
or	O
an	O
internal	O
control	O
database	O
at	O
the	O
human	O
genome	O
sequencing	O
center	O
were	O
filtered	O
out	O
.	O

The	O
highly	O
variable	O
phenotype	O
,	O
both	O
within	O
and	O
between	O
families	O
,	O
suggests	O
that	O
modifier	O
genes	O
and	O
/	O
or	O
environmental	O
factors	O
influence	O
the	O
expression	O
of	O
the	O
disease	O
.	O

Refined	O
genotyping	O
of	O
two	O
congenic	O
lines	O
10	O
.	O
R	O
and	O
10	O
.	O
2	O
delimited	O
the	O
ahl5	B-DISEASE
critical	O
interval	O
in	O
a	O
2	O
.	O
19	O
Mbp	O
region	O
(	O
red	O
box	O
)	O
defined	O
by	O
markers	O
D10Ntra205	O
and	O
D10Ntra222	O
.	O

Four	O
children	O
with	O
prelingual	O
,	O
bilateral	O
,	O
severe	O
to	O
profound	O
hearing	B-DISEASE
loss	I-DISEASE
were	O
homozygous	O
at	O
markers	O
D7S496	O
and	O
D7S2459	O
but	O
for	O
different	O
alleles	O
than	O
in	O
Family	O
Y	O
(	O
Figure	O
1D	O
)	O
.	O

Retinal	O
imaging	O
of	O
both	O
eyes	O
(	O
BE	O
)	O
of	O
the	O
proband	O
IV	O
:	O
3	O
at	O
age	O
35	O
.	O

The	O
synonymous	O
variants	O
c	B-VARIANT
.	I-VARIANT
1083A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
1083A	I-VARIANT
>	I-VARIANT
T	I-VARIANT
occur	O
at	O
the	O
-	O
2	O
position	O
of	O
the	O
5	O
'	O
(	O
donor	O
)	O
splice	O
site	O
of	O
FGFR2	B-GENE
exon	O
IIIc	O
(	O
Figure	O
2	O
A	O
)	O
.	O

Next	O
Generation	O
Sequencing	O
with	O
the	O
Illumina	O
MiSeq	O
system	O
allowed	O
us	O
to	O
perform	O
qualitative	O
and	O
quantitative	O
analysis	O
.	O

Fragmentation	O
of	O
genomic	O
DNA	O
samples	O
was	O
carried	O
out	O
either	O
by	O
nebulization	O
or	O
ultrasonication	O
.	O

Note	O
that	O
even	O
when	O
the	O
mutant	O
allele	O
is	O
expressed	O
(	O
patients	O
TCS16	B-DISEASE
and	O
TCS23	B-DISEASE
)	O
,	O
the	O
peak	O
heights	O
are	O
lower	O
.	O

The	O
solid	O
squares	O
(	O
male	O
)	O
and	O
circles	O
(	O
female	O
)	O
represent	O
affected	O
patients	O
.	O

Two	O
oligonucleotides	O
complementary	O
to	O
a	O
target	O
sequence	O
hybridise	O
next	O
to	O
each	O
other	O
on	O
the	O
target	O
,	O
separated	O
by	O
a	O
single	O
base	O
.	O

Individual	O
genes	O
from	O
these	O
clusters	O
were	O
extracted	O
.	O

In	O
humans	O
the	O
most	O
compelling	O
fact	O
is	O
that	O
bi	O
-	O
allelic	O
SLC26A4	B-GENE
mutations	O
are	O
found	O
in	O
only	O
a	O
minority	O
of	O
patients	O
,	O
even	O
those	O
with	O
the	O
most	O
severe	O
phenotype	O
of	O
EVA	B-DISEASE
-	O
Mondini	O
and	O
thyroid	B-DISEASE
dysfunction	I-DISEASE
or	O
goitre	B-DISEASE
.	O

The	O
distribution	O
of	O
mutant	O
SLC26A4	B-GENE
alleles	O
revealed	O
by	O
our	O
study	O
suggests	O
that	O
mutation	O
screening	O
of	O
four	O
exons	O
(	O
exons	O
19	O
,	O
10	O
,	O
17	O
and	O
15	O
)	O
following	O
c	B-VARIANT
.	I-VARIANT
IVS7	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
identification	O
should	O
be	O
a	O
priority	O
for	O
NSHI	B-DISEASE
genetic	O
testing	O
in	O
patients	O
with	O
EVA	B-DISEASE
.	O

After	O
retrospective	O
selection	O
using	O
the	O
more	O
stringent	O
criteria	O
,	O
15	O
subjects	O
were	O
selected	O
.	O

The	O
clinical	O
examination	O
and	O
the	O
MRI	O
confirmed	O
the	O
diagnosis	O
of	O
isolated	O
bilateral	O
optic	B-DISEASE
neuropathy	I-DISEASE
.	O

Computer	O
-	O
based	O
data	O
analysis	O
was	O
also	O
not	O
particularly	O
complicated	O
;	O
we	O
mostly	O
used	O
simple	O
text	O
-	O
parsing	O
scripts	O
and	O
/	O
or	O
commercial	O
spreadsheet	O
programs	O
with	O
filtering	O
capabilities	O
,	O
on	O
common	O
desktop	O
computers	O
.	O

All	O
participants	O
were	O
examined	O
by	O
a	O
multidisciplinary	O
team	O
of	O
healthcare	O
providers	O
that	O
included	O
a	O
neurologist	O
,	O
otolaryngologist	O
and	O
audiologist	O
.	O

Our	O
study	O
extends	O
the	O
spectrums	O
of	O
MYO7A	B-GENE
mutations	O
and	O
its	O
related	O
clinical	O
phenotypes	O
.	O

Finally	O
,	O
to	O
focus	O
on	O
likely	O
disease	O
-	O
causing	O
variants	O
,	O
we	O
prioritized	O
frameshift	O
,	O
indel	O
,	O
nonsense	O
,	O
missense	O
and	O
canonical	O
splice	O
site	O
variants	O
for	O
further	O
analysis	O
.	O

It	O
is	O
important	O
to	O
detect	O
both	O
point	O
mutations	O
and	O
large	O
deletions	O
or	O
duplications	O
with	O
a	O
single	O
technique	O
to	O
minimize	O
the	O
economic	O
cost	O
of	O
these	O
studies	O
,	O
increasing	O
the	O
detection	O
ratio	O
of	O
the	O
genetic	O
cause	O
of	O
the	O
disease	O
and	O
improving	O
the	O
genetic	O
diagnosis	O
of	O
Usher	B-DISEASE
syndrome	I-DISEASE
patients	O
.	O

Vestibular	O
function	O
was	O
normal	O
.	O

The	O
frequency	O
of	O
somatic	O
mutations	O
in	O
each	O
of	O
these	O
genes	O
is	O
low	O
(	O
<	O
1	O
.	O
3	O
%	O
)	O
,	O
as	O
is	O
the	O
frequency	O
of	O
germline	O
variants	O
(	O
<	O
0	O
.	O
3	O
%	O
)	O
.	O

According	O
to	O
Alamut	O
2	O
.	O
3	O
software	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
interactive	O
-	O
biosoftware	O
.	O
com	O
)	O
,	O
it	O
is	O
predicted	O
to	O
abolish	O
the	O
splice	O
acceptor	O
site	O
of	O
intron	O
19	O
and	O
to	O
create	O
a	O
cryptic	O
acceptor	O
site	O
1	O
bp	O
upstream	O
of	O
the	O
original	O
site	O
,	O
which	O
could	O
result	O
in	O
skipping	O
of	O
exon	O
20	O
in	O
the	O
mature	O
transcript	O
.	O

The	O
CLRN1	B-GENE
gene	O
is	O
complex	O
.	O

M	O
in	O
bleeders	O
[	O
45	O
and	O
31	O
-	O
63	O
]	O
,	O
(	O
mean	O
+	O
-	O
SD	O
:	O
47	O
+	O
-	O
17	O
)	O
;	O
M	O
in	O
nonbleeders	O
[	O
42	O
and	O
4	O
-	O
62	O
]	O
,	O
(	O
mean	O
+	O
-	O
SD	O
:	O
39	O
+	O
-	O
14	O
)	O
;	O
(	O
NS	O
)	O
:	O
P	O
=	O
0	O
.	O
18	O
.	O

For	O
MA2	O
,	O
family	O
history	O
of	O
the	O
index	O
case	O
(	O
2844	O
,	O
a	O
male	O
)	O
with	O
unaffected	O
parents	O
and	O
consanguinity	O
suggested	O
recessive	O
inheritance	O
caused	O
by	O
an	O
autozygous	O
mutation	O
.	O

Sequencing	O
of	O
PRPS1	B-GENE
revealed	O
a	O
novel	O
hemizygous	O
c	B-VARIANT
.	I-VARIANT
830A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
Gln277Pro	I-VARIANT
variant	O
changing	O
a	O
highly	O
conserved	O
amino	O
acid	O
residue	O
(	O
PhyloP	O
score	O
4	O
.	O
6	O
;	O
Figure	O
1	O
C	O
)	O
,	O
predicted	O
to	O
be	O
damaging	O
by	O
all	O
in	O
silico	O
predictions	O
(	O
PolyPhen	O
-	O
2	O
score	O
:	O
0	O
.	O
991	O
;	O
SIFT	O
score	O
:	O
0	O
.	O
01	O
;	O
MutationTaster	O
:	O
disease	O
causing	O
)	O
,	O
and	O
not	O
found	O
in	O
4	O
,	O
200	O
ethnically	O
-	O
matched	O
control	O
X	O
-	O
chromosomes	O
or	O
in	O
the	O
6	O
,	O
500	O
exomes	O
(	O
=	O
10	O
,	O
562	O
alleles	O
)	O
of	O
the	O
NHLBI	O
Exome	O
Variant	O
Server	O
(	O
EVS	O
)	O
.	O

The	O
main	O
limit	O
of	O
this	O
diagnostic	O
approach	O
is	O
the	O
impossibility	O
of	O
studying	O
other	O
USH	B-DISEASE
or	O
still	O
unknown	O
genes	O
and	O
to	O
detect	O
modifying	O
variants	O
in	O
additional	O
genes	O
that	O
could	O
influence	O
the	O
phenotype	O
determined	O
by	O
the	O
primary	O
USH	B-DISEASE
genes	O
.	O

Heterozygosity	O
of	O
the	O
human	O
androgen	O
receptor	O
region	O
in	O
the	O
target	O
samples	O
was	O
previously	O
checked	O
.	O

To	O
sequence	O
coding	O
exons	O
in	O
the	O
ahl5	B-DISEASE
interval	O
,	O
genomic	O
sequences	O
were	O
obtained	O
from	O
http	O
:	O
/	O
/	O
genome	O
.	O
ucsc	O
.	O
edu	O
and	O
PCR	O
primers	O
flanking	O
the	O
exons	O
were	O
designed	O
using	O
Primer3	O
http	O
:	O
/	O
/	O
Frodo	O
.	O
wi	O
.	O
mit	O
.	O
edu	O
.	O

Palmoplantar	B-DISEASE
keratoderma	I-DISEASE
was	O
not	O
observed	O
in	O
the	O
affected	O
members	O
of	O
Family	O
DE2624	O
,	O
thus	O
indicating	O
that	O
the	O
phenotype	O
associated	O
with	O
GJB2	B-GENE
p	B-VARIANT
.	I-VARIANT
R75Q	I-VARIANT
in	O
this	O
family	O
was	O
nonsyndromic	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Indeed	O
,	O
gender	O
-	O
related	O
variations	O
and	O
intrafamilial	O
phenotypes	O
heterogeneity	O
of	O
ADOA	B-DISEASE
have	O
been	O
reported	O
[	O
31	O
]	O
.	O

For	O
MA7	O
,	O
family	O
history	O
suggested	O
dominant	O
inheritance	O
of	O
CRD	B-DISEASE
.	O

To	O
extract	O
potentially	O
RP	B-DISEASE
-	O
causing	O
variants	O
,	O
we	O
focused	O
only	O
on	O
variants	O
that	O
could	O
change	O
the	O
amino	O
acid	O
sequence	O
,	O
such	O
as	O
non	O
-	O
synonymous	O
variants	O
,	O
splice	O
acceptor	O
and	O
donor	O
site	O
variants	O
,	O
and	O
insertion	O
/	O
deletion	O
polymorphisms	O
.	O

Potential	O
disease	O
-	O
causing	O
variants	O
were	O
evaluated	O
by	O
SIFT	O
prediction	O
(	O
http	O
:	O
/	O
/	O
sift	O
.	O
jcvi	O
.	O
org	O
/	O
)	O
.	O

Retinal	O
cryosections	O
were	O
incubated	O
in	O
10	O
%	O
bovine	O
serum	O
albumin	O
in	O
phosphate	O
buffered	O
saline	O
(	O
PBS	O
)	O
for	O
1	O
hour	O
,	O
incubated	O
with	O
the	O
appropriate	O
primary	O
antibody	O
overnight	O
at	O
4	O
deg	O
C	O
,	O
rinsed	O
in	O
PBS	O
,	O
incubated	O
with	O
the	O
appropriate	O
secondary	O
antibody	O
for	O
1	O
hour	O
at	O
room	O
temperature	O
,	O
and	O
rinsed	O
again	O
in	O
PBS	O
.	O

The	O
first	O
STGD	B-DISEASE
cohort	O
was	O
from	O
China	O
recruited	O
by	O
Dr	O
.	O

Complex	O
IV	O
activity	O
was	O
measured	O
in	O
a	O
50	O
mM	O
KH	O
2	O
PO	O
4	O
buffer	O
,	O
using	O
15	O
u	O
M	O
reduced	O
cytochrome	O
c	O
on	O
10	O
5	O
cells	O
permeabilized	O
by	O
2	O
.	O
5	O
mM	O
beta	O
-	O
D	O
-	O
dodecylmaltoside	O
.	O

Unfortunately	O
,	O
DNA	O
samples	O
were	O
not	O
available	O
from	O
the	O
parents	O
in	O
this	O
family	O
and	O
we	O
could	O
not	O
confirm	O
pathogenicity	O
in	O
a	O
segregation	O
study	O
.	O

One	O
possible	O
explanation	O
may	O
be	O
different	O
composition	O
of	O
the	O
I	B-GENE
Ks	I-GENE
channel	O
complex	O
in	O
atria	O
and	O
ventricles	O
as	O
suggested	O
earlier	O
to	O
explain	O
a	O
mixed	O
phenotype	O
of	O
AF	B-DISEASE
and	O
QT	O
prolongation	O
in	O
a	O
patient	O
with	O
a	O
KCNQ1	B-GENE
mutation	O
[	O
18	O
]	O
.	O

The	O
medium	O
was	O
replaced	O
every	O
3	O
days	O
.	O

His	O
brother	O
was	O
also	O
homozygous	O
for	O
the	O
wild	O
-	O
type	O
sequence	O
,	O
as	O
were	O
his	O
parents	O
.	O

In	O
contrast	O
,	O
individual	O
V	O
:	O
7	O
(	O
52	O
yo	O
female	O
)	O
had	O
severe	O
to	O
profound	O
,	O
bilateral	O
,	O
sensorineural	O
hearing	O
impairment	O
.	O

The	O
pedigree	O
of	O
the	O
family	O
is	O
shown	O
.	O

The	O
latter	O
mutation	O
had	O
not	O
been	O
observed	O
prior	O
to	O
this	O
study	O
;	O
its	O
absence	O
in	O
well	O
over	O
200	O
control	O
samples	O
and	O
the	O
proximity	O
to	O
two	O
other	O
known	O
pathogenic	O
mutations	O
(	O
p	B-VARIANT
.	I-VARIANT
Gly255Glu	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT

While	O
GFM1	B-GENE
is	O
ubiquitously	O
expressed	O
,	O
the	O
effect	O
of	O
the	O
mutations	O
on	O
GFM1	B-GENE
protein	O
levels	O
was	O
shown	O
to	O
vary	O
from	O
no	O
protein	O
in	O
liver	O
,	O
to	O
60	O
%	O
of	O
normal	O
protein	O
levels	O
in	O
heart	O
.	O

Table	O
2	O
.	O

To	O
predict	O
whether	O
a	O
rare	O
missense	O
variant	O
is	O
deleterious	O
,	O
we	O
used	O
the	O
combined	O
results	O
of	O
three	O
computer	O
algorithms	O
:	O
Sort	O
Intolerant	O
From	O
Tolerant	O
(	O
SIFT	O
)	O
uses	O
sequence	O
homology	O
to	O
predict	O
whether	O
a	O
change	O
is	O
tolerated	O
or	O
deleterious	O
.	O

There	O
were	O
414	O
male	O
(	O
55	O
%	O
)	O
and	O
331	O
female	O
(	O
44	O
.	O
2	O
%	O
)	O
individuals	O
.	O

Whether	O
the	O
missense	O
mutation	O
causes	O
a	O
dominant	O
negative	O
effect	O
and	O
/	O
or	O
specifies	O
a	O
different	O
phenotype	O
is	O
not	O
clear	O
.	O

Patients	O
1	O
-	O
94	O
,	O
with	O
NSHL	B-DISEASE
were	O
recruited	O
through	O
the	O
Comprehensive	O
Hearing	O
Center	O
at	O
W	O
u	O
rzburg	O
University	O
Hospital	O
.	O

Hybridization	O
probes	O
(	O
0	O
.	O
5	O
~	O
1	O
.	O
6	O
kilobase	O
pairs	O
)	O
for	O
these	O
genes	O
were	O
generated	O
from	O
either	O
cDNA	O
clones	O
of	O
the	O
genes	O
or	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
of	O
targeted	O
gDNA	O
regions	O
.	O

To	O
identify	O
families	O
that	O
may	O
harbour	O
mutations	O
in	O
TMPRSS3	B-GENE
,	O
TMC1	B-GENE
,	O
USHIC	B-GENE
and	O
CDH23	B-GENE
,	O
we	O
carried	O
out	O
concordance	O
/	O
discordance	O
tests	O
using	O
polymorphic	O
microsatellite	O
markers	O
flanking	O
the	O
genes	O
(	O
Table	O
1	O
)	O
in	O
374	O
families	O
.	O

This	O
indicates	O
that	O
ER	O
stress	O
due	O
to	O
wolframin	B-GENE
deficiency	O
may	O
only	O
partially	O
account	O
for	O
disease	O
progression	O
after	O
the	O
onset	O
of	O
WSD	B-DISEASE
.	O

Blue	O
represents	O
c	B-VARIANT
.	I-VARIANT
1032G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
Green	O
c	B-VARIANT
.	I-VARIANT
569G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
Red	O
c	B-VARIANT
.	I-VARIANT
574C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
,	O
Black	O
D85N	B-VARIANT
-	O
KCNE1	B-GENE
(	O
Sequence	O
not	O
shown	O
)	O
.	O

Amino	O
acids	O
are	O
numbered	O
with	O
reference	O
to	O
GenBank	O
Accession	O
number	O
NP_036262	O
.	O

Regarding	O
the	O
two	O
in	O
frame	O
mutations	O
,	O
it	O
is	O
interesting	O
to	O
note	O
that	O
other	O
in	O
frame	O
alterations	O
,	O
two	O
deletions	O
(	O
c	B-VARIANT
.	I-VARIANT
3164_3205del	I-VARIANT
/	O
p	B-VARIANT
.	I-VARIANT
Gly1055_Gln1068del	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
3195_3215del	I-VARIANT
/	O
p	B-VARIANT
.	I-VARIANT
Glu1066_Ala1072del	I-VARIANT
)	O
and	O
one	O
duplication	O
(	O
c	B-VARIANT
.	I-VARIANT
3195_3215dup	I-VARIANT
/	O
p	B-VARIANT
.	I-VARIANT
Glu1066_Ala1072dup	I-VARIANT
)	O
have	O
previously	O
been	O
identified	O
in	O
exon	O
24	O
[	O
14	O
,	O
15	O
]	O
.	O

Onofrio	O
for	O
designing	O
PCR	O
primers	O
,	O
K	O
.	O

Molecular	O
diagnosis	O
would	O
definitely	O
help	O
with	O
clinical	O
diagnosis	O
,	O
and	O
acts	O
as	O
the	O
basis	O
of	O
prenatal	O
testing	O
and	O
gene	O
therapy	O
.	O

(	O
TIF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

To	O
date	O
,	O
more	O
than	O
100	O
mapped	O
loci	O
have	O
been	O
reported	O
,	O
and	O
55	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
genes	O
have	O
been	O
identified	O
(	O
http	O
:	O
/	O
/	O
hereditaryhearingloss	O
.	O
org	O
/	O
)	O
.	O

Detailed	O
clinical	O
and	O
developmental	O
histories	O
were	O
obtained	O
for	O
all	O
the	O
members	O
of	O
this	O
family	O
.	O

It	O
was	O
claimed	O
that	O
mutations	O
predicting	O
substitutions	O
in	O
the	O
MD	O
of	O
the	O
protein	O
are	O
more	O
frequently	O
associated	O
with	O
extrahematological	O
symptoms	O
than	O
those	O
predicting	O
substitutions	O
in	O
the	O
TD	O
.	O

1	O
)	O
.	O

It	O
is	O
known	O
that	O
mutations	O
in	O
LAMB2	B-GENE
can	O
cause	O
FSGS	B-DISEASE
24	O
,	O
25	O
.	O

Only	O
nonsynonymous	O
,	O
splice	O
site	O
disrupting	O
,	O
and	O
frameshift	O
heterozygous	O
variants	O
segregating	O
in	O
the	O
family	O
with	O
a	O
minor	O
allele	O
frequency	O
<	O
=	O
0	O
.	O
5	O
%	O
in	O
a	O
control	O
cohort	O
of	O
more	O
than	O
8000	O
individuals	O
(	O
1000	O
Genomes	O
Project	O
,	O
[	O
25	O
]	O
(	O
April	O
,	O
2012	O
release	O
)	O
;	O
6503	O
exomes	O
from	O
NHLBI	O
GO	O
Exome	O
Sequencing	O
Project	O
[	O
26	O
]	O
,	O
and	O
669	O
in	O
-	O
house	O
whole	O
-	O
exomes	O
)	O
were	O
considered	O
.	O

After	O
washes	O
,	O
Alexa	O
Fluor	O
568	O
goat	O
anti	O
-	O
rabbit	O
IgG	O
(	O
Molecular	O
Probes	O
)	O
diluted	O
1	O
:	O
500	O
were	O
used	O
for	O
20	O
min	O
at	O
room	O
temperature	O
.	O

The	O
other	O
six	O
comprise	O
four	O
hydrophilic	O
and	O
two	O
acidic	O
amino	O
acids	O
.	O

An	O
average	O
of	O
111	O
million	O
individual	O
paired	O
-	O
end	O
reads	O
of	O
100	O
bp	O
were	O
aligned	O
to	O
the	O
human	O
reference	O
genome	O
.	O

Currently	O
,	O
different	O
genotyping	O
techniques	O
,	O
such	O
as	O
single	O
-	O
strand	O
conformation	O
analysis	O
[	O
3	O
]	O
,	O
denaturing	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
[	O
4	O
]	O
,	O
arrayed	O
primer	O
extension	O
(	O
APEX	O
)	O
analysis	O
[	O
5	O
]	O
,	O
and	O
resequencing	O
microarrays	O
[	O
6	O
]	O
,	O
are	O
employed	O
for	O
the	O
detection	O
of	O
mutations	O
associated	O
with	O
disorders	O
showing	O
high	O
genetic	O
and	O
allelic	O
heterogeneity	O
.	O

The	O
syndrome	O
is	O
the	O
most	O
common	O
cause	O
of	O
combined	O
blindness	B-DISEASE
and	O
deafness	B-DISEASE
,	O
accounting	O
for	O
more	O
than	O
50	O
%	O
of	O
individuals	O
who	O
are	O
both	O
deaf	O
and	O
blind	O
,	O
about	O
18	O
%	O
of	O
RP	B-DISEASE
cases	O
,	O
and	O
5	O
%	O
of	O
all	O
cases	O
of	O
congenital	O
deafness	B-DISEASE
[	O
1	O
]	O
.	O

Cohn	O
et	O
al	O
.	O

Of	O
note	O
,	O
an	O
OSBPL2	B-GENE
frameshift	O
mutation	O
in	O
close	O
proximity	O
to	O
the	O
nucleotide	O
position	O
affected	O
by	O
the	O
mutation	O
reported	O
herein	O
has	O
recently	O
been	O
described	O
to	O
co	O
-	O
segregate	O
with	O
ADNSHL	B-DISEASE
in	O
a	O
large	O
Chinese	O
family	O
[	O
49	O
]	O
.	O

(	O
B	O
)	O
Magnified	O
ribbon	O
model	O
of	O
filamentous	O
actin	O
gamma	O
1	O
.	O

Apgar	O
scores	O
were	O
3	O
,	O
7	O
and	O
8	O
at	O
one	O
,	O
five	O
and	O
ten	O
minutes	O
respectively	O
.	O

In	O
addition	O
to	O
those	O
identified	O
by	O
detailed	O
ultrasound	O
scan	O
and	O
investigation	O
in	O
a	O
tertiary	O
Fetal	O
Medicine	O
Centre	O
,	O
phenotypic	O
information	O
was	O
collected	O
for	O
a	O
subset	O
of	O
cases	O
from	O
postmortem	O
reports	O
by	O
perinatal	O
pathologists	O
(	O
n	O
=	O
12	O
)	O
,	O
or	O
pediatric	O
follow	O
up	O
(	O
n	O
=	O
7	O
)	O
.	O

PCR	O
products	O
were	O
sequenced	O
using	O
an	O
ABI	O
3130XL	O
genetic	O
analyser	O
(	O
Applied	O
Biosystems	O
)	O
.	O

PCR	O
products	O
were	O
sequenced	O
in	O
both	O
forward	O
and	O
reverse	O
directions	O
on	O
an	O
ABI	O
3100	O
using	O
the	O
BigDye	O
Terminator	O
Cycle	O
Sequencing	O
Ready	O
Reaction	O
Kit	O
(	O
Applied	O
Biosystems	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
.	O

List	O
of	O
292	O
candidate	O
genes	O
shortlisted	O
for	O
exome	O
sequencing	O
studies	O
in	O
the	O
patient	O
with	O
VUR	B-DISEASE
and	O
proteinuria	B-DISEASE
.	O

,	O
2008	O
;	O
Zanna	O
et	O
al	O
.	O

Our	O
observations	O
also	O
suggested	O
another	O
possibility	O
that	O
KCNJ10	B-GENE
c	B-VARIANT
.	I-VARIANT
1042C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
R348C	I-VARIANT
)	O
is	O
a	O
benign	O
variant	O
in	O
the	O
Chinese	O
population	O
.	O

Besnard	O
et	O
al	O
.	O

USH1B	B-DISEASE
is	O
clinically	O
characterized	O
by	O
prelingual	O
severe	O
to	O
profound	O
HL	B-DISEASE
,	O
prepubertal	O
progressive	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
(	O
RP	B-DISEASE
)	O
,	O
and	O
vestibular	B-DISEASE
areflexia	I-DISEASE
.	O

Pathogenic	O
variants	O
were	O
found	O
in	O
49	O
genes	O
and	O
included	O
missense	O
variants	O
(	O
49	O
%	O
)	O
,	O
large	O
copy	O
number	O
changes	O
(	O
18	O
%	O
)	O
,	O
small	O
insertions	O
and	O
deletions	O
(	O
18	O
%	O
)	O
,	O
nonsense	O
variants	O
(	O
8	O
%	O
)	O
,	O
splice	O
-	O
site	O
alterations	O
(	O
6	O
%	O
)	O
,	O
and	O
promoter	O
variants	O
(	O
<	O
1	O
%	O
)	O
.	O

These	O
nine	O
variants	O
were	O
analyzed	O
using	O
the	O
Alamut	O
program	O
.	O

The	O
disease	O
haplotype	O
2	O
-	O
1	O
is	O
shown	O
by	O
black	O
bars	O
.	O

Competing	O
interests	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Control	O
subjects	O
consisted	O
of	O
0	O
-	O
18	O
years	O
of	O
age	O
healthy	O
children	O
that	O
were	O
primarily	O
recruited	O
from	O
the	O
Philadelphia	O
region	O
through	O
the	O
Hospital	O
'	O
s	O
Health	O
Care	O
Network	O
.	O

We	O
sequenced	O
6	O
exons	O
of	O
the	O
MARVELD2	B-GENE
gene	O
in	O
a	O
group	O
of	O
143	O
unrelated	O
hearing	B-DISEASE
impaired	I-DISEASE
Slovak	O
Roma	O
patients	O
.	O

That	O
the	O
majority	O
was	O
found	O
in	O
the	O
EC	O
domain	O
with	O
only	O
one	O
exception	O
found	O
in	O
the	O
cytoplasmic	O
domain	O
,	O
was	O
also	O
in	O
line	O
with	O
the	O
previous	O
reports	O
on	O
DFNB12	B-DISEASE
[	O
2	O
]	O
,	O
[	O
5	O
]	O
-	O
[	O
7	O
]	O
.	O

Variants	O
in	O
our	O
cohort	O
(	O
red	O
)	O
occur	O
at	O
residues	O
distal	O
to	O
the	O
DNA	O
binding	O
site	O
except	O
for	O
Arg	O
283	O
(	O
green	O
)	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
samples	O
using	O
a	O
FlexiGene	O
DNA	O
extraction	O
kit	O
(	O
QIAGEN	O
,	O
Hilden	O
,	O
Germany	O
)	O
.	O

Click	O
here	O
for	O
file	O
Homozygosity	O
for	O
the	O
CDH23	B-GENE
mutation	O
IVS45	B-VARIANT
-	I-VARIANT
9G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
was	O
found	O
in	O
patients	O
303	O
and	O
1235	O
,	O
while	O
patient	O
860	O
was	O
compound	O
heterozygous	O
for	O
IVS45	B-VARIANT
-	I-VARIANT
9G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
and	O
the	O
novel	O
nonsense	O
mutation	O
p	B-VARIANT
.	I-VARIANT
R736X	I-VARIANT
.	O

It	O
is	O
reported	O
that	O
GJB2	B-GENE
mutation	O
accounts	O
for	O
over	O
50	O
%	O
of	O
autosomal	O
recessive	O
inherited	O
deafness	B-DISEASE
cases	O
[	O
2	O
,	O
8	O
]	O
.	O

Mutations	O
in	O
the	O
C	O
-	O
propeptide	O
coding	O
region	O
have	O
been	O
identified	O
less	O
frequent	O
than	O
other	O
forms	O
of	O
mutation	O
.	O

Funding	O
:	O
This	O
work	O
was	O
supported	O
by	O
grants	O
from	O
the	O
Helsinki	O
University	O
Central	O
Hospital	O
Research	O
Funds	O
,	O
Academy	O
of	O
Finland	O
,	O
Sigrid	O
Juselius	O
Foundation	O
,	O
Foundation	O
for	O
Pediatric	O
Research	O
,	O
Emil	O
Aaltonen	O
Foundation	O
,	O
Research	O
Foundation	O
of	O
the	O
University	O
of	O
Helsinki	O
,	O
and	O
Finnish	O
Cultural	O
Foundation	O
.	O

Patient	O
'	O
s	O
eyes	O
are	O
covered	O
for	O
reasons	O
of	O
confidentiality	O
.	O

The	O
study	O
followed	O
the	O
tenets	O
of	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
was	O
approved	O
by	O
the	O
local	O
medical	O
ethics	O
committee	O
(	O
The	O
Ethical	O
Committee	O
of	O
Central	O
Region	O
(	O
De	O
VidenskabsetiskeKomiteer	O
for	O
Region	O
Hovedstaden	O
)	O
H	O
-	O
B	O
-	O
2007	O
-	O
110	O
)	O
.	O

Human	O
wild	O
-	O
type	O
residues	O
are	O
aligned	O
against	O
those	O
of	O
36	O
species	O
.	O

Partial	O
syndactyly	B-DISEASE
in	O
the	O
hands	O
and	O
feet	O
may	O
be	O
present	O
,	O
but	O
occurs	O
less	O
frequently	O
(	O
5	O
-	O
9	O
)	O
.	O

ELMOD3	B-GENE
was	O
immunostained	O
in	O
green	O
while	O
kinocilia	O
were	O
highlighted	O
with	O
acetylated	O
-	O
tubulin	O
antibody	O
(	O
red	O
)	O
.	O

Therefore	O
,	O
we	O
considered	O
that	O
this	O
novel	O
missense	O
variant	O
in	O
MCM2	B-GENE
was	O
responsible	O
for	O
the	O
autosomal	B-DISEASE
dominant	I-DISEASE
deafness	I-DISEASE
in	O
this	O
pedigree	O
.	O

A	O
number	O
of	O
neurodegenerative	B-DISEASE
disorders	I-DISEASE
including	O
Alzheimer	B-DISEASE
'	I-DISEASE
s	I-DISEASE
,	O
Huntington	B-DISEASE
'	I-DISEASE
s	I-DISEASE
,	O
and	O
prion	B-DISEASE
diseases	I-DISEASE
have	O
also	O
been	O
proposed	O
as	O
disorders	O
of	O
the	O
ER	O
stress	O
response	O
,	O
suggesting	O
that	O
WFS	B-DISEASE
may	O
also	O
represent	O
a	O
useful	O
model	O
of	O
much	O
more	O
common	O
neurodegenerative	B-DISEASE
diseases	I-DISEASE
[	O
33	O
]	O
.	O

(	O
A	O
)	O
In	O
total	O
,	O
32	O
%	O
of	O
the	O
south	O
China	O
population	O
of	O
patients	O
with	O
NSHI	B-DISEASE
could	O
be	O
diagnosed	O
with	O
hereditary	O
deafness	B-DISEASE
.	O

Among	O
the	O
five	O
patients	O
with	O
WFS1	B-GENE
compound	O
heterozygous	O
mutation	O
,	O
two	O
carried	O
2	O
non	O
-	O
inactivating	O
mutations	O
,	O
three	O
carried	O
1	O
inactivating	O
and	O
1	O
non	O
-	O
inactivating	O
.	O

Thyroid	O
hormone	O
assays	O
showed	O
that	O
total	O
T3	O
was	O
slightly	O
elevated	O
in	O
2	O
patients	O
,	O
but	O
this	O
was	O
of	O
no	O
clinical	O
significance	O
,	O
according	O
to	O
endocrinologists	O
from	O
Chinese	O
PLA	O
General	O
Hospital	O
.	O

The	O
BRCA2	B-GENE
missense	O
variants	O
in	O
the	O
cohort	O
are	O
located	O
throughout	O
the	O
protein	O
,	O
but	O
are	O
notably	O
absent	O
from	O
the	O
8	O
RAD51	O
-	O
binding	O
BRC	O
repeats	O
except	O
for	O
one	O
instance	O
of	O
a	O
conservative	O
change	O
in	O
repeat	O
8	O
,	O
c	B-VARIANT
.	I-VARIANT
6215C	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Ser2072Cys	I-VARIANT
)	O
,	O
predicted	O
to	O
be	O
possibly	O
damaging	O
by	O
PolyPhen	O
.	O

Therefore	O
,	O
in	O
the	O
process	O
of	O
designing	O
any	O
strategy	O
for	O
USH	B-DISEASE
molecular	O
diagnosis	O
,	O
taking	O
into	O
account	O
the	O
high	O
prevalence	O
of	O
novel	O
mutations	O
appears	O
to	O
be	O
of	O
major	O
importance	O
.	O

The	O
procedure	O
of	O
averaging	O
the	O
responses	O
evoked	O
separately	O
by	O
condensation	O
and	O
rarefaction	O
clicks	O
was	O
applied	O
to	O
cancel	O
the	O
cochlear	O
microphonic	O
and	O
extract	O
the	O
compound	O
action	O
potential	O
with	O
the	O
superimposed	O
summating	O
potential	O
.	O

A	O
total	O
of	O
2352	O
unrelated	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
patients	O
from	O
27	O
different	O
regions	O
of	O
China	O
were	O
included	O
in	O
this	O
study	O
.	O

With	O
respect	O
to	O
these	O
results	O
and	O
the	O
nature	O
of	O
the	O
two	O
variants	O
(	O
frameshift	O
)	O
,	O
we	O
suggest	O
the	O
pathogenicity	O
role	O
of	O
both	O
variants	O
.	O

[	O
12	O
]	O
.	O

Gipc3	B-GENE
mutations	O
associated	O
with	O
audiogenic	B-DISEASE
seizures	I-DISEASE
and	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
in	O
mouse	O
and	O
human	O
.	O

As	O
a	O
platelet	O
count	O
of	O
<	O
50	O
x	O
10	O
9	O
/	O
L	O
is	O
recommended	O
for	O
measures	O
to	O
prevent	O
bleeding	B-DISEASE
(	O
Slichter	O
2007	O
)	O
,	O
we	O
defined	O
two	O
groups	O
of	O
patients	O
with	O
a	O
platelet	O
count	O
under	O
or	O
above	O
50	O
x	O
10	O
9	O
/	O
L	O
.	O

A	O
.	O

Analyzed	O
the	O
data	O
:	O
XG	O
YYY	O
SSH	O
MYH	O
LPG	O
.	O

Deborah	O
Levy	O
;	O
Dr	O
.	O

Her	O
renal	O
function	O
remained	O
stable	O
on	O
no	O
medical	O
therapy	O
over	O
the	O
next	O
10	O
years	O
.	O

In	O
summary	O
,	O
depending	O
on	O
the	O
criteria	O
used	O
,	O
the	O
genetic	O
basis	O
of	O
27	O
-	O
37	O
%	O
of	O
the	O
sporadic	O
cases	O
of	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
was	O
likely	O
attributed	O
to	O
DNA	O
sequence	O
mutations	O
(	O
Table	O
1	O
)	O
.	O

At	O
least	O
100	O
unrelated	O
Japanese	O
controls	O
were	O
screened	O
for	O
these	O
mutations	O
employing	O
the	O
same	O
TaqMan	O
assay	O
.	O

Together	O
with	O
the	O
previous	O
literature	O
,	O
high	O
frequency	O
involved	O
progressive	O
nature	O
is	O
one	O
of	O
the	O
characteristic	O
features	O
of	O
the	O
patients	O
with	O
ACTG1	B-GENE
mutations	O
.	O

Sixty	O
-	O
seven	O
affected	O
individuals	O
were	O
identified	O
in	O
this	O
study	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
Thy1174Cys	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
Thr910Ala	I-VARIANT
substitutions	O
predicted	O
by	O
missense	O
mutations	O
do	O
not	O
affect	O
known	O
functional	O
domains	O
and	O
are	O
associated	O
with	O
a	O
mild	O
phenotype	O
compared	O
with	O
the	O
classic	O
phenotype	O
expected	O
for	O
mutations	O
at	O
other	O
sites	O
.	O

1B	O
)	O
.	O

YK	O
,	O
GC	O
,	O
and	O
SY	O
are	O
Seaver	O
Fellows	O
,	O
supported	O
by	O
the	O
Seaver	O
Foundation	O
.	O

When	O
nonsense	O
mediated	O
decay	O
was	O
inhibited	O
an	O
additional	O
transcript	O
was	O
seen	O
which	O
corresponded	O
to	O
the	O
use	O
of	O
the	O
GTGCAC	O
sequence	O
(	O
in	O
bold	O
)	O
as	O
a	O
donor	O
splice	O
site	O
.	O

Differently	O
from	O
all	O
others	O
,	O
Subject	O
9	O
had	O
no	O
improvement	O
of	O
speech	O
perception	O
with	O
cochlear	O
implant	O
use	O
(	O
not	O
shown	O
)	O
.	O

Genetic	O
analysis	O
was	O
performed	O
for	O
EYA1	B-GENE
,	O
SIX1	B-GENE
,	O
and	O
SIX5	B-GENE
genes	O
.	O

Similar	O
findings	O
have	O
been	O
obtained	O
in	O
one	O
Japanese	O
patient	O
harbouring	O
the	O
R445H	B-VARIANT
mutation	O
in	O
the	O
OPA1	B-GENE
gene	O
,	O
who	O
showed	O
no	O
response	O
bilaterally	O
on	O
caloric	O
testing	O
in	O
the	O
absence	O
of	O
vestibular	O
symptoms	O
(	O
Mizutari	O
et	O
al	O
.	O

A	O
p	B-VARIANT
.	I-VARIANT
P240L	I-VARIANT
mutation	O
in	O
CDH23	B-GENE
has	O
been	O
reported	O
to	O
be	O
pathogenic	O
[	O
43	O
]	O
.	O

After	O
checking	O
all	O
putative	O
pathogenic	O
variants	O
in	O
the	O
Exome	O
Variant	O
Server	O
of	O
the	O
NHLBI	O
Exome	O
Sequencing	O
Project	O
(	O
ESP	O
)	O
(	O
http	O
:	O
/	O
/	O
evs	O
.	O
gs	O
.	O
washington	O
.	O
edu	O
/	O
EVS	O
/	O
,	O
release	O
version	O
:	O
v	O
.	O
0	O
.	O
0	O
.	O
10	O
)	O
,	O
two	O
presumed	O
mutations	O
in	O
dominant	O
genes	O
(	O
c	B-VARIANT
.	I-VARIANT
1730C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
in	O
TOPORS	B-GENE
(	O
MIM	O
#	O
609507	O
)	O
and	O
c	B-VARIANT
.	I-VARIANT
1724C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
in	O
GUCY2D	B-GENE
(	O
MIM	O
#	O
600179	O
)	O
)	O
,	O
present	O
in	O
three	O
of	O
our	O
families	O
,	O
were	O
re	O
-	O
classified	O
to	O
'	O
benign	O
'	O
due	O
to	O
frequency	O
data	O
of	O
these	O
variants	O
.	O

Sequencing	O
of	O
each	O
library	O
was	O
carried	O
out	O
on	O
Roche	O
GS	O
Junior	O
sequencer	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
(	O
Sequencing	O
Method	O
Manual	O
GS	O
Junior	O
Titanium	O
Series	O
,	O
May	O
2010	O
,	O
Rev	O
.	O

Digital	O
slit	O
lamp	O
photography	O
showed	O
both	O
anterior	B-DISEASE
lenticonus	I-DISEASE
(	O
indicated	O
with	O
single	O
arrows	O
)	O
and	O
posterior	B-DISEASE
lenticonus	I-DISEASE
(	O
indicated	O
with	O
double	O
arrows	O
)	O
in	O
both	O
the	O
right	O
eye	O
(	O
A	O
,	O
B	O
)	O
and	O
the	O
left	O
eye	O
(	O
C	O
,	O
D	O
)	O
.	O

Systematic	O
filtering	O
of	O
variants	O
was	O
accomplished	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
and	O
is	O
summarized	O
in	O
Fig	O
.	O

Of	O
the	O
20	O
individuals	O
without	O
microdeletion	O
or	O
LOH	O
,	O
1	O
(	O
no	O
.	O

Likewise	O
,	O
the	O
remaining	O
missense	O
mutations	O
,	O
p	B-VARIANT
.	I-VARIANT
G319S	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R340W	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
V411M	I-VARIANT
,	O
are	O
located	O
in	O
the	O
DI	O
-	O
S5	O
-	O
S6	O
region	O
,	O
a	O
region	O
with	O
a	O
high	O
frequency	O
of	O
LQTS	B-DISEASE
-	O
associated	O
mutations	O
[	O
2	O
]	O
.	O

Further	O
investigation	O
is	O
required	O
to	O
study	O
the	O
function	O
of	O
MCM2	B-GENE
in	O
inner	O
ear	O
cells	O
.	O

Our	O
developed	O
targeted	O
NGS	O
method	O
based	O
on	O
HaloPlex	O
gene	O
target	O
enrichment	O
technology	O
for	O
the	O
genetic	O
diagnosis	O
of	O
Usher	B-DISEASE
syndrome	I-DISEASE
provides	O
nearly	O
complete	O
coverage	O
of	O
all	O
coding	O
regions	O
of	O
the	O
ten	O
USH	B-DISEASE
genes	O
and	O
four	O
related	O
and	O
candidate	O
USH	B-DISEASE
genes	O
.	O

The	O
identification	O
of	O
this	O
additional	O
novel	O
mutation	O
further	O
confirms	O
the	O
crucial	O
role	O
of	O
MYH14	B-GENE
in	O
auditory	O
function	O
.	O

The	O
chromosome	O
and	O
position	O
of	O
the	O
mutation	O
is	O
depicted	O
according	O
to	O
the	O
human	O
genome	O
assembly	O
,	O
hg19	O
.	O

Finally	O
,	O
45	O
%	O
of	O
our	O
unsolved	O
patients	O
had	O
single	O
deleterious	O
mutations	O
in	O
ABCA4	B-GENE
,	O
a	O
recessive	O
disease	O
gene	O
.	O

Her	O
father	O
was	O
60	O
years	O
old	O
and	O
was	O
phenotypic	O
ally	O
normal	O
.	O

2000	O
)	O
,	O
but	O
it	O
is	O
the	O
first	O
time	O
that	O
this	O
mutation	O
has	O
been	O
found	O
associated	O
with	O
macrothrombocytopenia	B-DISEASE
and	O
leukocyte	B-DISEASE
inclusions	I-DISEASE
(	O
Fig	O
.	O

Poland	O
:	O
Ewa	O
Piatkowska	O
,	O
Kielce	O
;	O
Barbara	O
Iwaniszewska	O
,	O
Torun	O
.	O

The	O
lack	O
of	O
whirlin	B-GENE
and	O
EPS8	B-GENE
colocalization	O
in	O
macaque	O
photoreceptor	O
cells	O
indicates	O
that	O
these	O
two	O
proteins	O
,	O
which	O
interact	O
directly	O
in	O
the	O
hair	O
bundles	O
of	O
cochlear	O
hair	O
cells	O
,	O
are	O
unlikely	O
to	O
interact	O
in	O
the	O
retina	O
.	O

Heterozygous	O
genotype	O
G	O
/	O
A	O
in	O
both	O
parents	O
,	O
II	O
-	O
2	O
and	O
II	O
-	O
3	O
.	O

(	O
A	O
)	O
Protein	O
Data	O
Bank	O
(	O
PDB	O
)	O
structure	O
3OJV	O
,	O
38	O
showing	O
extracellular	O
immunoglobulin	O
(	O
Ig	O
)	O
-	O
like	O
domains	O
2	O
and	O
3	O
,	O
from	O
amino	O
acids	O
147	O
-	O
359	O
.	O

28	O
This	O
same	O
mutation	O
was	O
previously	O
reported	O
in	O
another	O
patient	O
with	O
Bohring	B-DISEASE
-	I-DISEASE
Opitz	I-DISEASE
syndrome	I-DISEASE
.	O

All	O
primer	O
sequences	O
are	O
shown	O
in	O
Table	O
1	O
.	O

C	O
.	O

We	O
therefore	O
concluded	O
that	O
his	O
hearing	B-DISEASE
impairment	I-DISEASE
is	O
likely	O
caused	O
by	O
the	O
many	O
ear	B-DISEASE
infections	I-DISEASE
.	O

SE	O
is	O
the	O
guarantor	O
of	O
this	O
work	O
and	O
,	O
as	O
such	O
,	O
had	O
full	O
access	O
to	O
all	O
of	O
the	O
study	O
data	O
and	O
takes	O
full	O
responsibility	O
for	O
the	O
integrity	O
of	O
the	O
data	O
.	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Patients	O
with	O
history	O
of	O
meningitis	B-DISEASE
and	O
maternal	B-DISEASE
Cytomegalovirus	I-DISEASE
(	O
CMV	B-DISEASE
)	O
,	O
if	O
they	O
are	O
known	O
,	O
were	O
also	O
excluded	O
.	O

No	O
intragenic	O
aberrations	O
were	O
found	O
in	O
MLPA	O
analysis	O
of	O
FGFR1	B-GENE
;	O
all	O
the	O
FGFR1	B-GENE
mutations	O
were	O
detected	O
by	O
standard	O
sequencing	O
.	O

For	O
this	O
we	O
first	O
analyzed	O
the	O
aminoacylation	O
level	O
of	O
tRNAs	O
in	O
total	O
RNA	O
extract	O
isolated	O
from	O
fibroblast	O
cells	O
obtained	O
from	O
probands	O
II	O
.	O
1	O
and	O
II	O
.	O
3	O
from	O
family	O
LS06	O
as	O
well	O
as	O
their	O
mother	O
(	O
I	O
.	O
2	O
)	O
(	O
S8	O
Fig	O
)	O
.	O

Comparison	O
of	O
I	B-GENE
Ks	I-GENE
-	O
WT	O
and	O
I	B-GENE
Ks	I-GENE
-	O
G60D	B-VARIANT
channel	O
deactivation	O
.	O

One	O
is	O
transient	O
expression	O
during	O
the	O
development	O
of	O
hair	O
bundles	O
with	O
procadherin	B-GENE
15	I-GENE
(	O
PCDH15	B-GENE
)	O
and	O
CDH23	B-GENE
forming	O
side	O
links	O
and	O
kinociliary	O
links	O
at	O
their	O
N	O
-	O
termini	O
[	O
2	O
]	O
.	O

Uric	O
acid	O
in	O
serum	O
was	O
normal	O
in	O
all	O
three	O
subjects	O
(	O
for	O
an	O
overview	O
of	O
all	O
clinical	O
and	O
lab	O
details	O
,	O
see	O
Table	O
1	O
)	O
.	O

Data	O
was	O
processed	O
with	O
Picard	O
(	O
http	O
:	O
/	O
/	O
picard	O
.	O
sourceforge	O
.	O
net	O
/	O
)	O
,	O
which	O
utilizes	O
base	O
quality	O
-	O
score	O
recalibration	O
and	O
local	O
realignment	O
at	O
known	O
indels	O
8	O
and	O
BWA	O
7	O
for	O
mapping	O
reads	O
to	O
hg19	O
.	O

While	O
routine	O
testing	O
for	O
USH1	B-DISEASE
gene	O
mutations	O
is	O
hampered	O
by	O
the	O
number	O
and	O
size	O
of	O
the	O
genes	O
involved	O
in	O
most	O
populations	O
,	O
our	O
data	O
should	O
facilitate	O
molecular	O
diagnosis	O
of	O
deafness	B-DISEASE
and	O
Usher	B-DISEASE
syndrome	I-DISEASE
in	O
Quebec	O
(	O
>	O
60	O
%	O
of	O
cases	O
have	O
a	O
mutation	O
in	O
USH1C	B-GENE
and	O
>	O
90	O
%	O
of	O
cases	O
can	O
be	O
explained	O
by	O
ten	O
mutations	O
)	O
.	O

When	O
X	O
.	O
laevis	O
oocytes	O
were	O
subjected	O
to	O
voltage	O
protocols	O
at	O
60	O
bpm	O
no	O
accumulation	O
of	O
I	B-GENE
Ks	I-GENE
current	O
was	O
observed	O
.	O

supervised	O
the	O
genetic	O
and	O
linkage	O
studies	O
and	O
their	O
interpretation	O
,	O
supervised	O
the	O
functional	O
studies	O
and	O
their	O
interpretation	O
,	O
and	O
reviewed	O
and	O
edited	O
the	O
manuscript	O
.	O

Recently	O
,	O
Jindahra	O
et	O
al	O
.	O

This	O
variant	O
was	O
not	O
found	O
in	O
the	O
95	O
pan	O
-	O
ethnic	O
controls	O
.	O

She	O
carried	O
two	O
novel	O
missense	O
variants	O
Y375C	B-VARIANT
and	O
R470H	B-VARIANT
(	O
Figure	O
1	O
)	O
.	O

COL4A4	B-GENE
mutations	O
identified	O
in	O
Family	O
1	O
.	O

This	O
paper	O
is	O
dedicated	O
to	O
the	O
memory	O
of	O
Prof	O
.	O

All	O
subjects	O
or	O
next	O
of	O
kin	O
,	O
caretakers	O
,	O
or	O
guardians	O
on	O
the	O
behalf	O
of	O
the	O
minors	O
/	O
children	O
gave	O
prior	O
written	O
informed	O
consent	O
for	O
participation	O
in	O
the	O
project	O
,	O
and	O
the	O
Ethical	O
Committee	O
of	O
Shinshu	O
University	O
approved	O
the	O
study	O
and	O
the	O
consent	O
procedure	O
.	O

In	O
addition	O
,	O
our	O
approach	O
identified	O
interesting	O
phenotype	O
-	O
genotype	O
correlations	O
.	O

The	O
distal	O
ulna	O
shows	O
precocious	B-DISEASE
ossification	I-DISEASE
of	I-DISEASE
the	I-DISEASE
epiphysis	I-DISEASE
and	O
cupped	B-DISEASE
metaphysis	I-DISEASE
.	O

In	O
patient	O
II	O
-	O
2	O
,	O
peroneal	O
CMAPs	O
were	O
not	O
elicited	O
,	O
and	O
tibial	O
CMAPs	O
were	O
reduced	O
.	O

To	O
clarify	O
individual	O
etiology	O
in	O
such	O
heterogenous	O
diseases	O
,	O
one	O
-	O
by	O
-	O
one	O
gene	O
screening	O
based	O
on	O
conventional	O
PCR	O
-	O
based	O
direct	O
sequencing	O
of	O
candidate	O
genes	O
has	O
been	O
developed	O
,	O
and	O
currently	O
GJB2	B-GENE
has	O
become	O
the	O
first	O
to	O
be	O
screened	O
,	O
followed	O
by	O
several	O
commonly	O
encountered	O
genes	O
.	O

Thirty	O
-	O
six	O
Italian	O
patients	O
with	O
a	O
diagnosis	O
of	O
USH	B-DISEASE
were	O
recruited	O
.	O

Mean	O
values	O
are	O
denoted	O
by	O
a	O
white	O
dot	O
.	O

Here	O
we	O
report	O
four	O
consanguineous	O
Muslim	O
Arab	O
Israeli	O
families	O
segregating	O
USH1	B-DISEASE
.	O

Likewise	O
,	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
BLSW	O
mice	O
at	O
8	O
weeks	O
of	O
age	O
occurs	O
without	O
a	O
noticeable	O
hair	B-DISEASE
cell	I-DISEASE
loss	I-DISEASE
.	O

It	O
caused	O
a	O
shift	O
in	O
the	O
reading	O
frame	O
and	O
a	O
downstream	O
premature	O
termination	O
codon	O
.	O

Therefore	O
,	O
probably	O
GJB4	B-GENE
p	B-VARIANT
.	I-VARIANT
C169W	I-VARIANT
is	O
a	O
non	O
-	O
pathogenic	O
variant	O
.	O

A	O
27	O
-	O
year	O
-	O
old	O
Japanese	O
woman	O
previously	O
diagnosed	O
with	O
avasucular	B-DISEASE
necrosis	I-DISEASE
(	O
AVN	B-DISEASE
)	O
of	O
the	O
femoral	O
head	O
on	O
the	O
basis	O
of	O
radiological	O
findings	O
was	O
referred	O
to	O
the	O
study	O
site	O
for	O
surgical	O
management	O
of	O
a	O
painful	O
hip	O
joint	O
.	O

This	O
high	O
rate	O
of	O
consanguinity	O
consequently	O
leads	O
to	O
increased	O
homozygosity	O
of	O
rare	O
mutant	O
alleles	O
in	O
specific	O
families	O
and	O
villages	O
[	O
6	O
]	O
.	O

The	O
novel	O
nonsense	O
mutation	O
p	B-VARIANT
.	I-VARIANT
Q393X	I-VARIANT
leads	O
to	O
a	O
truncated	O
protein	O
lacking	O
the	O
entire	O
Eya	O
HR	O
domain	O
,	O
similar	O
to	O
other	O
previously	O
reported	O
mutations	O
.	O

Autosomal	B-DISEASE
recessive	I-DISEASE
nonsyndromic	I-DISEASE
hearing	I-DISEASE
impairment	I-DISEASE
(	O
arNSHI	B-DISEASE
)	O
is	O
the	O
most	O
common	O
type	O
of	O
inherited	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
accounting	O
for	O
approximately	O
80	O
%	O
of	O
inherited	O
prelingual	O
hearing	B-DISEASE
impairment	I-DISEASE
.	O

For	O
this	O
locus	O
,	O
only	O
one	O
informative	O
marker	O
has	O
been	O
used	O
(	O
D11S4186	O
)	O
.	O

The	O
search	O
for	O
extra	B-DISEASE
-	I-DISEASE
hematological	I-DISEASE
manifestations	I-DISEASE
revealed	O
severe	O
bilateral	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
intermediate	O
and	O
high	O
frequencies	O
)	O
in	O
both	O
the	O
adult	O
family	O
members	O
and	O
bilateral	O
cataract	O
in	O
the	O
proband	O
'	O
s	O
aunt	O
.	O

Splice	O
site	O
mutations	O
were	O
the	O
most	O
common	O
type	O
found	O
in	O
3	O
of	O
7	O
families	O
,	O
followed	O
by	O
one	O
missense	O
mutation	O
and	O
one	O
large	O
deletion	O
encompassing	O
the	O
whole	O
EYA1	B-GENE
gene	O
.	O

A	O
.	O

7	O
The	O
existence	O
of	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
is	O
still	O
controversial	O
.	O

To	O
identify	O
gene	O
defects	O
that	O
may	O
uncover	O
potential	O
cause	O
of	O
CAKUT	B-DISEASE
or	O
proteinuria	B-DISEASE
that	O
lead	O
to	O
kidney	O
dysfunction	O
in	O
the	O
patient	O
1184405	O
we	O
sequenced	O
the	O
coding	O
region	O
and	O
exon	O
-	O
intron	O
splice	O
junctions	O
of	O
292	O
genes	O
most	O
likely	O
associated	O
with	O
renal	O
anomalies	O
or	O
glomerular	O
disease	O
using	O
NGS	O
(	O
see	O
methods	O
)	O
.	O

The	O
majority	O
of	O
mutations	O
are	O
missense	O
mutations	O
and	O
all	O
mutations	O
predicting	O
a	O
truncated	O
NMMHC	B-GENE
-	I-GENE
IIA	I-GENE
are	O
located	O
in	O
the	O
last	O
exon	O
.	O

Our	O
data	O
indicate	O
that	O
the	O
disease	O
severity	O
may	O
be	O
associated	O
with	O
the	O
presence	O
of	O
MME	B-DISEASE
in	O
the	O
INL	O
as	O
reported	O
,	O
because	O
we	O
found	O
the	O
clearest	O
MME	B-DISEASE
in	O
the	O
patients	O
with	O
poorest	O
BCVA	O
,	O
although	O
some	O
other	O
factors	O
may	O
be	O
needed	O
for	O
MME	B-DISEASE
to	O
develop	O
other	O
than	O
disease	O
severity	O
.	O

Whole	O
-	O
exome	O
sequencing	O
allowed	O
us	O
to	O
screen	O
mutations	O
in	O
a	O
large	O
number	O
of	O
genes	O
at	O
the	O
same	O
time	O
and	O
to	O
detect	O
pathogenic	O
mutations	O
in	O
affected	O
individuals	O
who	O
were	O
not	O
identified	O
by	O
classical	O
genetic	O
studies	O
.	O

CT	O
scan	O
results	O
of	O
Patients	O
21	O
and	O
22	O
(	O
heterozygote	O
IVS7	B-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
and	O
N392Y	B-VARIANT
respectively	O
)	O
were	O
not	O
available	O
(	O
Table	O
1	O
)	O
.	O

NM_001256041	O
.	O
1	O
for	O
MYO1A	B-GENE
and	O
accession	O
no	O
.	O

The	O
healthy	O
control	O
individuals	O
(	O
all	O
had	O
negative	O
family	O
history	O
for	O
Usher	B-DISEASE
syndrome	I-DISEASE
)	O
came	O
from	O
all	O
regions	O
of	O
Quebec	O
.	O

GERP	O
score	O
can	O
be	O
interpreted	O
as	O
the	O
substitutions	O
expected	O
under	O
neutrality	O
minus	O
the	O
number	O
of	O
substitutions	O
observed	O
at	O
the	O
position	O
,	O
which	O
was	O
based	O
on	O
35	O
-	O
way	O
whole	O
-	O
genome	O
alignment	O
of	O
mammals	O
and	O
had	O
theoretical	O
maximum	O
value	O
of	O
6	O
.	O
18	O
.	O

T	O
o	O
th	O
et	O
al	O
.	O

One	O
individual	O
who	O
did	O
not	O
demonstrate	O
such	O
T	B-DISEASE
wave	I-DISEASE
anomalies	I-DISEASE
was	O
the	O
proband	O
of	O
L151	O
,	O
a	O
46	O
-	O
year	O
-	O
old	O
male	O
with	O
borderline	O
QTc	B-DISEASE
prolongation	I-DISEASE
(	O
460	O
ms	O
)	O
who	O
has	O
been	O
event	O
-	O
free	O
for	O
the	O
past	O
16	O
years	O
.	O

For	O
the	O
application	O
in	O
molecular	O
diagnosis	O
,	O
the	O
coverage	O
requirement	O
is	O
higher	O
.	O

Bait	O
density	O
reflects	O
the	O
density	O
of	O
repeat	O
element	O
;	O
target	O
regions	O
rich	O
in	O
repeat	O
element	O
tend	O
to	O
have	O
fewer	O
designed	O
baits	O
.	O
GW	O
and	O
BZ	O
contributed	O
equally	O
.	O

The	O
other	O
alterations	O
were	O
three	O
deletions	O
of	O
one	O
nucleotide	O
,	O
one	O
larger	O
deletion	O
of	O
21	O
nucleotides	O
,	O
and	O
one	O
duplication	O
.	O

For	O
eight	O
of	O
these	O
nine	O
patients	O
the	O
mutated	O
gene	O
had	O
not	O
been	O
analysed	O
previously	O
.	O

Furthermore	O
,	O
the	O
identification	O
of	O
a	O
recurrent	O
p	B-VARIANT
.	I-VARIANT
Gly1170Ser	I-VARIANT
mutation	O
in	O
patients	O
with	O
Legg	B-DISEASE
-	I-DISEASE
Calve	I-DISEASE
-	I-DISEASE
Perthes	I-DISEASE
disease	I-DISEASE
(	O
LCPD	B-DISEASE
)	O
and	O
/	O
or	O
primary	O
avascular	B-DISEASE
necrosis	I-DISEASE
of	I-DISEASE
femoral	I-DISEASE
head	I-DISEASE
(	O
ANFH	B-DISEASE
)	O
[	O
Miyamoto	O
et	O
al	O
.	O
,	O
2007	O
;	O
Su	O
et	O
al	O
.	O
,	O
2008	O
]	O
also	O
suggests	O
that	O
there	O
are	O
similar	O
disease	O
mechanisms	O
that	O
might	O
cause	O
phenotypes	O
within	O
a	O
LCPD	B-DISEASE
/	O
ANFH	B-DISEASE
-	O
MED	B-DISEASE
-	O
SEDc	B-DISEASE
disease	O
spectrum	O
.	O

Electrophysiological	O
analyses	O
and	O
muscle	O
and	O
nerve	O
biopsies	O
were	O
performed	O
,	O
along	O
with	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
of	O
the	O
brain	O
and	O
lower	O
extremities	O
.	O

All	O
authors	O
contributed	O
to	O
the	O
writing	O
and	O
critical	O
review	O
of	O
this	O
manuscript	O
.	O

We	O
are	O
grateful	O
to	O
engineer	O
Fabio	O
Saccomandi	O
who	O
wrote	O
the	O
software	O
for	O
data	O
acquisition	O
and	O
analysis	O
.	O

(	O
C	O
)	O
Schematic	O
physical	O
and	O
genetic	O
maps	O
of	O
DFNA56	B-GENE
locus	O
on	O
the	O
9q31	O
.	O
3	O
-	O
34	O
.	O
3	O
chromosomal	O
region	O
.	O

(	O
c	O
)	O
Model	O
of	O
CIB2	B-GENE
using	O
a	O
template	O
for	O
NMR	O
structure	O
of	O
CIB1	B-GENE
bound	O
to	O
alpha	O
II	O
beta	O
integrin	O
peptide	O
.	O

Of	O
these	O
the	O
11	O
cases	O
,	O
9	O
were	O
'	O
highly	O
probable	O
cases	O
'	O
carrying	O
mutations	O
in	O
one	O
of	O
the	O
204	O
deafness	B-DISEASE
genes	O
and	O
two	O
cases	O
were	O
classified	O
as	O
possibly	O
explained	O
(	O
Table	O
3	O
)	O
.	O

Coverage	O
and	O
read	O
depth	O
of	O
five	O
autozygous	O
regions	O
.	O

The	O
color	O
and	O
the	O
white	O
boxes	O
represent	O
the	O
coding	O
regions	O
and	O
the	O
untranslated	O
regions	O
on	O
exons	O
1	O
-	O
10	O
(	O
E1	O
-	O
E10	O
)	O
,	O
respectively	O
;	O
the	O
red	O
,	O
the	O
purple	O
,	O
and	O
the	O
orange	O
segments	O
indicate	O
the	O
coding	O
regions	O
on	O
the	O
final	O
exons	O
9C	O
,	O
9A	O
,	O
and	O
9B	O
(	O
splice	O
variants	O
)	O
,	O
respectively	O
.	O

2013	O
)	O
and	O
those	O
presented	O
in	O
this	O
report	O
,	O
as	O
many	O
as	O
83	O
genetic	O
alterations	O
have	O
now	O
been	O
described	O
.	O

Deactivation	O
time	O
constants	O
(	O
tau	O
)	O
were	O
obtained	O
by	O
fitting	O
the	O
tail	O
-	O
current	O
traces	O
to	O
a	O
mono	O
-	O
exponential	O
function	O
(	O
D	O
)	O
.	O

The	O
proband	O
,	O
a	O
57	O
-	O
year	O
-	O
old	O
man	O
,	O
was	O
referred	O
to	O
our	O
tertiary	O
referral	O
hospital	O
for	O
progressive	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
which	O
coexisted	O
with	O
optic	B-DISEASE
neuropathy	I-DISEASE
.	O

2	O
)	O
.	O

Clinical	O
and	O
audiological	O
evaluation	O
showed	O
that	O
27	O
of	O
these	O
patients	O
with	O
biallelic	O
DFNB1	B-GENE
mutations	O
had	O
bilateral	O
congenital	O
severe	O
or	O
profound	O
NSHL	O
with	O
no	O
evidence	O
of	O
progressive	O
phenotype	O
.	O

This	O
gene	O
encoding	O
an	O
aminoacyl	O
tRNA	O
synthetase	O
was	O
proposed	O
as	O
a	O
novel	O
gene	O
causative	O
of	O
USH3	B-DISEASE
[	O
9	O
]	O
.	O

This	O
means	O
with	O
a	O
raw	O
sequence	O
output	O
of	O
20	O
GB	O
per	O
lane	O
,	O
a	O
planned	O
coverage	O
of	O
100	O
x	O
and	O
a	O
target	O
region	O
of	O
less	O
than	O
500	O
kb	O
,	O
there	O
would	O
be	O
room	O
for	O
200	O
samples	O
assuming	O
an	O
enrichment	O
factor	O
of	O
0	O
.	O
5	O
.	O

The	O
discovery	O
of	O
novel	O
variants	O
in	O
the	O
LAMA5	B-GENE
gene	O
has	O
not	O
been	O
reported	O
before	O
.	O

TCS	B-DISEASE
patients	O
had	O
approximately	O
18	O
%	O
less	O
TCOF1	B-GENE
transcript	O
levels	O
than	O
normal	O
individuals	O
.	O

DAPI	O
(	O
D	O
)	O
was	O
used	O
to	O
label	O
cell	O
nuclei	O
.	O

GJB2	B-GENE
mutation	O
was	O
detected	O
in	O
9	O
.	O
05	O
%	O
of	O
Uyghur	O
patients	O
and	O
16	O
.	O
56	O
%	O
of	O
Han	O
Chinese	O
patients	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
,	O
respectively	O
.	O

Whole	O
-	O
mount	O
tissues	O
were	O
mounted	O
in	O
ProLong	O
Gold	O
Antifade	O
Reagent	O
(	O
Life	O
Technologies	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Audiometric	O
examination	O
consisted	O
on	O
otoscopic	O
exploration	O
,	O
pure	O
-	O
tone	O
audiometry	O
,	O
and	O
speech	O
audiometry	O
.	O

These	O
genes	O
were	O
selected	O
since	O
they	O
are	O
well	O
-	O
known	O
cancer	B-DISEASE
genes	O
that	O
can	O
carry	O
clinically	O
relevant	O
mutations	O
.	O

For	O
a	O
given	O
electrode	O
location	O
,	O
decreasing	O
current	O
levels	O
resulted	O
in	O
increased	O
latencies	O
and	O
attenuated	O
wave	O
V	O
amplitudes	O
(	O
vertical	O
dashed	O
lines	O
,	O
right	O
)	O
.	O

Analyzed	O
the	O
data	O
:	O
HY	O
SN	O
SU	O
.	O

Characterization	O
of	O
the	O
proteins	O
encoded	O
by	O
these	O
genes	O
will	O
enable	O
an	O
understanding	O
of	O
the	O
biological	O
mechanisms	O
involved	O
in	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Although	O
our	O
patients	O
are	O
genetically	O
heterogeneous	O
,	O
ophthalmological	O
findings	O
and	O
age	O
at	O
detection	O
are	O
similar	O
to	O
other	O
series	O
[	O
4	O
]	O
,	O
[	O
32	O
]	O
,	O
[	O
33	O
]	O
.	O

7	O
,	O
8	O
Progressive	O
sensorineural	O
hearing	B-DISEASE
loss	I-DISEASE
has	O
been	O
reported	O
in	O
about	O
one	O
third	O
of	O
the	O
Norrie	B-DISEASE
disease	I-DISEASE
cases	O
.	O

performed	O
experiments	O
,	O
contributed	O
reagents	O
and	O
analysed	O
data	O
(	O
Fig	O
.	O

We	O
therefore	O
posed	O
two	O
questions	O
of	O
the	O
group	O
of	O
genes	O
harboring	O
de	O
novo	O
functional	O
mutations	O
:	O
do	O
the	O
protein	O
products	O
of	O
these	O
genes	O
interact	O
with	O
each	O
other	O
more	O
than	O
expected	O
,	O
and	O
are	O
they	O
unusually	O
enriched	O
in	O
,	O
or	O
connected	O
to	O
,	O
prior	O
curated	O
lists	O
of	O
ASD	B-DISEASE
-	O
implicated	O
genes	O
?	O
Using	O
an	O
in	O
silico	O
approach	O
(	O
DAPPLE	O
)	O
14	O
,	O
15	O
the	O
protein	O
-	O
protein	O
connectivity	O
in	O
the	O
set	O
of	O
113	O
genes	O
harboring	O
'	O
functional	O
'	O
de	O
novo	O
mutations	O
was	O
evaluated	O
.	O

Three	O
Turkish	O
,	O
one	O
Ecuadorian	O
,	O
and	O
one	O
Nigerian	O
families	O
were	O
included	O
based	O
on	O
either	O
inner	B-DISEASE
ear	I-DISEASE
anomalies	I-DISEASE
detected	O
in	O
probands	O
or	O
X	O
-	O
linked	O
family	O
histories	O
.	O

We	O
are	O
indebted	O
to	O
the	O
family	O
members	O
for	O
their	O
invaluable	O
cooperation	O
and	O
for	O
providing	O
the	O
blood	O
samples	O
.	O

The	O
ears	O
of	O
the	O
mutation	O
carrying	O
individuals	O
have	O
an	O
increased	O
Fletcher	O
Index	O
(	O
FI	O
;	O
mean	O
threshold	O
for	O
0	O
.	O
5	O
,	O
1	O
,	O
and	O
2	O
kHz	O
)	O
and	O
a	O
decreased	O
maximum	O
speech	O
recognition	O
score	O
(	O
MSRS	O
)	O
.	O

*	O
highlights	O
pedigrees	O
that	O
have	O
been	O
abbreviated	O
for	O
this	O
figure	O
.	O

High	O
-	O
fat	O
diet	O
,	O
amino	O
acid	O
starvation	O
,	O
environmental	O
toxins	O
,	O
hypoxia	O
,	O
or	O
radiation	O
are	O
other	O
oxidative	O
stressors	O
(	O
3	O
,	O
5	O
,	O
24	O
)	O
.	O

Estimates	O
of	O
its	O
ancestry	O
unveiled	O
a	O
major	O
contribution	O
of	O
European	O
ancestry	O
(	O
>	O
60	O
%	O
)	O
followed	O
by	O
African	O
ancestry	O
and	O
a	O
minor	O
(	O
<	O
10	O
%	O
)	O
native	O
Brazilian	O
Amerindian	O
ancestry	O
[	O
27	O
-	O
30	O
]	O
.	O

Another	O
mutation	O
identified	O
in	O
patients	O
USH01	O
-	O
III	O
:	O
1	O
and	O
USH01	O
-	O
III	O
:	O
2	O
was	O
a	O
missense	O
one	O
,	O
p	B-VARIANT
.	I-VARIANT
Met946Arg	I-VARIANT
.	O

The	O
novel	O
mutation	O
(	O
c	B-VARIANT
.	I-VARIANT
1888	I-VARIANT
G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
in	O
exon	O
29	O
of	O
COL2A1	B-GENE
may	O
resulti	O
in	O
changes	O
in	O
the	O
protein	O
(	O
p	B-VARIANT
.	I-VARIANT
G630S	I-VARIANT
)	O
is	O
highly	O
conserved	O
across	O
species	O
,	O
including	O
H	O
.	O
sapiens	O
,	O
M	O
.	O
mulatta	O
,	O
R	O
.	O
norvegicus	O
,	O
D	O
.	O
rerio	O
,	O
and	O
C	O
.	O

Where	O
applicable	O
,	O
DNA	O
from	O
affected	O
and	O
unaffected	O
family	O
members	O
was	O
analyzed	O
for	O
segregation	O
analysis	O
of	O
putatively	O
causative	O
sequence	O
variants	O
.	O

Among	O
these	O
patients	O
,	O
more	O
severe	O
visual	O
dysfunction	O
was	O
present	O
in	O
the	O
elders	O
.	O

Venous	O
blood	O
was	O
collected	O
into	O
PAXgene	O
Blood	O
RNA	O
tubes	O
(	O
Qiagen	O
)	O
from	O
individuals	O
II	O
-	O
1	O
(	O
Family	O
1	O
)	O
and	O
III	O
-	O
1	O
(	O
Family	O
2	O
)	O
,	O
and	O
RNA	O
was	O
extracted	O
according	O
to	O
the	O
associated	O
protocol	O
.	O

The	O
patient	O
,	O
a	O
62	O
-	O
year	O
-	O
old	O
woman	O
,	O
was	O
referred	O
for	O
acute	O
,	O
painless	O
,	O
and	O
severe	O
visual	B-DISEASE
loss	I-DISEASE
in	O
her	O
right	O
eye	O
.	O

Previously	O
reported	O
recessive	O
mutations	O
within	O
ILDR1	B-GENE
have	O
been	O
shown	O
to	O
cause	O
severe	O
to	O
profound	O
nonsyndromic	B-DISEASE
sensorineural	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
SNHL	B-DISEASE
)	O
,	O
DFNB42	B-DISEASE
.	O

Therefore	O
,	O
we	O
used	O
WES	O
to	O
identify	O
the	O
gene	O
responsible	O
for	O
the	O
disease	O
in	O
this	O
family	O
.	O

A	O
:	O
Expression	O
of	O
WFS1	B-GENE
mRNA	O
in	O
skin	O
fibroblasts	O
.	O

USH1C	B-GENE
encodes	O
for	O
harmonin	O
,	O
a	O
scaffolding	O
protein	O
that	O
is	O
required	O
for	O
normal	O
mechanosensory	O
function	O
in	O
cochlear	O
hair	O
cells	O
[	O
17	O
]	O
.	O

Adjusted	O
P	O
-	O
values	O
were	O
assessed	O
by	O
gene	O
-	O
dropping	O
permutation	O
,	O
flipping	O
the	O
allele	O
transmitted	O
from	O
parent	O
to	O
affected	O
offspring	O
,	O
and	O
using	O
the	O
default	O
mode	O
with	O
the	O
adaptative	O
permutation	O
approach	O
.	O

(	O
c	O
)	O
Patients	O
suspected	O
of	O
CHARGE	B-DISEASE
syndrome	I-DISEASE
were	O
tested	O
for	O
CHD7	B-GENE
.	O

ERG	O
showed	O
no	O
recordable	O
pattern	O
in	O
four	O
patients	O
and	O
could	O
not	O
be	O
conducted	O
in	O
one	O
patient	O
.	O

The	O
submetaphyseal	O
regions	O
have	O
a	O
striated	O
pattern	O
.	O

Since	O
then	O
,	O
mutations	O
of	O
14	O
other	O
mt	O
-	O
aaRSs	O
have	O
been	O
associated	O
with	O
mitochondrial	B-DISEASE
disease	I-DISEASE
[	O
6	O
,	O
7	O
]	O
,	O
including	O
NARS2	B-GENE
,	O
which	O
has	O
recently	O
been	O
linked	O
to	O
intellectual	B-DISEASE
disability	I-DISEASE
,	O
epilepsy	B-DISEASE
and	O
myopathy	B-DISEASE
[	O
8	O
]	O
.	O

A	O
pseudogene	O
with	O
99	O
.	O
6	O
%	O
coding	O
sequence	O
identity	O
makes	O
it	O
impossible	O
to	O
rely	O
on	O
NGS	O
for	O
STRC	B-GENE
screening	O
,	O
and	O
a	O
Sanger	O
sequencing	O
protocol	O
excluding	O
the	O
pseudogene	O
is	O
recommended	O
.	O

The	O
c	B-VARIANT
.	I-VARIANT
3742G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
mutation	O
was	O
predicted	O
to	O
cause	O
a	O
glutamic	O
acid	O
change	O
to	O
lysine	O
at	O
the	O
highly	O
conserved	O
codon	O
1248	O
in	O
the	O
first	O
MyTH4	O
-	O
FERM	O
tandem	O
domain	O
,	O
which	O
mediates	O
the	O
interaction	O
between	O
myosin	B-GENE
VIIA	I-GENE
and	O
the	O
scaffold	O
protein	O
Sans	O
(	O
USH1G	B-GENE
)	O
[	O
25	O
]	O
.	O

,	O
2008	O
)	O
,	O
and	O
the	O
sequestration	O
of	O
pro	O
-	O
apoptotic	O
cytochrome	O
c	O
molecules	O
within	O
the	O
mitochondrial	O
cristae	O
spaces	O
(	O
Cipolat	O
et	O
al	O
.	O

WES	O
allows	O
for	O
screening	O
of	O
mutations	O
in	O
a	O
large	O
number	O
of	O
genes	O
at	O
the	O
same	O
time	O
and	O
is	O
cost	O
effective	O
compared	O
to	O
other	O
genetic	O
testing	O
options	O
when	O
the	O
number	O
of	O
genes	O
is	O
large	O
.	O

For	O
example	O
,	O
although	O
similar	O
in	O
age	O
a	O
23	O
year	O
old	O
affected	O
woman	O
of	O
family	O
PKDF505	O
has	O
significantly	O
better	O
hearing	O
,	O
especially	O
at	O
low	O
frequencies	O
,	O
than	O
her	O
21year	O
old	O
sister	O
(	O
Figure	O
4	O
)	O
.	O

JMvH	O
:	O
acquisition	O
of	O
data	O
,	O
revising	O
the	O
manuscript	O
.	O

Husain	O
,	O
Ms	O
.	O

The	O
temporal	O
bone	O
CT	O
scan	O
was	O
performed	O
in	O
all	O
of	O
10	O
patients	O
and	O
temporal	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
was	O
available	O
for	O
analysis	O
in	O
4	O
patients	O
.	O

The	O
c	B-VARIANT
.	I-VARIANT
3562A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
variation	O
that	O
we	O
predicted	O
to	O
be	O
pathogenic	O
was	O
detected	O
in	O
two	O
patients	O
,	O
II	O
-	O
1	O
of	O
the	O
KNUF25	O
family	O
and	O
II	O
-	O
6	O
of	O
the	O
YS	O
-	O
149	O
family	O
,	O
both	O
in	O
the	O
heterozygous	O
state	O
(	O
Figure	O
3	O
)	O
.	O

A	O
genetic	O
variant	O
was	O
considered	O
a	O
disease	O
-	O
causing	O
mutation	O
if	O
it	O
resulted	O
in	O
an	O
amino	O
acid	O
substitution	O
,	O
interfered	O
with	O
a	O
splice	O
site	O
or	O
had	O
previously	O
been	O
shown	O
to	O
be	O
associated	O
with	O
cLQTS	B-DISEASE
and	O
was	O
not	O
found	O
in	O
in	O
silico	O
controls	O
and	O
had	O
not	O
previously	O
been	O
described	O
as	O
a	O
polymorphism	O
.	O

In	O
contrast	O
to	O
our	O
initial	O
expectations	O
,	O
these	O
prevalences	O
,	O
particularly	O
in	O
Slovakia	O
,	O
are	O
lower	O
than	O
previously	O
reported	O
for	O
the	O
Roma	O
population	O
in	O
the	O
Czech	O
Republic	O
(	O
15	O
.	O
8	O
%	O
)	O
[	O
10	O
]	O
.	O

For	O
the	O
Han	O
Chinese	O
population	O
,	O
SLC26A4	B-GENE
mutation	O
frequency	O
was	O
9	O
.	O
84	O
%	O
(	O
19	O
/	O
193	O
)	O
,	O
involving	O
11	O
mutations	O
:	O
IVS7	B-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
2168A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
1079	I-VARIANT
T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
1975G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
754	I-VARIANT
T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
,	O
IVS9	B-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
IVS11	B-VARIANT
+	I-VARIANT
47	I-VARIANT
T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
2265C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
IVS5	B-VARIANT
+	I-VARIANT
27	I-VARIANT
T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
,	O
IVS7	B-VARIANT
+	I-VARIANT
35A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
and	O
IVS7	B-VARIANT
+	I-VARIANT
40G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
.	O

Based	O
on	O
incidence	O
data	O
for	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
and	O
auditory	B-DISEASE
neuropathy	I-DISEASE
,	O
we	O
excluded	O
variants	O
with	O
an	O
MAF	O
>	O
0	O
.	O
001	O
.	O

Mutations	O
within	O
this	O
protein	O
negatively	O
affect	O
the	O
integrity	O
of	O
mtDNA	O
.	O

The	O
PCR	O
products	O
were	O
purified	O
on	O
Qia	O
-	O
quick	O
spin	O
columns	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
CA	O
)	O
and	O
sequenced	O
using	O
the	O
BigDye	O
Terminator	O
Cycle	O
Sequencing	O
kit	O
(	O
version	O
v3	O
.	O
1	O
)	O
and	O
ABI	O
3130	O
automated	O
DNA	O
sequencers	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
,	O
)	O
with	O
Sequence	O
Analysis	O
Software	O
(	O
Sequencing	O
Analysis	O
version	O
3	O
.	O
7	O
)	O
.	O

Sanger	O
DNA	O
sequencing	O
was	O
further	O
conducted	O
for	O
single	O
mutation	O
conformation	O
.	O

[	O
14	O
]	O
proposed	O
that	O
single	O
mutations	O
in	O
both	O
SLC26A4	B-GENE
and	O
KCNJ10	B-GENE
lead	O
to	O
digenic	O
NSEVA	B-DISEASE
.	O

Using	O
Sanger	O
sequencing	O
,	O
eight	O
participating	O
members	O
(	O
three	O
affected	O
,	O
five	O
unaffected	O
)	O
in	O
family	O
7162	O
were	O
genotyped	O
to	O
identify	O
the	O
mutations	O
.	O

The	O
total	O
number	O
of	O
reads	O
after	O
filtering	O
and	O
mapping	O
was	O
325	O
.	O
272	O
,	O
with	O
an	O
average	O
read	O
length	O
of	O
250	O
bp	O
.	O

The	O
Danish	O
National	O
Research	O
Foundation	O
,	O
The	O
John	O
and	O
Birthe	O
Meyer	O
Foundation	O
,	O
The	O
Research	O
Foundation	O
of	O
the	O
Heart	O
Centre	O
Rigshospitalet	O
,	O
The	O
Arvid	O
Nilsson	O
Foundation	O
,	O
and	O
Director	O
Ib	O
Henriksens	O
Foundation	O
.	O
Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Variants	O
were	O
either	O
nonsynonymous	O
variants	O
or	O
splice	O
site	O
variants	O
(	O
8	O
bp	O
splice	O
acceptor	O
,	O
20	O
bp	O
splice	O
donor	O
)	O
.	O

Severe	O
to	O
profound	O
bilateral	O
hearing	B-DISEASE
impairment	I-DISEASE
was	O
indicated	O
.	O

A	O
rigorous	O
clinical	O
evaluation	O
involving	O
audiological	O
tests	O
,	O
imaging	O
,	O
and	O
laboratory	O
tests	O
,	O
including	O
molecular	O
genetic	O
tests	O
,	O
is	O
needed	O
to	O
reach	O
precise	O
etiologic	O
diagnoses	O
[	O
4	O
,	O
5	O
]	O
.	O

We	O
then	O
performed	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
of	O
FLAG	O
-	O
tagged	O
POLR1C	B-GENE
followed	O
by	O
high	O
-	O
throughput	O
sequencing	O
(	O
ChIP	O
-	O
Seq	O
)	O
,	O
as	O
a	O
proxy	O
of	O
gene	O
transcription	O
activity	O
22	O
23	O
24	O
,	O
to	O
investigate	O
the	O
impact	O
of	O
POLR1C	B-GENE
mutations	O
on	O
gene	O
occupancy	O
by	O
POLR1	O
and	O
POLR3	O
.	O

The	O
3D	O
structural	O
model	O
of	O
the	O
mutant	O
TBX1	B-GENE
was	O
built	O
up	O
using	O
the	O
xLeap	O
module	O
in	O
the	O
AMBER	O
suite	O
(	O
version	O
8	O
.	O
0	O
)	O
[	O
14	O
]	O
.	O

Colordiscrimination	O
also	O
exhibited	O
large	O
variations	O
,	O
tritan	B-DISEASE
defects	I-DISEASE
being	O
common	O
and	O
with	O
no	O
correlation	O
to	O
visual	O
acuity	O
.	O

To	O
investigate	O
if	O
wild	O
-	O
type	O
and	O
R192	B-VARIANT
*	I-VARIANT
CD164	B-GENE
with	O
intact	O
extracellular	O
domain	O
would	O
exhibit	O
a	O
similar	O
trafficking	O
difference	O
as	O
the	O
C	O
-	O
terminal	O
region	O
,	O
HEK	O
cells	O
were	O
stably	O
transfected	O
with	O
constructs	O
encoding	O
human	O
full	O
-	O
length	O
wild	O
-	O
type	O
CD164	B-GENE
and	O
the	O
truncated	O
CD164	B-GENE
R192	B-VARIANT
*	I-VARIANT
,	O
respectively	O
.	O

Genome	O
Analysis	O
Tool	O
Kit	O
version	O
1	O
.	O
4	O
[	O
16	O
]	O
was	O
used	O
for	O
variant	O
calling	O
.	O

Both	O
of	O
their	O
outcomes	O
were	O
poorer	O
compared	O
with	O
other	O
patients	O
,	O
and	O
the	O
authors	O
hypothesized	O
that	O
it	O
was	O
because	O
the	O
encoded	O
protein	O
is	O
also	O
expressed	O
in	O
the	O
spiral	O
ganglion	O
.	O

Hybrid	O
minigenes	O
in	O
pSPL3	O
or	O
pSPL3b	O
vector	O
were	O
transiently	O
transfected	O
into	O
HeLa	O
cells	O
using	O
Fugene	O
6	O
Transfection	O
reagent	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
at	O
3	O
u	O
L	O
per	O
u	O
g	O
of	O
DNA	O
,	O
and	O
the	O
transfected	O
cells	O
were	O
harvested	O
24	O
hours	O
after	O
transfection	O
.	O

USH1C	B-GENE
haplotypes	O
are	O
represented	O
by	O
vertical	O
colored	O
bars	O
(	O
c	B-VARIANT
.	I-VARIANT
216G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
-	I-VARIANT
associated	I-VARIANT
haplotype	O
in	O
red	O
)	O
.	O

As	O
the	O
MPS	O
diagnostic	O
panel	O
of	O
the	O
present	O
study	O
only	O
targeted	O
the	O
coding	O
sequences	O
and	O
splicing	O
sites	O
of	O
known	O
deafness	B-DISEASE
genes	O
,	O
genetic	O
defects	O
in	O
regulatory	O
elements	O
,	O
e	O
.	O
g	O
.	O
,	O
un	O
-	O
translated	O
regions	O
(	O
UTRs	O
)	O
,	O
enhancers	O
,	O
promoters	O
,	O
and	O
intronic	O
splicing	O
regulatory	O
elements	O
,	O
could	O
not	O
be	O
examined	O
.	O

Smith	O
for	O
assistance	O
with	O
enzyme	O
assays	O
and	O
DNA	O
preparation	O
,	O
M	O
.	O

Her	O
clinical	O
phenotype	O
was	O
STGD	B-DISEASE
with	O
characteristic	O
atrophic	B-DISEASE
maculopathy	I-DISEASE
and	O
retinal	B-DISEASE
flecks	I-DISEASE
.	O

For	O
the	O
15	O
genes	O
(	O
646	O
amplicons	O
)	O
in	O
our	O
setting	O
,	O
the	O
fusion	O
primer	O
approach	O
is	O
cost	O
prohibitive	O
,	O
since	O
the	O
adapter	O
sequence	O
needs	O
to	O
be	O
incorporated	O
in	O
every	O
single	O
primer	O
set	O
.	O

Briefly	O
,	O
genomic	O
DNA	O
was	O
isolated	O
from	O
peripheral	O
blood	O
leukocytes	O
using	O
QIAamp	O
DNA	O
blood	O
mini	O
kit	O
(	O
Cat	O
No	O
51106	O
)	O
according	O
to	O
manufacturer	O
'	O
s	O
instructions	O
.	O

We	O
performed	O
systematic	O
germline	O
variant	O
and	O
somatic	O
mutation	O
analyses	O
for	O
the	O
sample	O
set	O
,	O
as	O
illustrated	O
in	O
Fig	O
.	O

However	O
,	O
screening	O
strategy	O
of	O
other	O
hearing	B-DISEASE
loss	I-DISEASE
genes	O
is	O
difficult	O
and	O
Sanger	O
sequencing	O
of	O
the	O
candidate	O
genes	O
,	O
such	O
as	O
CDH23	B-GENE
,	O
with	O
many	O
exons	O
is	O
time	O
consuming	O
.	O

Our	O
multiplexed	O
NGS	O
experiments	O
were	O
conducted	O
on	O
14	O
patient	O
samples	O
with	O
19	O
genes	O
commonly	O
associated	O
with	O
AS	B-DISEASE
or	O
FSGS	B-DISEASE
including	O
steroid	O
resistant	O
nephrotic	B-DISEASE
syndrome	I-DISEASE
.	O

We	O
transiently	O
co	O
-	O
transfected	O
GFP	O
-	O
ELMOD3	B-GENE
constructs	O
with	O
Espn	O
constructs	O
,	O
where	O
the	O
latter	O
was	O
used	O
to	O
over	O
-	O
elongate	O
the	O
microvilli	O
at	O
the	O
CL4	O
cell	O
surface	O
[	O
26	O
]	O
(	O
Figure	O
5A	O
-	O
5B	O
)	O
.	O

In	O
the	O
control	O
groups	O
,	O
Gipc3	B-GENE
343G	O
/	O
A	O
heterozygotes	O
,	O
irrespective	O
of	O
the	O
presence	O
or	O
absence	O
of	O
the	O
transgene	O
(	O
tg	O
(	O
+	O
/	O
-	O
)	O
G	O
/	O
A	O
)	O
,	O
expressed	O
normal	O
hearing	O
thresholds	O
(	O
Fig	O
.	O

G	O
:	O
Partial	O
facial	O
photograph	O
of	O
affected	O
individual	O
IV	O
-	O
3	O
showing	O
blue	B-DISEASE
iris	I-DISEASE
.	O

The	O
p	B-VARIANT
.	I-VARIANT
A93T	I-VARIANT
was	O
found	O
associated	O
with	O
p	B-VARIANT
.	I-VARIANT
R583G	I-VARIANT
in	O
KCNQ1	B-GENE
in	O
an	O
isolated	O
proband	O
,	O
where	O
family	O
data	O
were	O
not	O
attainable	O
.	O

Figure	O
1	O
depicts	O
the	O
major	O
criteria	O
for	O
identification	O
of	O
causative	O
variants	O
in	O
the	O
affected	O
families	O
,	O
including	O
target	O
enrichment	O
,	O
massively	O
parallel	O
sequencing	O
,	O
variant	O
calling	O
,	O
and	O
data	O
filtering	O
.	O

Interestingly	O
,	O
the	O
activation	O
of	O
these	O
receptors	O
by	O
ryanodine	O
stimulates	O
the	O
insulin	O
secretion	O
at	O
low	O
glucose	O
concentrations	O
[	O
32	O
]	O
.	O

A	O
recent	O
study	O
of	O
100	O
unrelated	O
patients	O
with	O
EVA	B-DISEASE
in	O
European	O
Caucasians	O
by	O
Albert	O
et	O
al	O
.	O

This	O
study	O
is	O
the	O
first	O
report	O
of	O
a	O
large	O
cohort	O
of	O
MYH9	B-DISEASE
-	I-DISEASE
RD	I-DISEASE
patients	O
recruited	O
in	O
France	O
since	O
2002	O
.	O

The	O
modelling	O
accuracy	O
increases	O
with	O
larger	O
scanning	O
windows	O
(	O
28	O
>	O
21	O
>	O
14	O
)	O
,	O
and	O
probabilities	O
>	O
0	O
.	O
5	O
indicate	O
a	O
high	O
likelihood	O
of	O
coiled	O
-	O
coil	O
conformation	O
.	O

This	O
is	O
consistent	O
with	O
our	O
functional	O
data	O
showing	O
that	O
CD164	B-GENE
R192	B-VARIANT
*	I-VARIANT
lacking	O
the	O
sorting	O
motif	O
is	O
accumulated	O
on	O
the	O
cell	O
surface	O
.	O

Concerning	O
Retinal	B-DISEASE
Dystrophies	I-DISEASE
(	O
RD	B-DISEASE
)	O
,	O
almost	O
200	O
causative	O
genes	O
have	O
been	O
reported	O
to	O
date	O
,	O
and	O
most	O
families	O
carry	O
private	O
mutations	O
.	O

In	O
addition	O
,	O
polymorphic	O
changes	O
were	O
also	O
identified	O
(	O
Table	O
2	O
)	O
.	O

Each	O
vector	O
was	O
transfected	O
into	O
the	O
HeLa	O
cells	O
,	O
and	O
transcribed	O
to	O
mRNA	O
in	O
the	O
cells	O
.	O

First	O
,	O
we	O
found	O
c	B-VARIANT
.	I-VARIANT

Of	O
the	O
six	O
Palestinian	O
families	O
enrolled	O
in	O
this	O
study	O
,	O
a	O
causative	O
mutation	O
was	O
found	O
in	O
only	O
one	O
.	O

The	O
allele	O
frequencies	O
were	O
10	O
.	O
36	O
%	O
(	O
40	O
/	O
386	O
)	O
,	O
2	O
.	O
07	O
%	O
(	O
8	O
/	O
386	O
)	O
,	O
1	O
.	O
30	O
%	O
(	O
5	O
/	O
386	O
)	O
,	O
0	O
.	O
78	O
%	O
(	O
3	O
/	O
386	O
)	O
,	O
0	O
.	O
26	O
%	O
(	O
1	O
/	O
386	O
)	O
,	O
0	O
.	O
26	O
%	O
(	O
1	O
/	O
386	O
)	O
,	O
0	O
.	O
26	O
%	O
(	O
1	O
/	O
386	O
)	O
,	O
0	O
.	O
26	O
%	O
(	O
1	O
/	O
386	O
)	O
and	O
0	O
.	O
26	O
%	O
(	O
1	O
/	O
386	O
)	O
in	O
Han	O
Chinese	O
patients	O
,	O
respectively	O
.	O

Presently	O
,	O
18	O
COCH	B-GENE
mutations	O
have	O
been	O
identified	O
in	O
DFNA9	B-DISEASE
families	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
hgmd	O
.	O
org	O
/	O
,	O
designed	O
by	O
P	O
.	O
D	O
.	O
Stenson	O
HGMD	O
(	O
r	O
)	O
)	O
,	O
most	O
of	O
which	O
are	O
located	O
in	O
the	O
LCCL	O
region	O
.	O

Sixteen	O
patients	O
(	O
1	O
to16	O
)	O
had	O
EVA	B-DISEASE
and	O
two	O
pathogenic	O
mutant	O
alleles	O
,	O
consistent	O
with	O
autosomal	B-DISEASE
recessive	I-DISEASE
disorder	I-DISEASE
caused	O
by	O
bi	O
-	O
allelic	O
loss	O
of	O
function	O
of	O
pendrin	O
protein	O
(	O
Table	O
1	O
)	O
.	O

1	O
and	O
2	O
)	O
.	O

The	O
SureSelect	O
Human	O
All	O
Exon	O
50	O
Mb	O
kit	O
(	O
Agilent	O
)	O
was	O
used	O
for	O
in	O
-	O
solution	O
enrichment	O
of	O
coding	O
exons	O
and	O
flanking	O
intronic	O
sequences	O
following	O
the	O
manufacturer	O
'	O
s	O
standard	O
protocol	O
.	O

Compared	O
to	O
the	O
findings	O
of	O
Kalay	O
et	O
al	O
.	O

It	O
has	O
been	O
suggested	O
that	O
SLC26A4	B-GENE
would	O
play	O
a	O
more	O
considerable	O
role	O
in	O
HI	B-DISEASE
of	O
Asian	O
populations	O
,	O
such	O
as	O
Iranians	O
,	O
than	O
other	O
populations	O
[	O
11	O
-	O
15	O
,	O
24	O
]	O
.	O

Functional	O
studies	O
were	O
performed	O
using	O
either	O
minigenes	O
as	O
splicing	O
reporters	O
or	O
cultured	O
cells	O
obtained	O
from	O
a	O
heterozygous	O
carrier	O
.	O

The	O
example	O
in	O
Figure	O
1	O
C	O
shows	O
a	O
CNV	O
gain	O
.	O

The	O
GP	O
of	O
RP	O
#	O
022	O
showed	O
ring	O
scotoma	O
with	O
a	O
preserved	O
peripheral	O
visual	O
field	O
,	O
whereas	O
that	O
of	O
another	O
four	O
patients	O
was	O
severely	O
constricted	O
.	O

Consanguineous	O
family	O
:	O
*	O
parents	O
first	O
cousins	O
.	O

We	O
thank	O
Sharat	O
Chandra	O
for	O
critical	O
reading	O
of	O
the	O
manuscript	O
and	O
helpful	O
discussions	O
.	O
Primary	B-DISEASE
distal	I-DISEASE
renal	I-DISEASE
tubular	I-DISEASE
acidosis	I-DISEASE
(	O
dRTA	B-DISEASE
)	O
caused	O
by	O
mutations	O
in	O
the	O
genes	O
that	O
codify	O
for	O
the	O
H	O
+	O
-	O
ATPase	O
pump	O
subunits	O
is	O
a	O
heterogeneous	O
disease	O
with	O
a	O
poor	O
phenotype	O
-	O
genotype	O
correlation	O
.	O

(	O
a	O
)	O
shows	O
an	O
A	O
-	O
to	O
-	O
G	O
change	O
at	O
nucleotide	O
position	O
A605	O
-	O
2	O
,	O
which	O
resulted	O
in	O
a	O
splice	O
site	O
alteration	O
c	B-VARIANT
.	I-VARIANT
605	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
.	O

After	O
the	O
first	O
denaturation	O
step	O
at	O
98	O
deg	O
C	O
for	O
1	O
min	O
,	O
the	O
thermal	O
cycler	O
was	O
stopped	O
at	O
85	O
deg	O
C	O
and	O
5	O
u	O
l	O
of	O
diluted	O
DNA	O
polymerase	O
(	O
Takara	O
LA	O
Taq	O
)	O
was	O
added	O
.	O

B	O
:	O
Eye	O
fundus	O
photography	O
.	O

Overall	O
,	O
75	O
mutant	O
alleles	O
(	O
including	O
the	O
unclassified	O
missense	O
variants	O
)	O
were	O
identified	O
in	O
41	O
unrelated	O
patients	O
.	O

Variants	O
were	O
not	O
included	O
in	O
dbSNP130	O
unless	O
they	O
were	O
reported	O
in	O
HGMD	O
or	O
were	O
previously	O
defined	O
as	O
a	O
pathogenic	O
blindness	O
mutation	O
.	O

Invader	O
-	O
based	O
multi	O
-	O
gene	O
screening	O
for	O
13	O
genes	O
/	O
46	O
mutations	O
commonly	O
found	O
in	O
Japanese	O
,	O
identified	O
the	O
responsible	O
mutations	O
in	O
approximately	O
30	O
%	O
of	O
deafness	B-DISEASE
patients	O
[	O
3	O
]	O
,	O
accelerating	O
the	O
clinical	O
application	O
of	O
gene	O
screening	O
.	O

According	O
to	O
the	O
HHL	B-DISEASE
homepage	O
,	O
more	O
than	O
140	O
NSHHL	B-DISEASE
loci	O
have	O
been	O
mapped	O
,	O
and	O
approximately	O
65	O
genes	O
have	O
been	O
identified	O
(	O
see	O
http	O
:	O
/	O
/	O
hereditaryhearingloss	O
.	O
org	O
/	O
)	O
.	O

A	O
62	O
-	O
year	O
-	O
old	O
Caucasian	O
woman	O
consulted	O
for	O
blurred	B-DISEASE
vision	I-DISEASE
.	O

Fundus	O
autofluorescence	O
(	O
FA	O
)	O
showed	O
central	O
hypo	O
-	O
fluorescence	O
,	O
and	O
optical	O
coherence	O
tomography	O
(	O
OCT	O
)	O
showed	O
severe	O
foveal	O
thinning	O
.	O

GJHZ20130417140916986	O
)	O
.	O
This	O
is	O
an	O
open	O
-	O
access	O
article	O
distributed	O
under	O
the	O
terms	O
of	O
the	O
Creative	O
Commons	O
Attribution	O
License	O
,	O
which	O
permits	O
unrestricted	O
use	O
,	O
distribution	O
,	O
and	O
reproduction	O
in	O
any	O
medium	O
,	O
provided	O
the	O
original	O
work	O
is	O
properly	O
cited	O
.	O

To	O
examine	O
the	O
detailed	O
distribution	O
of	O
MCM2	B-GENE
in	O
the	O
cochlea	O
,	O
whole	O
-	O
mount	O
preparation	O
of	O
hair	O
cells	O
and	O
serial	O
section	O
of	O
cochlea	O
were	O
made	O
for	O
immunofluorescence	O
using	O
two	O
kinds	O
of	O
anti	O
-	O
MCM2	B-GENE
antibody	O
.	O

The	O
GIPC3	B-GENE
sequences	O
(	O
wild	O
type	O
and	O
p	B-VARIANT
.	I-VARIANT
H170N	I-VARIANT
)	O
were	O
each	O
aligned	O
with	O
the	O
PDZ	O
domain	O
in	O
GIPC2	B-GENE
(	O
PDB	O
code	O
:	O
3GGE	O
-	O
chain	O
B	O
)	O
.	O

A	O
total	O
of	O
5	O
u	O
g	O
genomic	O
DNA	O
at	O
a	O
concentration	O
of	O
20	O
-	O
500	O
ng	O
/	O
u	O
l	O
in	O
Tris	O
/	O
EDTA	O
was	O
used	O
as	O
input	O
material	O
for	O
NimbleGen	O
capture	O
methods	O
to	O
generate	O
2	O
x	O
100	O
paired	O
-	O
end	O
reads	O
.	O

2011	O
;	O
Baux	O
et	O
al	O
.	O

Both	O
probands	O
had	O
no	O
mutations	O
in	O
genes	O
previously	O
associated	O
with	O
AF	B-DISEASE
.	O

Our	O
patient	O
'	O
s	O
anteroposterior	O
(	O
AP	O
)	O
radiographs	O
of	O
the	O
other	O
sites	O
(	O
knees	O
,	O
ankles	O
,	O
spine	O
,	O
hands	O
,	O
elbows	O
)	O
revealed	O
almost	O
normal	O
findings	O
(	O
Figures	O
5	O
and	O
6	O
)	O
.	O

cLQTS	B-DISEASE
provides	O
the	O
archetypical	O
monogenic	O
disorder	O
for	O
studying	O
the	O
genetic	O
basis	O
of	O
inherited	O
arrhythmia	B-DISEASE
syndromes	I-DISEASE
in	O
that	O
it	O
is	O
relatively	O
common	O
(	O
prevalence	O
of	O
1	O
:	O
2	O
500	O
to	O
1	O
:	O
5	O
000	O
)	O
,	O
3	O
and	O
more	O
than	O
700	O
disease	O
-	O
causing	O
mutations	O
have	O
been	O
identified	O
in	O
13	O
genes	O
encoding	O
different	O
cardiac	O
ion	O
channels	O
or	O
membrane	O
adaptors	O
.	O

cDNA	O
was	O
obtained	O
from	O
leukocytes	O
and	O
platelets	O
and	O
the	O
sequences	O
corresponding	O
to	O
exons	O
40	O
-	O
41	O
were	O
analyzed	O
.	O

The	O
plasmid	O
was	O
adapted	O
from	O
the	O
Gateway	O
cloning	O
technology	O
(	O
Life	O
technologies	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

In	O
the	O
USH1	B-DISEASE
patient	O
,	O
we	O
found	O
three	O
presumably	O
pathogenic	O
mutations	O
in	O
MYO7A	B-GENE
(	O
c	B-VARIANT
.	I-VARIANT
6657T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
)	O
,	O
USH1G	B-GENE
(	O
c	B-VARIANT
.	I-VARIANT
46C	I-VARIANT
>	I-VARIANT
G	I-VARIANT
;	I-VARIANT
p	B-VARIANT
.	I-VARIANT
L16V	I-VARIANT
)	O
and	O
USH2A	B-GENE
(	O
c	B-VARIANT
.	I-VARIANT
9921T	I-VARIANT
>	I-VARIANT
G	I-VARIANT
)	O
.	O

The	O
14	O
designed	O
amplicons	O
(	O
red	O
)	O
for	O
nine	O
exons	O
are	O
shown	O
under	O
the	O
exon	O
-	O
intron	O
structure	O
.	O

They	O
were	O
recruited	O
from	O
the	O
Federaci	O
o	O
n	O
de	O
Afectados	O
de	O
Retinosis	O
Pigmentaria	O
de	O
Espa	O
n	O
a	O
(	O
FARPE	O
)	O
and	O
also	O
from	O
the	O
Ophthalmology	O
and	O
ENT	O
Services	O
of	O
several	O
Spanish	O
Hospitals	O
as	O
part	O
of	O
a	O
large	O
-	O
scale	O
study	O
on	O
the	O
genetics	O
of	O
Usher	B-DISEASE
syndrome	I-DISEASE
in	O
the	O
Spanish	O
population	O
.	O

[	O
11	O
]	O
identified	O
three	O
novel	O
homozygous	O
TECTA	B-GENE
gene	O
mutations	O
in	O
Iranian	O
families	O
,	O
including	O
one	O
frameshift	O
mutation	O
(	O
266delT	B-VARIANT
)	O
in	O
exon	O
3	O
that	O
creates	O
a	O
stop	O
codon	O
at	O
position	O
122	O
of	O
the	O
protein	O
(	O
122X	O
)	O
.	O

To	O
date	O
,	O
18	O
mutations	O
in	O
CLRN1	B-GENE
have	O
been	O
reported	O
.	O

Two	O
novel	O
missense	O
variants	O
,	O
p	B-VARIANT
.	I-VARIANT
S190L	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
G379D	I-VARIANT
,	O
were	O
found	O
in	O
a	O
heterozygous	O
state	O
.	O

In	O
this	O
study	O
we	O
combined	O
autozygosity	O
mapping	O
and	O
whole	O
exome	O
sequencing	O
in	O
a	O
family	O
with	O
3	O
affected	O
children	O
having	O
nonsyndromic	O
hearing	B-DISEASE
loss	I-DISEASE
born	O
to	O
consanguineous	O
parents	O
.	O

We	O
did	O
not	O
identify	O
this	O
variant	O
in	O
590	O
Dutch	O
control	O
alleles	O
,	O
and	O
,	O
importantly	O
,	O
the	O
resulting	O
amino	O
acid	O
change	O
Ala426Thr	B-VARIANT
has	O
been	O
shown	O
to	O
affect	O
protein	O
function	O
(	O
Lee	O
et	O
al	O
.	O

Furthermore	O
,	O
it	O
is	O
intriguing	O
that	O
OPA1	B-GENE
mutational	O
carriers	O
can	O
be	O
non	O
-	O
penetrant	O
for	O
optic	B-DISEASE
nerve	I-DISEASE
failure	I-DISEASE
,	O
but	O
yet	O
manifest	O
other	O
deficits	O
including	O
deafness	B-DISEASE
,	O
myopathy	B-DISEASE
and	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
,	O
besides	O
progressive	B-DISEASE
external	I-DISEASE
ophthalmoplegia	I-DISEASE
.	O

Of	O
the	O
12	O
identified	O
mutations	O
,	O
three	O
were	O
in	O
MYO7A	B-GENE
,	O
one	O
in	O
CDH23	B-GENE
,	O
six	O
in	O
USH2A	B-GENE
,	O
and	O
two	O
in	O
GPR98	B-GENE
(	O
Table	O
1	O
and	O
Figure	O
S3	O
)	O
.	O

James	O
Sellers	O
from	O
National	O
Heart	O
Lung	O
and	O
Blood	O
Institute	O
for	O
donating	O
baculovirus	O
expressing	O
Xenopus	O
calmodulin	O
and	O
protocol	O
of	O
ATPase	O
activity	O
experiments	O
and	O
Dr	O
.	O

Identification	O
of	O
4	O
p	B-VARIANT
.	I-VARIANT
Arg127His	I-VARIANT
homozygous	O
patients	O
out	O
of	O
125	O
deafness	B-DISEASE
patients	O
in	O
the	O
current	O
study	O
and	O
the	O
previously	O
reported	O
cases	O
of	O
9	O
heterozygous	O
cases	O
and	O
1	O
compound	O
heterozygous	O
case	O
in	O
70	O
deaf	O
patients	O
by	O
Bukhari	O
et	O
al	O
.	O

Although	O
our	O
approach	O
involved	O
sequencing	O
of	O
many	O
genes	O
not	O
relevant	O
to	O
a	O
particular	O
case	O
,	O
the	O
benefit	O
of	O
doing	O
so	O
is	O
that	O
many	O
cases	O
with	O
distinct	O
phenotypes	O
can	O
be	O
analyzed	O
simultaneously	O
,	O
allowing	O
more	O
flexibility	O
of	O
patient	O
inclusion	O
.	O

Filled	O
symbols	O
for	O
males	O
(	O
squares	O
)	O
and	O
females	O
(	O
circles	O
)	O
represent	O
affected	O
individuals	O
,	O
and	O
empty	O
,	O
unaffected	O
ones	O
;	O
An	O
arrow	O
denotes	O
the	O
proband	O
.	O

A	O
35	O
-	O
year	O
-	O
old	O
man	O
presented	O
for	O
evaluation	O
of	O
a	O
gait	O
disorder	O
progressing	O
since	O
childhood	O
,	O
cognitive	B-DISEASE
impairment	I-DISEASE
,	O
and	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O

The	O
Ganzfeld	O
-	O
ERG	O
showed	O
an	O
almost	O
normal	O
response	O
flash	O
visual	O
-	O
evoked	O
potential	O
in	O
both	O
eyes	O
and	O
a	O
significant	O
bilateral	B-DISEASE
global	I-DISEASE
retinal	I-DISEASE
degeneration	I-DISEASE
.	O

Data	O
on	O
1511	O
independent	O
probands	O
and	O
1545	O
family	O
members	O
were	O
collected	O
from	O
33	O
ear	O
,	O
nose	O
and	O
throat	O
departments	O
nationwide	O
in	O
Japan	O
and	O
registered	O
in	O
our	O
gene	O
bank	O
.	O

The	O
disease	O
haplotype	O
is	O
shown	O
with	O
a	O
black	O
or	O
a	O
gray	O
box	O
and	O
the	O
normal	O
haplotypes	O
are	O
shown	O
with	O
open	O
boxes	O
.	O

sapiens	O
,	O
NP_068602	O
.	O
2	O
;	O
M	O
.	O

PCR	O
products	O
were	O
directly	O
sequenced	O
to	O
confirm	O
the	O
accuracy	O
.	O

Allele	O
frequency	O
among	O
unrelated	O
deaf	O
and	O
controls	O
of	O
the	O
same	O
population	O
of	O
origin	O
as	O
the	O
proband	O
Sanger	O
sequencing	O
of	O
the	O
entire	O
coding	O
region	O
of	O
TMC1	B-GENE
in	O
genomic	O
DNA	O
of	O
the	O
seven	O
probands	O
heterozygous	O
for	O
TMC1	B-GENE
p	B-VARIANT
.	I-VARIANT
S647P	I-VARIANT
revealed	O
TMC1	B-GENE
c	B-VARIANT
.	I-VARIANT
1165C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R389X	I-VARIANT
[	O
14	O
]	O
as	O
the	O
second	O
pathogenic	O
allele	O
in	O
two	O
probands	O
.	O

We	O
thank	O
Corinne	O
Chauve	O
,	O
Catherine	O
Meunier	O
,	O
France	O
Michel	O
,	O
and	O
Isabelle	O
Sargis	O
for	O
expert	O
technical	O
assistance	O
.	O

None	O
of	O
the	O
10	O
SLC26A4	B-GENE
variants	O
was	O
found	O
in	O
the	O
normal	O
-	O
hearing	O
control	O
group	O
.	O

Mutations	O
were	O
described	O
according	O
to	O
the	O
Human	O
Genome	O
Variant	O
Society	O
(	O
HGVS	O
)	O
nomenclature	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
hgvs	O
.	O
org	O
/	O
mutnomen	O
)	O
with	O
nucleotide	O
numbering	O
based	O
on	O
the	O
mRNA	O
sequence	O
(	O
NM_021830	O
.	O
4	O
)	O
of	O
C10orf2	B-GENE
(	O
http	O
:	O
/	O
/	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
nuccore	O
/	O
NM_021830	O
)	O
.	O

performed	O
the	O
molecular	O
modeling	O
;	O
R	O
.	O
A	O
.	O
A	O
.	O
,	O
S	O
.	O
A	O
.	O
,	O
T	O
.	O
H	O
.	O
,	O
S	O
.	O
N	O
.	O
K	O
.	O

Disease	O
-	O
associated	O
mutations	O
are	O
marked	O
;	O
the	O
frameshift	O
and	O
nonsense	O
mutations	O
are	O
marked	O
with	O
red	O
amino	O
acids	O
,	O
missense	O
mutations	O
are	O
marked	O
with	O
blue	O
amino	O
acids	O
,	O
and	O
the	O
deleted	O
amino	O
acids	O
replaced	O
by	O
an	O
insertion	O
are	O
marked	O
with	O
green	O
.	O

Table	O
S2	O
,	O
Positions	O
with	O
a	O
minor	O
allele	O
in	O
the	O
reference	O
sequence	O
.	O

From	O
this	O
set	O
of	O
variants	O
,	O
we	O
identified	O
putative	O
de	O
novo	O
mutations	O
as	O
sites	O
where	O
both	O
parents	O
were	O
homozygous	O
for	O
the	O
reference	O
sequence	O
and	O
the	O
offspring	O
was	O
heterozygous	O
and	O
each	O
genotype	O
call	O
was	O
made	O
confidently	O
(	O
see	O
Supplementary	O
Information	O
)	O
.	O

FP	O
contributed	O
to	O
the	O
primer	O
design	O
.	O

On	O
OCT	O
,	O
there	O
was	O
a	O
schisis	O
-	O
like	O
change	O
in	O
her	O
macula	O
(	O
Figure	O
3C	O
)	O
.	O

Funding	O
:	O
This	O
work	O
was	O
supported	O
by	O
the	O
(	O
then	O
)	O
Ministry	O
of	O
Health	O
and	O
Welfare	O
,	O
Japan	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
mhlw	O
.	O
go	O
.	O
jp	O
/	O
english	O
/	O
)	O
(	O
S	O
.	O
U	O
.	O
)	O
and	O
a	O
Grant	O
-	O
in	O
-	O
Aid	O
for	O
Scientific	O
Research	O
from	O
the	O
(	O
then	O
)	O
Ministry	O
of	O
Education	O
,	O
Science	O
and	O
Culture	O
of	O
Japan	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
mext	O
.	O
go	O
.	O
jp	O
/	O
english	O
/	O
)	O
(	O
S	O
.	O
U	O
.	O
)	O
.	O

Further	O
investigation	O
of	O
this	O
possibility	O
may	O
provide	O
insight	O
into	O
the	O
molecular	O
effects	O
of	O
heterozygous	O
mutations	O
.	O

CI	O
and	O
Complex	O
IV	O
(	O
CIV	O
)	O
dipstick	O
activity	O
assays	O
were	O
performed	O
on	O
10	O
mu	O
g	O
and	O
15	O
mu	O
g	O
,	O
respectively	O
,	O
of	O
cleared	O
cell	O
lysates	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
(	O
Mitosciences	O
)	O
.	O

*	O
Consensus	O
genotype	O
with	O
quality	O
score	O
of	O
at	O
least	O
20	O
.	O

Only	O
one	O
representative	O
image	O
for	O
each	O
mutation	O
(	O
left	O
panel	O
for	O
position	O
c	O
.	O
3742G	O
,	O
right	O
panel	O
for	O
position	O
c	O
.	O
6051	O
+	O
1G	O
)	O
was	O
selected	O
to	O
be	O
shown	O
in	O
the	O
paper	O
.	O

We	O
used	O
Weinberg	O
'	O
s	O
proband	O
method	O
to	O
correct	O
for	O
possible	O
ascertainment	O
bias	O
by	O
excluding	O
probands	O
from	O
the	O
calculation	O
as	O
previously	O
described	O
[	O
23	O
,	O
34	O
]	O
.	O

After	O
Solexa	O
HiSeq	O
2000	O
sequencing	O
,	O
high	O
-	O
quality	O
reads	O
were	O
retrieved	O
from	O
raw	O
reads	O
by	O
filtering	O
out	O
the	O
low	O
quality	O
reads	O
and	O
adaptor	O
sequences	O
using	O
the	O
Solexa	O
QA	O
package	O
[	O
7	O
]	O
and	O
the	O
cutadapt	O
program	O
(	O
http	O
:	O
/	O
/	O
code	O
.	O
google	O
.	O
com	O
/	O
p	O
/	O
cutadapt	O
/	O
)	O
,	O
respectively	O
.	O

E	O
:	O
upper	O
,	O
Sequence	O
presents	O
the	O
heterozygous	O
splicing	O
site	O
mutation	O
c	B-VARIANT
.	I-VARIANT
8559	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
identified	O
in	O
patient	O
073021	O
,	O
lower	O
,	O
the	O
corresponding	O
complimentary	O
strand	O
sequence	O
.	O

Roux	O
,	O
unpublished	O
results	O
)	O
,	O
therefore	O
these	O
patients	O
cannot	O
all	O
be	O
random	O
carriers	O
and	O
it	O
is	O
most	O
likely	O
that	O
the	O
second	O
mutation	O
has	O
not	O
yet	O
been	O
detected	O
.	O

13	O
.	O
4	O
+	O
-	O
9	O
.	O
9	O
years	O
,	O
p	O
=	O
0	O
.	O
008	O
,	O
and	O
optic	B-DISEASE
atrophy	I-DISEASE
9	O
.	O
6	O
+	O
-	O
6	O
.	O
9	O
years	O
vs	O
.	O

The	O
detection	O
rate	O
of	O
mutations	O
was	O
40	O
.	O
4	O
%	O
for	O
the	O
patients	O
with	O
congenital	O
or	O
early	O
-	O
onset	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
i	O
.	O
e	O
.	O

Multiplex	O
ligation	O
dependent	O
probe	O
amplification	O
(	O
MLPA	O
)	O
analysis	O
was	O
performed	O
on	O
the	O
patients	O
in	O
whom	O
no	O
variant	O
or	O
only	O
one	O
variant	O
was	O
identified	O
in	O
the	O
USH2A	B-GENE
gene	O
and	O
on	O
the	O
carriers	O
of	O
a	O
variant	O
in	O
homozygosity	O
in	O
which	O
study	O
of	O
the	O
parents	O
did	O
not	O
confirm	O
the	O
Mendelian	O
inheritance	O
of	O
the	O
variant	O
detected	O
in	O
the	O
proband	O
(	O
Figure	O
1	O
)	O
.	O

No	O
evidence	O
of	O
conal	B-DISEASE
or	I-DISEASE
extra	I-DISEASE
-	I-DISEASE
conal	I-DISEASE
mass	I-DISEASE
.	O

These	O
genes	O
contributed	O
to	O
20	O
%	O
of	O
all	O
440	O
diagnoses	O
,	O
including	O
one	O
dominant	O
diagnosis	O
.	O

Colville	O
et	O
al	O
.	O

Asterisks	O
indicate	O
families	O
in	O
which	O
homozygous	O
blocks	O
were	O
calculated	O
by	O
overlapping	O
sequence	O
data	O
from	O
two	O
individuals	O
.	O

Two	O
of	O
the	O
recurring	O
mutations	O
,	O
KCNQ1	B-GENE
p	B-VARIANT
.	I-VARIANT
Y111C	I-VARIANT
and	O
KCNQ1	B-GENE
p	B-VARIANT
.	I-VARIANT
R518	I-VARIANT
*	I-VARIANT
,	O
were	O
identified	O
in	O
26	O
of	O
the	O
103	O
cases	O
,	O
thus	O
accounting	O
for	O
approximately	O
25	O
%	O
of	O
the	O
mutations	O
in	O
the	O
Swedish	O
LQTS	B-DISEASE
population	O
.	O

Pedigree	O
of	O
a	O
family	O
with	O
two	O
sisters	O
with	O
USH2	B-DISEASE
.	O

DNA	O
samples	O
were	O
obtained	O
for	O
9	O
unaffected	O
and	O
10	O
affected	O
individuals	O
.	O

Supported	O
by	O
grants	O
BO	O
2954	O
/	O
1	O
-	O
1	O
(	O
Deutsche	O
Forschungsgemeinschaft	O
)	O
,	O
Koeln	O
Fortune	O
Program	O
,	O
grant	O
113	O
/	O
2004	O
(	O
Faculty	O
of	O
Medicine	O
,	O
University	O
of	O
Cologne	O
)	O
and	O
Forschung	O
contra	O
Blindheit	O
-	O
Initiative	O
Usher	O
Syndrom	O
e	O
.	O
V	O
.	O

We	O
combined	O
DNA	O
from	O
these	O
individuals	O
into	O
5	O
pools	O
of	O
CI	O
patients	O
and	O
2	O
pools	O
of	O
HapMap	O
controls	O
,	O
with	O
each	O
pool	O
containing	O
DNA	O
from	O
20	O
or	O
21	O
individuals	O
.	O

Sinha	O
;	O
J	O
.	O
P	O
.	O

The	O
dissected	O
cochlear	O
sensory	O
epithelial	O
layer	O
was	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
,	O
washed	O
several	O
times	O
,	O
and	O
incubated	O
in	O
a	O
blocking	O
solution	O
(	O
10	O
%	O
goat	O
serum	O
/	O
PBS	O
/	O
0	O
.	O
25	O
%	O
Triton	O
X	O
-	O
100	O
)	O
for	O
1	O
h	O
.	O

The	O
frequency	O
(	O
8	O
.	O
7	O
%	O
)	O
is	O
the	O
second	O
most	O
common	O
next	O
to	O
GJB2	B-GENE
that	O
is	O
found	O
in	O
16	O
.	O
2	O
%	O
of	O
overall	O
and	O
25	O
.	O
6	O
%	O
of	O
congenital	O
hearing	B-DISEASE
loss	I-DISEASE
patients	O
.	O

Previous	O
study	O
showed	O
that	O
this	O
new	O
technique	O
is	O
especially	O
fit	O
for	O
diseases	O
in	O
recessive	O
inheritance	O
mode	O
,	O
because	O
in	O
domiant	O
inherited	O
mode	O
the	O
heterozygosity	O
will	O
be	O
causative	O
and	O
be	O
clinically	O
effective	O
and	O
too	O
many	O
functional	O
SNPs	O
would	O
be	O
identified	O
.	O

Cardiac	O
events	O
are	O
often	O
prompted	O
by	O
physical	O
activity	O
or	O
by	O
intense	O
emotion	O
or	O
stress	O
,	O
but	O
can	O
also	O
occur	O
at	O
rest	O
or	O
during	O
sleep	O
[	O
5	O
,	O
6	O
]	O
.	O

In	O
contrast	O
to	O
Imboden	O
et	O
al	O
.	O

PMID	O
,	O
pubmed	O
identification	O
number	O
;	O
RGD	O
,	O
rat	O
genome	O
database	O
(	O
http	O
:	O
/	O
/	O
rgd	O
.	O
mcw	O
.	O
edu	O
/	O
)	O
.	O

We	O
identified	O
a	O
novel	O
GJB2	B-GENE
mutation	O
,	O
which	O
is	O
the	O
first	O
one	O
shown	O
to	O
alter	O
the	O
acceptor	O
splice	O
site	O
of	O
the	O
single	O
intron	O
of	O
the	O
GJB2	B-GENE
gene	O
.	O

The	O
authors	O
declare	O
no	O
competing	O
financial	O
interests	O
.	O

All	O
100	O
exons	O
of	O
COL4A3	B-GENE
/	I-GENE
A4	I-GENE
genes	O
were	O
screened	O
for	O
mutations	O
using	O
the	O
SURVEYOR	O
endonuclease	O
(	O
Transgenomic	O
,	O
Cheshire	O
,	O
UK	O
)	O
,	O
which	O
cleaves	O
double	O
-	O
stranded	O
DNA	O
at	O
positions	O
of	O
mismatches	O
,	O
as	O
previously	O
described	O
[	O
23	O
]	O
,	O
[	O
24	O
]	O
.	O

The	O
total	O
scan	O
depth	O
was	O
2	O
mm	O
,	O
the	O
axial	O
resolution	O
was	O
5	O
mu	O
m	O
,	O
and	O
transverse	O
resolution	O
was	O
15	O
mu	O
m	O
.	O

USH2A	B-GENE
is	O
thought	O
to	O
be	O
involved	O
in	O
74	O
to	O
90	O
percent	O
of	O
cases	O
of	O
USH2	B-DISEASE
[	O
11	O
]	O
.	O

Among	O
these	O
ten	O
families	O
,	O
eight	O
are	O
described	O
in	O
this	O
study	O
.	O

All	O
CACNA1D	B-GENE
mutations	O
occurred	O
in	O
tumors	O
without	O
KCNJ5	B-GENE
or	O
CTNN1B	B-GENE
mutations	O
.	O

caballus	O
,	O
XP_001499990	O
.	O
1	O
;	O
F	O
.	O

Upon	O
complete	O
sequencing	O
analysis	O
of	O
OPA1	B-GENE
coding	O
exons	O
and	O
adjacent	O
intronic	O
regions	O
,	O
11	O
heterozygous	O
mutations	O
in	O
OPA1	B-GENE
(	O
Table	O
2	O
,	O
Figure	O
1	O
)	O
were	O
detected	O
in	O
12	O
of	O
193	O
(	O
6	O
.	O
2	O
%	O
)	O
families	O
,	O
among	O
which	O
eight	O
were	O
novel	O
and	O
three	O
were	O
known	O
.	O

Prediction	O
analysis	O
showed	O
that	O
this	O
nonsense	O
mutation	O
should	O
lead	O
to	O
an	O
abnormally	O
short	O
protein	O
of	O
only	O
6	O
amino	O
acids	O
(	O
p	B-VARIANT
.	I-VARIANT
Arg6	I-VARIANT
*	I-VARIANT
)	O
.	O

The	O
mutant	O
and	O
WT	O
proteins	O
were	O
transiently	O
expressed	O
in	O
BHK	O
-	O
21	O
cells	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
Leu265Ser	I-VARIANT
mutation	O
in	O
the	O
ELMO	O
domain	O
impaired	O
each	O
of	O
these	O
activities	O
.	O

Obviously	O
,	O
this	O
strategy	O
only	O
applies	O
to	O
Danish	O
ADOA	B-DISEASE
patients	O
,	O
however	O
,	O
it	O
must	O
be	O
emphasized	O
that	O
for	O
other	O
populations	O
the	O
fraction	O
of	O
deletions	O
detectable	O
by	O
MLPA	O
analysis	O
and	O
mutations	O
detectable	O
by	O
DNA	O
sequence	O
analysis	O
must	O
be	O
determined	O
and	O
probably	O
both	O
kinds	O
of	O
analyses	O
must	O
be	O
performed	O
to	O
achieve	O
a	O
high	O
detection	O
rate	O
.	O

III	O
-	O
3	O
born	O
in	O
2007	O
with	O
L	O
-	O
HSCR	B-DISEASE
,	O
was	O
operated	O
at	O
the	O
age	O
of	O
15	O
months	O
.	O

Variants	O
from	O
the	O
masterVar	O
files	O
from	O
all	O
genomes	O
were	O
merged	O
into	O
a	O
single	O
VCF	O
v4	O
.	O
1	O
file	O
with	O
mkvcf	O
(	O
beta	O
)	O
from	O
the	O
CGA	O
tools	O
suite	O
,	O
version	O
1	O
.	O
6	O
.	O
0	O
.	O

The	O
results	O
of	O
the	O
MLPA	O
indicated	O
that	O
patient	O
8	O
had	O
a	O
heterozygous	O
deletion	O
encompassing	O
the	O
whole	O
EYA1	B-GENE
gene	O
.	O

Approximately	O
70	O
%	O
of	O
hereditary	O
deafness	B-DISEASE
is	O
non	O
-	O
syndromic	O
,	O
of	O
which	O
~	O
80	O
%	O
is	O
categorized	O
as	O
autosomal	O
recessive	O
(	O
DFNB	O
)	O
,	O
~	O
15	O
-	O
20	O
%	O
as	O
autosomal	O
dominant	O
(	O
DFNA	O
)	O
,	O
~	O
1	O
%	O
as	O
X	O
-	O
linked	O
(	O
DFN	O
)	O
,	O
and	O
~	O
>	O
=	O
1	O
%	O
as	O
mitochondrial	O
or	O
chromosome	O
aberrations	O
[	O
1	O
]	O
.	O

*	O
All	O
subjects	O
have	O
congenital	O
deafness	B-DISEASE
and	O
RP	B-DISEASE
.	O

7a	O
-	O
f	O
)	O
,	O
J	O
.	O
O	O
.	O
,	O
K	O
.	O
R	O
.	O

Fragments	O
which	O
indicated	O
differences	O
from	O
a	O
known	O
negative	O
control	O
,	O
were	O
sequenced	O
bidirectionally	O
on	O
an	O
ABI	O
3100	O
Genetic	O
Analyzer	O
(	O
Applied	O
Biosystems	O
)	O
.	O

In	O
patients	O
DF25	O
-	O
V	O
.	O
3	O
and	O
DF99	O
-	O
IV	O
.	O
1	O
,	O
a	O
nonsense	O
mutation	O
,	O
c	B-VARIANT
.	I-VARIANT
52A	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Lys18	I-VARIANT
*	I-VARIANT
)	O
,	O
and	O
a	O
frameshift	O
mutation	O
,	O
c	B-VARIANT
.	I-VARIANT
1195_1196delAG	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Leu399Alafs	I-VARIANT
*	I-VARIANT
24	I-VARIANT
)	O
,	O
were	O
identified	O
in	O
exon	O
1	O
and	O
2	O
of	O
USH1G	B-GENE
(	O
NM_173477	O
)	O
,	O
respectively	O
.	O

(	O
DOCX	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

The	O
Genome	O
Analysis	O
Toolkit	O
(	O
GATK	O
)	O
43	O
,	O
44	O
was	O
used	O
for	O
base	O
quality	O
score	O
recalibration	O
and	O
indel	O
realignment	O
as	O
well	O
as	O
for	O
single	O
nucleotide	O
variant	O
and	O
indel	O
discovery	O
and	O
genotyping	O
using	O
standard	O
hard	O
filtering	O
parameters	O
43	O
.	O

Mutations	O
in	O
Usher	B-DISEASE
syndrome	I-DISEASE
-	O
related	O
genes	O
were	O
detected	O
in	O
three	O
families	O
,	O
including	O
one	O
double	O
heterozygous	O
mutation	O
of	O
CDH23	B-GENE
and	O
PCDH15	B-GENE
.	O

Seven	O
patients	O
,	O
four	O
from	O
the	O
same	O
family	O
,	O
had	O
two	O
genetic	O
variants	O
.	O

The	O
two	O
heterozygous	O
deletions	O
NM_206933	O
.	O
2	O
:	O
c	B-VARIANT
.	I-VARIANT
4628_4987del	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
6806_7451del	I-VARIANT
could	O
be	O
confirmed	O
by	O
qPCR	O
and	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
.	O

(	O
D	O
)	O
Confocal	O
images	O
of	O
COS7	O
cells	O
co	O
-	O
transfected	O
with	O
cMYC	O
-	O
tagged	O
HOMER2	B-GENE
WT	O
and	O
FLAG	O
-	O
tagged	O
HOMER2	B-GENE
p	B-VARIANT
.	I-VARIANT
Arg185Pro	I-VARIANT
immuno	O
-	O
stained	O
with	O
Alexa	O
-	O
Fluor	O
-	O
568	O
and	O
Alexa	O
-	O
Fluor	O
-	O
488	O
,	O
respectively	O
;	O
cell	O
nuclei	O
stained	O
with	O
DAPI	O
(	O
blue	O
)	O
.	O

A	O
continued	O
refinement	O
of	O
the	O
NGS	O
technology	O
will	O
further	O
improve	O
the	O
sequencing	O
accuracy	O
and	O
reduce	O
the	O
cost	O
.	O

He	O
was	O
born	O
at	O
full	O
term	O
,	O
and	O
the	O
prenatal	O
and	O
neonatal	O
history	O
was	O
unremarkable	O
.	O

The	O
mutation	O
detection	O
rate	O
for	O
the	O
current	O
NGS	O
approach	O
was	O
87	O
.	O
5	O
%	O
for	O
the	O
12	O
RD	B-DISEASE
patients	O
with	O
24	O
known	O
mutations	O
(	O
21	O
/	O
24	O
=	O
87	O
.	O
5	O
%	O
)	O
.	O

This	O
observation	O
is	O
in	O
disagreement	O
with	O
the	O
observations	O
of	O
Votruba	O
et	O
al	O
.	O

The	O
RNFL	O
is	O
very	O
thin	O
in	O
this	O
area	O
.	O

This	O
is	O
consistent	O
with	O
the	O
previous	O
description	O
of	O
prelingual	O
,	O
bilateral	O
profound	O
hearing	B-DISEASE
loss	I-DISEASE
across	O
all	O
frequencies	O
for	O
ESRRB	B-GENE
-	O
related	O
HI	B-DISEASE
[	O
2	O
]	O
.	O

Below	O
,	O
we	O
describe	O
exemplary	O
constellations	O
with	O
CNVs	O
contributing	O
to	O
retinal	O
disease	O
.	O

A	O
total	O
of	O
2063	O
unrelated	O
NSHI	B-DISEASE
students	O
from	O
23	O
different	O
regions	O
of	O
China	O
were	O
included	O
in	O
this	O
sequencing	O
study	O
.	O

Histopathological	O
analysis	O
of	O
the	O
distal	O
sural	O
nerve	O
biopsy	O
was	O
performed	O
at	O
19	O
years	O
of	O
age	O
(	O
patient	O
II	O
-	O
2	O
)	O
.	O

Coverage	O
of	O
targeted	O
sequencing	O
is	O
not	O
perfect	O
to	O
miss	O
some	O
exons	O
,	O
but	O
usually	O
considered	O
good	O
enough	O
or	O
not	O
for	O
the	O
further	O
analysis	O
,	O
especially	O
in	O
the	O
experiments	O
with	O
many	O
targets	O
.	O

We	O
mapped	O
the	O
disease	O
locus	O
to	O
chromosome	O
11q23	O
-	O
24	O
region	O
,	O
overlapping	O
with	O
the	O
DFNA8	B-GENE
/	I-GENE
12	I-GENE
locus	O
.	O

Panel	O
D	O
shows	O
the	O
proband	O
'	O
s	O
local	O
macroaneurysm	B-DISEASE
with	O
limited	O
retinal	B-DISEASE
hemorrhage	I-DISEASE
.	O

(	O
DOC	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

In	O
conclusion	O
,	O
our	O
cohort	O
greatly	O
extends	O
the	O
number	O
of	O
mutations	O
known	O
for	O
MYH9	B-DISEASE
-	I-DISEASE
RD	I-DISEASE
.	O

Unlike	O
other	O
affected	O
family	O
members	O
,	O
the	O
age	O
at	O
onset	O
of	O
hearing	B-DISEASE
impairment	I-DISEASE
of	O
individual	O
III	O
-	O
8	O
was	O
8	O
years	O
.	O

DNA	O
sequence	O
analysis	O
of	O
exon	O
9	O
and	O
flanking	O
sequences	O
of	O
the	O
OPA1	B-GENE
gene	O
in	O
family	O
F1	O
.	O

Although	O
several	O
founder	O
mutations	O
underlying	O
different	O
USH	B-DISEASE
types	O
have	O
been	O
reported	O
in	O
the	O
Jewish	O
population	O
[	O
3	O
-	O
5	O
]	O
,	O
the	O
genetic	O
basis	O
for	O
USH	B-DISEASE
in	O
the	O
Arab	O
population	O
has	O
not	O
been	O
studied	O
.	O

I	O
/	O
V	O
-	O
curves	O
were	O
constructed	O
by	O
measuring	O
the	O
current	O
at	O
the	O
end	O
of	O
a	O
voltage	O
-	O
step	O
to	O
potentials	O
ranging	O
from	O
-	O
100	O
to	O
+	O
60	O
mV	O
for	O
TEVC	O
recordings	O
or	O
+	O
40	O
mV	O
for	O
patch	O
-	O
clamp	O
experiments	O
,	O
respectively	O
.	O

The	O
organ	O
of	O
Corti	O
and	O
spiral	O
ganglion	O
at	O
the	O
apex	O
were	O
of	O
normal	O
appearance	O
(	O
Fig	O
.	O

In	O
order	O
to	O
determine	O
carrier	O
frequency	O
in	O
general	O
population	O
,	O
SLC26A4	B-GENE
exons	O
2	O
-	O
21	O
of	O
50	O
normal	O
hearing	O
individuals	O
were	O
analyzed	O
by	O
DHPLC	O
.	O

A	O
panel	O
of	O
candidate	O
genetic	O
loci	O
for	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
,	O
including	O
38	O
known	O
RP	B-DISEASE
genes	O
,	O
was	O
selected	O
for	O
preliminary	O
linkage	O
and	O
haplotype	O
analysis	O
.	O

Computer	O
analysis	O
to	O
predict	O
the	O
effect	O
of	O
missense	O
variants	O
on	O
MYO7A	B-GENE
protein	O
function	O
was	O
performed	O
with	O
sorting	O
intolerant	O
from	O
tolerant	O
(	O
SIFT	O
;	O
http	O
:	O
/	O
/	O
sift	O
.	O
jcvi	O
.	O
org	O
/	O
)	O
,	O
and	O
polymorphism	O
phenotyping	O
(	O
PolyPhen2	O
;	O
http	O
:	O
/	O
/	O
genetics	O
.	O
bwh	O
.	O
harvard	O
.	O
edu	O
/	O
pph2	O
/	O
)	O
.	O

Four	O
missense	O
variants	O
were	O
classified	O
as	O
possibly	O
-	O
pathogenic	O
(	O
UV3	O
)	O
.	O

(	O
Dnastar	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
were	O
used	O
for	O
sequence	O
analysis	O
.	O

Among	O
145	O
hearing	B-DISEASE
impaired	I-DISEASE
probands	O
who	O
visited	O
our	O
tertiary	O
referral	O
center	O
and	O
who	O
were	O
willing	O
to	O
participate	O
the	O
genetic	O
test	O
from	O
May	O
2010	O
through	O
April	O
2012	O
,	O
30	O
probands	O
with	O
syndromic	O
features	O
were	O
excluded	O
.	O

The	O
exon	O
trapping	O
expression	O
vector	O
pSPL3	O
was	O
kindly	O
provided	O
by	O
S	O
.	O

fold	O
,	O
aggregation	O
tendency	O
and	O
/	O
or	O
interactions	O
)	O
of	O
the	O
rest	O
of	O
the	O
protein	O
.	O

Actually	O
,	O
detected	O
mutations	O
were	O
confirmed	O
to	O
be	O
pathogenic	O
in	O
selected	O
families	O
(	O
Fig	O
.	O

Thirty	O
-	O
six	O
of	O
the	O
LQTS	B-DISEASE
genotype	O
-	O
negative	O
index	O
cases	O
were	O
also	O
analysed	O
for	O
mutations	O
in	O
23	O
of	O
the	O
105	O
functionally	O
most	O
important	O
exons	O
(	O
8	O
-	O
15	O
,	O
44	O
-	O
50	O
,	O
83	O
,	O
88	O
-	O
105	O
)	O
of	O
the	O
gene	O
RYR2	B-GENE
(	O
NM_001035	O
.	O
2	O
)	O
.	O

The	O
amino	O
acid	O
substitution	O
is	O
predicted	O
to	O
be	O
damaging	O
if	O
the	O
score	O
is	O
<	O
0	O
.	O
05	O
,	O
and	O
tolerated	O
if	O
the	O
score	O
is	O
>	O
0	O
.	O
05	O
.	O

Wolfram	B-DISEASE
syndrome	I-DISEASE
,	O
also	O
referred	O
to	O
as	O
DIDMOAD	B-DISEASE
(	O
diabetes	B-DISEASE
insipidus	I-DISEASE
,	O
diabetes	B-DISEASE
mellitus	I-DISEASE
,	O
optic	B-DISEASE
atrophy	I-DISEASE
,	O
and	O
deafness	B-DISEASE
)	O
,	O
is	O
a	O
rare	O
autosomal	O
recessive	O
syndrome	O
(	O
OMIM	O
#	O
222300	O
)	O
characterized	O
by	O
juvenile	O
-	O
onset	O
diabetes	B-DISEASE
,	O
progressive	O
neurologic	B-DISEASE
degeneration	I-DISEASE
,	O
and	O
endocrine	B-DISEASE
dysfunction	I-DISEASE
.	O

Finally	O
,	O
four	O
mutations	O
occur	O
in	O
genes	O
that	O
are	O
strong	O
genetic	O
candidates	O
with	O
no	O
existing	O
(	O
OMIM	O
or	O
PubMed	O
)	O
literature	O
support	O
for	O
germ	O
-	O
line	O
disease	O
association	O
(	O
SLC9A1	B-GENE
,	O
HNRNPU	B-GENE
,	O
CELSR3	B-GENE
,	O
and	O
EWSR1	B-GENE
)	O
(	O
Supplementary	O
Table	O
S7	O
online	O
)	O
.	O

Usher	B-DISEASE
syndrome	I-DISEASE
is	O
an	O
autosomal	O
recessive	O
disorder	O
manifesting	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
and	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
,	O
and	O
having	O
three	O
clinical	O
subtypes	O
.	O

Perl	O
scripts	O
and	O
ANNOVAR	O
were	O
used	O
to	O
annotate	O
variants	O
and	O
search	O
the	O
relevant	O
known	O
SNPs	O
and	O
indels	O
from	O
dbSNP135	O
and	O
the	O
1000	O
Genome	O
database	O
.	O

The	O
generated	O
model	O
structure	O
was	O
further	O
optimized	O
by	O
energy	O
minimization	O
using	O
the	O
YASARA	O
server	O
[	O
19	O
]	O
.	O

This	O
project	O
was	O
not	O
meant	O
to	O
address	O
a	O
thorough	O
examination	O
of	O
the	O
behaviour	O
of	O
every	O
mutation	O
.	O

The	O
majority	O
of	O
the	O
"	O
normal	O
"	O
plasma	O
inhibin	O
B	O
concentrations	O
correspond	O
probably	O
to	O
the	O
absence	O
of	O
physiological	O
pubertal	O
increase	O
in	O
these	O
concentrations	O
and	O
/	O
or	O
partial	O
HH	B-DISEASE
.	O

Approximately	O
85	O
%	O
of	O
disease	O
-	O
related	O
mutations	O
in	O
Mendelian	O
disorders	O
have	O
been	O
found	O
in	O
the	O
protein	O
-	O
coding	O
regions	O
(	O
exons	O
and	O
splice	O
sites	O
)	O
,	O
although	O
this	O
portion	O
constitutes	O
only	O
approximately	O
1	O
%	O
of	O
the	O
human	O
genome	O
[	O
5	O
]	O
.	O

YN	O
,	O
HO	O
and	O
KF	O
were	O
involved	O
in	O
reviewing	O
the	O
literature	O
and	O
proofreading	O
the	O
manuscript	O
,	O
and	O
were	O
major	O
contributors	O
in	O
writing	O
the	O
manuscript	O
.	O

Bdp1	B-GENE
shows	O
expression	O
in	O
the	O
stria	O
vascularis	O
(	O
red	O
arrow	O
)	O
,	O
Reissner	O
'	O
s	O
membrane	O
(	O
red	O
arrowhead	O
)	O
,	O
basilar	O
membrane	O
(	O
black	O
arrowhead	O
)	O
,	O
and	O
spiral	O
ligament	O
(	O
black	O
arrow	O
)	O
.	O

In	O
contrast	O
,	O
all	O
14	O
control	O
probes	O
of	O
the	O
same	O
patient	O
located	O
in	O
other	O
chromosomal	O
regions	O
demonstrated	O
values	O
same	O
as	O
the	O
reference	O
peak	O
with	O
suitable	O
normalization	O
ratios	O
(	O
0	O
.	O
8	O
~	O
1	O
.	O
2	O
)	O
.	O

(	O
c	O
)	O
Acoustic	O
startle	O
reflex	O
of	O
5	O
-	O
day	O
-	O
old	O
morphants	O
.	O

This	O
work	O
was	O
supported	O
by	O
National	O
Natural	O
Science	O
Foundation	O
of	O
China	O
(	O
81101339	O
,	O
81001476	O
)	O
;	O
Natural	O
Science	O
Foundation	O
of	O
Hunan	O
Province	O
,	O
China	O
(	O
10JJ4020	O
,	O
10JJ5029	O
)	O
;	O
Construction	O
Fund	O
for	O
Key	O
Subjects	O
of	O
the	O
Third	O
Xiangya	O
Hospital	O
,	O
Central	O
South	O
University	O
,	O
China	O
;	O
Postgraduates	O
Innovative	O
Pilot	O
Scheme	O
of	O
Hunan	O
Province	O
(	O
7138000008	O
)	O
,	O
China	O
;	O
the	O
Fundamental	O
Research	O
Funds	O
for	O
the	O
Central	O
Universities	O
of	O
Central	O
South	O
University	O
(	O
2014zzts360	O
)	O
;	O
and	O
Students	O
Innovative	O
Pilot	O
Scheme	O
of	O
Central	O
South	O
University	O
(	O
YC12417	O
)	O
,	O
China	O
.	O

Dominant	O
mutations	O
and	O
mitochondrial	O
mutations	O
are	O
themselves	O
diagnostic	O
criteria	O
for	O
molecular	O
diagnosis	O
.	O

A	O
mammalian	O
expression	O
plasmid	O
containing	O
an	O
open	O
reading	O
frame	O
of	O
human	O
MCM2	B-GENE
cDNA	O
with	O
a	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
tag	O
at	O
the	O
3	O
'	O
end	O
was	O
obtained	O
from	O
Origene	O
(	O
Rockville	O
,	O
MD	O
,	O
USA	O
)	O
.	O

average	O
of	O
125	O
,	O
250	O
,	O
and	O
500	O
Hz	O
.	O

The	O
percentages	O
refer	O
to	O
reads	O
mapped	O
to	O
the	O
targeted	O
region	O
(	O
on	O
-	O
target	O
)	O
,	O
sequences	O
partially	O
mapped	O
to	O
the	O
targeted	O
region	O
(	O
overlap	O
-	O
target	O
)	O
,	O
or	O
reads	O
completely	O
aligned	O
out	O
of	O
region	O
(	O
off	O
-	O
target	O
)	O
.	O

For	O
FFPE	O
samples	O
,	O
DNA	O
was	O
prepared	O
using	O
the	O
QiaAmp	O
DNA	O
FFPE	O
tissue	O
kit	O
(	O
Qiagen	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Inhibition	O
of	O
protein	O
expression	O
with	O
cycloheximide	O
indicated	O
that	O
WT	O
CLRN1	O
-	O
HA	O
remained	O
stable	O
.	O

GJB3	B-GENE
mutation	O
is	O
rarely	O
detected	O
in	O
European	O
and	O
North	O
American	O
populations	O
[	O
38	O
]	O
.	O

After	O
quantification	O
,	O
each	O
amplicon	O
library	O
was	O
diluted	O
to	O
20pM	O
and	O
the	O
same	O
amount	O
of	O
the	O
6	O
libraries	O
for	O
6	O
patients	O
were	O
pooled	O
for	O
one	O
sequence	O
reaction	O
.	O

In	O
two	O
,	O
large	O
,	O
three	O
-	O
generational	O
families	O
with	O
autosomal	O
dominant	O
progressive	B-DISEASE
external	I-DISEASE
ophthalmoplegia	I-DISEASE
(	O
IT	O
-	O
1	O
and	O
IT	O
-	O
3	O
)	O
,	O
the	O
penetrance	O
of	O
visual	B-DISEASE
failure	I-DISEASE
was	O
low	O
(	O
2	O
/	O
13	O
,	O
15	O
.	O
4	O
%	O
)	O
,	O
and	O
if	O
these	O
are	O
excluded	O
,	O
only	O
four	O
of	O
the	O
remaining	O
91	O
cases	O
(	O
4	O
.	O
4	O
%	O
)	O
were	O
visually	O
asymptomatic	O
with	O
normal	O
optic	O
nerve	O
parameters	O
.	O

The	O
mean	O
threshold	O
level	O
of	O
4	O
kHz	O
was	O
the	O
lowest	O
among	O
the	O
six	O
frequencies	O
,	O
followed	O
by	O
that	O
of	O
8	O
kHz	O
,	O
most	O
significantly	O
involving	O
high	O
frequencies	O
.	O

The	O
Branch	O
A	O
was	O
diagnosed	O
as	O
DFNB12	B-DISEASE
caused	O
by	O
the	O
compound	O
heterozygote	O
for	O
two	O
missense	O
mutations	O
;	O
and	O
Branch	O
B	O
was	O
diagnosed	O
as	O
DFNB4	B-DISEASE
with	O
enlarged	O
vestibular	O
aqueduct	O
because	O
of	O
a	O
homozygous	O
splice	O
-	O
site	O
mutation	O
.	O

BLSW	O
.	O
CAST	O
-	O
+	O
/	O
ahl5	B-DISEASE
heterozygotes	O
had	O
normal	O
thresholds	O
at	O
2	O
months	O
of	O
age	O
(	O
21	O
+	O
-	O
6	O
dBSPL	O
)	O
,	O
but	O
exhibited	O
significantly	O
elevated	O
thresholds	O
at	O
12	O
months	O
.	O

This	O
reduction	O
in	O
the	O
amount	O
of	O
this	O
protein	O
is	O
thought	O
to	O
disrupt	O
normal	O
development	O
before	O
and	O
after	O
birth	O
.	O

The	O
mutation	O
frequencies	O
are	O
significantly	O
higher	O
in	O
NSD	B-DISEASE
patients	O
than	O
in	O
control	O
subjects	O
for	O
either	O
ethnicity	O
,	O
supporting	O
the	O
profound	O
role	O
of	O
prevalent	O
deafness	O
-	O
associated	O
genetic	O
testing	O
in	O
the	O
etiological	O
diagnosis	O
of	O
NSD	B-DISEASE
patients	O
.	O

In	O
addition	O
,	O
it	O
is	O
interesting	O
to	O
note	O
that	O
this	O
is	O
not	O
the	O
first	O
report	O
of	O
CRB1	B-GENE
mutations	O
causing	O
disease	O
in	O
a	O
patient	O
originally	O
diagnosed	O
with	O
STGD	B-DISEASE
.	O

The	O
exome	O
deep	O
sequencing	O
,	O
called	O
whole	O
-	O
exome	O
sequencing	O
(	O
WES	O
)	O
analysis	O
,	O
has	O
already	O
provided	O
the	O
opportunity	O
to	O
detect	O
causal	O
gene	O
variants	O
in	O
dominant	O
and	O
recessive	O
disorders	O
[	O
14	O
]	O
,	O
[	O
15	O
]	O
and	O
it	O
has	O
been	O
recently	O
proposed	O
as	O
a	O
powerful	O
tool	O
to	O
improve	O
the	O
molecular	O
diagnostic	O
of	O
neonatal	O
diabetes	B-DISEASE
and	O
maturity	O
onset	O
diabetes	B-DISEASE
of	O
the	O
young	O
(	O
MODY	B-DISEASE
)	O
[	O
16	O
]	O
,	O
[	O
17	O
]	O
.	O

Many	O
glomerular	B-DISEASE
diseases	I-DISEASE
are	O
categorized	O
according	O
to	O
well	O
-	O
defined	O
histopathological	O
patterns	O
.	O

All	O
procedures	O
in	O
this	O
study	O
were	O
approved	O
by	O
the	O
institutional	O
review	O
boards	O
at	O
Seoul	O
National	O
University	O
Hospital	O
(	O
IRBY	O
-	O
H	O
-	O
0905	O
-	O
041	O
-	O
281	O
)	O
and	O
Seoul	O
National	O
University	O
Bundang	O
Hospital	O
(	O
SNUBH	O
:	O
IRB	O
-	O
B	O
-	O
1007	O
-	O
105	O
-	O
402	O
)	O
.	O

This	O
interval	O
contains	O
the	O
gene	O
underlying	O
the	O
USH1B	B-GENE
locus	O
,	O
MYO7A	B-GENE
.	O

Severe	O
CI	B-DISEASE
deficiency	I-DISEASE
was	O
observed	O
in	O
muscle	O
biopsy	O
and	O
fibroblasts	O
(	O
9	O
%	O
of	O
normal	O
control	O
mean	O
in	O
both	O
samples	O
relative	O
to	O
citrate	O
synthase	O
)	O
.	O

The	O
patient	O
had	O
big	O
toes	O
that	O
were	O
short	O
and	O
broad	O
,	O
and	O
mild	O
clinodactyly	O
of	O
the	O
fifth	O
digits	O
of	O
both	O
hands	O
.	O

Cochlear	O
implantation	O
in	O
patients	O
with	O
syndromic	O
hearing	B-DISEASE
loss	I-DISEASE
is	O
challenging	O
in	O
both	O
surgical	O
and	O
audiologic	O
aspects	O
.	O

For	O
Usher	B-DISEASE
syndrome	I-DISEASE
,	O
several	O
NGS	O
methods	O
have	O
been	O
developed	O
.	O

The	O
mutation	O
removed	O
the	O
main	O
donor	O
site	O
and	O
created	O
a	O
new	O
donor	O
splice	O
-	O
site	O
leading	O
to	O
a	O
deletion	O
of	O
24	O
-	O
bp	O
(	O
Fig	O
.	O

Visual	O
acuity	O
converted	O
from	O
Snellen	O
acuities	O
into	O
Log	O
Mar	O
.	O

The	O
cGMP	O
-	O
binding	O
site	O
is	O
important	O
for	O
the	O
function	O
of	O
CNGA1	B-GENE
as	O
a	O
cation	O
channel	O
.	O

The	O
conserved	O
amino	O
acids	O
are	O
shown	O
with	O
a	O
grey	O
background	O
,	O
and	O
residue	O
129	O
and	O
310	O
is	O
indicated	O
with	O
a	O
black	O
box	O
.	O

The	O
significance	O
level	O
was	O
set	O
at	O
P	O
<	O
0	O
.	O
05	O
.	O

Low	O
quality	O
of	O
reads	O
(	O
<	O
20	O
)	O
and	O
genotyping	O
(	O
<	O
30	O
)	O
were	O
then	O
ruled	O
out	O
.	O

The	O
predicted	O
interaction	O
between	O
Met305	O
and	O
ATP	O
in	O
bovine	O
beta	O
-	O
actin	O
,	O
a	O
protein	O
with	O
a	O
99	O
%	O
identity	O
to	O
ACTG1	B-GENE
,	O
implies	O
that	O
the	O
mutation	O
of	O
Met305	O
may	O
influence	O
ATP	O
binding	O
of	O
ACTG1	B-GENE
,	O
which	O
is	O
essential	O
for	O
polymerization	O
of	O
G	O
-	O
actin	O
to	O
F	O
-	O
actin	O
.	O

Several	O
genome	O
-	O
wide	O
databases	O
(	O
dbSNP	O
Build	O
135	O
,	O
1000	O
Genomes	O
Project	O
database	O
build	O
20110521	O
[	O
26	O
]	O
and	O
the	O
public	O
Exome	O
Variant	O
Server	O
,	O
NHLBI	O
,	O
Seattle	O
,	O
build	O
ESP6500	O
[	O
27	O
]	O
)	O
were	O
checked	O
for	O
the	O
presence	O
of	O
the	O
identified	O
variants	O
.	O

Despite	O
the	O
impressive	O
diagnostic	O
rate	O
found	O
here	O
,	O
it	O
should	O
be	O
remembered	O
that	O
,	O
using	O
current	O
techniques	O
,	O
it	O
is	O
not	O
yet	O
possible	O
to	O
establish	O
a	O
genetic	O
diagnosis	O
in	O
many	O
(	O
23	O
%	O
)	O
cLQTS	B-DISEASE
families	O
.	O

Autosomal	O
dominant	O
progressive	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
,	O
DFNA20	B-GENE
/	O
26	O
(	O
MIM	O
:	O
604717	O
)	O
,	O
is	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
gamma	O
-	O
actin	O
gene	O
on	O
chromosome	O
17	O
at	O
q25	O
.	O
3	O
.	O

II	O
:	O
4	O
is	O
a	O
male	O
patient	O
diagnosed	O
with	O
bilateral	O
moderate	O
to	O
severe	O
NSHHL	B-DISEASE
since	O
he	O
was	O
3	O
y	O
.	O
o	O
.	O

The	O
combined	O
maximum	O
parametric	O
LOD	O
score	O
of	O
2	O
.	O
4	O
was	O
not	O
obtained	O
.	O

OPA1	B-GENE
cleavage	O
has	O
been	O
reported	O
9	O
.	O

The	O
aggravation	O
rates	O
for	O
0	O
.	O
5	O
kHz	O
,	O
2	O
kHz	O
,	O
and	O
4	O
kHz	O
were	O
0	O
.	O
28	O
,	O
0	O
.	O
24	O
,	O
and	O
0	O
.	O
20	O
dB	O
/	O
yr	O
,	O
respectively	O
.	O

The	O
allele	O
frequencies	O
are	O
estimates	O
that	O
depend	O
on	O
the	O
sampled	O
individuals	O
and	O
the	O
assigned	O
ancestry	O
labels	O
and	O
may	O
differ	O
from	O
estimates	O
derived	O
from	O
other	O
individuals	O
or	O
ancestral	O
groupings	O
.	O

The	O
large	O
dark	O
areas	O
in	O
the	O
GP	O
correspond	O
to	O
the	O
enlarged	O
blind	O
spot	O
due	O
to	O
optic	B-DISEASE
neuropathy	I-DISEASE
.	O

Computed	O
tomography	O
scan	O
of	O
the	O
temporal	O
bone	O
for	O
patient	O
IV	O
-	O
8	O
(	O
from	O
family	O
Iranian	O
3	O
)	O
with	O
bilateral	O
enlarged	B-DISEASE
vestibular	I-DISEASE
aqueduct	I-DISEASE
.	O

Our	O
results	O
indicate	O
a	O
minor	O
causative	O
role	O
for	O
DFNB31	B-GENE
in	O
Usher	B-DISEASE
syndrome	I-DISEASE
.	O

CDH23	B-GENE
is	O
the	O
second	O
commonly	O
mutated	O
gene	O
and	O
mutations	O
in	O
MYO7A	B-GENE
and	O
CDH23	B-GENE
together	O
account	O
for	O
80	O
%	O
of	O
USH1	B-DISEASE
[	O
11	O
]	O
,	O
[	O
12	O
]	O
.	O

Patients	O
IV	O
-	O
4	O
,	O
IV	O
-	O
5	O
,	O
IV	O
-	O
8	O
,	O
IV	O
-	O
9	O
,	O
V	O
-	O
1	O
,	O
and	O
V	O
-	O
2	O
were	O
homozygous	O
for	O
this	O
variant	O
.	O

She	O
complained	O
of	O
a	O
mild	O
hearing	O
difficulty	O
but	O
had	O
not	O
been	O
wearing	O
hearing	O
aids	O
.	O

Taken	O
in	O
total	O
,	O
these	O
independent	O
gene	O
set	O
analyses	O
,	O
along	O
with	O
the	O
modest	O
enrichment	O
of	O
de	O
novo	O
variants	O
over	O
background	O
rates	O
in	O
ASD	B-DISEASE
,	O
indicate	O
that	O
a	O
proportion	O
of	O
the	O
de	O
novo	O
events	O
observed	O
in	O
this	O
study	O
likely	O
contribute	O
to	O
autism	B-DISEASE
risk	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
variations	O
in	O
OTOF	B-GENE
,	O
PJVK	B-GENE
,	O
and	O
GJB2	B-GENE
genes	O
,	O
as	O
well	O
as	O
in	O
mitochondrial	B-GENE
12S	I-GENE
rRNA	I-GENE
,	O
in	O
sporadic	O
postlingual	O
ANSD	B-DISEASE
patients	O
living	O
in	O
northwest	O
China	O
.	O

The	O
clinical	O
features	O
of	O
AN	B-DISEASE
can	O
vary	O
considerably	O
with	O
respect	O
to	O
onset	O
age	O
,	O
etiology	O
,	O
severity	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
the	O
site	O
of	O
lesion	O
.	O

The	O
alleles	O
forming	O
the	O
risk	O
haplotypes	O
are	O
boxed	O
.	O

auditory	O
brainstem	O
response	O
dominant	O
optic	B-DISEASE
atrophy	I-DISEASE
electrocochleography	O
pure	O
tone	O
average	O
Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Recent	O
studies	O
have	O
only	O
begun	O
discovering	O
genetic	O
complexities	O
unknown	O
before	O
the	O
advent	O
of	O
NGS	O
technologies	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
DW	O
,	O
HW	O
,	O
WS	O
,	O
DD	O
,	O
XL	O
,	O
XH	O
,	O
DW	O
,	O
SC	O
,	O
ZY	O
,	O
NY	O
,	O
JuW	O
and	O
JiW	O
.	O

We	O
wish	O
to	O
thank	O
Joris	O
Veltman	O
for	O
helpful	O
discussion	O
,	O
Michael	O
Kwint	O
for	O
technical	O
help	O
and	O
Christian	O
Gilissen	O
for	O
bioinformatic	O
support	O
.	O
To	O
describe	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
four	O
Greek	O
pedigrees	O
with	O
autosomal	B-DISEASE
dominant	I-DISEASE
optic	I-DISEASE
atrophy	I-DISEASE
(	O
ADOA	B-DISEASE
)	O
and	O
OPA1	B-GENE
mutations	O
.	O

In	O
contrast	O
,	O
the	O
other	O
5	O
variations	O
(	O
p	B-VARIANT
.	I-VARIANT
D187H	I-VARIANT
in	O
ACTG1	B-GENE
,	O
p	B-VARIANT
.	I-VARIANT
S288X	I-VARIANT
in	O
EYA4	B-GENE
,	O
p	B-VARIANT
.	I-VARIANT
I502V	I-VARIANT
in	O
MYO1F	B-GENE
,	O
p	B-VARIANT
.	I-VARIANT
P678S	I-VARIANT
in	O
DIAPH1	B-GENE
and	O
p	B-VARIANT
.	I-VARIANT
E232K	I-VARIANT
in	O
POU4F3	B-GENE
)	O
were	O
absent	O
in	O
all	O
100	O
normal	O
controls	O
in	O
this	O
study	O
.	O

Mutation	O
information	O
was	O
extracted	O
from	O
the	O
full	O
text	O
,	O
as	O
its	O
original	O
description	O
,	O
all	O
the	O
novel	O
mutations	O
were	O
claimed	O
in	O
the	O
papers	O
by	O
the	O
authors	O
,	O
and	O
then	O
were	O
confirmed	O
by	O
searching	O
the	O
previous	O
literature	O
and	O
the	O
Human	O
Gene	O
Mutation	O
Database	O
.	O

If	O
so	O
,	O
HSD17B4	B-GENE
would	O
be	O
added	O
to	O
a	O
small	O
but	O
growing	O
list	O
of	O
disease	O
gene	O
products	O
that	O
can	O
be	O
dual	O
localized	O
to	O
these	O
two	O
compartments	O
(	O
e	O
.	O
g	O
.	O

Mutations	O
in	O
exons	O
14	O
-	O
18	O
of	O
COMP	B-GENE
,	O
which	O
encodes	O
the	O
C	O
-	O
terminal	O
domain	O
were	O
identified	O
in	O
approximately	O
13	O
%	O
(	O
8	O
/	O
64	O
)	O
of	O
PSACH	B-DISEASE
and	O
MED	B-DISEASE
patients	O
and	O
were	O
once	O
again	O
clustered	O
at	O
specific	O
residues	O
as	O
previously	O
noted	O
[	O
Kennedy	O
et	O
al	O
.	O
,	O
2005b	O
]	O
.	O

After	O
the	O
exclusion	O
of	O
GJB2	B-GENE
mutations	O
and	O
other	O
mutations	O
previously	O
reported	O
in	O
Tunisian	O
deaf	B-DISEASE
patients	O
,	O
we	O
performed	O
whole	O
exome	O
sequencing	O
in	O
patients	O
affected	O
with	O
severe	O
to	O
profound	B-DISEASE
deafness	I-DISEASE
,	O
from	O
four	O
unrelated	O
consanguineous	O
Tunisian	O
families	O
.	O

We	O
now	O
report	O
the	O
first	O
NUBPL	B-GENE
mutations	O
in	O
a	O
patient	O
with	O
CI	B-DISEASE
deficiency	I-DISEASE
,	O
a	O
male	O
who	O
presented	O
at	O
2	O
years	O
of	O
age	O
with	O
developmental	B-DISEASE
delay	I-DISEASE
,	O
leukodystrophy	B-DISEASE
and	O
elevated	B-DISEASE
CSF	I-DISEASE
lactate	I-DISEASE
(	O
see	O
Supplementary	O
Note	O
for	O
complete	O
clinical	O
description	O
)	O
.	O

The	O
remaining	O
mutations	O
were	O
private	O
,	O
appearing	O
in	O
one	O
or	O
two	O
families	O
only	O
.	O

2G	O
)	O
.	O

We	O
clinically	O
evaluated	O
9	O
young	O
patients	O
from	O
9	O
unrelated	O
families	O
(	O
6	O
males	O
,	O
3	O
females	O
)	O
.	O

The	O
Ethical	O
Review	O
Committee	O
(	O
Comit	O
e	O
de	O
Protection	O
des	O
Personnes	O
,	O
Ile	O
de	O
France	O
III	O
)	O
approved	O
this	O
retrospective	O
study	O
and	O
stated	O
that	O
"	O
This	O
study	O
appears	O
to	O
be	O
in	O
accordance	O
with	O
the	O
scientific	O
principles	O
generally	O
accepted	O
and	O
to	O
the	O
ethical	O
standards	O
of	O
research	O
.	O

Since	O
a	O
change	O
in	O
the	O
polarity	O
(	O
non	O
-	O
polar	O
to	O
polar	O
)	O
may	O
affect	O
insertion	O
of	O
the	O
protein	O
into	O
the	O
membrane	O
,	O
we	O
speculated	O
with	O
the	O
possibility	O
that	O
the	O
replacement	O
of	O
a	O
leucine	O
(	O
non	O
-	O
polar	O
)	O
to	O
an	O
arginine	O
(	O
polar	O
,	O
basic	O
)	O
may	O
result	O
in	O
defective	O
USH2A	B-GENE
membrane	O
anchorage	O
.	O

Autosomal	B-DISEASE
dominant	I-DISEASE
optic	I-DISEASE
atrophy	I-DISEASE
(	O
ADOA	B-DISEASE
,	O
OMIM	O
165500	O
)	O
is	O
a	O
hereditary	O
disorder	O
characterized	O
by	O
progressive	O
loss	B-DISEASE
of	I-DISEASE
visual	I-DISEASE
acuity	I-DISEASE
in	O
the	O
early	O
decades	O
of	O
life	O
,	O
color	B-DISEASE
vision	I-DISEASE
deficits	I-DISEASE
,	O
optic	B-DISEASE
nerve	I-DISEASE
pallor	I-DISEASE
,	O
and	O
central	O
or	O
centrocecal	O
visual	O
field	O
scotoma	O
[	O
1	O
,	O
2	O
]	O
.	O

Yellow	O
circle	O
denotes	O
p	O
.	O
T559	O
.	O

Heterozygosity	O
for	O
this	O
mutation	O
is	O
responsible	O
for	O
non	O
-	O
syndromic	O
low	O
-	O
frequency	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
a	O
Japanese	O
family	O
[	O
19	O
]	O
with	O
a	O
similar	O
phenotype	O
to	O
that	O
of	O
family	O
K13576	O
.	O

Among	O
them	O
,	O
five	O
mutations	O
were	O
previously	O
reported	O
:	O
p	B-VARIANT
.	I-VARIANT
D398E	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
Y474X	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
N727S	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R1856Q	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
R1939Q	I-VARIANT
.	O

1987	O
)	O
.	O

To	O
analyze	O
the	O
structural	O
impact	O
of	O
the	O
p	B-VARIANT
.	I-VARIANT
R668H	I-VARIANT
missense	O
mutation	O
on	O
the	O
myosin	B-GENE
VIIA	I-GENE
motor	O
domain	O
,	O
the	O
sequence	O
of	O
the	O
wild	O
-	O
type	O
myosin	B-GENE
VIIA	I-GENE
motor	O
domain	O
was	O
submitted	O
to	O
the	O
Phyre2	O
server	O
,	O
and	O
the	O
3	O
-	O
D	O
structure	O
of	O
the	O
myosin	B-GENE
VIIA	I-GENE
motor	O
domain	O
was	O
modeled	O
based	O
on	O
the	O
solved	O
motor	O
domain	O
structure	O
of	O
chick	O
smooth	O
muscle	O
myosin	O
(	O
PDB	O
ID	O
:	O
3JO4	O
)	O
[	O
18	O
]	O
.	O

Eighteen	O
family	O
members	O
including	O
11	O
patients	O
and	O
7	O
individuals	O
with	O
normal	O
hearing	O
participated	O
in	O
this	O
study	O
.	O

Coupling	O
efficiency	O
(	O
ATP	O
/	O
oxygen	O
[	O
ATP	O
/	O
O	O
]	O
)	O
was	O
measured	O
by	O
polarography	O
as	O
the	O
number	O
of	O
nanomoles	O
of	O
ATP	O
produced	O
from	O
ADP	O
+	O
Pi	O
per	O
nanomole	O
of	O
oxygen	O
consumed	O
by	O
permeabilized	O
cells	O
.	O

Genetic	O
testing	O
will	O
be	O
very	O
important	O
prognostic	O
information	O
together	O
with	O
various	O
hearing	O
tests	O
.	O

This	O
high	O
detection	O
rate	O
supports	O
the	O
sequencing	O
of	O
MYO7A	B-GENE
and	O
USH2A	B-GENE
genes	O
associated	O
with	O
MLPA	O
-	O
USH2A	B-GENE
as	O
the	O
first	O
step	O
in	O
the	O
molecular	O
diagnosis	O
of	O
Italian	O
patients	O
with	O
USH	B-DISEASE
.	O

Their	O
geographic	O
distribution	O
includes	O
different	O
regions	O
,	O
despite	O
a	O
presumed	O
isolation	O
of	O
certain	O
Roma	O
subpopulations	O
(	O
clans	O
)	O
in	O
these	O
countries	O
.	O

These	O
mutations	O
were	O
detected	O
in	O
more	O
than	O
5	O
patients	O
each	O
,	O
and	O
their	O
allele	O
frequencies	O
were	O
relatively	O
high	O
.	O

MYO15A	B-GENE
is	O
known	O
to	O
be	O
responsible	O
for	O
DFNB3	B-GENE
[	O
11	O
]	O
.	O

In	O
fact	O
,	O
digenic	O
inheritance	O
of	O
nonsyndromic	B-DISEASE
deafness	I-DISEASE
caused	O
by	O
mutations	O
in	O
the	O
GJB2	B-GENE
gene	O
and	O
other	O
connexin	O
genes	O
,	O
such	O
as	O
GJB3	B-GENE
,	O
GJB6	B-GENE
,	O
GJB4	B-GENE
,	O
or	O
GJA1	B-GENE
,	O
have	O
been	O
previously	O
reported	O
in	O
several	O
deaf	B-DISEASE
patients	O
[	O
33	O
-	O
35	O
]	O
.	O

Postlingual	B-DISEASE
progressive	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
,	O
primarily	O
affecting	O
higher	O
frequencies	O
,	O
is	O
the	O
clinical	O
finding	O
in	O
most	O
cases	O
of	O
autosomal	B-DISEASE
dominant	I-DISEASE
nonsyndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
ADNSHL	B-DISEASE
)	O
[	O
1	O
]	O
.	O

The	O
rate	O
in	O
congenital	O
hearing	B-DISEASE
loss	I-DISEASE
patients	O
also	O
increased	O
when	O
restricting	O
to	O
the	O
patients	O
with	O
moderate	O
or	O
more	O
severe	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
>	O
50	O
dB	O
;	O
40	O
.	O
7	O
%	O
)	O
or	O
severe	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
>	O
70	O
dB	O
;	O
44	O
.	O
3	O
%	O
)	O
(	O
Fig	O
.	O

cDNA	O
was	O
amplified	O
using	O
a	O
forward	O
primer	O
in	O
FGFR2	B-GENE
exon	O
IIIa	O
(	O
5	O
'	O
-	O
TCGGAGGAGACGTAGAGTTTGTCTGC	O
-	O
3	O
'	O
)	O
used	O
in	O
combination	O
with	O
a	O
reverse	O
primer	O
in	O
exon	O
11	O
(	O
encoding	O
the	O
transmembrane	O
(	O
TM	O
)	O
domain	O
;	O
5	O
'	O
-	O
TGTTACCTGTCTCCGCAGGGGGATA	O
-	O
3	O
'	O
)	O
.	O

In	O
genomic	O
DNA	O
from	O
the	O
proband	O
D28C	O
,	O
two	O
variants	O
were	O
observed	O
in	O
the	O
TMC1	B-GENE
gene	O
,	O
corresponding	O
to	O
the	O
known	O
mutation	O
c	B-VARIANT
.	I-VARIANT
1810C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R604X	I-VARIANT
[	O
11	O
]	O
and	O
a	O
novel	O
variant	O
c	B-VARIANT
.	I-VARIANT
1939T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
S647P	I-VARIANT
(	O
Table	O
2	O
)	O
.	O

This	O
project	O
was	O
supported	O
by	O
grants	O
from	O
the	O
BMBF	O
(	O
German	O
LEUKONET	O
)	O
and	O
the	O
Deutsche	O
Forschungsgemeinschaft	O
(	O
GA354	O
/	O
7	O
-	O
1	O
)	O
.	O
Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

*	O
:	O
stop	O
codon	O
disrupted	O
by	O
the	O
mutation	O
.	O

Also	O
included	O
were	O
11	O
cases	O
with	O
a	O
specific	O
skeletal	B-DISEASE
disorder	I-DISEASE
but	O
for	O
which	O
there	O
was	O
at	O
the	O
time	O
no	O
known	O
associated	O
gene	O
.	O

These	O
investigators	O
did	O
not	O
test	O
each	O
subject	O
directly	O
,	O
and	O
did	O
not	O
assess	O
olfaction	O
or	O
color	O
vision	O
,	O
so	O
it	O
is	O
not	O
clear	O
whether	O
these	O
features	O
were	O
also	O
present	O
prior	O
to	O
diabetes	B-DISEASE
.	O

PCR	O
was	O
done	O
to	O
catch	O
the	O
target	O
gene	O
.	O

Values	O
are	O
given	O
in	O
millivolt	O
(	O
mV	O
)	O
.	O

The	O
COL4A3	B-GENE
-	O
p	B-VARIANT
.	I-VARIANT
(	I-VARIANT
G1334E	I-VARIANT
)	I-VARIANT
mutation	O
was	O
used	O
as	O
a	O
positive	O
control	O
for	O
activation	O
of	O
UPR	O
markers	O
[	O
19	O
]	O
.	O

Finally	O
,	O
analysis	O
of	O
the	O
SLC4A1	B-GENE
gene	O
in	O
those	O
patients	O
with	O
a	O
negative	O
result	O
for	O
the	O
previous	O
studies	O
.	O

With	O
respect	O
to	O
the	O
common	O
exonic	O
PEX1	B-GENE
mutations	O
,	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
has	O
been	O
described	O
[	O
9	O
,	O
12	O
,	O
23	O
,	O
24	O
]	O
.	O

The	O
asterisk	O
sign	O
indicates	O
individuals	O
clinically	O
and	O
genetically	O
examined	O
.	O

[	O
16	O
]	O
The	O
c	B-VARIANT
.	I-VARIANT
2708_2711delTTAG	I-VARIANT
mutation	O
is	O
located	O
as	O
the	O
first	O
four	O
nucleotides	O
in	O
exon	O
27	O
.	O

Pedigrees	O
were	O
constructed	O
using	O
Cyrillic	O
2	O
.	O
1	O
(	O
Cyrillic	O
Software	O
,	O
Oxfordshire	O
,	O
United	O
Kingdom	O
)	O
.	O

(	O
A	O
)	O
Platelet	O
count	O
(	O
PC	O
)	O
and	O
size	O
[	O
median	O
and	O
range	O
]	O
.	O

Hajime	O
Sano	O
and	O
Makito	O
Okamoto	O
(	O
Kitasato	O
University	O
)	O
,	O
Dr	O
.	O

Genetic	O
underlying	O
defects	O
may	O
be	O
overlooked	O
if	O
the	O
method	O
used	O
for	O
the	O
analysis	O
is	O
confined	O
to	O
the	O
screening	O
of	O
a	O
set	O
of	O
mutations	O
in	O
particular	O
genes	O
.	O

The	O
average	O
amount	O
of	O
mappable	O
sequence	O
data	O
per	O
sample	O
was	O
31	O
Mb	O
,	O
resulting	O
in	O
an	O
evenly	O
distributed	O
average	O
coverage	O
of	O
26	O
x	O
per	O
exon	O
per	O
sample	O
(	O
evenness	O
score	O
=	O
97	O
.	O
3	O
%	O
;	O
Figs	O
.	O

Over	O
60	O
%	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
is	O
caused	O
by	O
genetic	O
factors	O
,	O
70	O
%	O
of	O
which	O
is	O
non	O
-	O
syndromic	O
(	O
3	O
,	O
4	O
)	O
.	O

Coverage	O
metrics	O
for	O
19	O
gene	O
custom	O
exomes	O
nex	O
-	O
gen	O
sequencing	O
in	O
patients	O
with	O
suspected	O
Alports	B-DISEASE
.	O

In	O
addition	O
,	O
a	O
transition	O
mutation	O
c	B-VARIANT
.	I-VARIANT
368T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Ile123Thr	I-VARIANT
)	O
of	O
CIB2	B-GENE
co	O
-	O
segregated	O
with	O
ARNSHI	B-DISEASE
in	O
Turkish	O
DFNB48	B-DISEASE
family	O
802	O
(	O
Figs	O
.	O

Novel	O
variants	O
were	O
classified	O
as	O
UV4	O
,	O
based	O
on	O
a	O
frequency	O
<	O
0	O
.	O
236	O
%	O
in	O
controls	O
,	O
identification	O
in	O
trans	O
to	O
a	O
pathogenic	O
/	O
probably	O
pathogenic	O
mutation	O
and	O
segregation	O
with	O
USH	B-DISEASE
in	O
only	O
one	O
family	O
(	O
ie	O
,	O
probably	O
pathogenic	O
)	O
,	O
and	O
UV3	O
(	O
likely	O
pathogenic	O
)	O
as	O
above	O
but	O
phase	O
of	O
the	O
variant	O
could	O
not	O
be	O
ascertained	O
due	O
to	O
missing	O
family	O
data	O
.	O

The	O
set	O
of	O
high	O
-	O
confidence	O
interactors	O
of	O
POLR1C	B-GENE
for	O
a	O
given	O
mutant	O
analysis	O
was	O
identified	O
by	O
comparing	O
the	O
spectral	O
counts	O
of	O
the	O
interactors	O
obtained	O
from	O
the	O
purifications	O
of	O
the	O
paired	O
WT	O
POLR1C	B-GENE
and	O
the	O
MUT	O
POLR1C	B-GENE
to	O
those	O
of	O
the	O
proteins	O
purified	O
with	O
an	O
empty	O
vector	O
(	O
EV	O
)	O
of	O
the	O
FLAG	O
tag	O
(	O
nonspecific	O
interaction	O
)	O
.	O

USH3	B-DISEASE
is	O
rare	O
except	O
in	O
some	O
populations	O
with	O
founder	O
effects	O
where	O
it	O
is	O
responsible	O
for	O
more	O
than	O
40	O
%	O
of	O
the	O
Finnish	O
and	O
Jewish	O
Ashkenazi	O
USH	B-DISEASE
cases	O
(	O
Saihan	O
et	O
al	O
.	O

Focal	B-DISEASE
segmental	I-DISEASE
glomerulosclerosis	I-DISEASE
(	O
FSGS	B-DISEASE
)	O
is	O
the	O
third	O
leading	O
cause	O
of	O
end	B-DISEASE
-	I-DISEASE
stage	I-DISEASE
kidney	I-DISEASE
disease	I-DISEASE
(	O
ESKD	B-DISEASE
)	O
in	O
the	O
USA	O
and	O
its	O
incidence	O
is	O
estimated	O
at	O
23	O
per	O
million	O
population	O
1	O
.	O

Dysfunction	B-DISEASE
of	I-DISEASE
the	I-DISEASE
Bruch	I-DISEASE
membrane	I-DISEASE
[	I-DISEASE
24	I-DISEASE
]	I-DISEASE
and	I-DISEASE
the	I-DISEASE
internal	I-DISEASE
limiting	I-DISEASE
membrane	I-DISEASE
[	O
12	O
]	O
due	O
to	O
abnormal	B-DISEASE
type	I-DISEASE
IV	I-DISEASE
collagen	I-DISEASE
were	O
prosposed	O
to	O
be	O
involved	O
.	O

This	O
rare	O
condition	O
was	O
further	O
confirmed	O
by	O
intra	O
-	O
familial	O
validation	O
.	O

One	O
of	O
the	O
most	O
common	O
forms	O
of	O
syndromic	O
RP	B-DISEASE
is	O
Usher	B-DISEASE
syndrome	I-DISEASE
,	O
characterized	O
by	O
the	O
combination	O
of	O
RP	B-DISEASE
,	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
and	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
.	O

Numbers	O
of	O
rare	O
variants	O
detected	O
in	O
genomic	O
DNA	O
of	O
probands	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
a	O
Missense	O
variants	O
predicted	O
to	O
be	O
benign	O
by	O
PolyPhen2	O
and	O
SIFT	O
are	O
excluded	O
from	O
the	O
missense	O
mutations	O
listed	O
above	O
.	O

The	O
M34T	B-VARIANT
variant	O
is	O
the	O
most	O
frequent	O
,	O
with	O
a	O
carrier	O
frequency	O
of	O
1	O
/	O
43	O
(	O
2	O
.	O
3	O
%	O
)	O
.	O

NARS2	B-GENE
expression	O
was	O
assessed	O
with	O
Western	O
Blot	O
in	O
transduced	O
patient	O
cells	O
to	O
monitor	O
the	O
transduction	O
efficiency	O
,	O
using	O
an	O
anti	O
-	O
NARS2	B-GENE
antibody	O
.	O

Analysis	O
of	O
the	O
RT	O
-	O
PCR	O
amplification	O
of	O
nasal	O
cells	O
allowed	O
us	O
to	O
confirm	O
that	O
four	O
of	O
the	O
eight	O
studied	O
variants	O
,	O
one	O
MYO7A	B-GENE
(	O
c	B-VARIANT
.	I-VARIANT
5856G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
and	O
three	O
CDH23	B-GENE
(	O
c	B-VARIANT
.	I-VARIANT
2289	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
6049G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
8722	I-VARIANT
+	I-VARIANT
1delG	I-VARIANT
)	O
,	O
were	O
affecting	O
the	O
splicing	O
process	O
.	O

For	O
example	O
,	O
CDH23	B-GENE
:	O
p	B-VARIANT
.	I-VARIANT
R1060W	I-VARIANT
,	O
reported	O
as	O
presumably	O
pathogenic	O
in	O
a	O
digenic	O
USH	B-DISEASE
case	O
,	O
18	O
has	O
previously	O
been	O
published	O
as	O
likely	O
non	O
-	O
pathogenic	O
.	O

Truncated	O
proteins	O
are	O
not	O
detected	O
in	O
TCS	B-DISEASE
patients	O
'	O
fibroblasts	O
and	O
lymphocytes	O
,	O
suggesting	O
that	O
mRNA	O
bearing	O
PTCs	O
are	O
being	O
degraded	O
by	O
nonsense	B-DISEASE
mediated	I-DISEASE
mRNA	I-DISEASE
decay	I-DISEASE
(	O
NMD	B-DISEASE
)	O
[	O
5	O
]	O
;	O
however	O
,	O
NMD	B-DISEASE
has	O
never	O
been	O
demonstrated	O
in	O
human	O
or	O
mouse	O
cells	O
with	O
null	O
mutations	O
in	O
TCOF1	B-GENE
.	O

*	O
de	O
novo	O
-	O
mutation	O
;	O
#	O
Testicular	O
volume	O
less	O
than	O
4	O
mL	O
in	O
males	O
or	O
no	O
spontaneous	O
thelarche	O
in	O
females	O
;	O
SS	O
Testicular	O
volume	O
6	O
mL	O
at	O
the	O
age	O
of	O
33	O
;	O
$	O
?	O
A	O
brother	O
with	O
normosmic	O
HH	B-DISEASE
,	O
cleft	B-DISEASE
lip	I-DISEASE
and	I-DISEASE
palate	I-DISEASE
,	O
and	O
limb	B-DISEASE
anomalies	I-DISEASE
.	O

In	O
their	O
study	O
,	O
2	O
HDR	B-DISEASE
patients	O
developed	O
end	B-DISEASE
-	I-DISEASE
stage	I-DISEASE
renal	I-DISEASE
failure	I-DISEASE
.	O

The	O
patient	O
IV	O
-	O
8	O
contained	O
the	O
same	O
phenotype	O
(	O
Fig	O
.	O

A	O
large	O
proportion	O
of	O
the	O
variants	O
reported	O
here	O
(	O
21	O
)	O
are	O
novel	O
.	O

The	O
effect	O
of	O
this	O
mutation	O
on	O
EDN3	B-GENE
was	O
predicted	O
to	O
be	O
probably	O
damaging	O
by	O
PolyPhen	O
-	O
2	O
with	O
a	O
score	O
of	O
1	O
(	O
score	O
ranges	O
from	O
0	O
to	O
a	O
positive	O
number	O
,	O
where	O
0	O
is	O
neutral	O
,	O
and	O
a	O
high	O
positive	O
number	O
is	O
damaging	O
)	O
.	O

As	O
evident	O
in	O
Fig	O
.	O

Patient	O
2	O
-	O
II	O
-	O
1	O
was	O
found	O
to	O
have	O
a	O
new	O
heterozygous	O
single	O
base	O
-	O
pair	O
deletion	O
at	O
position	O
1899	O
(	O
c	B-VARIANT
.	I-VARIANT
1899delT	I-VARIANT
)	O
.	O

The	O
proband	O
is	O
most	O
affected	O
in	O
low	O
frequencies	O
with	O
ascending	O
audiological	O
curve	O
.	O

Next	O
,	O
we	O
assessed	O
accuracy	O
of	O
these	O
898	O
variants	O
using	O
known	O
genotypes	O
available	O
from	O
our	O
patient	O
controls	O
and	O
HapMap	O
controls	O
21	O
.	O

As	O
for	O
the	O
analysis	O
of	O
the	O
suspected	O
EYA4	B-GENE
mutation	O
,	O
PCR	O
primers	O
were	O
used	O
:	O
Forward	O
,	O
5	O
'	O
-	O
CCAAGAGTGAGG	O
CAATGAG	O
-	O
3	O
'	O
and	O
reverse	O
,	O
5	O
'	O
-	O
TCGGTACTGTAACACC	O
CAAA	O
-	O
3	O
'	O
.	O

Three	O
genes	O
have	O
been	O
found	O
to	O
cause	O
USH2	B-DISEASE
:	O
USH2A	B-GENE
(	O
USH2A	B-GENE
)	O
,	O
GPR98	B-GENE
(	O
USH2C	B-GENE
)	O
and	O
DFNB31	B-GENE
(	O
USH2D	B-GENE
)	O
.	O

In	O
two	O
families	O
,	O
we	O
report	O
phenotypic	O
variability	O
associated	O
with	O
different	O
mutations	O
of	O
the	O
same	O
mt	O
-	O
aaRSs	O
,	O
NARS2	B-GENE
.	O

(	O
A	O
)	O
Extended	O
pedigree	O
.	O

This	O
mutation	O
was	O
identified	O
in	O
an	O
Italian	O
USH1	B-DISEASE
patient	O
(	O
family	O
FRP	O
-	O
249	O
;	O
patient	O
RP	O
-	O
1265	O
)	O
in	O
exon	O
4	O
in	O
a	O
homozygous	O
state	O
.	O

(	O
A	O
)	O
Otic	O
capsule	O
morphology	O
in	O
non	O
-	O
injected	O
(	O
i	O
,	O
n	O
=	O
26	O
)	O
,	O
wtRNA	O
-	O
injected	O
(	O
ii	O
,	O
n	O
=	O
26	O
)	O
and	O
P185RNA	O
-	O
injected	O
(	O
iii	O
,	O
n	O
=	O
27	O
)	O
embryos	O
at	O
72	O
hpf	O
.	O

This	O
is	O
supported	O
by	O
the	O
immunohistochemical	O
finding	O
of	O
frequent	O
loss	O
of	O
alpha	O
3	O
,	O
alpha	O
4	O
,	O
and	O
alpha	O
5	O
signals	O
in	O
the	O
GBM	O
of	O
XLAS	B-DISEASE
patients	O
[	O
24	O
,	O
25	O
]	O
.	O

In	O
addition	O
,	O
we	O
can	O
confirm	O
that	O
the	O
analysis	O
of	O
nasal	O
epithelial	O
cells	O
is	O
an	O
alternative	O
method	O
to	O
discriminate	O
neutral	O
Usher	O
variants	O
from	O
those	O
with	O
a	O
pathogenic	O
effect	O
on	O
the	O
splicing	O
process	O
.	O

Indels	O
with	O
read	O
coverage	O
>	O
=	O
8	O
x	O
covered	O
by	O
reads	O
from	O
both	O
strands	O
were	O
predicted	O
.	O

These	O
data	O
support	O
the	O
assertion	O
that	O
nearly	O
all	O
of	O
the	O
common	O
variants	O
in	O
populations	O
related	O
to	O
those	O
in	O
the	O
1000	O
Genomes	O
Project	O
have	O
been	O
discovered	O
but	O
that	O
many	O
rare	O
variants	O
are	O
yet	O
to	O
be	O
identified	O
[	O
33	O
]	O
.	O

A	O
network	O
for	O
collaboration	O
with	O
national	O
medical	O
resources	O
has	O
been	O
set	O
up	O
in	O
countries	O
and	O
regions	O
such	O
as	O
Europe	O
,	O
North	O
America	O
,	O
and	O
Japan	O
[	O
12	O
,	O
13	O
]	O
.	O

(	O
A	O
)	O
An	O
average	O
number	O
of	O
candidate	O
SNVs	O
with	O
standard	O
errors	O
were	O
shown	O
at	O
five	O
filtering	O
steps	O
.	O

Founder	O
mutation	O
(	O
s	O
)	O
could	O
occur	O
in	O
ABCA4	B-GENE
exons	O
,	O
introns	O
,	O
or	O
in	O
other	O
retinal	B-DISEASE
disease	I-DISEASE
genes	O
.	O

WS	B-DISEASE
type	I-DISEASE
IV	I-DISEASE
has	O
an	O
additional	O
feature	O
of	O
Hirschsprung	B-DISEASE
disease	I-DISEASE
[	O
2	O
]	O
.	O

Scale	O
bar	O
applies	O
to	O
all	O
panels	O
and	O
is	O
10	O
u	O
m	O
.	O

Wang	O
for	O
bioinformatics	O
support	O
.	O

We	O
also	O
used	O
DNA	O
from	O
50	O
Chinese	O
familial	O
patients	O
with	O
ARNSHL	B-DISEASE
and	O
208	O
ethnicity	O
-	O
matched	O
negative	O
samples	O
to	O
perform	O
extended	O
variants	O
analysis	O
.	O

Furthermore	O
,	O
differences	O
in	O
triggers	O
such	O
as	O
the	O
well	O
-	O
documented	O
beta	O
-	O
adrenergic	O
stimulation	O
[	O
36	O
]	O
or	O
the	O
more	O
recently	O
described	O
modulation	O
by	O
natriuretic	O
peptide	O
precursor	O
A	O
may	O
be	O
involved	O
[	O
23	O
,	O
37	O
]	O
.	O

There	O
are	O
different	O
methods	O
for	O
STRC	B-GENE
CNV	O
detection	O
.	O

Six	O
of	O
the	O
seven	O
male	O
subjects	O
had	O
hearing	B-DISEASE
loss	I-DISEASE
with	O
a	O
mean	O
age	O
of	O
diagnosis	O
of	O
8	O
.	O
2	O
+	O
-	O
2	O
.	O
1	O
(	O
range	O
6	O
-	O
11	O
.	O
9	O
)	O
years	O
.	O

This	O
phenotype	O
is	O
fully	O
compatible	O
with	O
the	O
diagnosis	O
of	O
X	B-DISEASE
-	I-DISEASE
linked	I-DISEASE
non	I-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
sensorineural	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
DFN2	B-DISEASE
)	O
[	O
5	O
]	O
.	O

proposed	O
that	O
angulin	B-GENE
-	I-GENE
2	I-GENE
/	O
ILDR1	B-GENE
was	O
not	O
required	O
for	O
initial	O
recruitment	O
of	O
tricellulin	B-GENE
to	O
TCs	O
in	O
vivo	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
introducing	O
the	O
mutations	O
G25V	B-VARIANT
(	O
c	B-VARIANT
.	I-VARIANT
74	I-VARIANT
C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
)	O
and	O
G60D	B-VARIANT
(	O
c	B-VARIANT
.	I-VARIANT
179	I-VARIANT
G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
into	O
human	O
KCNE1	B-GENE
cDNA	O
[	O
Genbank	O
:	O
NM_000219	O
.	O
3	O
]	O
and	O
in	O
vitro	O
transcription	O
were	O
performed	O
using	O
standard	O
procedures	O
.	O

The	O
present	O
functional	O
studies	O
revealed	O
that	O
mutation	O
of	O
the	O
conserved	O
Arg205	O
to	O
Gln	O
does	O
not	O
abolish	O
the	O
actin	O
activity	O
of	O
myosin	B-GENE
VI	I-GENE
but	O
significantly	O
decreases	O
V	O
max	O
.	O

Relationship	O
errors	O
were	O
evaluated	O
with	O
the	O
help	O
of	O
the	O
program	O
Graphical	O
Representation	O
of	O
Relationships	O
[	O
22	O
]	O
.	O

In	O
OPA1	B-GENE
-	O
M	O
implanted	O
patients	O
no	O
acoustically	O
-	O
evoked	O
ABRs	O
had	O
been	O
obtained	O
before	O
cochlear	O
implantation	O
in	O
the	O
ear	O
using	O
the	O
cochlear	O
implant	O
,	O
except	O
for	O
Subject	O
3	O
,	O
who	O
showed	O
a	O
markedly	O
delayed	O
wave	O
V	O
in	O
response	O
to	O
acoustic	O
stimulation	O
.	O

,	O
2004	O
)	O
.	O

Such	O
efforts	O
resulted	O
in	O
restoration	O
of	O
protein	O
function	O
in	O
both	O
of	O
the	O
Usher	B-DISEASE
genes	O
targeted	O
,	O
and	O
it	O
would	O
be	O
of	O
future	O
interest	O
to	O
determine	O
whether	O
the	O
premature	O
truncation	O
of	O
SANS	O
caused	O
by	O
USH1G	B-GENE
nonsense	O
mutations	O
reported	O
to	O
date	O
are	O
restored	O
using	O
similar	O
strategies	O
.	O

B	O
:	O
The	O
macula	O
was	O
involved	O
.	O

The	O
high	O
number	O
of	O
novel	O
and	O
private	O
variants	O
and	O
the	O
poor	O
prevalence	O
of	O
variants	O
common	O
in	O
other	O
ethnic	O
groups	O
suggest	O
a	O
difference	O
in	O
the	O
spectrum	O
of	O
USH2A	B-GENE
sequence	O
variants	O
between	O
Italian	O
patients	O
with	O
USH	B-DISEASE
and	O
other	O
populations	O
.	O

B	O
.	O

The	O
variant	O
list	O
derived	O
from	O
analysing	O
patient	O
2093	O
(	O
a	O
male	O
)	O
described	O
a	O
homozygous	O
missense	O
variant	O
in	O
BBS2	B-GENE
(	O
c	B-VARIANT
.	I-VARIANT
1895G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R632P	I-VARIANT
)	O
as	O
the	O
most	O
likely	O
candidate	O
.	O

Neuronal	O
responses	O
were	O
captured	O
through	O
subdermal	O
needle	O
electrodes	O
inserted	O
at	O
the	O
vertex	O
,	O
filtered	O
,	O
amplified	O
and	O
displayed	O
.	O

No	O
.	O

Genotype	O
-	O
phenotype	O
correlations	O
for	O
diagnostic	O
age	O
,	O
fluctuation	B-DISEASE
,	O
vertigo	B-DISEASE
,	O
tinnitus	B-DISEASE
and	O
goiter	B-DISEASE
are	O
summarized	O
in	O
Figure	O
1	O
.	O

Figure	O
A	O
includes	O
35	O
patients	O
with	O
c	B-VARIANT
.	I-VARIANT
983A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
mutation	O
and	O
figure	O
B	O
includes	O
21	O
patients	O
with	O
c	B-VARIANT
.	I-VARIANT
2708_2711delTTAG	I-VARIANT
mutation	O
.	O

Moreover	O
,	O
the	O
p	B-VARIANT
.	I-VARIANT
Arg18His	I-VARIANT
variant	O
has	O
an	O
MAF	O
of	O
0	O
.	O
28	O
%	O
which	O
is	O
not	O
compatible	O
with	O
a	O
mutation	O
causing	O
a	O
rare	O
autosomal	O
dominant	O
disorder	O
.	O

The	O
ophthalmological	O
investigation	O
in	O
this	O
family	O
showed	O
variability	O
in	O
the	O
clinical	O
onset	O
and	O
diagnosis	O
of	O
RP	B-DISEASE
among	O
patients	O
.	O

For	O
119	O
patients	O
molecular	O
genetic	O
analyses	O
were	O
requested	O
owing	O
to	O
the	O
clinical	O
suspicion	O
of	O
WS	B-DISEASE
.	O

A	O
female	O
patient	O
developed	O
insulin	O
treated	O
DM	B-DISEASE
at	O
7	O
years	O
of	O
age	O
.	O

To	O
improve	O
this	O
diagnosis	O
yield	O
,	O
others	O
have	O
promoted	O
algorithms	O
for	O
phenotype	O
-	O
driven	O
bioinformatics	O
analysis	O
of	O
patients	O
[	O
98	O
]	O
.	O

In	O
other	O
words	O
,	O
individuals	O
from	O
the	O
undiagnosed	O
group	O
show	O
a	O
large	O
variety	O
of	O
different	O
variants	O
,	O
resulting	O
in	O
the	O
extensive	O
heterogeneity	O
in	O
the	O
multidimensional	O
scaling	O
plot	O
.	O

Of	O
167	O
selected	O
missense	O
mutations	O
163	O
were	O
<	O
1	O
%	O
allele	O
frequencies	O
in	O
both	O
the	O
1000	O
genome	O
project	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
1000genomes	O
.	O
org	O
/	O
node	O
/	O
home	O
)	O
and	O
the	O
NHLB	O
grand	O
opportunity	O
exome	O
sequencing	O
project	O
:	O
6500	O
exomes	O
(	O
http	O
:	O
/	O
/	O
esp	O
.	O
gs	O
.	O
washington	O
.	O
edu	O
/	O
drupal	O
/	O
)	O
.	O

For	O
the	O
second	O
screening	O
,	O
using	O
the	O
probes	O
for	O
these	O
26	O
mutations	O
,	O
a	O
large	O
cohort	O
of	O
probands	O
(	O
n	O
=	O
1396	O
)	O
was	O
screened	O
using	O
Taqman	O
amplification	O
-	O
based	O
mutation	O
analysis	O
followed	O
by	O
Sanger	O
sequencing	O
.	O

We	O
developed	O
a	O
routine	O
pipeline	O
to	O
detect	O
even	O
a	O
low	O
-	O
level	O
allele	O
of	O
NLRP3	B-GENE
with	O
statistical	O
significance	O
using	O
massively	O
parallel	O
DNA	O
sequencing	O
.	O

This	O
skipping	O
would	O
yield	O
a	O
truncated	O
protein	O
with	O
a	O
premature	O
termination	O
codon	O
due	O
to	O
a	O
frameshift	O
(	O
p	B-VARIANT
.	I-VARIANT
N591GfsX18	I-VARIANT
)	O
.	O

2012	O
)	O
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
GraphPad	O
Prism	O
5	O
.	O
0	O
(	O
GraphPad	O
Software	O
,	O
Inc	O
.	O

Except	O
for	O
auditory	O
-	O
pigmentary	O
disorder	O
,	O
dystopia	B-DISEASE
canthorum	I-DISEASE
is	O
the	O
typical	O
phenotype	O
of	O
WS1	B-DISEASE
(	O
Table	O
1	O
)	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Slanting	O
arrow	O
,	O
the	O
proband	O
.	O

Eighteen	O
(	O
39	O
%	O
)	O
boys	O
had	O
associated	O
malformations	O
or	O
syndromes	O
.	O

Details	O
regarding	O
the	O
number	O
of	O
affected	O
individuals	O
who	O
had	O
WES	O
per	O
family	O
are	O
outlined	O
in	O
Table	O
1	O
.	O

Of	O
these	O
,	O
52	O
%	O
are	O
in	O
the	O
MYO7A	B-GENE
gene	O
,	O
followed	O
by	O
CDH23	B-GENE
(	O
28	O
%	O
)	O
,	O
PCDH15	B-GENE
(	O
13	O
%	O
)	O
,	O
USH1C	B-GENE
(	O
6	O
%	O
)	O
,	O
and	O
USH1G	B-GENE
(	O
1	O
%	O
)	O
.	O

Although	O
simple	O
comparison	O
regarding	O
frequency	O
is	O
difficult	O
because	O
of	O
sampling	O
bias	O
,	O
it	O
is	O
estimated	O
that	O
the	O
frequency	O
of	O
OTOF	B-GENE
mutations	O
in	O
Japanese	O
may	O
be	O
almost	O
equal	O
to	O
other	O
populations	O
.	O

After	O
separation	O
of	O
these	O
protein	O
lysates	O
in	O
SDS	O
-	O
PAGE	O
and	O
transfer	O
of	O
the	O
proteins	O
onto	O
nitrocellulose	O
membrane	O
,	O
the	O
membrane	O
was	O
blotted	O
with	O
1	O
:	O
1000	O
rabbit	O
anti	O
-	O
MCM2	B-GENE
antibody	O
(	O
#	O
3619	O
,	O
Cell	O
Signaling	O
)	O
diluted	O
in	O
5	O
%	O
non	O
-	O
fat	O
milk	O
/	O
Tris	O
-	O
based	O
saline	O
/	O
0	O
.	O
05	O
%	O
Tween	O
20	O
solution	O
.	O

To	O
date	O
,	O
only	O
eleven	O
families	O
of	O
Pakistani	O
,	O
three	O
of	O
Roma	O
and	O
one	O
of	O
Iranian	O
origin	O
with	O
MARVELD2	B-GENE
-	O
associated	O
deafness	B-DISEASE
are	O
known	O
in	O
the	O
existing	O
literature	O
[	O
3	O
,	O
4	O
,	O
7	O
,	O
10	O
,	O
9	O
]	O
.	O

Missense	O
germline	O
variants	O
were	O
further	O
filtered	O
to	O
retain	O
only	O
those	O
identified	O
as	O
deleterious	O
by	O
the	O
Ensembl	O
implementation	O
of	O
Condel	O
,	O
a	O
software	O
program	O
that	O
employs	O
a	O
weighted	O
approach	O
to	O
calculate	O
the	O
functional	O
impact	O
of	O
missense	O
variants	O
from	O
scores	O
calculated	O
by	O
SIFT	O
65	O
and	O
PolyPhen	O
-	O
2	O
.	O

Moreover	O
,	O
we	O
found	O
evidence	O
for	O
historical	O
meiotic	O
recombinations	O
of	O
both	O
intragenic	O
SNPs	O
and	O
a	O
closely	O
flanking	O
microsatellite	O
marker	O
(	O
haplotypes	O
1	O
to	O
4	O
and	O
6	O
to	O
8	O
,	O
respectively	O
)	O
.	O

Analysis	O
of	O
the	O
relatives	O
indicated	O
that	O
this	O
duplication	O
was	O
also	O
present	O
in	O
the	O
affected	O
father	O
and	O
brother	O
.	O

Molecular	O
diagnostics	O
is	O
particularly	O
challenging	O
for	O
isolated	O
RP	B-DISEASE
patients	O
,	O
who	O
constitute	O
majority	O
of	O
RP	B-DISEASE
cases	O
[	O
van	O
den	O
Born	O
et	O
al	O
.	O
,	O
1992	O
;	O
Najera	O
et	O
al	O
.	O
,	O
1995	O
;	O
Hayakawa	O
et	O
al	O
.	O
,	O
1997	O
]	O
.	O

cone	O
-	O
rod	B-DISEASE
dystrophies	I-DISEASE
)	O
is	O
needed	O
to	O
maximize	O
the	O
mutation	O
detection	O
rate	O
.	O

Scott	O
Ataxia	B-DISEASE
demonstrates	O
substantial	O
phenotypic	O
and	O
genetic	O
heterogeneity	O
.	O

We	O
found	O
no	O
significant	O
Osbpl2	B-GENE
upregulation	O
at	O
the	O
mRNA	O
level	O
in	O
homozygous	O
Mir96	O
mutant	O
mice	O
.	O

The	O
patterns	O
of	O
the	O
audiograms	O
were	O
similar	O
.	O

Our	O
study	O
demonstrates	O
an	O
integrated	O
approach	O
that	O
utilizes	O
biological	O
and	O
clinicopathologic	O
information	O
in	O
screening	O
defined	O
set	O
of	O
genes	O
for	O
gleaning	O
insights	O
into	O
disease	O
etiology	O
using	O
NGS	O
.	O

The	O
similar	O
~	O
40	O
kDa	O
band	O
was	O
detected	O
with	O
reduced	O
intensity	O
in	O
mutant	O
BLSW	O
cochlea	O
and	O
testis	O
.	O

The	O
authors	O
would	O
like	O
to	O
thank	O
all	O
patients	O
and	O
their	O
families	O
for	O
their	O
friendly	O
cooperation	O
.	O
Mutations	O
of	O
fibroblast	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
2	I-GENE
(	O
FGFR2	B-GENE
)	O
account	O
for	O
a	O
higher	O
proportion	O
of	O
genetic	O
cases	O
of	O
craniosynostosis	B-DISEASE
than	O
any	O
other	O
gene	O
,	O
and	O
are	O
associated	O
with	O
a	O
wide	O
spectrum	O
of	O
severity	O
of	O
clinical	O
problems	O
.	O

Exome	O
sequencing	O
also	O
detected	O
two	O
heterozygous	O
missense	O
variants	O
that	O
were	O
specific	O
to	O
group	O
1	O
(	O
Table	O
S1	O
)	O
.	O

CIB2	B-GENE
belongs	O
to	O
a	O
family	O
of	O
calcium	O
and	O
integrin	O
-	O
binding	O
proteins	O
containing	O
four	O
EF	O
-	O
hand	O
domains	O
that	O
change	O
conformation	O
upon	O
binding	O
Ca	O
2	O
+	O
,	O
and	O
presumably	O
mediate	O
intracellular	O
Ca	O
2	O
+	O
signaling	O
.	O

A	O
summary	O
of	O
this	O
article	O
was	O
previously	O
presented	O
at	O
the	O
Annual	O
Meeting	O
of	O
the	O
American	O
Society	O
of	O
Human	O
Genetics	O
,	O
2013	O
,	O
in	O
Boston	O
,	O
MA	O
,	O
USA	O
.	O

Our	O
results	O
indicated	O
that	O
splicing	O
was	O
of	O
key	O
importance	O
to	O
the	O
function	O
of	O
DSPP	B-GENE
and	O
that	O
this	O
splice	O
donor	O
site	O
might	O
be	O
a	O
sensitive	O
mutation	O
hot	O
spot	O
of	O
DGI	B-DISEASE
-	I-DISEASE
II	I-DISEASE
(	O
another	O
"	O
hot	O
spot	O
"	O
was	O
reported	O
as	O
g	B-VARIANT
.	I-VARIANT
6191G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
c	B-VARIANT
.	I-VARIANT
52G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
)	O
[	O
11	O
]	O
,	O
[	O
12	O
]	O
,	O
[	O
14	O
]	O
)	O
.	O

If	O
no	O
candidate	O
variants	O
were	O
found	O
,	O
the	O
23	O
genes	O
responsible	O
for	O
syndromic	O
hearing	B-DISEASE
loss	I-DISEASE
were	O
subjected	O
to	O
the	O
same	O
procedures	O
.	O

There	O
was	O
mild	O
dysarthria	O
,	O
moderate	O
upper	O
and	O
lower	O
extremity	O
dysmetria	O
,	O
and	O
moderate	O
gait	O
ataxia	B-DISEASE
(	O
Brief	O
Ataxia	B-DISEASE
Rating	O
Scale	O
:	O
13	O
/	O
30	O
)	O
.	O

Lysates	O
were	O
incubated	O
16h	O
with	O
protein	O
A	O
-	O
Sepharose	O
CL	O
-	O
4B	O
beads	O
and	O
centrifuged	O
at	O
10	O
,	O
000	O
g	O
for	O
3	O
min	O
.	O

(	O
C	O
)	O
Pedigree	O
of	O
the	O
Family	O
3	O
demonstrating	O
that	O
PS	B-DISEASE
was	O
transmitted	O
by	O
autosomal	O
dominant	O
trait	O
and	O
(	O
D	O
)	O
DNA	O
-	O
sequence	O
showing	O
portion	O
of	O
FGFR2	B-GENE
exon	O
8	O
of	O
an	O
affected	O
member	O
.	O

The	O
pedigree	O
contains	O
five	O
affected	O
males	O
and	O
is	O
consistent	O
with	O
X	O
-	O
linked	O
recessive	O
inheritance	O
(	O
4D	O
)	O
.	O

In	O
the	O
same	O
manner	O
,	O
the	O
MNCVs	O
of	O
the	O
peroneal	O
and	O
tibial	O
nerves	O
were	O
determined	O
by	O
stimulation	O
at	O
the	O
knee	O
and	O
ankle	O
while	O
recording	O
CMAPs	O
over	O
the	O
extensor	O
digitorum	O
brevis	O
and	O
adductor	O
hallucis	O
,	O
respectively	O
.	O

Three	O
of	O
the	O
five	O
mutations	O
,	O
c	B-VARIANT
.	I-VARIANT
567_586	I-VARIANT
+	I-VARIANT
17del	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Asp189_Gln505delinsGluGlyGlyAlaLeuAlaGly	I-VARIANT
)	O
,	O
c	B-VARIANT
.	I-VARIANT
456_459dupTTCC	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Ile154PhefsX162	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
667C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Arg223X	I-VARIANT
)	O
,	O
are	O
predicted	O
to	O
encode	O
premature	O
truncated	O
proteins	O
affecting	O
the	O
paired	O
-	O
type	O
homeodomain	O
[	O
20	O
]	O
.	O

Funding	O
:	O
This	O
work	O
was	O
supported	O
by	O
the	O
Alkek	O
Foundation	O
for	O
Research	O
,	O
Sid	O
Richardson	O
Foundation	O
,	O
Brown	O
Foundation	O
Research	O
and	O
Bintliff	O
Foundation	O
for	O
Research	O
.	O

Candidate	O
variants	O
were	O
prioritised	O
as	O
described	O
previously	O
and	O
Sanger	O
sequenced	O
to	O
confirm	O
the	O
presence	O
of	O
the	O
mutation	O
.	O

The	O
biotinylated	O
cRNA	O
-	O
DNA	O
hybrids	O
were	O
purified	O
with	O
streptavidin	O
-	O
conjugated	O
magnetic	O
beads	O
,	O
washed	O
,	O
and	O
the	O
cRNA	O
probes	O
were	O
digested	O
,	O
following	O
cleaning	O
of	O
the	O
captured	O
DNA	O
fragments	O
with	O
AmpPure	O
XP	O
beads	O
.	O

This	O
variability	O
reflects	O
selection	O
bias	O
(	O
i	O
.	O
e	O
.	O
,	O
including	O
only	O
a	O
select	O
ethnicity	O
or	O
only	O
patients	O
with	O
a	O
positive	O
family	O
history	O
for	O
hearing	B-DISEASE
loss	I-DISEASE
)	O
,	O
platform	O
bias	O
(	O
i	O
.	O
e	O
.	O
,	O
including	O
only	O
a	O
limited	O
number	O
of	O
genes	O
)	O
,	O
and	O
analytic	O
bias	O
(	O
i	O
.	O
e	O
.	O
,	O
neglecting	O
to	O
consider	O
copy	O
number	O
variations	O
in	O
the	O
analysis	O
)	O
(	O
Hoppman	O
et	O
al	O
.	O

The	O
low	O
quality	O
variations	O
were	O
filtered	O
out	O
by	O
the	O
following	O
criteria	O
:	O
(	O
i	O
)	O
quality	O
score	O
<	O
20	O
(	O
Q20	O
)	O
;	O
(	O
ii	O
)	O
average	O
copy	O
number	O
at	O
the	O
allele	O
site	O
>	O
=	O
2	O
;	O
(	O
iii	O
)	O
distance	O
of	O
two	O
adjacent	O
SNPs	O
<	O
5	O
bp	O
;	O
and	O
(	O
iv	O
)	O
sequencing	O
depth	O
<	O
4	O
or	O
>	O
500	O
.	O

Numerous	O
non	O
-	O
synonymous	O
polymorphisms	O
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
an	O
effect	O
in	O
cardiac	O
repolarisation	O
currents	O
.	O

1	O
)	O
.	O

The	O
interpretation	O
of	O
normal	O
plasma	O
AMH	O
levels	O
is	O
difficult	O
,	O
as	O
the	O
deficiency	O
in	O
gonadotropins	O
decrease	O
its	O
concentration	O
whereas	O
the	O
absence	O
of	O
testosterone	O
increases	O
its	O
concentration	O
.	O

et	O
al	O
.	O

In	O
the	O
case	O
of	O
missense	O
prediction	O
programs	O
(	O
SIFT	O
[	O
Ng	O
&	O
Henikoff	O
,	O
2003	O
]	O
,	O
PolyPhen	O
[	O
Adzhubei	O
et	O
al	O
.	O
,	O
2010	O
]	O
,	O
MutPred	O
[	O
Li	O
et	O
al	O
.	O
,	O
2009	O
]	O
)	O
,	O
the	O
different	O
scores	O
for	O
the	O
three	O
different	O
tools	O
were	O
combined	O
by	O
a	O
majority	O
vote	O
resulting	O
in	O
a	O
single	O
classification	O
as	O
"	O
pathogenic	O
,	O
"	O
"	O
unknown	O
,	O
"	O
or	O
"	O
benign	O
.	O

The	O
PCRs	O
were	O
first	O
tested	O
on	O
Human	O
Genomic	O
DNA	O
(	O
Roche	O
diagnostics	O
)	O
.	O

The	O
proteins	O
encoded	O
by	O
these	O
genes	O
are	O
involved	O
in	O
a	O
broad	O
array	O
of	O
molecular	O
and	O
cellular	O
mechanisms	O
essential	O
for	O
the	O
development	O
and	O
maintenance	O
of	O
normal	O
auditory	O
function	O
[	O
3	O
]	O
.	O

5E	O
and	O
5H	O
)	O
.	O

No	O
extraocular	O
neurologic	O
sign	O
presented	O
in	O
the	O
proband	O
and	O
his	O
parents	O
(	O
Table	O
4	O
)	O
.	O

Bonnet	O
et	O
al	O
.	O

In	O
house	O
Perl	O
scripts	O
were	O
used	O
to	O
select	O
the	O
variants	O
shared	O
by	O
all	O
affected	O
individuals	O
,	O
predicted	O
to	O
produce	O
a	O
high	O
or	O
moderate	O
impact	O
,	O
including	O
intron	O
-	O
exon	O
junctions	O
,	O
non	O
-	O
annotated	O
variants	O
(	O
synonymous	O
,	O
non	O
-	O
synonymous	O
,	O
and	O
non	O
-	O
sense	O
mutations	O
)	O
in	O
coding	O
regions	O
,	O
or	O
short	O
coding	O
insertions	O
or	O
deletions	O
.	O

These	O
variants	O
were	O
then	O
filtered	O
out	O
with	O
the	O
inheritance	O
pattern	O
of	O
the	O
family	O
,	O
allele	O
frequency	O
in	O
normal	O
hearing	O
80	O
control	O
subjects	O
,	O
clinical	O
features	O
.	O

Bait	O
density	O
and	O
replication	O
were	O
adjusted	O
using	O
coverage	O
data	O
from	O
exome	O
sequencing	O
samples	O
,	O
captured	O
with	O
the	O
Agilent	O
SureSelect	O
Human	O
All	O
Exon	O
v1	O
(	O
38	O
Mb	O
)	O
system	O
(	O
see	O
ESM	O
Fig	O
.	O

Known	O
heterozygous	O
carriers	O
of	O
AS	B-DISEASE
therefore	O
require	O
long	O
-	O
term	O
medical	O
follow	O
-	O
up	O
[	O
4	O
]	O
.	O

A	O
monobloc	O
procedure	O
without	O
distraction	O
(	O
Le	O
Fort	O
III	O
and	O
an	O
advancement	O
of	O
the	O
forehead	O
)	O
was	O
performed	O
.	O

It	O
is	O
clinically	O
and	O
genetically	O
heterogeneous	O
and	O
is	O
the	O
most	O
common	O
cause	O
underlying	O
deafness	B-DISEASE
and	O
blindness	B-DISEASE
of	O
genetic	O
origin	O
.	O

Patient	O
and	O
affected	O
sib	O
are	O
homozygous	O
for	O
the	O
mutation	O
.	O

We	O
expressed	O
and	O
purified	O
GST	O
alone	O
and	O
used	O
it	O
as	O
a	O
negative	O
control	O
in	O
all	O
of	O
our	O
assays	O
.	O

All	O
data	O
are	O
presented	O
as	O
the	O
mean	O
+	O
-	O
SEM	O
and	O
are	O
derived	O
from	O
at	O
least	O
triplicates	O
(	O
*	O
P	O
<	O
0	O
.	O
05	O
as	O
compared	O
with	O
controls	O
considered	O
significant	O
)	O
.	O

The	O
most	O
common	O
USH1C	B-GENE
transcript	O
,	O
USH1C_v2	O
,	O
lacks	O
exons	O
16	O
-	O
21	O
and	O
exon	O
27	O
,	O
while	O
two	O
relatively	O
rare	O
variants	O
(	O
USH1C_v1	O
and	O
USH1C_v3	O
)	O
lack	O
exon	O
15	O
.	O

While	O
several	O
reviews	O
and	O
editorials	O
suggest	O
that	O
WES	O
is	O
poised	O
to	O
facilitate	O
a	O
dramatic	O
advancement	O
in	O
our	O
ability	O
to	O
arrive	O
at	O
a	O
genetic	O
diagnosis	O
for	O
a	O
particular	O
patient	O
with	O
a	O
rare	O
genetic	O
disease	O
[	O
Bick	O
and	O
Dimmock	O
,	O
2011	O
;	O
Kingsmore	O
and	O
Saunders	O
,	O
2011	O
;	O
Majewski	O
et	O
al	O
.	O
,	O
2011	O
;	O
Singleton	O
,	O
2011	O
]	O
,	O
studies	O
demonstrating	O
improvement	O
over	O
traditional	O
testing	O
based	O
on	O
diagnostic	O
success	O
rate	O
,	O
cost	O
effectiveness	O
,	O
or	O
time	O
to	O
diagnosis	O
are	O
still	O
lacking	O
.	O

About	O
14	O
%	O
(	O
39	O
/	O
284	O
)	O
of	O
our	O
cases	O
were	O
due	O
to	O
mutations	O
in	O
SLC26A4	B-GENE
.	O

2013	O
)	O
.	O

The	O
mutations	O
were	O
not	O
present	O
in	O
the	O
controls	O
(	O
100	O
normal	O
Chinese	O
subjects	O
=	O
200	O
chromosomes	O
)	O
according	O
to	O
the	O
RFLP	O
analysis	O
.	O

In	O
this	O
family	O
,	O
a	O
novel	O
splice	O
site	O
mutation	O
c	B-VARIANT
.	I-VARIANT
IVS25	I-VARIANT
+	I-VARIANT
3G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
was	O
found	O
in	O
intron	O
25	O
of	O
MYO15A	B-GENE
and	O
is	O
predicted	O
to	O
change	O
the	O
highly	O
conserved	O
donor	O
splice	O
site	O
of	O
intron	O
25	O
from	O
GG	O
to	O
AG	O
.	O

The	O
reaction	O
was	O
performed	O
in	O
a	O
10	O
u	O
l	O
volume	O
containing	O
9	O
.	O
4	O
u	O
l	O
PCR	O
product	O
,	O
0	O
.	O
1	O
mu	O
l	O
BSA	O
(	O
100	O
mu	O
g	O
/	O
ml	O
)	O
,	O
and	O
0	O
.	O
5	O
mu	O
l	O
enzyme	O
(	O
4	O
U	O
/	O
mu	O
l	O
)	O
.	O

No	O
other	O
mutation	O
was	O
identified	O
in	O
the	O
rest	O
of	O
known	O
hearing	B-DISEASE
loss	I-DISEASE
associated	O
genes	O
,	O
including	O
ACTG1	B-GENE
,	O
CCDC50	B-GENE
,	O
COCH	B-GENE
,	O
COL11A2	B-GENE
,	O
DFNA5	B-GENE
,	O
DIAPH1	B-GENE
,	O
and	O
EYA4	B-GENE
et	O
al	O
.	O

Nevertheless	O
,	O
we	O
suggest	O
performing	O
arhinencephaly	O
,	O
endocrinology	O
and	O
olfactory	O
evaluations	O
in	O
patients	O
with	O
ectrodactyly	B-DISEASE
,	O
with	O
or	O
without	O
additional	O
malformations	O
.	O

(	O
a	O
)	O
Family	O
pedigree	O
of	O
JSNY	O
-	O
045	O
and	O
audiograms	O
of	O
two	O
deaf	B-DISEASE
siblings	O
and	O
their	O
parents	O
.	O

Likewise	O
,	O
the	O
p	B-VARIANT
.	I-VARIANT
Asn342Ser	I-VARIANT
mutation	O
is	O
also	O
located	O
in	O
a	O
highly	O
conserved	O
EC	O
calcium	O
-	O
binding	O
site	O
(	O
DXNDN	O
)	O
.	O

Transient	O
transfection	O
of	O
podocytes	O
with	O
equal	O
amounts	O
of	O
normal	O
single	O
COL4A3	B-GENE
-	O
WT	O
and	O
mutant	O
COL4A3	B-GENE
constructs	O
resulted	O
in	O
equal	O
expression	O
of	O
genes	O
as	O
tested	O
by	O
qPCR	O
(	O
not	O
shown	O
)	O
.	O

The	O
arrow	O
marks	O
the	O
position	O
of	O
the	O
p	B-VARIANT
.	I-VARIANT
S288X	I-VARIANT
mutation	O
.	O

Although	O
knockdown	O
of	O
homer2	B-GENE
altered	O
neither	O
ear	O
size	O
nor	O
morphology	O
(	O
p	O
>	O
0	O
.	O
5	O
)	O
(	O
S3	O
Fig	O
)	O
,	O
injection	O
of	O
in	O
vitro	O
synthesized	O
mRNA	O
encoding	O
HOMER2	B-GENE
P185	O
-	O
mutant	O
RNA	O
(	O
P185RNA	O
)	O
resulted	O
in	O
significantly	O
smaller	O
ear	O
size	O
in	O
larvae	O
as	O
compared	O
to	O
injections	O
with	O
WT	O
HOMER2	B-GENE
(	O
wtRNA	O
)	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
(	O
Fig	O
3A	O
i	O
-	O
iii	O
and	O
3B	O
;	O
S4	O
Fig	O
)	O
.	O

The	O
proband	O
is	O
heterozygous	O
for	O
two	O
novel	O
variants	O
in	O
MYO15A	B-GENE
(	O
Tables	O
2	O
and	O
3	O
)	O
.	O

So	O
it	O
is	O
also	O
considered	O
benign	O
.	O

14	O
Specifically	O
,	O
we	O
removed	O
heterozygous	O
variants	O
in	O
the	O
child	O
when	O
>	O
70	O
%	O
of	O
reads	O
were	O
reference	O
,	O
discarded	O
cases	O
where	O
>	O
10	O
%	O
non	O
-	O
reference	O
reads	O
in	O
a	O
parent	O
matched	O
the	O
child	O
'	O
s	O
call	O
,	O
removed	O
calls	O
where	O
the	O
offspring	O
depth	O
was	O
<	O
10	O
%	O
of	O
the	O
parents	O
total	O
depth	O
,	O
and	O
retained	O
only	O
variants	O
with	O
genotype	O
quality	O
>	O
=	O
20	O
for	O
the	O
three	O
samples	O
.	O

Additionally	O
we	O
demonstrate	O
decreased	O
steady	O
-	O
state	O
levels	O
of	O
mt	B-GENE
-	I-GENE
tRNA	I-GENE
Asn	I-GENE
in	O
fibroblasts	O
from	O
the	O
Leigh	B-DISEASE
syndrome	I-DISEASE
patients	O
.	O

The	O
first	O
ophthalmological	O
symptoms	O
were	O
detected	O
at	O
the	O
age	O
of	O
8	O
years	O
old	O
as	O
night	O
blindness	B-DISEASE
and	O
tunnel	O
vision	O
.	O

Single	O
strand	O
conformation	O
polymorphism	O
analysis	O
for	O
the	O
two	O
mutations	O
identified	O
in	O
the	O
current	O
study	O
.	O

Forty	O
USH	B-DISEASE
patients	O
were	O
successfully	O
sequenced	O
,	O
8	O
USH	B-DISEASE
patients	O
from	O
the	O
test	O
group	O
and	O
32	O
patients	O
from	O
the	O
group	O
composed	O
of	O
USH	B-DISEASE
patients	O
without	O
genetic	O
diagnosis	O
.	O

Similarly	O
,	O
the	O
variants	O
c	B-VARIANT
.	I-VARIANT
4338_4339del	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Cys1447Glnfs	I-VARIANT
*	I-VARIANT
29	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
8559	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
p	O
.	O
?	O
)	O
,	O
which	O
,	O
respectively	O
,	O
have	O
a	O
high	O
prevalence	O
in	O
French	O
Canadian	O
[	O
40	O
]	O
and	O
Japanese	O
[	O
35	O
]	O
patients	O
with	O
USH	B-DISEASE
was	O
not	O
detected	O
in	O
our	O
series	O
.	O

Genetic	O
testing	O
for	O
OPA1	B-GENE
mutations	O
assist	O
in	O
the	O
diagnosis	O
.	O

(	O
A	O
)	O
MGG	O
blood	O
smears	O
(	O
n	O
=	O
99	O
,	O
positive	O
92	O
)	O
;	O
A1	O
:	O
typical	O
large	O
oval	O
shape	O
inclusions	O
;	O
A2	O
:	O
different	O
aspects	O
of	O
the	O
inclusions	O
;	O
A3	O
:	O
negative	O
control	O
.	O

Hirokazu	O
Sakamoto	O
at	O
Kobe	O
Children	O
'	O
s	O
Hospital	O
,	O
Hyogo	O
,	O
Japan	O
,	O
who	O
collected	O
DNA	O
samples	O
and	O
clinical	O
data	O
from	O
the	O
subjects	O
.	O

Our	O
study	O
provides	O
evidence	O
that	O
wolframin	O
-	O
deficient	O
subjects	O
with	O
infancy	O
-	O
onset	O
and	O
poorly	O
controlled	O
diabetes	B-DISEASE
experience	O
a	O
faster	O
progression	O
of	O
neurodegenerative	O
disease	O
than	O
those	O
with	O
good	O
diabetes	B-DISEASE
control	O
.	O

Bekheirnia	O
et	O
al	O
.	O

Using	O
this	O
approach	O
likely	O
pathogenic	O
mutation	O
(	O
s	O
)	O
were	O
identified	O
in	O
12	O
out	O
of	O
20	O
cases	O
(	O
60	O
%	O
)	O
.	O

Apparently	O
,	O
the	O
PJVK	B-GENE
gene	O
is	O
important	O
in	O
ANSD	B-DISEASE
patients	O
,	O
although	O
its	O
mutations	O
are	O
also	O
related	O
to	O
SNHL	B-DISEASE
[	O
29	O
]	O
,	O
[	O
35	O
]	O
.	O

taurus	O
,	O
NP_001091933	O
.	O
1	O
;	O
M	O
.	O

These	O
10	O
SNPs	O
,	O
which	O
apparently	O
do	O
not	O
affect	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
were	O
also	O
present	O
in	O
our	O
in	O
-	O
house	O
database	O
.	O

Performed	O
the	O
experiments	O
:	O
KM	O
KT	O
HI	O
YK	O
NO	O
MA	O
Y	O
.	O

The	O
c	B-VARIANT
.	I-VARIANT
2708_2711delTTAG	I-VARIANT
mutation	O
was	O
present	O
on	O
at	O
least	O
two	O
haplotypes	O
and	O
has	O
been	O
repeatedly	O
reported	O
in	O
various	O
ethnic	O
groups	O
,	O
thus	O
represents	O
a	O
mutational	O
hotspot	O
.	O

p	B-VARIANT
.	I-VARIANT
S1114P	I-VARIANT
associated	O
with	O
p	B-VARIANT
.	I-VARIANT
D1424N	I-VARIANT
in	O
the	O
propositus	O
and	O
his	O
three	O
sons	O
.	O

On	O
the	O
other	O
hand	O
,	O
copy	O
number	O
variations	O
could	O
be	O
another	O
possibility	O
in	O
patients	O
with	O
or	O
without	O
heterozygous	O
variants	O
because	O
the	O
deletion	O
of	O
exons	O
or	O
the	O
entire	O
gene	O
in	O
one	O
or	O
both	O
allele	O
may	O
be	O
missed	O
by	O
amplification	O
and	O
direct	O
sequencing	O
.	O

Mutations	O
in	O
the	O
optic	B-GENE
atrophy	I-GENE
1	I-GENE
gene	I-GENE
,	O
OPA1	B-GENE
(	O
MIM	O
no	O
.	O

It	O
attaches	O
along	O
its	O
medial	O
side	O
to	O
the	O
surface	O
of	O
the	O
spiral	O
limbus	O
,	O
stretches	O
across	O
the	O
spiral	O
sulcus	O
,	O
and	O
lies	O
over	O
the	O
surface	O
of	O
the	O
organ	O
of	O
Corti	O
where	O
it	O
affixes	O
to	O
the	O
tips	O
of	O
the	O
sensory	O
hair	O
bundles	O
of	O
the	O
outer	O
hair	O
cells	O
[	O
1	O
]	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
MHS	O
U	O
-	O
KK	O
JYC	O
.	O

At	O
72	O
hours	O
post	O
fertilization	O
(	O
hpf	O
)	O
,	O
live	O
larvae	O
were	O
submerged	O
in	O
3	O
mu	O
M	O
FM1	O
-	O
43	O
FX	O
(	O
Invitrogen	O
,	O
Grand	O
Island	O
,	O
NY	O
,	O
USA	O
)	O
for	O
30	O
sec	O
.	O

In	O
line	O
with	O
previous	O
reports	O
,	O
WSD	B-DISEASE
was	O
autoantibody	O
-	O
negative	O
and	O
not	O
commonly	O
complicated	O
by	O
ketoacidosis	B-DISEASE
in	O
our	O
cohort	O
(	O
6	O
,	O
15	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
excluded	O
the	O
role	O
of	O
other	O
common	O
variants	O
in	O
the	O
mtDNA	B-GENE
12SrRNA	I-GENE
gene	O
and	O
GJB2	B-GENE
gene	O
in	O
the	O
1555A	B-VARIANT
>	I-VARIANT
G	I-VARIANT
positive	O
individuals	O
using	O
the	O
Deafness	B-DISEASE
Gene	O
Mutation	O
Detection	O
Array	O
and	O
Sanger	O
sequencing	O
.	O

JZ	O
,	O
FY	O
and	O
MH	O
participated	O
in	O
sequence	O
alignment	O
and	O
performed	O
the	O
statistical	O
analyses	O
.	O

In	O
addition	O
,	O
the	O
frequency	O
of	O
identified	O
mutations	O
or	O
variants	O
in	O
this	O
study	O
was	O
investigated	O
using	O
in	O
-	O
house	O
exome	O
sequencing	O
data	O
from	O
575	O
unaffected	O
Japanese	O
controls	O
at	O
Yokohama	O
City	O
University	O
.	O

Phospho	O
-	O
specific	O
antibodies	O
(	O
phospho	O
-	O
p44	O
/	O
42	O
MAPK	O
)	O
were	O
used	O
to	O
determine	O
phosphorylation	O
of	O
MAPK	O
.	O

This	O
generated	O
a	O
fusion	O
protein	O
with	O
a	O
His6	O
tag	O
at	O
the	O
N	O
-	O
terminus	O
.	O

Clinical	O
studies	O
ruled	O
out	O
Charcot	B-DISEASE
-	I-DISEASE
Marie	I-DISEASE
-	I-DISEASE
Tooth	I-DISEASE
disease	I-DISEASE
and	O
pontocerebellar	B-DISEASE
hypoplasia	I-DISEASE
.	O

One	O
patient	O
(	O
A	O
,	O
patient	O
GF	O
)	O
shows	O
a	O
typical	O
form	O
of	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
while	O
the	O
other	O
one	O
(	O
B	O
,	O
patient	O
GS	O
)	O
presents	O
with	O
an	O
atypical	O
fundus	O
appearance	O
with	O
mild	O
retinal	B-DISEASE
dystrophy	I-DISEASE
and	O
rare	O
pigment	O
deposits	O
.	O

-	I-VARIANT
22	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
mutation	O
seems	O
to	O
belong	O
to	O
this	O
group	O
of	O
hypomorphic	O
alleles	O
given	O
the	O
hearing	O
phenotype	O
observed	O
in	O
the	O
three	O
affected	O
siblings	O
of	O
family	O
S1599	O
(	O
mild	O
HI	B-DISEASE
of	O
late	O
postlingual	O
onset	O
)	O
.	O

S1	O
)	O
.	O

They	O
were	O
labeled	O
as	O
deleterious	O
by	O
the	O
predictive	O
software	O
Alamut	O
2	O
.	O
2	O
.	O

A	O
maximum	O
20	O
-	O
bp	O
overlap	O
into	O
repeats	O
was	O
allowed	O
in	O
order	O
to	O
capture	O
small	O
exons	O
that	O
are	O
closely	O
flanked	O
on	O
one	O
or	O
both	O
sides	O
by	O
short	O
interspersed	O
elements	O
(	O
SINEs	O
)	O
.	O

We	O
discovered	O
a	O
novel	O
heterozygous	O
missense	O
mutation	O
in	O
exon	O
8	O
of	O
WFS1	B-GENE
(	O
i	O
.	O
e	O
.	O
,	O
Y669H	B-VARIANT
)	O
which	O
is	O
likely	O
responsible	O
for	O
the	O
LFSNHL	B-DISEASE
phenotype	O
in	O
this	O
particular	O
Taiwanese	O
family	O
.	O

In	O
particular	O
,	O
Synofzik	O
and	O
colleagues	O
recently	O
described	O
a	O
male	O
with	O
an	O
intermediate	O
phenotype	O
between	O
CMTX5	B-DISEASE
and	O
Arts	B-DISEASE
syndrome	I-DISEASE
and	O
a	O
carrier	O
female	O
affected	O
with	O
DFN2	O
due	O
to	O
X	O
-	O
chromosome	O
inactivation	O
skewing	O
[	O
7	O
]	O
.	O

One	O
hundred	O
twelve	O
genes	O
listed	O
in	O
Table	O
S1	O
,	O
including	O
54	O
genes	O
reported	O
to	O
be	O
causative	O
of	O
non	O
-	O
syndromic	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
Hereditary	O
Hearing	B-DISEASE
loss	I-DISEASE
Homepage	O
;	O
http	O
:	O
/	O
/	O
hereditaryhearingloss	O
.	O
org	O
/	O
)	O
and	O
22	O
reported	O
to	O
cause	O
syndromic	O
hearing	B-DISEASE
loss	I-DISEASE
were	O
selected	O
for	O
sequencing	O
.	O

The	O
genome	O
-	O
wide	O
linkage	O
analysis	O
of	O
F013	O
located	O
the	O
deafness	O
gene	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
9	O
.	O

The	O
coding	O
exon	O
(	O
Exon	O
2	O
)	O
and	O
flanking	O
intronic	O
regions	O
of	O
GJB2	B-GENE
gene	O
were	O
PCR	O
amplified	O
with	O
forward	O
primer	O
5	O
'	O
TTGGTGTTTGCTCAGGAAGA	O
3	O
'	O
and	O
reverse	O
primer	O
5	O
'	O
GGCCTACAGGGGTTTCAAAT	O
3	O
'	O
[	O
8	O
]	O
.	O

Additional	O
chromatin	O
modifiers	O
with	O
somatic	O
mutations	O
and	O
/	O
or	O
germline	O
truncation	O
variants	O
are	O
included	O
.	O

5	O
,	O
31	O
,	O
33	O
,	O
34	O
Thus	O
,	O
both	O
claudins	O
are	O
required	O
to	O
form	O
a	O
permeability	O
barrier	O
against	O
cations	O
.	O

Mutations	O
in	O
the	O
less	O
commonly	O
screened	O
deafness	B-DISEASE
genes	O
were	O
heterogeneous	O
and	O
contributed	O
to	O
a	O
significant	O
percentage	O
(	O
17	O
.	O
4	O
%	O
)	O
of	O
causes	O
for	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
deafness	I-DISEASE
.	O

Coding	O
regions	O
and	O
intron	O
/	O
exon	O
boundaries	O
of	O
the	O
TCOF1	B-GENE
gene	O
were	O
amplified	O
in	O
28	O
reactions	O
using	O
specific	O
primers	O
[	O
13	O
]	O
.	O

Fisher	O
exact	O
test	O
used	O
to	O
determine	O
statistical	O
significance	O
with	O
*	O
p	O
<	O
0	O
.	O
05	O
and	O
*	O
*	O
p	O
<	O
0	O
.	O
005	O
Table	O
1	O
Reported	O
ethnic	O
and	O
phenotypic	O
characteristics	O
of	O
patients	O
evaluated	O
in	O
this	O
study	O
NP	O
not	O
provided	O
,	O
SNHL	B-DISEASE
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
Diagnostic	O
rates	O
are	O
dependent	O
on	O
patient	O
-	O
specific	O
clinical	O
and	O
phenotypic	O
characteristics	O
and	O
are	O
shown	O
as	O
the	O
percentage	O
of	O
patients	O
with	O
the	O
noted	O
characteristic	O
.	O

15	O
-	O
18	O
However	O
,	O
the	O
structure	O
of	O
the	O
bicellular	O
junctions	O
between	O
hair	O
cells	O
and	O
supporting	O
cells	O
,	O
especially	O
between	O
an	O
outer	O
hair	O
cell	O
and	O
adjacent	O
Deiter	O
'	O
s	O
cell	O
are	O
more	O
elaborate	O
and	O
highly	O
specialized	O
to	O
maintain	O
the	O
ionic	O
barrier	O
between	O
endolymph	O
and	O
perilymph	O
.	O

These	O
can	O
also	O
be	O
part	O
of	O
the	O
behavioral	O
phenotype	O
of	O
ASD	B-DISEASE
.	O

(	O
a	O
)	O
Family	O
pedigrees	O
showing	O
autosomal	O
dominant	O
inheritance	O
.	O

This	O
position	O
170	O
coincides	O
with	O
a	O
key	O
ligand	O
binding	O
pocket	O
[	O
36	O
]	O
,	O
[	O
37	O
]	O
and	O
the	O
mutation	O
from	O
histidine	O
to	O
asparagine	O
is	O
predicted	O
to	O
alter	O
the	O
ligand	O
binding	O
site	O
with	O
a	O
change	O
of	O
substrate	O
specificity	O
resulting	O
in	O
an	O
adverse	O
alteration	O
in	O
the	O
protein	O
function	O
.	O

We	O
assessed	O
the	O
polymorphism	O
765C	B-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
referred	O
to	O
as	O
SNP1	O
[	O
27	O
]	O
)	O
in	O
159	O
unrelated	O
patients	O
(	O
see	O
Table	O
3	O
)	O
.	O

Furthermore	O
,	O
variants	O
in	O
genes	O
for	O
which	O
variation	O
is	O
infrequently	O
observed	O
may	O
be	O
flagged	O
as	O
an	O
unusual	O
finding	O
that	O
bears	O
further	O
scrutiny	O
.	O

In	O
both	O
families	O
,	O
the	O
LOD	O
score	O
for	O
the	O
TMPRSS3	B-GENE
region	O
reached	O
the	O
theoretical	O
maximum	O
LOD	O
score	O
.	O

A	O
different	O
MID	O
sequence	O
was	O
used	O
for	O
every	O
patient	O
(	O
Figure	O
3	O
)	O
.	O

Clinical	O
and	O
genetically	O
unaffected	O
individuals	O
are	O
indicated	O
by	O
a	O
clear	O
symbol	O
.	O

Yet	O
given	O
the	O
prevalence	O
of	O
cancer	B-DISEASE
in	O
the	O
United	O
States	O
[	O
63	O
]	O
,	O
about	O
40	O
%	O
(	O
272	O
)	O
of	O
these	O
681	O
individuals	O
will	O
eventually	O
develop	O
cancer	B-DISEASE
.	O

The	O
MLPA	O
reaction	O
(	O
P361	O
-	O
A1	O
/	O
P362	O
-	O
A2	O
SALSA	O
MLPA	O
kit	O
;	O
MRC	O
Holland	O
,	O
Amsterdam	O
,	O
The	O
Netherlands	O
)	O
was	O
performed	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
recommendations	O
.	O

Anti	O
-	O
WFS1	B-GENE
antibody	O
and	O
anti	O
-	O
protein	O
disulfide	O
isomerase	O
(	O
anti	O
-	O
PDI	O
)	O
antibody	O
were	O
obtained	O
from	O
Proteintech	O
Group	O
(	O
Chicago	O
,	O
IL	O
)	O
and	O
Stressgen	O
(	O
Victoria	O
,	O
BC	O
,	O
Canada	O
)	O
,	O
respectively	O
.	O

Structural	O
and	O
local	O
environment	O
for	O
position	O
170	O
with	O
the	O
H	O
-	O
bond	O
patterns	O
are	O
shown	O
.	O

The	O
distal	O
breakpoint	O
(	O
arrowhead	O
)	O
is	O
defined	O
by	O
unaffected	O
individual	O
V	O
:	O
5	O
(	O
PKDF282	O
)	O
at	O
D15SA975	O
(	O
78	O
.	O
56	O
Mb	O
)	O
.	O

This	O
study	O
was	O
not	O
designed	O
to	O
order	O
clinical	O
diagnostic	O
assessments	O
solely	O
for	O
research	O
purposes	O
;	O
as	O
such	O
,	O
assessment	O
of	O
phenotypes	O
and	O
estimations	O
of	O
potential	O
aetiologies	O
for	O
hearing	B-DISEASE
loss	I-DISEASE
are	O
limited	O
to	O
what	O
was	O
observed	O
by	O
physicians	O
in	O
the	O
course	O
of	O
routine	O
clinical	O
care	O
for	O
patients	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

PolyPhen2	O
classification	O
for	O
this	O
variant	O
was	O
probably	O
damaging	O
(	O
score	O
1	O
.	O
0	O
)	O
and	O
MutPred	O
predicted	O
the	O
g	O
score	O
(	O
probability	O
of	O
deleterious	O
mutation	O
)	O
as	O
0	O
.	O
850	O
.	O

2014	O
;	O
Pandya	O
et	O
al	O
.	O

Affected	O
individuals	O
did	O
not	O
have	O
delays	O
in	O
gross	O
motor	O
development	O
.	O

KCNJ10	B-GENE
c	B-VARIANT
.	I-VARIANT
1042C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
R348C	I-VARIANT
)	O
,	O
the	O
reported	O
EVA	B-DISEASE
-	O
related	O
mutation	O
,	O
was	O
not	O
found	O
in	O
patients	O
with	O
NSEVA	B-DISEASE
who	O
lacked	O
mutations	O
in	O
either	O
one	O
or	O
both	O
alleles	O
of	O
SLC26A4	B-GENE
.	O

T	O
.	O

USH1G	B-GENE
contains	O
three	O
exons	O
,	O
spans	O
7	O
.	O
2	O
kb	O
,	O
and	O
encodes	O
a	O
scaffolding	O
protein	O
(	O
SANS	O
)	O
with	O
460	O
amino	O
acids	O
.	O

Each	O
reaction	O
was	O
performed	O
in	O
triplicate	O
and	O
this	O
was	O
repeated	O
three	O
times	O
.	O

They	O
successfully	O
confirmed	O
the	O
causative	O
mutations	O
in	O
all	O
positive	O
controls	O
and	O
detected	O
additional	O
variants	O
in	O
the	O
other	O
selected	O
genes	O
[	O
50	O
]	O
.	O

The	O
cells	O
were	O
collected	O
by	O
centrifugation	O
and	O
lysed	O
by	O
resuspension	O
in	O
1	O
.	O
5	O
ml	O
25	O
mM	O
HEPES	O
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
100	O
mM	O
NaCl	O
,	O
and	O
1	O
%	O
CHAPS	O
.	O

[	O
17	O
]	O
.	O

-	I-VARIANT
23	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
allele	O
was	O
not	O
transcribed	O
or	O
the	O
transcript	O
was	O
unstable	O
.	O

1	O
,	O
2	O
Because	O
of	O
the	O
Mendelian	O
nature	O
of	O
nonsyndromic	B-DISEASE
HL	I-DISEASE
(	O
NSHL	B-DISEASE
)	O
,	O
the	O
search	O
for	O
new	O
genes	O
has	O
witnessed	O
profound	O
achievement	O
,	O
particularly	O
in	O
the	O
past	O
decade	O
.	O

Size	O
and	O
location	O
of	O
the	O
homozygous	O
blocks	O
containing	O
the	O
causative	O
mutations	O
in	O
the	O
studied	O
families	O
.	O

Harstfield	B-DISEASE
syndrome	I-DISEASE
is	O
the	O
rare	O
and	O
unique	O
association	O
of	O
holoprosencephaly	B-DISEASE
(	O
HPE	B-DISEASE
)	O
and	O
ectrodactyly	B-DISEASE
,	O
with	O
or	O
without	O
cleft	B-DISEASE
lip	I-DISEASE
and	I-DISEASE
palate	I-DISEASE
,	O
and	O
variable	O
additional	O
features	O
.	O

There	O
are	O
data	O
to	O
suggest	O
that	O
the	O
MyTH4	O
/	O
FERM	O
domain	O
in	O
myosin	B-GENE
VIIA	I-GENE
is	O
required	O
for	O
its	O
localization	O
to	O
stereocilia	O
tips	O
[	O
25	O
-	O
27	O
]	O
,	O
a	O
process	O
that	O
is	O
essential	O
for	O
the	O
formation	O
of	O
the	O
transmembrane	O
actin	O
microfilament	O
assembly	O
complex	O
at	O
the	O
stereocilia	O
tips	O
.	O

SU	O
conceived	O
of	O
the	O
study	O
,	O
and	O
participated	O
in	O
its	O
design	O
and	O
coordination	O
and	O
helped	O
to	O
draft	O
the	O
manuscript	O
.	O

Genetic	O
factors	O
contribute	O
to	O
approximately	O
half	O
of	O
the	O
cases	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
[	O
1	O
]	O
,	O
which	O
can	O
be	O
either	O
syndromic	O
or	O
non	O
-	O
syndromic	O
.	O

The	O
severity	O
of	O
the	O
genetic	O
lesions	O
and	O
their	O
effects	O
on	O
NARS2	B-GENE
protein	O
structure	O
cosegregate	O
with	O
the	O
phenotype	O
.	O

CACNA1D	B-GENE
encodes	O
Ca	O
V	O
1	O
.	O
3	O
,	O
the	O
alpha	O
1	O
(	O
pore	O
-	O
forming	O
)	O
subunit	O
of	O
an	O
L	O
-	O
type	O
(	O
long	O
-	O
lasting	O
)	O
voltage	O
-	O
gated	O
calcium	O
channel	O
.	O

Thus	O
,	O
many	O
of	O
the	O
potential	O
reasons	O
for	O
failure	O
in	O
the	O
WES	O
approach	O
need	O
to	O
be	O
solved	O
fully	O
in	O
order	O
to	O
realize	O
the	O
promise	O
of	O
WES	O
for	O
routine	O
diagnosis	O
of	O
Mendelian	O
disorders	O
.	O

In	O
order	O
to	O
understand	O
the	O
spectrum	O
and	O
frequency	O
of	O
GJB2	B-GENE
mutations	O
in	O
the	O
Chinese	O
population	O
,	O
the	O
coding	O
region	O
of	O
the	O
GJB2	B-GENE
gene	O
from	O
2063	O
unrelated	O
patients	O
with	O
NSHI	B-DISEASE
was	O
PCR	O
amplified	O
and	O
sequenced	O
.	O

Of	O
622	O
missense	O
mutations	O
,	O
254	O
mutations	O
were	O
confirmed	O
by	O
Sanger	O
sequencing	O
.	O

Peripheral	O
blood	O
was	O
collected	O
from	O
affected	O
patients	O
,	O
their	O
parents	O
and	O
unaffected	O
relatives	O
where	O
available	O
.	O

Therefore	O
,	O
it	O
seems	O
that	O
glycosylation	O
is	O
not	O
the	O
sole	O
determining	O
factor	O
for	O
destabilization	O
of	O
mutated	O
CLRN1	B-GENE
proteins	O
in	O
general	O
.	O

van	O
der	O
Velde	O
-	O
Visser	O
for	O
excellent	O
technical	O
assistance	O
.	O

The	O
current	O
study	O
documented	O
the	O
following	O
observations	O
;	O
1	O
)	O
WFS	B-DISEASE
was	O
confirmed	O
to	O
be	O
rare	O
with	O
the	O
prevalence	O
being	O
1	O
/	O
710	O
,	O
000	O
in	O
the	O
Japanese	O
population	O
.	O

Algorithm	O
for	O
the	O
study	O
of	O
USH3	B-DISEASE
in	O
our	O
series	O
.	O

(	O
d	O
)	O
Palestinian	O
and	O
Turkish	O
individuals	O
with	O
the	O
716A	O
(	O
239D	O
)	O
mutation	O
share	O
an	O
extended	O
haplotype	O
of	O
126	O
-	O
260	O
kilobases	O
flanking	O
pendrin	B-GENE
(	O
yellow	O
boxes	O
)	O
,	O
based	O
on	O
markers	O
polymorphic	O
among	O
wild	O
-	O
type	O
(	O
716T	O
)	O
haplotypes	O
.	O

Group	O
3	O
is	O
defined	O
as	O
individuals	O
with	O
compound	O
heterozygous	O
mutations	O
found	O
in	O
group	O
1	O
and	O
group	O
2	O
.	O

Parametric	O
linkage	O
analysis	O
was	O
carried	O
out	O
with	O
Merlin	O
using	O
an	O
autosomal	O
-	O
dominant	O
mode	O
of	O
inheritance	O
with	O
complete	O
penetrance	O
and	O
a	O
disease	O
gene	O
frequency	O
of	O
0	O
.	O
0001	O
,	O
SNP	O
allele	O
frequencies	O
from	O
CEU	O
and	O
genetic	O
distances	O
from	O
the	O
Affymetrix	O
100K	O
Marshfield	O
cM	O
map	O
.	O

Biotinylated	O
probes	O
were	O
hybridized	O
overnight	O
with	O
fragmented	O
genomic	O
DNA	O
(	O
gDNA	O
)	O
at	O
47	O
deg	O
C	O
in	O
a	O
thermocycler	O
(	O
Bio	O
-	O
Rad	O
T100	O
,	O
Hercules	O
,	O
CA	O
)	O
.	O

(	O
IA	O
and	O
IIA	O
)	O
Anterior	O
view	O
of	O
craniofacial	O
features	O
of	O
PS	B-DISEASE
parents	O
;	O
(	O
IB	O
and	O
IIB	O
)	O
Showing	O
lateral	O
view	O
of	O
craniofacial	O
features	O
.	O

Photos	O
of	O
patient	O
at	O
2	O
years	O
(	O
a	O
)	O
and	O
17	O
years	O
(	O
b	O
)	O
show	O
prominent	B-DISEASE
metopic	I-DISEASE
ridge	I-DISEASE
or	O
trigonocephaly	B-DISEASE
(	O
mid	O
-	O
forehead	O
in	O
a	O
)	O
,	O
high	B-DISEASE
-	I-DISEASE
arched	I-DISEASE
eyebrows	I-DISEASE
,	O
ptosis	B-DISEASE
,	O
flat	B-DISEASE
philtrum	I-DISEASE
and	O
wide	B-DISEASE
mouth	I-DISEASE
,	O
and	O
a	O
suggestion	O
of	O
low	B-DISEASE
-	I-DISEASE
set	I-DISEASE
ears	I-DISEASE
.	O

Specific	O
primers	O
were	O
designed	O
using	O
Primer3	O
Plus	O
software	O
based	O
on	O
the	O
MCM2	B-GENE
mRNA	O
sequence	O
of	O
guinea	O
pig	O
in	O
GenBank	O
(	O
XM_003461494	O
.	O
2	O
)	O
.	O

DNA	O
sequencing	O
of	O
the	O
coding	O
and	O
near	O
-	O
coding	O
regions	O
of	O
genes	O
relevant	O
to	O
each	O
patient	O
'	O
s	O
clinical	O
presentation	O
revealed	O
37	O
sequence	O
variations	O
of	O
known	O
or	O
uncertain	O
pathogenicity	O
in	O
9	O
genes	O
from	O
25	O
patients	O
.	O

Based	O
upon	O
these	O
initial	O
observations	O
,	O
we	O
believe	O
that	O
the	O
phenotypic	O
spectrum	O
of	O
IOSCA	B-DISEASE
may	O
be	O
wider	O
than	O
reported	O
previously	O
.	O

The	O
missense	O
c	B-VARIANT
.	I-VARIANT
2035G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
mutation	O
was	O
found	O
in	O
two	O
siblings	O
(	O
cases	O
16	O
.	O
1	O
and	O
16	O
.	O
2	O
)	O
in	O
heterozygosis	O
(	O
their	O
father	O
was	O
also	O
heterozygous	O
for	O
this	O
mutation	O
)	O
.	O

In	O
a	O
study	O
that	O
included	O
84	O
patients	O
without	O
a	O
prior	O
molecular	O
diagnosis	O
,	O
five	O
(	O
6	O
%	O
)	O
were	O
diagnosed	O
with	O
a	O
mitochondrial	O
disorder	O
after	O
exome	O
sequencing	O
[	O
Lieber	O
et	O
al	O
.	O
,	O
2013	O
]	O
.	O

Overall	O
,	O
combined	O
sequence	O
variation	O
and	O
CNV	O
analysis	O
increased	O
the	O
detection	O
rate	O
from	O
36	O
.	O
7	O
%	O
(	O
29	O
/	O
79	O
)	O
to	O
43	O
.	O
0	O
%	O
(	O
34	O
/	O
79	O
)	O
among	O
79	O
sporadic	O
patients	O
clinically	O
diagnosed	O
with	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O

The	O
most	O
frequent	O
mutation	O
was	O
p	B-VARIANT
.	I-VARIANT
H723R	I-VARIANT
that	O
accounted	O
for	O
36	O
.	O
0	O
%	O
,	O
and	O
the	O
second	O
was	O
c	B-VARIANT
.	I-VARIANT
919	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
found	O
in	O
7	O
.	O
0	O
%	O
,	O
followed	O
by	O
c	B-VARIANT
.	I-VARIANT
1707	I-VARIANT
+	I-VARIANT
5G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
4	O
.	O
0	O
%	O
)	O
.	O

This	O
study	O
was	O
approved	O
by	O
the	O
Ethnic	O
Committee	O
of	O
Chinese	O
PLA	O
General	O
Hospital	O
.	O

The	O
variant	O
list	O
following	O
analysis	O
of	O
patient	O
114	O
(	O
a	O
male	O
)	O
highlighted	O
the	O
heterozygous	O
PROM1	B-GENE
mutation	O
(	O
c	B-VARIANT
.	I-VARIANT
1117C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R373C	I-VARIANT
)	O
which	O
was	O
previously	O
identified	O
in	O
patients	O
with	O
a	O
diagnosis	O
of	O
cone	B-DISEASE
-	I-DISEASE
rod	I-DISEASE
dystrophy	I-DISEASE
[	O
22	O
]	O
,	O
[	O
23	O
]	O
as	O
the	O
possible	O
cause	O
of	O
disease	O
symptoms	O
.	O

The	O
pathogenicity	O
of	O
all	O
new	O
missense	O
changes	O
identified	O
in	O
patients	O
was	O
evaluated	O
using	O
the	O
in	O
silico	O
predictors	O
SIFT	O
(	O
http	O
:	O
/	O
/	O
sift	O
.	O
jcvi	O
.	O
org	O
/	O
[	O
15	O
]	O
)	O
and	O
PolyPhen	O
-	O
2	O
(	O
http	O
:	O
/	O
/	O
genetics	O
.	O
bwh	O
.	O
harvard	O
.	O
edu	O
/	O
pph2	O
/	O
[	O
16	O
]	O
)	O
.	O

Interpretation	O
of	O
variants	O
as	O
pathogenic	O
,	O
likely	O
pathogenic	O
,	O
VUS	O
,	O
likely	O
benign	O
and	O
benign	O
is	O
continuously	O
refined	O
based	O
on	O
increasingly	O
robust	O
data	O
.	O

In	O
the	O
process	O
of	O
sequence	O
variant	O
calling	O
,	O
we	O
focused	O
only	O
on	O
variants	O
included	O
in	O
coding	O
exons	O
and	O
in	O
corresponding	O
canonical	O
splicing	O
sites	O
of	O
known	O
Usher	B-DISEASE
genes	O
,	O
considering	O
as	O
relevant	O
for	O
splicing	O
sites	O
investigations	O
only	O
the	O
exons	O
boundaries	O
plus	O
2	O
base	O
pairs	O
.	O

All	O
had	O
spontaneous	O
testicular	O
growth	O
while	O
on	O
testosterone	O
replacement	O
therapy	O
(	O
TRT	O
)	O
.	O

receives	O
funding	O
from	O
Helse	O
Vest	O
(	O
RHF	O
)	O
and	O
the	O
Norwegian	O
Research	O
Council	O
.	O

In	O
our	O
study	O
population	O
,	O
mutations	O
in	O
SLC26A4	B-GENE
were	O
identified	O
in	O
9	O
.	O
79	O
%	O
(	O
23	O
/	O
235	O
)	O
of	O
individuals	O
,	O
which	O
was	O
lower	O
than	O
that	O
in	O
typical	O
areas	O
of	O
China	O
(	O
18	O
.	O
66	O
%	O
,	O
chi	O
2	O
=	O
8	O
.	O
1030	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
but	O
higher	O
than	O
that	O
in	O
Uyghur	O
patients	O
(	O
2	O
.	O
01	O
%	O
,	O
chi	O
2	O
=	O
11	O
.	O
1711	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
[	O
41	O
]	O
.	O

This	O
file	O
contains	O
Supporting	O
Figures	O
and	O
Tables	O
.	O

2a	O
,	O
proband	O
)	O
was	O
the	O
second	O
child	O
of	O
healthy	O
,	O
non	O
-	O
consanguineous	O
Korean	O
parents	O
.	O

Hearing	B-DISEASE
loss	I-DISEASE
was	O
evaluated	O
using	O
pure	O
-	O
tone	O
audiometry	O
(	O
PTA	O
)	O
classified	O
by	O
a	O
pure	O
-	O
tone	O
average	O
over	O
500	O
,	O
1000	O
,	O
2000	O
and	O
4000	O
Hz	O
in	O
the	O
better	O
hearing	O
ears	O
.	O

Splice	O
site	O
prediction	O
was	O
performed	O
using	O
the	O
following	O
online	O
available	O
prediction	O
tools	O
,	O
NetGene2	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
cbs	O
.	O
dtu	O
.	O
dk	O
/	O
services	O
/	O
NetGene2	O
)	O
,	O
HSF	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
umd	O
.	O
be	O
/	O
HSF	O
/	O
)	O
,	O
BDGP	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
fruitfly	O
.	O
org	O
/	O
seq_tools	O
/	O
splice	O
.	O
html	O
)	O
,	O
GENSCAN	O
(	O
http	O
:	O
/	O
/	O
genes	O
.	O
mit	O
.	O
edu	O
/	O
GENSCAN	O
.	O
html	O
)	O
.	O

SNVs	O
and	O
indels	O
were	O
called	O
using	O
VarScan	O
v2	O
.	O
2	O
.	O
9	O
(	O
with	O
parameters	O
-	O
-	O
min	O
-	O
coverage	O
3	O
-	O
-	O
min	O
-	O
var	O
-	O
freq	O
0	O
.	O
20	O
-	O
-	O
p	O
-	O
value	O
0	O
.	O
10	O
-	O
-	O
strand	O
-	O
filter	O
1	O
-	O
-	O
map	O
-	O
quality	O
10	O
)	O
with	O
the	O
false	O
-	O
positive	O
filter	O
59	O
and	O
GATK	O
60	O
v5336	O
(	O
with	O
parameters	O
-	O
T	O
IndelGenotyperV2	O
-	O
-	O
window_size	O
300	O
)	O
.	O

Seven	O
different	O
point	O
mutations	O
,	O
five	O
novel	O
,	O
were	O
detected	O
.	O

Furthermore	O
,	O
the	O
KCNJ10	B-GENE
c	B-VARIANT
.	I-VARIANT
1042C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
mutation	O
,	O
which	O
was	O
suggested	O
to	O
be	O
a	O
potentially	O
pathological	O
mutation	O
,	O
was	O
shown	O
to	O
reduce	O
K	O
+	O
conductance	O
activity	O
[	O
14	O
]	O
.	O

This	O
particular	O
genetic	O
region	O
of	O
the	O
WFS1	B-GENE
gene	O
product	O
is	O
highly	O
conserved	O
among	O
healthy	O
humans	O
,	O
Mus	O
sp	O
.	O
,	O
and	O
Rattus	O
sp	O
.	O

Visual	O
fields	O
usually	O
show	O
central	O
,	O
paracentral	O
,	O
or	O
centrocecal	O
scotomas	O
.	O

To	O
analyze	O
the	O
possible	O
functional	O
pathogenic	O
effects	O
of	O
the	O
variants	O
,	O
2	O
types	O
of	O
prediction	O
programs	O
,	O
SIFT	O
(	O
http	O
:	O
/	O
/	O
sift	O
.	O
jcvi	O
.	O
org	O
)	O
and	O
Mutation	O
taster	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
mutationtaster	O
.	O
org	O
)	O
,	O
were	O
used	O
.	O

The	O
SIFT	O
(	O
Sorting	O
Intolerant	O
from	O
Tolerant	O
)	O
[	O
46	O
]	O
and	O
Polyphen	O
[	O
47	O
]	O
software	O
programs	O
were	O
used	O
to	O
predict	O
the	O
influence	O
of	O
any	O
amino	O
acid	O
substitution	O
on	O
the	O
protein	O
structure	O
and	O
function	O
.	O

In	O
one	O
patient	O
no	O
point	O
mutation	O
was	O
identified	O
,	O
and	O
the	O
quantitative	O
analysis	O
could	O
not	O
be	O
performed	O
(	O
RP	O
-	O
531	O
)	O
.	O

The	O
age	O
of	O
onset	O
of	O
the	O
condition	O
in	O
most	O
family	O
members	O
before	O
10	O
-	O
years	O
(	O
Table	O
1	O
)	O
,	O
however	O
the	O
age	O
at	O
onset	O
in	O
the	O
condition	O
in	O
most	O
patients	O
with	O
LCPD	B-DISEASE
was	O
earlier	O
than	O
the	O
patients	O
with	O
ANFH	B-DISEASE
.	O

Diagnostic	O
Results	O
of	O
36	O
RP	B-DISEASE
Patients	O
with	O
Validated	O
Pathogenic	O
Variants	O
Patient	O
,	O
patient	O
identifier	O
;	O
Gene	O
,	O
RefSeq	O
gene	O
name	O
of	O
the	O
gene	O
in	O
which	O
mutations	O
were	O
identified	O
;	O
Inheritance	O
,	O
possible	O
inheritance	O
of	O
phenotype	O
for	O
known	O
mutations	O
in	O
the	O
corresponding	O
gene	O
;	O
Validated	O
mutation	O
M1	O
and	O
Validated	O
mutation	O
M2	O
,	O
cDNA	O
and	O
protein	O
annotation	O
of	O
the	O
identified	O
mutations	O
.	O

The	O
GJB2	B-GENE
mutation	O
was	O
detected	O
in	O
16	O
.	O
67	O
%	O
(	O
7	O
/	O
42	O
)	O
of	O
minority	O
patients	O
and	O
17	O
.	O
62	O
%	O
(	O
34	O
/	O
193	O
)	O
of	O
Chinese	O
Han	O
patients	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

It	O
was	O
believed	O
that	O
EYA4	B-GENE
mutations	O
led	O
to	O
syndromic	O
and	O
non	O
-	O
syndromic	O
SNHL	B-DISEASE
.	O

Dominant	O
or	O
recessive	O
FGFR1	B-GENE
mutations	O
are	O
responsible	O
for	O
Hartsfield	B-DISEASE
syndrome	I-DISEASE
,	O
consistent	O
with	O
the	O
known	O
roles	O
of	O
FGFR1	B-GENE
in	O
vertebrate	O
ontogeny	O
and	O
conditional	O
Fgfr1	B-GENE
-	O
deficient	O
mice	O
.	O

Her	O
cognitive	O
development	O
was	O
normal	O
,	O
but	O
she	O
had	O
severe	O
speech	O
and	O
language	O
delay	O
.	O

Segregation	O
analysis	O
independently	O
identified	O
15	O
SNVs	O
co	O
-	O
segregating	O
with	O
NSHL	B-DISEASE
(	O
green	O
dots	O
)	O
.	O

Consistent	O
with	O
previous	O
reports	O
,	O
diabetes	B-DISEASE
was	O
the	O
first	O
manifestation	O
of	O
Wolfram	B-DISEASE
syndrome	I-DISEASE
in	O
most	O
patients	O
in	O
this	O
study	O
.	O

However	O
,	O
a	O
heterozygous	O
mutation	O
in	O
a	O
recessive	O
gene	O
may	O
be	O
relevant	O
to	O
the	O
hearing	B-DISEASE
loss	I-DISEASE
phenotype	O
if	O
it	O
coexists	O
with	O
another	O
heterozygous	O
mutation	O
[	O
5	O
]	O
,	O
and	O
it	O
is	O
a	O
low	O
frequency	O
in	O
the	O
general	O
Korean	O
population	O
might	O
not	O
rule	O
out	O
the	O
possibility	O
that	O
it	O
is	O
pathogenic	O
.	O

It	O
encodes	O
both	O
long	O
and	O
short	O
isoforms	O
with	O
the	O
long	O
isoform	O
containing	O
six	O
C2	O
domains	O
and	O
the	O
C	O
-	O
terminal	O
transmembrane	O
domain	O
,	O
and	O
the	O
short	O
isoform	O
containing	O
only	O
the	O
last	O
three	O
C2	O
domains	O
[	O
9	O
]	O
.	O

Genomic	O
DNA	O
was	O
then	O
extracted	O
from	O
the	O
blood	O
using	O
RelaxGene	O
Blood	O
DNA	O
System	O
(	O
TIAGEN	O
Biotech	O
,	O
Beijing	O
,	O
China	O
)	O
.	O

Two	O
are	O
brothers	O
(	O
cases	O
2	O
and	O
3	O
)	O
and	O
their	O
mother	O
also	O
had	O
KS	B-DISEASE
.	O

(	O
TIF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Ten	O
of	O
these	O
sequence	O
variations	O
were	O
detected	O
more	O
than	O
once	O
(	O
35delG	B-VARIANT
,	O
M34T	B-VARIANT
,	O
V37I	B-VARIANT
,	O
V27I	B-VARIANT
,	O
W24X	B-VARIANT
,	O
E47X	B-VARIANT
,	O
Y68C	B-VARIANT
,	O
R127H	B-VARIANT
,	O
V153I	B-VARIANT
,	O
F83L	B-VARIANT
)	O
,	O
with	O
relative	O
frequencies	O
ranging	O
between	O
2	O
,	O
3	O
%	O
to	O
0	O
,	O
09	O
%	O
and	O
7	O
of	O
these	O
were	O
not	O
previously	O
reported	O
(	O
Y68C	B-VARIANT
,	O
IVS1	B-VARIANT
-	I-VARIANT
7G	I-VARIANT
/	I-VARIANT
A	I-VARIANT
,	O
G4D	B-VARIANT
,	O
Q7Q	B-VARIANT
,	O
T26T	B-VARIANT
,	O
H67R	B-VARIANT
,	O
D159D	B-VARIANT
)	O
.	O

CDH23	B-GENE
homodimers	O
interact	O
in	O
trans	O
with	O
PCDH15	B-GENE
homodimers	O
to	O
form	O
filaments	O
,	O
and	O
they	O
play	O
a	O
key	O
role	O
in	O
the	O
mechanoelectrical	O
transduction	O
channel	O
at	O
the	O
top	O
of	O
the	O
lower	O
stereocilia	O
[	O
3	O
-	O
5	O
]	O
.	O

The	O
incidence	O
of	O
non	O
-	O
syndromic	O
EVA	B-DISEASE
accounts	O
for	O
13	O
.	O
73	O
%	O
of	O
hereditary	O
hearing	B-DISEASE
loss	I-DISEASE
[	O
22	O
]	O
.	O

To	O
date	O
,	O
2	O
mutations	O
at	O
the	O
p	O
.	O
R75	O
amino	O
acid	O
residue	O
of	O
connexin	B-GENE
26	I-GENE
have	O
been	O
related	O
to	O
autosomal	B-DISEASE
dominant	I-DISEASE
SNHI	I-DISEASE
with	O
or	O
without	O
palmoplantar	B-DISEASE
keratoderma	I-DISEASE
:	O
p	B-VARIANT
.	I-VARIANT
R75W	I-VARIANT
[	O
31	O
]	O
,	O
[	O
32	O
]	O
and	O
p	B-VARIANT
.	I-VARIANT
R75Q	I-VARIANT
[	O
26	O
]	O
,	O
[	O
27	O
]	O
.	O

TNC	B-GENE
expression	O
changes	O
during	O
development	O
until	O
adulthood	O
.	O

His	O
grandmother	O
(	O
I	O
-	O
2	O
)	O
had	O
undergone	O
a	O
kidney	O
biopsy	O
at	O
age	O
55	O
and	O
this	O
was	O
reported	O
as	O
showing	O
typical	O
LM	O
and	O
IF	O
findings	O
of	O
IgA	O
nephropathy	B-DISEASE
.	O

The	O
symbols	O
'	O
o	O
'	O
and	O
'	O
x	O
'	O
denote	O
air	O
conduction	O
pure	O
-	O
tone	O
thresholds	O
,	O
and	O
the	O
'	O
<	O
'	O
and	O
'	O
>	O
'	O
symbols	O
denote	O
bone	O
conduction	O
thresholds	O
in	O
the	O
right	O
and	O
the	O
left	O
ears	O
,	O
respectively	O
.	O

A	O
full	O
list	O
of	O
variants	O
is	O
shown	O
in	O
Table	O
S4	O
.	O

We	O
would	O
like	O
to	O
thank	O
the	O
patients	O
and	O
their	O
families	O
for	O
their	O
collaboration	O
.	O

We	O
report	O
five	O
families	O
,	O
each	O
with	O
a	O
novel	O
MYH9	B-GENE
mutation	O
.	O

All	O
the	O
remaining	O
missense	O
mutations	O
in	O
KCNH2	B-GENE
,	O
except	O
p	B-VARIANT
.	I-VARIANT
A913V	I-VARIANT
,	O
were	O
conserved	O
to	O
the	O
level	O
of	O
zebrafish	O
.	O

Hearing	O
levels	O
of	O
the	O
right	O
ear	O
and	O
left	O
ear	O
are	O
marked	O
with	O
red	O
and	O
blue	O
lines	O
,	O
respectively	O
.	O

Summary	O
of	O
the	O
ACTB	B-GENE
and	O
ACTG1	B-GENE
mutations	O
in	O
18	O
patients	O
with	O
Baraitser	B-DISEASE
-	I-DISEASE
Winter	I-DISEASE
syndrome	I-DISEASE
Abbreviations	O
:	O
Chr	O
:	O
chromosome	O
.	O

Although	O
this	O
argument	O
assumes	O
the	O
common	O
variant	O
-	O
common	O
disease	O
hypothesis	O
,	O
it	O
is	O
also	O
conceivable	O
that	O
rare	O
alleles	O
with	O
strong	O
effects	O
in	O
homozygous	O
or	O
heterozygous	O
state	O
may	O
be	O
strong	O
contributors	O
to	O
ARHI	B-DISEASE
.	O

Overlapping	O
audiograms	O
of	O
the	O
better	O
-	O
hearing	O
ear	O
of	O
20	O
subjects	O
with	O
homozygous	O
or	O
compound	O
heterozygous	O
CDH23	B-GENE
mutations	O
.	O

The	O
selected	O
list	O
of	O
genes	O
includes	O
the	O
most	O
frequently	O
mutated	O
recessive	O
genes	O
in	O
patients	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
Table	O
1	O
)	O
.	O

A	O
female	O
patient	O
had	O
profound	O
deafness	B-DISEASE
from	O
the	O
age	O
of	O
10	O
months	O
confirmed	O
by	O
audiometric	O
test	O
;	O
at	O
age	O
of	O
5	O
years	O
a	O
cochlear	O
implant	O
was	O
inserted	O
.	O

the	O
KCNE1	B-GENE
:	O
p	B-VARIANT
.	I-VARIANT
D91E	I-VARIANT
mentioned	O
above	O
)	O
that	O
have	O
not	O
previously	O
been	O
associated	O
with	O
disease	O
and	O
have	O
a	O
population	O
frequency	O
less	O
than	O
1	O
:	O
4	O
000	O
may	O
raise	O
questions	O
about	O
their	O
possible	O
role	O
in	O
disease	O
causation	O
.	O

The	O
paternal	O
lineage	O
carries	O
a	O
heterozygous	O
p	B-VARIANT
.	I-VARIANT
Gly272Asp	I-VARIANT
(	O
Red	O
)	O
only	O
,	O
while	O
the	O
maternal	O
lineage	O
carries	O
a	O
heterozygous	O
c	B-VARIANT
.	I-VARIANT
605	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
Blue	O
)	O
.	O

The	O
asterisk	O
indicates	O
previously	O
reported	O
as	O
polymorphism	O
by	O
Tlili	O
et	O
al	O
.	O

Pedigree	O
analysis	O
confirmed	O
that	O
the	O
COL4A3	B-GENE
mutations	O
were	O
compound	O
heterozygous	O
and	O
subsequent	O
clinical	O
work	O
-	O
up	O
confirmed	O
dual	O
disease	O
,	O
Alport	B-DISEASE
syndrome	I-DISEASE
and	O
VUR	B-DISEASE
.	O

This	O
pedigree	O
demonstrates	O
nonsyndromic	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
of	O
autosomal	O
dominant	O
inheritance	O
.	O

In	O
light	O
of	O
the	O
three	O
additional	O
pairs	O
of	O
compound	O
heterozygous	O
mutations	O
identified	O
in	O
Chinese	O
patients	O
with	O
JLNS	B-DISEASE
in	O
this	O
study	O
,	O
it	O
appears	O
that	O
compound	O
mutations	O
in	O
KCNQ1	B-GENE
may	O
be	O
a	O
primary	O
cause	O
of	O
JLNS	B-DISEASE
among	O
Chinese	O
individuals	O
.	O

None	O
of	O
these	O
additional	O
mutations	O
were	O
nonsense	O
or	O
frame	O
-	O
shifting	O
mutations	O
,	O
but	O
the	O
conservation	O
of	O
the	O
corresponding	O
amino	O
acid	O
residues	O
in	O
the	O
orthologous	O
genes	O
(	O
ush2a	B-GENE
,	O
myo7a	B-GENE
,	O
whrn	B-GENE
)	O
of	O
Ciona	O
savignyi	O
[	O
72	O
]	O
,	O
a	O
cnidarian	O
which	O
is	O
evolutionary	O
distant	O
of	O
about	O
520	O
million	O
years	O
from	O
man	O
[	O
73	O
]	O
,	O
argues	O
in	O
favor	O
of	O
their	O
pathogenicity	O
(	O
Figure	O
4	O
)	O
.	O

Neurological	O
examinations	O
included	O
assessments	O
of	O
cranial	O
nerve	O
function	O
,	O
motor	O
activity	O
,	O
muscle	B-DISEASE
weakness	I-DISEASE
,	O
sensory	B-DISEASE
impairment	I-DISEASE
and	O
reflexes	O
.	O

Interestingly	O
,	O
in	O
unrelated	O
Ashkenazi	O
Jewish	O
and	O
Finnish	O
populations	O
,	O
USH3	B-DISEASE
comprises	O
40	O
%	O
of	O
all	O
the	O
USH	B-DISEASE
cases	O
,	O
suggesting	O
multiple	O
founder	O
effects	O
[	O
9	O
,	O
32	O
]	O
.	O

Understanding	O
genetic	O
etiology	O
can	O
provide	O
valuable	O
clues	O
of	O
prognosis	O
(	O
i	O
.	O
e	O
.	O
,	O
whether	O
losses	O
will	O
worsen	O
)	O
,	O
optimal	O
intervention	O
(	O
e	O
.	O
g	O
.	O
,	O
hearing	O
aids	O
,	O
CI	O
,	O
sign	O
language	O
)	O
,	O
and	O
the	O
risk	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
recurrence	O
in	O
future	O
children	O
and	O
other	O
family	O
members	O
[	O
6	O
-	O
9	O
]	O
.	O

B	O
)	O
Close	O
-	O
up	O
view	O
of	O
the	O
structure	O
showing	O
the	O
wild	O
type	O
residue	O
cysteine	O
(	O
green	O
)	O
and	O
the	O
mutant	O
residue	O
tryptophan	O
(	O
red	O
)	O
.	O

The	O
SULF1	B-GENE
gene	O
(	O
belonging	O
to	O
the	O
TDT	O
analysis	O
list	O
)	O
encodes	O
an	O
enzyme	O
with	O
arylsulphatase	O
activity	O
acting	O
on	O
cell	O
-	O
surface	O
heparan	O
sulphate	O
proteoglycans	O
.	O

The	O
mutation	O
c	B-VARIANT
.	I-VARIANT
257C	I-VARIANT
>	I-VARIANT
G	I-VARIANT
located	O
within	O
exon	O
3	O
in	O
the	O
N	O
-	O
terminal	O
region	O
of	O
TECTA	B-GENE
,	O
upstream	O
from	O
the	O
ENT	O
-	O
like	O
domain	O
,	O
resulted	O
in	O
a	O
single	O
amino	O
acid	O
substitution	O
:	O
serine	O
to	O
cysteine	O
.	O

For	O
the	O
p	B-VARIANT
.	I-VARIANT
E2496E	I-VARIANT
mutation	O
,	O
an	O
evident	O
increase	O
of	O
band	O
b	O
(	O
corresponding	O
to	O
the	O
aberrant	O
transcript	O
that	O
only	O
contains	O
37pb	O
of	O
the	O
exon	O
40	O
)	O
can	O
be	O
observed	O
with	O
regard	O
to	O
the	O
WT	O
minigene	O
expression	O
product	O
.	O

Then	O
G	O
-	O
actin	O
was	O
homogenized	O
into	O
F	O
-	O
actin	O
in	O
buffer	O
A	O
containing	O
50	O
mM	O
KCL	O
and	O
2	O
mM	O
MgCl	O
2	O
at	O
4	O
deg	O
C	O
.	O

The	O
shared	O
variants	O
of	O
three	O
affected	O
individuals	O
after	O
filtering	O
were	O
PCR	O
amplified	O
and	O
analyzed	O
on	O
an	O
automated	O
sequencer	O
(	O
ABI	O
3730	O
Applied	O
Biosystems	O
)	O
.	O

Advances	O
in	O
molecular	O
genetics	O
,	O
including	O
the	O
discovery	O
of	O
the	O
COL4A	O
family	O
of	O
genes	O
,	O
have	O
led	O
to	O
the	O
use	O
of	O
genetic	O
testing	O
in	O
confirming	O
a	O
diagnosis	O
of	O
AS	B-DISEASE
.	O

In	O
vitro	O
functional	O
analysis	O
of	O
the	O
identified	O
NLRP3	B-GENE
mosaic	O
mutations	O
.	O

Mendelian	O
inheritance	O
errors	O
were	O
identified	O
and	O
removed	O
with	O
linkdatagen	O
,	O
and	O
MERLIN	O
was	O
used	O
to	O
remove	O
genotyping	O
errors	O
identified	O
based	O
on	O
the	O
inferred	O
unlikely	O
double	O
recombination	O
events	O
between	O
tightly	O
linked	O
markers	O
[	O
17	O
]	O
.	O

By	O
sequencing	O
exons	O
8	O
,	O
10	O
,	O
and	O
19	O
of	O
SLC26A4	B-GENE
in	O
2352	O
patients	O
,	O
we	O
identified	O
342	O
patients	O
with	O
mutations	O
or	O
variants	O
,	O
of	O
which	O
116	O
were	O
homozygotes	O
and	O
226	O
were	O
heterozygotes	O
.	O

At	O
this	O
frequency	O
,	O
the	O
electric	O
signal	O
of	O
control	O
flies	O
closely	O
follows	O
all	O
light	O
pulses	O
,	O
while	O
dCib2	O
RNAi	O
flies	O
skip	O
the	O
majority	O
of	O
pulses	O
and	O
show	O
only	O
a	O
very	O
weak	O
response	O
to	O
a	O
few	O
pulses	O
.	O

The	O
authors	O
thank	O
the	O
participating	O
individuals	O
for	O
their	O
cooperation	O
and	O
their	O
efforts	O
in	O
collecting	O
the	O
genetic	O
information	O
and	O
DNA	O
specimens	O
.	O

We	O
identified	O
a	O
glycine	O
substitution	O
mutation	O
(	O
c	B-VARIANT
.	I-VARIANT

The	O
proteins	O
encoded	O
,	O
also	O
known	O
as	O
usherins	O
,	O
are	O
multidomain	O
proteins	O
.	O

A	O
similar	O
analysis	O
of	O
the	O
four	O
patients	O
in	O
MOL0125	O
did	O
not	O
reveal	O
any	O
large	O
homozygous	O
regions	O
.	O

Eighty	O
-	O
five	O
unrelated	O
hearing	B-DISEASE
impaired	I-DISEASE
Roma	O
patients	O
,	O
irrespective	O
of	O
their	O
GJB2	B-GENE
status	O
,	O
were	O
analyzed	O
for	O
the	O
presence	O
of	O
the	O
identified	O
c	B-VARIANT
.	I-VARIANT
1331	I-VARIANT
+	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
mutation	O
in	O
MARVELD2	B-GENE
gene	O
.	O

In	O
addition	O
to	O
the	O
6	O
recurrent	O
GJB2	B-GENE
mutations	O
,	O
a	O
novel	O
homozygous	O
change	O
c	B-VARIANT
.	I-VARIANT
598G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Gly200Arg	I-VARIANT
)	O
was	O
found	O
in	O
one	O
consanguineous	O
family	O
DFR10	O
(	O
Table	O
2	O
)	O
;	O
as	O
predicted	O
by	O
the	O
HOPE	O
server	O
the	O
larger	O
side	O
chain	O
of	O
the	O
mutant	O
residue	O
arginine	O
might	O
well	O
affect	O
the	O
proper	O
folding	O
of	O
the	O
cysteine	O
rich	O
domain	O
.	O

The	O
most	O
frequently	O
identified	O
mutation	O
of	O
KCNJ10	B-GENE
in	O
this	O
study	O
was	O
c	B-VARIANT
.	I-VARIANT
812G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
R271H	I-VARIANT
)	O
.	O

C	O
)	O
Amino	O
acid	O
sequence	O
conservation	O
of	O
p	O
.	O
Val33	O
across	O
7	O
species	O
.	O

Model	O
of	O
PRS	B-GENE
-	I-GENE
I	I-GENE
with	O
p	B-VARIANT
.	I-VARIANT
Ser16Pro	I-VARIANT
based	O
on	O
the	O
crystal	O
structure	O
of	O
human	O
PRS	B-GENE
-	I-GENE
I	I-GENE
(	O
PDB	O
:	O
2H06	O
)	O
and	O
close	O
-	O
up	O
of	O
the	O
mutation	O
showing	O
the	O
loss	O
of	O
a	O
hydrogen	O
bound	O
with	O
residue	O
Gln13	O
.	O

There	O
are	O
also	O
anecdotal	O
reports	O
of	O
skull	O
defects	O
,	O
vertebral	B-DISEASE
anomalies	I-DISEASE
,	O
radial	O
aplasia	O
,	O
eye	O
anomalies	O
or	O
cardiac	O
malformation	O
(	O
see	O
online	O
supplementary	O
table	O
S1	O
)	O
.	O

We	O
thank	O
the	O
participants	O
of	O
the	O
Deafness	O
Gene	O
Study	O
Consortium	O
:	O
Drs	O
.	O

There	O
is	O
usually	O
a	O
low	O
number	O
(	O
1	O
-	O
40	O
)	O
of	O
such	O
variants	O
,	O
even	O
in	O
individuals	O
from	O
consanguineous	O
families	O
.	O

There	O
was	O
no	O
family	O
history	O
of	O
deafness	B-DISEASE
;	I-DISEASE
however	O
,	O
subsequent	O
auditory	O
assessment	O
in	O
the	O
index	O
case	O
revealed	O
mild	O
left	O
-	O
sided	O
presbyacusis	B-DISEASE
with	O
more	O
marked	O
hearing	B-DISEASE
loss	I-DISEASE
down	O
to	O
60	O
dB	O
on	O
the	O
right	O
.	O

Variations	O
identified	O
in	O
CLDN14	B-GENE
showed	O
8	O
single	O
nucleotide	O
variations	O
in	O
48	O
unrelated	O
Korean	O
patients	O
(	O
Table	O
2	O
)	O
.	O

+	O
Primers	O
were	O
designed	O
and	O
synthesized	O
herein	O
(	O
Methods	O
)	O
.	O

In	O
addition	O
,	O
co	O
-	O
segregation	O
analyses	O
of	O
the	O
novel	O
missense	O
variants	O
were	O
performed	O
in	O
all	O
families	O
where	O
samples	O
from	O
relatives	O
were	O
available	O
.	O

The	O
1000	O
Genomes	O
Project	O
,	O
Exome	O
Variant	O
Server	O
,	O
and	O
the	O
ExAC	O
Browser	O
were	O
searched	O
in	O
order	O
to	O
determine	O
whether	O
the	O
variants	O
were	O
previously	O
reported	O
.	O

Results	O
from	O
four	O
non	O
-	O
synonymous	O
SNV	O
effects	O
prediction	O
programs	O
,	O
from	O
left	O
to	O
right	O
:	O
PolyPhen2	O
,	O
SIFT	O
,	O
LRT	O
,	O
MutationTaster	O
.	O

We	O
also	O
observed	O
in	O
individual	O
patients	O
that	O
febrile	O
infections	O
and	O
general	B-DISEASE
anesthesia	I-DISEASE
may	O
induce	O
acute	B-DISEASE
neurologic	I-DISEASE
deterioration	I-DISEASE
in	O
Wolfram	B-DISEASE
syndrome	I-DISEASE
,	O
indicating	O
that	O
these	O
conditions	O
may	O
constitute	O
an	O
additional	O
source	O
of	O
ER	O
stress	O
enhancement	O
.	O

Summary	O
of	O
OPA1	B-GENE
mutations	O
and	O
molecular	O
profile	O
identified	O
in	O
patients	O
with	O
DOA	O
+	O
phenotypes	O
a	O
For	O
DOA	O
+	O
patients	O
where	O
muscle	O
biopsies	O
were	O
available	O
for	O
histochemical	O
and	O
molecular	O
analysis	O
(	O
n	O
=	O
28	O
)	O
.	O

Whereas	O
there	O
are	O
numerous	O
reports	O
describing	O
the	O
features	O
of	O
WFS	B-DISEASE
based	O
on	O
retrospective	O
observations	O
,	O
the	O
use	O
of	O
different	O
diagnostic	O
criteria	O
and	O
a	O
different	O
focus	O
on	O
clinical	O
details	O
of	O
this	O
syndrome	O
complicate	O
determination	O
of	O
the	O
natural	O
history	O
of	O
WFS	B-DISEASE
[	O
6	O
]	O
,	O
[	O
16	O
]	O
,	O
[	O
17	O
]	O
,	O
[	O
18	O
]	O
,	O
[	O
19	O
]	O
,	O
[	O
20	O
]	O
.	O

This	O
is	O
the	O
first	O
report	O
to	O
describe	O
mutation	O
analysis	O
of	O
the	O
complete	O
coding	O
sequence	O
of	O
USH2A	B-GENE
in	O
the	O
Chinese	O
population	O
.	O

This	O
study	O
is	O
a	O
comprehensive	O
clinical	O
and	O
genetic	O
analysis	O
of	O
172	O
Usher	B-DISEASE
patients	O
and	O
evaluates	O
the	O
contribution	O
of	O
digenic	O
inheritance	O
.	O

*	O
Marker	O
order	O
was	O
established	O
using	O
the	O
sequence	O
map	O
from	O
the	O
UCSC	O
Genome	O
Bioinformatics	O
site	O
.	O

Funding	O
:	O
This	O
work	O
was	O
supported	O
by	O
PI07	O
/	O
0558	O
,	O
PI08	O
/	O
90311	O
and	O
PI10	O
/	O
01825	O
,	O
from	O
the	O
Spanish	O
Ministry	O
of	O
Science	O
and	O
Innovation	O
and	O
GVPRE	O
/	O
2008	O
/	O
024	O
from	O
the	O
Conselleria	O
de	O
Sanitat	O
de	O
la	O
Comunitat	O
Valenciana	O
.	O

Truncation	O
at	O
residue	O
357	O
would	O
eliminate	O
the	O
active	O
site	O
at	O
serine	O
401	O
and	O
much	O
of	O
the	O
domain	O
,	O
abrogating	O
TMPRSS3	B-GENE
serine	O
protease	O
activity	O
.	O

The	O
other	O
known	O
mutation	O
is	O
a	O
2	O
bp	O
deletion	O
,	O
c	B-VARIANT
.	I-VARIANT
1639_1640delAG	I-VARIANT
(	O
patient	O
TCS	B-DISEASE
4	O
)	O
,	O
localized	O
in	O
exon	O
10	O
(	O
Figure	O
1C	O
)	O
[	O
8	O
,	O
13	O
]	O
.	O

Each	O
circle	O
represents	O
one	O
measurement	O
and	O
the	O
line	O
indicates	O
the	O
mean	O
of	O
the	O
response	O
.	O

Wolfram	B-DISEASE
Syndrome	I-DISEASE
(	O
WS	B-DISEASE
)	O
is	O
an	O
autosomal	O
recessive	O
neurodegenerative	B-DISEASE
disorder	I-DISEASE
characterized	O
by	O
Diabetes	B-DISEASE
Insipidus	I-DISEASE
,	O
Diabetes	B-DISEASE
Mellitus	I-DISEASE
,	O
Optic	B-DISEASE
Atrophy	I-DISEASE
,	O
and	O
Deafness	B-DISEASE
identified	O
by	O
the	O
acronym	O
"	O
DIDMOAD	B-DISEASE
"	O
.	O

The	O
authors	O
are	O
grateful	O
to	O
the	O
families	O
for	O
their	O
collaboration	O
in	O
this	O
study	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
L555V	I-VARIANT
mutation	O
in	O
USH2A	B-GENE
has	O
been	O
found	O
in	O
homozygous	O
state	O
in	O
one	O
Spanish	O
patient	O
,	O
together	O
with	O
a	O
biallelic	O
splice	O
site	O
variant	O
(	O
c	B-VARIANT
.	I-VARIANT
1841	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
)	O
[	O
26	O
]	O
.	O

To	O
identify	O
additional	O
mutations	O
,	O
we	O
sequenced	O
all	O
exons	O
,	O
exon	O
-	O
intron	O
boundaries	O
and	O
3	O
'	O
and	O
5	O
'	O
untranslated	O
repeat	O
of	O
POLR1C	B-GENE
(	O
see	O
Supplementary	O
Table	O
3	O
for	O
primers	O
)	O
in	O
16	O
other	O
individuals	O
selected	O
on	O
the	O
basis	O
of	O
clinical	O
(	O
compatible	O
neurological	O
features	O
with	O
at	O
least	O
one	O
non	O
-	O
neurological	O
feature	O
such	O
as	O
dental	B-DISEASE
abnormalities	I-DISEASE
or	O
hypogonadotropic	B-DISEASE
hypogonadism	I-DISEASE
,	O
together	O
with	O
hypomyelination	B-DISEASE
on	O
MRI	O
)	O
and	O
/	O
or	O
radiological	O
characteristics	O
(	O
typical	O
MRI	O
features	O
of	O
4H	B-DISEASE
leukodystrophy	I-DISEASE
)	O
3	O
10	O
11	O
but	O
negative	O
for	O
POLR3A	B-GENE
and	O
POLR3B	B-GENE
mutations	O
and	O
uncovered	O
five	O
additional	O
compound	O
heterozygous	O
or	O
homozygous	O
cases	O
(	O
Supplementary	O
Table	O
2	O
,	O
Fig	O
.	O

WHISP	O
(	O
Women	O
'	O
s	O
Health	O
Initiative	O
Exome	O
Sequencing	O
Project	O
,	O
part	O
of	O
the	O
Women	O
'	O
s	O
Health	O
Initiative	O
(	O
WHI	O
)	O
)	O
data	O
for	O
614	O
samples	O
were	O
downloaded	O
from	O
dbGaP	O
(	O
dbGaP	O
Study	O
Accession	O
:	O
phs000281	O
.	O
v4	O
.	O
p2	O
)	O
,	O
verified	O
for	O
file	O
integrity	O
,	O
and	O
then	O
imported	O
as	O
BAM	O
files	O
into	O
our	O
data	O
warehouse	O
.	O

No	O
signal	O
was	O
detected	O
in	O
empty	O
vector	O
transfected	O
cells	O
,	O
showing	O
that	O
the	O
endogenous	O
CD164	B-GENE
was	O
expressed	O
at	O
a	O
low	O
level	O
compared	O
to	O
the	O
exogenous	O
CD164	B-GENE
in	O
these	O
experiments	O
.	O

Two	O
patients	O
also	O
had	O
macular	O
involvement	O
.	O

N	O
.	O
I	O
.	O
W	O
.	O

Two	O
Czech	O
families	O
are	O
from	O
the	O
Northwest	O
region	O
(	O
U	O
st	O
i	O
nad	O
Labem	O
)	O
and	O
one	O
from	O
South	O
Bohemia	O
(	O
C	O
esk	O
e	O
Bud	O
e	O
jovice	O
)	O
.	O

Further	O
analysis	O
of	O
OPA1	B-GENE
in	O
individuals	O
with	O
mild	O
visual	O
impairment	O
and	O
temporal	O
disc	O
pallor	O
may	O
be	O
helpful	O
in	O
disclosing	O
the	O
real	O
frequency	O
of	O
DOA	B-DISEASE
in	O
Chinese	O
.	O

It	O
has	O
been	O
recognized	O
that	O
diabetes	B-DISEASE
mellitus	I-DISEASE
is	O
a	O
hallmark	O
manifestation	O
and	O
usually	O
appears	O
earliest	O
among	O
the	O
components	O
of	O
WFS	B-DISEASE
.	O

This	O
was	O
later	O
updated	O
to	O
49	O
mutations	O
(	O
Balduini	O
et	O
al	O
.	O

A	O
genetic	O
cause	O
has	O
been	O
reported	O
in	O
around	O
30	O
%	O
of	O
HH	B-DISEASE
cases	O
,	O
with	O
most	O
gene	O
mutations	O
identified	O
in	O
association	O
with	O
Kallmann	B-DISEASE
syndrome	I-DISEASE
(	O
KS	B-DISEASE
)	O
that	O
includes	O
HH	B-DISEASE
,	O
hyposmia	B-DISEASE
or	O
anosmia	B-DISEASE
and	O
frequently	O
other	O
malformations	O
.	O

The	O
geometric	O
mean	O
of	O
three	O
genes	O
(	O
ACTB	O
,	O
HTRP	O
and	O
TBP	O
)	O
was	O
used	O
to	O
normalize	O
for	O
cDNA	O
content	O
.	O

NMD	O
was	O
also	O
inhibited	O
in	O
a	O
normal	O
cell	O
line	O
as	O
a	O
control	O
.	O

The	O
constructed	O
model	O
covered	O
the	O
target	O
sequence	O
of	O
myosin	B-GENE
VIIa	I-GENE
(	O
residues	O
3	O
-	O
769	O
)	O
.	O

C	O
:	O
Normal	O
sequence	O
.	O

The	O
Altaians	O
are	O
the	O
indigenous	O
Asian	O
population	O
of	O
the	O
Altai	O
Mountain	O
region	O
considered	O
as	O
a	O
melting	O
-	O
pot	O
and	O
a	O
dispersion	O
center	O
for	O
world	O
-	O
wide	O
human	O
expansions	O
in	O
the	O
past	O
.	O

We	O
thank	O
Dr	O
.	O

Somatic	O
mutations	O
in	O
this	O
tumor	B-DISEASE
suppressor	O
are	O
found	O
in	O
a	O
wide	O
range	O
of	O
tumors	B-DISEASE
,	O
and	O
germline	O
mutations	O
can	O
cause	O
Li	B-DISEASE
-	I-DISEASE
Fraumeni	I-DISEASE
syndrome	I-DISEASE
,	O
a	O
condition	O
leading	O
to	O
a	O
high	O
,	O
early	O
-	O
onset	O
risk	O
of	O
multiple	O
types	O
of	O
cancer	B-DISEASE
.	O

The	O
mutations	O
in	O
kindred	O
L148	O
.	O

It	O
is	O
apparent	O
that	O
over	O
-	O
expression	O
of	O
all	O
chains	O
induces	O
XBP1	O
splicing	O
,	O
as	O
evidenced	O
by	O
the	O
appearance	O
of	O
the	O
spliced	O
band	O
(	O
s	O
)	O
when	O
the	O
PCR	O
product	O
is	O
cut	O
with	O
the	O
restriction	O
enzyme	O
Pst1	O
.	O

49	O
Apart	O
from	O
the	O
variants	O
described	O
above	O
and	O
reported	O
in	O
Table	O
2	O
,	O
a	O
number	O
of	O
synonymous	O
(	O
i	O
.	O
e	O
.	O

The	O
former	O
one	O
,	O
c	B-VARIANT
.	I-VARIANT
1343	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
refers	O
to	O
a	O
G	O
to	O
A	O
substitution	O
at	O
the	O
first	O
nucleotide	O
of	O
the	O
intron	O
12	O
,	O
the	O
absolutely	O
conserved	O
donor	O
splice	O
site	O
,	O
which	O
is	O
right	O
adjacent	O
to	O
the	O
coding	O
nucleotide	O
numbered	O
as	O
c	O
.	O
1343	O
,	O
the	O
last	O
nucleotide	O
of	O
exon	O
12	O
.	O

Haplotype	O
analysis	O
of	O
the	O
c	B-VARIANT
.	I-VARIANT
1331	I-VARIANT
+	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
mutation	O
supports	O
the	O
hypothesis	O
of	O
a	O
common	O
ancestry	O
for	O
Slovak	O
,	O
Czech	O
and	O
Hungarian	O
Roma	O
patients	O
,	O
as	O
well	O
as	O
a	O
common	O
origin	O
of	O
the	O
mutation	O
in	O
Roma	O
and	O
Pakistani	O
patients	O
.	O

Electronystagmography	O
with	O
a	O
bithermal	O
caloric	O
test	O
demonstrated	O
non	O
specific	O
finding	O
.	O

Computerized	O
tomography	O
studies	O
in	O
patients	O
with	O
DFNX2	B-GENE
showed	O
abnormal	O
dilatation	O
of	O
the	O
internal	O
acoustic	O
canal	O
and	O
abnormal	O
communication	O
between	O
the	O
internal	O
acoustic	O
canal	O
and	O
inner	O
ear	O
compartments	O
.	O

PSPS1	B-GENE
is	O
mutated	O
in	O
females	O
with	O
syndromic	B-DISEASE
retinitis	I-DISEASE
pigmentosa	I-DISEASE
from	O
a	O
three	O
-	O
generation	O
family	O
.	O

GJB2	B-GENE
,	O
SLC26A4	B-GENE
and	O
mitochondrial	B-GENE
DNA	I-GENE
(	I-GENE
mtDNA	I-GENE
)	I-GENE
12S	I-GENE
rRNA	I-GENE
are	O
thought	O
to	O
be	O
the	O
most	O
common	O
causes	O
of	O
nonsyndromic	B-DISEASE
autosomal	I-DISEASE
recessive	I-DISEASE
deafness	I-DISEASE
in	O
Asian	O
people	O
.	O

The	O
authors	O
thank	O
all	O
referring	O
physicians	O
for	O
their	O
cooperation	O
in	O
this	O
study	O
.	O

While	O
both	O
proteins	O
are	O
potentially	O
interacting	O
partners	O
for	O
HOMER2	B-GENE
,	O
to	O
date	O
only	O
an	O
interaction	O
with	O
TRPC1	B-GENE
(	O
MIM	O
602343	O
)	O
has	O
been	O
established	O
[	O
13	O
]	O
.	O

Four	O
probands	O
with	O
auditory	B-DISEASE
neuropathy	I-DISEASE
were	O
also	O
included	O
in	O
this	O
study	O
group	O
:	O
three	O
had	O
no	O
known	O
additional	O
relevant	O
phenotypic	O
findings	O
;	O
one	O
had	O
brachycephaly	O
,	O
asymmetric	O
facies	O
and	O
cupped	O
ears	O
.	O

Cataract	B-DISEASE
diagnosis	O
was	O
established	O
as	O
the	O
presence	O
of	O
lens	O
opaque	O
spots	O
at	O
ophthalmological	O
examination	O
.	O

These	O
regions	O
were	O
analyzed	O
with	O
the	O
conventional	O
Sanger	O
sequencing	O
method	O
for	O
patient	O
3	O
,	O
since	O
we	O
couldn	O
'	O
t	O
confirm	O
a	O
causal	O
mutation	O
in	O
this	O
patient	O
.	O

As	O
a	O
result	O
,	O
E193	O
causes	O
dilated	O
cardiomyopathy	B-DISEASE
,	O
unlike	O
the	O
other	O
mutations	O
[	O
9	O
]	O
.	O

Family	O
PKDF536	O
.	O

In	O
conclusion	O
,	O
there	O
is	O
considerable	O
genetic	O
and	O
allelic	O
heterogeneity	O
that	O
accounts	O
for	O
recessively	O
inherited	O
deafness	B-DISEASE
in	O
Pakistan	O
(	O
Table	O
2	O
)	O
.	O

Systematic	O
population	O
-	O
wide	O
genomic	O
analysis	O
may	O
be	O
the	O
most	O
effective	O
way	O
to	O
identify	O
all	O
critical	O
genes	O
and	O
alleles	O
for	O
heterogeneous	O
phenotypes	O
in	O
communities	O
with	O
many	O
small	O
isolates	O
.	O

PCR	O
primers	O
covered	O
nucleotides	O
8	O
,	O
225	O
-	O
8	O
,	O
247	O
(	O
forward	O
)	O
and	O
13	O
,	O
707	O
-	O
13	O
,	O
729	O
(	O
reverse	O
)	O
of	O
the	O
revised	O
Cambridge	O
reference	O
sequence	O
(	O
NC_012920	O
.	O
1	O
)	O
.	O

2006	O
,	O
2011	O
;	O
Baux	O
et	O
al	O
.	O

Chromosome	O
position	O
is	O
reported	O
in	O
the	O
x	O
-	O
axis	O
while	O
LOD	O
score	O
is	O
indicated	O
in	O
the	O
y	O
-	O
axis	O
.	O

Primers	O
and	O
Sanger	O
sequencing	O
tracks	O
are	O
available	O
upon	O
request	O
.	O

We	O
screened	O
17	O
Japanese	O
USH1	B-DISEASE
patients	O
(	O
aged	O
9	O
to	O
64	O
years	O
)	O
:	O
three	O
from	O
autosomal	O
recessive	O
families	O
(	O
non	O
-	O
affected	O
parents	O
and	O
two	O
or	O
more	O
affected	O
siblings	O
)	O
,	O
and	O
14	O
from	O
sporadic	O
families	O
.	O

We	O
describe	O
their	O
clinical	O
presentation	O
,	O
associated	O
malformations	O
and	O
the	O
plasma	O
inhibin	O
B	O
and	O
antim	O
u	O
llerian	O
hormone	O
(	O
AMH	O
)	O
concentrations	O
,	O
and	O
compared	O
them	O
to	O
the	O
genetic	O
analyses	O
.	O

Sequence	O
reactions	O
were	O
completed	O
with	O
a	O
5	O
x	O
sequencing	O
buffer	O
and	O
BigDye	O
Terminator	O
(	O
Applied	O
Biosystems	O
,	O
Life	O
Technologies	O
)	O
.	O

Pu	O
Dai	O
,	O
Yongyi	O
Yuan	O
and	O
Deliang	O
Huang	O
carried	O
out	O
the	O
molecular	O
genetic	O
studies	O
,	O
participated	O
in	O
the	O
sequence	O
alignment	O
and	O
drafted	O
the	O
manuscript	O
.	O

In	O
PSACH	B-DISEASE
patient	O
ESDN	O
-	O
01040	O
,	O
we	O
identified	O
a	O
heterozygous	O
c	B-VARIANT
.	I-VARIANT
700C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
,	O
which	O
resulted	O
in	O
a	O
p	B-VARIANT
.	I-VARIANT
Pro234Ser	I-VARIANT
substitution	O
in	O
the	O
fourth	O
EGF	O
-	O
like	O
repeat	O
of	O
COMP	B-GENE
;	O
both	O
of	O
these	O
unclassified	O
variants	O
had	O
not	O
previously	O
been	O
reported	O
and	O
were	O
not	O
present	O
in	O
the	O
dbSNP	O
database	O
version	O
130	O
(	O
May	O
2009	O
)	O
.	O

In	O
addition	O
,	O
about	O
a	O
quarter	O
of	O
the	O
mutations	O
are	O
located	O
in	O
the	O
intronic	O
regions	O
adjacent	O
to	O
exon	O
-	O
intron	O
boundaries	O
,	O
which	O
usually	O
affect	O
splicing	O
[	O
20	O
]	O
.	O

Of	O
these	O
DNA	O
sequence	O
variations	O
,	O
14	O
were	O
understood	O
to	O
be	O
novel	O
at	O
the	O
time	O
this	O
manuscript	O
was	O
written	O
.	O

Although	O
34	O
%	O
of	O
the	O
males	O
in	O
this	O
series	O
had	O
undergone	O
surgery	O
for	O
bilateral	O
cryptorchidism	B-DISEASE
during	O
childhood	O
,	O
only	O
34	O
%	O
of	O
these	O
were	O
referred	O
for	O
a	O
pediatric	O
endocrine	O
investigation	O
.	O

Note	O
affected	O
individuals	O
have	O
only	O
528	O
bp	O
fragment	O
due	O
to	O
loss	O
of	O
the	O
Eco72I	O
site	O
,	O
the	O
normal	O
sibling	O
has	O
345	O
and	O
183	O
bp	O
fragments	O
,	O
and	O
both	O
carrier	O
parents	O
have	O
all	O
the	O
three	O
fragments	O
.	O

In	O
brief	O
,	O
targeted	O
exome	O
sequencing	O
of	O
the	O
144	O
known	O
genes	O
is	O
sufficient	O
and	O
clinically	O
utilizable	O
to	O
comprehensively	O
reveal	O
genetic	O
defects	O
in	O
patients	O
with	O
genetic	O
retinal	O
disease	O
.	O

Hereditary	B-DISEASE
cardiomyopathies	I-DISEASE
are	O
primary	B-DISEASE
myocardial	I-DISEASE
diseases	I-DISEASE
that	O
typically	O
manifest	O
with	O
ventricular	B-DISEASE
dilatation	I-DISEASE
,	O
hypertrophy	B-DISEASE
,	O
and	O
dysfunction	B-DISEASE
.	O

The	O
PC	B-GENE
gene	O
encodes	O
the	O
enzyme	O
pyruvate	O
carboxylase	O
,	O
which	O
is	O
a	O
mitochondrial	O
enzyme	O
involved	O
in	O
gluconeogenesis	O
,	O
lipogenesis	O
,	O
insulin	O
secretion	O
,	O
and	O
synthesis	O
of	O
the	O
neurotransmitter	O
glutamate	O
.	O

The	O
multistep	O
analysis	O
described	O
by	O
Baux	O
et	O
al	O
.	O

The	O
SANS	O
protein	O
contains	O
three	O
ankyrin	O
domains	O
at	O
the	O
N	O
-	O
terminal	O
end	O
(	O
amino	O
acids	O
31	O
-	O
129	O
)	O
and	O
a	O
PDZ	O
-	O
binding	O
motif	O
at	O
the	O
C	O
-	O
terminal	O
end	O
.	O

In	O
older	O
patients	O
,	O
the	O
ONL	O
showed	O
thinning	O
also	O
in	O
the	O
foveal	O
area	O
and	O
cystoid	O
macular	O
edema	O
was	O
evident	O
in	O
some	O
cases	O
(	O
Fig	O
.	O

When	O
pedigrees	O
were	O
available	O
,	O
the	O
use	O
of	O
an	O
automated	O
and	O
robust	O
SNP	O
-	O
based	O
genotyping	O
microarray	O
greatly	O
diminished	O
the	O
number	O
of	O
candidates	O
.	O

,	O
1985	O
;	O
Payne	O
et	O
al	O
.	O

Filamentous	O
actin	O
was	O
detected	O
with	O
rhodamine	O
phalloidin	O
(	O
Life	O
Technologies	O
)	O
in	O
PBS	O
/	O
0	O
.	O
1	O
%	O
Triton	O
-	O
X100	O
for	O
one	O
hour	O
.	O

Myosin	B-GENE
VIIA	I-GENE
has	O
been	O
implicated	O
in	O
Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
1B	I-DISEASE
,	O
atypical	B-DISEASE
Usher	I-DISEASE
syndrome	I-DISEASE
,	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
autosomal	I-DISEASE
recessive	I-DISEASE
hearing	I-DISEASE
impairment	I-DISEASE
(	O
DFNB2	B-DISEASE
)	O
and	B-DISEASE
autosomal	I-DISEASE
dominant	I-DISEASE
hearing	I-DISEASE
impairment	I-DISEASE
(	O
DFNA11	B-DISEASE
)	O
[	O
4	O
]	O
,	O
[	O
5	O
]	O
,	O
[	O
6	O
]	O
,	O
[	O
7	O
]	O
,	O
[	O
8	O
]	O
.	O

Three	O
prevalent	O
deafness	B-DISEASE
-	I-DISEASE
associated	I-DISEASE
genes	O
,	O
GJB2	B-GENE
,	O
SLC26A4	B-GENE
,	O
and	O
mtDNA	B-GENE
12SrRNA	I-GENE
,	O
were	O
first	O
screened	O
for	O
mutations	O
in	O
all	O
participating	O
family	O
members	O
.	O

Then	O
we	O
compared	O
these	O
variants	O
in	O
two	O
affected	O
members	O
with	O
the	O
dbSNP135	O
,	O
HapMap	O
project	O
,	O
1000	O
Genome	O
Project	O
,	O
and	O
YH	O
database	O
.	O

The	O
subjects	O
with	O
de	O
novo	O
activating	O
CACNA1D	B-GENE
mutations	O
represent	O
a	O
previously	O
undescribed	O
Mendelian	O
syndrome	O
featuring	O
primary	O
aldosteronism	B-DISEASE
.	O

This	O
will	O
provide	O
more	O
precise	O
genotype	O
-	O
phenotype	O
correlations	O
.	O

No	O
de	O
novo	O
mutations	O
were	O
detected	O
in	O
patients	O
,	O
as	O
every	O
parent	O
of	O
patients	O
carrying	O
bi	O
-	O
allelic	O
GJB2	B-GENE
/	O
GJB6	B-GENE
mutations	O
was	O
heterozygous	O
for	O
one	O
of	O
the	O
mutations	O
.	O

An	O
electrode	O
placed	O
on	O
the	O
forehead	O
provided	O
a	O
ground	O
.	O

Screening	O
of	O
143	O
unrelated	O
hearing	B-DISEASE
impaired	I-DISEASE
Roma	O
individuals	O
from	O
Slovakia	O
detected	O
the	O
c	B-VARIANT
.	I-VARIANT
1331	I-VARIANT
+	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
mutation	O
in	O
a	O
homozygous	O
state	O
in	O
five	O
(	O
3	O
.	O
5	O
%	O
)	O
and	O
in	O
a	O
heterozygous	O
state	O
in	O
one	O
affected	O
individual	O
.	O

Five	O
families	O
were	O
attributed	O
to	O
USH2A	B-GENE
and	O
1	O
family	O
to	O
USH1B	B-GENE
locus	O
.	O

Note	O
hyeprfluorescent	O
rings	O
around	O
the	O
foveas	O
in	O
the	O
younger	O
patients	O
,	O
and	O
hypofluorescent	O
areas	O
of	O
atrophy	O
that	O
encroach	O
upon	O
the	O
macula	O
in	O
the	O
33	O
year	O
-	O
old	O
patient	O
and	O
invade	O
the	O
macula	O
in	O
the	O
72	O
year	O
-	O
old	O
.	O

To	O
give	O
priority	O
to	O
identification	O
of	O
the	O
deleterious	O
mutations	O
,	O
we	O
adopted	O
a	O
series	O
of	O
filtering	O
strategies	O
to	O
focus	O
on	O
non	O
-	O
synonymous	O
variants	O
(	O
missense	O
,	O
nonsense	O
and	O
splice	O
variants	O
)	O
using	O
a	O
combination	O
of	O
filtering	O
against	O
HapMap	O
28	O
,	O
SNP	O
databases	O
and	O
mutiple	O
algorithms	O
(	O
PolyPhen	O
,	O
SIFT	O
,	O
PANTHER	O
and	O
Pmut	O
)	O
.	O

It	O
involves	O
more	O
than	O
100	O
different	O
genes	O
with	O
autosomal	O
dominant	O
(	O
DFNA	O
)	O
,	O
autosomal	O
recessive	O
(	O
DFNB	O
)	O
,	O
X	O
-	O
linked	O
(	O
DFN	O
)	O
,	O
and	O
maternal	O
inheritance	O
[	O
5	O
]	O
,	O
with	O
autosomal	O
recessive	O
being	O
the	O
most	O
common	O
.	O

Nerve	O
conduction	O
studies	O
revealed	O
absent	O
long	O
latency	O
responses	O
in	O
the	O
legs	O
,	O
symmetrically	O
reduced	O
motor	O
conduction	O
velocities	O
in	O
arms	O
and	O
legs	O
with	O
normal	O
amplitudes	O
;	O
needle	O
examination	O
was	O
normal	O
.	O

The	O
reported	O
age	O
of	O
onset	O
and	O
severity	O
of	O
hearing	B-DISEASE
impairment	I-DISEASE
in	O
the	O
present	O
families	O
showed	O
a	O
wide	O
variation	O
.	O

However	O
,	O
his	O
hearing	O
was	O
affected	O
by	O
a	O
slight	O
change	O
of	O
body	O
temperature	O
.	O

An	O
average	O
Cq	O
of	O
27	O
was	O
obtained	O
(	O
Figure	O
1	O
)	O
.	O

These	O
defects	O
are	O
usually	O
missed	O
by	O
standard	O
sequencing	O
methods	O
which	O
are	O
not	O
able	O
to	O
detect	O
large	O
scale	O
deletions	O
as	O
well	O
as	O
variants	O
located	O
within	O
promoter	O
or	O
intronic	O
regions	O
.	O

Although	O
it	O
might	O
be	O
interesting	O
to	O
analyze	O
whether	O
the	O
expected	O
coverage	O
for	O
exon	O
amplicons	O
from	O
multiplex	O
PCRs	O
is	O
more	O
robust	O
than	O
with	O
an	O
enrichment	O
approach	O
,	O
there	O
is	O
a	O
much	O
simpler	O
way	O
to	O
deal	O
with	O
it	O
.	O

Among	O
several	O
polymorphisms	O
,	O
a	O
missense	O
mutation	O
Y669H	B-VARIANT
(	O
2005T	B-VARIANT
>	I-VARIANT
C	I-VARIANT
)	O
in	O
exon	O
8	O
of	O
WFS1	B-GENE
was	O
identified	O
in	O
members	O
of	O
a	O
Taiwanese	O
family	O
diagnosed	O
with	O
LFSNHL	B-DISEASE
but	O
not	O
in	O
any	O
of	O
the	O
control	O
subjects	O
.	O

The	O
relative	O
amount	O
for	O
each	O
transcript	O
was	O
calculated	O
by	O
a	O
standard	O
curve	O
of	O
cycle	O
thresholds	O
for	O
serial	O
dilutions	O
of	O
cDNA	O
samples	O
and	O
normalized	O
to	O
the	O
amount	O
of	O
beta	O
-	O
actin	O
.	O

Consistent	O
with	O
published	O
data	O
,	O
the	O
871Leu	O
-	O
form	O
is	O
the	O
predominant	O
isoform	O
in	O
Africans	O
whereas	O
the	O
Pro	O
-	O
form	O
is	O
more	O
frequent	O
in	O
Europeans	O
.	O

The	O
physical	O
examinations	O
of	O
all	O
members	O
revealed	O
no	O
signs	O
of	O
systemic	O
illness	O
or	O
dysmorphic	O
features	O
.	O

"	O
The	O
remaining	O
variants	O
were	O
classified	O
as	O
"	O
pathogenic	O
.	O

Three	O
of	O
these	O
patients	O
are	O
members	O
of	O
families	O
in	O
which	O
a	O
region	O
of	O
interest	O
has	O
previously	O
been	O
characterized	O
by	O
linkage	O
studies	O
.	O

However	O
,	O
the	O
molecular	O
etiology	O
of	O
most	O
patients	O
with	O
WS2	B-DISEASE
is	O
still	O
unknown	O
[	O
19	O
]	O
.	O

These	O
changes	O
were	O
also	O
analyzed	O
with	O
NNSPLICE	O
and	O
Splice	O
View	O
,	O
but	O
neither	O
was	O
found	O
to	O
affect	O
,	O
create	O
,	O
or	O
eliminate	O
any	O
donor	O
or	O
acceptor	O
splice	O
site	O
.	O

The	O
scale	O
bar	O
in	O
G	O
is	O
100	O
mu	O
m	O
and	O
applies	O
to	O
D	O
-	O
G	O
.	O

In	O
contrast	O
,	O
p	B-VARIANT
.	I-VARIANT
T237I	I-VARIANT
in	O
the	O
ENT	O
domain	O
is	O
associated	O
with	O
high	B-DISEASE
-	I-DISEASE
frequency	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
our	O
patient	O
for	O
publication	O
of	O
this	O
case	O
report	O
and	O
any	O
accompanying	O
images	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
performed	O
a	O
mutation	O
screening	O
of	O
the	O
USH1C	B-GENE
gene	O
by	O
direct	O
sequencing	O
in	O
33	O
USH	B-DISEASE
patients	O
.	O

The	O
pathogenicity	O
of	O
the	O
latter	O
was	O
fully	O
supported	O
by	O
in	O
silico	O
predictions	O
(	O
Table	O
2	O
)	O
.	O

Error	O
bars	O
:	O
standard	O
deviation	O
of	O
control	O
samples	O
.	O

To	O
identify	O
inherited	O
recessive	O
and	O
X	O
-	O
linked	O
SNVs	O
and	O
indels	O
,	O
we	O
first	O
merged	O
the	O
VCFs	O
from	O
the	O
three	O
variant	O
callers	O
for	O
each	O
individual	O
,	O
and	O
then	O
we	O
identified	O
genes	O
harboring	O
rare	O
,	O
high	O
-	O
quality	O
,	O
functional	O
variants	O
(	O
predicted	O
protein	O
consequences	O
were	O
essential	O
splice	O
site	O
,	O
stop	O
gained	O
,	O
frameshift	O
coding	O
,	O
non	O
-	O
synonymous	O
,	O
stop	O
lost	O
)	O
under	O
the	O
different	O
plausible	O
modes	O
of	O
inheritance	O
(	O
recessive	O
or	O
X	O
-	O
linked	O
)	O
.	O

USH3	B-DISEASE
is	O
characterized	O
by	O
progressive	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
,	O
and	O
variable	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
;	I-DISEASE
the	O
progressiveness	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
is	O
a	O
distinctive	O
feature	O
of	O
USH1	B-DISEASE
and	O
USH2	B-DISEASE
[	O
13	O
]	O
.	O

b	O
A	O
Polyphen2	O
score	O
is	O
predicted	O
to	O
be	O
"	O
probably	O
damaging	O
"	O
if	O
it	O
is	O
>	O
0	O
.	O
85	O
,	O
"	O
possibly	O
damaging	O
"	O
if	O
between	O
0	O
.	O
85	O
and	O
0	O
.	O
2	O
,	O
and	O
"	O
benign	O
"	O
if	O
<	O
0	O
.	O
2	O
.	O

WFS	B-DISEASE
:	O
Wolfram	B-DISEASE
syndrome	I-DISEASE
;	O
ER	O
:	O
Endoplasmic	O
reticulum	O
;	O
MRI	O
:	O
Magnetic	O
resonance	O
imaging	O
;	O
WASI	O
:	O
Wechsler	O
abbreviated	O
scale	O
of	O
intelligence	O
;	O
UPSIT	O
:	O
University	O
of	O
Pennsylvania	O
smell	O
identification	O
test	O
;	O
IQ	O
:	O
Intelligence	O
quotient	O
The	O
authors	O
report	O
no	O
conflicts	O
of	O
interest	O
.	O

6	O
We	O
modeled	O
a	O
Poisson	O
process	O
consistent	O
with	O
the	O
expected	O
distribution	O
defined	O
by	O
the	O
mutation	O
model	O
and	O
with	O
the	O
observed	O
data	O
.	O

Variants	O
of	O
KCNJ10	B-GENE
have	O
also	O
been	O
considered	O
as	O
a	O
risk	O
factor	O
for	O
seizure	O
susceptibility	O
in	O
genetic	O
association	O
studies	O
[	O
27	O
]	O
and	O
biallelic	O
mutations	O
in	O
KCNJ10	B-GENE
in	O
humans	O
are	O
known	O
to	O
cause	O
a	O
syndromic	O
form	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
EAST	B-DISEASE
syndrome	I-DISEASE
(	O
epilepsy	B-DISEASE
,	O
ataxia	B-DISEASE
,	O
sensorineural	B-DISEASE
deafness	I-DISEASE
and	O
renal	B-DISEASE
tubulopathy	I-DISEASE
)	O
[	O
28	O
]	O
.	O

Variants	O
were	O
consistent	O
with	O
the	O
known	O
pattern	O
of	O
inheritance	O
of	O
the	O
respective	O
gene	O
(	O
i	O
.	O
e	O
.	O
,	O
homozygous	O
/	O
compound	O
heterozygous	O
or	O
heterozygous	O
)	O
.	O

However	O
,	O
unlike	O
these	O
two	O
rare	O
mutations	O
,	O
three	O
other	O
mutations	O
(	O
p	B-VARIANT
.	I-VARIANT
Val85Asp	I-VARIANT
;	I-VARIANT
p	B-VARIANT
.	I-VARIANT
Met133ArgfsX23	I-VARIANT
;	I-VARIANT
p	B-VARIANT
.	I-VARIANT
Ala94Val	I-VARIANT
)	O
account	O
for	O
approximately	O
89	O
%	O
of	O
the	O
CLDN14	B-GENE
alleles	O
we	O
found	O
in	O
our	O
cohort	O
of	O
Pakistani	O
families	O
segregating	O
deafness	B-DISEASE
(	O
Table	O
1	O
)	O
.	O

NA	O
,	O
gene	O
not	O
analyzed	O
by	O
Sanger	O
sequencing	O
;	O
Undef	O
,	O
data	O
not	O
accurate	O
enough	O
to	O
clearly	O
discriminate	O
a	O
clinical	O
subtype	O
.	O

The	O
advantage	O
was	O
that	O
all	O
samples	O
could	O
be	O
simultaneously	O
sequenced	O
and	O
analyzed	O
for	O
variations	O
in	O
these	O
genes	O
at	O
an	O
average	O
read	O
depth	O
of	O
200X	O
thus	O
significantly	O
increasing	O
the	O
efficiency	O
of	O
obtaining	O
sequence	O
data	O
.	O

As	O
shown	O
in	O
Figure	O
2	O
,	O
the	O
number	O
of	O
patients	O
with	O
GSDs	B-DISEASE
reported	O
each	O
year	O
in	O
the	O
CBM	O
database	O
increased	O
gradually	O
since	O
1978	O
and	O
rapidly	O
increased	O
starting	O
in	O
1994	O
.	O

The	O
affected	O
individuals	O
had	O
a	O
total	O
of	O
68	O
missense	O
,	O
10	O
frameshift	O
,	O
3	O
indel	O
,	O
5	O
nonsense	O
,	O
and	O
3	O
splice	O
variants	O
.	O

One	O
novel	O
frameshift	O
mutation	O
was	O
identified	O
,	O
431_450del19	B-VARIANT
(	O
Table	O
1	O
)	O
.	O

It	O
is	O
also	O
only	O
the	O
second	O
study	O
dealing	O
with	O
MARVELD2	B-GENE
mutations	O
in	O
SNHL	B-DISEASE
in	O
Europe	O
,	O
as	O
well	O
as	O
in	O
the	O
Roma	O
population	O
in	O
general	O
.	O

Nucleotide	O
numbering	O
of	O
OPA1	B-GENE
gene	O
mutations	O
reflects	O
cDNA	O
numbering	O
with	O
+	O
1	O
corresponding	O
to	O
the	O
A	O
of	O
the	O
ATG	O
translation	O
initiation	O
codon	O
of	O
the	O
GenBank	O
reference	O
sequence	O
NM_015560	O
.	O
2	O
.	O

We	O
also	O
characterized	O
in	O
detail	O
the	O
variants	O
in	O
five	O
genes	O
of	O
particular	O
clinical	O
interest	O
,	O
BRCA1	B-GENE
,	O
BRCA2	B-GENE
,	O
KRAS	B-GENE
,	O
TP53	B-GENE
,	O
and	O
PTEN	B-GENE
.	O

Of	O
20	O
cases	O
with	O
a	O
suspected	O
skeletal	B-DISEASE
disorder	I-DISEASE
but	O
without	O
a	O
specific	O
diagnosis	O
,	O
four	O
causative	O
mutations	O
were	O
identified	O
.	O

To	O
validate	O
and	O
test	O
the	O
segregation	O
pattern	O
of	O
the	O
prioritized	O
variants	O
,	O
primers	O
were	O
designed	O
to	O
amplify	O
the	O
encompassing	O
genomic	O
region	O
.	O

From	O
that	O
point	O
of	O
view	O
,	O
MPS	O
has	O
the	O
potential	O
power	O
to	O
identify	O
such	O
rare	O
genes	O
/	O
mutations	O
.	O

Indeed	O
,	O
mean	O
disyllable	O
recognition	O
scores	O
as	O
measured	O
in	O
the	O
presence	O
of	O
competing	O
noise	O
at	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
+	O
5	O
,	O
increased	O
from	O
7	O
%	O
in	O
the	O
pre	O
-	O
implant	O
condition	O
to	O
53	O
%	O
as	O
evaluated	O
after	O
1	O
-	O
year	O
'	O
s	O
experience	O
with	O
the	O
cochlear	O
implant	O
.	O

Three	O
micrograms	O
of	O
genomic	O
DNA	O
was	O
fragmented	O
using	O
the	O
Covaris	O
shearing	O
system	O
(	O
Covaris	O
inc	O
.	O
,	O
MA	O
,	O
USA	O
)	O
.	O

The	O
focus	O
of	O
the	O
study	O
was	O
the	O
analysis	O
of	O
variations	O
not	O
described	O
previously	O
,	O
located	O
in	O
the	O
PAX3	B-GENE
and	O
MITF	B-GENE
gene	O
concerning	O
their	O
association	O
with	O
the	O
clinical	O
phenotype	O
of	O
Waardenburg	B-DISEASE
syndrome	I-DISEASE
(	O
WS	B-DISEASE
)	O
types	O
1	O
and	O
2	O
.	O

The	O
final	O
library	O
size	O
was	O
300	O
to	O
400	O
bp	O
,	O
including	O
the	O
adapter	O
sequences	O
.	O

Sequence	O
capture	O
,	O
enrichment	O
,	O
elution	O
,	O
and	O
NGS	O
were	O
conducted	O
in	O
collaboration	O
with	O
the	O
BGI	O
-	O
Shenzhen	O
as	O
previously	O
stated	O
[	O
27	O
]	O
.	O

[	O
28	O
]	O
found	O
two	O
homozygous	O
missense	O
mutations	O
,	O
c	B-VARIANT
.	I-VARIANT
92C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
P31L	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
461T	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
L154W	I-VARIANT
)	O
,	O
in	O
two	O
consanguineous	O
Pakistani	O
families	O
with	O
isolated	O
RP	B-DISEASE
and	O
no	O
audiological	O
symptoms	O
.	O

For	O
statistical	O
significance	O
we	O
used	O
the	O
p	O
value	O
<	O
0	O
.	O
05	O
.	O

(	O
F	O
)	O
Co	O
-	O
occurrence	O
error	O
rate	O
in	O
both	O
strands	O
.	O

Currently	O
,	O
no	O
therapeutic	O
intervention	O
is	O
known	O
to	O
alter	O
the	O
progression	O
or	O
the	O
life	O
expectancy	O
of	O
affected	O
individuals	O
.	O

20	O
,	O
21	O
Three	O
fluorescently	O
labeled	O
microsatellite	O
markers	O
(	O
D21S2078	O
,	O
D21S1252	O
and	O
D21S2080	O
)	O
linked	O
to	O
CLDN14	B-GENE
were	O
PCR	O
-	O
genotyped	O
as	O
described	O
.	O

Mutation	O
of	O
this	O
threonine	O
to	O
a	O
methionine	O
could	O
either	O
interfere	O
with	O
the	O
cleavage	O
of	O
the	O
incorrectly	O
paired	O
aminoacyl	O
-	O
tRNA	O
molecule	O
,	O
or	O
perturb	O
the	O
discrimination	O
of	O
the	O
cognate	O
amino	O
acid	O
,	O
possibly	O
leading	O
to	O
leucine	O
hydrolization	O
from	O
Leu	O
-	O
tRNA	O
Leu	O
.	O

The	O
upper	O
dark	O
dots	O
indicate	O
the	O
wild	O
-	O
type	O
is	O
absent	O
and	O
the	O
green	O
dots	O
below	O
indicate	O
the	O
1555A	B-VARIANT
>	I-VARIANT
G	I-VARIANT
homoplasmic	O
mutation	O
(	O
A	O
)	O
.	O

Therefore	O
,	O
we	O
evaluated	O
the	O
temporal	O
bones	O
of	O
the	O
affected	O
children	O
of	O
Family	O
Y	O
by	O
computed	O
tomography	O
(	O
CT	O
)	O
scan	O
.	O

The	O
encoded	O
protein	O
stimulates	O
adenylyl	O
cyclase	O
(	O
AC	O
)	O
,	O
thereby	O
generating	O
the	O
second	O
messenger	O
cAMP	O
.	O

Tuffery	O
-	O
Giraud	O
and	O
I	O
.	O

Quantification	O
,	O
after	O
normalizing	O
against	O
actin	O
expression	O
,	O
revealed	O
a	O
reduction	O
in	O
expression	O
levels	O
by	O
69	O
%	O
of	O
the	O
mutant	O
Gipc3	B-GENE
(	O
115Arg	O
)	O
protein	O
compared	O
with	O
that	O
for	O
wild	O
-	O
type	O
Gipc3	B-GENE
(	O
115Gly	O
)	O
(	O
Fig	O
.	O

5	O
,	O
31	O
,	O
32	O
Mouse	O
mutants	O
of	O
Cldn14	B-GENE
and	O
Cldn9	O
both	O
display	O
cochlear	O
hair	O
cell	O
loss	O
by	O
the	O
second	O
week	O
of	O
life	O
,	O
which	O
progresses	O
rapidly	O
to	O
include	O
the	O
entire	O
cochlea	O
within	O
the	O
next	O
few	O
weeks	O
.	O

Recombinant	O
vectors	O
were	O
employed	O
for	O
transfection	O
of	O
HEK293T	O
cells	O
that	O
were	O
incubated	O
at	O
37	O
deg	O
C	O
for	O
24	O
hours	O
.	O

Louis	O
,	O
MO	O
,	O
USA	O
;	O
1	O
:	O
400	O
)	O
and	O
Anti	O
-	O
cMYC	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
.	O

RP	B-DISEASE
developed	O
within	O
the	O
first	O
decade	O
of	O
their	O
life	O
.	O

4	O
)	O
.	O

As	O
perchlorate	O
discharge	O
testing	O
is	O
not	O
a	O
general	O
clinical	O
practice	O
in	O
China	O
,	O
it	O
was	O
not	O
used	O
in	O
this	O
study	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
detected	O
two	O
novel	O
pathogenic	O
mutations	O
in	O
the	O
USH1C	B-GENE
gene	O
.	O

F	O
.	O
G	O
.	O

,	O
2005	O
;	O
Starr	O
et	O
al	O
.	O

7	O
)	O
.	O

The	O
pedigree	O
suggested	O
an	O
autosomal	O
dominant	O
mode	O
of	O
inheritance	O
,	O
and	O
thus	O
we	O
assumed	O
an	O
autosomal	O
dominant	O
model	O
with	O
default	O
values	O
of	O
full	O
penetrance	O
(	O
f	O
0	O
,	O
f	O
1	O
,	O
f	O
2	O
)	O
=	O
(	O
0	O
,	O
1	O
,	O
1	O
)	O
and	O
disease	O
allele	O
frequency	O
=	O
1e	O
-	O
05	O
.	O

A	O
molecular	O
model	O
of	O
myosin	B-GENE
XVa	I-GENE
was	O
constructed	O
based	O
on	O
the	O
crystal	O
structure	O
of	O
the	O
talin	O
head	O
FERM	O
domain	O
(	O
PDB	O
ID	O
:	O
3ivf	O
)	O
,	O
a	O
protein	O
domain	O
that	O
binds	O
F	O
-	O
actin	O
in	O
vitro	O
and	O
in	O
vivo	O
at	O
a	O
specific	O
site	O
within	O
the	O
actin	O
filament	O
.	O

C	O
:	O
Dystopia	B-DISEASE
canthorum	I-DISEASE
(	O
W	O
index	O
:	O
1	O
.	O
96	O
)	O
,	O
brilliant	O
blue	O
iris	O
,	O
and	O
synophyris	O
were	O
present	O
in	O
a	O
30	O
-	O
year	O
old	O
woman	O
(	O
III	O
:	O
7	O
)	O
.	O

To	O
demonstrate	O
the	O
power	O
of	O
this	O
approach	O
in	O
practice	O
,	O
we	O
applied	O
our	O
new	O
pipeline	O
for	O
10	O
CINCA	B-DISEASE
/	O
NOMID	B-DISEASE
patients	O
in	O
whom	O
we	O
failed	O
to	O
detect	O
mutations	O
in	O
the	O
NLRP3	B-GENE
gene	O
using	O
a	O
conventional	O
direct	O
DNA	O
sequencing	O
approach	O
.	O

Similar	O
to	O
that	O
seen	O
in	O
the	O
rat	O
(	O
Figure	O
3D	O
)	O
,	O
the	O
stereocilia	O
of	O
inner	O
hair	O
cells	O
in	O
the	O
mouse	O
organ	O
of	O
Corti	O
were	O
more	O
intensely	O
labeled	O
than	O
those	O
of	O
outer	O
hair	O
cells	O
(	O
Figure	O
4A	O
)	O
.	O

To	O
establish	O
a	O
genetic	O
diagnosis	O
in	O
a	O
cLQTS	B-DISEASE
family	O
is	O
in	O
most	O
cases	O
complicated	O
,	O
as	O
described	O
above	O
,	O
and	O
is	O
best	O
done	O
as	O
a	O
collaborative	O
effort	O
involving	O
cardiologists	O
,	O
clinical	O
geneticists	O
and	O
molecular	O
geneticists	O
.	O

As	O
the	O
papillomacular	O
bundle	O
was	O
shown	O
to	O
be	O
preferentially	O
involved	O
before	O
[	O
8	O
,	O
9	O
,	O
17	O
]	O
,	O
we	O
focused	O
in	O
our	O
study	O
on	O
macular	O
SDOCT	O
volume	O
scans	O
.	O

Mutations	O
in	O
GJB2	B-GENE
and	O
SLC26A4	B-GENE
were	O
previously	O
excluded	O
.	O

These	O
included	O
13	O
known	O
/	O
putative	O
MODY	B-DISEASE
genes	O
(	O
GCK	B-GENE
,	O
HNF1A	B-GENE
,	O
HNF4A	B-GENE
,	O
HNF1B	B-GENE
,	O
NEUROD1	B-GENE
,	O
INS	B-GENE
,	O
CEL	B-GENE
,	O
PDX1	B-GENE
,	O
PAX4	B-GENE
,	O
BLK	B-GENE
,	O
KLF11	B-GENE
,	O
KCNJ11	B-GENE
and	O
ABCC8	B-GENE
)	O
,	O
two	O
genes	O
where	O
mutations	O
cause	O
diabetes	B-DISEASE
through	O
lipodystrophy	O
(	O
LMNA	B-GENE
and	O
PPARG	B-GENE
)	O
,	O
the	O
m	B-VARIANT
.	I-VARIANT
3243	I-VARIANT
region	O
of	O
the	O
mitochondrial	O
genome	O
(	O
where	O
the	O
m	B-VARIANT
.	I-VARIANT
3243A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
mutation	O
causes	O
MIDD	B-DISEASE
)	O
and	O
20	O
neonatal	B-DISEASE
diabetes	I-DISEASE
genes	O
(	O
GCK	B-GENE
,	O
KCNJ11	B-GENE
,	O
ABCC8	B-GENE
,	O
INS	B-GENE
,	O
PDX1	B-GENE
,	O
PTF1A	B-GENE
,	O
HNF1B	B-GENE
,	O
NEUROD1	B-GENE
,	O
NEUROG3	B-GENE
,	O
RFX6	B-GENE
,	O
EIF2AK3	B-GENE
,	O
FOXP3	B-GENE
,	O
GLIS3	B-GENE
,	O
SLC19A2	B-GENE
,	O
SLC2A2	B-GENE
,	O
IER3IP1	B-GENE
,	O
ZFP57	B-GENE
,	O
WFS1	B-GENE
,	O
GATA6	B-GENE
and	O
GATA4	B-GENE
)	O
.	O

Genome	O
-	O
wide	O
studies	O
estimate	O
that	O
the	O
initial	O
founder	O
Roma	O
population	O
originated	O
from	O
Northwest	O
India	O
approximately	O
1	O
.	O
5	O
thousand	O
years	O
ago	O
.	O

The	O
structural	O
template	O
(	O
3GGE	O
)	O
and	O
the	O
models	O
each	O
have	O
two	O
alpha	O
-	O
helices	O
and	O
six	O
beta	O
-	O
strands	O
.	O

The	O
type	B-GENE
II	I-GENE
collagen	I-GENE
gene	I-GENE
is	O
about	O
30	O
kb	O
in	O
length	O
with	O
54	O
exons	O
,	O
among	O
which	O
exons	O
1	O
-	O
5	O
encoding	O
the	O
N	O
-	O
terminal	O
region	O
,	O
exons	O
6	O
-	O
48	O
encode	O
the	O
core	O
area	O
which	O
is	O
composed	O
of	O
a	O
triple	O
helical	O
domain	O
,	O
and	O
exons	O
49	O
-	O
52	O
encoding	O
the	O
C	O
-	O
terminal	O
region	O
.	O

Even	O
if	O
WS	B-DISEASE
is	O
characterized	O
by	O
a	O
wide	O
differential	O
diagnosis	O
including	O
other	O
causes	O
of	O
neurodegeneration	B-DISEASE
,	O
it	O
should	O
be	O
suspected	O
in	O
a	O
young	O
with	O
diabetes	B-DISEASE
mellitus	I-DISEASE
and	O
optic	B-DISEASE
atrophy	I-DISEASE
,	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
polyuria	B-DISEASE
and	O
polydipsia	B-DISEASE
but	O
adequate	O
glucose	O
control	O
[	O
44	O
]	O
.	O

Background	O
shading	O
separates	O
categories	O
.	O

The	O
c	B-VARIANT
.	I-VARIANT
1220delG	I-VARIANT
mutation	O
of	O
USH1C	B-GENE
accounts	O
for	O
23	O
%	O
of	O
RP	B-DISEASE
among	O
Yemenite	O
Jewish	O
patients	O
in	O
our	O
cohort	O
.	O

Variants	O
were	O
annotated	O
using	O
Annovar	O
(	O
6	O
)	O
and	O
coding	O
transcripts	O
from	O
GencodeV7	O
(	O
7	O
)	O
.	O

This	O
would	O
be	O
consistent	O
with	O
TBX1C	B-GENE
having	O
the	O
primary	O
biological	O
function	O
.	O

We	O
also	O
studied	O
the	O
TJP2	B-GENE
structure	O
models	O
to	O
establish	O
the	O
molecular	O
differences	O
between	O
wild	O
type	O
(	O
p	O
.	O
A112	O
)	O
and	O
mutant	O
type	O
(	O
p	O
.	O
T112	O
)	O
.	O

We	O
thank	O
Orly	O
Yaron	O
(	O
Tel	O
Aviv	O
University	O
Genome	O
High	O
-	O
Throughput	O
Sequencing	O
Laboratory	O
)	O
,	O
Mariana	O
Kotler	O
(	O
Danyel	O
Biotech	O
)	O
,	O
Danielle	O
Lenz	O
and	O
Amiel	O
Dror	O
for	O
their	O
help	O
and	O
the	O
Wolfson	O
Family	O
Charitable	O
Trust	O
for	O
providing	O
equipment	O
support	O
.	O
These	O
authors	O
contributed	O
equally	O
to	O
this	O
work	O
.	O

2c	O
)	O
.	O

In	O
five	O
(	O
27	O
%	O
)	O
of	O
the	O
subjects	O
,	O
school	O
screening	O
or	O
teachers	O
were	O
the	O
first	O
to	O
identify	O
a	O
vision	O
problem	O
,	O
which	O
led	O
in	O
some	O
cases	O
to	O
the	O
diagnosis	O
of	O
WFS	B-DISEASE
.	O

Discovery	O
screen	O
sensitivity	O
was	O
estimated	O
from	O
genotype	O
data	O
using	O
sites	O
where	O
>	O
=	O
1	O
individual	O
in	O
the	O
pool	O
contained	O
a	O
variant	O
compared	O
to	O
hg18	O
,	O
whereas	O
specificity	O
was	O
calculated	O
at	O
sites	O
where	O
all	O
individuals	O
contained	O
the	O
hg18	O
reference	O
allele	O
.	O

Thus	O
,	O
there	O
may	O
be	O
protective	O
factor	O
(	O
s	O
)	O
for	O
cardiovascular	O
lesion	O
and	O
susceptibility	O
factor	O
(	O
s	O
)	O
for	O
developmental	O
delay	O
in	O
groups	O
1	O
+	O
2	O
.	O

These	O
authors	O
reported	O
the	O
USH1C	B-GENE
gene	O
as	O
responsible	O
for	O
the	O
disease	O
in	O
7	O
%	O
of	O
cases	O
in	O
a	O
cohort	O
of	O
UK	O
and	O
USA	O
patients	O
,	O
and	O
in	O
6	O
%	O
of	O
the	O
French	O
USH1	B-DISEASE
population	O
,	O
respectively	O
.	O

We	O
investigated	O
the	O
clinical	O
and	O
molecular	O
characteristics	O
of	O
three	O
of	O
the	O
four	O
mtDNA	O
1095T	B-VARIANT
>	I-VARIANT
C	I-VARIANT
pedigrees	O
.	O

Java	O
and	O
R	O
code	O
that	O
can	O
be	O
used	O
to	O
derive	O
the	O
read	O
counts	O
from	O
bam	O
files	O
as	O
well	O
as	O
the	O
normalized	O
exon	O
-	O
specific	O
coverage	O
are	O
provided	O
as	O
supporting	O
information	O
(	O
bam2readcounts	O
.	O
zip	O
)	O
.	O

In	O
comparison	O
to	O
the	O
human	O
sequence	O
,	O
mouse	O
Elmod3	B-GENE
includes	O
only	O
three	O
known	O
alternatively	O
spliced	O
transcripts	O
(	O
Figure	O
2A	O
)	O
.	O

Cq	O
values	O
for	O
the	O
15	O
genes	O
.	O

Significant	O
thickness	O
map	O
of	O
retinal	O
nerve	O
fiber	O
layer	O
(	O
RNFL	O
)	O
indicated	O
in	O
A	O
(	O
thinning	O
parts	O
are	O
showed	O
in	O
red	O
)	O
.	O

Funding	O
:	O
This	O
study	O
was	O
supported	O
by	O
National	O
Institutes	O
of	O
Health	O
-	O
National	O
Institute	O
on	O
Deafness	B-DISEASE
and	O
Other	O
Communication	O
Disorders	O
grant	O
R01DC009645	O
to	O
MT	O
.	O

This	O
proportion	O
is	O
just	O
slightly	O
higher	O
than	O
a	O
previous	O
estimate	O
(	O
51	O
%	O
)	O
for	O
a	O
single	O
gene	O
disorder	O
in	O
profound	O
childhood	O
deafness	B-DISEASE
[	O
47	O
]	O
.	O

When	O
point	O
mutations	O
and	O
small	O
insertions	O
/	O
deletions	O
were	O
excluded	O
by	O
direct	O
sequencing	O
,	O
copy	O
number	O
analysis	O
by	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
was	O
performed	O
to	O
detect	O
larger	O
deletions	O
and	O
duplications	O
.	O

Each	O
of	O
the	O
other	O
known	O
genes	O
for	O
hearing	B-DISEASE
loss	I-DISEASE
is	O
responsible	O
for	O
only	O
a	O
small	O
proportion	O
of	O
cases	O
.	O

Although	O
a	O
large	O
number	O
of	O
deafness	B-DISEASE
genes	O
and	O
mutations	O
have	O
already	O
been	O
identified	O
,	O
our	O
study	O
demonstrates	O
that	O
the	O
full	O
mutation	O
spectrum	O
in	O
these	O
genes	O
is	O
still	O
not	O
defined	O
.	O

D	O
.	O

Like	O
our	O
patient	O
,	O
individuals	O
with	O
DBP	B-DISEASE
deficiency	I-DISEASE
often	O
show	O
an	O
elevated	O
ratio	O
of	O
pristanic	O
to	O
phytanic	O
acid	O
in	O
plasma	O
,	O
reflective	O
of	O
dysfunctional	O
beta	O
-	O
oxidation	O
in	O
the	O
peroxisome	O
[	O
10	O
]	O
.	O

Serum	O
levels	O
of	O
alkaline	O
phosphatase	O
(	O
ALP	O
)	O
increased	O
(	O
1	O
,	O
198	O
U	O
/	O
L	O
)	O
after	O
birth	O
.	O

In	O
patient	O
28	O
,	O
557	O
,	O
compound	O
heterozygous	O
mutations	O
were	O
detected	O
in	O
the	O
autosomal	O
recessive	O
RP	B-DISEASE
gene	O
USH2A	B-GENE
.	O

Analyzed	O
the	O
data	O
:	O
CMW	O
ME	O
-	O
A	O
DAP	O
IMC	O
.	O

We	O
did	O
not	O
find	O
any	O
pathogenic	O
or	O
potentially	O
pathogenic	O
variants	O
in	O
USH1G	B-GENE
in	O
the	O
entire	O
cohort	O
.	O

Due	O
to	O
the	O
rarity	O
of	O
the	O
MinK	O
variant	O
and	O
the	O
known	O
association	O
between	O
mutations	O
in	O
the	O
N	O
-	O
terminus	O
of	O
MinK	O
and	O
adverse	O
drug	O
effects	O
,	O
we	O
consider	O
it	O
a	O
significant	O
finding	O
.	O

It	O
was	O
then	O
cloned	O
into	O
the	O
EcoR	O
I	O
/	O
Xho	O
I	O
sites	O
of	O
pLRT	O
to	O
construct	O
the	O
recombinant	O
plasmid	O
.	O

In	O
this	O
report	O
,	O
the	O
genetic	O
analysis	O
of	O
a	O
Tunisian	O
cohort	O
of	O
dRTA	B-DISEASE
patients	O
as	O
well	O
as	O
a	O
new	O
diagnostic	O
strategy	O
to	O
facilitate	O
the	O
genetic	O
testing	O
in	O
North	O
Africans	O
with	O
dRTA	B-DISEASE
and	O
SNHL	B-DISEASE
is	O
presented	O
.	O

Consistently	O
with	O
a	O
recessive	O
inheritance	O
model	O
,	O
only	O
homozygous	O
or	O
compound	O
heterozygous	O
variants	O
shared	O
among	O
affected	O
individuals	O
were	O
considered	O
.	O

FGFR1	B-GENE
mutations	O
also	O
cause	O
KS	B-DISEASE
.	O

Both	O
GERP	O
+	O
+	O
and	O
PhyloP	O
values	O
estimated	O
a	O
high	O
degree	O
of	O
conservation	O
of	O
serine	O
at	O
position	O
16	O
of	O
PRS	B-GENE
-	I-GENE
I	I-GENE
across	O
species	O
(	O
Additional	O
file	O
3	O
)	O
,	O
and	O
was	O
confirmed	O
by	O
multiple	O
sequence	O
alignment	O
(	O
Figure	O
1	O
B	O
)	O
,	O
being	O
the	O
first	O
missense	O
mutation	O
identified	O
in	O
this	O
gene	O
from	O
the	O
first	O
alpha	O
-	O
helix	O
to	O
the	O
fourth	O
beta	O
-	O
strand	O
(	O
aminoacids	O
1	O
to	O
43	O
,	O
Figure	O
1	O
C	O
)	O
.	O

Gly1734	O
(	O
G1734	O
)	O
is	O
conserved	O
during	O
evolution	O
.	O

This	O
protein	O
is	O
predominantly	O
expressed	O
in	O
cochlear	O
hair	O
cells	O
and	O
contributes	O
to	O
the	O
structural	O
maintenance	O
of	O
stereocilia	O
,	O
cuticular	O
plates	O
and	O
adherens	O
junctions	O
[	O
22	O
]	O
.	O

A	O
.	O

[	O
44	O
]	O
reported	O
that	O
microcysts	O
could	O
also	O
be	O
observed	O
using	O
en	O
face	O
OCT	O
imaging	O
.	O

Little	O
is	O
known	O
about	O
the	O
molecular	O
architecture	O
of	O
BDP1	B-GENE
except	O
the	O
conservation	O
of	O
its	O
segment	O
of	O
amino	O
acids	O
299	O
-	O
347	O
that	O
contains	O
the	O
SANT	O
domain	O
.	O

All	O
subjects	O
showed	O
moderate	O
to	O
profound	O
bilateral	O
sensorineural	O
hearing	B-DISEASE
impairment	I-DISEASE
on	O
audiograms	O
.	O

Primers	O
were	O
iteratively	O
designed	O
using	O
PRIMER3	O
software	O
on	O
the	O
hg17	O
reference	O
sequence	O
(	O
150	O
-	O
600bp	O
amplicon	O
length	O
,	O
no	O
buffer	O
)	O
and	O
validated	O
on	O
3	O
HapMap	O
CEU	O
samples	O
,	O
using	O
three	O
design	O
iterations	O
.	O

5	O
-	O
7	O
9	O
Despite	O
the	O
variable	O
expressivity	O
of	O
Hartsfield	B-DISEASE
syndrome	I-DISEASE
,	O
we	O
postulated	O
that	O
mutations	O
in	O
a	O
single	O
key	O
developmental	O
gene	O
underlie	O
the	O
co	O
-	O
occurrence	O
of	O
HPE	B-DISEASE
and	O
ectrodactyly	B-DISEASE
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
EEZ	O
A	O
.	O

p	B-VARIANT
.	I-VARIANT
H723R	I-VARIANT
is	O
most	O
prevalent	O
in	O
the	O
Japanese	O
and	O
Korean	O
populations	O
,	O
8	O
whereas	O
c	B-VARIANT
.	I-VARIANT
919	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
is	O
most	O
common	O
in	O
the	O
Chinese	O
.	O

25	O
,	O
36	O
The	O
p	B-VARIANT
.	I-VARIANT
G169R	I-VARIANT
in	O
CEACAM16	B-GENE
is	O
found	O
in	O
this	O
deafness	B-DISEASE
family	O
.	O

She	O
had	O
a	O
positive	O
Romberg	O
test	O
and	O
can	O
walk	O
in	O
tandem	O
gait	O
.	O

The	O
frequencies	O
of	O
mosaicism	O
identified	O
in	O
these	O
patients	O
by	O
the	O
MPS	O
approach	O
were	O
consistent	O
with	O
those	O
that	O
were	O
identified	O
by	O
the	O
subcloning	O
and	O
subsequent	O
capillary	O
DNA	O
sequencing	O
method	O
(	O
data	O
not	O
shown	O
)	O
.	O

Considering	O
the	O
four	O
programs	O
(	O
Splice	O
View	O
,	O
NNSplice	O
,	O
NetGene2	O
and	O
HSF	O
)	O
the	O
score	O
-	O
values	O
were	O
calculated	O
.	O

The	O
mutations	O
detected	O
by	O
the	O
array	O
subsequently	O
increased	O
,	O
and	O
currently	O
include	O
612	O
previously	O
identified	O
disease	O
-	O
associated	O
variants	O
in	O
the	O
nine	O
known	O
USH	B-DISEASE
genes	O
[	O
25	O
]	O
.	O

(	O
PDF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O
Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

By	O
PCR	O
and	O
subsequent	O
gel	O
electrophoresis	O
,	O
difference	O
in	O
PCR	O
product	O
length	O
was	O
found	O
between	O
the	O
cells	O
transfected	O
with	O
wild	O
type	O
and	O
mutant	O
DSPP	B-GENE
alleles	O
.	O

Plots	O
of	O
the	O
relative	O
open	O
probabilities	O
of	O
activation	O
were	O
calculated	O
by	O
dividing	O
peak	O
-	O
current	O
voltage	O
plots	O
by	O
the	O
normalized	O
maximum	O
conductance	O
(	O
I	O
peak	O
/	O
(	O
V	O
-	O
V	O
rev	O
)	O
)	O
26	O
and	O
fitted	O
with	O
the	O
Boltzmann	O
function	O
according	O
to	O
:	O
(	O
2	O
)	O
P	O
open	O
(	O
V	O
)	O
=	O
1	O
1	O
+	O
e	O
-	O
(	O
V	O
-	O
V	O
1	O
/	O
2	O
)	O
k	O
with	O
P	O
open	O
being	O
the	O
open	O
probability	O
at	O
the	O
desired	O
voltage	O
.	O

Phenotypes	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
associated	O
with	O
TECTA	B-GENE
can	O
range	O
from	O
mild	O
to	O
severe	O
and	O
have	O
pre	O
or	O
postlingual	O
onset	O
[	O
13	O
]	O
.	O

The	O
3	O
families	O
in	O
this	O
study	O
posed	O
well	O
-	O
recognized	O
diagnostic	O
challenges	O
in	O
kidney	B-DISEASE
disease	I-DISEASE
,	O
including	O
atypical	O
or	O
late	O
clinical	O
presentation	O
with	O
unavailable	O
or	O
inconclusive	O
pathology	O
findings	O
:	O
patients	O
from	O
family	O
1	O
and	O
family	O
2	O
in	O
this	O
study	O
were	O
initially	O
diagnosed	O
with	O
MsPGN	B-DISEASE
,	O
IgAN	B-DISEASE
and	O
FSGS	B-DISEASE
.	O

Although	O
current	O
genetic	O
technologies	O
,	O
such	O
as	O
linkage	O
analysis	O
and	O
Sanger	O
sequencing	O
,	O
are	O
very	O
reliable	O
methods	O
for	O
identifying	O
genomic	O
variations	O
associated	O
with	O
genetic	O
disorders	O
,	O
they	O
are	O
not	O
well	O
suited	O
for	O
the	O
analysis	O
of	O
heterogeneous	O
diseases	O
.	O

Approximately	O
50	O
%	O
of	O
congenital	O
hearing	B-DISEASE
loss	I-DISEASE
cases	O
and	O
70	O
%	O
of	O
childhood	O
hearing	B-DISEASE
loss	I-DISEASE
cases	O
are	O
attributed	O
to	O
genetic	O
mutations	O
[	O
1	O
]	O
.	O

PolyPhen	O
(	O
polymorphism	O
phenotyping	O
)	O
:	O
"	O
Probably	O
damaging	O
"	O
(	O
it	O
is	O
believed	O
most	O
likely	O
to	O
affect	O
protein	O
function	O
or	O
structure	O
)	O
,	O
"	O
Possibly	O
damaging	O
"	O
(	O
it	O
is	O
believed	O
to	O
affect	O
protein	O
function	O
or	O
structure	O
)	O
,	O
"	O
Benign	O
"	O
(	O
most	O
likely	O
lacking	O
any	O
phenotypic	O
effect	O
)	O
.	O

These	O
mutations	O
included	O
21	O
missense	O
,	O
8	O
nonsense	O
,	O
9	O
frameshifts	O
,	O
9	O
intronic	O
mutations	O
and	O
6	O
large	O
rearrangements	O
.	O

In	O
summary	O
,	O
we	O
identified	O
a	O
TBX1	B-GENE
mutation	O
by	O
exome	O
sequencing	O
in	O
a	O
family	O
with	O
chromosome	O
22q11	O
.	O
2	O
deletion	O
-	O
like	O
phenotype	O
.	O

This	O
may	O
provide	O
evidence	O
for	O
the	O
progression	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
demonstrated	O
in	O
some	O
of	O
the	O
patients	O
with	O
EYA1	B-GENE
mutations	O
considering	O
the	O
possible	O
role	O
of	O
EYA1	B-GENE
in	O
the	O
maintenance	O
and	O
survival	O
of	O
the	O
hair	O
cells	O
and	O
the	O
supporting	O
cells	O
.	O

Novel	O
mutations	O
are	O
indicated	O
in	O
bold	O
type	O
.	O

Legend	O
:	O
m	O
,	O
male	O
;	O
f	O
,	O
female	O
;	O
n	O
.	O
d	O
.	O
,	O
not	O
done	O
;	O
ref	O
,	O
reference	O
value	O
;	O
SARA	O
,	O
scale	O
for	O
the	O
Assessment	O
and	O
Rating	O
of	O
Ataxia	B-DISEASE
,	O
reaching	O
from	O
0	O
to	O
40	O
,	O
with	O
higher	O
scores	O
indicating	O
more	O
severe	O
ataxia	B-DISEASE
;	O
scores	O
<	O
3	O
points	O
are	O
considered	O
unspecific	O
.	O

Monoallelic	O
mutations	O
in	O
recessive	O
disease	O
genes	O
represent	O
a	O
challenge	O
for	O
interpretation	O
regarding	O
their	O
causality	O
in	O
the	O
patient	O
,	O
especially	O
if	O
there	O
are	O
no	O
biallelic	O
mutations	O
in	O
another	O
gene	O
for	O
the	O
trait	O
that	O
would	O
qualify	O
such	O
mutations	O
as	O
incidental	O
findings	O
(	O
i	O
.	O
e	O
.	O

PS	B-DISEASE
patient	O
is	O
heterozygous	O
at	O
position	O
1075	O
,	O
as	O
revealed	O
by	O
the	O
nucleotide	O
change	O
of	O
G	O
to	O
C	O
(	O
arrow	O
)	O
,	O
causing	O
the	O
substitution	O
of	O
a	O
valine	O
to	O
leucine	O
(	O
Val359Leu	B-VARIANT
)	O
.	O

The	O
inheritance	O
pattern	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
this	O
family	O
is	O
autosomal	O
dominant	O
.	O

In	O
addition	O
,	O
six	O
of	O
the	O
ten	O
USH	B-DISEASE
genes	O
consist	O
of	O
more	O
than	O
20	O
exons	O
,	O
each	O
,	O
which	O
made	O
mutational	O
analysis	O
by	O
Sanger	O
sequencing	O
of	O
PCR	O
-	O
amplified	O
exons	O
from	O
genomic	O
DNA	O
tedious	O
and	O
costly	O
.	O

The	O
molecular	O
diagnosis	O
of	O
this	O
family	O
may	O
provide	O
new	O
insights	O
for	O
genetic	O
counseling	O
of	O
families	O
affected	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
may	O
help	O
to	O
solve	O
the	O
molecular	O
basis	O
of	O
hearing	B-DISEASE
impairment	I-DISEASE
.	O

Although	O
previous	O
studies	O
have	O
used	O
MPS	O
technology	O
to	O
detect	O
somatic	O
mosaicism	O
,	O
it	O
was	O
unclear	O
how	O
sensitive	O
this	O
method	O
is	O
to	O
detect	O
a	O
low	O
-	O
level	O
somatic	O
mosaicism	O
using	O
the	O
MPS	O
platform	O
because	O
this	O
platform	O
is	O
generally	O
error	O
-	O
prone	O
.	O

We	O
also	O
appreciated	O
the	O
patients	O
whose	O
participation	O
made	O
this	O
study	O
possible	O
.	O

It	O
shares	O
significant	O
similarity	O
with	O
MYH9	B-GENE
,	O
MYH10	B-GENE
,	O
and	O
MYH11	B-GENE
,	O
with	O
highest	O
conservation	O
in	O
the	O
myosin	O
head	O
domain	O
.	O

C	O
.	O

Primers	O
used	O
in	O
PCR	O
/	O
sequencing	O
reaction	O
of	O
WFS1	B-GENE
coding	O
region	O
*	O
*	O
WFS1	B-GENE
sequence	O
based	O
on	O
the	O
GenBank	O
entry	O
(	O
accession	O
number	O
:	O
AC004599	O
)	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
report	O
decreased	O
expression	O
levels	O
of	O
TCOF1	B-GENE
in	O
TCS	B-DISEASE
adult	O
human	O
cells	O
,	O
but	O
it	O
is	O
still	O
unknown	O
if	O
this	O
finding	O
is	O
associated	O
to	O
any	O
phenotype	O
in	O
adulthood	O
.	O

His	O
father	O
also	O
has	O
hearing	B-DISEASE
loss	I-DISEASE
based	O
on	O
anamnestic	O
evaluation	O
.	O

Thirteen	O
(	O
45	O
%	O
)	O
were	O
due	O
to	O
a	O
de	O
novo	O
mutation	O
,	O
seven	O
(	O
24	O
%	O
)	O
were	O
due	O
to	O
a	O
newly	O
homozygous	O
genotype	O
,	O
five	O
(	O
17	O
%	O
)	O
were	O
due	O
to	O
a	O
newly	O
hemizygous	O
genotype	O
,	O
and	O
four	O
(	O
14	O
%	O
)	O
were	O
due	O
to	O
a	O
compound	O
heterozygous	O
genotype	O
.	O

See	O
Methods	O
for	O
details	O
.	O

Three	O
types	O
have	O
been	O
described	O
:	O
oncogenes	O
,	O
tumor	B-DISEASE
suppressor	O
genes	O
,	O
and	O
predisposition	O
genes	O
[	O
46	O
]	O
.	O

Our	O
case	O
shows	O
that	O
OPA1	B-GENE
analysis	O
can	O
be	O
useful	O
in	O
late	O
-	O
onset	O
cases	O
of	O
ADOA	B-DISEASE
when	O
the	O
main	O
secondary	O
causes	O
of	O
optic	B-DISEASE
atrophies	I-DISEASE
have	O
been	O
excluded	O
.	O

Both	O
parents	O
were	O
heterozygous	O
and	O
all	O
the	O
affected	O
offspring	O
were	O
homozygous	O
for	O
the	O
mutation	O
while	O
the	O
healthy	O
siblings	O
were	O
heterozygous	O
(	O
WT	O
/	O
MUT	O
)	O
and	O
homozygous	O
(	O
WT	O
/	O
WT	O
)	O
respectively	O
.	O

The	O
libraries	O
were	O
amplified	O
for	O
five	O
cycles	O
with	O
flanking	O
primers	O
(	O
forward	O
primer	O
PE	O
1	O
.	O
0	O
and	O
reverse	O
primer	O
SureSelect	O
Indexing	O
Pre	O
-	O
Capture	O
PCR	O
)	O
.	O

Although	O
the	O
differences	O
in	O
remission	O
period	O
and	O
insulin	O
requirement	O
between	O
the	O
WSD	B-DISEASE
and	O
type	B-DISEASE
1	I-DISEASE
diabetes	I-DISEASE
groups	O
did	O
not	O
reach	O
statistical	O
significance	O
,	O
a	O
high	O
degree	O
of	O
variability	O
was	O
noted	O
in	O
these	O
features	O
among	O
patients	O
with	O
WSD	B-DISEASE
.	O

In	O
2011	O
,	O
using	O
Ush1g	B-GENE
knockout	O
mice	O
experiments	O
,	O
Caberlotto	O
and	O
colleagues	O
[	O
17	O
]	O
concluded	O
that	O
Sans	O
belongs	O
to	O
the	O
USH1	B-DISEASE
protein	O
network	O
required	O
for	O
the	O
cohesion	O
of	O
hair	O
bundles	O
in	O
cochlear	O
hair	O
cells	O
during	O
the	O
early	O
stages	O
of	O
their	O
development	O
.	O

On	O
the	O
whole	O
,	O
out	O
of	O
the	O
36	O
patients	O
with	O
USH	B-DISEASE
in	O
our	O
series	O
,	O
27	O
(	O
75	O
%	O
)	O
carried	O
two	O
pathogenic	O
variants	O
in	O
the	O
same	O
gene	O
(	O
five	O
in	O
the	O
MYO7A	B-GENE
gene	O
and	O
22	O
in	O
the	O
USH2A	B-GENE
gene	O
)	O
and	O
therefore	O
could	O
be	O
considered	O
genetically	O
characterized	O
.	O

A	O
comparison	O
of	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
Eya	O
VR	O
domain	O
partial	O
region	O
showed	O
that	O
p	B-VARIANT
.	I-VARIANT
S288X	I-VARIANT
is	O
highly	O
conserved	O
among	O
various	O
vertebrate	O
species	O
(	O
Fig	O
.	O

A	O
novel	O
homozygous	O
missense	O
mutation	O
was	O
identified	O
in	O
TMPRSS3	B-GENE
(	O
MIM_605511	O
)	O
,	O
c	B-VARIANT
.	I-VARIANT
726C	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Cys242Trp	I-VARIANT
)	O
that	O
co	O
-	O
segregated	O
with	O
hearing	B-DISEASE
impairment	I-DISEASE
in	O
family	O
DFR24	O
(	O
Figure	O
1	O
)	O
and	O
was	O
predicted	O
to	O
be	O
probably	O
damaging	O
by	O
Polyphen2	O
and	O
deleterious	O
by	O
SIFT	O
(	O
Table	O
2	O
)	O
.	O

The	O
primers	O
were	O
synthesised	O
by	O
the	O
Synthetic	O
DNA	O
Laboratory	O
(	O
University	O
of	O
Cape	O
Town	O
,	O
Cape	O
Town	O
,	O
South	O
Africa	O
)	O
and	O
Applied	O
Biosystems	O
(	O
Copenhagen	O
,	O
Denmark	O
)	O
.	O

We	O
show	O
that	O
the	O
Quebec	O
population	O
is	O
the	O
second	O
population	O
in	O
the	O
world	O
in	O
which	O
USH1C	B-GENE
is	O
the	O
major	O
genetic	O
USH1	B-DISEASE
subtype	O
,	O
which	O
is	O
rare	O
in	O
all	O
other	O
populations	O
studied	O
to	O
date	O
.	O

Liu	O
Jun	O
.	O
Hereditary	O
hearing	B-DISEASE
loss	I-DISEASE
is	O
one	O
of	O
the	O
most	O
common	O
heterogeneous	O
disorders	O
,	O
and	O
genetic	O
variants	O
that	O
can	O
cause	O
hearing	B-DISEASE
loss	I-DISEASE
have	O
been	O
identified	O
in	O
over	O
sixty	O
genes	O
.	O

We	O
found	O
a	O
c	B-VARIANT
.	I-VARIANT
637G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
transversion	O
variant	O
in	O
NARS2	B-GENE
.	O

[	O
6	O
]	O
,	O
male	O
patients	O
with	O
COL4A5	B-GENE
deletions	O
or	O
splice	O
or	O
truncating	O
mutations	O
had	O
two	O
-	O
to	O
fourfold	O
greater	O
odds	O
of	O
developing	O
ocular	B-DISEASE
abnormalities	I-DISEASE
than	O
those	O
with	O
missense	O
mutations	O
.	O

Collectively	O
,	O
six	O
(	O
6	O
%	O
)	O
of	O
94	O
NSHL	B-DISEASE
individuals	O
were	O
diagnosed	O
with	O
homozygous	O
or	O
compound	O
heterozygous	O
mutations	O
causing	O
DFNB16	B-DISEASE
and	O
five	O
(	O
5	O
%	O
)	O
as	O
heterozygous	O
mutation	O
carriers	O
.	O

Evolutionary	O
conservation	O
of	O
the	O
sequences	O
and	O
structures	O
of	O
the	O
proteins	O
and	O
nucleic	O
acids	O
was	O
assessed	O
using	O
the	O
ConSeq	O
server	O
(	O
http	O
:	O
/	O
/	O
conseq	O
.	O
tau	O
.	O
ac	O
.	O
il	O
/	O
)	O
.	O

37	O
-	O
39	O
Our	O
finding	O
of	O
bilateral	B-DISEASE
CNH	I-DISEASE
in	O
AIFM1	B-GENE
-	O
related	O
ANSD	B-DISEASE
implies	O
that	O
MRI	O
screening	O
may	O
identify	O
the	O
site	O
of	O
lesion	O
in	O
some	O
patients	O
with	O
this	O
phenotype	O
.	O

Immunolocalization	O
of	O
EPS8	B-GENE
in	O
the	O
mouse	O
cochlea	O
and	O
macaque	O
retina	O
.	O

All	O
OPA1	B-GENE
exons	O
and	O
at	O
least	O
30	O
bp	O
of	O
flanking	O
intronic	O
sequences	O
were	O
amplified	O
by	O
PCR	O
;	O
fragments	O
were	O
purified	O
and	O
directly	O
sequenced	O
using	O
BigDye	O
Terminator	O
protocol	O
on	O
an	O
automated	O
3100	O
ABI	O
Prism	O
Genetic	O
Analyzer	O
(	O
Applied	O
Biosystem	O
)	O
.	O

Workflow	O
for	O
the	O
PCR	O
enrichment	O
approach	O
.	O

However	O
,	O
further	O
analysis	O
indicated	O
that	O
this	O
patient	O
was	O
actually	O
compound	O
heterozygous	O
:	O
one	O
allele	O
contained	O
both	O
the	O
p	B-VARIANT
.	I-VARIANT
G56R	I-VARIANT
missense	O
mutation	O
and	O
a	O
branch	O
site	O
mutation	O
that	O
caused	O
skipping	O
of	O
exon	O
10	O
,	O
and	O
the	O
other	O
allele	O
contained	O
a	O
complex	O
chromosomal	O
rearrangement	O
involving	O
deletion	O
of	O
exons	O
1	O
-	O
4	O
and	O
duplication	O
of	O
exon	O
7	O
of	O
NUBPL	B-GENE
.	O

It	O
is	O
also	O
possible	O
causative	O
genes	O
resided	O
beyond	O
the	O
204	O
target	O
deafness	B-DISEASE
genes	O
or	O
that	O
true	O
causative	O
genes	O
were	O
not	O
sufficiently	O
covered	O
by	O
TRS	O
-	O
204	O
.	O

FDS	O
and	O
CMTNS	O
scores	O
were	O
7	O
and	O
28	O
,	O
respectively	O
,	O
both	O
in	O
the	O
severe	O
disability	O
category	O
.	O

Our	O
report	O
of	O
two	O
novel	O
WFS1	B-GENE
mutations	O
expands	O
the	O
molecular	O
spectrum	O
of	O
Wolfram	B-DISEASE
syndrome	I-DISEASE
.	O

Inner	O
ear	O
explants	O
were	O
harvested	O
from	O
C57BL	O
/	O
6J	O
mice	O
at	O
P2	O
.	O

(	O
A	O
)	O
At	O
P02	O
,	O
ELMOD3	B-GENE
immunoreactivity	O
(	O
green	O
)	O
was	O
found	O
in	O
the	O
stereocilia	O
of	O
outer	O
hair	O
cells	O
and	O
in	O
the	O
kinocilia	O
of	O
both	O
outer	O
and	O
inner	O
hair	O
cells	O
.	O

Red	O
line	O
represents	O
a	O
DOC	O
of	O
40	O
reads	O
,	O
the	O
minimum	O
limit	O
for	O
a	O
proper	O
validation	O
.	O

Considering	O
the	O
high	O
mutation	O
rate	O
of	O
the	O
EYA1	B-GENE
gene	O
in	O
Korean	O
patients	O
with	O
BOR	B-DISEASE
/	O
BO	B-DISEASE
syndrome	O
,	O
the	O
mutational	O
analysis	O
of	O
EYA1	B-GENE
should	O
be	O
an	O
integral	O
part	O
of	O
the	O
diagnosis	O
of	O
BOR	B-DISEASE
/	O
BO	B-DISEASE
syndrome	O
in	O
the	O
East	O
Asian	O
population	O
.	O

This	O
finding	O
has	O
been	O
reported	O
in	O
previous	O
studies	O
by	O
others	O
[	O
22	O
,	O
23	O
]	O
.	O

The	O
most	O
variable	O
gene	O
is	O
TNFRSF14	O
,	O
with	O
39	O
variant	O
positions	O
per	O
kb	O
(	O
Table	O
S4	O
in	O
File	O
S1	O
)	O
.	O

The	O
exons	O
and	O
flanking	O
50	O
bp	O
of	O
42	O
known	O
human	O
deafness	B-DISEASE
genes	O
were	O
selected	O
for	O
capture	O
and	O
NGS	O
sequencing	O
with	O
an	O
Illumina	O
Genome	O
Analyzer	O
IIX	O
(	O
Solexa	O
)	O
.	O

One	O
change	O
at	O
position	O
m	O
.	O
2363A	O
>	O
G	O
in	O
16S	O
rRNA	O
has	O
never	O
been	O
seen	O
before	O
in	O
mitochondrial	O
DNA	O
databases	O
.	O

Pedigrees	O
and	O
haplotypes	O
from	O
four	O
Spanish	O
families	O
with	O
CLRN1	B-GENE
mutations	O
.	O

Proband	O
II	O
-	O
2	O
had	O
been	O
diagnosed	O
with	O
progressive	O
myopia	B-DISEASE
in	O
the	O
local	O
hospital	O
since	O
she	O
first	O
complained	O
decreased	B-DISEASE
visual	I-DISEASE
acuity	I-DISEASE
in	O
both	O
eyes	O
at	O
age	O
14	O
.	O

Deep	O
tendon	O
reflexes	O
were	O
normal	O
in	O
the	O
arms	O
,	O
exaggerated	O
in	O
the	O
legs	O
.	O

4	O
)	O
.	O

Wrote	O
the	O
paper	O
:	O
MJA	O
EA	O
RR	O
MA	O
MDL	O
TJ	O
JMM	O
.	O

Our	O
recent	O
study	O
by	O
screening	O
for	O
just	O
the	O
most	O
common	O
mutation	O
,	O
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
,	O
in	O
3004	O
Chinese	O
NSHI	B-DISEASE
patients	O
revealed	O
that	O
488	O
(	O
16	O
.	O
3	O
%	O
)	O
patients	O
carried	O
at	O
least	O
one	O
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
mutant	O
allele	O
,	O
with	O
233	O
(	O
7	O
.	O
8	O
%	O
)	O
homozygotes	O
and	O
255	O
(	O
8	O
.	O
5	O
%	O
)	O
heterozygotes	O
[	O
28	O
]	O
,	O
though	O
the	O
frequencies	O
of	O
homozygote	O
and	O
heterozygote	O
of	O
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
varied	O
from	O
0	O
%	O
to	O
14	O
.	O
7	O
%	O
and	O
from	O
1	O
.	O
7	O
%	O
to	O
16	O
.	O
1	O
%	O
respectively	O
in	O
the	O
populations	O
examined	O
in	O
this	O
study	O
.	O

Currently	O
,	O
no	O
intervention	O
is	O
known	O
to	O
alter	O
the	O
progression	O
or	O
life	O
expectancy	O
in	O
WFS	B-DISEASE
,	O
but	O
earlier	O
recognition	O
of	O
the	O
syndrome	O
in	O
individuals	O
could	O
improve	O
their	O
quality	O
of	O
life	O
by	O
allowing	O
earlier	O
intervention	O
for	O
the	O
various	O
debilitating	O
components	O
of	O
WFS	B-DISEASE
.	O

Two	O
different	O
forms	O
of	O
usherin	B-GENE
have	O
been	O
revealed	O
.	O

Finally	O
,	O
a	O
solitary	O
heterozygous	O
missense	O
variant	O
,	O
c	B-VARIANT
.	I-VARIANT
505G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
in	O
exon	O
3	O
of	O
CEACAM16	B-GENE
,	O
was	O
mapped	O
to	O
the	O
linkage	O
region	O
on	O
chr19q13	O
.	O
31	O
-	O
13	O
.	O
33	O
(	O
Figure	O
2	O
-	O
b	O
)	O
.	O

Function	O
of	O
proteins	O
with	O
missense	O
variations	O
was	O
assessed	O
by	O
Polymorphism	O
Phenotyping	O
-	O
2	O
(	O
PolyPhen	O
-	O
2	O
,	O
http	O
:	O
/	O
/	O
genetics	O
.	O
bwh	O
.	O
harvard	O
.	O
edu	O
/	O
pph2	O
/	O
)	O
and	O
Sorting	O
Intolerant	O
From	O
Tolerant	O
(	O
SIFT	O
,	O
http	O
:	O
/	O
/	O
sift	O
.	O
jcvi	O
.	O
org	O
/	O
)	O
,	O
and	O
that	O
of	O
proteins	O
with	O
in	O
-	O
frame	O
amino	O
acid	O
deletions	O
was	O
evaluated	O
by	O
PROVEAN	O
predictions	O
(	O
http	O
:	O
/	O
/	O
provean	O
.	O
jcvi	O
.	O
org	O
/	O
index	O
.	O
php	O
)	O
.	O

Mutations	O
in	O
pendrin	B-GENE
can	O
cause	O
either	O
non	O
-	O
syndromic	O
hearing	B-DISEASE
loss	I-DISEASE
or	O
Pendred	B-DISEASE
syndrome	I-DISEASE
,	O
[	O
6	O
]	O
which	O
,	O
in	O
addition	O
to	O
sensorineural	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
includes	O
thyroid	B-DISEASE
enlargement	I-DISEASE
(	O
goitre	B-DISEASE
)	O
and	O
temporal	B-DISEASE
bone	I-DISEASE
abnormalities	I-DISEASE
of	I-DISEASE
the	I-DISEASE
inner	I-DISEASE
ear	I-DISEASE
,	O
ranging	O
from	O
isolated	B-DISEASE
enlargement	I-DISEASE
of	I-DISEASE
the	I-DISEASE
vestibular	I-DISEASE
aqueduct	I-DISEASE
(	O
EVA	B-DISEASE
)	O
to	O
Mondini	B-DISEASE
dysplasia	I-DISEASE
-	I-DISEASE
-	I-DISEASE
a	I-DISEASE
complex	O
malformation	B-DISEASE
of	I-DISEASE
the	I-DISEASE
cochlear	I-DISEASE
spiral	I-DISEASE
[	O
21	O
]	O
.	O

The	O
whiskers	O
represent	O
the	O
minimum	O
and	O
maximum	O
LogMAR	O
values	O
,	O
the	O
ends	O
of	O
the	O
boxes	O
are	O
the	O
upper	O
and	O
lower	O
quartiles	O
,	O
the	O
vertical	O
length	O
of	O
the	O
boxes	O
indicate	O
the	O
interquartile	O
range	O
,	O
and	O
the	O
line	O
within	O
the	O
boxes	O
represent	O
the	O
median	O
LogMAR	O
values	O
for	O
each	O
group	O
.	O

This	O
might	O
explain	O
the	O
high	O
prevalence	O
1	O
:	O
12	O
,	O
000	O
of	O
Kjer	O
-	O
type	O
optic	B-DISEASE
atrophy	I-DISEASE
in	O
Denmark	O
.	O

Only	O
one	O
patient	O
in	O
our	O
study	O
had	O
mutations	O
in	O
MYO7A	B-GENE
,	O
the	O
most	O
common	O
USH1	B-DISEASE
gene	O
in	O
most	O
other	O
populations	O
;	O
this	O
patient	O
was	O
compound	O
heterozygous	O
for	O
the	O
previously	O
reported	O
missense	O
mutation	O
c	B-VARIANT
.	I-VARIANT
1370C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
A457V	I-VARIANT
)	O
[	O
20	O
]	O
,	O
and	O
a	O
novel	O
nonsense	O
mutation	O
,	O
c	B-VARIANT
.	I-VARIANT
2443C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Q815X	I-VARIANT
)	O
.	O

Consanguineous	O
marriage	O
was	O
indicated	O
.	O

James	O
R	O
.	O

Exome	O
sequencing	O
identified	O
nine	O
heterozygous	O
non	O
-	O
synonymous	O
variants	O
(	O
six	O
missense	O
variants	O
,	O
two	O
in	O
-	O
frame	O
microdeletions	O
,	O
and	O
one	O
frameshift	O
variant	O
)	O
that	O
were	O
specific	O
to	O
groups	O
1	O
+	O
2	O
(	O
namely	O
,	O
they	O
were	O
present	O
in	O
groups	O
1	O
+	O
2	O
and	O
absent	O
from	O
group	O
3	O
as	O
well	O
as	O
from	O
1000	O
Genomes	O
,	O
dbSNP135	O
,	O
and	O
our	O
in	O
-	O
house	O
exome	O
data	O
from	O
70	O
individuals	O
)	O
(	O
Table	O
S1	O
)	O
.	O

2	O
)	O
.	O

This	O
work	O
was	O
supported	O
by	O
grants	O
from	O
the	O
LHW	O
-	O
Stiftung	O
,	O
ERC	O
grant	O
"	O
Hair	O
bundle	O
"	O
(	O
ERC	O
-	O
2011	O
-	O
AdG	O
294570	O
)	O
,	O
Foundation	O
BNP	O
Paribas	O
,	O
"	O
Lifesenses	O
"	O
Labex	O
,	O
the	O
Tassili	O
Project	O
and	O
the	O
Algerian	O
government	O
.	O
Academic	O
Editor	O
:	O
Marcela	O
Votruba	O
Purpose	O
.	O

4A	O
)	O
.	O

We	O
compared	O
our	O
identified	O
germline	O
truncation	O
and	O
missense	O
variants	O
to	O
those	O
present	O
in	O
the	O
COSMIC	O
and	O
OMIM	O
databases	O
to	O
determine	O
whether	O
any	O
were	O
reported	O
in	O
other	O
studies	O
.	O

In	O
the	O
SureSelect	O
library	O
,	O
76	O
already	O
reported	O
genes	O
responsible	O
for	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
and	O
syndromic	O
hearing	B-DISEASE
loss	I-DISEASE
were	O
contained	O
.	O

In	O
dominantly	O
inherited	O
cases	O
,	O
for	O
which	O
such	O
a	O
filter	O
cannot	O
be	O
applied	O
,	O
there	O
would	O
be	O
a	O
priori	O
no	O
such	O
a	O
way	O
of	O
distinguishing	O
pathogenic	O
variants	O
form	O
rare	O
DNA	O
changes	O
or	O
sequencing	O
false	O
calls	O
.	O

KCNJ10	B-GENE
c	B-VARIANT
.	I-VARIANT
1042C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
was	O
shown	O
to	O
reduce	O
K	O
+	O
conductance	O
activity	O
and	O
was	O
therefore	O
considered	O
a	O
potential	O
pathological	O
mutation	O
.	O

(	O
DOCX	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Cd164	B-GENE
expression	O
was	O
confirmed	O
in	O
the	O
spiral	O
ganglions	O
neurons	O
,	O
hair	O
cells	O
in	O
the	O
organ	O
of	O
Corti	O
,	O
cells	O
of	O
Kolliker	O
'	O
s	O
organ	O
,	O
cells	O
of	O
the	O
spiral	O
prominence	O
and	O
in	O
the	O
stria	O
vascularis	O
.	O

The	O
LOD	O
score	O
obtained	O
for	O
each	O
genetic	O
marker	O
is	O
presented	O
in	O
Table	O
S1	O
.	O

Presently	O
,	O
85	O
recessive	O
deafness	B-DISEASE
(	O
DFNB	O
)	O
loci	O
have	O
been	O
registered	O
and	O
35	O
of	O
the	O
corresponding	O
genes	O
have	O
been	O
identified	O
as	O
documented	O
on	O
the	O
Hereditary	O
Hearing	B-DISEASE
Loss	I-DISEASE
Homepage	O
http	O
:	O
/	O
/	O
hereditaryhearingloss	O
.	O
org	O
.	O

Audiometric	O
measurements	O
were	O
obtained	O
at	O
specific	O
ages	O
for	O
each	O
patient	O
as	O
denoted	O
by	O
each	O
hearing	O
assessment	O
.	O

Horseradish	O
peroxidase	O
-	O
conjugated	O
anti	O
-	O
rabbit	O
or	O
anti	O
-	O
goat	O
secondary	O
antibody	O
and	O
DAB	O
were	O
used	O
to	O
visualize	O
the	O
signal	O
.	O

For	O
the	O
CUHK	O
-	O
HL	B-DISEASE
V1	O
kit	O
,	O
under	O
the	O
fourfold	O
tiling	O
of	O
120	O
bp	O
baits	O
,	O
the	O
expected	O
density	O
should	O
be	O
1	O
/	O
30	O
;	O
low	O
bait	O
density	O
was	O
defined	O
as	O
<	O
1	O
/	O
50	O
based	O
on	O
the	O
empirical	O
bait	O
density	O
distribution	O
.	O

Analysis	O
of	O
the	O
parents	O
'	O
DNA	O
showed	O
that	O
the	O
proband	O
had	O
inherited	O
one	O
mutation	O
from	O
each	O
parent	O
.	O

Family	O
MOL0125	O
is	O
non	O
-	O
consanguineous	O
with	O
four	O
affected	O
siblings	O
and	O
family	O
MOL0486	O
is	O
consanguineous	O
(	O
the	O
parents	O
are	O
first	O
cousins	O
)	O
with	O
two	O
affected	O
sisters	O
(	O
Fig	O
.	O

SHL	B-DISEASE
comprises	O
the	O
remaining	O
30	O
%	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
cases	O
,	O
and	O
it	O
appears	O
accompanied	O
by	O
other	O
medical	O
or	O
physical	O
findings	O
.	O

The	O
c	B-VARIANT
.	I-VARIANT
567_586	I-VARIANT
+	I-VARIANT
17del	I-VARIANT
mutation	O
in	O
Family	O
A	O
was	O
not	O
present	O
in	O
the	O
patient	O
'	O
s	O
father	O
but	O
sample	O
from	O
her	O
mother	O
was	O
not	O
available	O
.	O

The	O
genetic	O
causes	O
in	O
Branch	O
B	O
and	O
C	O
(	O
SLC26A4	B-GENE
:	O
c	B-VARIANT
.	I-VARIANT
919	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
,	O
mtDNA	B-GENE
:	O
A1555G	B-VARIANT
)	O
represent	O
the	O
most	O
common	O
HL	B-DISEASE
-	O
causing	O
mutations	O
in	O
China	O
,	O
19	O
with	O
an	O
allele	O
frequency	O
of	O
0	O
.	O
008	O
in	O
our	O
in	O
-	O
house	O
database	O
;	O
whereas	O
both	O
of	O
the	O
CDH23	B-GENE
mutations	O
in	O
Branch	O
A	O
are	O
private	O
.	O

The	O
benefits	O
of	O
cochlear	O
implantation	O
for	O
patients	O
with	O
ANSD	B-DISEASE
has	O
varied	O
[	O
34	O
,	O
35	O
]	O
,	O
but	O
implantation	O
has	O
been	O
shown	O
to	O
be	O
effective	O
for	O
the	O
patients	O
with	O
OTOF	B-GENE
mutations	O
[	O
15	O
,	O
16	O
,	O
36	O
]	O
,	O
because	O
their	O
auditory	O
nerves	O
and	O
spiral	O
ganglions	O
are	O
preserved	O
.	O

The	O
arrow	O
indicates	O
the	O
changed	O
base	O
.	O

His	O
head	O
circumference	O
was	O
35	O
cm	O
.	O

Wang	O
was	O
involved	O
in	O
sample	O
collection	O
.	O

Analyzed	O
the	O
data	O
:	O
MYH	O
HZ	O
FY	O
JD	O
JQL	O
.	O

B	O
)	O
Atypical	O
image	O
obtained	O
in	O
the	O
patient	O
RP	O
-	O
531	O
,	O
in	O
whom	O
CNV	O
analysis	O
could	O
not	O
be	O
performed	O
.	O

Abbreviations	O
:	O
Wild	O
type	O
(	O
+	O
)	O
;	O
c	B-VARIANT
.	I-VARIANT
8559	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
M1	O
)	O
;	O
p	B-VARIANT
.	I-VARIANT
T3936P	I-VARIANT
(	O
M2	O
)	O
;	O
p	B-VARIANT
.	I-VARIANT
R34fs	I-VARIANT
(	O
M3	O
)	O
;	O
p	B-VARIANT
.	I-VARIANT
S2828fs	I-VARIANT
(	O
M4	O
)	O
;	O
p	B-VARIANT
.	I-VARIANT
W3150X	I-VARIANT
(	O
M5	O
)	O
.	O

No	O
mutations	O
at	O
the	O
positions	O
of	O
V2	O
-	O
V7	O
from	O
Braun	O
et	O
al	O
2013	O
were	O
observed	O
.	O

Peroxisomes	O
are	O
ubiquitous	O
cellular	O
organelles	O
with	O
functions	O
in	O
ether	O
lipid	O
biosynthesis	O
,	O
alpha	O
-	O
oxidation	O
of	O
phytanic	O
acid	O
,	O
beta	O
-	O
oxidation	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
(	O
VLCFAs	O
)	O
and	O
of	O
bile	O
acid	O
precursors	O
and	O
docosahexaenoic	O
acid	O
(	O
DHA	O
)	O
precursors	O
,	O
and	O
in	O
hydrogen	O
peroxide	O
metabolism	O
[	O
3	O
]	O
.	O

These	O
mutations	O
were	O
heterozygous	O
in	O
4	O
unrelated	O
patients	O
who	O
carried	O
only	O
one	O
mutant	O
allele	O
.	O

For	O
example	O
,	O
the	O
patient	O
of	O
trio	O
19	O
(	O
of	O
Middle	O
Eastern	O
origin	O
)	O
is	O
homozygous	O
for	O
a	O
frameshift	O
mutation	O
in	O
TECPR2	B-GENE
,	O
which	O
causes	O
autosomal	B-DISEASE
-	I-DISEASE
recessive	I-DISEASE
spastic	I-DISEASE
paraplegia	I-DISEASE
-	I-DISEASE
49	I-DISEASE
(	O
SPG49	B-DISEASE
;	O
OMIM	O
615031	O
)	O
.	O

Clinical	O
evaluations	O
of	O
patients	O
were	O
conducted	O
by	O
physicians	O
in	O
accordance	O
with	O
routine	O
clinical	O
care	O
for	O
patients	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
the	O
physicians	O
'	O
best	O
clinical	O
judgement	O
.	O

This	O
study	O
was	O
supported	O
by	O
the	O
Japanese	O
Ministry	O
of	O
Education	O
,	O
Science	O
,	O
Sports	O
,	O
and	O
Culture	O
,	O
and	O
the	O
Japanese	O
Ministry	O
of	O
Health	O
,	O
Labor	O
,	O
and	O
Welfare	O
.	O

The	O
mode	O
of	O
inheritance	O
and	O
the	O
main	O
clinical	O
features	O
correspond	O
to	O
late	O
onset	O
autosomal	B-DISEASE
recessive	I-DISEASE
RP	I-DISEASE
.	O

The	O
first	O
PCR	O
amplifications	O
were	O
performed	O
in	O
50	O
-	O
mu	O
l	O
reactions	O
using	O
30	O
ng	O
of	O
genomic	O
DNA	O
,	O
1	O
x	O
PrimeSTAR	O
GXL	O
buffer	O
,	O
0	O
.	O
2	O
mM	O
of	O
each	O
dNTP	O
,	O
12	O
.	O
5	O
pmol	O
of	O
each	O
forward	O
and	O
reverse	O
primer	O
,	O
and	O
1	O
.	O
25	O
U	O
of	O
PrimeSTAR	O
GXL	O
DNA	O
polymerase	O
(	O
Takara	O
Bio	O
,	O
Shiga	O
,	O
Japan	O
)	O
.	O

6	O
:	O
7623	O
doi	O
:	O
10	O
.	O
1038	O
/	O
ncomms8623	O
(	O
2015	O
)	O
.	O

For	O
novel	O
genes	O
,	O
by	O
literature	O
mining	O
and	O
database	O
queries	O
we	O
have	O
obtained	O
indications	O
about	O
their	O
biological	O
relevance	O
for	O
pancreatic	O
beta	O
-	O
cell	O
(	O
Figure	O
S3	O
)	O
and	O
by	O
gene	O
ontology	O
(	O
GO	O
)	O
classification	O
we	O
group	O
them	O
in	O
three	O
main	O
categories	O
of	O
cellular	O
components	O
such	O
as	O
transmembrane	O
,	O
cytosolic	O
and	O
mitochondrial	O
proteins	O
(	O
Table	O
4	O
)	O
.	O

These	O
mutations	O
may	O
result	O
in	O
pathogenesis	O
and	O
deafness	B-DISEASE
and	O
may	O
have	O
important	O
roles	O
in	O
the	O
functions	O
of	O
myosin	B-GENE
XVA	I-GENE
.	O

None	O
of	O
these	O
mutations	O
has	O
been	O
described	O
in	O
our	O
previous	O
work	O
[	O
25	O
]	O
.	O

Since	O
environmental	O
and	O
other	O
genetic	O
factors	O
may	O
modulate	O
the	O
effects	O
of	O
SLC26A4	B-GENE
mutations	O
on	O
the	O
development	O
of	O
goiter	O
,	O
the	O
expression	O
of	O
goiter	O
in	O
PS	B-DISEASE
patients	O
is	O
variable	O
and	O
may	O
have	O
incomplete	O
penetrance	O
[	O
11	O
]	O
.	O

S	O
.	O
F	O
.	O

42	O
A	O
study	O
suggested	O
that	O
the	O
absence	O
of	O
the	O
IgC	O
2	O
(	O
A	O
)	O
domain	O
could	O
not	O
affect	O
the	O
CEACAM16	B-GENE
protein	O
to	O
form	O
the	O
oligomer	O
,	O
36	O
but	O
we	O
suggest	O
the	O
G169R	B-VARIANT
mutation	O
at	O
the	O
IgC	O
2	O
(	O
A	O
)	O
domain	O
may	O
change	O
the	O
spatial	O
structure	O
and	O
thereby	O
decrease	O
the	O
stability	O
and	O
polymerizing	O
ability	O
of	O
the	O
protein	O
,	O
and	O
possibly	O
speed	O
up	O
its	O
degradation	O
.	O

The	O
only	O
coding	O
exon	O
of	O
KCNJ10	B-GENE
was	O
amplified	O
in	O
a	O
20	O
-	O
u	O
l	O
PCR	O
reaction	O
mixture	O
containing	O
20	O
ng	O
of	O
genomic	O
DNA	O
template	O
,	O
0	O
.	O
0625	O
units	O
of	O
Taq	O
DNA	O
polymerase	O
(	O
Biomed	O
,	O
Cat	O
:	O
Pc01	O
,	O
Lot	O
:	O
211841XB	O
)	O
,	O
and	O
40	O
nM	O
primers	O
.	O

The	O
diagnostic	O
criteria	O
established	O
in	O
several	O
studies	O
during	O
the	O
past	O
few	O
decades	O
[	O
3	O
,	O
7	O
]	O
include	O
slowly	O
progressive	O
bilateral	B-DISEASE
visual	I-DISEASE
impairment	I-DISEASE
,	O
dyschromatopsia	B-DISEASE
,	O
loss	B-DISEASE
of	I-DISEASE
sensitivity	I-DISEASE
in	I-DISEASE
the	I-DISEASE
central	I-DISEASE
visual	I-DISEASE
field	I-DISEASE
,	O
and	O
temporal	B-DISEASE
optic	I-DISEASE
disc	I-DISEASE
atrophy	I-DISEASE
beginning	O
before	O
the	O
age	O
of	O
10	O
years	O
[	O
8	O
]	O
.	O

However	O
,	O
it	O
was	O
found	O
to	O
be	O
in	O
a	O
heterozygous	O
state	O
without	O
a	O
second	O
mutation	O
.	O

Generation	O
of	O
cell	O
lines	O
stably	O
expressing	O
FLAG	O
-	O
tagged	O
POLR1C	B-GENE
subunits	O
(	O
WT	O
and	O
mutated	O
)	O
and	O
affinity	O
purification	O
from	O
the	O
soluble	O
fraction	O
were	O
performed	O
using	O
standard	O
procedures	O
38	O
39	O
.	O

We	O
enrolled	O
a	O
Caucasian	O
woman	O
(	O
patient	O
1184405	O
)	O
whose	O
past	O
medical	O
history	O
is	O
significant	O
for	O
vesicoureteral	B-DISEASE
reflux	I-DISEASE
(	O
VUR	B-DISEASE
)	O
diagnosed	O
at	O
age	O
two	O
,	O
several	O
urinary	O
tract	O
infections	O
and	O
hydronephrosis	B-DISEASE
.	O

Thus	O
,	O
33	O
.	O
8	O
%	O
of	O
our	O
USH1	B-DISEASE
patients	O
remain	O
genetically	O
uncharacterized	O
.	O

A	O
common	O
clinical	O
scenario	O
is	O
the	O
identification	O
of	O
a	O
child	O
with	O
partial	O
hearing	B-DISEASE
loss	I-DISEASE
who	O
then	O
slowly	O
progresses	O
to	O
deafness	B-DISEASE
over	O
a	O
period	O
of	O
years	O
.	O

Fivegene	O
screening	O
will	O
most	O
likely	O
be	O
even	O
more	O
informative	O
in	O
other	O
South	O
African	O
sub	O
-	O
populations	O
with	O
a	O
greater	O
genetic	O
diversity	O
.	O

D356V	B-VARIANT
is	O
the	O
first	O
deafness	O
-	O
associated	O
missense	O
mutation	O
reported	O
in	O
otoancorin	B-GENE
.	O

The	O
last	O
cycle	O
was	O
followed	O
by	O
a	O
final	O
extension	O
of	O
3	O
min	O
at	O
72	O
deg	O
C	O
.	O

SNPs	O
and	O
InDels	O
were	O
annotated	O
using	O
the	O
exome	O
-	O
assistant	O
program	O
(	O
http	O
:	O
/	O
/	O
122	O
.	O
228	O
.	O
158	O
.	O
106	O
/	O
exomeassistant	O
)	O
.	O

3C	O
)	O
.	O

Spinal	B-DISEASE
anomalies	I-DISEASE
such	O
as	O
the	O
cervical	B-DISEASE
spine	I-DISEASE
fusion	I-DISEASE
are	O
rare	O
in	O
Pfeiffer	B-DISEASE
syndrome	I-DISEASE
15	O
)	O
,	O
but	O
coccygeal	B-DISEASE
anomaly	I-DISEASE
occurred	O
in	O
one	O
other	O
case	O
in	O
Korea	O
7	O
)	O
.	O

In	O
this	O
study	O
we	O
therefore	O
performed	O
a	O
number	O
of	O
functional	O
studies	O
to	O
characterise	O
CD164	B-GENE
and	O
the	O
effect	O
of	O
the	O
mutation	O
.	O

Macular	O
edema	O
does	O
not	O
existed	O
in	O
any	O
patient	O
,	O
although	O
retinal	B-DISEASE
degeneration	I-DISEASE
in	O
the	O
macular	O
region	O
is	O
observed	O
in	O
RP	O
#	O
002	O
,	O
RP	O
#	O
021	O
and	O
RP	O
#	O
094	O
(	O
A	O
,	O
C	O
and	O
E	O
)	O
.	O

61	O
Flies	O
were	O
maintained	O
on	O
standard	O
agar	O
/	O
cornmeal	O
/	O
molasses	O
media	O
at	O
25	O
deg	O
C	O
.	O

This	O
would	O
result	O
in	O
a	O
frameshift	O
and	O
premature	O
protein	O
truncation	O
and	O
is	O
an	O
additional	O
argument	O
in	O
favour	O
of	O
the	O
pathogenicity	O
of	O
this	O
DNA	O
change	O
.	O

28	O
years	O
.	O

a	O
.	O

22	O
At	O
the	O
beginning	O
of	O
this	O
study	O
SLC4A7	B-GENE
was	O
considered	O
as	O
a	O
potential	O
positional	O
candidate	O
gene	O
for	O
type	B-DISEASE
2	I-DISEASE
Usher	I-DISEASE
syndrome	I-DISEASE
in	O
humans	O
.	O

The	O
mean	O
age	O
of	O
onset	O
of	O
visual	B-DISEASE
loss	I-DISEASE
was	O
8	O
.	O
2	O
years	O
(	O
SD	O
=	O
0	O
.	O
9	O
years	O
)	O
for	O
the	O
pure	O
DOA	B-DISEASE
group	O
,	O
and	O
7	O
.	O
7	O
years	O
(	O
SD	O
=	O
0	O
.	O
9	O
years	O
)	O
for	O
the	O
DOA	O
+	O
group	O
.	O

B	O
:	O
Overlapping	O
audiograms	O
of	O
the	O
subjects	O
with	O
non	O
-	O
p	B-VARIANT
.	I-VARIANT
P240L	I-VARIANT
homozygous	O
mutations	O
.	O

(	O
A	O
-	O
B	O
)	O
Fundus	O
photographies	O
show	O
pale	B-DISEASE
and	I-DISEASE
atrophic	I-DISEASE
papilla	I-DISEASE
,	O
narrowed	O
vessels	O
,	O
diffuse	O
hypopigmentation	B-DISEASE
,	O
bone	B-DISEASE
spicules	I-DISEASE
,	O
and	O
retinal	B-DISEASE
pigment	I-DISEASE
epithelium	I-DISEASE
(	I-DISEASE
RPE	I-DISEASE
)	I-DISEASE
atrophy	I-DISEASE
in	O
the	O
mid	O
-	O
periphery	O
of	O
BE	O
,	O
and	O
a	O
well	O
-	O
defined	O
atrophic	O
macular	O
lesion	O
in	O
the	O
right	O
eye	O
(	O
RE	O
)	O
.	O

Fratter	O
and	O
colleagues	O
presented	O
the	O
clinical	O
and	O
laboratory	O
findings	O
in	O
a	O
large	O
cohort	O
of	O
33	O
adPEO	B-DISEASE
patients	O
,	O
investigating	O
their	O
phenotypic	O
spectrum	O
.	O

However	O
we	O
think	O
that	O
this	O
is	O
unlikely	O
to	O
account	O
for	O
a	O
significant	O
proportion	O
of	O
these	O
cases	O
.	O

A	O
series	O
of	O
random	O
lights	O
of	O
different	O
intensities	O
are	O
flashed	O
in	O
the	O
peripheral	O
field	O
of	O
vision	O
of	O
the	O
patient	O
.	O

Targeted	O
DNA	O
fragments	O
were	O
captured	O
by	O
hybridization	O
to	O
the	O
capture	O
array	O
and	O
sequenced	O
on	O
Illumina	O
HiSeq2000	O
Analyzers	O
for	O
90	O
cycles	O
per	O
read	O
.	O

All	O
patients	O
presented	O
with	O
a	O
non	O
-	O
gap	O
metabolic	B-DISEASE
acidosis	I-DISEASE
(	O
plasma	O
pH	O
7	O
.	O
23	O
+	O
-	O
0	O
.	O
15	O
;	O
bicarbonate	O
9	O
.	O
67	O
+	O
-	O
0	O
.	O
62	O
mEq	O
/	O
L	O
)	O
,	O
and	O
inability	O
to	O
renal	O
acidification	O
,	O
as	O
shown	O
by	O
alkaline	O
urine	O
(	O
urine	O
pH	O
7	O
+	O
-	O
0	O
.	O
67	O
)	O
.	O

Nevertheless	O
,	O
a	O
previous	O
study	O
[	O
11	O
]	O
performed	O
in	O
six	O
families	O
with	O
the	O
recurrent	O
p	B-VARIANT
.	I-VARIANT
Ile386fs	I-VARIANT
mutation	O
found	O
they	O
presented	O
with	O
different	O
haplotypes	O
at	O
the	O
ATP6V1B1	B-GENE
locus	O
,	O
concluding	O
that	O
a	O
founder	O
effect	O
was	O
not	O
the	O
cause	O
of	O
the	O
high	O
prevalence	O
of	O
this	O
mutation	O
in	O
their	O
population	O
.	O

C	O
.	O

Evidence	O
in	O
mice	O
suggests	O
that	O
HSD17B4	B-GENE
may	O
play	O
an	O
important	O
role	O
in	O
lipid	O
homeostasis	O
in	O
the	O
testes	O
,	O
specifically	O
in	O
Sertoli	O
cells	O
[	O
19	O
]	O
.	O

The	O
carotid	O
and	O
the	O
transcranial	O
Doppler	O
scans	O
showed	O
no	O
prominent	O
stenosis	B-DISEASE
or	O
occlusion	B-DISEASE
of	I-DISEASE
the	I-DISEASE
major	I-DISEASE
intracranial	I-DISEASE
large	I-DISEASE
arteries	I-DISEASE
.	O

All	O
intron	O
-	O
exon	O
boundaries	O
and	O
coding	O
exons	O
were	O
sequenced	O
for	O
nine	O
genes	O
(	O
GJA10	B-GENE
,	O
POU3F2	B-GENE
,	O
C6orf168	B-GENE
,	O
LIN28B	B-GENE
,	O
Hsa	B-GENE
-	I-GENE
mir	I-GENE
-	I-GENE
587	I-GENE
,	O
SOBP	B-GENE
,	O
FOXO3	B-GENE
AMD1	B-GENE
,	O
and	O
LAMA4	B-GENE
)	O
.	O

Mercer	O
et	O
al	O
.	O

Those	O
with	O
large	O
chromosomal	O
deletions	O
can	O
present	O
with	O
body	O
part	O
malformations	O
,	O
cataracts	B-DISEASE
,	O
basal	B-DISEASE
ganglia	I-DISEASE
calcifications	I-DISEASE
,	O
severe	O
mental	B-DISEASE
weakness	I-DISEASE
,	O
or	O
autism	B-DISEASE
17	O
)	O
,	O
suggesting	O
that	O
the	O
chromosomal	O
deletion	O
may	O
involve	O
other	O
gene	O
(	O
s	O
)	O
.	O

Author	O
Contributions	O
:	O
Laboratory	O
work	O
:	O
AS	O
,	O
CS	O
,	O
GC	O
,	O
OJ	O
,	O
ZP	O
,	O
JDB	O
,	O
DM	O
,	O
IN	O
,	O
YW	O
,	O
LL	O
,	O
YH	O
,	O
SG	O
,	O
ELC	O
,	O
NGC	O
,	O
ETG	O
Data	O
Processing	O
:	O
BMN	O
,	O
KES	O
,	O
EL	O
,	O
AK	O
,	O
JF	O
,	O
MF	O
,	O
KS	O
,	O
TF	O
,	O
KG	O
,	O
EB	O
,	O
RP	O
,	O
MDP	O
,	O
SG	O
,	O
SY	O
,	O
VM	O
,	O
JL	O
,	O
JDB	O
,	O
AS	O
,	O
CS	O
,	O
UN	O
,	O
JGR	O
,	O
JRW	O
,	O
BEB	O
,	O
SEL	O
,	O
CFL	O
,	O
LSW	O
,	O
OV	O
Statistical	O
Analysis	O
:	O
BMN	O
,	O
LL	O
,	O
KES	O
,	O
CS	O
,	O
BFV	O
,	O
JM	O
,	O
ER	O
,	O
SS	O
,	O
PP	O
,	O
YK	O
,	O
AM	O
,	O
RD	O
,	O
CFL	O
,	O
LSW	O
,	O
HL	O
,	O
TZ	O
,	O
EB	O
,	O
RAG	O
,	O
JDB	O
,	O
CB	O
,	O
EHC	O
,	O
JSS	O
,	O
GDS	O
,	O
BD	O
,	O
KR	O
,	O
MJD	O
PIs	O
/	O
Study	O
design	O
:	O
EB	O
,	O
RAG	O
,	O
EHC	O
,	O
JDB	O
,	O
KR	O
,	O
BD	O
,	O
GDS	O
,	O
JSS	O
,	O
MJD	O
;	O
Yan	O
Kou	O
,	O
Li	O
Liu	O
,	O
Avi	O
Ma	O
'	O
ayan	O
,	O
Kaitlin	O
E	O
.	O

It	O
is	O
possible	O
that	O
,	O
in	O
addition	O
to	O
NMD	B-DISEASE
,	O
other	O
mechanisms	O
of	O
transcriptional	O
regulation	O
could	O
be	O
resulting	O
in	O
this	O
observed	O
differential	O
allelic	O
expression	O
,	O
such	O
as	O
epigenetic	O
,	O
environmental	O
or	O
stochastic	O
events	O
[	O
27	O
,	O
28	O
]	O
.	O

To	O
measure	O
[	O
14	O
C	O
]	O
formate	O
uptake	O
,	O
sorted	O
cells	O
in	O
the	O
24	O
-	O
well	O
culture	O
cluster	O
were	O
first	O
incubated	O
for	O
30	O
min	O
in	O
a	O
solution	O
containing	O
130	O
mM	O
NaCl	O
,	O
20	O
mM	O
HEPES	O
,	O
5	O
mM	O
KCl	O
,	O
5	O
mM	O
glucose	O
,	O
2	O
mM	O
CaCl	O
2	O
and	O
1	O
mM	O
MgCl	O
2	O
(	O
pH	O
7	O
.	O
3	O
and	O
305	O
Osm	O
/	O
L	O
)	O
.	O

Because	O
about	O
2	O
/	O
3	O
of	O
RPGR	B-GENE
mutations	O
reside	O
in	O
ORF15	B-GENE
RPGR	B-GENE
[	O
37	O
]	O
,	O
its	O
inaccessibility	O
causes	O
a	O
diagnostic	O
gap	O
.	O

The	O
standard	O
deviation	O
was	O
7	O
.	O
8	O
years	O
for	O
onset	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
the	O
female	O
group	O
and	O
three	O
of	O
the	O
11	O
females	O
(	O
27	O
%	O
)	O
had	O
no	O
hearing	B-DISEASE
loss	I-DISEASE
at	O
ages	O
10	O
.	O
9	O
,	O
11	O
.	O
7	O
,	O
and	O
15	O
.	O
8	O
years	O
.	O

Genotypes	O
of	O
43	O
individuals	O
with	O
Usher	B-DISEASE
syndrome	I-DISEASE
Biallelic	O
mutations	O
were	O
identified	O
in	O
36	O
individuals	O
in	O
USH2A	B-GENE
(	O
transcript	O
NM_206933	O
.	O
2	O
)	O
,	O
MYO7A	B-GENE
(	O
transcript	O
NM_000260	O
.	O
3	O
)	O
,	O
GRP98	B-GENE
(	O
transcript	O
NM_032119	O
.	O
3	O
)	O
.	O

Chr	O
:	O
chromosome	O
;	O
Ref	O
:	O
reference	O
base	O
;	O
Obs	O
:	O
observed	O
base	O
;	O
NCBI	O
RS	O
:	O
NCBI	O
Reference	O
Sequence	O
;	O
Variant	O
Category	O
:	O
NS	O
SNV	O
=	O
nonsynonymous	O
single	O
nucleotide	O
variant	O
,	O
S	O
SNV	O
=	O
synonymous	O
single	O
nucleotide	O
variant	O
;	O
Note	O
:	O
NC	O
=	O
Not	O
confirmed	O
by	O
Sanger	O
sequencing	O
,	O
C	O
=	O
Confirmed	O
by	O
Sanger	O
sequencing	O
,	O
E	O
=	O
excluded	O
.	O

The	O
control	O
group	O
was	O
composed	O
of	O
192	O
unrelated	O
Japanese	O
individuals	O
who	O
had	O
normal	O
hearing	O
shown	O
by	O
auditory	O
testing	O
.	O

Our	O
integrated	O
analysis	O
of	O
germline	O
and	O
somatic	O
variants	O
identifies	O
a	O
set	O
of	O
known	O
ovarian	B-DISEASE
cancer	I-DISEASE
susceptibility	O
variants	O
and	O
prioritizes	O
a	O
set	O
of	O
variants	O
without	O
previous	O
association	O
with	O
ovarian	B-DISEASE
cancer	I-DISEASE
susceptibility	O
.	O

The	O
majority	O
of	O
mutations	O
that	O
result	O
in	O
dominant	O
type	B-DISEASE
2	I-DISEASE
Stickler	I-DISEASE
syndrome	I-DISEASE
have	O
been	O
found	O
to	O
affect	O
consensus	O
splice	O
sites	O
in	O
the	O
COL11A1	B-GENE
gene	O
and	O
result	O
in	O
exon	O
skipping	O
.	O

For	O
the	O
OPA1	B-GENE
gene	O
,	O
cDNA	O
numbering	O
+	O
1	O
corresponds	O
to	O
A	O
in	O
the	O
ATG	O
translation	O
initiation	O
codon	O
of	O
OPA1	B-GENE
isoform	O
1	O
.	O

Importantly	O
,	O
one	O
of	O
the	O
most	O
interesting	O
findings	O
of	O
this	O
study	O
was	O
the	O
detection	O
of	O
ATP6V1B1	B-GENE
c	B-VARIANT
.	I-VARIANT
1155dupC	I-VARIANT
mutation	O
in	O
homozygosis	O
in	O
12	O
patients	O
from	O
9	O
families	O
.	O

The	O
mean	O
age	O
for	O
the	O
probands	O
'	O
first	O
visit	O
to	O
the	O
eye	O
clinic	O
was	O
about	O
15	O
years	O
(	O
15	O
+	O
-	O
8	O
.	O
8	O
years	O
;	O
ranging	O
from	O
4	O
to	O
35	O
years	O
)	O
.	O

Sections	O
were	O
viewed	O
using	O
an	O
Olympus	O
BX61	O
microscope	O
equipped	O
with	O
motorized	O
z	O
-	O
axis	O
and	O
epifluorescence	O
illumination	O
.	O

11	O
)	O
,	O
whereby	O
the	O
ahl5	B-DISEASE
QTL	O
accounts	O
for	O
~	O
60	O
%	O
of	O
the	O
variation	O
observed	O
.	O

[	O
16	O
]	O
reported	O
a	O
gradual	O
reduction	O
in	O
peripapillary	O
RNFL	B-DISEASE
thickness	I-DISEASE
with	O
age	O
in	O
10	O
ADOA	B-DISEASE
patients	O
with	O
OPA1	B-GENE
mutations	O
as	O
well	O
as	O
in	O
30	O
healthy	O
subjects	O
using	O
Stratus	O
OCT	O
.	O

Ocular	O
evaluation	O
of	O
12	O
patients	O
showed	O
a	O
spectrum	O
of	O
findings	O
(	O
Table	O
S5	O
)	O
.	O

In	O
total	O
,	O
33	O
of	O
the	O
37	O
mutations	O
were	O
novel	O
pathogenic	O
mutations	O
.	O

Remarkable	O
is	O
the	O
typical	O
ski	O
-	O
slope	O
audiogram	O
configuration	O
for	O
patients	O
with	O
postlingual	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
as	O
seen	O
in	O
,	O
for	O
example	O
,	O
individuals	O
A5	O
,	O
F3	O
,	O
D6	O
,	O
and	O
H3	O
.	O

In	O
total	O
,	O
98	O
nucleotide	O
variants	O
were	O
identified	O
,	O
8	O
of	O
which	O
are	O
causative	O
mutations	O
and	O
90	O
are	O
simple	O
polymorphisms	O
,	O
32	O
exonic	O
and	O
58	O
intronic	O
.	O

The	O
onset	O
of	O
deafness	B-DISEASE
of	O
34	O
patients	O
was	O
unclear	O
.	O

PCR	O
products	O
were	O
sequenced	O
using	O
forward	O
primers	O
to	O
screen	O
for	O
mutations	O
in	O
KCNJ10	B-GENE
(	O
Doobio	O
Biotechnology	O
Co	O
.	O
,	O
China	O
)	O
.	O

YJX	O
and	O
SC	O
collected	O
the	O
samples	O
,	O
performed	O
most	O
of	O
the	O
experiments	O
,	O
and	O
draft	O
the	O
manuscript	O
.	O

Three	O
clinical	O
types	O
can	O
be	O
distinguished	O
[	O
1	O
]	O
.	O

We	O
thank	O
David	O
Baux	O
for	O
helpful	O
discussion	O
and	O
careful	O
reading	O
of	O
the	O
manuscript	O
.	O

The	O
clinical	O
characteristics	O
and	O
genotypes	O
of	O
the	O
patients	O
are	O
listed	O
in	O
Table	O
1	O
.	O

Protein	O
structural	O
models	O
for	O
GIPC3	B-GENE
(	O
the	O
wild	O
type	O
and	O
p	B-VARIANT
.	I-VARIANT
H170N	I-VARIANT
)	O
were	O
built	O
(	O
Figures	O
4A	O
and	O
4B	O
)	O
.	O

For	O
splice	O
-	O
site	O
mutations	O
,	O
24	O
possible	O
candidates	O
for	O
causative	O
mutations	O
were	O
selected	O
because	O
SNVs	O
within	O
+	O
/	O
-	O
2base	O
from	O
the	O
exon	O
-	O
intron	O
junction	O
site	O
were	O
considered	O
to	O
be	O
important	O
for	O
splicing	O
[	O
21	O
]	O
,	O
[	O
22	O
]	O
.	O

These	O
findings	O
and	O
especially	O
the	O
clinical	O
features	O
of	O
the	O
two	O
affected	O
sibs	O
of	O
FRP	O
-	O
360	O
illustrate	O
the	O
impressive	O
wide	O
spectrum	O
of	O
sensorineural	O
hearing	B-DISEASE
impairment	I-DISEASE
in	O
type	O
and	O
degree	O
and	O
the	O
high	O
degree	O
of	O
intersubject	O
and	O
intrafamiliar	O
variability	O
due	O
to	O
CLRN1	B-GENE
mutations	O
as	O
previously	O
reported	O
[	O
14	O
]	O
.	O

However	O
the	O
mtDNA	O
in	O
the	O
pooled	O
samples	O
was	O
not	O
uniformly	O
distributed	O
across	O
patients	O
,	O
primarily	O
due	O
to	O
biases	O
introduced	O
by	O
whole	O
genome	O
amplification	O
(	O
Supplementary	O
Fig	O
.	O

We	O
analyzed	O
a	O
two	O
-	O
generation	O
ARNSHL	B-DISEASE
family	O
(	O
family	O
1953	O
)	O
including	O
two	O
affected	O
siblings	O
(	O
16	O
and	O
24	O
years	O
old	O
)	O
and	O
unaffected	O
parents	O
(	O
Figure	O
1A	O
)	O
.	O

Family	O
PKDF800	O
was	O
enrolled	O
from	O
the	O
Punjab	O
province	O
,	O
while	O
family	O
PKDF941	O
was	O
originated	O
from	O
the	O
Khyber	O
Pakhtunkhwa	O
province	O
of	O
Pakistan	O
.	O

Its	O
exact	O
incidence	O
is	O
currently	O
unknown	O
,	O
and	O
a	O
mutation	O
in	O
one	O
of	O
the	O
identified	O
KS	B-DISEASE
genes	O
has	O
only	O
been	O
found	O
in	O
~	O
30	O
%	O
of	O
the	O
patients	O
.	O

This	O
feature	O
is	O
compatible	O
with	O
the	O
stable	O
nature	O
of	O
most	O
of	O
the	O
DFNA8	B-DISEASE
/	I-DISEASE
12	I-DISEASE
cases	O
,	O
except	O
those	O
in	O
which	O
a	O
cysteine	O
residue	O
is	O
mutated	O
[	O
12	O
]	O
,	O
[	O
13	O
]	O
,	O
[	O
16	O
]	O
.	O

The	O
large	O
number	O
of	O
these	O
genes	O
,	O
as	O
well	O
as	O
in	O
some	O
cases	O
their	O
large	O
size	O
,	O
has	O
heretofore	O
precluded	O
comprehensive	O
genetic	O
diagnosis	O
in	O
these	O
populations	O
.	O

In	O
summary	O
,	O
we	O
have	O
combined	O
both	O
the	O
Deafness	B-DISEASE
Gene	O
Mutation	O
Detection	O
Array	O
and	O
exome	O
sequencing	O
to	O
identify	O
deafness	B-DISEASE
causative	O
variants	O
in	O
this	O
composite	O
family	O
with	O
deaf	B-DISEASE
by	O
deaf	B-DISEASE
mating	O
.	O

PE	O
:	O
Pseudoexon	O
40	O
.	O

These	O
programs	O
generated	O
a	O
pathogenic	O
nature	O
prediction	O
for	O
the	O
change	O
.	O

Also	O
,	O
overexpression	O
of	O
the	O
mutant	O
chain	O
activated	O
the	O
UPR	O
signalling	O
cascade	O
to	O
a	O
greater	O
extent	O
compared	O
to	O
WT	O
chains	O
[	O
19	O
]	O
.	O

The	O
prevalences	O
of	O
biallelic	O
mutations	O
in	O
SLC26A4	B-GENE
were	O
0	O
%	O
,	O
92	O
%	O
,	O
92	O
%	O
,	O
and	O
0	O
%	O
,	O
and	O
prevalences	O
of	O
monoallelic	O
mutations	O
were	O
3	O
.	O
6	O
%	O
,	O
6	O
.	O
0	O
%	O
,	O
6	O
.	O
0	O
%	O
,	O
and	O
12	O
.	O
5	O
%	O
in	O
the	O
four	O
respective	O
aforementioned	O
groups	O
.	O

We	O
therefore	O
investigated	O
whether	O
ELMOD3	B-GENE
also	O
possesses	O
GAP	O
activity	O
against	O
Arl2	O
.	O

Scheme	O
of	O
the	O
EYS	B-GENE
gene	O
with	O
non	O
-	O
coding	O
(	O
light	O
grey	O
)	O
and	O
coding	O
(	O
black	O
)	O
exons	O
.	O

All	O
identified	O
mutations	O
and	O
variants	O
in	O
CNGA1	B-GENE
gene	O
are	O
summarized	O
in	O
Table	O
2	O
and	O
sequence	O
data	O
are	O
given	O
in	O
Figure	O
2	O
.	O

Anomalies	B-DISEASE
on	I-DISEASE
limb	I-DISEASE
development	I-DISEASE
were	O
not	O
observed	O
in	O
all	O
5	O
patients	O
.	O

1	O
B	O
)	O
.	O

At	O
diagnosis	O
,	O
22	O
(	O
47	O
.	O
8	O
%	O
)	O
boys	O
were	O
aged	O
less	O
than	O
one	O
year	O
,	O
9	O
(	O
19	O
%	O
)	O
between	O
1	O
and	O
11	O
years	O
,	O
and	O
15	O
(	O
32	O
.	O
6	O
%	O
)	O
11	O
to	O
17	O
.	O
6	O
years	O
.	O

Andrea	O
M	O
.	O

The	O
temporal	O
bone	O
CT	O
scan	O
was	O
performed	O
with	O
a	O
16	O
multidetector	O
row	O
CT	O
scanner	O
(	O
Somatom	O
Sensation	O
16	O
;	O
Siemens	O
,	O
Erlangen	O
,	O
Germany	O
)	O
using	O
a	O
standard	O
temporal	O
bone	O
protocol	O
.	O

Cells	O
transfected	O
with	O
EGFP	O
-	O
vector	O
only	O
were	O
used	O
as	O
a	O
negative	O
control	O
.	O

Considering	O
individual	O
scores	O
,	O
all	O
the	O
OPA1	B-GENE
-	O
M	O
patients	O
improved	O
performances	O
when	O
using	O
the	O
cochlear	O
implant	O
.	O

The	O
method	O
was	O
performed	O
in	O
concordance	O
with	O
the	O
International	O
Society	O
for	O
Clinical	O
Electrophysiology	O
of	O
Vision	O
standard	O
protocol	O
(	O
ISCEV	O
)	O
.	O

The	O
results	O
of	O
the	O
analysis	O
of	O
the	O
novel	O
MYO7A	B-GENE
variants	O
are	O
summarized	O
in	O
Table	O
2	O
.	O

A	O
.	O

The	O
latter	O
predisposes	O
to	O
re	O
-	O
entrant	O
ventricular	B-DISEASE
arrhythmia	I-DISEASE
.	O

Our	O
work	O
searching	O
for	O
novel	O
deafness	B-DISEASE
genes	O
in	O
other	O
autozygous	O
areas	O
in	O
the	O
remaining	O
families	O
is	O
ongoing	O
.	O

Fifty	O
four	O
of	O
the	O
probands	O
were	O
male	O
(	O
58	O
.	O
0	O
%	O
)	O
and	O
39	O
(	O
41	O
.	O
9	O
%	O
)	O
were	O
female	O
and	O
overall	O
mean	O
age	O
for	O
CI	O
was	O
8	O
.	O
9	O
years	O
(	O
10	O
months	O
-	O
72	O
years	O
)	O
.	O

The	O
adapter	O
-	O
ligated	O
templates	O
were	O
purified	O
by	O
the	O
Agencourt	O
AMPure	O
SPRI	O
XP	O
beads	O
(	O
Beckman	O
Coulter	O
,	O
Brea	O
,	O
CA	O
,	O
USA	O
)	O
;	O
and	O
the	O
fragments	O
with	O
insert	O
size	O
about	O
250	O
bp	O
were	O
excised	O
.	O

However	O
,	O
the	O
distinctive	O
cyclic	O
structure	O
of	O
the	O
proline	O
side	O
chain	O
imparts	O
more	O
conformational	O
rigidity	O
than	O
is	O
afforded	O
by	O
other	O
amino	O
acids	O
.	O

But	O
this	O
is	O
actually	O
due	O
to	O
the	O
fact	O
that	O
DNA	O
samples	O
of	O
hearing	B-DISEASE
impaired	I-DISEASE
Hungarian	O
Roma	O
patients	O
were	O
only	O
available	O
from	O
this	O
particular	O
region	O
.	O

10	O
)	O
.	O

Unrelated	O
controls	O
(	O
100	O
)	O
were	O
collected	O
from	O
normal	O
volunteers	O
.	O

A	O
classification	O
into	O
one	O
of	O
the	O
three	O
Usher	B-DISEASE
subtypes	O
could	O
be	O
based	O
on	O
these	O
clinical	O
data	O
(	O
USH1	B-DISEASE
:	O
profound	O
HL	B-DISEASE
and	O
RP	B-DISEASE
before	O
puberty	O
and	O
often	O
VD	O
,	O
USH2	B-DISEASE
:	O
moderate	O
to	O
severe	O
HL	B-DISEASE
and	O
RP	B-DISEASE
with	O
onset	O
after	O
puberty	O
,	O
USH3	B-DISEASE
:	O
progressive	O
HL	B-DISEASE
with	O
variable	O
RP	B-DISEASE
)	O
.	O

LCPD	B-DISEASE
is	O
a	O
group	O
of	O
rare	O
inherited	B-DISEASE
chondrodysplastic	I-DISEASE
disorders	I-DISEASE
which	O
is	O
a	O
common	O
hip	O
disorder	O
in	O
children	O
characterized	O
by	O
coxa	B-DISEASE
plana	I-DISEASE
(	O
coxa	B-DISEASE
vara	I-DISEASE
and	O
elevation	O
of	O
the	O
greater	O
trochanter	O
of	O
the	O
femur	O
)	O
,	O
dislocation	O
of	O
the	O
hip	O
and	O
diminished	O
joint	O
mobility	O
.	O

Two	O
days	O
post	O
-	O
transfection	O
,	O
cells	O
were	O
lysed	O
and	O
wild	O
-	O
type	O
or	O
mutant	O
CD164	B-GENE
immunoprecipitated	O
using	O
the	O
appropriate	O
anti	O
-	O
tag	O
antibody	O
,	O
followed	O
by	O
immunoblotting	O
for	O
co	O
-	O
precipitation	O
of	O
the	O
other	O
CD164	B-GENE
form	O
.	O

All	O
patients	O
had	O
a	O
QT	O
C	O
interval	O
>	O
440	O
ms	O
for	O
men	O
and	O
450	O
ms	O
for	O
women	O
.	O

Of	O
these	O
,	O
only	O
~	O
12	O
,	O
000	O
represented	O
changes	O
that	O
could	O
potentially	O
alter	O
the	O
sequence	O
or	O
the	O
structure	O
of	O
coding	O
transcripts	O
.	O

To	O
date	O
,	O
a	O
molecular	O
genetic	O
diagnosis	O
is	O
attained	O
in	O
only	O
approximately	O
30	O
%	O
of	O
KS	B-DISEASE
patients	O
[	O
24	O
,	O
25	O
]	O
,	O
which	O
implies	O
the	O
existence	O
of	O
additional	O
genes	O
underlying	O
KS	B-DISEASE
.	O

Scheme	O
of	O
the	O
multiphasic	O
analysis	O
of	O
WES	O
data	O
(	O
C	O
)	O
.	O

Using	O
RFLP	O
or	O
SSCP	O
analysis	O
,	O
we	O
confirmed	O
the	O
five	O
mutations	O
cosegregated	O
with	O
the	O
USH2	B-DISEASE
phenotype	O
(	O
Figure	O
1	O
,	O
Figure	O
4	O
,	O
and	O
Figure	O
5	O
)	O
,	O
but	O
we	O
did	O
not	O
detect	O
them	O
in	O
100	O
normal	O
controls	O
.	O

Several	O
factors	O
can	O
influence	O
uniformity	O
and	O
unbiased	O
capture	O
and	O
these	O
include	O
biases	O
in	O
the	O
GC	O
content	O
as	O
we	O
clearly	O
illustrate	O
in	O
this	O
study	O
(	O
Figure	O
2	O
)	O
.	O

Novel	O
missense	O
variants	O
were	O
defined	O
as	O
pathogenic	O
if	O
they	O
were	O
1	O
)	O
non	O
-	O
synonymous	O
;	O
2	O
)	O
exhibited	O
a	O
low	O
carrier	O
rate	O
(	O
<	O
1	O
%	O
)	O
in	O
96	O
normal	O
in	O
-	O
house	O
control	O
Japanese	O
subjects	O
and	O
in	O
public	O
databases	O
[	O
(	O
dbSNP135	O
[	O
23	O
]	O
,	O
1000GENOME	O
[	O
24	O
]	O
,	O
and	O
NHLBI	O
Exome	O
Variant	O
Server	O
[	O
25	O
]	O
]	O
;	O
3	O
)	O
exhibited	O
high	O
amino	O
acid	O
conservation	O
among	O
12	O
primate	O
,	O
45	O
mammal	O
,	O
and	O
43	O
vertebrate	O
species	O
using	O
UCSC	O
Conservation	O
[	O
26	O
]	O
;	O
4	O
)	O
demonstrated	O
consistency	O
with	O
phenotypes	O
in	O
family	O
members	O
;	O
and	O
5	O
)	O
were	O
detected	O
in	O
patients	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
identified	O
as	O
heterozygous	O
in	O
association	O
with	O
another	O
previously	O
reported	O
or	O
determined	O
heterozygous	O
mutation	O
.	O

Recently	O
the	O
next	O
generation	O
DNA	O
sequencing	O
technology	O
has	O
come	O
of	O
age	O
[	O
6	O
]	O
.	O

Among	O
the	O
23	O
pathogenic	O
mutations	O
,	O
14	O
cause	O
truncated	O
connexin	O
26	O
proteins	O
due	O
to	O
nonsense	O
or	O
frame	O
-	O
shift	O
mutations	O
,	O
8	O
are	O
missense	O
mutations	O
,	O
and	O
one	O
is	O
a	O
deletion	O
of	O
one	O
amino	O
acid	O
.	O

According	O
to	O
familial	O
information	O
,	O
all	O
the	O
patients	O
started	O
to	O
walk	O
later	O
than	O
normal	O
,	O
at	O
about	O
two	O
years	O
of	O
age	O
,	O
and	O
had	O
balance	B-DISEASE
problems	I-DISEASE
,	O
indicating	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
.	O

Our	O
results	O
suggest	O
that	O
the	O
pathogenesis	O
underlying	O
the	O
hearing	B-DISEASE
loss	I-DISEASE
associated	O
with	O
these	O
mutations	O
is	O
the	O
result	O
of	O
reduced	O
membrane	O
expression	O
and	O
decreased	O
transport	O
capability	O
of	O
the	O
proteins	O
.	O

USH2A	B-GENE
,	O
located	O
on	O
chromosome	O
1q41	O
,	O
is	O
the	O
most	O
commonly	O
mutated	O
gene	O
in	O
Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
2	I-DISEASE
(	O
USH2	B-DISEASE
)	O
[	O
9	O
]	O
.	O

Amplification	O
conditions	O
were	O
94	O
deg	O
C	O
for	O
5	O
min	O
,	O
then	O
35	O
cycles	O
of	O
94	O
deg	O
C	O
for	O
30	O
s	O
,	O
56	O
-	O
60	O
deg	O
C	O
for	O
30	O
s	O
,	O
72	O
deg	O
C	O
for	O
30	O
s	O
or	O
60	O
s	O
,	O
and	O
a	O
final	O
extension	O
time	O
of	O
10	O
min	O
at	O
72	O
deg	O
C	O
.	O

The	O
findings	O
from	O
this	O
patient	O
are	O
consistent	O
with	O
the	O
increasing	O
evidence	O
of	O
intermediate	O
phenotypes	O
in	O
PRS	B-DISEASE
-	I-DISEASE
I	I-DISEASE
syndromes	I-DISEASE
,	O
recently	O
described	O
by	O
several	O
authors	O
[	O
6	O
,	O
7	O
,	O
12	O
,	O
37	O
]	O
.	O

Thus	O
,	O
GJB2	B-GENE
mutant	O
alleles	O
account	O
for	O
17	O
.	O
9	O
%	O
(	O
739	O
/	O
4126	O
)	O
of	O
the	O
total	O
alleles	O
in	O
2063	O
NSHI	B-DISEASE
patients	O
.	O

More	O
detail	O
and	O
descriptions	O
regarding	O
how	O
the	O
specific	O
activities	O
were	O
calculated	O
from	O
this	O
assay	O
can	O
be	O
found	O
in	O
the	O
report	O
by	O
Bowzard	O
et	O
al	O
[	O
29	O
]	O
.	O

However	O
,	O
the	O
podocyte	O
is	O
part	O
of	O
a	O
complex	O
glomerular	O
filtration	O
barrier	O
that	O
is	O
responsible	O
for	O
the	O
permselectivity	O
of	O
the	O
glomerulus	O
.	O

Transcripts	O
of	O
TBX1	B-GENE
.	O

Norrie	B-DISEASE
disease	I-DISEASE
appears	O
to	O
be	O
genetically	O
homogenous	O
as	O
it	O
is	O
caused	O
by	O
mutations	O
in	O
NDP	B-GENE
.	O

We	O
thank	O
nurses	O
Tiziana	O
Gavagnin	O
and	O
Alessia	O
Musig	O
who	O
collected	O
the	O
blood	O
samples	O
for	O
genetic	O
analysis	O
.	O

All	O
affected	O
members	O
in	O
these	O
families	O
were	O
diagnosed	O
as	O
having	O
hereditary	O
NSHL	B-DISEASE
by	O
a	O
complete	O
hearing	O
evaluation	O
,	O
general	O
examination	O
and	O
medical	O
history	O
collection	O
.	O

Despite	O
the	O
high	O
frequency	O
of	O
the	O
associated	O
malformations	O
and	O
excluding	O
the	O
patients	O
with	O
CHARGE	B-DISEASE
or	O
ichtyosis	B-DISEASE
,	O
the	O
4	O
patients	O
with	O
mutations	O
had	O
no	O
family	O
history	O
or	O
malformation	O
.	O

Our	O
data	O
confirm	O
that	O
WGS	O
of	O
a	O
healthy	O
individual	O
identifies	O
multiple	O
VUS	O
in	O
medically	O
important	O
genes	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
R205Q	I-VARIANT
mutation	O
of	O
myosin	B-GENE
VI	I-GENE
was	O
generated	O
by	O
PCR	O
-	O
based	O
site	O
-	O
directed	O
mutagenesis	O
[	O
41	O
]	O
using	O
Pfu	O
DNA	O
polymerase	O
.	O

Subsequently	O
,	O
a	O
secondary	O
antibody	O
Alexa	O
-	O
Fluor	O
568	O
Goat	O
anti	O
-	O
rabbit	O
(	O
Life	O
Technologies	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
;	O
1	O
:	O
1000	O
)	O
was	O
applied	O
for	O
1h	O
.	O

(	O
C	O
)	O
Error	O
rate	O
for	O
each	O
error	O
category	O
in	O
the	O
region	O
of	O
entire	O
amplicon	O
(	O
pale	O
blue	O
)	O
,	O
that	O
without	O
designed	O
primer	O
regions	O
(	O
light	O
blue	O
)	O
,	O
and	O
the	O
target	O
regions	O
(	O
CDS	O
+	O
flanking	O
intron	O
;	O
dark	O
blue	O
)	O
,	O
respectively	O
.	O

While	O
modifier	O
loci	O
could	O
theoretically	O
exist	O
in	O
any	O
part	O
of	O
the	O
genome	O
,	O
it	O
is	O
not	O
unreasonable	O
to	O
suggest	O
that	O
alterations	O
in	O
genes	O
important	O
to	O
skeletal	O
development	O
may	O
be	O
prime	O
candidates	O
[	O
2	O
]	O
.	O

As	O
arginine	O
702	O
,	O
even	O
asparagine	O
at	O
residue	O
1447	O
of	O
the	O
coiled	O
-	O
coil	O
tail	O
is	O
a	O
conserved	O
amino	O
acid	O
,	O
which	O
was	O
previously	O
found	O
to	O
be	O
hit	O
by	O
mutations	O
p	B-VARIANT
.	I-VARIANT
Asp1447His	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
Asp1447Val	I-VARIANT
in	O
a	O
few	O
MYH9	B-GENE
-	O
RD	O
patients	O
[	O
11	O
,	O
13	O
]	O
.	O

designed	O
the	O
study	O
.	O

Liu	O
et	O
al	O
.	O

The	O
patient	O
was	O
the	O
only	O
child	O
of	O
a	O
healthy	O
non	O
-	O
consanguineous	O
couple	O
.	O

However	O
,	O
comprehensive	O
genetic	O
tests	O
for	O
deafness	B-DISEASE
genes	O
by	O
Sanger	O
sequencing	O
is	O
extremely	O
expensive	O
and	O
time	O
-	O
consuming	O
.	O

Exon	O
1	O
to	O
8	O
of	O
the	O
WFS1	B-GENE
gene	O
,	O
including	O
flanking	O
intronic	O
regions	O
,	O
were	O
amplified	O
by	O
PCR	O
and	O
sequenced	O
on	O
an	O
automated	O
sequencer	O
(	O
ABI	O
3730	O
,	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
.	O

The	O
most	O
frequent	O
forms	O
of	O
syndromic	O
RP	B-DISEASE
are	O
Usher	O
and	O
Bardet	O
-	O
Biedl	O
syndromes	O
.	O

Thirty	O
-	O
nine	O
genes	O
underlying	O
non	O
-	O
syndromic	O
hearing	B-DISEASE
impairment	I-DISEASE
have	O
been	O
identified	O
and	O
more	O
than	O
a	O
dozen	O
genes	O
involved	O
in	O
syndromic	O
deafness	B-DISEASE
have	O
also	O
been	O
uncovered	O
[	O
3	O
]	O
.	O

The	O
expression	O
in	O
the	O
hair	O
cells	O
was	O
weaker	O
than	O
in	O
the	O
other	O
cell	O
types	O
,	O
consistent	O
with	O
the	O
mRNA	O
expression	O
pattern	O
of	O
cd164	B-GENE
in	O
the	O
Shared	O
Harvard	O
Inner	O
-	O
Ear	O
Laboratory	O
Database	O
(	O
SHIELD	O
)	O
database	O
.	O

M	O
.	O
S	O
.	O

Recently	O
we	O
showed	O
that	O
when	O
AB8	O
/	O
13	O
undifferentiated	O
podocytes	O
are	O
transiently	O
transfected	O
with	O
a	O
mutant	O
COL4A3	B-GENE
chain	O
carrying	O
mutation	O
p	B-VARIANT
.	I-VARIANT
(	I-VARIANT
G1334E	I-VARIANT
)	I-VARIANT
,	O
the	O
efficiency	O
of	O
secretion	O
of	O
the	O
mutant	O
chain	O
was	O
compromised	O
,	O
compared	O
to	O
WT	O
,	O
as	O
evidenced	O
by	O
increased	O
intracellular	O
retention	O
.	O

QuickChange	O
Site	O
-	O
Directed	O
Mutagenesis	O
Kit	O
(	O
Stratagene	O
,	O
Cambridge	O
,	O
UK	O
)	O
was	O
used	O
for	O
site	O
-	O
specific	O
mutagenesis	O
to	O
introduce	O
the	O
P185	O
mutation	O
(	O
S4	O
Table	O
)	O
.	O

1A	O
)	O
also	O
failed	O
the	O
new	O
born	O
hearing	O
screen	O
but	O
was	O
otherwise	O
normal	O
.	O

An	O
orange	O
box	O
indicates	O
the	O
area	O
shown	O
in	O
(	O
e	O
)	O
.	O

Remarkably	O
,	O
the	O
clinical	O
heterogeneity	O
of	O
retinal	O
disorders	O
was	O
highlighted	O
by	O
the	O
identification	O
of	O
RD3	B-GENE
-	O
up	O
to	O
now	O
associated	O
only	O
to	O
LCA	B-DISEASE
-	O
as	O
causative	O
of	O
RP	B-DISEASE
(	O
Table	O
1	O
)	O
,	O
increasing	O
the	O
phenotypes	O
associated	O
to	O
the	O
gene	O
mutations	O
.	O

After	O
two	O
missense	O
mutations	O
reported	O
in	O
one	O
Indian	O
and	O
one	O
Dutch	O
family	O
in	O
GIPC3	B-GENE
[	O
35	O
]	O
,	O
very	O
recently	O
six	O
more	O
missense	O
and	O
a	O
nonsense	O
mutations	O
were	O
described	O
in	O
seven	O
Pakistani	O
families	O
[	O
41	O
]	O
(	O
Figure	O
5	O
)	O
.	O

Recently	O
,	O
a	O
NOTCH2	B-GENE
variant	O
has	O
been	O
reported	O
in	O
one	O
MODY	B-DISEASE
affected	O
patient	O
[	O
16	O
]	O
,	O
therefore	O
similarly	O
to	O
other	O
MODY	B-DISEASE
causative	O
genes	O
[	O
29	O
]	O
-	O
[	O
31	O
]	O
,	O
that	O
are	O
resulted	O
also	O
CHI	B-DISEASE
causative	O
,	O
we	O
propose	O
NOTCH2	B-GENE
as	O
a	O
good	O
candidate	O
for	O
further	O
investigations	O
.	O

DNA	O
sequence	O
analysis	O
and	O
RFLP	O
analysis	O
of	O
other	O
family	O
members	O
showed	O
that	O
the	O
mutations	O
cosegregated	O
with	O
the	O
disease	O
.	O

The	O
three	O
electropherograms	O
show	O
the	O
homozygote	O
AA	O
,	O
heterozygote	O
GA	O
,	O
and	O
homozygote	O
GG	O
.	O

By	O
extending	O
our	O
standard	O
screening	O
protocol	O
,	O
we	O
identified	O
mutations	O
in	O
COMP	B-GENE
and	O
COL2A1	B-GENE
in	O
the	O
remaining	O
PSACH	B-DISEASE
patient	O
and	O
in	O
three	O
MED	B-DISEASE
patients	O
.	O

Identification	O
of	O
the	O
two	O
novel	O
MYO7A	B-GENE
mutations	O
and	O
their	O
cosegregation	O
with	O
the	O
disorder	O
in	O
the	O
family	O
.	O

Additional	O
functional	O
studies	O
,	O
for	O
example	O
comparing	O
fibroblast	O
cell	O
lines	O
from	O
NO	O
-	O
1	O
family	O
members	O
,	O
are	O
also	O
warranted	O
to	O
further	O
clarify	O
whether	O
there	O
is	O
a	O
synergistic	O
action	O
between	O
the	O
exon	O
5b	O
and	O
the	O
exon	O
8	O
variants	O
in	O
compound	O
heterozygous	O
individuals	O
,	O
contributing	O
to	O
disease	O
severity	O
.	O

The	O
pyruvate	O
is	O
subsequently	O
converted	O
to	O
lactate	O
by	O
L	O
-	O
lactate	O
dehydrogenase	O
resulting	O
in	O
the	O
oxidation	O
of	O
one	O
NADH	O
molecule	O
.	O

In	O
this	O
study	O
,	O
we	O
performed	O
a	O
comprehensive	O
mutations	O
screening	O
of	O
79	O
deafness	B-DISEASE
genes	O
in	O
a	O
large	O
cohort	O
of	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
deaf	I-DISEASE
probands	O
using	O
the	O
targeted	O
NGS	O
.	O

Even	O
if	O
newer	O
versions	O
of	O
enrichment	O
kits	O
usually	O
work	O
better	O
than	O
previous	O
ones	O
,	O
when	O
looking	O
at	O
single	O
genes	O
it	O
is	O
possible	O
to	O
find	O
some	O
specific	O
exceptions	O
(	O
like	O
in	O
the	O
case	O
of	O
USH2A	B-GENE
)	O
in	O
which	O
the	O
earlier	O
version	O
of	O
the	O
kit	O
gives	O
a	O
better	O
coverage	O
curve	O
(	O
Figure	O
S3	O
)	O
.	O

The	O
physicochemical	O
difference	O
between	O
Arg	O
and	O
Ser	O
was	O
found	O
to	O
be	O
moderate	O
since	O
a	O
Grantham	O
distance	O
of	O
110	O
(	O
0	O
-	O
215	O
)	O
was	O
obtained	O
.	O

The	O
strength	O
of	O
splice	O
sites	O
is	O
estimated	O
by	O
the	O
MaxEnt	O
scores	O
.	O

The	O
ophthalmological	O
examinations	O
of	O
III	O
-	O
1	O
,	O
I	O
-	O
1	O
,	O
I	O
-	O
2	O
,	O
II	O
-	O
3	O
,	O
and	O
II	O
-	O
4	O
were	O
unremarkable	O
except	O
that	O
both	O
of	O
II	O
-	O
3	O
and	O
II	O
-	O
4	O
were	O
moderately	O
myopic	O
.	O

Performed	O
the	O
experiments	O
:	O
MM	O
SN	O
.	O

Despite	O
the	O
exhaustive	O
screening	O
of	O
PCDH15	B-GENE
,	O
including	O
the	O
direct	O
sequencing	O
of	O
all	O
coding	O
exons	O
from	O
known	O
isoforms	O
and	O
including	O
a	O
search	O
for	O
large	O
rearrangements	O
,	O
only	O
one	O
heterozygous	O
mutation	O
,	O
c	B-VARIANT
.	I-VARIANT
1304_1305insC	I-VARIANT
,	O
was	O
identified	O
in	O
patient	O
RP	B-DISEASE
-	O
1286	O
.	O

The	O
rate	O
of	O
mitochondrial	O
ATP	O
synthesis	O
and	O
the	O
ATP	O
/	O
O	O
ratio	O
were	O
determined	O
in	O
cells	O
permeabilized	O
by	O
exposure	O
to	O
digitonin	O
,	O
as	O
described	O
below	O
[	O
24	O
]	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
JCX	O
MGZ	O
.	O

Variants	O
for	O
which	O
the	O
major	O
allele	O
in	O
one	O
population	O
is	O
the	O
minor	O
allele	O
in	O
another	O
population	O
are	O
those	O
for	O
which	O
the	O
minimum	O
frequency	O
in	O
any	O
group	O
is	O
<	O
0	O
.	O
5	O
,	O
the	O
maximum	O
frequency	O
is	O
>	O
0	O
.	O
5	O
,	O
and	O
both	O
values	O
are	O
significantly	O
different	O
from	O
each	O
other	O
and	O
from	O
0	O
.	O
5	O
by	O
one	O
-	O
sided	O
Fisher	O
'	O
s	O
exact	O
tests	O
.	O

Chromatograms	O
showing	O
wild	O
type	O
(	O
1A	O
)	O
,	O
hemizygous	O
NM_000307	O
.	O
4	O
:	O
c	B-VARIANT
.	I-VARIANT
772delG	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
(	I-VARIANT
Glu258ArgfsX30	I-VARIANT
)	I-VARIANT
)	O
mutation	O
in	O
the	O
affected	O
male	O
(	O
1B	O
)	O
and	O
c	B-VARIANT
.	I-VARIANT
772delG	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
(	I-VARIANT
Glu258ArgfsX30	I-VARIANT
)	I-VARIANT
)	O
mutation	O
in	O
the	O
female	O
carrier	O
(	O
1C	O
)	O
.	O

,	O
2006	O
)	O
,	O
and	O
is	O
also	O
implicated	O
in	O
maintenance	O
of	O
membrane	O
potential	O
and	O
oxidative	O
phosphorylation	O
(	O
Lodi	O
et	O
al	O
.	O

Because	O
female	O
carriers	O
are	O
unaffected	O
,	O
AIFM1	B-GENE
should	O
be	O
considered	O
in	O
small	O
pedigrees	O
with	O
apparent	O
autosomal	O
recessive	O
ANSD	B-DISEASE
if	O
X	O
-	O
linked	O
inheritance	O
cannot	O
be	O
excluded	O
.	O

We	O
identified	O
70	O
families	O
with	O
familial	O
FSGS	B-DISEASE
of	O
unknown	O
cause	O
.	O

Both	O
mutations	O
co	O
-	O
segregated	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
family	O
4794	O
,	O
but	O
were	O
absent	O
in	O
the	O
56	O
index	O
patients	O
and	O
108	O
ethnicity	O
-	O
matched	O
controls	O
.	O

It	O
is	O
therefore	O
functionally	O
equivalent	O
to	O
the	O
knock	O
-	O
out	O
of	O
the	O
orthologous	O
gene	O
in	O
Eps8	B-GENE
-	O
/	O
-	O
mice	O
,	O
which	O
are	O
also	O
profoundly	O
deaf	O
[	O
10	O
,	O
11	O
]	O
.	O

The	O
predicted	O
SIFT	O
score	O
(	O
<	O
0	O
.	O
05	O
)	O
and	O
the	O
absence	O
of	O
these	O
variants	O
in	O
healthy	O
controls	O
help	O
establish	O
the	O
pathogenicity	O
of	O
these	O
variants	O
.	O

Fundus	O
hypopigmentation	B-DISEASE
in	O
WS1	B-DISEASE
patients	O
have	O
been	O
demonstrated	O
in	O
the	O
Chinese	O
patients	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
we	O
describe	O
the	O
first	O
Saudi	O
family	O
with	O
USH1G	B-GENE
using	O
SNP	O
-	O
based	O
linkage	O
technology	O
.	O

During	O
the	O
neurotransmitter	O
release	O
at	O
IHCs	O
,	O
otoferlin	O
acts	O
on	O
mature	O
vesicles	O
and	O
thus	O
may	O
regulate	O
one	O
of	O
the	O
final	O
steps	O
in	O
the	O
signaling	O
pathway	O
[	O
21	O
]	O
.	O

The	O
benchmark	O
frequency	O
of	O
0	O
.	O
236	O
%	O
was	O
determined	O
based	O
on	O
the	O
MAF	O
of	O
the	O
most	O
common	O
USH	B-DISEASE
mutation	O
USH2A	B-GENE
:	O
p	B-VARIANT
.	I-VARIANT
Glu767SerfsX21	I-VARIANT
in	O
846	O
control	O
chromosomes	O
assayed	O
in	O
this	O
study	O
.	O

6a	O
,	O
b	O
)	O
and	O
impaired	O
responses	O
to	O
flicker	O
stimuli	O
at	O
high	O
frequencies	O
(	O
Fig	O
6c	O
,	O
d	O
)	O
.	O

In	O
MYO15A	B-GENE
two	O
splice	O
site	O
,	O
a	O
nonsense	O
and	O
a	O
missense	O
mutations	O
were	O
identified	O
.	O

With	O
the	O
availability	O
of	O
genotype	O
data	O
,	O
cancer	B-DISEASE
risk	O
prediction	O
methods	O
incorporating	O
genetic	O
marker	O
information	O
are	O
being	O
developed	O
,	O
for	O
which	O
ancestry	O
-	O
aware	O
allele	O
frequencies	O
can	O
be	O
an	O
essential	O
component	O
[	O
67	O
]	O
-	O
[	O
69	O
]	O
.	O

Usher	B-DISEASE
syndrome	I-DISEASE
(	O
USH	B-DISEASE
)	O
describes	O
a	O
group	O
of	O
autosomal	O
recessive	O
diseases	O
with	O
bilateral	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
and	O
visual	B-DISEASE
impairment	I-DISEASE
phenotypically	O
similar	O
to	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
(	O
RP	B-DISEASE
)	O
[	O
1	O
-	O
4	O
]	O
.	O

W6d	O
,	O
W7a	O
,	O
W7b	O
,	O
W8	O
,	O
W21	O
,	O
W26	O
,	O
W27a	O
)	O
or	O
psychiatric	B-DISEASE
problems	I-DISEASE
(	O
i	O
.	O
e	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
mutation	O
may	O
be	O
in	O
one	O
of	O
the	O
66	O
additional	O
genes	O
that	O
have	O
been	O
added	O
to	O
RetNet	O
since	O
the	O
capturing	O
reagent	O
was	O
manufactured	O
,	O
or	O
it	O
may	O
be	O
in	O
a	O
new	O
gene	O
that	O
has	O
never	O
been	O
implicated	O
in	O
retinal	B-DISEASE
dystrophy	I-DISEASE
.	O

The	O
liberated	O
pyruvate	O
was	O
determined	O
as	O
described	O
previously	O
[	O
42	O
]	O
.	O

The	O
identification	O
of	O
additional	O
mutations	O
in	O
TMC1	B-GENE
further	O
confirms	O
its	O
crucial	O
role	O
in	O
auditory	O
function	O
.	O

We	O
identified	O
2	O
known	O
causative	O
variants	O
,	O
GJB2	B-GENE
p	B-VARIANT
.	I-VARIANT
R75Q	I-VARIANT
(	O
c	B-VARIANT
.	I-VARIANT
224G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
and	O
MYO7A	B-GENE
p	B-VARIANT
.	I-VARIANT
T381M	I-VARIANT
(	O
c	B-VARIANT
.	I-VARIANT
1142C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
)	O
,	O
in	O
Family	O
DE2624	O
and	O
Family	O
DE3050	O
,	O
respectively	O
(	O
Figure	O
2	O
)	O
.	O

All	O
subjects	O
had	O
a	O
complete	O
medical	O
and	O
family	O
history	O
and	O
a	O
physical	O
examination	O
(	O
including	O
a	O
mixed	O
meal	O
challenge	O
test	O
)	O
by	O
a	O
pediatric	O
endocrinologist	O
(	O
BM	O
or	O
NHW	O
)	O
;	O
a	O
neurologic	O
history	O
and	O
complete	O
neurologic	O
exam	O
by	O
a	O
pediatric	O
neurologist	O
(	O
AP	O
and	O
AV	O
)	O
;	O
visual	O
acuity	O
,	O
refraction	O
,	O
assessment	O
of	O
nystagmus	O
,	O
color	O
vision	O
testing	O
,	O
pupillary	O
testing	O
and	O
dilated	O
fundus	O
exams	O
by	O
a	O
pediatric	O
optometrist	O
(	O
JH	O
)	O
;	O
audiology	O
exams	O
supervised	O
by	O
an	O
audiologist	O
(	O
RK	O
)	O
;	O
complete	O
family	O
history	O
by	O
a	O
genetic	O
counselor	O
(	O
LM	O
)	O
;	O
vestibular	O
examination	O
by	O
an	O
neurotolologist	O
(	O
TEH	O
)	O
;	O
urologic	O
evaluation	O
by	O
a	O
pediatric	O
urologist	O
(	O
PA	O
)	O
and	O
neuroimaging	O
supervised	O
by	O
a	O
pediatric	O
neuroradiologist	O
(	O
JS	O
)	O
,	O
and	O
psychological	O
,	O
and	O
cognitive	O
testing	O
supervised	O
by	O
a	O
neuropsychologist	O
(	O
TH	O
)	O
.	O

musculus	O
,	O
R	O
.	O

2005	O
,	O
2009	O
)	O
.	O

These	O
images	O
show	O
a	O
close	O
-	O
up	O
of	O
the	O
mutation	O
site	O
.	O

In	O
conclusion	O
,	O
SLC17A9	B-GENE
is	O
not	O
only	O
unrelated	O
to	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
this	O
family	O
;	O
its	O
haploinsufficiency	O
does	O
not	O
seem	O
to	O
cause	O
DSAP	B-DISEASE
either	O
.	O

Diagnosis	O
of	O
Diabetes	B-DISEASE
Insipidus	I-DISEASE
(	O
DI	B-DISEASE
)	O
was	O
based	O
on	O
the	O
clinical	O
findings	O
of	O
polyuria	B-DISEASE
,	O
polydipsia	B-DISEASE
,	O
an	O
osmolality	B-DISEASE
of	I-DISEASE
less	I-DISEASE
than	I-DISEASE
300	I-DISEASE
mOsm	I-DISEASE
per	I-DISEASE
kilogram	I-DISEASE
of	I-DISEASE
water	I-DISEASE
,	O
or	O
a	O
specific	O
gravity	O
of	O
less	O
than	O
1010	O
in	O
a	O
24	O
hour	O
urine	O
sample	O
without	O
glycosuria	B-DISEASE
and	O
ketonuria	O
[	O
14	O
]	O
.	O

Similar	O
to	O
NSHL	B-DISEASE
,	O
SHL	B-DISEASE
is	O
associated	O
with	O
a	O
growing	O
list	O
of	O
causative	O
genes	O
and	O
hearing	B-DISEASE
loss	I-DISEASE
syndromes	I-DISEASE
[	O
2	O
]	O
.	O

Regarding	O
the	O
origin	O
of	O
the	O
other	O
mutations	O
,	O
the	O
splice	O
-	O
site	O
(	O
c	B-VARIANT
.	I-VARIANT
175	I-VARIANT
-	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
;	O
p	O
.	O
?	O
)	O
defect	O
was	O
described	O
for	O
the	O
first	O
time	O
in	O
three	O
families	O
from	O
Algeria	O
and	O
Tunisia	O
[	O
11	O
]	O
.	O

Stapedial	O
acoustic	O
reflex	O
and	O
otoacoustic	O
emission	O
(	O
OAE	O
)	O
were	O
not	O
detected	O
at	O
all	O
frequencies	O
(	O
data	O
not	O
shown	O
)	O
.	O

Looking	O
at	O
the	O
bleeding	B-DISEASE
events	O
in	O
our	O
cohort	O
after	O
the	O
discovery	O
of	O
the	O
syndrome	O
,	O
the	O
bleeding	B-DISEASE
tendency	O
in	O
41	O
bleeders	O
was	O
associated	O
with	O
a	O
lower	O
platelet	O
count	O
(	O
P	O
=	O
0	O
.	O
0036	O
)	O
.	O

The	O
success	O
of	O
WES	O
in	O
providing	O
a	O
molecular	O
diagnosis	O
to	O
patients	O
has	O
broader	O
implications	O
with	O
regard	O
to	O
the	O
approach	O
and	O
thus	O
cost	O
of	O
testing	O
.	O

The	O
distribution	O
converged	O
within	O
10	O
8	O
trials	O
(	O
Supplementary	O
Figure	O
S4	O
)	O
and	O
this	O
,	O
in	O
turn	O
,	O
agreed	O
well	O
with	O
another	O
distribution	O
model	O
obtained	O
by	O
full	O
enumeration	O
of	O
all	O
possible	O
VAF	O
differences	O
within	O
the	O
data	O
set	O
.	O

In	O
a	O
recent	O
survey	O
,	O
USH	B-DISEASE
represented	O
10	O
.	O
8	O
%	O
of	O
inherited	O
retinal	O
dystrophies	O
in	O
southern	O
France	O
[	O
7	O
]	O
.	O

The	O
ethnic	O
minority	O
composition	O
in	O
Huaxia	O
school	O
(	O
30	O
.	O
2	O
%	O
)	O
is	O
consistent	O
with	O
that	O
of	O
the	O
province	O
'	O
s	O
.	O

Specifically	O
,	O
we	O
required	O
that	O
(	O
i	O
)	O
the	O
OMIM	O
disease	O
phenotype	O
overlapped	O
the	O
patient	O
'	O
s	O
clinical	O
features	O
;	O
(	O
ii	O
)	O
the	O
qualifying	O
genotype	O
was	O
consistent	O
with	O
the	O
reported	O
OMIM	O
inheritance	O
pattern	O
(	O
e	O
.	O
g	O
.	O
,	O
dominant	O
or	O
recessive	O
)	O
;	O
and	O
(	O
iii	O
)	O
the	O
qualifying	O
mutation	O
itself	O
was	O
reported	O
in	O
a	O
similarly	O
affected	O
patient	O
or	O
the	O
qualifying	O
mutation	O
was	O
of	O
the	O
same	O
functional	O
class	O
(	O
e	O
.	O
g	O
.	O
,	O
loss	O
-	O
of	O
-	O
function	O
,	O
missense	O
)	O
as	O
those	O
reported	O
in	O
a	O
similarly	O
affected	O
patient	O
.	O

UE	O
and	O
DE	O
refer	O
to	O
upstream	O
and	O
downstream	O
exons	O
of	O
the	O
cassette	O
,	O
respectively	O
.	O

Valle	O
;	O
E	O
.	O
J	O
.	O

At	O
48	O
h	O
posttransfection	O
protein	O
synthesis	O
was	O
stopped	O
by	O
incubating	O
the	O
cells	O
for	O
4	O
h	O
in	O
the	O
presence	O
of	O
50	O
u	O
g	O
/	O
ml	O
of	O
cycloheximide	O
.	O

Filled	O
symbols	O
display	O
affected	O
individuals	O
and	O
the	O
arrow	O
appoints	O
the	O
proband	O
of	O
the	O
family	O
.	O

RJT	O
and	O
JGP	O
performed	O
experiments	O
,	O
data	O
analysis	O
and	O
interpretation	O
of	O
results	O
.	O

This	O
included	O
gene	O
annotation	O
,	O
amino	O
acid	O
change	O
annotation	O
,	O
SIFT	O
scores	O
[	O
22	O
]	O
,	O
PolyPhen2	O
scores	O
[	O
23	O
]	O
,	O
dbSNP	O
identifiers	O
,	O
1000	O
Genomes	O
Project	O
allele	O
frequencies	O
,	O
and	O
NHLBI	O
-	O
ESP	O
5400	O
exome	O
project	O
allele	O
frequencies	O
.	O

The	O
project	O
was	O
financially	O
supported	O
by	O
the	O
EU	O
FP6	O
,	O
Integrated	O
Project	O
'	O
EVI	O
-	O
GENORET	O
'	O
(	O
LSHG	O
-	O
CT	O
-	O
2005	O
-	O
512036	O
;	O
S	O
.	O
K	O
)	O
Screening	O
of	O
mutations	O
in	O
the	O
paired	O
box	O
3	O
(	O
PAX3	B-GENE
)	O
gene	O
in	O
three	O
generations	O
of	O
a	O
Turkish	O
family	O
with	O
Waardenburg	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
1	I-DISEASE
(	O
WS1	B-DISEASE
)	O
.	O

ETC	O
studies	O
confirmed	O
this	O
suspicion	O
,	O
revealing	O
abnormal	O
complex	O
I	O
/	O
III	O
activity	O
.	O

Therefore	O
,	O
high	O
level	O
of	O
MCM2	B-GENE
will	O
affect	O
HEK293	O
cell	O
apoptosis	O
and	O
variant	O
MCM2	B-GENE
will	O
increase	O
the	O
apoptosis	O
of	O
HEK293	O
cells	O
even	O
more	O
significantly	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

A	O
mean	O
exome	O
coverage	O
of	O
81	O
.	O
65	O
x	O
was	O
obtained	O
to	O
accurately	O
call	O
variants	O
at	O
99	O
.	O
41	O
%	O
of	O
the	O
targeted	O
exome	O
[	O
12	O
,	O
13	O
]	O
.	O

Full	O
-	O
length	O
mouse	O
Gipc3	B-GENE
(	O
ref	O
.	O

In	O
isolated	O
MD	B-DISEASE
group	O
,	O
ages	O
ranged	O
from	O
14	O
months	O
to	O
26	O
years	O
and	O
the	O
average	O
age	O
was	O
8	O
years	O
.	O

Late	O
-	O
onset	O
cases	O
of	O
optic	B-DISEASE
atrophies	I-DISEASE
are	O
rarely	O
considered	O
to	O
be	O
caused	O
by	O
primary	O
hereditary	O
diseases	O
but	O
frequently	O
believed	O
to	O
be	O
due	O
to	O
secondary	O
causes	O
.	O

Gibbs	O
,	O
Kathryn	O
Roeder	O
,	O
Gerard	O
D	O
.	O

Before	O
NGS	O
paves	O
the	O
future	O
of	O
personalized	O
diagnosis	O
,	O
our	O
cost	O
-	O
and	O
time	O
-	O
effective	O
strategy	O
allows	O
a	O
quick	O
and	O
reliable	O
prioritization	O
of	O
candidates	O
,	O
which	O
is	O
suitable	O
and	O
affordable	O
for	O
middle	O
-	O
size	O
diagnostic	O
labs	O
with	O
moderate	O
to	O
high	O
number	O
of	O
family	O
cases	O
.	O

During	O
the	O
last	O
decade	O
,	O
many	O
deafness	B-DISEASE
loci	O
and	O
the	O
underlying	O
genes	O
have	O
been	O
identified	O
at	O
a	O
rapid	O
rate	O
.	O

Various	O
pathogenic	O
mutations	O
,	O
such	O
as	O
the	O
c	B-VARIANT
.	I-VARIANT
167G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
W56	I-VARIANT
*	I-VARIANT
)	O
,	O
c	B-VARIANT
.	I-VARIANT
242G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
R81H	I-VARIANT
)	O
,	O
c	B-VARIANT
.	I-VARIANT
254T	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
V85D	I-VARIANT
)	O
,	O
c	B-VARIANT
.	I-VARIANT
301G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
G101R	I-VARIANT
)	O
,	O
and	O
c	B-VARIANT
.	I-VARIANT
694G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
G232R	I-VARIANT
)	O
have	O
been	O
linked	O
with	O
ARNSHL	B-DISEASE
in	O
Caucasian	O
populations	O
[	O
7	O
]	O
,	O
[	O
19	O
]	O
.	O

The	O
SIFT	O
showed	O
scores	O
ranging	O
from	O
0	O
.	O
0	O
(	O
damaging	O
)	O
to	O
1	O
.	O
0	O
(	O
benign	O
)	O
that	O
were	O
calculated	O
using	O
position	O
-	O
specific	O
scoring	O
matrices	O
with	O
Dirichlet	O
priors	O
[	O
21	O
]	O
.	O

The	O
imaging	O
diagnostic	O
criterion	O
is	O
differet	O
about	O
Mondini	B-DISEASE
malformarion	I-DISEASE
.	O

Daly	O
are	O
lead	O
investigators	O
of	O
the	O
ARRA	O
Autism	B-DISEASE
Sequencing	O
Collaboration	O
.	O

All	O
analyses	O
were	O
performed	O
in	O
a	O
large	O
German	O
laboratory	O
specialised	O
in	O
genetic	O
diagnostics	O
.	O

Based	O
on	O
the	O
great	O
clinical	O
and	O
genetic	O
heterogeneities	O
,	O
there	O
has	O
been	O
hypothesis	O
concerning	O
the	O
relationship	O
between	O
the	O
localizations	O
of	O
the	O
mutations	O
and	O
the	O
diverse	O
clinical	O
phenotypes	O
.	O

The	O
condition	O
may	O
segregate	O
as	O
an	O
autosomal	O
dominant	O
RP	B-DISEASE
(	O
24	O
%	O
)	O
,	O
autosomal	O
recessive	O
(	O
41	O
%	O
)	O
,	O
or	O
X	O
-	O
linked	O
recessive	O
trait	O
(	O
22	O
%	O
)	O
.	O

The	O
USH2A	B-GENE
gene	O
is	O
located	O
on	O
human	O
chromosome	O
1q41	O
,	O
and	O
two	O
USH2A	B-GENE
transcripts	O
were	O
identified	O
:	O
the	O
shorter	O
one	O
consists	O
of	O
21	O
exons	O
and	O
the	O
longer	O
one	O
consists	O
of	O
72	O
exons	O
[	O
7	O
,	O
11	O
]	O
.	O

To	O
avoid	O
the	O
instability	O
that	O
might	O
occur	O
during	O
the	O
MD	O
simulations	O
,	O
the	O
solvated	O
systems	O
were	O
subjected	O
to	O
minimization	O
for	O
5000	O
cycles	O
with	O
protein	O
restrained	O
and	O
followed	O
by	O
another	O
5000	O
cycles	O
with	O
the	O
whole	O
systems	O
relaxed	O
.	O

Similar	O
structures	O
were	O
not	O
found	O
in	O
more	O
than	O
50	O
normal	O
controls	O
and	O
5	O
patients	O
with	O
advanced	O
glaucoma	O
in	O
our	O
department	O
.	O

It	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
GATA3	B-GENE
gene	O
leading	O
to	O
its	O
haploinsufficiency	O
.	O

M	O
.	O
S	O
.	O
H	O
.	O

Affected	O
patients	O
showed	O
variable	O
clinical	O
pictures	O
without	O
a	O
clear	O
genotype	O
-	O
phenotype	O
correlation	O
.	O

Deletions	O
were	O
reported	O
if	O
the	O
ratio	O
RPC	O
fell	O
below	O
75	O
%	O
.	O

Of	O
these	O
relatives	O
,	O
199	O
(	O
41	O
%	O
)	O
were	O
mutation	O
carriers	O
,	O
while	O
282	O
(	O
59	O
%	O
)	O
did	O
not	O
carry	O
a	O
mutation	O
.	O

(	O
2008	O
)	O
[	O
28	O
]	O
.	O

Clinical	O
diagnosis	O
and	O
evaluation	O
for	O
RP	B-DISEASE
were	O
based	O
on	O
the	O
decimal	O
best	O
-	O
corrected	O
visual	O
acuity	O
(	O
BCVA	O
)	O
,	O
slit	O
-	O
lamp	O
examination	O
,	O
fundus	O
examination	O
,	O
visual	O
fields	O
determined	O
using	O
kinetic	O
perimetry	O
(	O
Goldmann	O
perimeter	O
[	O
GP	O
]	O
;	O
Haag	O
Streit	O
,	O
Bern	O
,	O
Switzerland	O
)	O
and	O
electroretinography	O
(	O
ERG	O
)	O
findings	O
.	O

In	O
families	O
F1	O
,	O
F3	O
,	O
and	O
F4	O
,	O
a	O
previously	O
reported	O
in	O
-	O
frame	O
deletion	O
c	B-VARIANT
.	I-VARIANT
876_878delTGT	I-VARIANT
/	O
p	B-VARIANT
.	I-VARIANT
(	I-VARIANT
Val294del	I-VARIANT
)	O
,	O
the	O
frameshift	O
c	B-VARIANT
.	I-VARIANT
2366delA	I-VARIANT
/	O
p	B-VARIANT
.	I-VARIANT
(	I-VARIANT
Asn789Metfs	I-VARIANT
*	I-VARIANT
11	I-VARIANT
)	O
,	O
and	O
splice	O
-	O
site	O
c	B-VARIANT
.	I-VARIANT
1140	I-VARIANT
+	I-VARIANT
5G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
mutations	O
were	O
detected	O
,	O
respectively	O
.	O

The	O
~	O
37	O
kDa	O
band	O
(	O
arrow	O
head	O
)	O
and	O
~	O
29	O
kDa	O
band	O
(	O
dot	O
,	O
presumably	O
nonspecific	O
)	O
are	O
indicated	O
.	O

Scandinavian	O
,	O
French	O
,	O
European	O
,	O
and	O
Canadian	O
studies	O
[	O
12	O
,	O
14	O
,	O
16	O
,	O
24	O
-	O
26	O
]	O
previously	O
reported	O
the	O
nonsense	O
mutation	O
p	B-VARIANT
.	I-VARIANT
R626X	I-VARIANT
.	O

The	O
expected	O
effects	O
could	O
be	O
either	O
a	O
skip	O
of	O
exon	O
62	O
or	O
the	O
use	O
of	O
a	O
cryptic	O
site	O
localized	O
11	O
nucleotides	O
downstream	O
from	O
the	O
wild	O
-	O
type	O
acceptor	O
site	O
(	O
increased	O
strength	O
from	O
79	O
.	O
26	O
to	O
82	O
.	O
42	O
and	O
-	O
2	O
.	O
6	O
to	O
2	O
.	O
8	O
,	O
for	O
HSF	O
and	O
MaxEnt	O
,	O
respectively	O
)	O
.	O

We	O
used	O
site	O
-	O
directed	O
mutagenesis	O
to	O
introduce	O
several	O
mutations	O
with	O
the	O
following	O
reasoning	O
:	O
COL4A3	B-GENE
-	O
p	B-VARIANT
.	I-VARIANT
(	I-VARIANT
G1334E	I-VARIANT
)	I-VARIANT
was	O
previously	O
shown	O
to	O
induce	O
UPR	O
activation	O
[	O
19	O
]	O
and	O
served	O
as	O
a	O
positive	O
control	O
;	O
COL4A3	B-GENE
-	O
p	B-VARIANT
.	I-VARIANT
(	I-VARIANT
G871C	I-VARIANT
)	I-VARIANT
is	O
a	O
founder	O
mutation	O
in	O
the	O
Cypriot	O
population	O
,	O
predisposing	O
to	O
severe	O
CRF	B-DISEASE
/	O
ESKD	B-DISEASE
(	O
ref	O
.	O

The	O
Horizontal	O
red	O
line	O
indicates	O
the	O
median	O
age	O
of	O
the	O
group	O
and	O
the	O
blue	O
whiskers	O
represent	O
the	O
age	O
of	O
the	O
individual	O
sample	O
.	O

Although	O
many	O
de	O
novo	O
mutations	O
have	O
been	O
proposed	O
as	O
the	O
genetic	O
cause	O
of	O
RSTS	B-DISEASE
,	O
genetic	O
analyses	O
to	O
identify	O
mutations	O
have	O
often	O
yielded	O
inconsistent	O
results	O
due	O
to	O
inadequacies	O
in	O
the	O
analysis	O
methods	O
,	O
and	O
many	O
mutations	O
are	O
yet	O
to	O
be	O
confirmed	O
.	O

Blood	O
samples	O
were	O
obtained	O
from	O
deaf	O
patients	O
,	O
and	O
their	O
parents	O
and	O
sibs	O
(	O
when	O
possible	O
)	O
and	O
DNA	O
was	O
extracted	O
with	O
the	O
Nucleon	O
BACC3	O
DNA	O
extraction	O
kit	O
(	O
Amersham	O
Pharmacia	O
Biotech	O
,	O
Piscataway	O
,	O
NJ	O
)	O
.	O

(	O
2001	O
)	O
observed	O
that	O
homozygous	O
mutant	O
mice	O
with	O
a	O
targeted	O
deletion	O
of	O
the	O
ENT	O
domain	O
of	O
the	O
alpha	O
-	O
tectorin	O
gene	O
display	O
severe	O
elevation	O
of	O
the	O
mid	O
-	O
frequency	O
hearing	O
threshold	O
(	O
5	O
-	O
20	O
kHz	O
)	O
[	O
41	O
]	O
,	O
which	O
supported	O
their	O
genotype	O
-	O
phenotype	O
correlation	O
.	O

Further	O
studies	O
are	O
required	O
to	O
determine	O
the	O
long	O
-	O
term	O
benefit	O
these	O
patients	O
may	O
receive	O
from	O
cochlear	O
implantation	O
.	O

Hypoparathyroidism	B-DISEASE
,	O
sensorineural	B-DISEASE
deafness	I-DISEASE
,	O
and	O
renal	B-DISEASE
dysplasia	I-DISEASE
(	O
HDR	B-DISEASE
)	O
syndrome	O
(	O
MIM	O
146255	O
)	O
is	O
a	O
rare	O
autosomal	O
dominant	O
disease	O
characterized	O
by	O
hypoparathyroidism	B-DISEASE
,	O
sensorineural	B-DISEASE
deafness	I-DISEASE
,	O
and	O
renal	B-DISEASE
dysplasia	I-DISEASE
due	O
to	O
a	O
heterozygous	O
germline	O
mutation	O
of	O
the	O
GATA3	B-GENE
gene	O
located	O
on	O
chromosome	O
10p15	O
1	O
.	O

HEK293T	O
cells	O
(	O
The	O
European	O
Collection	O
of	O
Cell	O
Cultures	O
)	O
were	O
grown	O
to	O
80	O
%	O
confluence	O
on	O
10	O
cm	O
dishes	O
in	O
Dulbecco	O
'	O
s	O
modified	O
Eagle	O
'	O
s	O
medium	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
,	O
L	O
-	O
glutamine	O
(	O
2	O
mM	O
)	O
,	O
penicillin	O
G	O
(	O
100	O
units	O
/	O
ml	O
)	O
,	O
and	O
streptomycin	O
(	O
10	O
mg	O
/	O
ml	O
)	O
and	O
incubated	O
in	O
a	O
5	O
%	O
CO	O
2	O
humidified	O
atmosphere	O
.	O

3C	O
)	O
.	O

Furthermore	O
,	O
research	O
studies	O
have	O
focused	O
on	O
high	O
-	O
penetrance	O
susceptibility	O
alleles	O
,	O
but	O
cancer	B-DISEASE
is	O
generally	O
the	O
result	O
of	O
the	O
combined	O
effects	O
of	O
low	O
-	O
to	O
moderate	O
-	O
penetrance	O
risk	O
alleles	O
and	O
environmental	O
factors	O
[	O
5	O
]	O
.	O

(	O
b	O
)	O
RFLP	O
of	O
Nla	O
III	O
digested	O
the	O
fragment	O
flanking	O
the	O
2005T	B-VARIANT
>	I-VARIANT
C	I-VARIANT
region	O
of	O
LFSNHL	B-DISEASE
family	O
members	O
and	O
normal	O
controls	O
.	O

The	O
arginine	O
at	O
amino	O
acid	O
position	O
205	O
of	O
myosin	B-GENE
VI	I-GENE
is	O
highly	O
conserved	O
among	O
several	O
species	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
Asn342Ser	I-VARIANT
in	O
EC3	O
and	O
p	B-VARIANT
.	I-VARIANT
Glu1595Lys	I-VARIANT
in	O
EC15	O
are	O
associated	O
with	O
highly	O
conserved	O
EC	O
calcium	O
-	O
binding	O
sites	O
(	O
purple	O
)	O
in	O
the	O
linker	O
region	O
between	O
cadherin	O
repeats	O
.	O

The	O
effect	O
of	O
rare	O
or	O
private	O
non	O
-	O
synonymous	O
SNPs	O
was	O
assessed	O
by	O
the	O
PolyPhen	O
-	O
2	O
(	O
Prediction	O
of	O
functional	O
effects	O
of	O
human	O
nsSNPs	O
)	O
HumVar	O
score	O
[	O
42	O
]	O
and	O
SIFT	O
algorithm	O
(	O
Sorting	O
Tolerant	O
From	O
Intolerant	O
)	O
[	O
43	O
]	O
,	O
which	O
predict	O
damage	O
to	O
protein	O
function	O
or	O
structure	O
based	O
on	O
amino	O
acid	O
conservation	O
and	O
structural	O
data	O
.	O

Exons	O
are	O
represented	O
by	O
open	O
rectangles	O
and	O
are	O
numbered	O
,	O
and	O
intron	O
45	O
is	O
indicated	O
by	O
the	O
horizontal	O
line	O
.	O

The	O
local	O
medical	O
ethics	O
committees	O
at	O
the	O
Radboud	O
University	O
Nijmegen	O
,	O
the	O
Netherlands	O
,	O
the	O
University	O
of	O
Iowa	O
,	O
USA	O
and	O
the	O
University	O
of	O
Madras	O
,	O
India	O
approved	O
the	O
studies	O
.	O

Ten	O
samples	O
will	O
require	O
roughly	O
10	O
times	O
longer	O
,	O
as	O
the	O
Covaris	O
,	O
the	O
device	O
that	O
we	O
are	O
using	O
,	O
is	O
basically	O
limited	O
to	O
one	O
tube	O
.	O

He	O
had	O
blue	B-DISEASE
iris	I-DISEASE
,	O
faint	O
white	B-DISEASE
forelock	I-DISEASE
,	O
confluent	B-DISEASE
eyebrows	I-DISEASE
,	O
bilateral	B-DISEASE
calf	I-DISEASE
hypertrophy	I-DISEASE
,	O
mild	O
tendon	B-DISEASE
Achilles	I-DISEASE
contracture	I-DISEASE
,	O
exaggerated	B-DISEASE
lumbar	I-DISEASE
lordosis	I-DISEASE
,	O
and	O
a	O
waddling	B-DISEASE
gait	I-DISEASE
.	O

In	O
the	O
present	O
study	O
,	O
we	O
identified	O
a	O
new	O
mutation	O
(	O
c	B-VARIANT
.	I-VARIANT
541G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
;	O
p	B-VARIANT
.	I-VARIANT
A181	I-VARIANT
T	I-VARIANT
)	O
in	O
the	O
MYH14	B-GENE
gene	O
.	O

Right	O
optic	O
nerve	O
head	O
showed	O
a	O
cup	O
to	O
disc	O
ratio	O
of	O
0	O
.	O
45	O
and	O
severe	B-DISEASE
pallor	I-DISEASE
(	O
Figure	O
1A	O
)	O
.	O

DPOAEs	O
were	O
measured	O
unilaterally	O
(	O
left	O
ear	O
)	O
using	O
an	O
experimental	O
setup	O
and	O
testing	O
protocol	O
,	O
as	O
described	O
[	O
42	O
]	O
.	O

This	O
work	O
was	O
supported	O
by	O
T32	O
GM007337	O
to	O
the	O
University	O
of	O
Iowa	O
MSTP	O
and	O
by	O
NIDCD	O
RO1s	O
DC003544	O
,	O
DC002842	O
and	O
DC012049	O
to	O
RJHS	O
.	O

The	O
disclosure	O
of	O
the	O
same	O
variant	O
in	O
the	O
affected	O
members	O
of	O
the	O
Italian	O
and	O
Chinese	O
pedigrees	O
supports	O
its	O
pathogenic	O
nature	O
,	O
since	O
it	O
arose	O
independently	O
in	O
independent	O
genetic	O
backgrounds	O
.	O

All	O
patients	O
presented	O
with	O
mixed	O
type	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
ranging	O
from	O
moderate	O
to	O
profound	O
degree	O
(	O
Table	O
1	O
)	O
.	O

Additionally	O
,	O
the	O
space	O
for	O
placement	O
of	O
residue	O
69	O
is	O
narrow	O
.	O

Brain	O
MRI	O
findings	O
from	O
both	O
IOSCA	B-DISEASE
patients	O
revealed	O
high	O
-	O
intensity	O
lesions	O
of	O
the	O
middle	O
cerebellar	O
peduncles	O
.	O

For	O
the	O
purpose	O
of	O
this	O
study	O
,	O
frameshift	O
,	O
splice	O
site	O
,	O
and	O
nonsense	O
mutations	O
were	O
categorized	O
as	O
"	O
truncating	O
"	O
mutations	O
,	O
and	O
missense	O
and	O
in	O
-	O
frame	O
insertion	O
or	O
deletion	O
mutations	O
were	O
considered	O
"	O
non	O
-	O
truncating	O
"	O
mutations	O
.	O

Plain	O
radiographs	O
of	O
his	O
elbows	O
did	O
not	O
show	O
any	O
bony	O
fusion	O
or	O
abnormalities	O
.	O

Genomic	O
DNA	O
(	O
500	O
ng	O
)	O
was	O
sheared	O
by	O
fragmentation	O
(	O
with	O
a	O
majority	O
of	O
fragments	O
between	O
400	O
and	O
700	O
bp	O
)	O
.	O

The	O
funding	O
agencies	O
had	O
no	O
role	O
in	O
study	O
design	O
,	O
data	O
collection	O
and	O
analysis	O
,	O
decision	O
to	O
publish	O
,	O
or	O
preparation	O
of	O
the	O
manuscript	O
.	O
Mutations	O
in	O
CDH23	B-GENE
are	O
responsible	O
for	O
Usher	B-DISEASE
syndrome	I-DISEASE
1D	I-DISEASE
and	O
recessive	B-DISEASE
non	I-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O

lupus	O
)	O
,	O
NP_034992	O
.	O
2	O
(	O
M	O
.	O

Tick	O
marks	O
:	O
blue	O
,	O
variants	O
in	O
WS	B-DISEASE
individuals	O
;	O
red	O
,	O
variants	O
in	O
SNHI	B-DISEASE
individuals	O
;	O
green	O
,	O
variant	O
p	B-VARIANT
.	I-VARIANT
Arg703Cys	I-VARIANT
identified	O
in	O
MODY	B-DISEASE
individual	O
;	O
purple	O
with	O
asterisks	O
,	O
p	B-VARIANT
.	I-VARIANT
Trp314Arg	I-VARIANT
identified	O
in	O
current	O
study	O
showing	O
autosomal	O
dominant	O
inheritance	O
of	O
diabetes	B-DISEASE
.	O

Missense	O
changes	O
were	O
studied	O
using	O
different	O
programs	O
to	O
predict	O
whether	O
variants	O
are	O
deleterious	O
.	O

(	O
31	O
)	O
identified	O
a	O
single	O
heterozygous	O
WFS1	B-GENE
missense	O
mutation	O
(	O
encoding	O
p	B-VARIANT
.	I-VARIANT
Arg703Cys	I-VARIANT
)	O
in	O
a	O
family	O
with	O
diabetes	B-DISEASE
diagnosed	O
early	O
(	O
14	O
years	O
)	O
and	O
late	O
(	O
55	O
and	O
60	O
years	O
)	O
in	O
life	O
(	O
Fig	O
.	O

These	O
genes	O
have	O
not	O
usually	O
been	O
screened	O
and	O
therefore	O
mutations	O
in	O
them	O
have	O
not	O
been	O
diagnosed	O
by	O
the	O
conventional	O
approach	O
.	O

After	O
purification	O
,	O
amplicons	O
were	O
sequenced	O
on	O
the	O
3730	O
DNA	O
Analyzer	O
(	O
ABI	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
.	O

A	O
fourth	O
sibling	O
has	O
normal	O
hearing	O
and	O
vision	O
.	O

(	O
http	O
:	O
/	O
/	O
www	O
.	O
mlpa	O
.	O
com	O
/	O
)	O
.	O

attesting	O
the	O
complexity	O
of	O
hearing	O
mechanism	O
and	O
the	O
genetic	O
heterogeneity	O
of	O
HL	B-DISEASE
.	O

Patients	O
may	O
present	O
with	O
a	O
wide	O
spectrum	O
of	O
phenotypes	O
,	O
ranging	O
from	O
benign	O
familial	O
hematuria	B-DISEASE
(	O
BFH	O
)	O
or	O
thin	O
basement	O
membrane	O
nephropathy	B-DISEASE
(	O
TBMN	B-DISEASE
)	O
to	O
end	B-DISEASE
-	I-DISEASE
stage	I-DISEASE
renal	I-DISEASE
disease	I-DISEASE
(	O
ESRD	B-DISEASE
)	O
resulting	O
from	O
various	O
mutations	O
,	O
though	O
the	O
COL4A5	B-DISEASE
-	I-DISEASE
related	I-DISEASE
BFH	I-DISEASE
and	O
TBMN	B-DISEASE
were	O
considered	O
to	O
be	O
the	O
milder	O
subtypes	O
of	O
AS	B-DISEASE
[	O
5	O
-	O
7	O
]	O
.	O

Amplicons	O
were	O
purified	O
with	O
exonuclease	O
I	O
and	O
shrimp	O
alkaline	O
phosphatase	O
(	O
ExoSap	O
-	O
IT	O
,	O
USB	O
Corporation	O
,	O
Staufen	O
,	O
Germany	O
)	O
and	O
then	O
sequenced	O
for	O
both	O
sense	O
and	O
antisense	O
strands	O
using	O
an	O
automated	O
fluorescent	O
sequencing	O
method	O
(	O
Big	O
Dye	O
Terminator	O
Kit	O
v1	O
.	O
1	O
,	O
Applied	O
Biosystems	O
)	O
.	O

Mutations	O
in	O
CHD7	B-GENE
are	O
found	O
in	O
more	O
than	O
60	O
%	O
of	O
the	O
patients	O
with	O
typical	O
CHARGE	B-DISEASE
syndrome	I-DISEASE
.	O

Furthermore	O
,	O
claudin	O
14	O
orthologs	O
in	O
Armadillo	O
,	O
cow	O
and	O
hedgehog	O
have	O
a	O
valine	O
residue	O
at	O
position	O
86	O
.	O

This	O
target	O
was	O
a	O
coding	O
region	O
of	O
43	O
bp	O
in	O
the	O
large	O
exon	O
2	O
of	O
MYO15A	B-GENE
.	O

The	O
finding	O
of	O
recurrent	O
and	O
clustered	O
somatic	O
CACNA1D	B-GENE
mutations	O
strongly	O
suggests	O
a	O
gain	O
of	O
function	O
mechanism	O
.	O

The	O
diagnoses	O
of	O
LCPD	B-DISEASE
was	O
made	O
in	O
members	O
III	O
-	O
6	O
and	O
III	O
-	O
7	O
;	O
of	O
ANFH	B-DISEASE
in	O
members	O
IV	O
-	O
7	O
and	O
IV	O
-	O
8	O
.	O

During	O
the	O
simulations	O
,	O
the	O
integration	O
time	O
step	O
of	O
2	O
fs	O
was	O
adopted	O
and	O
structural	O
snapshots	O
were	O
flushed	O
every	O
500	O
steps	O
(	O
1	O
ps	B-DISEASE
)	O
.	O

Segregation	O
analysis	O
showed	O
that	O
the	O
patient	O
'	O
s	O
healthy	O
mother	O
carried	O
the	O
mutation	O
in	O
a	O
heterozygous	O
state	O
(	O
Figure	O
1	O
)	O
.	O

A	O
new	O
sequence	O
variation	O
,	O
IVS1	B-VARIANT
+	I-VARIANT
27G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
,	O
was	O
identified	O
in	O
one	O
Altaian	O
patient	O
with	O
severe	O
-	O
profound	O
HL	B-DISEASE
who	O
had	O
genotype	O
IVS1	B-VARIANT
+	I-VARIANT
27G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
/	O
[	O
V27I	B-VARIANT
;	I-VARIANT
E114G	B-VARIANT
]	O
(	O
Table	O
1	O
)	O
and	O
in	O
his	O
non	O
-	O
affected	O
mother	O
(	O
genotyped	O
IVS1	B-VARIANT
+	I-VARIANT
27G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
/	O
+	O
)	O
.	O

The	O
average	O
of	O
three	O
housekeeping	O
genes	O
was	O
used	O
for	O
normalization	O
.	O

D	O
:	O
Dystopia	B-DISEASE
canthorum	I-DISEASE
(	O
W	O
index	O
:	O
2	O
.	O
35	O
)	O
,	O
brilliant	O
blue	O
iris	O
,	O
and	O
synophyris	O
were	O
present	O
in	O
a	O
26	O
-	O
year	O
old	O
man	O
(	O
III	O
:	O
9	O
)	O
.	O

These	O
data	O
suggest	O
that	O
the	O
Ig	O
-	O
like	O
domain	O
of	O
angulin	B-GENE
-	I-GENE
2	I-GENE
/	O
ILDR1	B-GENE
,	O
where	O
p	B-VARIANT
.	I-VARIANT
P69H	I-VARIANT
resides	O
,	O
may	O
be	O
involved	O
in	O
the	O
localization	O
of	O
angulin	B-GENE
-	I-GENE
2	I-GENE
/	O
ILDR1	B-GENE
at	O
TCs	O
.	O

Sequences	O
of	O
primers	O
used	O
in	O
this	O
study	O
are	O
shown	O
in	O
Table	O
S3	O
.	O

The	O
sequence	O
alignment	O
portion	O
of	O
A	O
:	O
Laminin	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
-	O
like	O
domain	O
and	O
B	O
:	O
Fibronectin	O
type	O
3	O
domain	O
,	O
in	O
the	O
long	O
usherin	O
isoform	O
from	O
different	O
species	O
.	O

Cross	O
-	O
sectional	O
regression	O
data	O
conformed	O
to	O
individual	O
longitudinal	O
regression	O
data	O
.	O

The	O
stained	O
slides	O
were	O
examined	O
and	O
images	O
obtained	O
using	O
an	O
AxioCam	O
HRc	O
camera	O
mounted	O
on	O
a	O
Zeiss	O
microscope	O
.	O

Variants	O
within	O
several	O
genes	O
that	O
encode	O
components	O
of	O
the	O
same	O
protein	O
complex	O
can	O
cause	O
developmental	O
disorders	O
(	O
20	O
,	O
21	O
)	O
.	O

Increased	O
ALP	O
from	O
birth	O
might	O
reflect	O
prenatally	O
increased	O
osteoblastic	O
marker	O
gene	O
expression	O
resulting	O
from	O
mutations	O
in	O
FGFR2	B-GENE
gene	O
,	O
but	O
further	O
study	O
is	O
needed	O
.	O

3C	O
,	O
D	O
)	O
showed	O
normal	O
hearing	O
function	O
in	O
most	O
patients	O
(	O
five	O
out	O
of	O
six	O
)	O
below	O
40	O
years	O
of	O
age	O
,	O
while	O
patients	O
above	O
40	O
years	O
showed	O
higher	O
tendency	O
for	O
SNHL	B-DISEASE
(	O
three	O
out	O
of	O
four	O
patients	O
)	O
.	O

A	O
founder	O
effect	O
for	O
the	O
35delG	B-VARIANT
mutation	O
has	O
recently	O
been	O
described	O
[	O
27	O
]	O
,	O
which	O
explains	O
the	O
variable	O
frequency	O
of	O
this	O
mutation	O
in	O
different	O
populations	O
rather	O
than	O
resulting	O
from	O
a	O
mutational	O
hot	O
spot	O
.	O

Examinations	O
included	O
:	O
general	O
medical	O
,	O
neurologic	O
,	O
ophthalmologic	O
,	O
audiologic	O
,	O
vestibular	O
,	O
and	O
urologic	O
exams	O
,	O
cognitive	O
testing	O
and	O
neuroimaging	O
.	O

DNA	O
samples	O
were	O
obtained	O
from	O
her	O
62	O
-	O
year	O
-	O
old	O
(	O
II	O
-	O
1	O
)	O
and	O
59	O
-	O
year	O
-	O
old	O
(	O
II	O
-	O
2	O
)	O
brothers	O
,	O
who	O
both	O
had	O
a	O
pure	O
DOA	B-DISEASE
phenotype	O
,	O
and	O
OPA1	B-GENE
sequencing	O
confirmed	O
the	O
presence	O
of	O
the	O
same	O
heterozygous	O
c	B-VARIANT
.	I-VARIANT
2613	I-VARIANT
+	I-VARIANT
1g	I-VARIANT
>	I-VARIANT
a	I-VARIANT
variant	O
.	O

Deceased	O
.	O

Real	O
onset	O
may	O
have	O
been	O
earlier	O
in	O
many	O
cases	O
:	O
Retrospectively	O
,	O
the	O
parents	O
of	O
patient	O
V	O
:	O
3	O
assume	O
that	O
hearing	O
was	O
already	O
impaired	O
around	O
the	O
age	O
of	O
2	O
years	O
.	O

Pellets	O
of	O
5	O
x	O
10	O
6	O
fibroblasts	O
from	O
the	O
patient	O
and	O
controls	O
were	O
stored	O
at	O
-	O
80	O
deg	O
C	O
until	O
used	O
for	O
western	O
blot	O
analysis	O
.	O

Complementary	O
assays	O
considering	O
co	O
-	O
transfection	O
of	O
two	O
different	O
mutations	O
need	O
to	O
be	O
performed	O
.	O

1	O
F	O
,	O
which	O
indicates	O
the	O
numbers	O
of	O
positions	O
with	O
sequence	O
variations	O
in	O
both	O
strands	O
that	O
were	O
higher	O
than	O
the	O
threshold	O
along	O
the	O
horizontal	O
axis	O
.	O

Table	O
of	O
19	O
human	O
genes	O
targeted	O
for	O
the	O
nextgeneration	O
sequencing	O
.	O

RNA	O
from	O
a	O
normal	O
individual	O
was	O
used	O
as	O
a	O
positive	O
control	O
for	O
the	O
A	O
allele	O
and	O
a	O
negative	O
control	O
for	O
the	O
G	O
allele	O
.	O

OPA1	B-GENE
consists	O
of	O
five	O
domains	O
:	O
the	O
mitochondrial	O
target	O
signal	O
(	O
MTS	O
)	O
,	O
N	O
-	O
terminal	O
coiled	O
-	O
coil	O
domain	O
,	O
GTPase	O
domain	O
,	O
dynamin	O
central	O
region	O
,	O
and	O
C	O
-	O
terminal	O
coiled	O
-	O
coil	O
domain	O
.	O

By	O
investigating	O
the	O
coverage	O
distribution	O
of	O
each	O
single	O
amplicon	O
,	O
we	O
observed	O
an	O
uneven	O
distribution	O
of	O
the	O
coverage	O
,	O
which	O
could	O
not	O
be	O
ascribed	O
to	O
a	O
random	O
effect	O
.	O

Richards	O
,	O
and	O
N	O
.	O

There	O
seems	O
to	O
be	O
a	O
shift	O
in	O
mutation	O
from	O
IVS7	B-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
to	O
H723R	O
from	O
China	O
to	O
Japan	O
,	O
with	O
Korea	O
in	O
the	O
middle	O
.	O

A	O
parametric	O
linkage	O
analysis	O
was	O
run	O
assuming	O
a	O
fully	O
penetrant	O
autosomal	O
dominant	O
model	O
.	O

DNA	O
sequence	O
analysis	O
of	O
GJB2	B-GENE
,	O
mitochondrial	O
12S	O
rRNA	O
and	O
SLC26A4	B-GENE
were	O
performed	O
by	O
PCR	O
amplification	O
of	O
the	O
coding	O
exons	O
plus	O
approximated	O
50	O
-	O
100	O
bp	O
of	O
the	O
flanking	O
intron	O
regions	O
followed	O
by	O
Big	O
Dye	O
sequencing	O
and	O
analysis	O
using	O
ABI	O
3100	O
DNA	O
sequencing	O
machine	O
(	O
ABI	O
,	O
Foster	O
City	O
,	O
USA	O
.	O
)	O
and	O
ABI	O
3100	O
Analysis	O
Software	O
v	O
.	O
3	O
.	O
7	O
NT	O
according	O
to	O
manufacturer	O
'	O
s	O
procedures	O
.	O

Schmader	O
,	O
S	O
.	O

-	I-VARIANT
22	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
allele	O
of	O
a	O
c	B-VARIANT
.	I-VARIANT

PCR	O
was	O
carried	O
out	O
as	O
follows	O
:	O
35	O
cycles	O
of	O
denaturation	O
at	O
95	O
deg	O
C	O
for	O
30	O
seconds	O
;	O
annealing	O
at	O
60	O
deg	O
C	O
for	O
30	O
seconds	O
;	O
extension	O
at	O
72	O
deg	O
C	O
for	O
1	O
minute	O
.	O

However	O
,	O
the	O
absence	O
of	O
DNA	O
of	O
at	O
least	O
one	O
parent	O
hampers	O
a	O
definite	O
conclusion	O
.	O

Because	O
the	O
unaffected	O
father	O
was	O
deceased	O
,	O
seven	O
microsatellite	O
markers	O
surrounding	O
and	O
in	O
close	O
proximity	O
of	O
RHO	B-GENE
were	O
analyzed	O
to	O
determine	O
haplotypes	O
and	O
the	O
likelihood	O
of	O
a	O
de	O
novo	O
event	O
.	O

The	O
mutation	O
was	O
found	O
to	O
exert	O
a	O
dominant	O
negative	O
effect	O
on	O
native	O
IKs	O
.	O

Amplification	O
products	O
were	O
diluted	O
1	O
:	O
1000	O
to	O
reduce	O
pseudogene	O
carryover	O
from	O
gDNA	O
and	O
then	O
used	O
for	O
nested	O
PCR	O
.	O

Often	O
extended	O
kindreds	O
in	O
our	O
series	O
evaluated	O
thus	O
far	O
,	O
four	O
families	O
carried	O
novel	O
mutations	O
in	O
known	O
genes	O
and	O
six	O
families	O
are	O
likely	O
to	O
harbour	O
novel	O
mutations	O
in	O
novel	O
genes	O
for	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

A	O
:	O
The	O
patient	O
has	O
heterozygous	O
ACTG1	B-GENE
mutation	O
,	O
c	B-VARIANT
.	I-VARIANT
895C	I-VARIANT
>	I-VARIANT
G	I-VARIANT
.	O

,	O
2013	O
)	O
.	O

Two	O
mutations	O
,	O
p	B-VARIANT
.	I-VARIANT
W33C	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
D1424E	I-VARIANT
were	O
each	O
the	O
result	O
of	O
two	O
different	O
nucleotide	O
transitions	O
on	O
the	O
same	O
codon	O
,	O
c	B-VARIANT
.	I-VARIANT
99G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
or	O
c	B-VARIANT
.	I-VARIANT
99G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
in	O
exon	O
2	O
and	O
c	B-VARIANT
.	I-VARIANT
4272C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
or	O
c	B-VARIANT
.	I-VARIANT
4272C	I-VARIANT
>	I-VARIANT
G	I-VARIANT
in	O
exon	O
31	O
,	O
respectively	O
.	O

Affected	O
and	O
unaffected	O
individuals	O
are	O
represented	O
with	O
black	O
and	O
open	O
circles	O
,	O
respectively	O
.	O

Renal	O
biopsies	O
were	O
available	O
for	O
patients	O
of	O
21	O
/	O
57	O
(	O
36	O
.	O
8	O
%	O
)	O
families	O
,	O
since	O
biopsies	O
were	O
not	O
routinely	O
performed	O
in	O
the	O
presence	O
of	O
isolated	O
GMH	B-DISEASE
or	O
GMH	B-DISEASE
and	O
low	O
grade	O
proteinuria	B-DISEASE
(	O
14	O
families	O
)	O
.	O

The	O
952	O
successful	O
PCR	O
amplicons	O
were	O
combined	O
in	O
equimolar	O
amounts	O
,	O
concatenated	O
,	O
and	O
then	O
sheared	O
to	O
construct	O
libraries	O
.	O

Immunofluorescence	O
studies	O
used	O
an	O
anti	O
-	O
FLAG	O
(	O
dilution	O
1	O
/	O
300	O
)	O
antibody	O
and	O
the	O
secondary	O
antibody	O
Alexa	O
Fluor	O
488	O
(	O
1	O
/	O
200	O
)	O
to	O
localize	O
exogenously	O
expressed	O
FLAG	O
-	O
POLR1C	B-GENE
variants	O
in	O
HeLa	O
cells	O
.	O

SHO	O
and	O
JWK	O
contributed	O
to	O
the	O
data	O
interpretation	O
.	O

The	O
other	O
eight	O
deafness	B-DISEASE
genes	O
in	O
the	O
Jewish	O
population	O
have	O
low	O
prevalence	O
and	O
their	O
known	O
mutations	O
were	O
screened	O
only	O
in	O
subjects	O
manifesting	O
a	O
relevant	O
phenotype	O
or	O
ethnic	O
background	O
.	O

18	O
POU3F4	B-GENE
,	O
mutated	O
in	O
DFN3	B-GENE
families	O
,	O
encodes	O
a	O
polypeptide	O
of	O
361	O
amino	O
acids	O
with	O
bi	O
-	O
partite	O
DNA	O
-	O
binding	O
domains	O
(	O
POU	O
and	O
homeobox	O
)	O
,	O
and	O
thus	O
belongs	O
to	O
the	O
POU	O
family	O
of	O
transcription	O
factors	O
.	O

In	O
cells	O
transfected	O
with	O
wild	O
-	O
type	O
MCM2	B-GENE
cDNA	O
plasmid	O
,	O
G1	O
,	O
S	O
,	O
and	O
G2	O
phases	O
were	O
27	O
.	O
08	O
+	O
-	O
4	O
.	O
99	O
,	O
50	O
.	O
69	O
+	O
-	O
2	O
.	O
14	O
,	O
22	O
.	O
21	O
+	O
-	O
6	O
.	O
04	O
,	O
respectively	O
;	O
N	O
=	O
3	O
.	O

(	O
2013	O
)	O
evaluated	O
in	O
an	O
extensive	O
study	O
,	O
including	O
71	O
patients	O
,	O
the	O
sensitivity	O
of	O
a	O
NimbleGen	O
-	O
Roche	O
Junior	O
-	O
based	O
approach	O
as	O
a	O
clinical	O
test	O
.	O

In	O
situ	O
hybridization	O
in	O
neonatal	O
mice	O
cochlea	O
,	O
otoferlin	O
labeling	O
was	O
dominantly	O
seen	O
in	O
the	O
IHCs	O
,	O
but	O
faintly	O
in	O
the	O
OHCs	O
,	O
spiral	O
ganglion	O
cells	O
,	O
as	O
well	O
as	O
in	O
the	O
neuroepithelia	O
hair	O
cells	O
of	O
the	O
utricle	O
,	O
saccule	O
,	O
and	O
semicircular	O
canals	O
[	O
31	O
]	O
.	O

In	O
two	O
additional	O
patients	O
(	O
trio	O
24	O
and	O
trio	O
26	O
)	O
,	O
the	O
genetic	O
diagnoses	O
led	O
to	O
specific	O
diet	O
interventions	O
that	O
significantly	O
improved	O
the	O
patients	O
'	O
metabolic	O
conditions	O
.	O

The	O
constructs	O
were	O
further	O
sequenced	O
to	O
ascertain	O
the	O
absence	O
of	O
additional	O
sequence	O
changes	O
.	O

1C	O
)	O
.	O

Schematic	O
of	O
the	O
FGFR1	B-GENE
mutations	O
at	O
protein	O
level	O
.	O

Among	O
these	O
variants	O
,	O
all	O
frameshift	O
and	O
non	O
-	O
frameshift	O
indel	O
variants	O
,	O
nonsense	O
variants	O
,	O
and	O
splice	O
site	O
variants	O
were	O
included	O
for	O
further	O
analysis	O
.	O

In	O
addition	O
to	O
these	O
10	O
genes	O
,	O
three	O
other	O
genes	O
have	O
been	O
associated	O
with	O
USH	B-DISEASE
.	O

These	O
stereocilia	O
are	O
constantly	O
undergoing	O
actin	O
polymerization	O
at	O
their	O
tips	O
and	O
depolymerization	O
at	O
their	O
bases	O
[	O
21	O
]	O
.	O

GenBank	O
accession	O
numbers	O
NM_000095	O
.	O
2	O
(	O
COMP	B-GENE
)	O
;	O
NM_001844	O
.	O
4	O
(	O
COL2A1	B-GENE
)	O
.	O

These	O
differences	O
in	O
charge	O
and	O
size	O
are	O
predicted	O
to	O
affect	O
the	O
hydrophobic	O
interactions	O
with	O
the	O
membrane	O
lipids	O
.	O

This	O
association	O
between	O
SNPs	O
and	O
AF	B-DISEASE
was	O
strongest	O
in	O
patients	O
diagnosed	O
at	O
a	O
younger	O
age	O
.	O

There	O
were	O
six	O
patients	O
in	O
whom	O
either	O
optic	B-DISEASE
atrophy	I-DISEASE
(	O
i	O
.	O
e	O
.	O

Cell	O
-	O
surface	O
expression	O
levels	O
were	O
determined	O
using	O
an	O
anti	O
-	O
myc	O
primary	O
-	O
antibody	O
(	O
see	O
above	O
)	O
,	O
HRP	O
-	O
conjugated	O
secondary	O
antibody	O
and	O
assayed	O
using	O
3	O
,	O
3	O
`	O
,	O
5	O
,	O
5	O
`	O
tetramethylbenzidine	O
(	O
Sigma	O
,	O
Saint	O
Louis	O
,	O
MO	O
)	O
as	O
the	O
substrate	O
with	O
detection	O
at	O
450	O
nm	O
following	O
the	O
addition	O
of	O
0	O
.	O
5	O
M	O
H	O
2	O
SO	O
4	O
[	O
29	O
]	O
.	O

These	O
reads	O
mainly	O
come	O
from	O
low	O
complex	O
genomic	O
region	O
,	O
such	O
as	O
repetitive	O
sequences	O
,	O
and	O
account	O
for	O
about	O
4	O
%	O
of	O
total	O
effective	O
reads	O
.	O

To	O
evaluate	O
whether	O
the	O
currently	O
available	O
NGS	O
technologies	O
are	O
ready	O
for	O
USH	B-DISEASE
diagnostics	O
we	O
used	O
:	O
a	O
)	O
Whole	O
exome	O
sequencing	O
with	O
analysis	O
restricted	O
to	O
known	O
USH	B-DISEASE
genes	O
and	O
b	O
)	O
targeted	O
resequencing	O
of	O
the	O
known	O
USH	B-DISEASE
genes	O
starting	O
from	O
long	O
-	O
range	O
PCR	O
products	O
.	O

This	O
flow	O
diagram	O
represents	O
a	O
protocol	O
for	O
genetic	O
testing	O
in	O
patients	O
with	O
severe	O
to	O
profound	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Consensus	O
reached	O
by	O
the	O
ESDN	O
panel	O
after	O
review	O
.	O

In	O
particular	O
,	O
for	O
lower	O
complexity	O
samples	O
a	O
point	O
of	O
diminishing	O
returns	O
is	O
reached	O
when	O
the	O
number	O
of	O
counts	O
per	O
sequence	O
results	O
in	O
oversampling	O
with	O
no	O
increase	O
in	O
data	O
quality	O
.	O

One	O
Dai	O
patient	O
carried	O
homozygous	O
c	B-VARIANT
.	I-VARIANT
139G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
.	O

In	O
addition	O
,	O
the	O
residue	O
resides	O
in	O
the	O
conserved	O
region	O
of	O
the	O
protein	O
(	O
Figure	O
1	O
;	O
Figure	O
S1A	O
)	O
.	O

Ophthalmological	O
examination	O
included	O
stereoscopic	O
funduscopy	O
,	O
standard	O
ERG	O
,	O
perimetry	O
,	O
measurement	O
of	O
dark	O
adaptation	O
,	O
and	O
determination	O
of	O
best	O
-	O
corrected	O
visual	O
acuity	O
in	O
most	O
patients	O
.	O

The	O
primers	O
were	O
designed	O
using	O
Primer	O
5	O
software	O
based	O
on	O
the	O
sequences	O
of	O
54	O
exons	O
and	O
the	O
exon	O
-	O
intron	O
boundaries	O
of	O
the	O
COL2A1	B-GENE
gene	O
.	O

Non	O
-	O
pathogenic	O
variants	O
of	O
OTOF	B-GENE
identified	O
in	O
this	O
study	O
Patients	O
who	O
have	O
at	O
least	O
one	O
pathogenic	O
mutation	O
identified	O
in	O
this	O
study	O
ANSD	B-DISEASE
Auditory	B-DISEASE
neuropathy	I-DISEASE
spectrum	I-DISEASE
disorder	I-DISEASE
,	O
NSHL	B-DISEASE
Nonsyndromic	B-DISEASE
sensorineural	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O

We	O
next	O
considered	O
all	O
genes	O
broadly	O
associated	O
with	O
a	O
phenotype	O
of	O
ataxia	B-DISEASE
with	O
two	O
rare	O
variants	O
,	O
and	O
evaluated	O
their	O
likelihood	O
of	O
pathogenicity	O
.	O

Illumina	O
'	O
s	O
Paired	O
-	O
end	O
libraries	O
were	O
made	O
following	O
the	O
manufacturer	O
'	O
s	O
protocol	O
with	O
reagents	O
supplied	O
in	O
the	O
Illumina	O
DNA	O
sample	O
kit	O
.	O

Summary	O
of	O
Clinical	O
Data	O
of	O
Affected	O
Individuals	O
of	O
Family	O
GD	O
-	O
O031	O
.	O

Mild	O
platyspondyly	B-DISEASE
with	O
ovoid	B-DISEASE
-	I-DISEASE
pear	I-DISEASE
-	I-DISEASE
shaped	I-DISEASE
vertebral	I-DISEASE
bodies	I-DISEASE
.	O

Representative	O
CGH	O
microarray	O
from	O
a	O
patient	O
with	O
one	O
hit	O
in	O
ABCA4	B-GENE
.	O

Autosomal	B-DISEASE
recessive	I-DISEASE
non	I-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
ARNSHL	B-DISEASE
)	O
is	O
the	O
most	O
frequent	O
cause	O
of	O
hereditary	O
deafness	B-DISEASE
and	O
often	O
exhibits	O
the	O
most	O
severe	O
hearing	O
phenotype	O
.	O

The	O
PDE4C	B-GENE
gene	O
encodes	O
a	O
protein	O
belonging	O
to	O
the	O
cyclic	O
nucleotide	O
phosphodiesterase	O
subfamily	O
PDE4	O
.	O

Copy	O
number	O
variants	O
were	O
called	O
from	O
the	O
normalized	O
ratio	O
of	O
coverage	O
depth	O
comparing	O
tumor	O
and	O
normal	O
samples	O
,	O
and	O
changes	O
in	O
MAF	O
at	O
informative	O
SNPs	O
.	O

MYH9	B-GENE
is	O
a	O
large	O
gene	O
composed	O
of	O
41	O
exons	O
and	O
is	O
located	O
on	O
chromosome	O
22	O
q12	O
-	O
13	O
.	O

(	O
B	O
)	O
LSR	B-GENE
knockdown	O
cells	O
stably	O
expressing	O
the	O
mock	O
FLAG	O
vector	O
(	O
C	O
)	O
or	O
wild	O
-	O
type	O
(	O
WT	O
)	O
human	O
ILDR1	B-GENE
.	O

c	O
,	O
d	O
In	O
the	O
lower	O
leg	O
,	O
MRIs	O
revealed	O
moderate	O
involvement	O
of	O
superficial	O
posterior	O
compartment	O
muscles	O
,	O
including	O
the	O
soleus	O
and	O
gastrocnemius	O
muscles	O
(	O
arrows	O
)	O
;	O
however	O
,	O
anterior	O
and	O
lateral	O
compartment	O
muscles	O
were	O
spared	O
Lower	O
limb	O
MRIs	O
in	O
patient	O
II	O
-	O
1	O
.	O

Pendrin	O
is	O
a	O
member	O
of	O
the	O
anion	O
transporter	O
family	O
SLC26	O
,	O
which	O
mediates	O
the	O
exchange	O
of	O
anions	O
including	O
Cl	O
-	O
,	O
HCO	O
3	O
-	O
,	O
OH	O
-	O
,	O
I	O
-	O
,	O
or	O
formate	O
[	O
2	O
]	O
.	O

D	O
.	O
M	O
.	O

Due	O
to	O
the	O
patients	O
'	O
youth	O
,	O
premature	O
graying	O
of	O
the	O
hair	O
was	O
not	O
evaluated	O
in	O
four	O
patients	O
(	O
IV	O
:	O
4	O
was	O
15	O
years	O
old	O
,	O
IV	O
:	O
5	O
was	O
10	O
years	O
old	O
;	O
IV	O
:	O
3	O
and	O
IV	O
:	O
6	O
were	O
younger	O
than	O
2	O
years	O
old	O
)	O
.	O

SS	O
Exons	O
34	O
,	O
36	O
and	O
37	O
are	O
specific	O
to	O
isoforms	O
CD1	O
,	O
CD2	O
and	O
CD3	O
,	O
respectively	O
.	O

Defects	O
in	O
the	O
glomerular	O
basement	O
membrane	O
(	O
GBM	O
)	O
can	O
cause	O
Alport	B-DISEASE
Syndrome	I-DISEASE
(	O
AS	B-DISEASE
)	O
and	O
thin	B-DISEASE
basement	I-DISEASE
membrane	I-DISEASE
nephropathy	I-DISEASE
(	O
TBMN	B-DISEASE
)	O
.	O

23	O
34	O
Output	O
is	O
given	O
by	O
number	O
and	O
percentage	O
of	O
orthologues	O
conserved	O
to	O
those	O
surveyed	O
.	O

Up	O
-	O
to	O
-	O
date	O
several	O
studies	O
have	O
shown	O
the	O
feasibility	O
of	O
different	O
enrichment	O
and	O
NGS	O
approaches	O
for	O
the	O
molecular	O
diagnostics	O
of	O
Usher	B-DISEASE
syndrome	I-DISEASE
and	O
demonstrated	O
a	O
comparable	O
diagnostic	O
yield	O
as	O
the	O
above	O
described	O
ABI	O
Sanger	O
sequencing	O
-	O
based	O
studies	O
.	O

Among	O
39	O
patients	O
screened	O
for	O
WFS1	B-GENE
mutations	O
,	O
34	O
mutations	O
were	O
detected	O
,	O
13	O
of	O
which	O
were	O
novel	O
(	O
Table	O
3	O
)	O
.	O

Most	O
patients	O
with	O
RP	B-DISEASE
have	O
no	O
associated	O
systemic	O
disease	O
and	O
are	O
considered	O
to	O
have	O
non	O
-	O
syndromic	O
RP	B-DISEASE
.	O

First	O
,	O
SIFT	O
and	O
Polyphen	O
prediction	O
software	O
consistently	O
suggested	O
that	O
this	O
variant	O
was	O
"	O
damaging	O
"	O
(	O
Table	O
2	O
)	O
.	O

The	O
arrow	O
indicates	O
the	O
proband	O
(	O
II	O
-	O
2	O
)	O
,	O
and	O
filled	O
symbols	O
represent	O
affected	O
individuals	O
in	O
the	O
family	O
.	O

The	O
CC	O
region	O
is	O
required	O
for	O
homo	O
/	O
hetero	O
-	O
multimerization	O
to	O
form	O
tetrameric	O
hubs	O
(	O
in	O
which	O
the	O
CC	O
domains	O
align	O
in	O
a	O
parallel	O
fashion	O
)	O
and	O
for	O
interaction	O
with	O
Rho	O
family	O
GTPase	O
proteins	O
like	O
CDC42	B-GENE
(	O
MIM	O
116952	O
)	O
[	O
9	O
-	O
11	O
]	O
.	O

Na	O
+	O
/	O
K	O
+	O
ATPase	O
and	O
GAPDH	B-GENE
are	O
used	O
as	O
positive	O
controls	O
for	O
cell	O
membrane	O
and	O
cytoplasmic	O
protein	O
fractions	O
,	O
respectively	O
.	O

Genomic	O
DNA	O
from	O
31	O
individuals	O
,	O
including	O
18	O
patients	O
from	O
8	O
families	O
and	O
100	O
normal	O
controls	O
,	O
was	O
extracted	O
from	O
peripheral	O
blood	O
or	O
buccal	O
cells	O
using	O
either	O
the	O
FlexiGene	O
DNA	O
extraction	O
kit	O
(	O
QIAGEN	O
,	O
Hilden	O
,	O
Germany	O
)	O
or	O
the	O
Puregene	O
Buccal	O
Cell	O
Core	O
kit	O
,	O
respectively	O
(	O
QIAGEN	O
,	O
Hilden	O
,	O
Germany	O
)	O
.	O

Similar	O
to	O
his	O
brother	O
,	O
his	O
RP	B-DISEASE
onset	O
age	O
was	O
13	O
,	O
and	O
he	O
was	O
also	O
manifested	O
with	O
typical	O
RP	B-DISEASE
symptoms	O
(	O
Figure	O
3C	O
,	O
3D	O
)	O
.	O

PSACH	B-DISEASE
,	O
pseudoachondroplasia	B-DISEASE
;	O
SED	B-DISEASE
,	O
spondyloepiphyseal	B-DISEASE
dysplasia	I-DISEASE
;	O
(	O
S	O
)	O
EMD	B-DISEASE
,	O
(	B-DISEASE
spondylo	I-DISEASE
)	I-DISEASE
-	I-DISEASE
epi	I-DISEASE
-	I-DISEASE
metaphyseal	I-DISEASE
dysplasia	I-DISEASE
;	O
CHH	B-DISEASE
,	O
cartilage	B-DISEASE
hair	I-DISEASE
hypoplasia	I-DISEASE
;	O
AR	B-DISEASE
-	I-DISEASE
PSACH	I-DISEASE
,	O
autosomal	B-DISEASE
recessive	I-DISEASE
PSACH	I-DISEASE
;	O
pPSACH	B-DISEASE
,	O
pseudo	B-DISEASE
-	I-DISEASE
PSACH	I-DISEASE
.	O

The	O
efficiency	O
of	O
NDM	O
,	O
however	O
,	O
depends	O
on	O
the	O
exact	O
position	O
of	O
the	O
premature	O
stop	O
codon	O
[	O
16	O
]	O
.	O

Of	O
212	O
CTDs	B-DISEASE
patients	O
,	O
199	O
(	O
78	O
female	O
,	O
121	O
male	O
;	O
median	O
age	O
2	O
.	O
1	O
years	O
)	O
were	O
enrolled	O
because	O
they	O
were	O
negative	O
for	O
the	O
22q11	O
.	O
2	O
microdeletion	O
when	O
tested	O
by	O
MLPA	O
using	O
the	O
SALSA	O
P250	O
-	O
A1	O
MLPA	O
-	O
DiGeorge	O
syndrome	O
test	O
kit	O
(	O
MRC	O
-	O
Holland	O
,	O
Amsterdam	O
,	O
The	O
Netherlands	O
)	O
[	O
3	O
]	O
.	O

(	O
PDF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

(	O
XLSX	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Dominant	O
forms	O
of	O
CHI	B-DISEASE
are	O
due	O
to	O
either	O
activating	O
mutations	O
in	O
mitochondrial	O
matrix	O
enzymes	O
,	O
GLUD1	B-GENE
(	O
glutamate	O
dehydrogenase	O
1	O
)	O
and	O
UCP2	B-GENE
(	O
mitochondrial	O
uncoupling	O
protein	O
2	O
)	O
,	O
or	O
to	O
mutations	O
in	O
HNF4A	B-GENE
(	O
hepatocyte	O
nuclear	O
factor	O
4	O
alpha	O
)	O
and	O
SLC16A1	B-GENE
(	O
monocarboxylate	O
transporter	O
1	O
)	O
.	O

At	O
time	O
of	O
her	O
first	O
pregnancy	O
she	O
was	O
referred	O
to	O
our	O
Centre	O
at	O
17	O
weeks	O
of	O
gestation	O
following	O
a	O
sonogram	O
which	O
had	O
revealed	O
a	O
fetal	O
femur	O
length	O
below	O
the	O
3rd	O
centile	O
.	O

[	O
30	O
]	O
suggested	O
that	O
it	O
is	O
unlikely	O
that	O
this	O
variant	O
plays	O
a	O
pathogenic	O
role	O
in	O
deafness	B-DISEASE
.	O

Therefore	O
,	O
for	O
our	O
proband	O
,	O
we	O
hypothesize	O
that	O
a	O
post	O
-	O
zygotic	O
somatic	O
event	O
(	O
such	O
as	O
methylation	O
)	O
and	O
imprinting	O
defect	O
,	O
resulting	O
in	O
the	O
absence	O
of	O
expression	O
of	O
the	O
maternal	O
Gs	O
-	O
alpha	O
isoform	O
,	O
might	O
lead	O
to	O
the	O
expression	O
of	O
mutated	O
paternal	O
allele	O
in	O
some	O
affected	O
focal	O
area	O
of	O
the	O
pancreas	O
.	O

The	O
most	O
common	O
mutant	O
allele	O
was	O
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
,	O
followed	O
by	O
c	B-VARIANT
.	I-VARIANT
299_300delAT	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
512insAACG	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
139G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
176del16	I-VARIANT
,	O
which	O
accounted	O
for	O
11	O
.	O
1	O
%	O
(	O
52	O
/	O
470	O
)	O
,	O
1	O
.	O
7	O
%	O
(	O
8	O
/	O
470	O
)	O
,	O
1	O
.	O
1	O
%	O
(	O
5	O
/	O
470	O
)	O
,	O
0	O
.	O
6	O
%	O
(	O
3	O
/	O
470	O
)	O
and	O
0	O
.	O
6	O
%	O
(	O
3	O
/	O
470	O
)	O
,	O
respectively	O
.	O

17	O
The	O
pedigree	O
of	O
family	O
JX	O
-	O
H016	O
,	O
which	O
spanned	O
four	O
generations	O
and	O
comprised	O
53	O
members	O
,	O
consisted	O
of	O
three	O
branches	O
(	O
A	O
~	O
C	O
)	O
all	O
segregating	O
prelingual	B-DISEASE
HL	I-DISEASE
.	O

Frankland	O
and	O
T	O
.	O

At	O
48	O
h	O
after	O
transfection	O
,	O
cells	O
were	O
lysed	O
in	O
2	O
x	O
SDS	O
sample	O
buffer	O
,	O
containing	O
1mM	O
phenylmethanesulfonyl	O
fluoride	O
and	O
1	O
x	O
protease	O
inhibitor	O
cocktail	O
(	O
Sigma	O
)	O
.	O

Both	O
microarrays	O
were	O
designed	O
to	O
capture	O
the	O
coding	O
sequences	O
,	O
100	O
base	O
pairs	O
(	O
bp	O
)	O
flanking	O
regions	O
,	O
together	O
with	O
5	O
'	O
-	O
and	O
3	O
'	O
-	O
untranslated	O
regions	O
(	O
UTR	O
)	O
of	O
the	O
selected	O
targeted	O
genes	O
.	O

Family	O
4243	O
(	O
Figure	O
1	O
)	O
is	O
a	O
consanguineous	O
kindred	O
from	O
the	O
Sairiki	O
-	O
speaking	O
region	O
of	O
Punjab	O
,	O
Pakistan	O
.	O

This	O
is	O
an	O
important	O
finding	O
as	O
one	O
of	O
the	O
purposes	O
of	O
genetic	O
screening	O
in	O
cLQTS	B-DISEASE
probands	O
is	O
the	O
identification	O
of	O
asymptomatic	O
mutation	O
carriers	O
in	O
family	O
members	O
(	O
cascade	O
screening	O
)	O
in	O
order	O
to	O
clinically	O
assess	O
the	O
need	O
for	O
prophylaxis	O
.	O

This	O
region	O
of	O
the	O
protein	O
is	O
predicted	O
to	O
be	O
highly	O
hydrophobic	O
,	O
as	O
previously	O
shown	O
in	O
a	O
hydrophobicity	O
plot	O
(	O
Figure	O
5	O
)	O
.	O

Since	O
epidemiological	O
tests	O
of	O
association	O
of	O
mutations	O
with	O
deafness	B-DISEASE
were	O
not	O
feasible	O
for	O
such	O
rare	O
alleles	O
,	O
we	O
used	O
functional	O
and	O
bioinformatics	O
approaches	O
to	O
evaluate	O
their	O
consequences	O
.	O

Genomic	O
DNA	O
of	O
patients	O
and	O
family	O
members	O
was	O
extracted	O
from	O
peripheral	O
blood	O
by	O
standard	O
methods	O
.	O

Advances	O
in	O
sequencing	O
technologies	O
and	O
decreasing	O
costs	O
are	O
making	O
whole	O
genome	O
sequencing	O
(	O
WGS	O
)	O
and	O
whole	O
exome	O
sequencing	O
(	O
WES	O
)	O
increasingly	O
accessible	O
and	O
may	O
enable	O
the	O
transition	O
from	O
research	O
applications	O
and	O
consumer	O
genomics	O
to	O
routine	O
clinical	O
care	O
.	O

The	O
DABMap	O
Kit	O
(	O
Ventana	O
;	O
cat	O
.	O
no	O
760	O
-	O
124	O
)	O
with	O
hematoxylin	O
counterstain	O
(	O
cat	O
.	O
no	O
760	O
-	O
2021	O
)	O
and	O
bluing	O
reagent	O
(	O
cat	O
.	O
no	O
760	O
-	O
2037	O
)	O
were	O
used	O
.	O

Pure	O
tone	O
audiograms	O
of	O
I	O
:	O
2	O
,	O
II	O
:	O
1	O
,	O
and	O
II	O
:	O
3	O
show	O
a	O
predominantly	O
bilateral	O
low	O
-	O
tone	O
hearing	B-DISEASE
impairment	I-DISEASE
.	O

Hypoparathyroidism	B-DISEASE
in	O
HDR	B-DISEASE
syndrome	I-DISEASE
can	O
range	O
from	O
asymptomatic	O
to	O
myalgia	B-DISEASE
,	O
sensory	B-DISEASE
problems	I-DISEASE
,	O
and	O
a	O
pronounced	O
tetany	O
pattern	O
caused	O
by	O
hypocalcemia	B-DISEASE
.	O

As	O
expected	O
,	O
the	O
two	O
patients	O
with	O
p	B-VARIANT
.	I-VARIANT
R705H	I-VARIANT
developed	O
early	O
deafness	B-DISEASE
during	O
childhood	O
as	O
described	O
in	O
DFNA17	B-DISEASE
(	O
Lalwani	O
et	O
al	O
.	O

All	O
four	O
disorders	O
are	O
inherited	O
in	O
a	O
recessive	O
X	O
-	O
linked	O
manner	O
so	O
only	O
males	O
are	O
affected	O
.	O

Double	O
bars	O
indicate	O
the	O
consanguinity	O
of	O
the	O
family	O
.	O

Multiple	O
sequence	O
alignments	O
of	O
multiple	O
species	O
were	O
performed	O
with	O
Clustal	O
W	O
(	O
version	O
1	O
.	O
82	O
)	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
ebi	O
.	O
ac	O
.	O
uk	O
/	O
clustalw	O
/	O
#	O
)	O
.	O

Homer	O
proteins	O
are	O
encoded	O
by	O
three	O
genes	O
;	O
HOMER1	B-GENE
,	I-GENE
2	I-GENE
,	I-GENE
and	I-GENE
3	I-GENE
(	O
MIM	O
604798	O
,	O
MIM	O
604799	O
and	O
MIM	O
604800	O
,	O
respectively	O
)	O
that	O
are	O
translated	O
into	O
multiple	O
isoforms	O
as	O
a	O
result	O
of	O
alternative	O
splicing	O
[	O
7	O
]	O
.	O

In	O
addition	O
to	O
the	O
eight	O
pathogenic	O
mutations	O
detected	O
in	O
this	O
study	O
,	O
nine	O
nonpathogenic	O
sequence	O
variants	O
were	O
also	O
identified	O
.	O

For	O
the	O
case	O
diagnosed	O
as	O
Hajdu	B-DISEASE
-	I-DISEASE
Cheney	I-DISEASE
syndrome	I-DISEASE
(	O
sample	O
R41	O
)	O
,	O
no	O
mutation	O
was	O
found	O
in	O
the	O
expected	O
exon	O
(	O
exon	O
34	O
)	O
[	O
77	O
]	O
.	O

LCPD	B-DISEASE
emerges	O
prior	O
to	O
the	O
closure	O
of	O
the	O
femoral	O
head	O
epiphysis	O
,	O
and	O
ANFH	B-DISEASE
emerges	O
during	O
the	O
closure	O
[	O
6	O
]	O
.	O

In	O
this	O
article	O
,	O
the	O
participants	O
are	O
identified	O
by	O
their	O
trio	O
number	O
(	O
1	O
-	O
33	O
)	O
prefaced	O
by	O
F	O
for	O
the	O
fetus	O
,	O
M	O
for	O
the	O
mother	O
and	O
P	O
for	O
the	O
father	O
.	O

While	O
the	O
proband	O
from	O
family	O
49	O
had	O
moderate	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
normal	O
vestibular	O
function	O
,	O
the	O
proband	O
from	O
family	O
83	O
had	O
vestibular	B-DISEASE
hypofunction	I-DISEASE
with	O
moderate	O
to	O
severe	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

In	O
the	O
tTJ	O
,	O
tricellulin	O
provides	O
connection	O
between	O
three	O
epithelial	O
cells	O
,	O
thus	O
playing	O
a	O
critical	O
role	O
in	O
forming	O
an	O
epithelial	O
barrier	O
against	O
paracellular	O
flux	O
of	O
ions	O
and	O
solutes	O
,	O
which	O
is	O
essential	O
to	O
maintain	O
the	O
ion	O
composition	O
of	O
inner	O
ear	O
fluids	O
and	O
proper	O
hearing	O
function	O
[	O
5	O
]	O
.	O

5	O
CLDN14	B-GENE
mutations	O
are	O
a	O
common	O
cause	O
of	O
recessive	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
the	O
Pakistani	O
population	O
since	O
mutations	O
of	O
this	O
gene	O
account	O
for	O
2	O
.	O
25	O
%	O
(	O
18	O
of	O
800	O
families	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
4	O
-	O
3	O
.	O
5	O
%	O
)	O
of	O
deafness	B-DISEASE
in	O
the	O
NCEMB	O
Pakistani	O
study	O
cohort	O
(	O
Table	O
2	O
)	O
.	O

Four	O
programs	O
were	O
used	O
:	O
Neural	O
Network	O
SPLICE	O
(	O
NNSplice	O
)	O
0	O
.	O
9	O
from	O
the	O
Berkeley	O
Drosophila	O
Genome	O
Project	O
(	O
available	O
at	O
http	O
:	O
/	O
/	O
www	O
.	O
fruitfly	O
.	O
org	O
/	O
seq_tools	O
/	O
splice	O
.	O
html	O
)	O
,	O
Human	O
Splicing	O
Finder	O
(	O
HSF	O
)	O
-	O
Version	O
2	O
.	O
4	O
(	O
available	O
at	O
http	O
:	O
/	O
/	O
www	O
.	O
umd	O
.	O
be	O
/	O
HSF	O
/	O
)	O
,	O
NetGene2	O
(	O
available	O
at	O
http	O
:	O
/	O
/	O
www	O
.	O
cbs	O
.	O
dtu	O
.	O
dk	O
/	O
service	O
/	O
NetGene2	O
/	O
)	O
and	O
Spliceview	O
(	O
available	O
at	O
http	O
:	O
/	O
/	O
zeus2	O
.	O
itb	O
.	O
cnr	O
.	O
it	O
/	O
~	O
webgene	O
/	O
wwwspliceview_ex	O
.	O
html	O
)	O
.	O
Score	O
-	O
values	O
were	O
calculated	O
taking	O
into	O
account	O
the	O
bioinformatic	O
predictions	O
,	O
from	O
1	O
to	O
4	O
,	O
depending	O
on	O
how	O
many	O
of	O
the	O
four	O
programs	O
have	O
predicted	O
changes	O
on	O
the	O
splice	O
sites	O
.	O

Average	O
coverage	O
of	O
depth	O
in	O
the	O
target	O
region	O
was	O
326	O
.	O
5	O
and	O
94	O
.	O
2	O
%	O
of	O
them	O
were	O
over	O
20	O
coverage	O
.	O

Direct	O
sequencing	O
was	O
performed	O
using	O
the	O
BigDye	O
Terminator	O
Cycle	O
Sequencing	O
on	O
an	O
ABI	O
3100	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
California	O
,	O
USA	O
)	O
.	O

The	O
broad	O
spectrum	O
of	O
WFS1	B-GENE
mutations	O
identified	O
might	O
represent	O
different	O
effects	O
on	O
WFS1	B-GENE
protein	O
.	O

c	B-VARIANT
.	I-VARIANT
863	I-VARIANT
-	I-VARIANT
864insT	I-VARIANT
with	O
a	O
frameshift	O
at	O
codon	O
288	O
causes	O
a	O
premature	O
stop	O
at	O
position	O
290	O
and	O
c	B-VARIANT
.	I-VARIANT
881	I-VARIANT
-	I-VARIANT
882delAC	I-VARIANT
results	O
in	O
a	O
frameshift	O
at	O
codon	O
294	O
and	O
a	O
premature	O
stop	O
at	O
position	O
328	O
.	O

In	O
summary	O
,	O
we	O
have	O
reported	O
the	O
clinical	O
and	O
genetic	O
characteristics	O
of	O
a	O
non	O
-	O
consanguineous	O
Chinese	O
family	O
with	O
ARNSHL	B-DISEASE
by	O
WES	O
.	O

The	O
authors	O
are	O
grateful	O
to	O
the	O
families	O
who	O
made	O
this	O
research	O
possible	O
.	O

The	O
mechanisms	O
linking	O
HSD17B4	B-GENE
deficiency	O
and	O
azoospermia	B-DISEASE
remain	O
unclear	O
.	O

This	O
is	O
consistent	O
with	O
modeling	O
predictions	O
of	O
the	O
effects	O
of	O
CIB2	B-GENE
mutations	O
on	O
Ca	O
2	O
+	O
binding	O
affinity	O
of	O
CIB2	B-GENE
.	O

(	O
http	O
:	O
/	O
/	O
www	O
.	O
ch	O
.	O
embnet	O
.	O
org	O
/	O
software	O
/	O
COILS_form	O
.	O
html	O
)	O
.	O

Whole	O
exome	O
sequencing	O
of	O
30	O
arRP	B-DISEASE
/	O
spRP	B-DISEASE
patients	O
identified	O
disease	O
-	O
causing	O
gene	O
mutations	O
of	O
CNGA1	B-GENE
(	O
four	O
patients	O
)	O
,	O
EYS	B-GENE
(	O
three	O
patients	O
)	O
and	O
SAG	B-GENE
(	O
one	O
patient	O
)	O
in	O
eight	O
patients	O
and	O
potential	O
disease	O
-	O
causing	O
gene	O
variants	O
of	O
USH2A	B-GENE
(	O
two	O
patients	O
)	O
,	O
EYS	B-GENE
(	O
one	O
patient	O
)	O
,	O
TULP1	B-GENE
(	O
one	O
patient	O
)	O
and	O
C2orf71	B-GENE
(	O
one	O
patient	O
)	O
in	O
five	O
patients	O
.	O

The	O
MRI	O
can	O
rule	O
out	O
pituitary	O
stalk	O
interruption	O
syndrome	O
and	O
analyse	O
olfactory	O
bulbs	O
,	O
and	O
the	O
other	O
anatomical	O
structures	O
.	O

Six	O
are	O
new	O
.	O

Among	O
the	O
two	O
mutation	O
groups	O
57	O
%	O
and	O
54	O
%	O
was	O
in	O
the	O
best	O
visual	O
acuitycluster	O
.	O

Pedigrees	O
and	O
genotypes	O
of	O
Israeli	O
Arab	O
families	O
with	O
USH1	B-DISEASE
.	O

We	O
confirmed	O
this	O
mutation	O
by	O
Sanger	O
sequencing	O
(	O
Fig	O
.	O

This	O
result	O
agreed	O
with	O
the	O
profound	O
HI	B-DISEASE
of	O
this	O
subject	O
.	O

Further	O
,	O
results	O
were	O
visualized	O
after	O
being	O
analyzed	O
in	O
the	O
Broad	O
'	O
s	O
Integrative	O
Genomics	O
Viewer	O
(	O
IGV	O
)	O
.	O

In	O
five	O
families	O
with	O
TMC1	B-GENE
mutations	O
,	O
all	O
affected	O
members	O
were	O
homozygotes	O
,	O
whereas	O
in	O
two	O
families	O
affected	O
members	O
were	O
compound	O
heterozygotes	O
(	O
c	B-VARIANT
.	I-VARIANT
1566	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
/	O
p	B-VARIANT
.	I-VARIANT
I210del	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
1566	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
/	O
p	B-VARIANT
.	I-VARIANT
G267E	I-VARIANT
)	O
.	O

The	O
majority	O
of	O
mutations	O
found	O
in	O
this	O
study	O
were	O
found	O
in	O
the	O
Han	O
patient	O
group	O
(	O
1640	O
cases	O
)	O
only	O
except	O
c	O
.	O
35	O
insG	O
that	O
was	O
in	O
compound	O
heterozygous	O
with	O
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
found	O
in	O
two	O
Hui	O
patients	O
.	O

The	O
remaining	O
variants	O
are	O
shown	O
in	O
Table	O
2	O
.	O

The	O
homoplasmic	O
A1555G	B-VARIANT
mutation	O
was	O
carried	O
by	O
II	O
-	O
6	O
and	O
all	O
her	O
offsprings	O
,	O
and	O
presumably	O
also	O
carried	O
by	O
the	O
female	O
offsprings	O
in	O
the	O
fourth	O
generation	O
of	O
Branch	O
C	O
.	O

Autosomal	B-DISEASE
dominant	I-DISEASE
optic	I-DISEASE
atrophy	I-DISEASE
(	O
ADOA	B-DISEASE
;	O
MIM	O
no	O
.	O

a	O
Best	O
corrected	O
visual	B-DISEASE
acuity	I-DISEASE
(	O
decimal	O
)	O
.	O

C	O
.	O

However	O
,	O
we	O
identified	O
patients	O
with	O
causative	O
biallelic	O
mutations	O
in	O
recessive	O
RP	B-DISEASE
genes	O
who	O
additionally	O
carried	O
heterozygous	O
truncating	O
mutations	O
in	O
secondary	O
loci	O
.	O

B	O
Sequence	O
of	O
the	O
transcript	O
derived	O
from	O
the	O
c	B-VARIANT
.	I-VARIANT

All	O
results	O
are	O
displayed	O
as	O
mean	O
+	O
-	O
standard	O
error	O
of	O
the	O
mean	O
(	O
mean	O
+	O
-	O
SEM	O
)	O
.	O

Annotation	O
tracks	O
were	O
obtained	O
from	O
PolyPhen	O
-	O
2	O
.	O

K269del	I-VARIANT
)	O
affect	O
amino	O
acid	O
residues	O
located	O
in	O
the	O
motor	O
head	O
of	O
myosin	B-GENE
VIIa	I-GENE
,	O
and	O
have	O
previously	O
been	O
reported	O
in	O
USH1	B-DISEASE
patients	O
[	O
63	O
]	O
.	O

[	O
12	O
]	O
that	O
abolishes	O
the	O
+	O
4	O
/	O
+	O
5	O
positions	O
of	O
the	O
5	O
'	O
splice	O
site	O
(	O
SS	O
)	O
,	O
and	O
results	O
in	O
the	O
exon	O
skipping	O
of	O
exon	O
79	O
.	O

Milner	O
;	O
J	O
.	O

In	O
family	O
TB109	O
,	O
we	O
identified	O
a	O
novel	O
USH1G	B-GENE
mutation	O
(	O
c	B-VARIANT
.	I-VARIANT
206	I-VARIANT
-	I-VARIANT
207insC	I-VARIANT
)	O
,	O
which	O
brings	O
the	O
total	O
number	O
of	O
USH1G	B-GENE
mutations	O
reported	O
to	O
date	O
to	O
eight	O
.	O

Abbreviations	O
:	O
indels	O
,	O
insertions	O
-	O
deletions	O
;	O
SNV	O
,	O
single	O
-	O
nucleotide	O
variants	O
.	O

OPA3	B-GENE
mutations	O
result	O
in	O
optic	B-DISEASE
atrophy	I-DISEASE
associated	O
with	O
cataract	B-DISEASE
[	O
15	O
,	O
16	O
]	O
,	O
while	O
TMEM126A	B-GENE
mutations	O
are	O
responsible	O
for	O
an	O
autosomal	O
recessive	O
form	O
of	O
optic	B-DISEASE
atrophy	I-DISEASE
[	O
17	O
,	O
18	O
]	O
.	O

Although	O
it	O
was	O
an	O
advantage	O
that	O
the	O
region	O
of	O
interest	O
had	O
already	O
been	O
localized	O
by	O
linkage	O
analysis	O
for	O
patients	O
1	O
-	O
2	O
and	O
4	O
;	O
we	O
believe	O
that	O
we	O
would	O
have	O
found	O
the	O
mutation	O
without	O
the	O
knowledge	O
of	O
the	O
linked	O
region	O
.	O

Since	O
some	O
of	O
the	O
features	O
of	O
AS	B-DISEASE
[	O
16	O
]	O
,	O
[	O
17	O
]	O
and	O
patients	O
with	O
MYH9	B-GENE
mutations	O
overlap	O
,	O
it	O
is	O
possible	O
that	O
this	O
patient	O
disease	O
phenotype	O
is	O
a	O
result	O
of	O
interactions	O
between	O
these	O
two	O
genes	O
.	O

Of	O
these	O
cases	O
,	O
almost	O
80	O
%	O
show	O
autosomal	O
-	O
recessive	O
inheritance	O
.	O

endoplasmic	O
reticulum	O
ion	O
channels	O
)	O
,	O
and	O
at	O
the	O
mitochondrial	O
level	O
(	O
i	O
.	O
e	O
.	O

1	O
)	O
.	O

In	O
addition	O
,	O
the	O
p	B-VARIANT
.	I-VARIANT
Ala426Thr	I-VARIANT
variant	O
,	O
which	O
had	O
previously	O
been	O
reported	O
as	O
a	O
possible	O
polymorphism	O
,	O
was	O
found	O
in	O
one	O
family	O
.	O

However	O
,	O
the	O
number	O
of	O
cases	O
varied	O
geographically	O
.	O

In	O
Inner	O
Mongolia	O
,	O
China	O
,	O
mutations	O
in	O
SLC26A4	B-GENE
gene	O
account	O
for	O
at	O
least	O
12	O
.	O
6	O
%	O
(	O
17	O
/	O
135	O
)	O
of	O
the	O
patients	O
with	O
nonsyndromic	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

All	O
patients	O
showed	O
severe	O
to	O
profound	O
bilateral	O
sensorineural	O
hearing	B-DISEASE
impairment	I-DISEASE
on	O
audiograms	O
except	O
Patient	O
9	O
in	O
Table	O
1	O
whose	O
right	O
ear	O
pure	O
tone	O
average	O
(	O
PTA	O
)	O
is	O
55	O
dB	O
.	O

All	O
provided	O
clinical	O
and	O
phenotypic	O
data	O
were	O
recorded	O
.	O

Gene	O
level	O
overview	O
of	O
the	O
summarized	O
USH2A	B-GENE
mutations	O
.	O

DFNB1	B-GENE
genotypes	O
identified	O
in	O
30	O
patients	O
with	O
deafness	B-DISEASE
top	O
:	O
genotypes	O
of	O
the	O
23	O
familieswith	O
GJB2	B-GENE
biallelic	O
mutations	O
;	O
bottom	O
:	O
7	O
families	O
with	O
DFNB1	B-GENE
mutations	O
All	O
cases	O
presented	O
bilateral	O
,	O
congenital	O
hearing	B-DISEASE
loss	I-DISEASE
with	O
no	O
evidence	O
of	O
progression	O
*	O
novel	O
mutation	O
*	O
*	O
SC	O
:	O
Sporadic	O
case	O
;	O
AR	O
:	O
autosomal	O
recessive	O
;	O
cAR	O
:	O
autosomal	O
recessive	O
with	O
consanguinity	O
;	O
un	O
:	O
unknown	O
Sixteen	O
additional	O
patients	O
carried	O
2	O
GJB2	B-GENE
mutations	O
/	O
variants	O
with	O
a	O
controversial	O
pathogenic	O
effect	O
or	O
a	O
single	O
GJB2	B-GENE
sequence	O
variation	O
(	O
Table	O
2	O
)	O
.	O

We	O
report	O
43	O
genetic	O
variants	O
and	O
have	O
analyzed	O
genotype	O
-	O
phenotype	O
relationships	O
that	O
give	O
rise	O
to	O
a	O
more	O
complete	O
picture	O
of	O
this	O
highly	O
heterogeneous	O
but	O
important	O
rare	O
disease	O
.	O

The	O
pathogenic	O
mutation	O
of	O
TCS	B-DISEASE
patients	O
16	O
,	O
21	O
,	O
22	O
,	O
and	O
23	O
are	O
c	B-VARIANT
.	I-VARIANT
218_222insAACC	I-VARIANT
(	O
exon	O
3	O
)	O
,	O
c	B-VARIANT
.	I-VARIANT
4344dupA	I-VARIANT
(	O
exon	O
24	O
)	O
,	O
c	B-VARIANT
.	I-VARIANT
431delC	I-VARIANT
(	O
exon	O
5	O
)	O
,	O
and	O
c	B-VARIANT
.	I-VARIANT
4218dupG	I-VARIANT
(	O
exon	O
23	O
)	O
,	O
respectively	O
.	O

Functional	O
categorization	O
of	O
genes	O
with	O
causative	O
mutations	O
.	O

Ratio	O
RPC	O
was	O
calculated	O
from	O
patient	O
'	O
s	O
versus	O
controls	O
'	O
RPC	O
;	O
ratios	O
below	O
75	O
%	O
indicate	O
a	O
heterozygous	O
deletion	O
.	O

In	O
this	O
study	O
,	O
clinical	O
analysis	O
was	O
performed	O
in	O
10	O
patients	O
with	O
BOR	B-DISEASE
/	O
BO	B-DISEASE
syndrome	O
focusing	O
on	O
auditory	O
manifestations	O
and	O
rehabilitation	O
,	O
and	O
the	O
results	O
of	O
mutational	O
analysis	O
for	O
the	O
EYA1	B-GENE
,	O
SIX1	B-GENE
,	O
and	O
SIX5	B-GENE
genes	O
are	O
reported	O
.	O

SIT	O
,	O
The	O
Smell	O
Identification	O
Test	O
;	O
OB	O
,	O
olfactory	O
bulbs	O
;	O
F	O
,	O
female	O
;	O
M	O
,	O
male	O
;	O
nHH	O
,	O
normosmic	O
HH	O
;	O
R	O
,	O
right	O
;	O
A	O
,	O
anosmia	O
;	O
NA	O
,	O
not	O
assessed	O
FGFR1	B-GENE
MIM	O
#	O
136350	O
;	O
RefSeq	O
NM_023110	O
.	O
2	O
,	O
gi	O
:	O
105990521	O
KAL1	B-GENE
MIM	O
#	O
308700	O
;	O
RefSeq	O
NM_000216	O
.	O
2	O
,	O
gi	O
:	O
119395745	O
Variable	O
expressivity	O
of	O
FGFR1	B-GENE
mutations	O
was	O
noticed	O
within	O
families	O
(	O
Figure	O
1	O
)	O
.	O

By	O
sequencing	O
this	O
genetic	O
locus	O
,	O
we	O
discovered	O
a	O
mutation	O
in	O
the	O
CD164	B-GENE
gene	O
that	O
is	O
passed	O
on	O
to	O
all	O
the	O
affected	O
individuals	O
.	O

8p23	O
.	O
1	O
,	O
which	O
contains	O
a	O
beta	O
-	O
defensin	O
cluster	O
,	O
was	O
detected	O
as	O
a	O
region	O
with	O
high	O
copy	O
number	O
(	O
II	O
-	O
9	O
)	O
and	O
low	O
copy	O
number	O
(	O
II	O
-	O
3	O
and	O
II	O
-	O
7	O
)	O
(	O
Figure	O
2	O
)	O
.	O

None	O
of	O
the	O
10	O
individuals	O
with	O
copy	O
-	O
neutral	O
LOH	O
exhibited	O
a	O
homozygous	O
pathogenic	O
mutation	O
;	O
one	O
(	O
no	O
.	O

Susceptibility	O
to	O
metabotropic	B-GENE
glutamate	I-GENE
receptor	I-GENE
7	I-GENE
(	O
mGluR7	B-GENE
)	O
-	O
mediated	O
excitotoxicity	O
was	O
suggested	O
as	O
risk	O
factor	O
for	O
ARHI	B-DISEASE
3	O
.	O

Vestibular	O
functions	O
of	O
all	O
the	O
patients	O
were	O
normal	O
.	O

A	O
mutation	O
in	O
the	O
5	O
'	O
or	O
3	O
'	O
untranslated	O
region	O
cannot	O
be	O
excluded	O
.	O

This	O
process	O
resulted	O
in	O
a	O
total	O
of	O
616	O
putative	O
cancer	O
related	O
genes	O
.	O

Families	O
with	O
no	O
identified	O
mutation	O
in	O
GJB2	B-GENE
and	O
MYO15A	B-GENE
were	O
further	O
genotyped	O
using	O
the	O
Illumina	O
HumanOmniExpress	O
whole	O
genome	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
microarray	O
(	O
>	O
700	O
K	O
SNPs	O
)	O
or	O
the	O
Illumina	O
Human	O
Linkage	O
-	O
12	O
panel	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocols	O
.	O

PCR	O
primers	O
were	O
designed	O
to	O
amplify	O
exons	O
and	O
surrounding	O
intronic	O
regions	O
of	O
the	O
7	O
exons	O
of	O
CD164	B-GENE
(	O
RefSeq	O
nos	O
.	O

Allele	O
and	O
genotype	O
frequencies	O
were	O
calculated	O
for	O
each	O
locus	O
and	O
tested	O
for	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
(	O
HWE	O
)	O
considering	O
only	O
parents	O
.	O

It	O
has	O
also	O
been	O
reported	O
that	O
some	O
common	O
molecular	O
etiologies	O
,	O
such	O
as	O
GJB2	B-GENE
and	O
SLC26A4	B-GENE
mutations	O
,	O
in	O
the	O
general	O
Chinese	O
deaf	B-DISEASE
population	O
are	O
rare	O
in	O
the	O
Tibetan	O
Chinese	O
deaf	B-DISEASE
population	O
[	O
28	O
]	O
.	O

Duplicate	O
reads	O
were	O
removed	O
using	O
Picard	O
(	O
http	O
:	O
/	O
/	O
picard	O
.	O
sourceforge	O
.	O
net	O
)	O
,	O
and	O
clean	O
reads	O
localised	O
to	O
the	O
target	O
region	O
were	O
collected	O
and	O
analysed	O
by	O
SOAPsnp	O
(	O
V	O
.	O
1	O
.	O
03	O
)	O
.	O

We	O
identified	O
COL4A4	B-GENE
missense	O
variants	O
[	O
c	B-VARIANT
.	I-VARIANT
G2636A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Gly879Glu	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
C4715T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Pro1572Leu	I-VARIANT
)	O
]	O
in	O
the	O
21	O
-	O
year	O
-	O
old	O
male	O
proband	O
from	O
family	O
1	O
,	O
who	O
had	O
been	O
diagnosed	O
with	O
mesangial	B-DISEASE
proliferative	I-DISEASE
nephropathy	I-DISEASE
at	O
age	O
14	O
.	O

The	O
mutation	O
NM_138691	O
.	O
2	O
:	O
c	B-VARIANT
.	I-VARIANT
236	I-VARIANT
+	I-VARIANT
1	I-VARIANT
G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
was	O
found	O
in	O
13	O
reads	O
out	O
of	O
26	O
.	O

AS	B-DISEASE
consists	O
of	O
a	O
triad	O
of	O
progressive	O
renal	B-DISEASE
failure	I-DISEASE
,	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
ocular	B-DISEASE
abnormalities	I-DISEASE
and	O
occurs	O
due	O
to	O
mutations	O
in	O
COL4A5	B-GENE
in	O
85	O
%	O
of	O
cases	O
13	O
.	O

However	O
,	O
in	O
both	O
cases	O
while	O
there	O
were	O
some	O
features	O
consistent	O
with	O
MED	B-DISEASE
,	O
it	O
was	O
also	O
noted	O
that	O
there	O
were	O
features	O
not	O
normally	O
associated	O
with	O
MED	B-DISEASE
such	O
as	O
short	B-DISEASE
trunk	I-DISEASE
and	O
severely	B-DISEASE
fragmented	I-DISEASE
hip	I-DISEASE
epiphyses	I-DISEASE
with	O
adjacent	B-DISEASE
metaphyseal	I-DISEASE
anomalies	I-DISEASE
.	O

By	O
qPCR	O
,	O
we	O
also	O
detected	O
heterozygous	O
deletions	O
in	O
both	O
parents	O
of	O
the	O
homozygous	O
patients	O
1	O
and	O
95	O
.	O

(	O
TIF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

The	O
pedigree	O
is	O
illustrated	O
in	O
figure	O
1	O
.	O

A	O
diagnosis	O
of	O
profound	B-DISEASE
sensorineural	I-DISEASE
hearing	I-DISEASE
impairment	I-DISEASE
was	O
made	O
according	O
to	O
the	O
ICD	O
-	O
10	O
criteria	O
based	O
on	O
the	O
audiometric	O
examination	O
.	O

Inhibition	O
of	O
actin	O
polymerization	O
by	O
latrunculin	O
A	O
reduces	O
F	O
-	O
actin	O
in	O
all	O
cells	O
,	O
but	O
while	O
20	O
%	O
of	O
F	O
-	O
actin	O
remains	O
in	O
normal	O
cells	O
,	O
55	O
%	O
of	O
F	O
-	O
actin	O
remains	O
in	O
beta	B-GENE
-	I-GENE
actin	I-GENE
-	O
p	B-VARIANT
.	I-VARIANT
Arg196His	I-VARIANT
cells	O
,	O
indicating	O
more	O
stabile	O
F	O
-	O
actin	O
,	O
and	O
only	O
5	O
%	O
remains	O
in	O
gamma	O
-	O
actin	O
-	O
p	B-VARIANT
.	I-VARIANT
Ser155Phe	I-VARIANT
cells	O
,	O
consistent	O
with	O
less	B-DISEASE
stabile	I-DISEASE
actin	I-DISEASE
filaments	I-DISEASE
associated	O
with	O
this	O
mutation	O
.	O

Among	O
the	O
three	O
types	O
,	O
USH1	B-DISEASE
is	O
the	O
most	O
severe	O
form	O
.	O

(	O
A	O
)	O
European	O
(	O
B	O
)	O
Central	O
Asian	O
(	O
C	O
)	O
East	O
Asian	O
(	O
D	O
)	O
African	O
(	O
E	O
)	O
African	O
-	O
European	O
(	O
F	O
)	O
Hispanic	O
(	O
G	O
)	O
Other	O
.	O

(	O
b	O
)	O
Audiograms	O
showing	O
ski	O
slope	O
type	O
high	O
frequency	O
hearing	B-DISEASE
loss	I-DISEASE
with	O
low	O
frequency	O
residual	O
hearing	O
initially	O
and	O
gradual	O
deterioration	O
with	O
age	O
.	O

This	O
was	O
confirmed	O
by	O
specifically	O
amplifying	O
and	O
sequencing	O
transcripts	O
which	O
included	O
the	O
255	O
bp	O
exon	O
9	O
(	O
figure	O
2	O
,	O
see	O
online	O
supplementary	O
figure	O
S2B	O
)	O
.	O

Analysis	O
of	O
additional	O
family	O
members	O
from	O
whom	O
DNA	O
was	O
available	O
only	O
confirmed	O
segregation	O
of	O
the	O
GUCY2D	B-GENE
mutation	O
(	O
c	B-VARIANT
.	I-VARIANT
2512C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R838C	I-VARIANT
)	O
with	O
disease	O
symptoms	O
in	O
the	O
family	O
.	O

In	O
our	O
study	O
,	O
we	O
could	O
analyze	O
RNA	O
from	O
nasal	O
epithelial	O
cells	O
from	O
patients	O
or	O
carriers	O
of	O
eight	O
variants	O
previously	O
analyzed	O
by	O
minigene	O
constructions	O
,	O
to	O
determine	O
their	O
effect	O
on	O
splicing	O
process	O
in	O
patient	O
'	O
s	O
tissues	O
.	O

We	O
found	O
suggestive	O
evidence	O
of	O
mosaicism	O
for	O
two	O
of	O
the	O
de	O
novo	O
mutations	O
:	O
c	B-VARIANT
.	I-VARIANT
313G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
105E	I-VARIANT
>	I-VARIANT
Q	I-VARIANT
)	O
in	O
PARD3B	B-GENE
(	O
ENST00000349953	O
)	O
in	O
F9	O
,	O
and	O
c	B-VARIANT
.	I-VARIANT
2921G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT

Normal	O
conduction	O
velocities	O
:	O
median	O
motor	O
nerve	O
>	O
=	O
50	O
.	O
5	O
m	O
/	O
s	O
;	O
ulnar	O
nerve	O
>	O
=	O
51	O
.	O
1	O
m	O
/	O
s	O
;	O
and	O
sural	O
nerve	O
>	O
=	O
32	O
.	O
1	O
m	O
/	O
s	O
.	O

There	O
have	O
been	O
several	O
reports	O
of	O
mutations	O
in	O
MYO15A	B-GENE
causing	O
hearing	B-DISEASE
loss	I-DISEASE
[	O
17	O
,	O
21	O
-	O
27	O
]	O
.	O

En	O
face	O
OCT	O
imaging	O
reveals	O
the	O
presence	O
of	O
the	O
cysts	O
in	O
patient	O
1	O
-	O
II	O
-	O
1	O
.	O

Patients	O
most	O
commonly	O
had	O
no	O
family	O
history	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
54	O
%	O
)	O
and	O
a	O
normal	O
physical	O
exam	O
(	O
61	O
%	O
)	O
.	O

However	O
the	O
variant	O
p	B-VARIANT
.	I-VARIANT
Arg271Cys	I-VARIANT
was	O
thought	O
to	O
be	O
a	O
protective	O
allele	O
against	O
focal	O
or	O
generalised	O
epilepsy	B-DISEASE
[	O
22	O
,	O
31	O
,	O
32	O
]	O
and	O
yet	O
this	O
was	O
found	O
in	O
one	O
of	O
our	O
patients	O
with	O
co	O
-	O
existing	O
seizures	B-DISEASE
and	O
Pendred	B-DISEASE
syndrome	I-DISEASE
.	O

Pure	O
-	O
tone	O
audiometry	O
testing	O
showed	O
that	O
her	O
father	O
had	O
moderate	O
high	O
-	O
frequency	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
whereas	O
her	O
mother	O
had	O
normal	O
hearing	O
.	O

Examples	O
of	O
CT	O
and	O
MRI	O
images	O
of	O
normal	O
children	O
and	O
children	O
with	O
SLC26A4	B-GENE
mutations	O
.	O

The	O
hydrophobic	O
pocket	O
which	O
includes	O
Lys338	O
of	O
ESRRB	B-GENE
may	O
have	O
a	O
similar	O
function	O
of	O
allowing	O
agonist	O
ligand	O
and	O
coactivator	O
binding	O
by	O
increasing	O
the	O
volume	O
for	O
ligand	O
interaction	O
and	O
providing	O
charged	O
residues	O
that	O
are	O
required	O
for	O
ligand	O
binding	O
.	O

RP	B-DISEASE
is	O
inherited	O
most	O
frequently	O
(	O
84	O
%	O
)	O
as	O
an	O
autosomal	O
recessive	O
trait	O
,	O
followed	O
by	O
autosomal	O
dominant	O
(	O
10	O
%	O
)	O
and	O
has	O
X	O
-	O
linked	O
recessive	O
(	O
6	O
%	O
)	O
patterns	O
in	O
the	O
white	O
USA	O
population	O
.	O

Furthermore	O
,	O
the	O
mitochondrial	O
lengths	O
in	O
the	O
fibroblasts	O
of	O
patient	O
were	O
much	O
larger	O
than	O
that	O
of	O
control	O
(	O
patient	O
,	O
28	O
.	O
4	O
+	O
-	O
5	O
.	O
8	O
mu	O
m	O
versus	O
control	O
,	O
6	O
.	O
9	O
+	O
-	O
1	O
.	O
4	O
mu	O
m	O
,	O
Fig	O
.	O

'	O
ZERO	O
CVG	O
TARGETS	O
PCT	O
'	O
represents	O
the	O
number	O
of	O
targets	O
that	O
did	O
not	O
reach	O
coverage	O
=	O
2	O
over	O
any	O
base	O
.	O

The	O
clinical	O
phenotype	O
,	O
which	O
is	O
distinct	O
from	O
the	O
classic	O
long	B-DISEASE
QT	I-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
1	I-DISEASE
,	O
is	O
consistent	O
with	O
the	O
loss	O
-	O
of	O
-	O
function	O
effect	O
of	O
the	O
p	B-VARIANT
.	I-VARIANT
R397Q	I-VARIANT
variant	O
on	O
trafficking	O
of	O
the	O
KCNQ1	B-GENE
protein	O
to	O
the	O
membrane	O
and	O
decreased	O
IKs	O
tail	O
current	O
density	O
.	O

Two	O
subjects	O
reported	O
tinnitus	B-DISEASE
and	O
vertigo	B-DISEASE
.	O

These	O
possibilities	O
have	O
not	O
been	O
investigated	O
,	O
and	O
RNA	O
studies	O
are	O
not	O
possible	O
in	O
this	O
instance	O
because	O
we	O
cannot	O
obtain	O
fresh	O
peripheral	O
blood	O
samples	O
.	O

2	O
.	O
91	O
options	O
of	O
EasyLinkage	O
ver	O
.	O

Final	O
results	O
were	O
verified	O
by	O
hand	O
on	O
up	O
to	O
date	O
online	O
tools	O
for	O
HGMD	O
22	O
,	O
SIFT	O
and	O
POLYPHEN2	O
,	O
accessed	O
2	O
/	O
17	O
/	O
2014	O
.	O

The	O
hCG	O
test	O
showed	O
no	O
significant	O
increase	O
(	O
cases	O
6	O
,	O
18	O
,	O
26	O
and	O
31	O
)	O
or	O
only	O
a	O
partial	O
increase	O
of	O
plasma	O
testosterone	O
concentrations	O
(	O
1	O
.	O
4	O
ng	O
/	O
mL	O
in	O
case	O
34	O
and	O
1	O
.	O
9	O
ng	O
/	O
mL	O
in	O
case	O
39	O
)	O
.	O

As	O
a	O
first	O
screening	O
analysis	O
,	O
we	O
performed	O
linkage	O
analysis	O
to	O
the	O
WFS1	B-GENE
locus	O
at	O
4p16	O
.	O
1	O
by	O
means	O
of	O
genotyping	O
of	O
markers	O
D4S432	O
,	O
D4S3023	O
,	O
DS2366	O
,	O
and	O
D4S2639	O
.	O

Reads	O
were	O
mapped	O
to	O
the	O
reference	O
human	O
genome	O
(	O
GRCh37	O
,	O
UCSC	O
hg19	O
)	O
using	O
the	O
Burrows	O
-	O
Wheeler	O
Aligner	O
(	O
http	O
:	O
/	O
/	O
bio	O
-	O
bwa	O
.	O
sourceforge	O
.	O
net	O
/	O
)	O
.	O

I	O
presents	O
the	O
heterozygous	O
,	O
one	O
-	O
base	O
-	O
deletion	O
mutation	O
c	B-VARIANT
.	I-VARIANT
7123delG	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT

2009	O
)	O
,	O
the	O
advent	O
of	O
targeted	O
genomic	O
enrichment	O
and	O
massively	O
parallel	O
sequencing	O
(	O
TGE	O
+	O
MPS	O
)	O
has	O
revolutionized	O
the	O
clinical	O
care	O
of	O
the	O
patient	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
by	O
making	O
comprehensive	O
genetic	O
testing	O
possible	O
(	O
Shearer	O
and	O
Smith	O
2015	O
)	O
.	O

The	O
sporadic	O
occurrence	O
of	O
RP	B-DISEASE
suggests	O
autosomal	O
recessive	O
inheritance	O
in	O
all	O
three	O
patients	O
,	O
making	O
a	O
dominant	O
-	O
negative	O
effect	O
of	O
the	O
TULP1	B-GENE
and	O
the	O
SAG	B-GENE
mutation	O
unlikely	O
.	O

Non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
deaf	I-DISEASE
probands	O
were	O
recruited	O
from	O
deaf	B-DISEASE
patients	O
seeking	O
genetic	O
testing	O
and	O
counseling	O
in	O
Xinhua	O
Hospital	O
,	O
Shanghai	O
,	O
China	O
.	O

While	O
for	O
TMPRSS3	B-GENE
(	O
c	B-VARIANT
.	I-VARIANT
726C	I-VARIANT
>	I-VARIANT
G	I-VARIANT
)	O
and	O
MSRB3	B-GENE
(	O
c	B-VARIANT
.	I-VARIANT
20T	I-VARIANT
>	I-VARIANT
G	I-VARIANT
)	O
variants	O
AciI	O
and	O
TseI	O
PCR	O
-	O
RFLP	O
were	O
performed	O
,	O
respectively	O
.	O

We	O
are	O
also	O
grateful	O
to	O
the	O
audiologists	O
Gao	O
Lei	O
,	O
Xie	O
Juan	O
and	O
Han	O
Li	O
-	O
ping	O
for	O
their	O
diagnostic	O
work	O
.	O

Further	O
,	O
likely	O
loss	O
-	O
of	O
-	O
function	O
truncation	O
variants	O
were	O
detected	O
in	O
several	O
other	O
genes	O
/	O
gene	O
family	O
members	O
and	O
syndromes	O
(	O
NF1	B-GENE
)	O
that	O
have	O
previously	O
been	O
associated	O
with	O
breast	O
and	O
/	O
or	O
ovarian	B-DISEASE
cancer	I-DISEASE
susceptibility	O
including	O
BLM	B-GENE
15	O
,	O
FANCD2	B-GENE
45	O
,	O
NF1	B-GENE
19	O
,	O
46	O
,	O
RAD51B	B-GENE
47	O
,	O
48	O
,	O
FANCA	B-GENE
49	O
,	O
FANCB	B-GENE
,	O
FANCL	B-GENE
,	O
FANCM	B-GENE
,	O
ATRIP	B-GENE
,	O
and	O
ATR	B-GENE
50	O
.	O

In	O
one	O
of	O
the	O
families	O
with	O
a	O
de	O
novo	O
mutation	O
(	O
SCN5A	B-GENE
p	B-VARIANT
.	I-VARIANT

Only	O
22	O
patients	O
could	O
be	O
solved	O
using	O
previously	O
known	O
STGD	B-DISEASE
causing	O
mutations	O
.	O

To	O
determine	O
the	O
effects	O
of	O
USH3	B-DISEASE
mutations	O
on	O
CLRN1	B-GENE
function	O
,	O
we	O
examined	O
the	O
cellular	O
distribution	O
and	O
stability	O
of	O
both	O
normal	O
and	O
mutant	O
CLRN1	B-GENE
in	O
vitro	O
.	O

I2084fs	I-VARIANT
)	O
,	O
c	B-VARIANT
.	I-VARIANT
9492_9498del	I-VARIANT
TGATGAT	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT

,	O
2009	O
)	O
.	O

We	O
aligned	O
reads	O
to	O
the	O
human	O
reference	O
genome	O
sequence	O
(	O
hg19	O
)	O
and	O
generated	O
SNP	O
and	O
indel	O
calls	O
for	O
all	O
samples	O
.	O

In	O
fact	O
,	O
the	O
only	O
instance	O
of	O
a	O
positive	O
genetic	O
diagnosis	O
associated	O
with	O
unilateral	O
hearing	B-DISEASE
loss	I-DISEASE
was	O
in	O
a	O
patient	O
with	O
a	O
family	O
history	O
of	O
BOR	B-DISEASE
syndrome	I-DISEASE
caused	O
by	O
a	O
truncating	O
variant	O
in	O
EYA1	O
,	O
a	O
well	O
-	O
recognized	O
phenotype	O
-	O
genotype	O
association	O
(	O
Chang	O
et	O
al	O
.	O

Ophthalmologic	O
examination	O
included	O
best	O
corrected	O
visual	O
acuity	O
determination	O
,	O
funduscopy	O
,	O
fluorescein	O
retinal	O
angiography	O
,	O
and	O
Goldmann	O
kinetic	O
perimetry	O
.	O

Other	O
missense	O
mutations	O
,	O
K77I	B-VARIANT
,	O
S391R	B-VARIANT
,	O
N392Y	B-VARIANT
,	O
T410M	B-VARIANT
,	O
and	O
H723R	B-VARIANT
,	O
have	O
been	O
reported	O
in	O
patients	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
[	O
24	O
,	O
25	O
,	O
50	O
]	O
.	O

TJ	O
carried	O
out	O
the	O
Splice	O
-	O
site	O
predictions	O
and	O
drafted	O
the	O
manuscript	O
.	O

By	O
the	O
subsequent	O
WES	O
analysis	O
,	O
we	O
verified	O
that	O
all	O
genes	O
located	O
in	O
ROH	O
segments	O
were	O
lacking	O
mutations	O
.	O

Under	O
these	O
conditions	O
the	O
expression	O
of	O
K	B-GENE
V	I-GENE
7	I-GENE
.	I-GENE
1	I-GENE
and	O
KCNE1	B-GENE
resulted	O
in	O
a	O
non	O
-	O
inactivating	O
K	B-GENE
V	I-GENE
7	I-GENE
.	I-GENE
1	I-GENE
/	O
KCNE1	B-GENE
current	O
with	O
marked	O
faster	O
activation	O
and	O
deactivation	O
kinetics	O
as	O
compared	O
to	O
when	O
the	O
channel	O
subunits	O
were	O
expressed	O
in	O
X	O
.	O
laevis	O
oocytes	O
.	O

The	O
Gipc3	B-GENE
343A	O
allele	O
disrupts	O
the	O
structure	O
of	O
the	O
stereocilia	O
bundle	O
and	O
affects	O
long	O
-	O
term	O
function	O
of	O
auditory	O
hair	O
cells	O
and	O
spiral	O
ganglion	O
neurons	O
.	O

Genetic	O
screening	O
was	O
performed	O
by	O
bi	O
-	O
directional	O
sequencing	O
of	O
PCR	O
amplified	O
exons	O
with	O
associated	O
flanking	O
intronic	O
regions	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
(	O
Quikchange	O
,	O
Stratagene	O
)	O
was	O
performed	O
to	O
introduce	O
the	O
Gly403Arg	B-VARIANT
,	O
Ile770Met	B-VARIANT
and	O
Gly403Asp	B-VARIANT
mutations	O
into	O
CACNA1D	B-GENE
.	O

In	O
all	O
the	O
families	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
history	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
was	O
established	O
post	O
priori	O
after	O
COL4A3	B-GENE
variants	O
were	O
identified	O
.	O

Chiba	O
-	O
Falek	O
;	O
E	O
.	O
T	O
.	O

The	O
beta	O
-	O
satellite	O
mutation	O
was	O
not	O
present	O
in	O
any	O
probands	O
in	O
our	O
series	O
,	O
nor	O
in	O
any	O
hearing	O
controls	O
in	O
our	O
series	O
.	O

Both	O
type	O
1	O
and	O
type	O
2	O
diabetes	B-DISEASE
have	O
been	O
shown	O
to	O
result	O
from	O
a	O
variety	O
of	O
genetic	O
risk	O
factors	O
and	O
environmental	O
components	O
.	O

Chifeng	O
is	O
a	O
typical	O
city	O
in	O
northern	O
China	O
with	O
a	O
population	O
of	O
4	O
.	O
61	O
million	O
,	O
and	O
Nantong	O
is	O
a	O
typical	O
city	O
in	O
southern	O
China	O
with	O
a	O
population	O
of	O
7	O
.	O
74	O
million	O
.	O

Average	O
mean	O
depths	O
were	O
226	O
.	O
39	O
and	O
197	O
.	O
96	O
for	O
solved	O
and	O
unsolved	O
cases	O
,	O
respectively	O
(	O
Additional	O
file	O
1	O
:	O
Table	O
S3	O
and	O
Figure	O
4	O
)	O
.	O

Some	O
recent	O
studies	O
even	O
demonstrated	O
that	O
the	O
mtDNA	O
mutations	O
could	O
well	O
be	O
discovered	O
in	O
exome	O
sequencing	O
in	O
which	O
mtDNA	O
was	O
not	O
specifically	O
targeted	O
(	O
e	O
.	O
g	O
.	O
,	O
Dinwiddie	O
et	O
al	O
.	O

A	O
total	O
of	O
seven	O
different	O
pathogenic	O
mutations	O
(	O
IVS7	B-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
,	O
E37X	B-VARIANT
,	O
K77I	B-VARIANT
,	O
S391R	B-VARIANT
,	O
N392Y	B-VARIANT
,	O
T410M	B-VARIANT
,	O
H723R	B-VARIANT
)	O
and	O
five	O
novel	O
,	O
probably	O
pathogenic	O
variants	O
(	O
Y375C	B-VARIANT
,	O
R470H	B-VARIANT
,	O
I491T	B-VARIANT
,	O
L597S	B-VARIANT
,	O
and	O
H723D	B-VARIANT
)	O
were	O
found	O
.	O

Interestingly	O
,	O
U1185	O
carried	O
,	O
in	O
addition	O
to	O
an	O
USH2A	B-GENE
pathogenic	O
genotype	O
,	O
the	O
c	B-VARIANT
.	I-VARIANT
496	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
variant	O
in	O
USH1C	B-GENE
.	O

In	O
hugely	O
sharp	O
contrast	O
,	O
Arginine	O
has	O
5	O
carbons	O
and	O
3	O
nitrogens	O
,	O
it	O
is	O
positively	O
charged	O
,	O
and	O
plays	O
a	O
role	O
in	O
protein	O
folding	O
by	O
creating	O
hydrogen	O
bonds	O
with	O
other	O
amino	O
acids	O
in	O
the	O
peptide	O
chain	O
.	O

Transcriptional	O
activation	O
of	O
luciferase	O
reporter	O
constructs	O
by	O
the	O
wild	O
-	O
type	O
and	O
mutant	O
TBX1	B-GENE
.	O

In	O
addition	O
to	O
these	O
causative	O
mutations	O
,	O
26	O
non	O
-	O
synonymous	O
variants	O
were	O
identified	O
in	O
the	O
CDH23	B-GENE
coding	O
exons	O
from	O
16	O
hearing	B-DISEASE
-	I-DISEASE
loss	I-DISEASE
patients	O
and	O
30	O
Korean	O
control	O
exomes	O
(	O
Table	O
3	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
no	O
clear	O
phenotype	O
-	O
genotype	O
correlation	O
could	O
be	O
established	O
between	O
RP	B-DISEASE
and	O
Usher	O
cases	O
.	O

Family	O
PKDF740	O
.	O

Moreover	O
,	O
an	O
association	O
between	O
WFS1	B-GENE
single	O
nucleotide	O
polymorphisms	O
and	O
an	O
increased	O
risk	O
of	O
type	B-DISEASE
2	I-DISEASE
diabetes	I-DISEASE
has	O
been	O
identified	O
in	O
European	O
populations	O
[	O
19	O
,	O
20	O
]	O
.	O

Previously	O
described	O
variant	O
.	O

All	O
5	O
patients	O
with	O
1555A	B-VARIANT
>	I-VARIANT
G	I-VARIANT
mutation	O
in	O
the	O
present	O
study	O
had	O
a	O
history	O
of	O
aminoglycoside	O
use	O
.	O

All	O
S6	O
segments	O
of	O
CACNA1D	B-GENE
were	O
sequenced	O
in	O
all	O
APAs	B-DISEASE
;	O
the	O
S6	O
segments	O
of	O
domains	O
I	O
and	O
II	O
were	O
sequenced	O
for	O
germline	O
mutations	O
in	O
patients	O
with	O
early	O
-	O
onset	O
hypertension	B-DISEASE
.	O

Exons	O
were	O
captured	O
using	O
the	O
Agilent	O
38Mb	O
SureSelect	O
v2	O
(	O
University	O
of	O
Pennsylvania	O
and	O
Broad	O
Institute	O
n	O
=	O
118	O
)	O
,	O
the	O
NimbleGen	O
Seq	O
Cap	O
EZ	O
SR	O
v2	O
(	O
Mt	O
Sinai	O
School	O
of	O
Medicine	O
,	O
Vanderbilt	O
University	O
n	O
=	O
51	O
)	O
,	O
or	O
NimbleGen	O
VCRome	O
2	O
.	O
1	O
(	O
Baylor	O
n	O
=	O
6	O
)	O
.	O

No	O
significant	O
difference	O
was	O
observed	O
for	O
the	O
age	O
at	O
onset	O
of	O
deafness	B-DISEASE
between	O
MDP	O
and	O
TDP	O
(	O
P	O
=	O
0	O
.	O
28	O
,	O
Fig	O
.	O

We	O
were	O
however	O
able	O
to	O
perform	O
PCR	O
on	O
DNA	O
extracted	O
from	O
serum	O
stored	O
at	O
the	O
transplant	O
unit	O
and	O
confirmed	O
that	O
he	O
too	O
had	O
the	O
identical	O
mutation	O
.	O

Erin	O
L	O
.	O

Morell	O
,	O
J	O
.	O

LOH	O
was	O
also	O
observed	O
for	O
several	O
BRCA2	B-GENE
missense	O
variants	O
.	O

All	O
subjects	O
gave	O
a	O
written	O
informed	O
consent	O
to	O
participate	O
in	O
the	O
study	O
.	O

Moreover	O
,	O
the	O
whole	O
coding	O
region	O
and	O
100	O
nucleotides	O
upstream	O
and	O
downstream	O
of	O
each	O
exon	O
(	O
intron	O
-	O
exon	O
boundaries	O
)	O
of	O
MARVELD2	B-GENE
gene	O
have	O
been	O
sequenced	O
.	O

Data	O
are	O
represented	O
as	O
means	O
+	O
-	O
SEM	O
of	O
n	O
>	O
=	O
3	O
independent	O
experiments	O
.	O

Healthy	O
controls	O
were	O
included	O
after	O
clinical	O
evaluation	O
and	O
ECG	O
recording	O
.	O

4	O
-	O
6	O
Approximately	O
60	O
%	O
of	O
CINCA	B-DISEASE
/	O
NOMID	B-DISEASE
patients	O
carry	O
heterozygous	O
germline	O
missense	O
mutations	O
in	O
the	O
NLRP3	B-GENE
coding	O
region	O
(	O
mutation	O
-	O
positive	O
patients	O
)	O
.	O

Resulting	O
images	O
were	O
quantified	O
using	O
Agilent	O
Feature	O
Extraction	O
software	O
and	O
analyzed	O
utilizing	O
Agilent	O
genomic	O
Workbench	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
genomics	O
.	O
agilent	O
.	O
com	O
)	O
.	O

Rather	O
,	O
their	O
pathogenic	O
effect	O
is	O
due	O
to	O
impaired	O
expression	O
of	O
the	O
mutant	O
alleles	O
.	O

To	O
minimize	O
the	O
number	O
of	O
variants	O
tied	O
with	O
ancestral	O
origins	O
,	O
only	O
missense	O
germline	O
variants	O
from	O
individuals	O
classified	O
as	O
Caucasian	O
by	O
Plink	O
were	O
used	O
for	O
downstream	O
significance	O
testing	O
.	O

Retinal	B-DISEASE
degeneration	I-DISEASE
in	O
the	O
macular	O
region	O
and	O
severely	O
decreased	O
BCVA	O
occurred	O
in	O
3	O
/	O
5	O
patients	O
suggesting	O
that	O
the	O
advanced	O
stage	O
of	O
CNGA1	B-GENE
mutations	O
included	O
degeneration	O
of	O
the	O
entire	O
retina	O
with	O
both	O
rod	O
and	O
cone	O
photoreceptors	O
.	O

DNA	O
samples	O
were	O
stored	O
at	O
-	O
80	O
deg	O
C	O
until	O
used	O
.	O

9	O
Array	O
comparative	O
genomic	O
hybridization	O
was	O
performed	O
using	O
a	O
Roche	O
NimbleGen	O
CGX	O
v1	O
315K	O
array	O
(	O
Roche	O
NimbleGen	O
,	O
Madison	O
,	O
WI	O
)	O
per	O
manufacturer	O
'	O
s	O
recommendations	O
using	O
healthy	O
pooled	O
male	O
and	O
female	O
reference	O
DNA	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
)	O
,	O
and	O
arrays	O
were	O
analyzed	O
using	O
Genoglyphix	O
software	O
(	O
Signature	O
Genomics	O
,	O
Spokane	O
,	O
WA	O
)	O
.	O

Indeed	O
,	O
TMPRSS3	B-GENE
[	O
3	O
]	O
,	O
TMC1	B-GENE
[	O
4	O
]	O
and	O
TMIE	B-GENE
[	O
7	O
]	O
,	O
were	O
identified	O
in	O
studies	O
involving	O
a	O
few	O
multi	O
-	O
affected	O
families	O
from	O
the	O
Indian	O
subcontinent	O
.	O

Both	O
amino	O
acid	O
changes	O
affect	O
highly	O
preserved	O
residues	O
(	O
Figure	O
2	O
)	O
.	O

(	O
TIF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

1	O
E	O
,	O
the	O
error	O
rates	O
at	O
most	O
residues	O
were	O
low	O
(	O
<	O
1	O
%	O
)	O
with	O
some	O
hotspots	O
for	O
each	O
type	O
of	O
error	O
.	O

53	O
%	O
were	O
attributableto	O
one	O
of	O
only	O
threesequence	O
variations	O
(	O
c	B-VARIANT
.	I-VARIANT
983A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
2708_2711delTTAG	I-VARIANT
,	O
or	O
c	B-VARIANT
.	I-VARIANT
2826_2836delinsGGATGCTCCA	I-VARIANT
)	O
.	O

Among	O
the	O
six	O
human	O
genes	O
encoding	O
actins	O
,	O
only	O
ACTB	B-GENE
and	O
ACTG1	B-GENE
are	O
ubiquitously	O
expressed	O
;	O
the	O
remaining	O
four	O
are	O
expressed	O
primarily	O
in	O
muscle	O
.	O

SS	O
Patient	O
7	O
has	O
severe	O
facial	O
anomalies	O
:	O
absence	O
of	O
nasal	O
wing	O
on	O
the	O
right	O
side	O
,	O
right	O
microphthalmia	O
and	O
eye	B-DISEASE
defect	I-DISEASE
.	O

Audiograms	O
of	O
affected	O
members	O
in	O
the	O
family	O
are	O
shown	O
in	O
Figure	O
1B	O
.	O

Table	O
S2	O
.	O

Asterisks	O
indicate	O
individuals	O
whose	O
DNA	O
was	O
used	O
for	O
exome	O
sequencing	O
.	O

Otterbein	O
et	O
al	O
.	O

Proteinuria	B-DISEASE
meant	O
a	O
level	O
of	O
proteinuria	B-DISEASE
over	O
0	O
.	O
5	O
g	O
/	O
24	O
h	O
.	O

FGFR2	B-GENE
,	O
like	O
the	O
other	O
members	O
of	O
the	O
FGFR	O
family	O
,	O
comprises	O
an	O
extracellular	O
ligand	O
-	O
binding	O
region	O
(	O
composed	O
of	O
three	O
immunoglobulin	O
-	O
like	O
domains	O
)	O
,	O
a	O
single	O
transmembrane	O
peptide	O
and	O
a	O
cytoplasmic	O
tyrosine	O
kinase	O
domain	O
.	O

WFS1	B-GENE
has	O
been	O
implicated	O
in	O
the	O
unfolded	O
protein	O
response	O
,	O
a	O
cellular	O
stress	O
response	O
induced	O
by	O
the	O
accumulation	O
of	O
unfolded	O
proteins	O
within	O
the	O
ER	O
lumen	O
,	O
which	O
is	O
pivotal	O
to	O
cellular	O
homeostasis	O
and	O
integrity	O
(	O
3	O
,	O
4	O
)	O
.	O

The	O
cochlear	O
tissues	O
of	O
basilar	O
membrane	O
,	O
spiral	O
ligament	O
and	O
the	O
vestibular	O
end	O
-	O
organ	O
of	O
saccule	O
macula	O
were	O
micro	O
-	O
dissected	O
out	O
as	O
has	O
been	O
described	O
.	O

One	O
in	O
a	O
thousand	O
children	O
develops	O
congenital	O
or	O
prelingual	O
deafness	B-DISEASE
.	O

In	O
this	O
study	O
,	O
we	O
performed	O
whole	O
exome	O
analysis	O
of	O
30	O
Japanese	O
arRP	B-DISEASE
/	O
spRP	B-DISEASE
patients	O
with	O
confirmation	O
in	O
an	O
additional	O
69	O
arRP	B-DISEASE
/	O
spRP	B-DISEASE
patients	O
.	O

It	O
is	O
difficult	O
to	O
determine	O
the	O
exact	O
prevalence	O
of	O
the	O
c	B-VARIANT
.	I-VARIANT
1331	I-VARIANT
+	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
homozygotes	O
in	O
Slovakia	O
due	O
to	O
missing	O
data	O
describing	O
the	O
number	O
of	O
deaf	B-DISEASE
Romanies	O
in	O
the	O
country	O
.	O

Sequencing	O
data	O
from	O
101	O
normal	O
Tibetan	O
children	O
were	O
used	O
as	O
control	O
.	O

Conservation	O
thresholds	O
were	O
selected	O
from	O
training	O
data	O
:	O
all	O
disease	O
-	O
associated	O
missense	O
variants	O
in	O
HGMD	O
version	O
2009	O
.	O
1	O
,	O
and	O
all	O
dbSNP128	O
sites	O
annotated	O
as	O
nonsynonymous	O
,	O
excluding	O
those	O
present	O
in	O
HGMD	O
.	O

Due	O
to	O
the	O
phenotypic	O
overlap	O
with	O
the	O
latter	O
cases	O
,	O
the	O
predicted	O
severity	O
of	O
the	O
HSD17B4	B-GENE
mutations	O
,	O
and	O
biochemical	O
evidence	O
of	O
altered	O
peroxisomal	O
fatty	O
acid	O
metabolism	O
,	O
we	O
reached	O
a	O
diagnosis	O
of	O
HSD17B4	B-GENE
deficiency	O
in	O
our	O
patient	O
.	O

Subcellular	O
localization	O
of	O
CLRN1	O
-	O
HA	O
was	O
examined	O
by	O
confocal	O
microscopy	O
.	O

The	O
nonsense	O
mutation	O
,	O
c	B-VARIANT
.	I-VARIANT
11235C	I-VARIANT
>	I-VARIANT
G	I-VARIANT
,	O
would	O
generate	O
a	O
PTC	O
,	O
and	O
further	O
lead	O
to	O
dysfunction	O
or	O
a	O
reduction	O
of	O
usherin	B-GENE
through	O
truncation	O
of	O
the	O
generated	O
protein	O
or	O
NMD	O
,	O
respectively	O
.	O

The	O
patient	O
also	O
underwent	O
surgeries	O
in	O
skull	O
.	O

Exons	O
are	O
represented	O
by	O
open	O
rectangles	O
and	O
are	O
numbered	O
.	O

The	O
proband	O
F2	O
II	O
:	O
1	O
is	O
the	O
father	O
of	O
patient	O
F2	O
III	O
:	O
1	O
,	O
patient	O
F3	O
II	O
:	O
11	O
is	O
the	O
father	O
of	O
proband	O
F3	O
III	O
:	O
24	O
,	O
and	O
patient	O
F4	O
II	O
:	O
1	O
is	O
the	O
father	O
of	O
proband	O
F4	O
III	O
:	O
1	O
(	O
Figure	O
1A	O
,	O
Figure	O
2A	O
,	O
Figure	O
3A	O
,	O
Figure	O
4A	O
)	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
HA	O
ARD	O
RAC	O
RJHS	O
.	O

The	O
underlying	O
mechanisms	O
for	O
the	O
etiology	O
of	O
NSEVA	B-DISEASE
/	O
PS	B-DISEASE
remain	O
elusive	O
;	O
however	O
,	O
studies	O
that	O
have	O
screened	O
for	O
SLC26A4	B-GENE
mutations	O
in	O
patients	O
with	O
NSEVA	B-DISEASE
/	O
PS	B-DISEASE
and	O
subsequent	O
studies	O
of	O
these	O
mutant	O
proteins	O
have	O
been	O
informative	O
[	O
2	O
]	O
.	O

The	O
plasmid	O
was	O
transformed	O
into	O
Escherichia	O
coli	O
strain	O
DH5	O
alpha	O
to	O
amplify	O
and	O
was	O
subsequently	O
extracted	O
for	O
further	O
use	O
.	O

In	O
this	O
study	O
,	O
all	O
6	O
patients	O
with	O
this	O
mutation	O
were	O
associated	O
with	O
diabetes	B-DISEASE
mellitus	I-DISEASE
and	O
progressive	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Ten	O
patients	O
with	O
hyperthyroidism	O
but	O
normal	O
hearing	O
were	O
enrolled	O
as	O
positive	O
control	O
for	O
ultrasound	O
scan	O
of	O
the	O
thyroid	O
and	O
the	O
levels	O
of	O
thyroid	O
hormone	O
.	O

He	O
subsequently	O
had	O
a	O
cochlear	O
implant	O
at	O
2	O
years	O
of	O
age	O
.	O

Coding	O
and	O
flanking	O
intron	O
sequences	O
of	O
exons	O
2	O
to	O
8	O
of	O
the	O
WFS1	B-GENE
gene	O
(	O
GenBank	O
accession	O
number	O
AC004599	O
)	O
were	O
amplified	O
by	O
PCR	O
using	O
13	O
primer	O
pairs	O
(	O
Table	O
1	O
)	O
.	O

The	O
absence	O
of	O
adrenal	B-DISEASE
hyperplasia	I-DISEASE
by	O
CT	O
scan	O
in	O
subject	O
1555	O
-	O
1	O
at	O
age	O
9	O
is	O
noteworthy	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
RC	O
MH	O
PC	O
SS	O
HL	O
SJ	O
.	O

The	O
platelet	O
count	O
was	O
significantly	O
lower	O
in	O
bleeders	O
than	O
in	O
nonbleeders	O
,	O
P	O
=	O
0	O
.	O
0036	O
,	O
whereas	O
no	O
significant	O
difference	O
was	O
observed	O
for	O
the	O
platelet	O
size	O
between	O
the	O
two	O
groups	O
(	O
Fig	O
.	O

During	O
sample	O
preparation	O
,	O
bar	O
-	O
coding	O
index	O
tags	O
were	O
ligated	O
to	O
the	O
fragments	O
in	O
order	O
to	O
permit	O
simultaneous	O
sequencing	O
of	O
12	O
samples	O
.	O

The	O
current	O
study	O
is	O
the	O
first	O
report	O
of	O
mutations	O
causing	O
isolated	O
ADOA	B-DISEASE
in	O
Greek	O
families	O
enabling	O
genetic	O
counseling	O
of	O
the	O
probands	O
and	O
their	O
families	O
.	O

In	O
family	O
2	O
,	O
a	O
novel	O
COL4A3	B-GENE
missense	O
mutation	O
c	B-VARIANT
.	I-VARIANT
G2290A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Gly997Glu	I-VARIANT
)	O
was	O
identified	O
in	O
a	O
45	O
-	O
year	O
-	O
old	O
male	O
diagnosed	O
with	O
focal	B-DISEASE
segmental	I-DISEASE
glomerulosclerosis	I-DISEASE
and	O
was	O
present	O
in	O
all	O
his	O
affected	O
family	O
members	O
,	O
who	O
exhibited	O
disease	O
ranging	O
from	O
isolated	O
microscopic	B-DISEASE
hematuria	I-DISEASE
to	O
end	B-DISEASE
stage	I-DISEASE
renal	I-DISEASE
disease	I-DISEASE
(	O
ESRD	B-DISEASE
)	O
.	O

In	O
particular	O
,	O
pedigree	O
RP	O
#	O
002	O
with	O
a	O
homozygous	O
c	B-VARIANT
.	I-VARIANT
191delG	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
G64VfsX29	I-VARIANT
)	O
mutation	O
,	O
RP	O
#	O
019	O
with	O
compound	O
heterozygous	O
c	B-VARIANT
.	I-VARIANT
265delC	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
L89FfsX4	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
1429delG	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
V477YfsX17	I-VARIANT
)	O
mutations	O
,	O
RP	O
#	O
021	O
with	O
a	O
homozygous	O
c	B-VARIANT
.	I-VARIANT
191delG	I-VARIANT
mutation	O
and	O
RP	O
#	O
029	O
with	O
a	O
homozygous	O
c	B-VARIANT
.	I-VARIANT
265delC	I-VARIANT
mutation	O
were	O
identified	O
.	O

This	O
suggests	O
that	O
the	O
genetic	O
heterogeneity	O
of	O
USH	B-DISEASE
is	O
much	O
higher	O
and	O
makes	O
the	O
NGS	O
technologies	O
cost	O
-	O
effective	O
in	O
terms	O
of	O
diagnostic	O
power	O
only	O
in	O
the	O
cases	O
due	O
to	O
mutations	O
in	O
the	O
known	O
genes	O
.	O

The	O
audiology	O
results	O
were	O
characterized	O
in	O
terms	O
of	O
hearing	O
level	O
and	O
audiogram	O
shape	O
.	O

This	O
hypothesis	O
is	O
supported	O
by	O
suspected	O
skeletal	B-DISEASE
disorder	I-DISEASE
cases	O
for	O
which	O
we	O
succeeded	O
in	O
defining	O
the	O
diagnosis	O
using	O
sequence	O
data	O
.	O

(	O
(	O
b	O
)	O
and	O
(	O
c	O
)	O
)	O
Infrared	O
(	O
IR	O
)	O
images	O
of	O
the	O
case	O
show	O
a	O
hyporeflective	O
region	O
with	O
perimacular	O
ring	O
shape	O
.	O

The	O
authors	O
declare	O
no	O
conflicts	O
of	O
interest	O
.	O

A	O
study	O
indicated	O
that	O
the	O
c	B-VARIANT
.	I-VARIANT
109G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
mutation	O
had	O
an	O
allelic	O
frequency	O
of	O
6	O
.	O
7	O
%	O
(	O
185	O
/	O
2744	O
)	O
in	O
a	O
Han	O
patient	O
group	O
(	O
excluding	O
all	O
cases	O
with	O
two	O
clearly	O
pathogenic	O
mutations	O
)	O
;	O
this	O
rate	O
was	O
significantly	O
higher	O
than	O
the	O
control	O
population	O
(	O
2	O
.	O
8	O
%	O
,	O
17	O
/	O
602	O
;	O
P	O
=	O
0	O
.	O
0003	O
)	O
[	O
17	O
]	O
.	O

The	O
c	B-VARIANT
.	I-VARIANT
1331	I-VARIANT
+	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
mutation	O
is	O
shown	O
in	O
bold	O
.	O

2	O
)	O
.	O

Genotype	O
and	O
phenotype	O
of	O
all	O
Waardenburg	B-DISEASE
syndrome	I-DISEASE
index	O
patients	O
'	O
De	O
novo	O
'	O
,	O
under	O
consideration	O
of	O
provided	O
information	O
concerning	O
kinship	O
,	O
no	O
paternity	O
testing	O
was	O
performed	O
.	O

This	O
indicated	O
that	O
the	O
hearing	B-DISEASE
impairment	I-DISEASE
was	O
most	O
severe	O
at	O
high	O
frequencies	O
,	O
followed	O
by	O
mid	O
frequencies	O
and	O
then	O
low	O
frequencies	O
.	O

We	O
also	O
included	O
11	O
NSHL	B-DISEASE
patients	O
as	O
mutations	O
in	O
the	O
targeted	O
genes	O
have	O
been	O
found	O
albeit	O
only	O
accounting	O
for	O
a	O
minority	O
of	O
cases	O
.	O

Lugar	O
;	O
S	O
.	O
M	O
.	O

None	O
of	O
the	O
mutations	O
identified	O
in	O
Baraitser	B-DISEASE
-	I-DISEASE
Winter	I-DISEASE
syndrome	I-DISEASE
patients	O
were	O
present	O
in	O
this	O
large	O
dataset	O
.	O

We	O
thank	O
Camille	O
Le	O
Henanff	O
for	O
her	O
precious	O
help	O
for	O
the	O
immunofluorescence	O
study	O
.	O

The	O
expression	O
data	O
of	O
TCOF1	B-GENE
transcripts	O
was	O
determined	O
by	O
relative	O
quantification	O
in	O
comparison	O
to	O
a	O
pool	O
of	O
RNA	O
from	O
10	O
controls	O
.	O

With	O
the	O
combination	O
of	O
Invader	O
assay	O
and	O
direct	O
sequencing	O
,	O
and	O
restriction	O
to	O
patients	O
with	O
EVA	B-DISEASE
,	O
the	O
mutation	O
detection	O
rate	O
was	O
elevated	O
to	O
17	O
/	O
22	O
cases	O
(	O
77	O
.	O
3	O
%	O
,	O
Fig	O
.	O

After	O
the	O
products	O
were	O
purified	O
,	O
we	O
performed	O
standard	O
cycle	O
sequencing	O
reaction	O
with	O
ABI	O
Big	O
Dye	O
terminators	O
in	O
an	O
ABI	O
3130xl	O
sequencer	O
(	O
Life	O
Technologies	O
)	O
.	O

The	O
existence	O
of	O
additional	O
exons	O
,	O
suggested	O
by	O
the	O
presence	O
of	O
larger	O
transcripts	O
,	O
was	O
confirmed	O
in	O
2004	O
when	O
van	O
Wijk	O
et	O
al	O
.	O

Noboru	O
Ogahara	O
at	O
the	O
Kanagawa	O
Children	O
'	O
s	O
Medical	O
Center	O
,	O
Dr	O
.	O

This	O
study	O
was	O
approved	O
by	O
the	O
IRB	O
at	O
the	O
National	O
Centre	O
of	O
Excellence	O
in	O
Molecular	O
Biology	O
(	O
NCEMB	O
)	O
,	O
Lahore	O
,	O
Pakistan	O
(	O
FWA00001758	O
)	O
,	O
the	O
Combined	O
Neuroscience	O
IRB	O
at	O
the	O
National	O
Institutes	O
of	O
Health	O
,	O
USA	O
(	O
OH	O
-	O
93	O
-	O
N	O
-	O
016	O
)	O
and	O
,	O
the	O
IRB	O
Committee	O
at	O
the	O
Cincinnati	O
Children	O
'	O
s	O
Hospital	O
Research	O
Foundation	O
,	O
USA	O
(	O
2009	O
-	O
0684	O
)	O
.	O

In	O
addition	O
,	O
inner	O
hair	O
cells	O
of	O
Eps8	B-GENE
-	O
/	O
-	O
mice	O
show	O
a	O
defective	O
maturation	O
[	O
11	O
]	O
.	O

To	O
date	O
,	O
two	O
genes	O
(	O
OPA1	B-GENE
and	O
OPA3	B-GENE
)	O
and	O
three	O
loci	O
(	O
OPA4	B-GENE
,	O
OPA5	B-GENE
and	O
OPA8	B-GENE
)	O
have	O
been	O
associated	O
with	O
autosomal	B-DISEASE
dominant	I-DISEASE
optic	I-DISEASE
atrophy	I-DISEASE
.	O

The	O
templates	O
,	O
used	O
as	O
backbone	O
,	O
were	O
the	O
crystal	O
structure	O
of	O
Pyrococcus	O
horikoshii	O
AsnRS	O
[	O
35	O
]	O
(	O
Protein	O
Data	O
Bank	O
access	O
#	O
1X55	O
)	O
and	O
the	O
dimeric	O
protein	O
form	O
of	O
mt	O
-	O
AsnRS	O
of	O
Entamoeba	O
histolytica	O
(	O
Protein	O
Data	O
Bank	O
access	O
#	O
3M4Q	O
)	O
.	O

Among	O
15	O
mutations	O
(	O
13	O
dominant	O
and	O
2	O
recessive	O
)	O
identified	O
in	O
ZP	O
domain	O
,	O
nine	O
of	O
them	O
(	O
all	O
dominant	O
)	O
result	O
in	O
postlingual	O
,	O
progressive	O
or	O
nonprogressive	O
hearing	B-DISEASE
impairment	I-DISEASE
involving	O
high	O
or	O
mid	O
frequencies	O
,	O
while	O
four	O
of	O
them	O
(	O
3	O
dominant	O
and	O
1	O
recessive	O
)	O
provoke	O
prelingual	O
nonprogressive	O
mid	O
-	O
frequency	O
hearing	B-DISEASE
impairment	I-DISEASE
.	O

C	O
.	O

C2A	O
-	O
F	O
:	O
C2	O
domains	O
.	O

PolyPhen	O
:	O
"	O
Probably	O
damaging	O
"	O
(	O
it	O
is	O
believed	O
most	O
likely	O
to	O
affect	O
protein	O
function	O
or	O
structure	O
)	O
,	O
"	O
Possibly	O
damaging	O
"	O
(	O
it	O
is	O
believed	O
to	O
affect	O
protein	O
function	O
or	O
structure	O
)	O
,	O
"	O
Benign	O
"	O
(	O
most	O
likely	O
lacking	O
any	O
phenotypic	O
effect	O
)	O
.	O

Thus	O
,	O
it	O
is	O
likely	O
that	O
,	O
together	O
with	O
environmental	O
factors	O
,	O
the	O
combination	O
of	O
hitherto	O
unknown	O
calcium	O
metabolism	O
-	O
related	O
functional	O
variants	O
would	O
underlie	O
different	O
serum	O
calcium	O
values	O
between	O
groups	O
1	O
and	O
2	O
.	O

We	O
next	O
assessed	O
the	O
pathogenicity	O
of	O
variants	O
detected	O
within	O
the	O
3	O
patients	O
with	O
causal	O
mtDNA	O
mutations	O
(	O
in	O
ND3	O
25	O
,	O
ND5	O
26	O
,	O
and	O
MT	O
-	O
TW	O
26	O
)	O
and	O
the	O
8	O
patients	O
with	O
recessive	O
-	O
type	O
variants	O
in	O
previously	O
reported	O
CI	O
disease	O
genes	O
:	O
NDUFS4	B-GENE
10	O
,	O
27	O
-	O
31	O
,	O
NDUFAF2	B-GENE
17	O
,	O
NDUFV1	B-GENE
32	O
,	O
and	O
NDUFS8	B-GENE
33	O
(	O
Table	O
3	O
)	O
.	O

b	O
.	O

Since	O
the	O
first	O
description	O
of	O
the	O
disease	O
[	O
6	O
]	O
,	O
the	O
classic	O
presentation	O
of	O
ADOA	B-DISEASE
has	O
widened	O
to	O
include	O
less	O
typical	O
features	O
.	O

Among	O
the	O
33	O
patients	O
originally	O
classified	O
as	O
USH2	B-DISEASE
,	O
two	O
potentially	O
disease	O
-	O
causing	O
USH2A	B-GENE
variants	O
were	O
found	O
in	O
22	O
(	O
66	O
.	O
6	O
%	O
)	O
cases	O
while	O
one	O
single	O
variant	O
was	O
detected	O
in	O
another	O
three	O
patients	O
(	O
9	O
.	O
1	O
%	O
)	O
for	O
a	O
total	O
of	O
47	O
/	O
66	O
(	O
71	O
.	O
2	O
%	O
)	O
alleles	O
in	O
agreement	O
with	O
the	O
detection	O
rate	O
reported	O
in	O
other	O
studies	O
that	O
investigated	O
other	O
ethnic	O
groups	O
[	O
16	O
,	O
18	O
,	O
19	O
,	O
34	O
,	O
35	O
,	O
38	O
]	O
.	O

For	O
each	O
sample	O
,	O
compared	O
to	O
the	O
reference	O
genome	O
(	O
hg19	O
)	O
,	O
an	O
average	O
of	O
200	O
(	O
+	O
/	O
-	O
7	O
)	O
variants	O
were	O
found	O
,	O
including	O
silent	O
(	O
60	O
%	O
)	O
,	O
and	O
missense	O
or	O
nonsense	O
(	O
40	O
%	O
)	O
variants	O
.	O

Population	O
estimates	O
of	O
allele	O
frequencies	O
were	O
obtained	O
from	O
a	O
control	O
group	O
of	O
3	O
,	O
505	O
European	O
individuals	O
from	O
the	O
National	O
Heart	O
,	O
Lung	O
,	O
and	O
Blood	O
Institute	O
(	O
NHLBI	O
)	O
exome	O
data	O
set	O
(	O
https	O
:	O
/	O
/	O
esp	O
.	O
gs	O
.	O
washington	O
.	O
edu	O
/	O
drupal	O
/	O
)	O
,	O
and	O
from	O
379	O
European	O
,	O
246	O
African	O
,	O
286	O
ASN	O
,	O
and	O
181	O
AMR	O
descent	O
individuals	O
from	O
the	O
1000	O
genomes	O
project	O
.	O

Rabbit	O
polyclonal	O
antisera	O
(	O
Covance	O
)	O
were	O
raised	O
against	O
Gipc3	O
-	O
specific	O
peptides	O
(	O
Princeton	O
Biomolecules	O
)	O
.	O

Interestingly	O
,	O
the	O
other	O
one	O
(	O
c	B-VARIANT
.	I-VARIANT
163_164	I-VARIANT
+	I-VARIANT
13del15A	I-VARIANT
)	O
involves	O
nucleotides	O
in	O
the	O
first	O
exon	O
and	O
the	O
first	O
intron	O
of	O
the	O
USH1G	B-GENE
gene	O
,	O
and	O
is	O
expected	O
to	O
lead	O
to	O
aberrant	O
splicing	O
and	O
generation	O
of	O
a	O
truncated	O
protein	O
[	O
16	O
]	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
S288X	I-VARIANT
mutation	O
in	O
EYA4	B-GENE
was	O
identified	O
in	O
the	O
KNUF24	O
family	O
(	O
Figure	O
2	O
b	O
)	O
.	O

In	O
samples	O
SR	O
-	O
903	O
and	O
SR	O
-	O
903B	O
,	O
the	O
numbers	O
of	O
remaining	O
variants	O
were	O
five	O
and	O
three	O
,	O
respectively	O
(	O
Table	O
1	O
,	O
Additional	O
file	O
2	O
:	O
Table	O
S1	O
)	O
.	O

c	B-VARIANT
.	I-VARIANT
8722	I-VARIANT
+	I-VARIANT
1delG	I-VARIANT
(	O
CDH23	B-GENE
)	O
.	O

,	O
2006	O
;	O
Frezza	O
et	O
al	O
.	O

Additional	O
file	O
1	O
:	O
Table	O
S1	O
.	O

(	O
B	O
)	O
DNA	O
sequencing	O
analysis	O
of	O
EYA4	B-GENE
exon	O
13	O
shows	O
the	O
c	B-VARIANT
.	I-VARIANT
1177C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
change	O
in	O
an	O
affected	O
family	O
member	O
(	O
III	O
-	O
2	O
)	O
and	O
a	O
normal	O
control	O
.	O

The	O
upper	O
part	O
shows	O
the	O
exome	O
sequencing	O
reads	O
(	O
horizontal	O
grey	O
bars	O
with	O
mismatching	O
bases	O
highlighted	O
)	O
aligned	O
to	O
chromosome	O
8	O
.	O

"	O
7S	O
"	O
and	O
"	O
NC1	O
"	O
refer	O
to	O
the	O
canonical	O
cysteine	O
-	O
rich	O
,	O
25	O
-	O
amino	O
acid	O
N	O
-	O
terminal	O
domain	O
and	O
the	O
C	O
-	O
terminal	O
globular	O
non	O
-	O
collagenous	O
domains	O
respectively	O
which	O
flank	O
the	O
central	O
triple	O
helical	O
domain	O
.	O

It	O
leads	O
to	O
a	O
truncated	O
protein	O
and	O
leads	O
to	O
congenital	O
severe	O
to	O
profound	O
hearing	B-DISEASE
loss	I-DISEASE
[	O
40	O
]	O
,	O
[	O
41	O
]	O
,	O
[	O
42	O
]	O
,	O
[	O
43	O
]	O
.	O

Mutations	O
located	O
in	O
exons	O
32	O
and	O
33	O
were	O
associated	O
with	O
either	O
type	O
I	O
or	O
type	B-DISEASE
II	I-DISEASE
/	I-DISEASE
III	I-DISEASE
inclusions	I-DISEASE
.	O

We	O
wish	O
to	O
thank	O
especially	O
the	O
'	O
Associazione	O
Amici	O
del	O
Centro	O
Dino	O
Ferrari	O
'	O
for	O
their	O
support	O
.	O

The	O
mutations	O
in	O
exon	O
34	O
,	O
however	O
,	O
point	O
to	O
an	O
essential	O
biological	O
role	O
of	O
CD1	O
,	O
or	O
of	O
an	O
as	O
yet	O
uncharacterized	O
protocadherin	B-GENE
-	I-GENE
15	I-GENE
isoform	O
that	O
contains	O
the	O
amino	O
acid	O
sequence	O
encoded	O
by	O
this	O
exon	O
,	O
in	O
the	O
hair	O
cells	O
.	O

This	O
variant	O
was	O
originally	O
identified	O
,	O
but	O
not	O
validated	O
,	O
from	O
large	O
-	O
scale	O
sequencing	O
of	O
expressed	O
sequence	O
tags	O
21	O
.	O

Normosmic	O
patients	O
were	O
also	O
screened	O
for	O
mutations	O
in	O
GNRHR	B-GENE
,	O
GNRH1	B-GENE
,	O
KISS1R	B-GENE
,	O
KISS1	B-GENE
,	O
TAC3	B-GENE
,	O
and	O
TACR3	B-GENE
,	O
which	O
are	O
genes	O
that	O
only	O
regulate	O
secretion	O
and	O
/	O
or	O
action	O
of	O
GnRH	O
from	O
hypothalamus	O
or	O
pituitary	O
without	O
interfering	O
development	O
of	O
olfactory	O
track	O
.	O

"	O
This	O
will	O
initiate	O
the	O
download	O
of	O
a	O
compressed	O
(	O
pdf	O
)	O
archive	O
that	O
contains	O
the	O
file	O
.	O

Nerve	O
conduction	O
studies	O
(	O
NCSs	O
)	O
were	O
performed	O
using	O
surface	O
electrodes	O
in	O
the	O
median	O
,	O
ulnar	O
,	O
peroneal	O
,	O
tibial	O
,	O
and	O
sural	O
nerves	O
.	O

The	O
GJB2	B-GENE
gene	O
mutational	O
site	O
exhibits	O
racial	O
differences	O
:	O
the	O
high	O
-	O
incidence	O
mutational	O
site	O
is	O
30_35delG	B-VARIANT
in	O
Caucasians	O
,	O
167delT	B-VARIANT
in	O
Jews	O
,	O
and	O
233_235delC	B-VARIANT
in	O
Japanese	O
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
participants	O
.	O

ILM	O
:	O
inner	O
limiting	O
membrane	O
;	O
RPE	O
:	O
retinal	O
pigment	O
epithelium	O
.	O

(	O
A	O
)	O
Pedigree	O
structure	O
of	O
Family	O
1	O
,	O
2	O
and	O
3	O
.	O

Homozygosity	O
mapping	O
is	O
an	O
effective	O
approach	O
to	O
determine	O
the	O
mutated	O
genes	O
in	O
consanguineous	O
families	O
.	O

MRPB	O
provided	O
analytical	O
support	O
and	O
supervised	O
the	O
project	O
.	O

Additionally	O
,	O
some	O
patients	O
had	O
red	O
-	O
green	O
defects	O
of	O
different	O
magnitudes	O
,	O
whileothers	O
had	O
no	O
detectable	O
color	B-DISEASE
vision	I-DISEASE
defect	I-DISEASE
.	O

The	O
genetic	O
and	O
molecular	O
bases	O
of	O
Perrault	B-DISEASE
syndrome	I-DISEASE
have	O
long	O
remained	O
unknown	O
;	O
the	O
advent	O
of	O
next	O
-	O
generation	O
sequencing	O
(	O
NGS	O
)	O
has	O
been	O
fundamental	O
to	O
allow	O
comprehensive	O
genetic	O
analysis	O
and	O
gene	O
discovery	O
for	O
such	O
rare	O
inherited	O
condition	O
,	O
irrespective	O
of	O
preexisting	O
linkage	O
data	O
in	O
a	O
patient	O
'	O
s	O
family	O
.	O

All	O
patients	O
were	O
seen	O
at	O
Montreal	O
Children	O
'	O
s	O
Hospital	O
McGill	O
Ocular	O
Genetics	O
clinic	O
(	O
MOGL	O
)	O
and	O
informed	O
consent	O
was	O
obtained	O
.	O

None	O
out	O
of	O
100	O
chromosomes	O
tested	O
showed	O
these	O
changes	O
.	O

AA	O
and	O
SB	O
participated	O
in	O
patients	O
'	O
and	O
controls	O
'	O
genomic	O
DNA	O
extraction	O
.	O

Audiometric	O
tests	O
included	O
otoscopy	O
and	O
standard	O
pure	O
-	O
tone	O
audiometry	O
.	O

The	O
three	O
most	O
common	O
mutations	O
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
299_c	I-VARIANT
.	I-VARIANT
300delAT	I-VARIANT
,	O
and	O
c	B-VARIANT
.	I-VARIANT
176_c	I-VARIANT
.	I-VARIANT
191del16	I-VARIANT
account	O
for	O
100	O
%	O
of	O
GJB2	B-GENE
mutations	O
in	O
18	O
Mongolian	O
individuals	O
analyzed	O
.	O

Two	O
mutations	O
were	O
found	O
,	O
p	B-VARIANT
.	I-VARIANT
I57T	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
V65M	I-VARIANT
,	O
both	O
previously	O
described	O
in	O
other	O
populations	O
as	O
associated	O
with	O
LQTS	B-DISEASE
[	O
57	O
,	O
58	O
]	O
and	O
shown	O
to	O
interfere	O
with	O
Kv7	O
.	O
1	O
function	O
[	O
59	O
]	O
in	O
a	O
way	O
compatible	O
with	O
an	O
association	O
with	O
LQTS	B-DISEASE
.	O

B	O
.	O

The	O
reads	O
were	O
aligned	O
to	O
our	O
BED	O
file	O
of	O
bait	O
probe	O
(	O
capture	O
)	O
targets	O
,	O
and	O
reads	O
that	O
were	O
not	O
included	O
in	O
the	O
captured	O
sequences	O
were	O
discarded	O
.	O

,	O
1997	O
)	O
.	O

(	O
2000	O
)	O
proposed	O
OTOR	O
'	O
s	O
possible	O
role	O
in	O
human	O
deafness	B-DISEASE
based	O
upon	O
its	O
preferential	O
and	O
abundant	O
expression	O
in	O
the	O
cochlea	O
[	O
10	O
]	O
.	O

The	O
pathogenic	O
effect	O
of	O
these	O
variants	O
is	O
clear	O
.	O

The	O
PTA	O
1	O
,	O
2	O
,	O
4	O
kHz	O
levels	O
at	O
which	O
speech	O
recognition	O
scores	O
of	O
50	O
%	O
were	O
attained	O
in	O
the	O
TMPRSS3	B-GENE
and	O
the	O
presbyacusis	B-DISEASE
patients	O
were	O
95	O
and	O
87	O
dB	O
,	O
respectively	O
.	O

In	O
our	O
Korean	O
population	O
,	O
five	O
phenotypic	O
markers	O
were	O
especially	O
rewarding	O
,	O
and	O
the	O
detection	O
rate	O
of	O
this	O
approach	O
driven	O
by	O
these	O
five	O
phenotypic	O
markers	O
reached	O
83	O
.	O
3	O
%	O
.	O

6	O
The	O
extremely	O
high	O
genetic	O
heterogeneity	O
of	O
HL	B-DISEASE
makes	O
genetic	O
testing	O
particularly	O
challenging	O
.	O

Nine	O
genes	O
have	O
been	O
identified	O
responsible	O
so	O
far	O
[	O
3	O
,	O
4	O
]	O
.	O

NM_006016	O
.	O
4	O
and	O
NM_001142404	O
.	O
1	O
)	O
.	O

Screening	O
of	O
the	O
TBX1	B-GENE
coding	O
sequence	O
identified	O
a	O
de	O
novo	O
variant	O
,	O
as	O
well	O
as	O
one	O
known	O
polymorphism	O
G310S	B-VARIANT
(	O
Figure	O
1	O
)	O
.	O

In	O
total	O
,	O
42	O
unrelated	O
European	O
patients	O
and	O
two	O
affected	O
sisters	O
(	O
12	O
-	O
0880	O
and	O
12	O
-	O
0878	O
in	O
Table	O
1	O
)	O
with	O
Usher	B-DISEASE
syndrome	I-DISEASE
were	O
included	O
in	O
this	O
study	O
.	O

The	O
tyrosine	O
residue	O
at	O
position	O
537	O
is	O
part	O
of	O
a	O
highly	O
conserved	O
module	O
across	O
higher	O
eukaryotes	O
except	O
for	O
Drosophila	O
,	O
in	O
which	O
it	O
'	O
s	O
replaced	O
by	O
a	O
serine	O
.	O

Situations	O
like	O
this	O
facilitate	O
molecular	O
testing	O
and	O
diagnosis	O
of	O
new	O
families	O
.	O

We	O
observed	O
that	O
while	O
heterozygous	O
mutations	O
in	O
two	O
genes	O
of	O
the	O
same	O
pathway	O
only	O
coexisted	O
in	O
HSCR	B-DISEASE
-	O
affected	O
individuals	O
,	O
a	O
de	O
novo	O
CNV	O
could	O
account	O
for	O
the	O
heterochromia	B-DISEASE
iridum	I-DISEASE
phenotype	O
presented	O
by	O
the	O
only	O
family	O
member	O
displaying	O
WS4	B-DISEASE
features	O
.	O

p	B-VARIANT
.	I-VARIANT
E316K	I-VARIANT
is	O
located	O
in	O
subdomain	O
3	O
of	O
actin	O
gamma	O
1	O
,	O
which	O
is	O
a	O
highly	O
conserved	O
actin	O
domain	O
of	O
ACTG1	B-GENE
.	O

Haplotype	O
analysis	O
was	O
constructed	O
with	O
the	O
Cyrillic	O
software	O
version	O
2	O
.	O
1	O
(	O
Cyrillic	O
Software	O
,	O
Wallingford	O
,	O
UK	O
)	O
.	O

The	O
age	O
of	O
onset	O
was	O
quite	O
variable	O
.	O

Molecular	O
analysis	O
of	O
HLA	O
-	O
DR	O
and	O
HLA	O
-	O
DQ	O
regions	O
revealed	O
1	O
heterodimer	O
for	O
type	B-DISEASE
1	I-DISEASE
DM	I-DISEASE
susceptibility	O
.	O

Segregation	O
analysis	O
of	O
mutations	O
with	O
disease	O
phenotypes	O
was	O
performed	O
for	O
all	O
family	O
members	O
.	O

There	O
is	O
considerable	O
clinical	O
variability	O
within	O
cases	O
diagnosed	O
as	O
PS	B-DISEASE
based	O
on	O
the	O
severity	O
of	O
craniofacial	O
manifestations	O
and	O
associated	O
anomalies	O
(	O
10	O
)	O
.	O

Of	O
these	O
,	O
two	O
variants	O
c	B-VARIANT
.	I-VARIANT
47T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
L16S	B-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
4996A	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
S1666C	B-VARIANT
)	O
were	O
found	O
in	O
the	O
homozygous	O
state	O
in	O
unaffected	O
members	O
as	O
well	O
as	O
in	O
the	O
affected	O
members	O
,	O
suggesting	O
that	O
these	O
two	O
variants	O
are	O
non	O
-	O
pathogenic	O
.	O

(	O
2004	O
)	O
discovered	O
this	O
mutation	O
in	O
a	O
cohort	O
of	O
patients	O
,	O
which	O
had	O
suffered	O
swimming	O
-	O
triggered	O
arrhythmias	O
.	O

To	O
assess	O
the	O
likelihood	O
of	O
creating	O
or	O
eliminating	O
splice	O
sites	O
of	O
the	O
c	B-VARIANT
.	I-VARIANT
1935G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
mutation	O
,	O
splice	O
site	O
scores	O
were	O
predicted	O
by	O
the	O
Neural	O
Network	O
Based	O
Program	O
and	O
the	O
Splice	O
View	O
program	O
.	O

Six	O
boys	O
,	O
first	O
seen	O
at	O
the	O
onset	O
of	O
the	O
study	O
,	O
were	O
given	O
i	O
.	O
m	O
.	O

Hemoglobin	O
A1c	O
and	O
oral	O
glucose	O
tolerance	O
test	O
results	O
ND	O
=	O
Not	O
done	O
.	O

MCM2	B-GENE
was	O
stained	O
with	O
Alexa	O
Fluor	O
488	O
.	O

Three	O
siblings	O
affected	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
RP	B-DISEASE
from	O
a	O
consanguineous	O
family	O
(	O
Figure	O
1	O
)	O
of	O
Saudi	O
Arabian	O
origin	O
were	O
recruited	O
for	O
this	O
study	O
.	O

A	O
c	B-VARIANT
.	I-VARIANT
190_194del	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
S64fs	I-VARIANT
)	O
mutation	O
was	O
identified	O
in	O
the	O
father	O
,	O
presumably	O
causing	O
premature	O
termination	O
.	O

The	O
ages	O
of	O
these	O
patients	O
ranged	O
from	O
0	O
to	O
25	O
years	O
(	O
median	O
:	O
5	O
years	O
)	O
.	O

This	O
mutation	O
was	O
predicted	O
to	O
"	O
affect	O
protein	O
function	O
"	O
by	O
SIFT	O
,	O
"	O
probably	O
damaging	O
"	O
by	O
PolyPhen	O
-	O
2	O
,	O
and	O
"	O
disease	O
causing	O
"	O
by	O
MutationTaster	O
(	O
Table	O
2	O
)	O
.	O

Our	O
ex	O
vivo	O
studies	O
reveal	O
that	O
fluorescently	O
tagged	O
ELMOD3	B-GENE
localized	O
with	O
the	O
actin	O
-	O
based	O
microvilli	O
of	O
LLC	O
-	O
PK1	O
-	O
CL4	O
epithelial	O
cells	O
,	O
in	O
the	O
stereocilia	O
of	O
sensory	O
hair	O
cells	O
of	O
mouse	O
organ	O
of	O
Corti	O
explants	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
to	O
the	O
actin	O
cytoskeleton	O
of	O
MDCK	O
cells	O
,	O
whereas	O
the	O
deafness	B-DISEASE
-	O
associated	O
allele	O
(	O
p	B-VARIANT
.	I-VARIANT
Leu265Ser	I-VARIANT
)	O
was	O
deficient	O
in	O
each	O
case	O
.	O

The	O
two	O
antibodies	O
showed	O
the	O
same	O
expression	O
pattern	O
in	O
the	O
cochlea	O
.	O

No	O
audiological	O
data	O
were	O
available	O
for	O
IV	O
:	O
12	O
,	O
a	O
39	O
-	O
years	O
old	O
carrier	O
of	O
the	O
OSBPL2	B-GENE
mutation	O
,	O
who	O
does	O
not	O
use	O
hearing	O
aids	O
but	O
claims	O
worse	O
hearing	O
in	O
stressful	O
situations	O
.	O

To	O
confirm	O
the	O
somatic	O
mutational	O
frequency	O
that	O
was	O
identified	O
based	O
on	O
the	O
454	O
sequencing	O
data	O
,	O
we	O
subcloned	O
the	O
PCR	O
products	O
and	O
performed	O
capillary	O
DNA	O
sequencing	O
as	O
previously	O
described	O
.	O

To	O
date	O
,	O
over	O
90	O
different	O
loci	O
correlated	O
with	O
the	O
non	O
-	O
syndromic	O
disease	O
have	O
been	O
mapped	O
[	O
2	O
]	O
.	O

The	O
mapping	O
results	O
excluded	O
the	O
other	O
known	O
arRP	B-DISEASE
loci	O
with	O
the	O
exception	O
of	O
the	O
USH2A	B-GENE
.	O

Exons	O
with	O
a	O
normalized	O
coverage	O
around	O
0	O
.	O
5	O
and	O
below	O
2	O
SD	O
of	O
the	O
mean	O
were	O
classified	O
as	O
heterozygously	O
deleted	O
and	O
further	O
analyzed	O
by	O
qPCR	O
and	O
MLPA	O
.	O

In	O
the	O
photoreceptor	O
cells	O
,	O
myosin	B-GENE
VIIA	I-GENE
is	O
present	O
at	O
the	O
connecting	O
cilium	O
and	O
regulates	O
opsin	O
transport	O
[	O
18	O
]	O
.	O

The	O
same	O
mutation	O
was	O
subsequently	O
verified	O
in	O
all	O
four	O
affected	O
family	O
members	O
(	O
II	O
:	O
1	O
,	O
III	O
:	O
1	O
,	O
III	O
:	O
3	O
,	O
and	O
IV	O
:	O
1	O
;	O
Figure	O
1	O
)	O
,	O
while	O
being	O
absent	O
in	O
unaffected	O
members	O
and	O
100	O
ethnically	O
matched	O
normal	O
controls	O
by	O
Sanger	O
sequencing	O
(	O
Figure	O
2	O
)	O
.	O

Area	O
of	O
basement	O
membrane	O
denudation	O
with	O
loss	O
of	O
podocyte	O
cytoplasm	O
(	O
arrow	O
)	O
.	O

TMC1	B-GENE
gene	O
encodes	O
a	O
transmembrane	O
channel	O
-	O
like	O
protein	O
and	O
is	O
expressed	O
in	O
mouse	O
vestibular	O
and	O
cochlear	O
hair	O
cells	O
.	O

The	O
c	B-VARIANT
.	I-VARIANT
206	I-VARIANT
-	I-VARIANT
207insC	I-VARIANT
mutation	O
was	O
not	O
identified	O
among	O
98	O
chromosomes	O
derived	O
from	O
ethnically	O
-	O
matched	O
normal	O
controls	O
.	O

RT	O
-	O
PCR	O
and	O
sequencing	O
analysis	O
of	O
p	B-VARIANT
.	I-VARIANT
Ser16Pro	I-VARIANT
in	O
mRNA	O
.	O

ABR	O
thresholds	O
in	O
12	O
-	O
month	O
-	O
old	O
females	O
(	O
12f	O
,	O
n	O
=	O
30	O
)	O
and	O
males	O
(	O
12	O
m	O
,	O
n	O
=	O
30	O
)	O
are	O
given	O
.	O

COL2A1	B-GENE
mutations	O
identified	O
in	O
two	O
MED	B-DISEASE
patients	O
(	O
ESDN	O
-	O
00050	O
and	O
-	O
00283	O
)	O
that	O
affected	O
conserved	O
glycine	O
residues	O
in	O
the	O
triple	O
helical	O
region	O
of	O
type	O
II	O
collagen	O
.	O

Thick	O
and	O
thin	O
rectangles	O
depict	O
exons	O
and	O
introns	O
,	O
respectively	O
.	O

In	O
the	O
last	O
proband	O
,	O
the	O
c	B-VARIANT
.	I-VARIANT
4338G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
mutation	O
in	O
exon	O
30	O
lead	O
to	O
the	O
p	B-VARIANT
.	I-VARIANT
Asp1447Tyr	I-VARIANT
substitution	O
.	O

Another	O
three	O
(	O
10	O
%	O
)	O
were	O
homozygous	O
for	O
both	O
polymorphisms	O
(	O
c	O
.	O
-	O
137	O
CC	O
and	O
c	O
.	O
-	O
53	O
GG	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
utilized	O
targeted	O
exome	O
sequencing	O
(	O
TES	O
)	O
to	O
study	O
genetic	O
defects	O
in	O
five	O
USH	B-DISEASE
families	O
and	O
attempted	O
to	O
establish	O
a	O
strategy	O
useful	O
for	O
genetic	O
diagnosis	O
of	O
USH	B-DISEASE
patients	O
.	O

The	O
other	O
is	O
a	O
T	O
-	O
to	O
-	O
C	O
transition	O
,	O
c	B-VARIANT
.	I-VARIANT
-	I-VARIANT
137T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
.	O

Genetic	O
counseling	O
prior	O
to	O
analysis	O
of	O
genes	O
potentially	O
revealing	O
Usher	B-DISEASE
syndrome	I-DISEASE
(	O
CDH23	B-GENE
,	O
PCDH15	B-GENE
and	O
MYO7A	B-GENE
)	O
is	O
important	O
and	O
this	O
should	O
be	O
explained	O
to	O
parents	O
who	O
agree	O
to	O
have	O
this	O
type	O
of	O
diagnostics	O
performed	O
for	O
their	O
child	O
.	O

Excluded	O
from	O
the	O
study	O
were	O
patients	O
with	O
CAKUT	B-DISEASE
associated	O
with	O
prominent	O
involvement	O
of	O
other	O
organs	O
(	O
syndromic	O
CAKUT	B-DISEASE
)	O
.	O

However	O
,	O
the	O
carrier	O
rate	O
of	O
approximately	O
0	O
.	O
44	O
%	O
solely	O
for	O
the	O
USH1C	B-GENE
mutation	O
c	B-VARIANT
.	I-VARIANT
216G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
in	O
the	O
Quebec	O
population	O
suggests	O
an	O
incidence	O
of	O
Usher	B-DISEASE
syndrome	I-DISEASE
type	O
1C	O
of	O
0	O
.	O
5	O
per	O
100	O
,	O
000	O
(	O
assuming	O
random	O
mating	O
and	O
complete	O
penetrance	O
)	O
,	O
based	O
on	O
c	B-VARIANT
.	I-VARIANT
216G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
alone	O
.	O

Among	O
the	O
various	O
types	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
is	O
caused	O
by	O
damage	O
to	O
the	O
inner	O
ear	O
.	O

The	O
PCR	O
reactions	O
were	O
performed	O
in	O
50	O
-	O
mu	O
l	O
volumes	O
using	O
0	O
.	O
5	O
mu	O
l	O
of	O
the	O
first	O
PCR	O
products	O
,	O
1	O
x	O
PrimeSTAR	O
GXL	O
buffer	O
,	O
0	O
.	O
2	O
mM	O
of	O
each	O
dNTP	O
,	O
12	O
.	O
5	O
pmol	O
of	O
each	O
forward	O
and	O
reverse	O
primer	O
,	O
and	O
1	O
.	O
25	O
U	O
of	O
PrimeSTAR	O
GXL	O
DNA	O
polymerase	O
to	O
attach	O
the	O
anchor	O
sequences	O
for	O
MPS	O
.	O

At	O
least	O
one	O
-	O
gene	O
variant	O
was	O
found	O
in	O
14	O
%	O
and	O
16	O
%	O
of	O
the	O
juvenile	O
and	O
typical	O
RP	B-DISEASE
groups	O
respectively	O
.	O

In	O
these	O
cases	O
,	O
in	O
which	O
the	O
second	O
mutated	O
allele	O
escapes	O
detection	O
,	O
the	O
region	O
that	O
contains	O
the	O
mutation	O
may	O
have	O
been	O
excluded	O
from	O
our	O
study	O
.	O

All	O
solutions	O
were	O
made	O
with	O
1XPBS	O
.	O

A	O
mutation	O
of	O
the	O
COL2A1	B-GENE
gene	O
was	O
detected	O
.	O

For	O
the	O
families	O
that	O
could	O
not	O
be	O
excluded	O
on	O
the	O
basis	O
of	O
marker	O
discordance	O
among	O
affected	O
siblings	O
,	O
complete	O
TMPRSS3	B-GENE
(	O
13	O
exons	O
)	O
,	O
TMC1	B-GENE
(	O
24	O
exons	O
)	O
,	O
USH1C	B-GENE
(	O
28	O
exons	O
)	O
and	O
CDH23	B-GENE
(	O
70	O
exons	O
)	O
transcript	O
structures	O
,	O
comprising	O
exonic	O
and	O
flanking	O
intronic	O
regions	O
,	O
were	O
analyzed	O
by	O
direct	O
sequencing	O
.	O

A	O
total	O
of	O
7	O
nonsense	O
mutations	O
were	O
identified	O
in	O
GJB2	B-GENE
,	O
MYO15A	B-GENE
and	O
TMC1	B-GENE
,	O
these	O
nonsense	O
mutations	O
are	O
likely	O
to	O
cause	O
nonsense	O
mediated	O
decay	O
(	O
NMD	O
)	O
because	O
they	O
are	O
either	O
present	O
in	O
the	O
middle	O
or	O
near	O
the	O
5	O
'	O
end	O
of	O
the	O
gene	O
.	O

(	O
2011	O
)	O
used	O
a	O
panel	O
targeting	O
246	O
deafness	B-DISEASE
genes	O
,	O
however	O
,	O
their	O
cohort	O
mainly	O
comprised	O
multiplex	O
families	O
[	O
19	O
]	O
.	O

(	O
b	O
)	O
COCH	B-GENE
c	B-VARIANT
.	I-VARIANT
113G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
G38D	I-VARIANT
)	O
missense	O
mutation	O
in	O
the	O
JSNY	O
-	O
027	O
family	O
.	O

Whether	O
the	O
hearing	O
deficit	O
in	O
these	O
mice	O
is	O
due	O
to	O
abnormal	O
hair	O
bundle	O
morphology	O
remains	O
to	O
be	O
elucidated	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

We	O
demonstrate	O
that	O
despite	O
attaining	O
the	O
expected	O
quality	O
metrics	O
for	O
the	O
number	O
of	O
reads	O
,	O
the	O
amount	O
of	O
DNA	O
generated	O
,	O
the	O
target	O
coverage	O
and	O
the	O
average	O
depth	O
across	O
the	O
intended	O
target	O
,	O
a	O
marked	O
unevenness	O
of	O
capture	O
of	O
one	O
region	O
compared	O
with	O
other	O
regions	O
was	O
evident	O
(	O
Figure	O
2	O
)	O
.	O

Median	O
depth	O
(	O
X	O
)	O
:	O
This	O
number	O
of	O
depth	O
is	O
the	O
median	O
depth	O
when	O
depth	O
of	O
all	O
sites	O
was	O
in	O
an	O
ascending	O
sort	O
.	O

In	O
the	O
future	O
,	O
patients	O
with	O
BOR	B-DISEASE
/	O
BO	B-DISEASE
syndrome	O
may	O
be	O
good	O
candidates	O
of	O
active	O
middle	O
ear	O
implants	O
considering	O
the	O
failure	O
of	O
hearing	O
gain	O
by	O
conventional	O
middle	O
ear	O
reconstruction	O
techniques	O
.	O

Clinically	O
,	O
the	O
patient	O
'	O
s	O
ocular	O
phenotype	O
was	O
STGD	B-DISEASE
(	O
diagnosed	O
by	O
three	O
retinal	O
specialists	O
)	O
but	O
her	O
molecular	O
diagnosis	O
was	O
autosomal	B-DISEASE
recessive	I-DISEASE
bestrophinopathy	I-DISEASE
as	O
she	O
carries	O
homozygous	O
BEST1	B-GENE
mutations	O
.	O

In	O
accord	O
with	O
our	O
patients	O
,	O
this	O
patient	O
was	O
found	O
to	O
have	O
more	O
severe	O
degeneration	O
in	O
one	O
eye	O
,	O
along	O
with	O
severe	O
central	B-DISEASE
vision	I-DISEASE
impairment	I-DISEASE
occurring	O
at	O
age	O
37	O
,	O
though	O
unlike	O
our	O
patients	O
no	O
fundus	O
flecks	O
were	O
observed	O
26	O
.	O

Our	O
observations	O
suggest	O
that	O
the	O
overall	O
contribution	O
of	O
TMPRSS3	B-GENE
,	O
TMC1	B-GENE
,	O
USH1C	B-GENE
,	O
CDH23	B-GENE
and	O
TMIE	B-GENE
mutations	O
for	O
ARNSHL	B-DISEASE
is	O
low	O
in	O
India	O
:	O
1	O
.	O
2	O
%	O
of	O
the	O
hearing	B-DISEASE
impaired	I-DISEASE
examined	O
showed	O
mutations	O
in	O
TMPRSS3	B-GENE
,	O
1	O
.	O
6	O
%	O
in	O
TMC1	B-GENE
,	O
1	O
.	O
8	O
%	O
in	O
USH1C	B-GENE
,	O
1	O
.	O
8	O
%	O
in	O
CDH23	B-GENE
and	O
1	O
.	O
6	O
%	O
in	O
TMIE	B-GENE
.	O

The	O
medical	O
history	O
was	O
obtained	O
by	O
use	O
of	O
a	O
questionnaire	O
regarding	O
the	O
following	O
aspects	O
:	O
subjective	O
degree	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
age	O
at	O
onset	O
,	O
evolution	O
,	O
symmetry	O
of	O
the	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
hearing	O
aids	O
,	O
presence	O
of	O
tinnitus	O
,	O
pressure	O
in	O
the	O
ears	O
or	O
vertigo	O
,	O
medication	O
,	O
noise	O
exposure	O
,	O
pathologic	O
changes	O
in	O
the	O
ear	O
,	O
and	O
other	O
relevant	O
clinical	O
manifestations	O
.	O

A	O
total	O
of	O
10	O
mutations	O
have	O
been	O
reported	O
so	O
far	O
in	O
the	O
EDN3	B-GENE
gene	O
in	O
WS	B-DISEASE
patients	O
of	O
different	O
ethnic	O
origins	O
[	O
2	O
,	O
9	O
,	O
25	O
-	O
30	O
]	O
.	O

Twenty	O
families	O
were	O
included	O
in	O
this	O
study	O
based	O
on	O
the	O
presence	O
of	O
both	O
parental	O
consanguinity	O
and	O
at	O
least	O
two	O
members	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
Figure	O
S1	O
)	O
.	O

However	O
,	O
none	O
of	O
our	O
patients	O
with	O
one	O
SLC26A4	B-GENE
missense	O
mutation	O
carried	O
any	O
of	O
the	O
reported	O
FOXI	B-GENE
or	O
KCNJ10	B-GENE
mutations	O
.	O

These	O
results	O
suggest	O
that	O
Y375C	B-VARIANT
,	O
R470H	B-VARIANT
and	O
I491T	B-VARIANT
are	O
most	O
likely	O
pathogenic	O
.	O

None	O
of	O
our	O
patients	O
heterozygous	O
for	O
one	O
GJB2	B-GENE
mutant	O
allele	O
or	O
the	O
controls	O
with	O
normal	O
hearing	O
carried	O
the	O
IVS1	B-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
mutation	O
or	O
variant	O
in	O
exon1	O
and	O
basal	O
promoter	O
of	O
GJB2	B-GENE
.	O

Hereditary	O
hearing	B-DISEASE
loss	I-DISEASE
allele	O
-	O
specific	O
PCR	O
based	O
universal	O
array	O
(	O
ASPUA	O
)	O
(	O
CapitalBio	O
,	O
Beijing	O
,	O
China	O
)	O
was	O
used	O
to	O
simultaneously	O
screen	O
9	O
mutations	O
causing	O
hereditary	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
GJB2	B-GENE
:	O
c	B-VARIANT
.	I-VARIANT
35delG	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
176del16	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
299	I-VARIANT
-	I-VARIANT
300delAT	I-VARIANT
;	O
GJB3	B-GENE
:	O
c	B-VARIANT
.	I-VARIANT
538C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
R180X	B-VARIANT
)	O
;	O
SLC26A4	B-GENE
:	O
c	B-VARIANT
.	I-VARIANT
IVS7	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
2168A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
H723R	I-VARIANT
)	O
;	O
mtDNA	B-GENE
12S	I-GENE
rRNA	I-GENE
:	O
1555A	B-VARIANT
>	I-VARIANT
G	I-VARIANT
,	O
1494C	B-VARIANT
>	I-VARIANT
T	I-VARIANT
)	O
.	O

For	O
all	O
affected	O
members	O
of	O
each	O
family	O
,	O
late	O
-	O
onset	O
,	O
progressive	O
hearing	B-DISEASE
loss	I-DISEASE
was	O
observed	O
.	O

The	O
four	O
probands	O
were	O
F1	O
II	O
:	O
5	O
,	O
F2	O
II	O
:	O
1	O
,	O
F3	O
III	O
:	O
24	O
,	O
and	O
F4	O
III	O
:	O
1	O
.	O

-	O
Family	O
3	O
In	O
this	O
family	O
,	O
besides	O
the	O
proband	O
,	O
the	O
patient	O
'	O
s	O
mother	O
and	O
grandmother	O
were	O
affected	O
by	O
PS	B-DISEASE
.	O

In	O
this	O
study	O
,	O
we	O
combined	O
targeted	O
genomic	O
capture	O
and	O
massively	O
parallel	O
sequencing	O
(	O
MPS	O
)	O
to	O
address	O
this	O
issue	O
.	O

Clinical	O
examinations	O
of	O
index	O
patients	O
with	O
the	O
two	O
latter	O
mutations	O
demonstrated	O
large	O
inter	O
-	O
and	O
intra	O
-	O
familial	O
variations	O
apparently	O
.	O

Mutations	O
are	O
located	O
evenly	O
throughout	O
the	O
protein	O
and	O
no	O
"	O
hot	O
spots	O
"	O
were	O
observed	O
.	O

(	O
A	O
-	O
F	O
)	O
The	O
spatio	O
-	O
temporal	O
expression	O
pattern	O
of	O
ELMOD3	B-GENE
in	O
the	O
rat	O
organ	O
of	O
Corti	O
.	O

(	O
A	O
)	O
The	O
top	O
panel	O
shows	O
the	O
pedigree	O
and	O
genotype	O
of	O
each	O
family	O
.	O

Figure	O
S2	O
.	O

Finally	O
,	O
although	O
we	O
performed	O
a	O
genome	O
-	O
wide	O
germline	O
copy	O
number	O
analysis	O
using	O
SNP	O
array	O
data	O
,	O
our	O
manual	O
review	O
of	O
the	O
results	O
indicated	O
many	O
false	O
positives	O
with	O
very	O
few	O
passing	O
our	O
review	O
criteria	O
.	O

The	O
average	O
age	O
for	O
menopause	O
in	O
Pakistan	O
is	O
estimated	O
to	O
be	O
49	O
.	O
3	O
years	O
[	O
41	O
]	O
,	O
suggesting	O
that	O
these	O
two	O
affected	O
females	O
may	O
have	O
experienced	O
early	O
menopause	O
.	O

34	O
Mouse	O
CEACAM16	B-GENE
and	O
its	O
human	O
counterpart	O
are	O
well	O
conserved	O
.	O

In	O
the	O
mutant	O
allele	O
(	O
g	O
)	O
,	O
a	O
heterozygous	O
one	O
base	O
-	O
pair	O
deletion	O
indicated	O
by	O
a	O
vertical	O
arrow	O
can	O
be	O
seen	O
(	O
c	B-VARIANT
.	I-VARIANT
1899delT	I-VARIANT
)	O
.	O

EVA	B-DISEASE
is	O
the	O
most	O
common	O
form	O
of	O
inner	O
ear	O
malformations	O
associated	O
with	O
prelingual	O
or	O
postlingual	O
sensorineural	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
and	O
is	O
an	O
important	O
feature	O
of	O
PS	B-DISEASE
[	O
10	O
]	O
.	O

As	O
noted	O
with	O
a	O
dagger	O
symbol	O
in	O
table	O
1	O
,	O
atypical	O
phenotypes	O
were	O
observed	O
in	O
nine	O
patients	O
.	O

Our	O
results	O
are	O
in	O
contrast	O
to	O
an	O
NGS	O
study	O
of	O
a	O
different	O
ethnic	O
group	O
[	O
48	O
]	O
,	O
which	O
showed	O
TMC1	B-GENE
mutations	O
to	O
be	O
the	O
prevalent	O
candidate	O
cause	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

This	O
variant	O
was	O
not	O
found	O
in	O
a	O
screen	O
of	O
500	O
normal	O
-	O
hearing	O
ethnicity	O
-	O
matched	O
controls	O
(	O
250	O
women	O
,	O
250	O
men	O
,	O
750	O
X	O
chromosomes	O
)	O
.	O

Found	O
in	O
1	O
/	O
872	O
(	O
0	O
.	O
11	O
%	O
)	O
control	O
chromosomes	O
.	O

Purification	O
of	O
target	O
sequences	O
,	O
library	O
preparation	O
,	O
and	O
NGS	O
processing	O
was	O
performed	O
by	O
BGI	O
-	O
Shenzen	O
(	O
Shenzhen	O
,	O
China	O
)	O
,	O
as	O
previously	O
described	O
[	O
23	O
]	O
.	O

Group	O
2	O
includes	O
individuals	O
carrying	O
missense	O
mutations	O
and	O
/	O
or	O
single	O
amino	O
acid	O
insertions	O
in	O
both	O
alleles	O
.	O

Every	O
individual	O
in	O
the	O
cohort	O
carries	O
multiple	O
nonsynonymous	O
variants	O
in	O
the	O
cancer	B-DISEASE
susceptiblity	O
genes	O
,	O
with	O
an	O
average	O
of	O
68	O
variants	O
per	O
person	O
(	O
range	O
:	O
49	O
-	O
97	O
)	O
(	O
Figure	O
1A	O
)	O
,	O
and	O
99	O
%	O
of	O
the	O
individuals	O
carry	O
rare	O
variants	O
(	O
median	O
:	O
6	O
rare	O
variants	O
,	O
range	O
:	O
0	O
-	O
32	O
)	O
.	O

B	O
-	O
cells	O
autoantibodies	O
were	O
absent	O
.	O

Therefore	O
,	O
cells	O
expressing	O
p	B-VARIANT
.	I-VARIANT
R44C	I-VARIANT
variant	O
MCM2	B-GENE
may	O
not	O
significantly	O
affect	O
their	O
proliferation	O
.	O

They	O
exhibited	O
symmetric	O
progressive	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
that	O
ranged	O
from	O
moderate	O
to	O
profound	O
in	O
degree	O
with	O
sloping	O
,	O
flat	O
or	O
U	O
-	O
shaped	O
audio	O
profiles	O
.	O

Nonetheless	O
,	O
important	O
statistics	O
that	O
arise	O
from	O
this	O
work	O
concern	O
the	O
proportion	O
of	O
patients	O
who	O
demonstrated	O
a	O
progressive	O
renal	O
disease	O
.	O

Because	O
of	O
the	O
extensive	O
genetic	O
heterogeneity	O
of	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
the	O
identification	O
of	O
the	O
causative	O
mutation	O
in	O
single	O
patients	O
has	O
been	O
the	O
exception	O
until	O
recently	O
.	O

The	O
auditory	O
phenotype	O
was	O
inferred	O
from	O
medical	O
and	O
developmental	O
history	O
interviews	O
with	O
subject	O
SH23	O
-	O
99	O
.	O

Extracted	O
DNA	O
was	O
PCR	O
amplified	O
,	O
purified	O
and	O
hybridized	O
to	O
the	O
SureSelect	O
biotinylated	O
RNA	O
library	O
for	O
target	O
capture	O
(	O
Agilent	O
)	O
.	O

The	O
referring	O
physician	O
made	O
a	O
diagnosis	O
of	O
familial	O
FSGS	B-DISEASE
and	O
the	O
family	O
was	O
referred	O
to	O
our	O
group	O
for	O
genetic	O
studies	O
.	O

Total	O
protein	O
expression	O
of	O
WT	O
and	O
G169R	B-VARIANT
CEACAM16	B-GENE
is	O
very	O
similar	O
(	O
Cells	O
)	O
;	O
total	O
beta	O
-	O
actin	O
loads	O
from	O
both	O
preparations	O
are	O
comparable	O
(	O
lower	O
panel	O
)	O
.	O

This	O
work	O
was	O
supported	O
by	O
the	O
Wellcome	O
Trust	O
(	O
WT098051	O
)	O
;	O
and	O
SPARKS	O
-	O
-	O
The	O
Children	O
'	O
s	O
Medical	O
Research	O
Charity	O
(	O
09RTF07	O
to	O
S	O
.	O
C	O
.	O
H	O
.	O

Dental	O
examination	O
showed	O
enamel	B-DISEASE
hypoplasia	I-DISEASE
and	O
abnormal	B-DISEASE
teeth	I-DISEASE
color	I-DISEASE
.	O

The	O
c	B-VARIANT
.	I-VARIANT
740G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
R247H	I-VARIANT
)	O
mutation	O
was	O
predicted	O
to	O
disrupt	O
the	O
coiled	O
-	O
coil	O
forming	O
potential	O
,	O
and	O
in	O
addition	O
,	O
fibroblasts	O
harvested	O
from	O
both	O
family	O
members	O
showed	O
mitochondrial	B-DISEASE
network	I-DISEASE
abnormalities	I-DISEASE
and	O
oxidative	B-DISEASE
phosphorylation	I-DISEASE
uncoupling	I-DISEASE
,	O
with	O
a	O
greater	O
susceptibility	O
to	O
undergo	O
apoptosis	O
(	O
Cornille	O
et	O
al	O
.	O

Parents	O
of	O
most	O
of	O
the	O
patients	O
were	O
available	O
for	O
the	O
study	O
,	O
and	O
had	O
normal	O
hearing	O
.	O

The	O
x	O
-	O
axis	O
is	O
the	O
exon	O
location	O
sequentially	O
arranged	O
for	O
the	O
deafness	B-DISEASE
genes	O
listed	O
in	O
the	O
Additional	O
file	O
1	O
:	O
Table	O
S1	O
.	O

Thirteen	O
out	O
of	O
the	O
38	O
screened	O
alleles	O
carried	O
pathogenic	O
PCDH15	B-GENE
variants	O
(	O
34	O
.	O
2	O
%	O
)	O
.	O

A	O
total	O
of	O
35	O
.	O
74	O
%	O
deaf	B-DISEASE
patients	O
showed	O
evidence	O
of	O
genetic	O
involvement	O
,	O
based	O
on	O
either	O
genetic	O
screening	O
or	O
family	O
history	O
,	O
and	O
17	O
.	O
45	O
%	O
,	O
9	O
.	O
79	O
%	O
,	O
and	O
8	O
.	O
51	O
%	O
of	O
these	O
patients	O
were	O
determined	O
to	O
have	O
inherited	O
hearing	B-DISEASE
impairment	I-DISEASE
caused	O
by	O
GJB2	B-GENE
,	O
SLC26A4	B-GENE
,	O
and	O
mtDNA	O
1555A	B-VARIANT
>	I-VARIANT
G	I-VARIANT
mutations	O
.	O

The	O
common	O
Caucasian	O
mutation	O
c	O
.	O
35delG	B-VARIANT
was	O
not	O
found	O
.	O

However	O
,	O
it	O
is	O
difficult	O
to	O
obtain	O
conclusions	O
due	O
to	O
the	O
low	O
number	O
of	O
patients	O
included	O
in	O
those	O
studies	O
(	O
thirteen	O
and	O
twelve	O
USH	B-DISEASE
patients	O
respectively	O
)	O
,	O
whereas	O
in	O
our	O
series	O
32	O
USH	B-DISEASE
patients	O
previously	O
unscreened	O
were	O
sequenced	O
.	O

Blue	O
stars	O
,	O
individuals	O
whose	O
samples	O
were	O
subjected	O
to	O
genome	O
-	O
wide	O
SNP	O
genotyping	O
for	O
linkage	O
analysis	O
.	O

Y	O
axis	O
indicates	O
the	O
percentage	O
of	O
Usher	B-DISEASE
exons	O
basepair	O
sequenced	O
.	O

In	O
addition	O
,	O
the	O
intra	O
-	O
or	O
inter	O
-	O
familial	O
variability	O
of	O
the	O
phenotype	O
and	O
incomplete	O
penetrance	O
observed	O
in	O
patients	O
with	O
mutations	O
in	O
the	O
known	O
WS4	B-DISEASE
genes	O
,	O
also	O
suggest	O
the	O
involvement	O
of	O
additional	O
unknown	O
loci	O
that	O
may	O
modify	O
the	O
effect	O
of	O
the	O
mutations	O
in	O
the	O
main	O
WS4	B-DISEASE
genes	O
.	O

We	O
demonstrate	O
different	O
frequencies	O
of	O
the	O
c	B-VARIANT
.	I-VARIANT
1331	I-VARIANT
+	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
mutation	O
in	O
hearing	B-DISEASE
impaired	I-DISEASE
Romanies	O
from	O
3	O
Central	O
European	O
countries	O
.	O

The	O
high	O
incidence	O
of	O
DSPP	B-GENE
variants	O
we	O
found	O
in	O
category	O
III	O
(	O
Table	O
1	O
)	O
is	O
unlikely	O
to	O
be	O
caused	O
by	O
platform	O
-	O
specific	O
errors	O
,	O
because	O
we	O
didn	O
'	O
t	O
find	O
similar	O
results	O
in	O
other	O
batches	O
of	O
samples	O
we	O
processed	O
(	O
unpublished	O
data	O
)	O
.	O

Stability	O
of	O
the	O
marker	O
was	O
unaltered	O
by	O
cycloheximide	O
treatment	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
mutation	O
was	O
also	O
present	O
,	O
in	O
the	O
heterozygous	O
state	O
,	O
in	O
one	O
clinically	O
unaffected	O
sibling	O
and	O
in	O
both	O
unaffected	O
parents	O
,	O
and	O
was	O
absent	O
from	O
the	O
other	O
two	O
unaffected	O
siblings	O
.	O

Meanwhile	O
,	O
coverage	O
of	O
targeted	O
exons	O
for	O
>	O
10	O
reads	O
were	O
ranged	O
from	O
90	O
.	O
7	O
%	O
to	O
92	O
.	O
3	O
%	O
and	O
>	O
20	O
reads	O
from	O
81	O
.	O
6	O
%	O
to	O
85	O
.	O
0	O
%	O
.	O

Till	O
date	O
,	O
only	O
three	O
patients	O
with	O
Tietz	B-DISEASE
syndrome	I-DISEASE
and	O
mutation	O
in	O
the	O
MITF	B-GENE
gene	O
have	O
been	O
described	O
.	O

(	O
A	O
)	O
Rapid	O
cell	O
death	O
in	O
transfected	O
THP	O
-	O
1	O
cells	O
.	O

Mutations	O
in	O
COL2A1	B-GENE
have	O
been	O
identified	O
in	O
the	O
Torrance	O
type	O
[	O
7	O
]	O
.	O

Libraries	O
were	O
sequenced	O
on	O
a	O
HiSeq2000	O
(	O
Illumina	O
)	O
to	O
at	O
least	O
80x	O
average	O
coverage	O
of	O
the	O
target	O
region	O
.	O

Two	O
-	O
point	O
linkage	O
analysis	O
was	O
carried	O
out	O
using	O
MLINK	O
of	O
the	O
FASTLINK	O
package	O
[	O
5	O
]	O
,	O
and	O
multipoint	O
linkage	O
analysis	O
was	O
performed	O
with	O
Allegro	O
[	O
6	O
]	O
,	O
while	O
haplotypes	O
were	O
reconstructed	O
using	O
SimWalk2	O
[	O
7	O
]	O
.	O

Matrix	O
of	O
phenotypes	O
in	O
the	O
cohort	O
.	O

Considerable	O
proportion	O
of	O
patients	O
with	O
HH	B-DISEASE
(	O
8	O
%	O
of	O
KS	B-DISEASE
probands	O
)	O
may	O
recover	O
in	O
early	O
adulthood	O
.	O

Hearing	B-DISEASE
loss	I-DISEASE
in	O
32	O
%	O
(	O
69	O
/	O
216	O
)	O
of	O
Japanese	O
cochlear	O
implantees	O
was	O
recently	O
explained	O
genetically	O
using	O
a	O
molecular	O
genetic	O
test	O
protocol	O
incorporating	O
their	O
Invader	O
assay	O
and	O
TRS	O
[	O
3	O
]	O
but	O
no	O
clue	O
was	O
unearthed	O
regarding	O
the	O
remaining	O
unsolved	O
cases	O
.	O

Temporal	O
CT	O
scan	O
revealed	O
EVA	B-DISEASE
and	O
/	O
or	O
other	O
inner	B-DISEASE
ear	I-DISEASE
malformation	I-DISEASE
in	O
39	O
patients	O
.	O

Sensitivity	O
to	O
audiogenic	B-DISEASE
seizures	I-DISEASE
is	O
highest	O
at	O
2	O
-	O
3	O
weeks	O
of	O
age	O
,	O
but	O
then	O
susceptibility	O
gradually	O
decreases	O
and	O
mice	O
become	O
resistant	O
at	O
6	O
weeks	O
of	O
age	O
.	O

OPA1	B-GENE
is	O
the	O
most	O
frequently	O
mutated	O
ADOA	B-DISEASE
gene	O
[	O
10	O
,	O
11	O
]	O
.	O

Yellow	O
:	O
individual	O
affected	O
with	O
HSCR	B-DISEASE
and	O
meningocele	B-DISEASE
.	O

After	O
incubation	O
,	O
cells	O
were	O
visualised	O
by	O
confocal	O
microscopy	O
[	O
12	O
]	O
.	O

Shown	O
are	O
representative	O
blots	O
with	O
differential	O
expression	O
levels	O
of	O
BiP	O
and	O
p	O
-	O
PERK	O
for	O
the	O
various	O
mutant	O
proteins	O
.	O

4a	O
,	O
b	O
and	O
Supplementary	O
Table	O
S2	O
)	O
.	O

SG	O
and	O
EA	O
performed	O
the	O
molecular	O
analysis	O
of	O
COL2A1	B-GENE
gene	O
.	O

Variations	O
of	O
this	O
work	O
are	O
noted	O
under	O
the	O
schematic	O
diagram	O
,	O
and	O
other	O
missense	O
mutations	O
outside	O
the	O
function	O
domains	O
are	O
shown	O
above	O
it	O
.	O

5c	O
)	O
.	O

To	O
calculate	O
the	O
expected	O
de	O
novo	O
rate	O
,	O
we	O
assessed	O
the	O
mutability	O
of	O
all	O
possible	O
trinucleotide	O
contexts	O
in	O
the	O
intergenic	O
region	O
of	O
the	O
human	O
genome	O
for	O
variation	O
in	O
two	O
fashions	O
:	O
fixed	O
genomic	O
differences	O
compared	O
to	O
chimpanzee	O
and	O
baboon	O
12	O
and	O
variation	O
identified	O
from	O
the	O
1	O
,	O
000	O
Genomes	O
project	O
.	O

Finally	O
,	O
this	O
array	O
does	O
not	O
include	O
some	O
recently	O
identified	O
RP	B-DISEASE
genes	O
such	O
as	O
the	O
Eyes	O
Shut	O
homolog	O
(	O
EYS	O
)	O
gene	O
,	O
which	O
is	O
presumed	O
to	O
be	O
a	O
major	O
gene	O
for	O
recessive	O
RP	B-DISEASE
in	O
the	O
Spanish	O
population	O
[	O
26	O
]	O
.	O

An	O
additional	O
five	O
individuals	O
(	O
two	O
affected	O
and	O
three	O
unaffected	O
)	O
(	O
blue	O
)	O
were	O
recruited	O
for	O
Sanger	O
validation	O
and	O
further	O
filtering	O
.	O

SNP	O
array	O
CNV	O
detection	O
was	O
performed	O
with	O
an	O
Illumina	O
Omni1	O
-	O
Quad	O
v1	O
.	O
0	O
chip	O
(	O
Illumina	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
specifications	O
.	O

PS	B-DISEASE
patient	O
is	O
heterozygous	O
at	O
position	O
1075	O
,	O
as	O
revealed	O
by	O
the	O
nucleotide	O
change	O
of	O
G	O
to	O
C	O
(	O
arrow	O
)	O
,	O
causing	O
the	O
substitution	O
of	O
a	O
valine	O
to	O
leucine	O
(	O
Val359Leu	B-VARIANT
)	O
.	O

-	I-VARIANT
23	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
[	O
12	O
]	O
,	O
had	O
been	O
identified	O
to	O
date	O
in	O
this	O
simple	O
gene	O
containing	O
just	O
two	O
exons	O
.	O

Disclaimer	O
:	O
Supplementary	O
materials	O
have	O
been	O
peer	O
-	O
reviewed	O
but	O
not	O
copyedited	O
.	O

The	O
C212Y	B-VARIANT
mutation	O
in	O
CRB1	B-GENE
is	O
a	O
novel	O
splicing	O
mutation	O
,	O
leading	O
to	O
a	O
loss	O
of	O
that	O
exon	O
and	O
a	O
frame	O
shift	O
in	O
the	O
CRB1	B-GENE
protein	O
,	O
while	O
the	O
C948T	B-VARIANT
mutation	O
was	O
previously	O
reported	O
to	O
cause	O
RP	B-DISEASE
.	O

Moreover	O
,	O
a	O
high	O
stimulation	O
rate	O
reduced	O
the	O
duration	O
of	O
the	O
response	O
evoked	O
by	O
the	O
last	O
click	O
in	O
the	O
stimulus	O
sequence	O
(	O
range	O
2	O
.	O
1	O
-	O
3	O
.	O
5	O
ms	O
)	O
to	O
the	O
values	O
seen	O
in	O
controls	O
(	O
range	O
1	O
.	O
9	O
-	O
3	O
.	O
4	O
ms	O
)	O
(	O
Santarelli	O
et	O
al	O
.	O

This	O
was	O
confirmed	O
by	O
segregation	O
in	O
the	O
family	O
.	O

The	O
mutation	O
segregated	O
with	O
the	O
phenotype	O
and	O
was	O
absent	O
in	O
1200	O
Danish	O
control	O
individuals	O
and	O
in	O
databases	O
with	O
whole	O
-	O
genome	O
and	O
exome	O
sequence	O
data	O
.	O

Mutations	O
in	O
the	O
OTOF	B-GENE
gene	O
,	O
encoding	O
otoferlin	O
,	O
are	O
reported	O
to	O
be	O
the	O
major	O
causes	O
of	O
nonsyndromic	O
recessive	O
ANSD	B-DISEASE
[	O
10	O
-	O
12	O
]	O
.	O

Thus	O
,	O
the	O
results	O
are	O
comparable	O
throughout	O
the	O
whole	O
period	O
.	O

From	O
the	O
cases	O
reported	O
in	O
literature	O
and	O
in	O
this	O
study	O
(	O
see	O
online	O
supplementary	O
table	O
S4	O
)	O
,	O
it	O
is	O
not	O
possible	O
to	O
confirm	O
that	O
KS	B-DISEASE
is	O
systematically	O
part	O
of	O
Hartsfield	B-DISEASE
syndrome	I-DISEASE
.	O

Males	O
have	O
increased	O
perilymphatic	O
pressure	O
,	O
which	O
is	O
responsible	O
for	O
gusher	O
during	O
stapes	O
surgery	O
.	O

The	O
percentage	O
of	O
the	O
genetic	O
variants	O
in	O
our	O
French	O
cohort	O
is	O
43	O
/	O
83	O
(	O
51	O
.	O
8	O
%	O
)	O
.	O

To	O
exclude	O
pseudogene	O
sequences	O
,	O
two	O
long	O
-	O
range	O
(	O
LR	O
)	O
PCR	O
products	O
were	O
generated	O
for	O
subsequent	O
nested	O
PCR	O
.	O

WES	O
produced	O
sequence	O
reads	O
in	O
a	O
total	O
length	O
of	O
4	O
.	O
51	O
Gb	O
,	O
92	O
%	O
of	O
the	O
reads	O
were	O
mapped	O
to	O
gene	O
regions	O
with	O
an	O
average	O
coverage	O
of	O
31	O
.	O
17	O
reads	O
per	O
nucleotide	O
(	O
Table	O
S3	O
)	O
.	O

Mutations	O
in	O
the	O
CNGA1	B-GENE
gene	O
were	O
identified	O
for	O
the	O
first	O
time	O
in	O
a	O
Japanese	O
population	O
with	O
a	O
high	O
frequency	O
of	O
5	O
.	O
1	O
%	O
for	O
homozygous	O
or	O
compound	O
heterozygous	O
mutations	O
.	O

4	O
)	O
.	O

a	O
.	O

Half	O
fill	O
symbols	O
in	O
family	O
PKDF108	O
are	O
individuals	O
(	O
ages	O
72	O
and	O
75	O
years	O
)	O
that	O
have	O
age	O
related	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

235delC	B-VARIANT
was	O
the	O
hotspot	O
mutation	O
in	O
nonsyndromic	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
NSHL	B-DISEASE
)	O
patients	O
,	O
whereas	O
35delG	B-VARIANT
was	O
not	O
found	O
.	O

Dashed	O
line	O
indicates	O
minimum	O
conservation	O
required	O
for	O
'	O
likely	O
deleterious	O
'	O
variants	O
.	O

To	O
date	O
,	O
the	O
only	O
USH	B-DISEASE
gene	O
associated	O
with	O
nonsyndromic	B-DISEASE
RP	I-DISEASE
is	O
USH2A	B-GENE
,	O
underlying	O
USH2	B-DISEASE
(	O
in	O
which	O
HL	B-DISEASE
is	O
not	O
profound	O
and	O
vestibular	O
function	O
is	O
usually	O
normal	O
)	O
[	O
3	O
,	O
12	O
]	O
.	O

CNV	O
analysis	O
should	O
routinely	O
be	O
applied	O
in	O
targeted	O
NGS	O
,	O
and	O
mutations	O
in	O
non	O
-	O
coding	O
exons	O
give	O
reason	O
to	O
systematically	O
include	O
5	O
'	O
-	O
UTRs	O
in	O
disease	O
gene	O
or	O
exome	O
panels	O
.	O

Other	O
mutant	O
pendrins	O
(	O
p	B-VARIANT
.	I-VARIANT
S314L	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
A360V	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R409C	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
L506R	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
C662Y	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
R776G	I-VARIANT
)	O
were	O
also	O
localized	O
to	O
the	O
cytosol	O
,	O
indicating	O
retention	O
in	O
the	O
intracellular	O
region	O
.	O

Among	O
them	O
,	O
18	O
variants	O
were	O
reported	O
,	O
of	O
which	O
eight	O
are	O
novel	O
.	O

In	O
mouse	O
hair	O
cell	O
cultures	O
,	O
however	O
,	O
CLRN1	B-GENE
associates	O
with	O
tubulin	O
and	O
not	O
with	O
actin	O
,	O
and	O
localizes	O
to	O
post	O
-	O
transgolgi	O
vesicles	O
,	O
suggesting	O
a	O
potential	O
function	O
for	O
CLRN1	B-GENE
in	O
vesicle	O
transport	O
[	O
31	O
]	O
.	O

(	O
A	O
)	O
Sanger	O
sequencing	O
traces	O
of	O
the	O
p	B-VARIANT
.	I-VARIANT
T237I	I-VARIANT
heterozygote	O
and	O
the	O
wildtype	O
.	O

ACTG1	B-GENE
(	O
NM_001199954	O
)	O
,	O
which	O
is	O
responsible	O
for	O
DFNA20	O
/	O
26	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
encodes	O
gamma	O
-	O
actin	O
,	O
one	O
of	O
the	O
non	O
-	O
muscle	O
cytoskeletal	O
proteins	O
.	O

We	O
performed	O
COL4	B-GENE
alpha	I-GENE
1	I-GENE
,	O
COL4	B-GENE
alpha	I-GENE
3	I-GENE
and	O
COL4	B-GENE
alpha	I-GENE
5	I-GENE
immunohistochemistry	O
and	O
found	O
strong	O
COL4	B-GENE
alpha	I-GENE
1	I-GENE
immunoreactivity	O
in	O
the	O
glomerular	O
capillary	O
loops	O
,	O
and	O
tubular	O
basement	O
membrane	O
,	O
weak	O
COL4	B-GENE
alpha	I-GENE
5	I-GENE
in	O
glomerular	O
capillary	O
loops	O
and	O
basement	O
membrane	O
of	O
distal	O
tubules	O
and	O
no	O
COL4	B-GENE
alpha	I-GENE
3	I-GENE
immunoreactivity	O
(	O
Figure	O
4	O
)	O
.	O

SNHI	B-DISEASE
,	O
sensorineural	O
hearing	B-DISEASE
impairment	I-DISEASE
;	O
ADNSHL	B-DISEASE
,	O
autosomal	B-DISEASE
dominant	I-DISEASE
nonsyndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
;	O
ARNSHL	B-DISEASE
,	O
autosomal	B-DISEASE
recessive	I-DISEASE
nonsyndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
;	O
MPS	O
,	O
massively	O
parallel	O
sequencing	O
.	O

Data	O
are	O
given	O
as	O
mean	O
+	O
-	O
s	O
.	O
d	O
.	O

Blood	O
samples	O
were	O
collected	O
from	O
individuals	O
for	O
genomic	O
DNA	O
isolation	O
.	O

As	O
summarized	O
in	O
Table	O
1	O
,	O
two	O
hundred	O
sixty	O
-	O
four	O
Japanese	O
patients	O
with	O
bilateral	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
from	O
33	O
ENT	O
departments	O
nationwide	O
participated	O
in	O
the	O
present	O
study	O
.	O

The	O
same	O
kind	O
of	O
mutation	O
was	O
found	O
in	O
TCS	B-DISEASE
6	O
patient	O
in	O
exon	O
12	O
.	O

No	O
other	O
pathogenic	O
mutations	O
were	O
found	O
.	O

The	O
variants	O
and	O
allele	O
frequencies	O
are	O
listed	O
in	O
Table	O
S1	O
in	O
File	O
S1	O
.	O

-	I-VARIANT
23	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
GJB2	B-GENE
transcripts	O
generated	O
from	O
this	O
allele	O
were	O
not	O
detected	O
in	O
a	O
lymphoblastoid	O
cell	O
line	O
derived	O
from	O
a	O
c	B-VARIANT
.	I-VARIANT

DNAs	O
were	O
extracted	O
by	O
the	O
standard	O
method	O
of	O
phenol	O
/	O
chloroform	O
[	O
21	O
]	O
.	O

This	O
work	O
was	O
also	O
supported	O
by	O
the	O
Higher	O
Education	O
Commission	O
and	O
Ministry	O
of	O
Science	O
and	O
Technology	O
,	O
Islamabad	O
,	O
Pakistan	O
,	O
to	O
Sh	O
.	O
R	O
.	O

Our	O
study	O
shows	O
that	O
,	O
in	O
humans	O
,	O
lack	O
of	O
accurate	O
FGFR1	B-GENE
activation	O
can	O
disrupt	O
both	O
brain	O
and	O
hand	O
/	O
foot	O
midline	O
development	O
,	O
and	O
that	O
FGFR1	B-GENE
loss	O
-	O
of	O
-	O
function	O
mutations	O
are	O
responsible	O
for	O
a	O
wider	O
spectrum	O
of	O
clinical	O
anomalies	O
than	O
previously	O
thought	O
,	O
ranging	O
in	O
severity	O
from	O
seemingly	O
isolated	B-DISEASE
hypogonadotropic	I-DISEASE
hypogonadism	I-DISEASE
,	O
through	O
Kallmann	B-DISEASE
syndrome	I-DISEASE
with	O
or	O
without	O
additional	O
features	O
,	O
to	O
Hartsfield	B-DISEASE
syndrome	I-DISEASE
at	O
its	O
most	O
severe	O
end	O
.	O

MLPA	O
results	O
were	O
visualized	O
with	O
the	O
MLPA	O
module	O
of	O
the	O
SeqPilot	O
software	O
(	O
JSI	O
Medical	O
Systems	O
)	O
.	O

This	O
strategy	O
for	O
clinical	O
and	O
genetic	O
diagnosis	O
will	O
enable	O
prediction	O
of	O
phenotypes	O
and	O
enhance	O
rehabilitation	O
.	O

Hearing	O
thresholds	O
were	O
obtained	O
between	O
250	O
-	O
8000	O
Hz	O
in	O
a	O
sound	O
-	O
treated	O
room	O
.	O

Most	O
of	O
these	O
changes	O
are	O
clearly	O
polymorphic	O
as	O
they	O
were	O
detected	O
in	O
high	O
frequencies	O
and	O
represent	O
known	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
.	O

X	O
chromosome	O
inactivation	O
skewing	O
was	O
reported	O
as	O
percentage	O
of	O
the	O
predominant	O
allele	O
and	O
was	O
considered	O
skewed	O
when	O
the	O
predominant	O
allele	O
exceeded	O
74	O
%	O
,	O
non	O
-	O
skewed	O
between	O
50	O
%	O
and	O
65	O
%	O
and	O
undetermined	O
between	O
66	O
%	O
and	O
74	O
%	O
[	O
36	O
]	O
.	O

Subjects	O
were	O
enrolled	O
from	O
the	O
representative	O
deaf	O
populations	O
registered	O
with	O
Xinjiang	O
local	O
institutes	O
,	O
including	O
Kashi	O
Municipal	O
Special	O
Education	O
School	O
,	O
Kashi	O
Municipal	O
Disabled	O
People	O
'	O
s	O
Association	O
,	O
Changji	O
Municipal	O
Special	O
Education	O
School	O
,	O
Urumqi	O
Lingual	O
Training	O
School	O
,	O
and	O
Otorhinolaryngology	O
Outpatient	O
Clinic	O
,	O
the	O
First	O
Affiliated	O
Hospital	O
of	O
Xinjiang	O
Medical	O
University	O
.	O

Overall	O
,	O
40	O
%	O
of	O
the	O
probands	O
,	O
a	O
proportion	O
similar	O
to	O
that	O
observed	O
in	O
other	O
populations	O
[	O
20	O
]	O
,	O
could	O
be	O
given	O
a	O
molecular	O
genetic	O
diagnosis	O
.	O

The	O
sift	O
prediction	O
of	O
seven	O
variants	O
(	O
p	B-VARIANT
.	I-VARIANT
D87Y	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
S93R	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
G222V	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
S314L	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R409C	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
L506R	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
C662Y	I-VARIANT
)	O
was	O
damaging	O
,	O
while	O
the	O
other	O
three	O
(	O
p	B-VARIANT
.	I-VARIANT
A360V	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
A664V	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
R776G	I-VARIANT
)	O
was	O
tolerated	O
.	O

Competing	O
financial	O
interests	O
The	O
authors	O
declare	O
no	O
competing	O
financial	O
interests	O
.	O

Base	O
recalibration	O
and	O
variant	O
calling	O
were	O
performed	O
using	O
the	O
GATK	O
unified	O
genotyper	O
(	O
known	O
single	O
nucleotide	O
polymorphisms	O
[	O
SNPs	O
]	O
and	O
insertions	O
/	O
deletions	O
[	O
indels	O
]	O
from	O
dbSNP137	O
,	O
Mills	O
and	O
1000G	O
gold	O
standard	O
indels	O
b37	O
sites	O
,	O
and	O
1000G	O
phase1	O
indels	O
b37	O
sites	O
)	O
.	O

The	O
ConSeq	O
server	O
revealed	O
that	O
all	O
of	O
the	O
causative	O
mutations	O
were	O
located	O
at	O
a	O
well	O
-	O
conserved	O
site	O
.	O

Homozygous	O
PJVK	B-GENE
-	O
mutated	O
knock	O
-	O
in	O
mice	O
showed	O
mimic	O
phenotype	O
of	O
patients	O
with	O
PJVK	B-GENE
mutations	O
,	O
such	O
as	O
abnormal	O
ABR	O
and	O
preserved	O
function	O
of	O
IHCs	O
and	O
OHCs	O
.	O

The	O
discovered	O
patient	O
mutations	O
were	O
absent	O
from	O
all	O
other	O
patient	O
and	O
HapMap	O
samples	O
sequenced	O
,	O
except	O
as	O
noted	O
below	O
.	O

According	O
to	O
one	O
model	O
,	O
a	O
downstream	O
complex	O
of	O
two	O
ATPases	O
,	O
PEX1	B-GENE
and	O
PEX6	B-GENE
,	O
and	O
the	O
peroxisomal	O
membrane	O
protein	O
PEX26	B-GENE
are	O
thought	O
to	O
mediate	O
recycling	O
of	O
PEX5	B-GENE
into	O
the	O
cytosol	O
[	O
5	O
,	O
6	O
]	O
.	O

Sequencing	O
of	O
the	O
coding	O
region	O
of	O
the	O
GJB2	B-GENE
gene	O
reveals	O
that	O
14	O
.	O
9	O
%	O
of	O
the	O
patients	O
carry	O
two	O
pathogenic	O
GJB2	B-GENE
mutation	O
and	O
6	O
.	O
1	O
%	O
carry	O
only	O
one	O
mutant	O
allele	O
.	O

Heterozygous	O
deletion	O
of	O
exon	O
4	O
in	O
the	O
CRX	B-GENE
gene	O
in	O
patient	O
110	O
and	O
his	O
father	O
.	O

The	O
mutation	O
in	O
this	O
domain	O
hindered	O
the	O
progress	O
of	O
protein	O
folding	O
into	O
the	O
triple	O
helical	O
domain	O
,	O
which	O
caused	O
post	O
-	O
translational	O
overmodification	O
of	O
the	O
protein	O
amino	O
-	O
terminal	O
to	O
the	O
mutation	O
site	O
[	O
24	O
]	O
.	O

Overall	O
,	O
CHI	B-DISEASE
causative	O
mutations	O
have	O
been	O
documented	O
in	O
10	O
genes	O
,	O
allowing	O
a	O
molecular	O
diagnosis	O
for	O
nearly	O
50	O
%	O
of	O
CHI	B-DISEASE
patients	O
[	O
3	O
]	O
,	O
[	O
4	O
]	O
.	O

Fundus	O
examination	O
revealed	O
severe	O
optic	B-DISEASE
disc	I-DISEASE
atrophy	I-DISEASE
in	O
both	O
eyes	O
(	O
Figure	O
1	O
)	O
.	O

In	O
our	O
cohort	O
,	O
deafness	B-DISEASE
was	O
the	O
most	O
frequent	O
of	O
these	O
symptoms	O
with	O
an	O
early	O
age	O
of	O
onset	O
(	O
median	O
16	O
years	O
)	O
and	O
was	O
isolated	O
in	O
most	O
cases	O
or	O
associated	O
with	O
nephropathy	B-DISEASE
occurring	O
at	O
a	O
later	O
median	O
age	O
of	O
27	O
years	O
.	O

We	O
hypothesized	O
that	O
if	O
GFP	O
-	O
ELMOD3	B-GENE
associated	O
with	O
the	O
actin	O
cytoskeleton	O
at	O
the	O
cell	O
membrane	O
,	O
then	O
treatment	O
of	O
the	O
cells	O
with	O
cyto	O
-	O
D	O
would	O
also	O
affect	O
ELMOD3	B-GENE
localization	O
.	O

With	O
the	O
cut	O
off	O
value	O
setting	O
in	O
this	O
study	O
,	O
we	O
could	O
obtain	O
high	O
sensitivity	O
(	O
93	O
.	O
5	O
%	O
sensitivity	O
on	O
the	O
basis	O
of	O
GJB2	B-GENE
,	O
SLC26A4	B-GENE
)	O
(	O
Fig	O
.	O

Mutations	O
of	O
the	O
C	O
-	O
propeptide	O
of	O
collagen	O
II	O
are	O
a	O
well	O
established	O
cause	O
of	B-DISEASE
type	I-DISEASE
II	I-DISEASE
collagenopathy	I-DISEASE
associated	O
with	O
brachydactyly	B-DISEASE
E	O
;	O
indeed	O
,	O
additional	O
cases	O
of	O
SPD	B-DISEASE
associated	O
to	O
analogous	O
mutations	O
of	O
C	O
propeptide	O
domain	O
of	O
COL2A1	B-GENE
have	O
been	O
previously	O
reported	O
[	O
4	O
,	O
5	O
]	O
.	O

These	O
mutations	O
are	O
associated	O
with	O
a	O
variable	O
transmission	O
(	O
mainly	O
recessive	O
transmission	O
)	O
and	O
can	O
be	O
associated	O
with	O
various	O
malformations	O
and	O
degrees	O
of	O
HH	B-DISEASE
including	O
reversibility	O
[	O
8	O
]	O
.	O

The	O
results	O
of	O
the	O
mixed	O
meal	O
tolerance	O
test	O
are	O
shown	O
in	O
Table	O
3	O
.	O

PRS	O
-	O
I	O
activity	O
was	O
lower	O
in	O
subject	O
II	O
-	O
1	O
than	O
in	O
subject	O
I	O
-	O
1	O
,	O
most	O
likely	O
due	O
to	O
severely	O
skewed	O
X	O
-	O
chromosome	O
inactivation	O
which	O
was	O
observed	O
in	O
this	O
subject	O
.	O

Nuclei	O
are	O
stained	O
using	O
TO	O
-	O
PRO	O
-	O
3	O
iodine	O
.	O

Table	O
S2	O
)	O
.	O

The	O
most	O
prevalent	O
tumorigenic	O
mutations	O
occur	O
at	O
residues	O
that	O
directly	O
contact	O
DNA	O
or	O
stabilize	O
the	O
structure	O
.	O

In	O
this	O
network	O
,	O
several	O
unconventional	O
myosins	O
,	O
as	O
myosin	B-GENE
XVa	I-GENE
,	O
have	O
also	O
been	O
found	O
[	O
16	O
-	O
18	O
]	O
.	O

-	I-VARIANT
23	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
splice	O
-	O
site	O
mutation	O
are	O
frequent	O
in	O
specific	O
populations	O
[	O
16	O
,	O
18	O
-	O
22	O
]	O
.	O

Not	O
only	O
were	O
similar	O
"	O
hot	O
spots	O
"	O
detected	O
,	O
adding	O
more	O
subjects	O
in	O
the	O
analysis	O
enhanced	O
the	O
true	O
peak	O
(	O
red	O
arrow	O
)	O
(	O
bottom	O
)	O
.	O

In	O
the	O
case	O
of	O
454	O
pyrosequencing	O
,	O
this	O
relies	O
on	O
the	O
quantification	O
of	O
emitted	O
light	O
during	O
a	O
single	O
nucleotide	O
flow	O
(	O
Margulies	O
et	O
al	O
.	O

In	O
humans	O
,	O
the	O
CaMK2	O
beta	O
and	O
delta	O
subtypes	O
represent	O
the	O
major	O
isoforms	O
that	O
are	O
highly	O
expressed	O
in	O
beta	O
-	O
cells	O
[	O
38	O
]	O
.	O

Numerous	O
other	O
recent	O
papers	O
have	O
noted	O
that	O
there	O
is	O
much	O
overlap	O
between	O
genes	O
causing	O
different	O
forms	O
of	O
retinal	B-DISEASE
disease	I-DISEASE
27	O
-	O
29	O
.	O

We	O
estimate	O
that	O
TMC1	B-GENE
mutations	O
explain	O
at	O
least	O
38	O
%	O
of	O
inherited	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
the	O
Moroccan	O
Jewish	O
population	O
.	O

The	O
diagnosis	O
of	O
profound	O
sensorineural	O
hearing	B-DISEASE
impairment	I-DISEASE
was	O
made	O
according	O
to	O
the	O
ICD	O
-	O
10	O
criteria	O
based	O
on	O
audiometric	O
examination	O
.	O

was	O
supported	O
by	O
an	O
Australian	O
NHMRC	O
Overseas	O
Biomedical	O
Postdoctoral	O
Training	O
Fellowship	O
.	O

We	O
think	O
that	O
the	O
diagnostic	O
interpretation	O
workflow	O
developed	O
in	O
this	O
study	O
can	O
also	O
be	O
applied	O
to	O
these	O
approaches	O
,	O
especially	O
given	O
the	O
fact	O
that	O
most	O
diagnostic	O
laboratories	O
will	O
focus	O
on	O
the	O
interpretation	O
and	O
reporting	O
of	O
variants	O
in	O
the	O
coding	O
part	O
of	O
our	O
genome	O
.	O

Specific	O
and	O
shared	O
POLR1	O
(	O
Pol	O
I	O
)	O
and	O
POLR3	O
(	O
Pol	O
III	O
)	O
subunits	O
are	O
identified	O
on	O
the	O
left	O
.	O

Band	O
C	O
is	O
the	O
heteroduplex	O
formation	O
from	O
band	O
A	O
and	O
band	O
B	O
.	O

Molecular	O
diagnosis	O
in	O
Usher	B-DISEASE
syndrome	I-DISEASE
is	O
hindered	O
by	O
significant	O
genetic	O
heterogeneity	O
,	O
the	O
large	O
size	O
of	O
some	O
of	O
the	O
Usher	B-DISEASE
genes	O
,	O
and	O
the	O
number	O
of	O
missense	O
changes	O
in	O
genes	O
such	O
as	O
MYO7A	B-GENE
and	O
USH2A	B-GENE
.	O

Classification	O
based	O
on	O
the	O
USHbase	O
database	O
https	O
:	O
/	O
/	O
grenada	O
.	O
lumc	O
.	O
nl	O
/	O
LOVD2	O
/	O
Usher_montpellier	O
/	O
USHbases	O
.	O
html	O
.	O

In	O
this	O
subset	O
of	O
dilated	B-DISEASE
cardiomyopathy	I-DISEASE
(	O
DCM	B-DISEASE
)	O
,	O
ventricular	B-DISEASE
dilation	I-DISEASE
and	O
dysfunction	B-DISEASE
become	O
apparent	O
as	O
the	O
disease	O
progresses	O
,	O
and	O
clinical	O
heart	B-DISEASE
failure	I-DISEASE
often	O
manifests	O
late	O
in	O
the	O
course	O
of	O
the	O
disease	O
.	O

Over	O
700	O
different	O
cLQTS	B-DISEASE
-	O
causing	O
mutations	O
in	O
13	O
genes	O
are	O
known	O
.	O

To	O
access	O
the	O
table	O
,	O
click	O
or	O
select	O
the	O
words	O
"	O
Appendix	O
1	O
.	O

We	O
detected	O
the	O
most	O
number	O
of	O
CNVs	O
on	O
the	O
DIAPH1	B-GENE
gene	O
,	O
which	O
is	O
located	O
on	O
Chromosome	O
5	O
.	O

Sequence	O
data	O
for	O
OSBPL2	B-GENE
(	O
MIM	O
606731	O
)	O
were	O
compared	O
to	O
the	O
reference	O
sequence	O
NM_144498	O
.	O
2	O
.	O

We	O
obtained	O
5	O
Gb	O
of	O
sequences	O
using	O
the	O
Illumina	O
GAII	O
and	O
45	O
Mb	O
using	O
the	O
GS	O
-	O
FLX	O
platform	O
corresponding	O
to	O
14	O
.	O
3	O
millions	O
and	O
0	O
.	O
22	O
millions	O
of	O
non	O
-	O
duplicated	O
mappable	O
reads	O
,	O
respectively	O
.	O

We	O
sequenced	O
these	O
positions	O
in	O
our	O
cohort	O
and	O
found	O
described	O
mutations	O
in	O
3	O
subjects	O
(	O
4	O
.	O
7	O
%	O
,	O
Supplementary	O
Table	O
1	O
)	O
.	O

The	O
residual	O
low	O
-	O
frequency	O
hearing	O
in	O
this	O
Saudi	O
family	O
was	O
not	O
as	O
significant	O
as	O
that	O
in	O
our	O
study	O
[	O
14	O
]	O
.	O

A	O
maternal	O
cousin	O
,	O
not	O
available	O
to	O
the	O
study	O
,	O
was	O
referred	O
to	O
have	O
congenital	B-DISEASE
hypoacusia	I-DISEASE
,	O
mental	B-DISEASE
retardation	I-DISEASE
,	O
and	O
caf	B-DISEASE
e	I-DISEASE
-	I-DISEASE
au	I-DISEASE
-	I-DISEASE
lait	I-DISEASE
spots	I-DISEASE
.	O

Earlier	O
,	O
it	O
was	O
shown	O
that	O
the	O
marriage	O
migrations	O
among	O
this	O
Altaian	O
subpopulation	O
were	O
,	O
in	O
their	O
majority	O
,	O
restricted	O
to	O
the	O
territory	O
of	O
this	O
region	O
[	O
21	O
]	O
.	O

The	O
targeted	O
NGS	O
data	O
were	O
also	O
reviewed	O
to	O
uncover	O
,	O
if	O
any	O
,	O
the	O
presence	O
of	O
copy	O
number	O
variation	O
in	O
the	O
targeted	O
genes	O
.	O

Four	O
of	O
the	O
family	O
members	O
underwent	O
an	O
oral	O
glucose	O
tolerance	O
test	O
(	O
a	O
75	O
-	O
g	O
glucose	O
load	O
)	O
.	O

GAPDH	O
has	O
been	O
used	O
as	O
a	O
positive	O
control	O
.	O

Depending	O
on	O
the	O
localisation	O
of	O
the	O
amino	O
acid	O
substitution	O
,	O
Hartsfield	B-DISEASE
syndrome	I-DISEASE
can	O
have	O
an	O
autosomal	O
dominant	O
or	O
autosomal	O
recessive	O
mode	O
of	O
inheritance	O
.	O

1	O
:	O
II	O
-	O
2	O
,	O
II	O
-	O
3	O
,	O
II	O
-	O
4	O
,	O
III	O
-	O
1	O
,	O
III	O
-	O
2	O
,	O
III	O
-	O
3	O
,	O
III	O
-	O
5	O
,	O
III	O
-	O
6	O
,	O
III	O
-	O
7	O
,	O
IV	O
-	O
1	O
,	O
IV	O
-	O
2	O
,	O
IV	O
-	O
4	O
,	O
and	O
IV	O
-	O
5	O
)	O
.	O

These	O
pictures	O
were	O
made	O
using	O
UCSF	O
Chimera	O
.	O

,	O
2008	O
;	O
Milone	O
et	O
al	O
.	O

5A	O
and	O
5B	O
)	O
.	O

After	O
informed	O
consent	O
was	O
obtained	O
from	O
patients	O
or	O
their	O
families	O
,	O
blood	O
samples	O
were	O
collected	O
.	O

Exon	O
8	O
DNA	O
from	O
the	O
four	O
affected	O
siblings	O
exhibited	O
an	O
overlapping	O
pattern	O
on	O
automated	O
DNA	O
sequencing	O
indicating	O
the	O
presence	O
of	O
a	O
frameshift	O
mutation	O
.	O

We	O
also	O
screened	O
for	O
the	O
neighbouring	O
deletion	O
of	O
GJB6	B-GENE
[	O
14	O
]	O
.	O

Indeed	O
,	O
the	O
complexity	O
and	O
phenotypic	O
variability	O
already	O
observed	O
in	O
genetically	O
heterogeneous	O
or	O
oligogenic	O
congenital	O
disorders	O
can	O
be	O
conceptually	O
understood	O
in	O
the	O
light	O
large	O
range	O
of	O
molecular	O
and	O
cellular	O
interactions	O
that	O
take	O
place	O
during	O
development	O
.	O

CD	O
means	O
cluster	O
of	O
differentiation	O
.	O

The	O
haplotype	O
segregating	O
with	O
the	O
ARNSHI	B-DISEASE
phenotype	O
is	O
shown	O
within	O
a	O
box	O
.	O

Constructs	O
were	O
verified	O
by	O
DNA	O
sequencing	O
using	O
the	O
BigDye	O
Terminator	O
v	O
3	O
.	O
1	O
following	O
the	O
manufacturer	O
'	O
s	O
instructions	O
and	O
electrophoresed	O
on	O
a	O
3730xl	O
capillary	O
sequencer	O
(	O
Applied	O
Biosystems	O
)	O
.	O

His	O
child	O
had	O
unilateral	O
microphthalmia	B-DISEASE
and	O
bilateral	O
coloboma	B-DISEASE
.	O

Subject	O
1444	O
-	O
1	O
was	O
diagnosed	O
with	O
hypertension	B-DISEASE
at	O
birth	O
(	O
blood	O
pressure	O
119	O
/	O
78	O
mmHg	O
;	O
>	O
99	O
th	O
percentile	O
)	O
with	O
biventricular	B-DISEASE
hypertrophy	I-DISEASE
,	O
a	O
ventricular	B-DISEASE
septal	I-DISEASE
defect	I-DISEASE
,	O
pulmonary	B-DISEASE
hypertension	I-DISEASE
,	O
and	O
second	B-DISEASE
-	I-DISEASE
degree	I-DISEASE
heart	I-DISEASE
block	I-DISEASE
.	O

The	O
p	B-VARIANT
.	I-VARIANT
Ala306Thr	I-VARIANT
mutation	O
has	O
a	O
fairly	O
similar	O
phenotypic	O
effect	O
as	O
p	B-VARIANT
.	I-VARIANT
Val199Met	I-VARIANT
(	O
families	O
A	O
/	O
G	O
versus	O
D	O
/	O
F	O
)	O
and	O
p	B-VARIANT
.	I-VARIANT
Cys107fs	I-VARIANT
(	O
families	O
D	O
/	O
F	O
versus	O
family	O
H	O
)	O
,	O
whereas	O
p	B-VARIANT
.	I-VARIANT
Val199Met	I-VARIANT
has	O
a	O
fairly	O
similar	O
effect	O
as	O
p	B-VARIANT
.	I-VARIANT
Thr70fs	I-VARIANT
(	O
family	O
B	O
versus	O
C	O
)	O
and	O
p	B-VARIANT
.	I-VARIANT
Cys107fs	I-VARIANT
(	O
families	O
A	O
/	O
G	O
versus	O
family	O
H	O
)	O
:	O
this	O
suggests	O
that	O
also	O
p	B-VARIANT
.	I-VARIANT
Ala306Thr	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
Thr70fs	I-VARIANT
must	O
have	O
fairly	O
similar	O
phenotypic	O
effects	O
.	O

Robert	O
Cunningham	O
Gerring	O
of	O
the	O
University	O
of	O
Miami	O
,	O
Miller	O
School	O
of	O
Medicine	O
for	O
comments	O
on	O
the	O
manuscript	O
.	O

Structure	O
optimization	O
and	O
modifications	O
were	O
made	O
with	O
Visual	O
Molecular	O
Dynamics	O
software	O
support	O
.	O

The	O
variants	O
that	O
had	O
previously	O
been	O
deemed	O
causative	O
in	O
each	O
sample	O
are	O
shown	O
in	O
Table	O
3	O
.	O

In	O
two	O
of	O
the	O
patients	O
with	O
severe	O
to	O
profound	O
hearing	B-DISEASE
loss	I-DISEASE
who	O
could	O
not	O
benefit	O
from	O
hearing	O
aids	O
,	O
cochlear	O
implantation	O
was	O
performed	O
.	O

RP	B-DISEASE
usually	O
occurs	O
in	O
the	O
2	O
nd	O
decade	O
.	O

As	O
a	O
result	O
,	O
a	O
smaller	O
fraction	O
of	O
the	O
detected	O
variants	O
had	O
to	O
be	O
verified	O
by	O
Sanger	O
sequencing	O
for	O
segregation	O
in	O
the	O
family	O
.	O

Each	O
of	O
the	O
other	O
variants	O
occurs	O
as	O
heterozygous	O
in	O
one	O
patient	O
.	O

(	O
E	O
)	O
In	O
P14	O
Homer2	B-GENE
-	O
/	O
-	O
mice	O
,	O
DPOAE	O
amplitudes	O
are	O
significantly	O
lower	O
in	O
the	O
high	O
frequencies	O
(	O
16	O
,	O
22	O
.	O
6	O
,	O
and	O
32	O
.	O
0	O
kHz	O
)	O
as	O
compared	O
to	O
their	O
WT	O
and	O
Homer2	B-GENE
+	O
/	O
-	O
littermates	O
.	O

All	O
subjects	O
denied	O
any	O
exposure	O
to	O
risk	O
factors	O
such	O
as	O
drugs	O
or	O
loud	O
noise	O
.	O

Several	O
genes	O
have	O
been	O
involved	O
in	O
non	O
-	O
syndromic	O
HPE	B-DISEASE
(	O
including	O
SHH	B-GENE
,	O
ZIC2	B-GENE
,	O
SIX3	B-GENE
,	O
GLI2	B-GENE
,	O
and	O
TGIF	B-GENE
)	O
or	O
ectrodactyly	B-DISEASE
(	O
such	O
as	O
P63	B-GENE
,	O
or	O
the	O
10q24	O
duplication	O
)	O
,	O
with	O
incomplete	O
penetrance	O
and	O
variable	O
expressivity	O
.	O

Clinical	O
diagnosis	O
of	O
dRTA	B-DISEASE
was	O
based	O
on	O
the	O
simultaneous	O
presence	O
of	O
non	O
-	O
gap	O
metabolic	B-DISEASE
acidosis	I-DISEASE
(	O
plasma	O
bicarbonate	O
<	O
20	O
mEq	O
/	O
L	O
)	O
and	O
inability	O
to	O
reduce	O
urinary	O
pH	O
below	O
5	O
.	O
5	O
[	O
20	O
]	O
.	O

The	O
difference	O
in	O
their	O
results	O
still	O
needs	O
to	O
be	O
explored	O
in	O
further	O
studies	O
.	O

All	O
TECTA	B-GENE
mutations	O
described	O
to	O
date	O
have	O
shown	O
significant	O
genotype	O
-	O
phenotype	O
correlation	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
[	O
5	O
-	O
13	O
]	O
.	O

A	O
third	O
band	O
was	O
also	O
observed	O
corresponding	O
to	O
the	O
heteroduplex	O
formation	O
from	O
the	O
two	O
smaller	O
transcripts	O
(	O
band	O
C	O
)	O
.	O

The	O
combination	O
of	O
linkage	O
analysis	O
and	O
exome	O
sequencing	O
provided	O
strong	O
evidence	O
that	O
TNC	B-GENE
may	O
be	O
responsible	O
for	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
this	O
family	O
.	O

Nitrogen	O
,	O
oxygen	O
,	O
phosphorus	O
,	O
and	O
magnesium	O
atoms	O
are	O
coloured	O
blue	O
,	O
red	O
,	O
orange	O
,	O
and	O
green	O
,	O
respectively	O
.	O

The	O
further	O
gene	O
sequencing	O
identified	O
187delG	B-VARIANT
/	O
187delG	B-VARIANT
for	O
GJB2	B-GENE
in	O
three	O
patients	O
(	O
Figure	O
1A	O
)	O
,	O
and	O
1503G	B-VARIANT
>	I-VARIANT
A	I-VARIANT
for	O
mtDNA	B-GENE
12S	I-GENE
rRNA	I-GENE
in	O
one	O
patient	O
(	O
Figure	O
1B	O
)	O
.	O

Two	O
of	O
the	O
mutations	O
found	O
in	O
this	O
study	O
are	O
truncating	O
:	O
the	O
p	B-VARIANT
.	I-VARIANT
Y63X	I-VARIANT
mutation	O
,	O
found	O
in	O
two	O
unrelated	O
families	O
who	O
were	O
carriers	O
of	O
Catalonian	O
origin	O
,	O
and	O
p	B-VARIANT
.	I-VARIANT
R207X	I-VARIANT
,	O
found	O
in	O
heterozygous	O
state	O
in	O
two	O
unrelated	O
families	O
who	O
were	O
carriers	O
of	O
Basque	O
origin	O
.	O

All	O
sequence	O
variants	O
highly	O
conserved	O
the	O
amino	O
acid	O
,	O
up	O
to	O
C	O
.	O
elegans	O
(	O
considering	O
15	O
species	O
)	O
.	O

5d	O
)	O
.	O

Hereditary	B-DISEASE
optic	I-DISEASE
neuropathy	I-DISEASE
(	O
HON	B-DISEASE
)	O
is	O
a	O
disease	O
entity	O
characterized	O
by	O
symmetric	O
,	O
bilateral	O
,	O
central	O
visual	B-DISEASE
loss	I-DISEASE
with	O
deviations	B-DISEASE
of	I-DISEASE
the	I-DISEASE
papillomacular	I-DISEASE
nerve	I-DISEASE
fiber	I-DISEASE
bundle	I-DISEASE
resulting	B-DISEASE
in	I-DISEASE
cupping	I-DISEASE
of	I-DISEASE
the	I-DISEASE
disk	I-DISEASE
and	O
in	O
central	B-DISEASE
or	I-DISEASE
cecocentral	I-DISEASE
scotomas	I-DISEASE
and	B-DISEASE
generalized	I-DISEASE
constriction	I-DISEASE
of	I-DISEASE
the	I-DISEASE
visual	I-DISEASE
fields	I-DISEASE
.	O

Furthermore	O
,	O
because	O
of	O
the	O
extreme	O
heterogeneities	O
of	O
causative	O
genes	O
,	O
studies	O
of	O
molecular	O
etiology	O
have	O
focused	O
mainly	O
upon	O
deafness	B-DISEASE
genes	O
,	O
such	O
as	O
,	O
GJB2	B-GENE
,	O
SLC26A4	B-GENE
,	O
or	O
OTOF	B-GENE
,	O
which	O
make	O
larger	O
contributions	O
to	O
deafness	B-DISEASE
in	O
local	O
populations	O
.	O

Samples	O
from	O
148	O
unrelated	O
normal	O
-	O
hearing	O
individuals	O
and	O
53	O
sporadic	O
NSHL	B-DISEASE
patients	O
were	O
also	O
collected	O
and	O
served	O
as	O
controls	O
.	O

34	O
Both	O
are	O
present	O
in	O
immature	O
chondrocytes	O
but	O
disappear	O
as	O
these	O
cartilage	O
precursors	O
differentiate	O
and	O
mature	O
.	O

or	O
sv	O
.	O
)	O
,	O
and	O
spiral	O
ligament	O
and	O
stria	O
vascularis	O
parts	O
(	O
sl	O
.	O

Usher	B-DISEASE
syndrome	I-DISEASE
(	O
USH	B-DISEASE
)	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
combined	O
deafness	B-DISEASE
-	O
blindness	B-DISEASE
,	O
and	O
accounts	O
for	O
approximately	O
50	O
%	O
of	O
all	O
hereditary	O
deafness	B-DISEASE
-	O
blindness	B-DISEASE
cases	O
[	O
5	O
]	O
.	O

Performed	O
the	O
experiments	O
:	O
MG	O
FJRA	O
GG	O
MV	O
MC	O
.	O

The	O
detailed	O
cellular	O
distribution	O
of	O
CD164	B-GENE
at	O
the	O
protein	O
level	O
within	O
the	O
inner	O
ear	O
has	O
however	O
not	O
been	O
determined	O
[	O
20	O
]	O
.	O

Protruding	O
from	O
the	O
apical	O
surface	O
of	O
the	O
hair	O
cells	O
,	O
stereocilia	O
are	O
organized	O
in	O
three	O
rows	O
of	O
decreasing	O
height	O
in	O
a	O
staircase	O
pattern	O
.	O

Moreover	O
,	O
people	O
with	O
different	O
ethnicities	O
may	O
have	O
different	O
mutation	O
spectrums	O
.	O

Thus	O
,	O
USH1J	B-DISEASE
and	O
DFNB48	B-DISEASE
are	O
caused	O
by	O
allelic	O
mutations	O
.	O

No	O
systemic	O
defects	O
were	O
identified	O
.	O

Today	O
,	O
the	O
vast	O
majority	O
of	O
mutations	O
in	O
the	O
MYO7A	B-GENE
are	O
associated	O
with	O
autosomal	O
recessive	O
hearing	B-DISEASE
loss	I-DISEASE
or	O
Usher	B-DISEASE
syndrome	I-DISEASE
.	O

Whole	O
-	O
exome	O
sequencing	O
was	O
carried	O
out	O
on	O
these	O
patients	O
after	O
a	O
failure	O
to	O
identify	O
mutations	O
in	O
the	O
DFNB	B-DISEASE
genes	O
frequently	O
involved	O
.	O

The	O
TNC	B-GENE
and	O
IGFALS	B-GENE
genes	O
are	O
involved	O
in	O
central	O
nervous	O
system	O
development	O
and	O
growth	O
.	O

[	O
11	O
]	O
identified	O
51	O
additional	O
exons	O
at	O
the	O
3	O
'	O
end	O
of	O
USH2A	B-GENE
in	O
2004	O
,	O
the	O
controversy	O
remains	O
whether	O
two	O
alleles	O
with	O
mutations	O
in	O
exons	O
22	O
-	O
73	O
could	O
lead	O
to	O
Usher	B-DISEASE
syndrome	I-DISEASE
.	O

We	O
did	O
not	O
identify	O
a	O
COL9A1	B-GENE
mutation	O
in	O
any	O
patient	O
sample	O
analyzed	O
.	O

USH	B-DISEASE
is	O
usually	O
distinguished	O
by	O
three	O
subtypes	O
[	O
4	O
]	O
.	O

RT	O
-	O
PCR	O
products	O
,	O
harbors	O
the	O
mutation	O
sequence	O
,	O
were	O
cloned	O
into	O
pJET	O
vector	O
;	O
individual	O
clones	O
were	O
picked	O
and	O
then	O
Sanger	O
sequenced	O
.	O

In	O
the	O
case	O
of	O
the	O
trichorhinophalangeal	B-DISEASE
syndrome	I-DISEASE
,	O
gene	O
deletions	O
can	O
cause	O
the	O
disease	O
,	O
which	O
may	O
not	O
be	O
detected	O
by	O
analysis	O
of	O
the	O
panel	O
.	O

Lane	O
3	O
refers	O
to	O
negative	O
control	O
and	O
M	O
indicates	O
size	O
marker	O
.	O

CT	O
images	O
were	O
performed	O
,	O
digitally	O
stored	O
,	O
and	O
displayed	O
by	O
using	O
the	O
Picture	O
Archiving	O
Communication	O
System	O
(	O
PACS	O
)	O
(	O
Centricity	O
;	O
GE	O
Healthcare	O
,	O
Milwaukee	O
,	O
WI	O
)	O
.	O

Mutations	O
in	O
GJB2	B-GENE
,	O
the	O
gene	O
most	O
frequently	O
involved	O
in	O
autosomal	B-DISEASE
recessive	I-DISEASE
deafness	I-DISEASE
in	O
Tunisia	O
[	O
10	O
]	O
-	O
[	O
12	O
]	O
,	O
and	O
mutations	O
in	O
other	O
DFNB	B-DISEASE
genes	O
that	O
had	O
previously	O
been	O
reported	O
in	O
Tunisian	O
deaf	B-DISEASE
patients	O
(	O
Table	O
S1	O
)	O
were	O
first	O
excluded	O
by	O
PCR	O
and	O
Sanger	O
sequencing	O
of	O
these	O
genes	O
in	O
the	O
patients	O
.	O

She	O
suffered	O
from	O
easy	O
bruising	B-DISEASE
and	O
epistaxis	B-DISEASE
.	O

Homo	O
=	O
homozygous	O
.	O

Individuals	O
1	O
-	O
93	O
were	O
run	O
on	O
Illumina	O
Omni1	O
-	O
Quad	O
microarrays	O
.	O

The	O
TMPRSS3	B-GENE
:	O
c	B-VARIANT
.	I-VARIANT
535G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
mutation	O
identified	O
in	O
this	O
family	O
is	O
a	O
missense	O
mutation	O
and	O
leads	O
to	O
an	O
amino	O
acid	O
change	O
from	O
Ala	O
to	O
Thr	O
(	O
p	B-VARIANT
.	I-VARIANT
Ala179Thr	I-VARIANT
)	O
.	O

We	O
now	O
report	O
the	O
results	O
of	O
an	O
8	O
-	O
year	O
study	O
of	O
MYH9	B-DISEASE
-	I-DISEASE
RD	I-DISEASE
in	O
France	O
leading	O
to	O
the	O
identification	O
of	O
a	O
series	O
of	O
109	O
patients	O
from	O
37	O
sporadic	O
cases	O
and	O
39	O
unrelated	O
families	O
from	O
among	O
295	O
patients	O
with	O
inherited	O
macrothrombocytopenia	B-DISEASE
analyzed	O
for	O
mutations	O
in	O
MYH9	B-GENE
in	O
our	O
center	O
after	O
phenotypic	O
exclusion	O
of	O
Bernard	B-DISEASE
-	I-DISEASE
Soulier	I-DISEASE
syndrome	I-DISEASE
,	O
Gray	B-DISEASE
Platelet	I-DISEASE
syndrome	I-DISEASE
,	O
Platelet	B-DISEASE
-	I-DISEASE
Von	I-DISEASE
Willebrand	I-DISEASE
Disease	I-DISEASE
and	O
Paris	B-DISEASE
-	I-DISEASE
Trousseau	I-DISEASE
syndrome	I-DISEASE
.	O

(	O
B	O
-	O
D	O
)	O
Later	O
in	O
development	O
,	O
ELMOD3	B-GENE
immunostaining	O
was	O
detected	O
in	O
the	O
stereocilia	O
bundles	O
and	O
microvilli	O
of	O
sensory	O
cells	O
and	O
also	O
in	O
the	O
supporting	O
cells	O
bodies	O
.	O

norvegicus	O
,	O
G	O
.	O

Responsible	O
mutations	O
were	O
confirmed	O
by	O
segregation	O
analysis	O
.	O

Both	O
affected	O
members	O
carried	O
the	O
mutation	O
.	O

Postlingual	B-DISEASE
progressive	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
,	O
affecting	O
primarily	O
the	O
high	O
frequencies	O
,	O
is	O
the	O
clinical	O
finding	O
in	O
most	O
cases	O
of	O
autosomal	B-DISEASE
dominant	I-DISEASE
nonsyndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
ADNSHL	B-DISEASE
)	O
.	O

For	O
the	O
affected	O
subject	O
II	O
:	O
5	O
,	O
gDNA	O
and	O
examinations	O
were	O
unavailable	O
.	O

The	O
E129K	B-VARIANT
mutation	O
,	O
involving	O
conversion	O
from	O
an	O
acidic	O
amino	O
acid	O
residue	O
(	O
Glu	O
)	O
to	O
an	O
alkaline	O
amino	O
acid	O
residue	O
(	O
Lys	O
)	O
,	O
occurs	O
within	O
the	O
evolutionarily	O
conserved	O
T	O
-	O
box	O
domain	O
in	O
the	O
highly	O
conserved	O
residue	O
found	O
in	O
TBX1	B-GENE
orthologues	O
of	O
human	O
,	O
chimpanzee	O
,	O
rat	O
,	O
mouse	O
,	O
cattle	O
,	O
chicken	O
,	O
Xenopus	O
,	O
and	O
Danio	O
rerio	O
(	O
Figure	O
1	O
B	O
)	O
.	O
We	O
also	O
detected	O
a	O
homozygous	O
single	O
nucleotide	O
polymorphism	O
c	B-VARIANT
.	I-VARIANT
928G	I-VARIANT
-	I-VARIANT
A	I-VARIANT
;	I-VARIANT
p	B-VARIANT
.	I-VARIANT
G310S	I-VARIANT
in	O
one	O
male	O
patient	O
with	O
HDHS	B-DISEASE
,	O
TA	B-DISEASE
,	O
VSD	B-DISEASE
,	O
TGA	B-DISEASE
,	O
pulmonary	B-DISEASE
stenosis	I-DISEASE
(	O
PS	B-DISEASE
)	O
,	O
and	O
atrial	B-DISEASE
septal	I-DISEASE
defect	I-DISEASE
(	O
ASD	B-DISEASE
)	O
.	O

every	O
15	O
days	O
,	O
3	O
times	O
)	O
,	O
which	O
restored	O
penis	O
length	O
to	O
normal	O
[	O
1	O
]	O
,	O
[	O
13	O
]	O
.	O

The	O
identified	O
variants	O
were	O
validated	O
by	O
the	O
resequencing	O
of	O
a	O
second	O
PCR	O
product	O
.	O

The	O
CD2	O
isoform	O
(	O
s	O
)	O
of	O
protocadherin	B-GENE
-	I-GENE
15	I-GENE
make	O
(	O
s	O
)	O
the	O
transient	O
kinociliary	O
links	O
[	O
71	O
]	O
,	O
whereas	O
the	O
protocadherin	B-GENE
-	I-GENE
15	I-GENE
isoforms	O
that	O
make	O
transient	O
interstereocilia	O
links	O
and	O
the	O
tip	O
-	O
links	O
are	O
still	O
unknown	O
.	O

We	O
then	O
confirmed	O
the	O
presence	O
of	O
the	O
novel	O
missense	O
mutations	O
c	B-VARIANT
.	I-VARIANT
6016	I-VARIANT
G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Asp2006Tyr	I-VARIANT
)	O
of	O
the	O
TECTA	B-GENE
gene	O
in	O
exon	O
20	O
of	O
the	O
rest	O
of	O
all	O
13	O
participated	O
subjects	O
with	O
hereditary	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
Figure	O
4	O
B	O
)	O
.	O

Variants	O
did	O
not	O
occur	O
with	O
a	O
frequency	O
of	O
more	O
than	O
15	O
%	O
within	O
all	O
100	O
blindness	O
samples	O
.	O

Table	O
2	O
Details	O
of	O
DFNB1	B-DISEASE
patients	O
in	O
our	O
cohort	O
with	O
cochlear	O
implantation	O
Details	O
of	O
DFNB1	B-DISEASE
patients	O
in	O
our	O
cohort	O
with	O
cochlear	O
implantation	O
Therefore	O
,	O
GJB2	B-GENE
screening	O
and	O
the	O
candidate	O
gene	O
approach	O
based	O
upon	O
phenotype	O
solved	O
43	O
.	O
0	O
%	O
(	O
40	O
/	O
93	O
)	O
of	O
the	O
cases	O
in	O
terms	O
of	O
genetic	O
etiology	O
,	O
leaving	O
53	O
probands	O
(	O
56	O
.	O
3	O
%	O
)	O
unanswered	O
in	O
this	O
population	O
.	O

It	O
is	O
possible	O
that	O
some	O
of	O
the	O
cases	O
presented	O
here	O
could	O
be	O
'	O
co	O
-	O
incidental	O
'	O
carriers	O
for	O
mutations	O
in	O
SLC26A4	B-GENE
which	O
do	O
not	O
contribute	O
to	O
their	O
phenotype	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
or	O
that	O
we	O
could	O
have	O
missed	O
single	O
or	O
multiple	O
exon	O
deletions	O
.	O

We	O
performed	O
WES	O
in	O
individual	O
III	O
-	O
1	O
and	O
this	O
identified	O
two	O
heterozygous	O
candidate	O
COL4A4	B-GENE
missense	O
mutations	O
,	O
c	B-VARIANT
.	I-VARIANT
G2636A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Gly879Glu	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
C4715T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Pro1572Leu	I-VARIANT
)	O
.	O

Alignment	O
of	O
hundreds	O
of	O
thousands	O
of	O
reads	O
on	O
a	O
reference	O
genome	O
is	O
a	O
huge	O
task	O
,	O
and	O
therefore	O
dedicated	O
software	O
needs	O
to	O
proceed	O
in	O
two	O
steps	O
:	O
a	O
fast	O
mapping	O
of	O
the	O
reads	O
is	O
first	O
performed	O
on	O
the	O
genome	O
to	O
identify	O
candidate	O
regions	O
and	O
is	O
followed	O
by	O
a	O
fine	O
alignment	O
of	O
the	O
same	O
reads	O
on	O
those	O
regions	O
.	O

All	O
of	O
them	O
have	O
early	O
onset	O
and	O
profound	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
see	O
audiogram	O
in	O
Additional	O
file	O
1	O
:	O
Figure	O
S1	O
)	O
.	O

Taqman	O
probes	O
used	O
for	O
real	O
time	O
relative	O
expression	O
analysis	O
of	O
ELMOD3	B-GENE
/	O
Elmod3	B-GENE
isoforms	O
.	O

Rivolta	O
et	O
al	O
.	O

PRKDC	B-GENE
encodes	O
DNA	O
-	O
PKcs	O
,	O
which	O
,	O
in	O
complex	O
with	O
Ku	O
,	O
is	O
required	O
for	O
the	O
DNA	O
double	O
-	O
strand	O
break	O
repair	O
mechanism	O
non	O
-	O
homologous	O
end	O
-	O
joining	O
.	O

Because	O
about	O
90	O
%	O
of	O
Chinese	O
EVA	B-DISEASE
patients	O
carried	O
at	O
least	O
one	O
allelic	O
mutation	O
in	O
exons	O
8	O
,	O
19	O
or	O
10	O
of	O
SLC26A4	B-GENE
[	O
17	O
]	O
,	O
[	O
18	O
]	O
,	O
[	O
23	O
]	O
,	O
we	O
designated	O
the	O
three	O
exons	O
as	O
hot	O
spot	O
regions	O
and	O
sequenced	O
these	O
first	O
in	O
all	O
2352	O
patients	O
.	O

Type	O
I	O
(	O
USH1	B-DISEASE
)	O
is	O
defined	O
by	O
profound	B-DISEASE
congenital	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
,	O
onset	O
of	O
RP	B-DISEASE
usually	O
within	O
the	O
first	O
decade	O
of	O
life	O
and	O
an	O
absence	B-DISEASE
of	I-DISEASE
vestibular	I-DISEASE
function	I-DISEASE
.	O

These	O
audiograms	O
represented	O
the	O
latest	O
audiological	O
examination	O
computed	O
in	O
April	O
2012	O
when	O
subjects	O
were	O
respectively	O
:	O
I	O
:	O
1	O
52	O
years	O
old	O
(	O
y	O
.	O
o	O
.	O
)	O
,	O
I	O
:	O
2	O
53	O
y	O
.	O
o	O
.	O
,	O
II	O
:	O
3	O
19	O
y	O
.	O
o	O
.	O
,	O
II	O
:	O
4	O
18	O
y	O
.	O
o	O
.	O
,	O
II	O
:	O
5	O
16	O
y	O
.	O
o	O
.	O
,	O
II	O
:	O
6	O
11	O
y	O
.	O
o	O
.	O

A	O
bigger	O
band	O
was	O
observed	O
corresponding	O
to	O
the	O
heteroduplex	O
from	O
the	O
two	O
transcripts	O
(	O
band	O
D	O
)	O
.	O

Mutations	O
identified	O
in	O
SCN5A	B-GENE
,	O
KCNE1	B-GENE
or	O
KCNE2	B-GENE
DK	O
:	O
Only	O
seen	O
in	O
patients	O
of	O
Danish	O
origin	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
distinguish	O
possible	O
phenotypic	O
differences	O
between	O
different	O
TMPRSS3	B-GENE
mutations	O
.	O

3	O
A	O
,	O
B	O
)	O
.	O

After	O
filtering	O
all	O
the	O
variants	O
,	O
obtained	O
with	O
data	O
analysis	O
and	O
filter	O
settings	O
as	O
described	O
in	O
'	O
Methods	O
'	O
,	O
we	O
obtained	O
a	O
list	O
of	O
171	O
variants	O
.	O

However	O
,	O
due	O
to	O
the	O
small	O
cohort	O
size	O
our	O
estimate	O
of	O
diagnostic	O
yield	O
has	O
a	O
broad	O
CI	O
.	O

Neuropsychiatric	O
manifestations	O
are	O
reported	O
in	O
the	O
third	O
decade	O
.	O

It	O
was	O
also	O
analysed	O
functionally	O
using	O
minigenes	O
,	O
by	O
cloning	O
the	O
normal	O
and	O
variant	O
alleles	O
into	O
the	O
splicing	O
reporter	O
USR13	O
.	O

We	O
also	O
recorded	O
the	O
presence	O
or	O
absence	O
of	O
any	O
extra	O
renal	O
manifestations	O
such	O
as	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
ocular	O
defects	O
a	O
priori	O
and	O
post	O
priori	O
.	O

By	O
contrast	O
,	O
only	O
six	O
pathogenic	O
mutations	O
are	O
known	O
outside	O
the	O
GJB2	B-GENE
coding	O
sequence	O
.	O

Three	O
Turkish	O
families	O
(	O
295	O
,	O
572	O
,	O
667	O
)	O
were	O
included	O
based	O
on	O
inner	B-DISEASE
ear	I-DISEASE
anomalies	I-DISEASE
detected	O
in	O
probands	O
.	O

Filtering	O
the	O
1609	O
variants	O
for	O
functional	O
effect	O
(	O
S2	O
Fig	O
)	O
,	O
one	O
variant	O
passed	O
through	O
the	O
filter	O
i	O
.	O
e	O
.	O

Mice	O
homozygous	O
for	O
the	O
targeted	O
deletion	O
of	O
homer2	B-GENE
(	O
Homer2	B-GENE
-	O
/	O
-	O
mice	O
generated	O
by	O
deletion	O
of	O
exon	O
3	O
[	O
32	O
]	O
)	O
show	O
extensive	O
behavioral	O
and	O
neurochemical	O
similarities	O
to	O
cocaine	O
or	O
alcohol	O
-	O
sensitized	O
animals	O
,	O
and	O
demonstrate	O
Homer2	B-GENE
involvement	O
in	O
appetitive	O
pathways	O
underlying	O
responses	O
to	O
those	O
drugs	O
and	O
their	O
induced	O
behavioral	O
/	O
cellular	O
neuroplasticity	O
within	O
the	O
nucleus	O
accumbens	O
[	O
33	O
,	O
34	O
]	O
.	O

The	O
range	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
was	O
described	O
as	O
follows	O
depending	O
on	O
the	O
PTA	O
:	O
low	O
frequency	O
,	O
125	O
-	O
1000	O
Hz	O
;	O
mid	O
-	O
frequency	O
,	O
1000	O
-	O
4000	O
Hz	O
;	O
and	O
high	O
frequency	O
,	O
4000	O
-	O
8000	O
Hz	O
.	O

No	O
HA	O
antigen	O
was	O
detected	O
in	O
AB8	O
/	O
13	O
cells	O
transfected	O
with	O
a	O
construct	O
expressing	O
the	O
empty	O
vectors	O
.	O

AD	B-DISEASE
-	I-DISEASE
MED	I-DISEASE
is	O
a	O
much	O
more	O
heterogeneous	O
disorder	O
,	O
both	O
at	O
the	O
phenotypic	O
and	O
genetic	O
levels	O
.	O

Thus	O
,	O
the	O
splicing	O
alteration	O
of	O
this	O
mutation	O
(	O
non	O
-	O
splicing	O
of	O
intron	O
3	O
)	O
was	O
proved	O
.	O

The	O
row	O
data	O
were	O
mapped	O
using	O
the	O
Burrows	O
Wheeler	O
Aligner	O
[	O
36	O
]	O
,	O
the	O
variants	O
were	O
called	O
using	O
the	O
Unified	O
Genotyper	O
,	O
and	O
the	O
data	O
underwent	O
further	O
processing	O
and	O
quality	O
control	O
[	O
35	O
]	O
,	O
[	O
36	O
]	O
.	O

A	O
.	O

The	O
eye	O
fundus	O
was	O
typical	O
of	O
RP	B-DISEASE
with	O
a	O
reduction	O
of	O
10	O
deg	O
in	O
OD	O
and	O
20	O
deg	O
in	O
OI	O
.	O

In	O
this	O
study	O
,	O
the	O
entire	O
coding	O
regions	O
of	O
the	O
TCOF1	B-GENE
gene	O
,	O
including	O
newly	O
described	O
exons	O
6A	O
and	O
16A	O
,	O
were	O
sequenced	O
in	O
46	O
unrelated	O
subjects	O
suspected	O
of	O
TCS	B-DISEASE
clinical	O
indication	O
.	O

All	O
the	O
DNA	O
fragments	O
were	O
verified	O
by	O
direct	O
sequencing	O
.	O

Likewise	O
,	O
all	O
the	O
referrals	O
came	O
from	O
geneticists	O
within	O
clinical	O
genetics	O
departments	O
and	O
also	O
included	O
three	O
referrals	O
from	O
members	O
of	O
the	O
ESDN	O
panel	O
.	O

Difficulties	O
arise	O
from	O
the	O
low	O
and	O
variable	O
coverage	O
in	O
many	O
other	O
targeted	O
assays	O
.	O

In	O
nonsyndromic	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
,	O
75	O
-	O
80	O
%	O
of	O
patients	O
show	O
an	O
autosomal	O
recessive	O
inheritance	O
and	O
18	O
%	O
of	O
patients	O
are	O
of	O
autosomal	O
dominant	O
inheritance	O
[	O
2	O
,	O
4	O
]	O
.	O

In	O
the	O
DNA	O
binding	O
domains	O
,	O
the	O
molecular	O
features	O
of	O
amino	O
acids	O
such	O
as	O
electric	O
property	O
and	O
acidity	O
significantly	O
influence	O
the	O
maintenance	O
of	O
the	O
structural	O
conformation	O
of	O
the	O
protein	O
[	O
34	O
,	O
35	O
]	O
.	O

Our	O
study	O
on	O
the	O
other	O
hand	O
,	O
demonstrates	O
that	O
when	O
seen	O
as	O
compound	O
mutations	O
,	O
they	O
can	O
also	O
cause	O
JLNS	B-DISEASE
.	O

The	O
GAP	O
reaction	O
was	O
performed	O
in	O
a	O
buffer	O
that	O
contained	O
25	O
mM	O
HEPES	O
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
2	O
.	O
5	O
mM	O
MgCl	O
2	O
,	O
100	O
mM	O
NaCl	O
,	O
1	O
mM	O
dithiothreitol	O
,	O
2	O
mM	O
ATP	O
,	O
1	O
mM	O
GTP	O
and	O
the	O
pre	O
-	O
loaded	O
Arl2	O
[	O
gamma	O
-	O
32	O
P	O
]	O
GTP	O
.	O

Therefore	O
,	O
we	O
overexpressed	O
wild	O
type	O
NARS2	B-GENE
in	O
patient	O
fibroblasts	O
.	O

Her	O
retinal	O
phenotype	O
was	O
indeed	O
more	O
severe	O
than	O
that	O
of	O
her	O
affected	O
relatives	O
who	O
were	O
homozygous	O
for	O
mutations	O
in	O
either	O
of	O
these	O
two	O
genes	O
[	O
5	O
]	O
.	O

In	O
the	O
Pakistani	O
DFNB2	B-GENE
family	O
,	O
one	O
deaf	O
patient	O
(	O
41	O
years	O
old	O
)	O
had	O
slightly	O
subnormal	O
rod	O
and	O
cone	O
responses	O
and	O
a	O
suboptimal	O
quality	O
electroretinogram	O
(	O
ERG	O
)	O
.	O

EVA	B-DISEASE
diagnosis	O
was	O
based	O
on	O
findings	O
of	O
a	O
diameter	O
of	O
>	O
1	O
.	O
5	O
mm	O
at	O
the	O
midpoint	O
between	O
the	O
common	O
crus	O
and	O
the	O
external	O
aperture	O
[	O
27	O
]	O
or	O
other	O
inner	O
ear	O
malformations	O
to	O
evaluate	O
Pendred	B-DISEASE
syndrome	I-DISEASE
.	O

Thus	O
,	O
the	O
diagnosis	O
is	O
not	O
always	O
easily	O
performed	O
due	O
to	O
phenotypic	O
and	O
genetic	O
overlap	O
.	O

The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O
http	O
:	O
/	O
/	O
www	O
.	O
biomedcentral	O
.	O
com	O
/	O
1471	O
-	O
2350	O
/	O
15	O
/	O
46	O
/	O
prepub	O
Pedigrees	O
of	O
two	O
families	O
with	O
ARNSHL	B-DISEASE
,	O
and	O
audiogram	O
of	O
patient	O
SR	O
-	O
209	O
.	O

Probands	O
were	O
characterised	O
as	O
having	O
prelingual	O
,	O
bilateral	O
hearing	B-DISEASE
loss	I-DISEASE
that	O
could	O
not	O
be	O
attributed	O
to	O
infection	O
or	O
trauma	O
.	O

Sanger	O
sequencing	O
was	O
employed	O
to	O
verify	O
the	O
identified	O
potential	O
disease	O
-	O
causing	O
variants	O
with	O
ABI3500	O
sequencer	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Each	O
sample	O
was	O
barcoded	O
for	O
multiplexing	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
at	O
the	O
Medical	O
Faculty	O
of	O
W	O
u	O
rzburg	O
University	O
.	O

Genetic	O
analysis	O
showed	O
the	O
mutation	O
Cys342Agr	B-VARIANT
in	O
the	O
exxon	O
10	O
of	O
FGFR2	B-GENE
in	O
heterozygosis	O
(	O
Fig	O
.	O

In	O
several	O
occasions	O
the	O
progression	O
of	O
heterozygous	O
patients	O
to	O
CRF	B-DISEASE
and	O
even	O
ESKD	B-DISEASE
has	O
been	O
challenged	O
by	O
the	O
suggestion	O
that	O
a	O
second	O
mutation	O
might	O
have	O
been	O
inherited	O
in	O
-	O
trans	O
in	O
the	O
same	O
gene	O
which	O
accounted	O
for	O
the	O
adverse	O
outcome	O
.	O

G48S	B-VARIANT
is	O
located	O
in	O
the	O
first	O
immunoglobulin	O
-	O
like	O
domain	O
,	O
which	O
is	O
involved	O
in	O
the	O
receptor	O
autoinhibition	O
,	O
and	O
interacts	O
with	O
the	O
second	O
and	O
the	O
third	O
immunoglobulin	O
-	O
like	O
domains	O
.	O

(	O
C	O
)	O
Sequence	O
analysis	O
of	O
OPA1	B-GENE
gene	O
in	O
Family	O
2	O
discloses	O
the	O
point	O
mutation	O
c	B-VARIANT
.	I-VARIANT
985	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
in	O
affected	O
members	O
.	O

Fifteen	O
were	O
classified	O
as	O
USH1	B-DISEASE
based	O
on	O
audiological	O
tests	O
,	O
vestibular	O
function	O
,	O
and	O
ophthalmologic	O
evaluations	O
,	O
whereas	O
four	O
were	O
non	O
-	O
classified	O
because	O
of	O
lack	O
of	O
data	O
.	O

The	O
enormous	O
potential	O
and	O
clinical	O
utility	O
of	O
NGS	O
is	O
highlighted	O
by	O
a	O
high	O
diagnostic	O
yield	O
achieved	O
by	O
the	O
identification	O
of	O
mutations	O
of	O
all	O
modes	O
of	O
inheritance	O
,	O
including	O
de	O
novo	O
mutations	O
.	O

The	O
variant	O
c	B-VARIANT
.	I-VARIANT
12528	I-VARIANT
-	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
intron	O
61	O
)	O
was	O
detected	O
in	O
two	O
families	O
:	O
in	O
a	O
homozygous	O
state	O
in	O
RP952	O
and	O
in	O
trans	O
to	O
c	B-VARIANT
.	I-VARIANT
10301delT	I-VARIANT
in	O
RP1590	O
(	O
Table	O
3	O
)	O
.	O

Cochlear	O
implantation	O
improves	O
speech	O
perception	O
and	O
synchronous	O
activation	O
of	O
auditory	O
pathways	O
by	O
bypassing	O
the	O
site	O
of	O
lesion	O
.	O

Following	O
informed	O
consent	O
,	O
three	O
-	O
five	O
milliliter	O
of	O
peripheral	O
blood	O
sample	O
was	O
collected	O
in	O
a	O
Vacutainer	O
EDTA	O
TM	O
tube	O
(	O
Beckton	O
-	O
Dickinson	O
,	O
Franklin	O
Lakes	O
,	O
NJ	O
)	O
from	O
each	O
individual	O
for	O
genomic	O
DNA	O
isolation	O
using	O
a	O
Wizard	O
(	O
r	O
)	O
Genomic	O
DNA	O
Extraction	O
Kit	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
)	O
.	O

Double	O
-	O
staining	O
shows	O
that	O
WT	O
CLRN1	O
-	O
HA	O
(	O
F	O
)	O
and	O
the	O
p	B-VARIANT
.	I-VARIANT
L54P	I-VARIANT
mutated	O
CLRN1	O
-	O
HA	O
(	O
C	O
)	O
colocalize	O
(	O
yellow	O
)	O
with	O
the	O
plasma	O
membrane	O
marker	O
whereas	O
the	O
known	O
mutation	O
p	B-VARIANT
.	I-VARIANT
N48K	I-VARIANT
(	O
I	O
)	O
does	O
not	O
colocalize	O
with	O
the	O
plasma	O
membrane	O
marker	O
.	O

The	O
motor	O
domain	O
(	O
amino	O
acids	O
1	O
,	O
224	O
-	O
1	O
,	O
899	O
)	O
contains	O
two	O
binding	O
sites	O
for	O
ATP	O
and	O
actin	O
,	O
the	O
switches	O
I	O
and	O
II	O
helix	O
,	O
a	O
relay	O
helix	O
,	O
an	O
SH3	O
helix	O
,	O
an	O
SH1	O
/	O
SH2	O
helix	O
,	O
and	O
a	O
converter	O
domain	O
.	O

Taking	O
into	O
account	O
the	O
power	O
of	O
linkage	O
studies	O
coupled	O
with	O
massively	O
parallel	O
sequencing	O
technologies	O
,	O
we	O
decided	O
to	O
apply	O
these	O
approaches	O
to	O
identify	O
the	O
causative	O
mutation	O
underlying	O
NSHHL	B-DISEASE
in	O
this	O
Qatari	O
family	O
.	O

These	O
mutations	O
are	O
likely	O
to	O
cause	O
severe	O
deteriorations	O
or	O
loss	O
of	O
WFS1	B-GENE
protein	O
function	O
.	O

The	O
GATA3	B-GENE
gene	O
is	O
20	O
kb	O
long	O
,	O
containing	O
six	O
exons	O
6	O
)	O
,	O
and	O
encodes	O
a	O
444	O
-	O
amino	O
acid	O
transcription	O
factor	O
comprising	O
two	O
transactivation	O
domains	O
(	O
TA1	O
,	O
TA2	O
)	O
and	O
two	O
zinc	O
finger	O
domains	O
(	O
ZF1	O
,	O
ZF2	O
)	O
7	O
)	O
.	O

Ogilvie	O
and	O
colleagues	O
initially	O
used	O
phylogenetic	O
profiling	O
to	O
identify	O
the	O
CI	O
assembly	O
factor	O
NDUFAF2	B-GENE
17	O
.	O

Total	O
RNA	O
was	O
extracted	O
from	O
the	O
transfected	O
HeLa	O
cells	O
using	O
an	O
RNeasy	O
Mini	O
Kit	O
(	O
Qiagen	O
,	O
Hilden	O
,	O
Germany	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Moreover	O
,	O
the	O
rate	O
-	O
induced	O
latency	O
shifts	O
of	O
ABR	O
wave	O
I	O
recorded	O
from	O
newborns	O
show	O
no	O
,	O
or	O
only	O
very	O
slight	O
,	O
differences	O
compared	O
to	O
adult	O
values	O
(	O
Salamy	O
et	O
al	O
.	O

This	O
result	O
indicates	O
that	O
the	O
space	O
around	O
residue	O
69	O
can	O
become	O
unstable	O
as	O
a	O
result	O
of	O
the	O
p	B-VARIANT
.	I-VARIANT
P69H	I-VARIANT
mutation	O
.	O

Analyzed	O
the	O
data	O
:	O
PLC	O
YHL	O
.	O

*	O
:	O
median	O
(	O
range	O
)	O
;	O
*	O
*	O
:	O
mean	O
value	O
+	O
-	O
SD	O
;	O
*	O
*	O
*	O
:	O
normal	O
ranges	O
.	O

The	O
parents	O
are	O
first	O
cousins	O
,	O
and	O
two	O
of	O
their	O
three	O
offspring	O
,	O
who	O
were	O
seen	O
by	O
us	O
at	O
the	O
ages	O
of	O
8	O
years	O
and	O
8	O
months	O
,	O
have	O
bilateral	O
profound	O
SNHL	B-DISEASE
,	O
which	O
was	O
detected	O
at	O
infancy	O
.	O

2002	O
)	O
.	O

Since	O
the	O
initial	O
reports	O
of	O
the	O
association	O
of	O
MYH9	B-GENE
mutations	O
and	O
inherited	O
macrothrombocytopenia	B-DISEASE
,	O
a	O
large	O
number	O
of	O
isolated	O
cases	O
or	O
series	O
have	O
been	O
published	O
.	O

This	O
mutation	O
was	O
not	O
found	O
in	O
the	O
other	O
unaffected	O
relatives	O
(	O
II	O
:	O
1	O
,	O
III	O
:	O
2	O
,	O
IV	O
:	O
1	O
,	O
and	O
IV	O
:	O
2	O
)	O
in	O
the	O
healthy	O
controls	O
(	O
Figure	O
4B	O
)	O
.	O

Of	O
these	O
14	O
novel	O
variants	O
,	O
7	O
were	O
interpreted	O
as	O
mutations	O
(	O
1	O
de	O
novo	O
missense	O
,	O
2	O
nonsense	O
,	O
2	O
splice	O
site	O
,	O
2	O
frameshift	O
)	O
and	O
7	O
were	O
deemed	O
to	O
be	O
of	O
uncertain	O
pathogenicity	O
(	O
4	O
missense	O
,	O
1	O
synonymous	O
,	O
2	O
splice	O
site	O
;	O
table	O
1	O
)	O
.	O

To	O
date	O
,	O
five	O
USH1	B-DISEASE
genes	O
have	O
been	O
identified	O
:	O
MYO7A	B-GENE
(	O
USH1B	B-GENE
)	O
,	O
CDH23	B-GENE
(	O
USH1D	B-GENE
)	O
,	O
PCDH15	B-GENE
(	O
USH1F	B-GENE
)	O
,	O
USH1C	B-GENE
(	O
USH1C	B-GENE
)	O
,	O
and	O
USH1G	B-GENE
(	O
USH1G	B-GENE
)	O
.	O

C	O
:	O
Normal	O
adult	O
(	O
I	O
:	O
2	O
from	O
family	O
A	O
)	O
.	O

In	O
the	O
USH2A	B-GENE
gene	O
,	O
34	O
sequence	O
variants	O
were	O
identified	O
in	O
25	O
patients	O
.	O

Affected	O
individuals	O
are	O
shaded	O
.	O

None	O
WFS1	B-GENE
mutations	O
was	O
found	O
in	O
the	O
100	O
normal	O
unrelated	O
controls	O
screened	O
by	O
sequencing	O
.	O

The	O
recording	O
electrode	O
(	O
a	O
cotton	O
wick	O
containing	O
0	O
.	O
9	O
%	O
NaCl	O
w	O
/	O
v	O
connected	O
to	O
a	O
silver	O
wire	O
)	O
was	O
positioned	O
on	O
the	O
surface	O
of	O
the	O
eye	O
,	O
and	O
the	O
indifferent	O
electrode	O
(	O
silver	O
wire	O
)	O
in	O
the	O
abdomen	O
.	O

Genetic	O
factors	O
are	O
responsible	O
for	O
approximately	O
50	O
%	O
of	O
cases	O
with	O
congenital	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
[	O
1	O
,	O
2	O
]	O
.	O

(	O
A	O
)	O
CL4	O
epithelial	O
cells	O
were	O
co	O
-	O
transfected	O
with	O
GFP	O
-	O
ELMOD3	B-GENE
and	O
un	O
-	O
tagged	O
Espin	O
expression	O
vectors	O
.	O

These	O
findings	O
support	O
a	O
role	O
for	O
Ca	O
V	O
1	O
.	O
3	O
in	O
normal	O
adrenal	O
cortex	O
and	O
APA	B-DISEASE
.	O

A	O
summary	O
of	O
the	O
exome	O
sequencing	O
results	O
for	O
the	O
two	O
families	O
is	O
provided	O
in	O
Table	O
1	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
T123N	I-VARIANT
mutation	O
was	O
found	O
in	O
4	O
subjects	O
but	O
,	O
based	O
on	O
our	O
recent	O
study	O
,	O
is	O
not	O
likely	O
to	O
be	O
a	O
pathologic	O
mutation	O
[	O
5	O
]	O
.	O

Pedigree	O
structure	O
of	O
the	O
family	O
with	O
USH2	B-DISEASE
/	O
RP	B-DISEASE
.	O

Targeted	O
genomic	O
enrichment	O
and	O
massively	O
parallel	O
sequencing	O
(	O
TGE	O
+	O
MPS	O
)	O
have	O
revolutionized	O
the	O
field	O
of	O
hereditary	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
HHL	B-DISEASE
)	O
by	O
making	O
comprehensive	O
genetic	O
testing	O
for	O
deafness	B-DISEASE
a	O
clinical	O
reality	O
and	O
by	O
accelerating	O
the	O
discovery	O
of	O
novel	O
deafness	B-DISEASE
-	O
causing	O
genes	O
[	O
1	O
,	O
2	O
]	O
.	O

The	O
chip	O
included	O
all	O
known	O
mutations	O
from	O
the	O
coding	O
region	O
and	O
adjacent	O
intronic	O
sequences	O
of	O
arRP	B-DISEASE
genes	O
.	O

Using	O
the	O
Agilent	O
4x180K	O
array	O
,	O
we	O
detected	O
an	O
additional	O
homozygous	O
deletion	O
in	O
syndromic	O
patient	O
95	O
.	O

Autosomal	B-DISEASE
recessive	I-DISEASE
nonsyndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
ARNSHL	B-DISEASE
)	O
is	O
the	O
most	O
common	O
type	O
and	O
accounts	O
for	O
~	O
80	O
%	O
of	O
cases	O
of	O
inherited	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Although	O
TBX1	B-GENE
mutations	O
have	O
been	O
identified	O
in	O
patients	O
with	O
22q11	O
.	O
2	O
deletion	O
syndrome	O
(	O
22q11	O
.	O
2DS	O
)	O
-	O
like	O
phenotypes	O
including	O
characteristic	O
craniofacial	O
features	O
,	O
cardiovascular	B-DISEASE
anomalies	I-DISEASE
,	O
hypoparathyroidism	B-DISEASE
,	O
and	O
thymic	B-DISEASE
hypoplasia	I-DISEASE
,	O
the	O
frequency	O
of	O
TBX1	B-GENE
mutations	O
remains	O
rare	O
in	O
deletion	O
-	O
negative	O
patients	O
.	O

The	O
genetic	O
heterogeneity	O
is	O
a	O
major	O
hurdle	O
to	O
the	O
efficient	O
discovery	O
of	O
disease	O
-	O
causing	O
genes	O
.	O

USH1	B-DISEASE
is	O
the	O
most	O
severe	O
form	O
of	O
USH	B-DISEASE
:	O
patients	O
display	O
a	O
congenital	O
and	O
profound	O
deafness	B-DISEASE
associated	O
with	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
as	O
well	O
as	O
prepubertal	O
onset	O
of	O
progressive	O
RP	B-DISEASE
[	O
2	O
]	O
,	O
[	O
3	O
]	O
.	O

None	O
had	O
a	O
normal	O
platelet	O
count	O
over	O
150	O
x	O
10	O
9	O
/	O
L	O
,	O
as	O
has	O
been	O
reported	O
in	O
very	O
rare	O
cases	O
(	O
Pecci	O
et	O
al	O
.	O

Both	O
of	O
the	O
misspliced	O
isoforms	O
resulted	O
in	O
premature	O
termination	O
of	O
the	O
message	O
and	O
were	O
only	O
detected	O
after	O
inhibition	O
of	O
nonsense	O
mediated	O
decay	O
.	O

Genes	O
responsible	O
for	O
inherited	O
deafness	B-DISEASE
(	O
DFN	O
)	O
with	O
neighbouring	O
microsatellite	O
markers	O
used	O
in	O
the	O
subgenome	O
scan	O
.	O

As	O
a	O
positive	O
control	O
,	O
we	O
used	O
alpha	O
-	O
actinin	O
,	O
which	O
is	O
known	O
to	O
bind	O
to	O
F	O
-	O
actin	O
.	O

Growing	O
evidence	O
suggests	O
that	O
these	O
proteins	O
are	O
organized	O
in	O
a	O
protein	O
"	O
interactome	O
"	O
[	O
11	O
-	O
13	O
]	O
in	O
the	O
inner	O
ear	O
and	O
the	O
retina	O
,	O
which	O
is	O
critical	O
for	O
the	O
development	O
,	O
maintenance	O
,	O
and	O
correct	O
function	O
of	O
the	O
sensorineural	O
cells	O
.	O

No	O
potential	O
conflicts	O
of	O
interest	O
relevant	O
to	O
this	O
article	O
were	O
reported	O
.	O

and	O
Q	O
.	O
Z	O
.	O

Relatives	O
of	O
patients	O
were	O
not	O
included	O
in	O
this	O
analysis	O
(	O
each	O
nuclear	O
and	O
/	O
or	O
extended	O
family	O
was	O
represented	O
by	O
only	O
the	O
proband	O
)	O
,	O
but	O
no	O
exclusions	O
were	O
otherwise	O
made	O
based	O
upon	O
age	O
,	O
age	O
of	O
onset	O
,	O
phenotype	O
or	O
previous	O
testing	O
.	O

Palmer	O
;	O
Z	O
.	O

II3	O
,	O
born	O
in	O
1968	O
,	O
was	O
medically	O
treated	O
until	O
the	O
age	O
of	O
3	O
,	O
when	O
she	O
was	O
submitted	O
to	O
a	O
Soave	O
operation	O
(	O
without	O
colostomy	O
)	O
and	O
finally	O
diagnosed	O
with	O
L	O
-	O
HSCR	B-DISEASE
.	O

USH2A	B-GENE
truncating	O
and	O
splice	O
-	O
site	O
mutations	O
+	O
:	O
Denotes	O
pathogenic	O
mutations	O
.	O

The	O
wild	O
-	O
type	O
residues	O
are	O
depicted	O
in	O
green	O
,	O
while	O
the	O
mutant	O
residues	O
are	O
shown	O
in	O
red	O
.	O

However	O
,	O
among	O
these	O
patients	O
,	O
Patient	O
1	O
-	O
II	O
-	O
1	O
had	O
the	O
thinnest	O
RNFL	O
in	O
the	O
peripheral	O
region	O
of	O
the	O
vertical	O
scan	O
.	O

Four	O
rare	O
heterozygous	O
variants	O
,	O
predicted	O
to	O
be	O
pathogenic	O
,	O
in	O
known	O
deafness	B-DISEASE
genes	O
were	O
detected	O
in	O
12	O
families	O
where	O
homozygous	O
causative	O
variants	O
were	O
already	O
identified	O
.	O

This	O
finding	O
is	O
in	O
agreement	O
with	O
previous	O
studies	O
[	O
16	O
,	O
32	O
-	O
35	O
]	O
that	O
reported	O
the	O
identification	O
of	O
molecular	O
variants	O
in	O
a	O
gene	O
not	O
corresponding	O
to	O
the	O
clinical	O
USH	B-DISEASE
type	O
and	O
suggests	O
that	O
the	O
procedure	O
of	O
molecular	O
genetics	O
should	O
also	O
include	O
genes	O
inconsistent	O
with	O
the	O
traditional	O
clinical	O
classification	O
of	O
USH	B-DISEASE
.	O

The	O
patients	O
carried	O
in	O
the	O
USH2A	B-GENE
gene	O
the	O
single	O
sequence	O
variant	O
c	B-VARIANT
.	I-VARIANT
4144T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Trp1382Arg	I-VARIANT
)	O
,	O
which	O
was	O
first	O
supposed	O
to	O
be	O
present	O
in	O
homozygosis	O
.	O

This	O
was	O
particularly	O
the	O
case	O
for	O
those	O
patients	O
in	O
whom	O
we	O
identified	O
MATN3	B-GENE
,	O
COL9A2	B-GENE
,	O
or	O
COL9A3	B-GENE
mutations	O
[	O
i	O
.	O
e	O
.	O
,	O
18	O
/	O
19	O
(	O
94	O
%	O
)	O
patients	O
with	O
these	O
mutations	O
had	O
a	O
correct	O
diagnosis	O
upon	O
referral	O
to	O
ESDN	O
;	O
see	O
Table	O
3	O
]	O
.	O

Coding	O
region	O
and	O
splice	O
junction	O
variants	O
(	O
6bp	O
)	O
common	O
to	O
probands	O
II	O
.	O
1	O
and	O
II	O
.	O
3	O
were	O
filtered	O
using	O
the	O
Annovar	O
"	O
filtered	O
annotation	O
"	O
functions	O
tool	O
[	O
59	O
]	O
.	O

Targeted	O
next	O
-	O
generation	O
sequencing	O
provided	O
a	O
comprehensive	O
and	O
efficient	O
diagnosis	O
for	O
known	O
deafness	B-DISEASE
genes	O
.	O

To	O
investigate	O
the	O
relation	O
between	O
genes	O
involved	O
in	O
TJ	O
function	O
and	O
hereditary	O
loss	B-DISEASE
of	I-DISEASE
sensorineural	I-DISEASE
hearing	I-DISEASE
in	O
the	O
Korean	O
population	O
,	O
we	O
selected	O
the	O
TJP2	B-GENE
and	O
CLDN14	B-GENE
genes	O
as	O
candidates	O
for	O
gene	O
screening	O
of	O
135	O
Korean	O
individuals	O
.	O

We	O
adopted	O
a	O
stepwise	O
approach	O
to	O
identify	O
the	O
causal	O
variants	O
for	O
each	O
patient	O
.	O

For	O
the	O
four	O
patients	O
with	O
DOA	O
+	O
features	O
but	O
no	O
multiple	O
mtDNA	O
deletions	O
on	O
long	O
-	O
range	O
PCR	O
,	O
COX	O
-	O
negative	O
fibres	O
were	O
also	O
not	O
detected	O
in	O
their	O
muscle	O
biopsies	O
(	O
mean	O
age	O
=	O
45	O
.	O
5	O
years	O
,	O
SD	O
=	O
7	O
.	O
9	O
years	O
,	O
range	O
=	O
35	O
.	O
0	O
-	O
54	O
.	O
0	O
years	O
)	O
.	O

Membranes	O
were	O
then	O
washed	O
three	O
times	O
in	O
TBS	O
-	O
Tween	O
-	O
0	O
.	O
1	O
%	O
and	O
incubated	O
with	O
1	O
:	O
10	O
,	O
000	O
horseradish	O
peroxidase	O
-	O
conjugated	O
rabbit	O
anti	O
-	O
mouse	O
secondary	O
antibody	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

For	O
various	O
primers	O
some	O
modifications	O
were	O
applied	O
.	O

The	O
VariantClassifier	O
algorithm	O
[	O
41	O
]	O
was	O
used	O
to	O
add	O
the	O
following	O
information	O
for	O
surviving	O
variants	O
:	O
gene	O
name	O
,	O
the	O
predicted	O
effect	O
on	O
gene	O
(	O
at	O
or	O
near	O
splice	O
site	O
)	O
and	O
protein	O
function	O
(	O
missense	O
,	O
nonsense	O
,	O
truncation	O
)	O
,	O
context	O
(	O
coding	O
or	O
non	O
-	O
coding	O
sequence	O
)	O
,	O
and	O
if	O
it	O
is	O
in	O
coding	O
sequence	O
,	O
the	O
amino	O
acid	O
change	O
.	O

Two	O
cases	O
were	O
SLC26A4	B-GENE
compound	O
heterozygous	O
or	O
homozygous	O
mutations	O
with	O
a	O
GJB2	B-GENE
heterozygous	O
mutation	O
.	O

We	O
also	O
thank	O
the	O
McGill	O
University	O
and	O
Genome	O
Quebec	O
Innovation	O
Center	O
,	O
the	O
IRCM	O
Molecular	O
Biology	O
and	O
Functional	O
Genomics	O
Platform	O
and	O
Denis	O
Faubert	O
,	O
Jos	O
e	O
e	O
Champagne	O
,	O
Sylvain	O
Tessier	O
and	O
Marguerite	O
Boulos	O
of	O
the	O
IRCM	O
Proteomics	O
Discovery	O
Platform	O
for	O
their	O
services	O
and	O
Dr	O
Fran	O
c	O
ois	O
Robert	O
and	O
Alexis	O
Blanchet	O
-	O
Cohen	O
for	O
bioinformatics	O
support	O
.	O

'	O
[	O
?	O
]	O
'	O
indicates	O
absence	O
of	O
the	O
9VNTR	O
(	O
t	O
,	O
t	O
)	O
allele	O
.	O

II	O
:	O
5	O
is	O
a	O
female	O
patient	O
diagnosed	O
with	O
bilateral	O
moderate	O
to	O
severe	O
NSHHL	B-DISEASE
since	O
the	O
girl	O
was	O
4	O
y	O
.	O
o	O
.	O

On	O
the	O
other	O
hand	O
,	O
WFS1	B-GENE
mutation	O
was	O
not	O
identified	O
in	O
some	O
patients	O
,	O
providing	O
evidence	O
of	O
genetic	O
heterogeneity	O
for	O
this	O
disease	O
.	O

By	O
contrast	O
,	O
the	O
patients	O
with	O
WFS1	B-GENE
variations	O
associated	O
with	O
either	O
a	O
single	O
amino	O
acid	O
substitution	O
or	O
deletion	O
presented	O
with	O
variable	O
disease	O
progressions	O
(	O
Figure	O
S2	O
in	O
File	O
S1	O
)	O
.	O

CREBBP	B-GENE
is	O
also	O
involved	O
in	O
multiple	O
signaling	O
pathways	O
and	O
in	O
other	O
cellular	O
functions	O
such	O
as	O
DNA	O
repair	O
,	O
cell	O
growth	O
,	O
differentiation	O
,	O
apoptosis	O
,	O
and	O
tumor	O
suppression	O
[	O
26	O
]	O
.	O

We	O
established	O
a	O
new	O
strategy	O
that	O
detects	O
SLC26A4	B-GENE
mutations	O
prior	O
to	O
the	O
temporal	O
bone	O
CT	O
scan	O
to	O
find	O
EVA	B-DISEASE
and	O
inner	B-DISEASE
ear	I-DISEASE
malformation	I-DISEASE
patients	O
.	O

Ahmed	O
et	O
al	O
.	O

We	O
clinically	O
evaluated	O
nine	O
unrelated	O
patients	O
(	O
six	O
males	O
and	O
three	O
females	O
)	O
from	O
nine	O
unrelated	O
families	O
,	O
referred	O
to	O
our	O
Pediatric	O
Clinic	O
.	O

Molecular	O
genetic	O
diagnosis	O
was	O
possible	O
in	O
9	O
(	O
75	O
.	O
0	O
%	O
)	O
of	O
12	O
recessive	O
families	O
.	O

The	O
patient	O
in	O
this	O
report	O
is	O
currently	O
under	O
regular	O
follow	O
-	O
up	O
by	O
otolaryngologists	O
.	O

Mutations	O
in	O
CLRN1	B-GENE
[	O
18	O
]	O
have	O
been	O
pinpointed	O
to	O
cause	O
USH	B-DISEASE
type	B-DISEASE
3	I-DISEASE
.	O

Two	O
patients	O
of	O
the	O
OPA1	B-GENE
-	O
M	O
group	O
had	O
vertigo	B-DISEASE
,	O
which	O
was	O
reported	O
as	O
a	O
disturbing	O
symptom	O
in	O
Subject	O
3	O
and	O
as	O
occurring	O
only	O
occasionally	O
in	O
Subject	O
8	O
.	O

Southern	O
blotting	O
and	O
long	O
-	O
PCR	O
analysis	O
on	O
muscle	O
-	O
derived	O
mtDNA	O
molecules	O
from	O
the	O
two	O
probands	O
showed	O
the	O
presence	O
of	O
several	O
bands	O
corresponding	O
to	O
multiple	O
-	O
deleted	O
genomes	O
(	O
Fig	O
.	O

SB	O
-	O
W	O
:	O
acquisition	O
of	O
data	O
,	O
revising	O
the	O
manuscript	O
.	O

I	O
Botillo	O
and	O
Dr	O
.	O

These	O
are	O
cases	O
of	O
double	O
heterozygosity	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
Q393X	I-VARIANT
allele	O
was	O
predicted	O
to	O
encode	O
a	O
truncated	O
protein	O
lacking	O
the	O
entire	O
C	O
-	O
terminal	O
Eya	O
homolog	O
region	O
(	O
Eya	O
HR	O
)	O
,	O
which	O
is	O
essential	O
for	O
the	O
interaction	O
with	O
the	O
transcription	O
factor	O
SIX3	B-GENE
.	O

b	O
Sequencing	O
chromatograms	O
of	O
C10orf2	B-GENE
mutations	O
.	O

We	O
evaluated	O
hearing	O
function	O
in	O
two	O
groups	O
of	O
subjects	O
with	O
OPA1	B-DISEASE
-	I-DISEASE
related	I-DISEASE
DOA	I-DISEASE
.	O

4A	O
-	O
D	O
,	O
the	O
morphology	O
of	O
mitochondria	O
in	O
patient	O
-	O
derived	O
fibroblasts	O
and	O
control	O
is	O
dramatically	O
different	O
.	O

We	O
investigated	O
a	O
cohort	O
of	O
isolated	O
CTD	O
patients	O
without	O
22q11	O
.	O
2	O
deletion	O
and	O
identified	O
one	O
novel	O
mutation	O
(	O
E129K	B-VARIANT
)	O
of	O
TBX1	B-GENE
.	O

[	O
33	O
]	O
.	O

It	O
is	O
not	O
clear	O
why	O
the	O
mutations	O
in	O
SLC26A4	B-GENE
account	O
for	O
much	O
lower	O
percentage	O
of	O
patients	O
with	O
EVA	B-DISEASE
in	O
Caucasian	O
patients	O
.	O

Similarly	O
,	O
peak	O
tail	O
-	O
currents	O
,	O
measured	O
at	O
-	O
120	O
mV	O
for	O
TEVC	O
or	O
-	O
40	O
mV	O
for	O
patch	O
-	O
clamping	O
experiments	O
following	O
the	O
depolarizing	O
step	O
,	O
were	O
plotted	O
against	O
the	O
membrane	O
potential	O
of	O
the	O
depolarizing	O
step	O
to	O
construct	O
the	O
activation	O
curves	O
.	O

To	O
investigate	O
a	O
possible	O
cochlear	O
role	O
of	O
BDP1	B-GENE
,	O
an	O
expression	O
study	O
in	O
the	O
mouse	O
inner	O
ear	O
at	O
postnatal	O
day	O
five	O
was	O
carried	O
out	O
demonstrating	O
a	O
strong	O
pattern	O
of	O
expression	O
in	O
specific	O
cell	O
types	O
in	O
the	O
cochlea	O
.	O

Mutation	O
analysis	O
of	O
PCDH15	B-GENE
included	O
additional	O
exons	O
recently	O
identified	O
and	O
was	O
performed	O
by	O
direct	O
sequencing	O
.	O

Five	O
of	O
the	O
seven	O
reported	O
mutations	O
are	O
located	O
in	O
the	O
motor	O
domain	O
,	O
while	O
two	O
of	O
these	O
mutations	O
are	O
in	O
the	O
IQ	O
motifs	O
(	O
Figure	O
3C	O
)	O
.	O

USH	B-DISEASE
type	I-DISEASE
3	I-DISEASE
(	O
USH3	B-DISEASE
)	O
is	O
characterized	O
by	O
variable	O
onset	O
of	O
progressive	O
HL	B-DISEASE
,	O
variable	O
onset	O
of	O
RP	B-DISEASE
,	O
and	O
variable	O
impairment	O
of	O
vestibular	O
function	O
(	O
normal	O
to	O
absent	O
)	O
[	O
1	O
]	O
,	O
[	O
2	O
]	O
.	O

In	O
Family	O
3187	O
,	O
the	O
affected	O
members	O
developed	O
progressive	O
down	O
-	O
sloping	O
bilateral	O
hearing	B-DISEASE
loss	I-DISEASE
beginning	O
in	O
their	O
teens	O
.	O

The	O
latter	O
are	O
genes	O
for	O
which	O
germline	O
mutations	O
may	O
predispose	O
to	O
cancer	B-DISEASE
but	O
which	O
have	O
few	O
somatic	O
mutations	O
.	O

Genomic	O
DNA	O
was	O
obtained	O
from	O
five	O
patients	O
with	O
congenital	O
HL	B-DISEASE
.	O

This	O
representation	O
confirms	O
that	O
the	O
type	O
3	O
genotype	O
results	O
in	O
the	O
most	O
severe	O
phenotype	O
with	O
an	O
average	O
survival	O
of	O
only	O
4	O
.	O
7	O
months	O
(	O
six	O
patients	O
)	O
.	O

Y375C	B-VARIANT
,	O
R470H	B-VARIANT
,	O
I491T	B-VARIANT
,	O
L597S	B-VARIANT
,	O
and	O
H723D	B-VARIANT
were	O
considered	O
pathogenic	O
,	O
as	O
they	O
are	O
located	O
in	O
an	O
evolutionarily	O
conserved	O
region	O
.	O

To	O
date	O
,	O
the	O
substantial	O
contribution	O
of	O
several	O
nuclear	O
genes	O
[	O
3	O
,	O
4	O
]	O
and	O
the	O
pathogenic	O
mitochondrial	O
mutations	O
in	O
NSHL	O
was	O
established	O
in	O
some	O
populations	O
[	O
5	O
,	O
6	O
]	O
.	O

Nevertheless	O
,	O
genetic	O
analyses	O
for	O
identifying	O
mutations	O
in	O
RSTS	B-DISEASE
have	O
often	O
yielded	O
inconsistent	O
results	O
,	O
probably	O
because	O
of	O
inadequacies	O
in	O
the	O
methods	O
used	O
for	O
the	O
analyses	O
,	O
and	O
many	O
mutations	O
remain	O
unconfirmed	O
.	O

A	O
prioritization	O
scheme	O
was	O
applied	O
to	O
identify	O
the	O
pathogenic	O
mutation	O
in	O
the	O
patient	O
,	O
similar	O
to	O
recent	O
studies	O
[	O
6	O
,	O
15	O
]	O
.	O

A	O
,	O
B	O
:	O
Fundus	O
photographs	O
of	O
individual	O
II	O
:	O
1	O
at	O
the	O
age	O
of	O
15	O
years	O
demonstrate	O
normal	O
optic	O
disc	O
and	O
blood	O
vessels	O
with	O
peripheral	O
temporal	O
degenerative	O
changes	O
and	O
atrophy	O
of	O
the	O
retina	O
.	O

Evidence	O
was	O
based	O
on	O
(	O
1	O
)	O
in	O
silico	O
evidence	O
and	O
(	O
2	O
)	O
co	O
-	O
occurrence	O
of	O
two	O
mutations	O
in	O
a	O
recessive	O
gene	O
.	O

The	O
proband	O
is	O
a	O
16	O
-	O
year	O
-	O
old	O
boy	O
:	O
The	O
left	O
ECG	O
showed	O
very	O
broad	O
and	O
notched	O
or	O
bifid	O
even	O
biphasic	O
T	O
waves	O
on	O
multi	O
-	O
leads	O
(	O
arrows	O
)	O
(	O
QTc	O
620	O
ms	O
)	O
before	O
he	O
had	O
received	O
a	O
pacemaker	O
;	O
the	O
right	O
one	O
showed	O
less	O
abnormal	O
ECG	O
5	O
months	O
after	O
pacemaker	O
+	O
propranolol	O
2	O
mg	O
/	O
Kg	O
(	O
QTc	O
514	O
ms	O
)	O
.	O

This	O
is	O
in	O
contrast	O
with	O
AS	B-DISEASE
where	O
proteinuria	B-DISEASE
and	O
secondary	O
FSGS	B-DISEASE
tend	O
to	O
occur	O
late	O
in	O
the	O
course	O
of	O
the	O
disease	O
14	O
.	O

An	O
adult	O
male	O
presented	O
with	O
cerebellar	B-DISEASE
ataxia	I-DISEASE
,	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
,	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
and	O
azoospermia	B-DISEASE
.	O

WS4	B-DISEASE
patients	O
with	O
different	O
pathogenic	O
mutations	O
in	O
the	O
same	O
gene	O
(	O
compound	O
heterozygotes	O
)	O
have	O
also	O
been	O
described	O
[	O
8	O
]	O
.	O

It	O
leads	O
to	O
the	O
change	O
of	O
aspartic	O
acid	O
in	O
position	O
679	O
by	O
tyrosine	O
[	O
11	O
]	O
.	O

Interestingly	O
,	O
the	O
two	O
younger	O
patients	O
had	O
more	O
severe	O
retinopathy	B-DISEASE
than	O
the	O
older	O
proband	O
.	O

204	O
deafness	B-DISEASE
genes	O
.	O

The	O
remaining	O
6	O
SNVs	O
have	O
been	O
further	O
investigated	O
as	O
reported	O
in	O
Table	O
1	O
.	O

13	O
14	O
The	O
MITF	B-GENE
gene	O
encodes	O
a	O
transcription	O
factor	O
with	O
a	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
leucine	O
zipper	O
motif	O
.	O

One	O
of	O
them	O
,	O
1228del	B-VARIANT
(	O
C	O
)	O
;	O
del409fs	B-VARIANT
/	I-VARIANT
ter440	I-VARIANT
in	O
W19	O
,	O
was	O
also	O
present	O
homozygously	O
in	O
W4	O
.	O

Briefly	O
,	O
the	O
DNA	O
libraries	O
were	O
grouped	O
into	O
pools	O
of	O
twelve	O
libraries	O
.	O

24	O
)	O
displayed	O
compound	O
heterozygous	O
pathogenic	O
mutations	O
,	O
1	O
(	O
no	O
.	O

It	O
provides	O
a	O
strong	O
possibility	O
that	O
p	B-VARIANT
.	I-VARIANT
P678S	I-VARIANT
is	O
the	O
pathogenic	O
mutation	O
causing	O
hereditary	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
family	O
KNUF46	O
.	O

ECL	O
Western	O
blotting	O
and	O
analysis	O
reagents	O
(	O
GE	O
Healthcare	O
)	O
were	O
used	O
for	O
chemiluminescent	O
detection	O
.	O

The	O
male	O
proband	O
(	O
III	O
-	O
2	O
in	O
Figure	O
1	O
C	O
)	O
,	O
born	O
after	O
an	O
uneventful	O
pregnancy	O
,	O
was	O
referred	O
for	O
craniofacial	O
assessment	O
at	O
the	O
age	O
of	O
three	O
months	O
.	O

(	O
a	O
)	O
Schematic	O
of	O
human	O
claudin14	O
.	O

Pendred	B-DISEASE
syndrome	I-DISEASE
and	O
nonsyndromic	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
associated	O
with	O
EVA	B-DISEASE
are	O
a	O
continuum	O
of	O
disease	O
characterized	O
as	O
being	O
associated	O
with	O
congenital	O
,	O
fluctuating	O
and	O
progressive	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
and	O
most	O
patients	O
have	O
vertigo	B-DISEASE
and	O
/	O
or	O
goiter	B-DISEASE
.	O

[	O
1	O
,	O
2	O
]	O
Monosymptomatic	O
optic	B-DISEASE
atrophy	I-DISEASE
shows	O
genetic	O
heterogeneity	O
with	O
at	O
least	O
eight	O
loci	O
;	O
OPA1	B-GENE
(	O
OMIM	O
605290	O
)	O
is	O
the	O
major	O
ADOA	B-DISEASE
gene	O
.	O

Chi	O
-	O
square	O
test	O
was	O
used	O
to	O
test	O
the	O
independence	O
between	O
the	O
genotype	O
765T	B-VARIANT
/	O
T	O
and	O
the	O
control	O
group	O
.	O

However	O
,	O
we	O
considered	O
this	O
change	O
a	O
presumed	O
non	O
-	O
pathogenic	O
variant	O
.	O

Deafness	B-DISEASE
is	O
the	O
most	O
common	O
birth	O
defect	O
and	O
the	O
most	O
frequent	O
sensorineural	B-DISEASE
disorder	I-DISEASE
[	O
1	O
]	O
.	O

1888	I-VARIANT
G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
of	O
COL2A1	B-GENE
resulting	O
in	O
LCPD	B-DISEASE
or	O
ANFH	B-DISEASE
in	O
a	O
Chinese	O
family	O
,	O
which	O
had	O
not	O
been	O
reported	O
previously	O
.	O

Black	O
circles	O
and	O
bars	O
,	O
mutations	O
and	O
copy	O
number	O
variations	O
detected	O
in	O
this	O
study	O
;	O
white	O
circles	O
and	O
grey	O
bars	O
,	O
previously	O
published	O
mutations	O
and	O
deletions	O
;	O
grey	O
circles	O
,	O
MITF	B-GENE
mutations	O
associated	O
with	O
Tietz	B-DISEASE
syndrome	I-DISEASE
.	O

The	O
levels	O
of	O
consanguinity	O
are	O
indicated	O
;	O
-	O
/	O
-	O
:	O
homozygous	O
mutant	O
;	O
+	O
/	O
-	O
:	O
heterozygous	O
;	O
+	O
/	O
+	O
:	O
homozygous	O
wild	O
type	O
.	O

Wrote	O
the	O
paper	O
:	O
ZR	O
.	O

We	O
say	O
"	O
nearly	O
"	O
because	O
incomplete	O
penetrance	O
has	O
been	O
observed	O
by	O
several	O
authors	O
.	O

Members	O
of	O
the	O
KNUF25	O
family	O
show	O
a	O
dominant	O
inheritance	O
pattern	O
(	O
Figure	O
3A	O
)	O
.	O

The	O
proportion	O
of	O
muscle	O
fibres	O
exhibiting	O
a	O
mitochondrial	O
oxidative	O
phosphorylation	O
defect	O
can	O
be	O
accurately	O
quantified	O
,	O
as	O
normal	O
COX	O
-	O
positive	O
fibres	O
stain	O
brown	O
;	O
whereas	O
COX	O
-	O
negative	O
fibres	O
are	O
highlighted	O
blue	O
as	O
a	O
result	O
of	O
impaired	O
complex	O
IV	O
activity	O
.	O

TMC1	B-GENE
is	O
the	O
sixth	O
most	O
common	O
cause	O
of	O
recessive	O
HL	B-DISEASE
worldwide	O
(	O
Hilgert	O
et	O
al	O
.	O

Today	O
,	O
most	O
genetic	O
diagnosis	O
for	O
the	O
deaf	O
is	O
limited	O
to	O
the	O
most	O
common	O
mutations	O
in	O
a	O
patient	O
'	O
s	O
population	O
of	O
origin	O
.	O

Richard	O
et	O
al	O
.	O

GBMs	O
are	O
very	O
thick	O
structures	O
(	O
average	O
width	O
:	O
female	O
326	O
nm	O
,	O
male	O
373	O
nm	O
)	O
that	O
play	O
a	O
crucial	O
role	O
in	O
establishing	O
and	O
maintaining	O
an	O
effective	O
and	O
properly	O
functioning	O
glomerular	O
filtration	O
barrier	O
(	O
GFB	O
)	O
[	O
10	O
]	O
.	O

(	O
B	O
)	O
Pure	O
-	O
tone	O
audiograms	O
for	O
family	O
PKDF468	O
V	O
:	O
2	O
(	O
25	O
-	O
year	O
-	O
old	O
female	O
)	O
and	O
V	O
:	O
5	O
(	O
20	O
-	O
year	O
-	O
old	O
male	O
)	O
.	O

A	O
measureable	O
rise	O
in	O
C	O
-	O
peptide	O
or	O
a	O
C	O
-	O
peptide	O
of	O
1	O
.	O
0	O
or	O
higher	O
at	O
baseline	O
was	O
found	O
in	O
seven	O
(	O
39	O
%	O
)	O
of	O
the	O
subjects	O
.	O

3c	O
,	O
d	O
)	O
.	O

Skeletal	O
muscle	O
biopsies	O
collected	O
from	O
34	O
OPA1	B-GENE
mutation	O
carriers	O
were	O
snap	O
frozen	O
in	O
melting	O
liquid	O
isopentane	O
(	O
-	O
150	O
deg	O
C	O
)	O
and	O
then	O
stored	O
at	O
-	O
80	O
deg	O
C	O
.	O

55	O
COS	O
-	O
7	O
cells	O
were	O
transfected	O
with	O
various	O
DsRed	O
-	O
tagged	O
constructs	O
using	O
Lipofectamine	O
2000	O
and	O
3	O
-	O
4	O
mu	O
g	O
of	O
DNA	O
per	O
~	O
1ml	O
of	O
serum	O
-	O
free	O
Opti	O
-	O
MEM	O
medium	O
(	O
Invitrogen	O
)	O
.	O

For	O
the	O
young	O
patients	O
,	O
conditioned	O
orientation	O
response	O
audiometry	O
or	O
auditory	O
steady	O
-	O
state	O
response	O
was	O
used	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
design	O
a	O
more	O
accurate	O
molecular	O
diagnosis	O
tool	O
.	O

(	O
A	O
-	O
C	O
)	O
Double	O
staining	O
for	O
F	O
-	O
actin	O
(	O
red	O
)	O
and	O
ELMOD3	B-GENE
(	O
green	O
)	O
in	O
the	O
mouse	O
inner	O
ear	O
epithelia	O
.	O

An	O
initial	O
candidate	O
gene	O
approach	O
assigned	O
STRC	B-GENE
(	O
MIM	O
:	O
606440	O
)	O
to	O
chromosome	O
15q15	O
.	O
3	O
encompassing	O
the	O
DFNB16	B-DISEASE
locus	O
(	O
4	O
)	O
.	O

Nested	O
PCRs	O
(	O
Table	O
S2	O
)	O
and	O
sequencing	O
continued	O
after	O
LR	O
-	O
PCR	O
products	O
were	O
verified	O
negative	O
for	O
a	O
three	O
-	O
nucleotide	O
frameshift	O
,	O
indicative	O
of	O
pSTRC	O
sequence	O
.	O

Next	O
-	O
generation	O
sequencing	O
(	O
NGS	O
)	O
can	O
overcome	O
these	O
limitations	O
through	O
its	O
ability	O
to	O
perform	O
parallel	O
sequencing	O
of	O
billions	O
of	O
nucleotides	O
at	O
a	O
low	O
cost	O
and	O
high	O
speed	O
[	O
1	O
-	O
4	O
]	O
.	O

We	O
used	O
the	O
following	O
scale	O
to	O
grade	O
the	O
degree	O
of	O
sensorineural	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
SNHL	B-DISEASE
)	O
:	O
slight	O
-	O
16	O
to	O
25	O
dB	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
mild	O
-	O
26	O
-	O
40	O
dB	O
,	O
moderate	O
-	O
41	O
-	O
55	O
dB	O
,	O
moderately	O
severe	O
-	O
56	O
-	O
70	O
dB	O
,	O
severe	O
-	O
71	O
-	O
90	O
dB	O
,	O
and	O
profound	O
-	O
>	O
90	O
dB	O
hearing	B-DISEASE
loss	I-DISEASE
[	O
13	O
]	O
.	O

N	O
.	O

suggested	O
that	O
hotspots	O
for	O
hearing	B-DISEASE
loss	I-DISEASE
mutations	O
are	O
variable	O
in	O
different	O
regions	O
in	O
China	O
[	O
5	O
]	O
.	O

No	O
consanguineous	O
marriage	O
was	O
identified	O
in	O
the	O
family	O
and	O
both	O
parents	O
had	O
normal	O
QT	O
intervals	O
.	O

Bridgers	O
,	O
J	O
.	O

2011	O
;	O
Neveling	O
et	O
al	O
.	O

All	O
efforts	O
were	O
made	O
to	O
minimize	O
suffering	O
.	O

2	O
)	O
,	O
and	O
bilateral	O
peripheral	O
RP	O
was	O
diagnosed	O
in	O
all	O
the	O
patients	O
examined	O
,	O
i	O
.	O
e	O
.	O
,	O
DF11	O
-	O
VI	O
.	O
1	O
,	O
DF11	O
-	O
VI	O
.	O
3	O
,	O
DF25	O
-	O
V	O
.	O
3	O
,	O
DF25	O
-	O
V	O
.	O
4	O
,	O
DF25	O
-	O
V	O
.	O
5	O
,	O
DF99	O
-	O
IV	O
.	O
1	O
,	O
DF103	O
-	O
III	O
.	O
1	O
,	O
and	O
DF103	O
-	O
III	O
.	O
2	O
.	O

The	O
454	O
pyrosequencing	O
-	O
related	O
errors	O
were	O
categorized	O
as	O
insertions	O
,	O
deletions	O
,	O
mismatches	O
,	O
or	O
ambiguous	O
base	O
calls	O
.	O

B	O
1472T	B-VARIANT
>	I-VARIANT
C	I-VARIANT
/	O
wt	O
.	O

We	O
discovered	O
four	O
novel	O
non	O
-	O
synonymous	O
mutations	O
:	O
COL4A3_G695R	B-VARIANT
,	O
COL4A3_L1474P	B-VARIANT
,	O
MYH9_L46F	B-VARIANT
and	O
SALL2_G792R	B-VARIANT
that	O
were	O
all	O
predicted	O
to	O
be	O
damaging	O
(	O
Figure	O
1b	O
)	O
.	O

When	O
his	O
body	O
temperature	O
was	O
below	O
36	O
.	O
5	O
deg	O
C	O
,	O
the	O
audiological	O
tests	O
showed	O
a	O
flat	O
audiogram	O
(	O
40	O
-	O
60dB	O
HL	O
)	O
,	O
normal	O
DPOAE	B-DISEASE
,	O
type	O
A	O
tympanogram	O
,	O
negative	O
results	O
of	O
temporal	O
bone	O
CT	O
and	O
MR	O
hydrography	O
of	O
the	O
inner	O
ear	O
,	O
and	O
absence	O
of	O
ABR	O
and	O
acoustical	O
stapedial	O
reflex	O
.	O

performed	O
statistical	O
analysis	O
.	O

This	O
suggests	O
that	O
the	O
p	B-VARIANT
.	I-VARIANT
Ala426Thr	I-VARIANT
mutation	O
has	O
a	O
milder	O
effect	O
than	O
the	O
p	B-VARIANT
.	I-VARIANT
Ala306Thr	I-VARIANT
mutation	O
.	O

A	O
very	O
large	O
intrafamilial	O
variation	O
is	O
evident	O
and	O
there	O
is	O
no	O
obvious	O
difference	O
between	O
the	O
two	O
groups	O
of	O
patients	O
.	O

Using	O
the	O
UCSC	O
Genome	O
Browser	O
(	O
http	O
:	O
/	O
/	O
genome	O
.	O
ucsc	O
.	O
edu	O
/	O
cgi	O
-	O
bin	O
/	O
hgGateway	O
)	O
,	O
we	O
found	O
that	O
there	O
are	O
approximately	O
47	O
genes	O
located	O
in	O
the	O
region	O
of	O
interest	O
.	O

The	O
majority	O
of	O
missense	O
mutations	O
that	O
cause	O
hearing	B-DISEASE
loss	I-DISEASE
related	O
to	O
TECTA	B-GENE
reside	O
in	O
the	O
zona	O
pellucida	O
and	O
zonadhesin	O
domains	O
of	O
the	O
gene	O
[	O
16	O
]	O
.	O

The	O
major	O
clinical	O
features	O
of	O
TCS	B-DISEASE
were	O
recognized	O
in	O
all	O
patients	O
.	O

Here	O
we	O
have	O
demonstrated	O
how	O
,	O
due	O
to	O
alternative	O
splicing	O
,	O
which	O
can	O
be	O
either	O
natural	O
or	O
pathogenic	O
in	O
origin	O
,	O
similar	O
null	O
/	O
missense	O
or	O
biallelic	O
null	O
mutations	O
result	O
in	O
Stickler	B-DISEASE
syndrome	I-DISEASE
rather	O
than	O
fibrochondrogenesis	B-DISEASE
(	O
table	O
1	O
)	O
.	O

Segregation	O
analysis	O
in	O
the	O
family	O
revealed	O
that	O
parents	O
were	O
heterozygotes	O
for	O
both	O
mutations	O
,	O
while	O
the	O
unaffected	O
sister	O
was	O
heterozygote	O
for	O
the	O
PDE6B	B-GENE
mutation	O
only	O
.	O

We	O
thank	O
Wolfram	O
Kress	O
and	O
Erdmute	O
Kunstmann	O
for	O
mutation	O
consultation	O
and	O
case	O
information	O
,	O
and	O
Jens	O
Gr	O
a	O
f	O
for	O
sequencing	O
work	O
.	O

In	O
some	O
instances	O
PEX1	B-GENE
deficiency	O
was	O
further	O
confirmed	O
by	O
complementation	O
analysis	O
[	O
14	O
]	O
.	O

As	O
a	O
control	O
for	O
pathogeneity	O
of	O
each	O
genomic	O
variation	O
,	O
72	O
Japanese	O
samples	O
were	O
used	O
in	O
this	O
study	O
,	O
because	O
they	O
were	O
1	O
)	O
ethnically	O
similar	O
,	O
2	O
)	O
had	O
normal	O
hearing	O
evaluated	O
by	O
pure	O
-	O
tone	O
audiometry	O
,	O
and	O
3	O
)	O
were	O
collected	O
from	O
throughout	O
the	O
nation	O
,	O
and	O
were	O
able	O
to	O
undergo	O
identical	O
procedures	O
.	O

Additional	O
findings	O
of	O
double	O
heterozygous	O
mutations	O
associated	O
with	O
hereditary	O
hearing	B-DISEASE
loss	I-DISEASE
have	O
been	O
reported	O
for	O
KCNJ10	B-GENE
and	O
SLC26A4	B-GENE
[	O
50	O
]	O
and	O
for	O
FOXI1	B-GENE
and	O
SLC26A4	B-GENE
[	O
51	O
]	O
,	O
and	O
some	O
mutated	O
genes	O
may	O
have	O
a	O
modifying	O
effect	O
[	O
52	O
]	O
.	O

2	O
)	O
.	O

Of	O
the	O
five	O
patients	O
showing	O
stable	O
hearing	B-DISEASE
loss	I-DISEASE
without	O
significant	O
progression	O
over	O
a	O
period	O
of	O
two	O
to	O
four	O
years	O
,	O
four	O
patients	O
were	O
members	O
of	O
a	O
single	O
family	O
.	O

Applying	O
conservative	O
filtering	O
strategies	O
to	O
the	O
genes	O
common	O
in	O
both	O
panels	O
,	O
42	O
of	O
the	O
80	O
target	O
genes	O
did	O
not	O
show	O
a	O
single	O
pathogenic	O
variant	O
in	O
23	O
probands	O
and	O
9	O
controls	O
.	O

Sequencing	O
of	O
the	O
products	O
showed	O
that	O
the	O
fragment	O
of	O
835	O
-	O
bp	O
corresponded	O
to	O
the	O
normal	O
allele	O
.	O

M	O
.	O
B	O
.	O

1	O
Minor	O
allele	O
frequency	O
is	O
from	O
dbSNP137	O
database	O
accessed	O
on	O
10	O
/	O
17	O
/	O
2012	O
.	O

(	O
B	O
)	O
Confocal	O
images	O
of	O
FLAG	O
-	O
tagged	O
HOMER2	B-GENE
p	B-VARIANT
.	I-VARIANT
Arg185Pro	I-VARIANT
-	O
transfected	O
HEK293	O
cells	O
immuno	O
-	O
stained	O
with	O
Alexa	O
-	O
Fluor	O
-	O
488	O
(	O
green	O
)	O
;	O
F	O
-	O
actin	O
immuno	O
-	O
stained	O
with	O
conjugated	O
Alexa	O
-	O
Fluor	O
-	O
647	O
-	O
phalloidin	O
(	O
blue	O
)	O
.	O

However	O
,	O
this	O
mutation	O
may	O
be	O
pathogenic	O
when	O
inherited	O
with	O
a	O
null	O
allele	O
such	O
as	O
in	O
DT35	O
.	O

In	O
both	O
patients	O
wave	O
V	O
was	O
recorded	O
with	O
increasing	O
latency	O
from	O
apical	O
to	O
basal	O
electrodes	O
(	O
vertical	O
dashed	O
lines	O
,	O
middle	O
)	O
.	O

H	O
.	O
V	O
.	O

6g	O
-	O
i	O
)	O
.	O

Copy	O
number	O
variations	O
explained	O
2	O
%	O
of	O
the	O
mutations	O
and	O
3	O
of	O
36	O
selected	O
cases	O
(	O
8	O
%	O
)	O
harboured	O
a	O
mutation	O
in	O
the	O
RYR2	B-GENE
gene	O
.	O

In	O
recent	O
years	O
,	O
the	O
mutation	O
analysis	O
has	O
been	O
performed	O
by	O
bi	O
-	O
directional	O
Sanger	O
sequencing	O
of	O
coding	O
regions	O
and	O
all	O
previous	O
patients	O
have	O
been	O
reanalysed	O
.	O

These	O
were	O
defined	O
by	O
minimum	O
and	O
maximum	O
PTA	O
levels	O
in	O
the	O
OPA1	B-GENE
-	O
H	O
group	O
,	O
whereas	O
the	O
OPA1	B-GENE
-	O
M	O
subjects	O
were	O
pooled	O
into	O
three	O
classes	O
characterized	O
by	O
increasing	O
PTA	O
values	O
(	O
Fig	O
.	O

A	O
series	O
of	O
studies	O
proved	O
a	O
founder	O
effect	O
for	O
these	O
frequent	O
mutations	O
[	O
11	O
]	O
,	O
[	O
15	O
]	O
.	O

Haplotype	O
analysis	O
was	O
performed	O
using	O
both	O
affected	O
and	O
unaffected	O
individuals	O
from	O
10	O
families	O
with	O
c	B-VARIANT
.	I-VARIANT
983A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
and	O
10	O
families	O
with	O
c	B-VARIANT
.	I-VARIANT
2708_2711delTTAG	I-VARIANT
(	O
Table	O
1	O
)	O
.	O

Sixty	O
-	O
five	O
patients	O
were	O
left	O
for	O
further	O
investigation	O
.	O

PS	B-DISEASE
has	O
been	O
associated	O
with	O
mutations	O
in	O
FGFR1	B-GENE
and	O
FGFR2	B-GENE
genes	O
.	O

Additional	O
markers	O
for	O
fine	O
mapping	O
of	O
the	O
linked	O
chromosomal	O
region	O
were	O
taken	O
from	O
the	O
Marshfield	O
chromosome	O
9	O
map	O
(	O
http	O
:	O
/	O
/	O
research	O
.	O
marshfieldclinic	O
.	O
org	O
/	O
genetics	O
)	O
and	O
were	O
also	O
amplified	O
using	O
fluorescent	O
-	O
labeled	O
primers	O
(	O
Table	O
S1	O
,	O
Shenggong	O
DNA	O
Technologies	O
,	O
Shanghai	O
China	O
)	O
.	O

also	O
receives	O
funding	O
from	O
the	O
Parkinson	O
'	O
s	O
Disease	O
Society	O
(	O
UK	O
)	O
,	O
the	O
Medical	O
Research	O
Council	O
Translational	O
Muscle	O
Centre	O
,	O
and	O
the	O
UK	O
NIHR	O
Biomedical	O
Research	O
Centre	O
in	O
Ageing	O
and	O
Age	O
related	O
disease	O
.	O

Pure	O
tone	O
audiometry	O
recording	O
of	O
representative	O
members	O
in	O
the	O
Mongolian	O
family	O
.	O

The	O
boy	O
was	O
observed	O
suffering	O
from	O
poor	O
vision	O
as	O
early	O
as	O
2	O
years	O
of	O
age	O
.	O

Brain	O
NMR	O
revealed	O
reducing	O
the	O
volume	O
of	O
posterior	O
pituitary	O
and	O
optic	B-DISEASE
nerve	I-DISEASE
atrophy	I-DISEASE
.	O

NS	O
P	O
>	O
0	O
.	O
05	O
;	O
*	O
*	O
*	O
P	O
<	O
0	O
.	O
001	O
.	O

In	O
conclusion	O
,	O
we	O
document	O
that	O
the	O
hearing	B-DISEASE
dysfunction	I-DISEASE
affecting	O
patients	O
with	O
mutations	O
in	O
the	O
OPA1	B-GENE
gene	O
is	O
underlain	O
by	O
degeneration	B-DISEASE
of	I-DISEASE
terminal	I-DISEASE
dendrites	I-DISEASE
at	O
an	O
early	O
stage	O
of	O
the	O
disease	O
,	O
whereas	O
demyelination	B-DISEASE
and	O
axonal	B-DISEASE
loss	I-DISEASE
may	O
become	O
prevalent	O
at	O
an	O
advanced	O
stage	O
.	O

[	O
7	O
]	O
,	O
except	O
those	O
for	O
exons	O
41	O
,	O
53	O
,	O
63	O
,	O
64	O
,	O
and	O
71	O
(	O
Appendix	O
1	O
)	O
.	O

Possible	O
explanations	O
are	O
:	O
1	O
)	O
the	O
existence	O
of	O
a	O
second	O
mutation	O
in	O
the	O
intron	O
or	O
regulatory	O
region	O
of	O
CDH23	B-GENE
,	O
which	O
has	O
not	O
been	O
explored	O
,	O
2	O
)	O
the	O
observed	O
mutations	O
are	O
rare	O
polymorphisms	O
,	O
3	O
)	O
the	O
screening	O
method	O
fails	O
to	O
detect	O
the	O
second	O
mutation	O
,	O
and	O
4	O
)	O
an	O
additional	O
modulatory	O
gene	O
may	O
contribute	O
to	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
for	O
example	O
,	O
PCDH15	B-GENE
)	O
.	O

This	O
study	O
detected	O
eight	O
different	O
mutations	O
of	O
the	O
USH2A	B-GENE
gene	O
isoform	O
b	O
in	O
one	O
non	O
-	O
syndromic	O
arRP	B-DISEASE
family	O
and	O
in	O
three	O
USH2	B-DISEASE
families	O
.	O

In	O
the	O
search	O
for	O
rare	O
disease	O
causing	O
mutations	O
with	O
high	O
impact	O
,	O
linkage	O
is	O
an	O
effective	O
method	O
for	O
eliminating	O
large	O
fractions	O
of	O
the	O
genome	O
,	O
but	O
segregation	O
and	O
rarity	O
alone	O
is	O
not	O
sufficient	O
to	O
implicate	O
a	O
specific	O
variant	O
as	O
pathogenic	O
.	O

Another	O
one	O
in	O
a	O
thousand	O
children	O
becomes	O
deaf	B-DISEASE
or	O
severely	O
hearing	B-DISEASE
impaired	I-DISEASE
before	O
adulthood	O
[	O
1	O
]	O
.	O

His	O
ECG	O
showed	O
marked	O
sinus	O
bradycardia	O
and	O
a	O
prolonged	O
QTc	O
of	O
620	O
ms	O
[	O
Figure	O
5	O
]	O
.	O

These	O
data	O
suggest	O
that	O
the	O
Asp187	O
residue	O
in	O
gamma	O
-	O
actin	O
contributes	O
to	O
the	O
interaction	O
with	O
microtubules	O
,	O
and	O
the	O
p	B-VARIANT
.	I-VARIANT
D187H	I-VARIANT
variant	O
inhibits	O
depolymerization	O
of	O
tubulin	O
in	O
leukemia	O
cells	O
.	O

Further	O
,	O
some	O
dRTA	B-DISEASE
patients	O
without	O
early	O
SNHL	B-DISEASE
were	O
found	O
to	O
present	O
mutations	O
in	O
the	O
ATP6V1B1	B-GENE
gene	O
as	O
well	O
[	O
10	O
,	O
11	O
]	O
.	O

Additional	O
file	O
2	O
:	O
Table	O
S2	O
.	O

The	O
pyruvate	O
is	O
subsequently	O
converted	O
to	O
lactate	O
by	O
L	O
-	O
lactate	O
dehydrogenase	O
resulting	O
in	O
the	O
oxidation	O
of	O
one	O
NADH	O
molecule	O
.	O

(	O
b	O
)	O
Elaborate	O
protrusions	O
significantly	O
increase	O
the	O
perimeter	O
of	O
mutant	O
cells	O
by	O
25	O
-	O
30	O
%	O
compared	O
to	O
control	O
.	O

,	O
2004	O
)	O
;	O
US	O
-	O
2	O
:	O
(	O
Milone	O
et	O
al	O
.	O

Affected	O
males	O
'	O
middle	O
and	O
inner	B-DISEASE
ear	I-DISEASE
anomalies	I-DISEASE
were	O
within	O
the	O
expected	O
spectrum	O
.	O

They	O
are	O
being	O
clinically	O
re	O
-	O
evaluated	O
,	O
however	O
we	O
cannot	O
rule	O
out	O
the	O
possibility	O
of	O
a	O
second	O
Hajdu	B-DISEASE
-	I-DISEASE
Cheney	I-DISEASE
syndrome	I-DISEASE
locus	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
according	O
to	O
standard	O
procedures	O
.	O

However	O
,	O
due	O
to	O
the	O
genetic	O
heterogeneity	O
of	O
the	O
disease	O
and	O
the	O
large	O
number	O
of	O
exons	O
of	O
the	O
nine	O
known	O
Usher	B-DISEASE
syndrome	I-DISEASE
genes	O
,	O
the	O
genetic	O
causes	O
for	O
a	O
large	O
proportion	O
of	O
Usher	B-DISEASE
syndrome	I-DISEASE
remain	O
unknown	O
.	O

This	O
provides	O
for	O
the	O
first	O
time	O
quantitative	O
evidence	O
that	O
WS	O
can	O
cause	O
profound	O
vestibular	B-DISEASE
loss	I-DISEASE
in	O
a	O
subset	O
of	O
subjects	O
.	O

Amplimers	O
were	O
size	O
-	O
separated	O
on	O
a	O
2	O
%	O
agarose	O
gel	O
and	O
stained	O
with	O
ethidium	O
bromide	O
.	O

EV	O
=	O
empty	O
vector	O
.	O

As	O
previously	O
mentioned	O
,	O
the	O
c	B-VARIANT
.	I-VARIANT
574C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
mutation	O
causes	O
a	O
substitution	O
of	O
an	O
arginine	O
(	O
R192	O
)	O
for	O
a	O
stop	O
codon	O
(	O
p	B-VARIANT
.	I-VARIANT
R192	I-VARIANT
*	I-VARIANT
)	O
,	O
thereby	O
deleting	O
the	O
last	O
six	O
amino	O
acids	O
of	O
the	O
CD164	B-GENE
C	O
-	O
terminus	O
(	O
RNYHTL	O
)	O
,	O
including	O
the	O
sorting	O
motif	O
.	O

2A	O
)	O
.	O

Polyphen	O
2	O
is	O
an	O
online	O
tool	O
widely	O
used	O
to	O
predict	O
the	O
putative	O
impact	O
on	O
protein	O
function	O
caused	O
by	O
an	O
amino	O
acid	O
residue	O
change	O
and	O
takes	O
into	O
account	O
a	O
variety	O
of	O
attributes	O
such	O
as	O
protein	O
structure	O
,	O
sequence	O
nature	O
and	O
conservation	O
.	O

Griffith	O
for	O
critique	O
of	O
the	O
manuscript	O
.	O

Another	O
possible	O
reason	O
for	O
the	O
increased	O
detection	O
rate	O
in	O
this	O
study	O
is	O
the	O
high	O
number	O
of	O
consanguineous	O
cases	O
in	O
the	O
local	O
Yorkshire	O
population	O
,	O
which	O
allows	O
filtering	O
on	O
the	O
basis	O
of	O
homozygosity	O
.	O

We	O
applied	O
a	O
stringent	O
assignment	O
of	O
pathogenicity	O
to	O
novel	O
missense	O
changes	O
.	O

The	O
allele	O
frequencies	O
were	O
2	O
.	O
38	O
%	O
(	O
2	O
/	O
84	O
)	O
,	O
1	O
.	O
19	O
%	O
(	O
1	O
/	O
84	O
)	O
,	O
1	O
.	O
19	O
%	O
(	O
1	O
/	O
84	O
)	O
,	O
1	O
.	O
19	O
%	O
(	O
1	O
/	O
84	O
)	O
,	O
1	O
.	O
19	O
%	O
(	O
1	O
/	O
84	O
)	O
and	O
1	O
.	O
19	O
%	O
(	O
1	O
/	O
84	O
)	O
for	O
IVS7	B-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
intron6	I-VARIANT
-	I-VARIANT
75_76insTGTG	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
2168A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
84A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
,	O
IVS11	B-VARIANT
+	I-VARIANT
47	I-VARIANT
T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
1548insG	I-VARIANT
,	O
respectively	O
.	O

Saihan	O
et	O
al	O
.	O

*	O
Homozygous	O
mutations	O
.	O

Yellow	O
-	O
orange	O
staining	O
indicates	O
an	O
overlap	O
of	O
the	O
CLRN1	O
-	O
HA	O
protein	O
(	O
red	O
)	O
and	O
subcellular	O
markers	O
(	O
green	O
)	O
.	O

CIDR	O
is	O
fully	O
funded	O
through	O
a	O
federal	O
contract	O
(	O
N01	O
-	O
HG	O
-	O
65403	O
)	O
from	O
the	O
NIH	O
to	O
Johns	O
Hopkins	O
University	O
.	O

The	O
principal	O
information	O
source	O
for	O
inclusion	O
of	O
genes	O
on	O
the	O
targeted	O
exome	O
panel	O
was	O
the	O
2010	O
skeletal	B-DISEASE
disorder	I-DISEASE
nosology	O
[	O
23	O
]	O
.	O

found	O
that	O
even	O
minor	O
changes	O
in	O
this	O
domain	O
may	O
lead	O
to	O
major	O
effects	O
on	O
the	O
structural	O
stability	O
of	O
the	O
actin	O
polymer	O
[	O
23	O
]	O
.	O

Seven	O
novel	O
mutations	O
(	O
two	O
missenses	O
,	O
one	O
7	O
-	O
bp	O
deletion	O
,	O
two	O
small	O
deletions	O
,	O
and	O
two	O
nonsenses	O
)	O
were	O
detected	O
in	O
the	O
four	O
families	O
after	O
sequencing	O
analysis	O
of	O
USH2A	B-GENE
.	O

This	O
can	O
be	O
explained	O
,	O
almost	O
in	O
part	O
,	O
by	O
the	O
high	O
rate	O
of	O
consanguinity	O
found	O
in	O
our	O
study	O
cohort	O
,	O
up	O
to	O
80	O
%	O
.	O

B	O
:	O
Overlapping	O
audiograms	O
of	O
the	O
subjects	O
with	O
biallelic	O
missense	O
mutations	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Mitochondrial	B-DISEASE
respiratory	I-DISEASE
chain	I-DISEASE
(	I-DISEASE
MRC	I-DISEASE
)	I-DISEASE
disease	I-DISEASE
represents	O
a	O
large	O
and	O
heterogeneous	O
group	O
of	O
energy	B-DISEASE
deficiency	I-DISEASE
disorders	I-DISEASE
.	O

Among	O
the	O
sequence	O
variants	O
found	O
in	O
this	O
study	O
,	O
eight	O
were	O
found	O
to	O
occur	O
in	O
a	O
heterozygous	O
condition	O
.	O

The	O
leukocyte	B-DISEASE
inclusions	I-DISEASE
of	O
this	O
patient	O
were	O
of	O
type	O
II	O
and	O
it	O
was	O
suggested	O
that	O
the	O
double	O
mutation	O
might	O
have	O
increased	O
myosin	O
aggregate	O
formation	O
.	O

We	O
performed	O
computational	O
analysis	O
with	O
the	O
programs	O
SIFT	O
,	O
PolyPhen	O
,	O
and	O
Pmut	O
to	O
infer	O
the	O
pathologic	O
effect	O
of	O
these	O
variants	O
.	O

Fundus	O
appearance	O
of	O
a	O
patient	O
with	O
Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
II	I-DISEASE
.	O

This	O
variant	O
is	O
predicted	O
to	O
interrupt	O
the	O
GLY	O
-	O
X	O
-	O
Y	O
repeat	O
structure	O
of	O
the	O
collagenous	O
domain	O
of	O
the	O
alpha	O
-	O
3	O
chain	O
.	O

Haplotype	O
analysis	O
confirmed	O
that	O
the	O
proband	O
and	O
his	O
affected	O
sister	O
were	O
compound	O
heterozygous	O
for	O
the	O
c	B-VARIANT
.	I-VARIANT
768C	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
S256R	I-VARIANT
)	O
and	O
the	O
c	B-VARIANT
.	I-VARIANT
854A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Q285R	I-VARIANT
)	O
mutations	O
.	O

Thus	O
,	O
we	O
can	O
safely	O
conclude	O
that	O
the	O
point	O
mutant	O
has	O
at	O
least	O
a	O
10	O
-	O
fold	O
lower	O
specific	O
activity	O
than	O
the	O
wild	O
-	O
type	O
protein	O
,	O
but	O
it	O
might	O
be	O
completely	O
inactive	O
as	O
an	O
Arl2	O
GAP	O
.	O

The	O
sequence	O
data	O
were	O
processed	O
with	O
standard	O
Ion	O
Torrent	O
Suite	O
Software	O
and	O
Torrent	O
Server	O
successively	O
mapped	O
to	O
human	O
genome	O
sequence	O
(	O
build	O
GRCh37	O
/	O
hg19	O
)	O
with	O
Torrent	O
Mapping	O
Alignment	O
Program	O
optimized	O
to	O
Ion	O
Torrent	O
data	O
.	O

A	O
pedigree	O
of	O
the	O
Chinese	O
Alport	O
kindred	O
is	O
shown	O
in	O
Figure	O
1	O
.	O

His	O
older	O
sister	O
(	O
II	O
:	O
1	O
,	O
MYO7A	B-GENE
homozygote	O
)	O
had	O
a	O
milder	O
retinal	O
phenotype	O
.	O

Output	O
was	O
passed	O
through	O
6	O
-	O
pole	O
Butterworth	O
high	O
-	O
pass	O
(	O
100	O
Hz	O
)	O
and	O
low	O
-	O
pass	O
(	O
3	O
kHz	O
)	O
filters	O
and	O
then	O
to	O
a	O
16	O
-	O
bit	O
analog	O
-	O
to	O
-	O
digital	O
converter	O
(	O
100	O
,	O
000	O
sample	O
/	O
s	O
)	O
.	O

All	O
patients	O
displayed	O
night	O
blindness	B-DISEASE
and	O
visual	B-DISEASE
field	I-DISEASE
loss	I-DISEASE
as	O
the	O
first	O
symptoms	O
,	O
and	O
the	O
eye	O
fundus	O
was	O
typical	O
of	O
RP	B-DISEASE
.	O

The	O
result	O
has	O
been	O
confirmed	O
on	O
two	O
different	O
blood	O
samplings	O
.	O

In	O
this	O
study	O
,	O
we	O
propose	O
a	O
possible	O
role	O
of	O
angulin	B-GENE
-	I-GENE
2	I-GENE
/	O
ILDR1	B-GENE
in	O
tTJ	O
formation	O
in	O
the	O
inner	O
ear	O
and	O
a	O
wider	O
audiologic	O
phenotypic	O
spectrum	O
of	O
DFNB42	B-DISEASE
caused	O
by	O
mutations	O
within	O
ILDR1	B-GENE
.	O

The	O
electrophysiological	O
findings	O
of	O
14	O
nerves	O
in	O
seven	O
affected	O
familial	O
members	O
were	O
obtained	O
(	O
see	O
online	O
supplementary	O
table	O
S11	O
)	O
.	O

We	O
examined	O
hearing	O
in	O
2	O
-	O
,	O
4	O
-	O
and	O
8	O
-	O
week	O
-	O
old	O
Homer2	B-GENE
-	O
/	O
-	O
,	O
Homer2	B-GENE
+	O
/	O
-	O
and	O
WT	O
Homer2	B-GENE
+	O
/	O
+	O
mice	O
and	O
observed	O
no	O
differences	O
between	O
age	O
-	O
matched	O
WT	O
and	O
Homer2	B-GENE
+	O
/	O
-	O
animals	O
(	O
P	O
>	O
0	O
.	O
2	O
)	O
,	O
however	O
Homer2	B-GENE
-	O
/	O
-	O
mice	O
showed	O
progressive	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
Fig	O
4	O
)	O
.	O

This	O
study	O
shows	O
how	O
an	O
exonic	O
mutation	O
that	O
weakens	O
the	O
5	O
'	O
splice	O
site	O
enhances	O
a	O
minor	O
alternative	O
splicing	O
without	O
abolishing	O
a	O
complete	O
exclusion	O
of	O
the	O
exon	O
and	O
therefore	O
causes	O
a	O
less	O
severe	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
than	O
the	O
USH1B	O
-	O
associated	O
alleles	O
.	O

Macular	O
degeneration	O
is	O
observed	O
in	O
this	O
patient	O
.	O

In	O
view	O
of	O
the	O
extensive	O
studies	O
conducted	O
worldwide	O
,	O
the	O
major	O
objective	O
of	O
this	O
study	O
was	O
to	O
begin	O
to	O
comprehensively	O
delineate	O
the	O
genetic	O
basis	O
of	O
ARNSHL	B-DISEASE
in	O
individuals	O
of	O
Saudi	O
Arabian	O
origin	O
.	O

This	O
discrepancy	O
may	O
also	O
result	O
from	O
differences	O
in	O
T	O
dosing	O
when	O
given	O
for	O
replacement	O
therapy	O
or	O
for	O
male	O
contraception	O
.	O

(	O
A	O
)	O
PCR	O
analysis	O
of	O
muscle	O
-	O
derived	O
mtDNA	O
showing	O
the	O
presence	O
of	O
multiple	O
deleted	O
mitochondrial	O
genomes	O
in	O
Patient	O
1	O
.	O

X	O
-	O
axis	O
denotes	O
sequencing	O
depth	O
,	O
and	O
y	O
-	O
axis	O
indicated	O
the	O
fraction	O
of	O
bases	O
that	O
achieves	O
at	O
or	O
above	O
a	O
given	O
sequencing	O
depth	O
.	O

The	O
failed	O
baits	O
(	O
632	O
)	O
were	O
redesigned	O
with	O
the	O
repeatmasker	O
filter	O
turned	O
off	O
.	O

In	O
the	O
initial	O
filtering	O
,	O
these	O
were	O
removed	O
and	O
only	O
the	O
remaining	O
variants	O
were	O
analyzed	O
.	O

Target	O
exon	O
resequencing	O
using	O
Massively	O
Parallel	O
DNA	O
Sequencing	O
(	O
MPS	O
)	O
is	O
a	O
new	O
powerful	O
strategy	O
to	O
discover	O
causative	O
genes	O
in	O
rare	O
Mendelian	O
disorders	O
such	O
as	O
deafness	B-DISEASE
.	O

Mean	O
audiometric	O
hearing	O
thresholds	O
for	O
right	O
and	O
left	O
ears	O
of	O
all	O
patients	O
of	O
part	O
A	O
(	O
triangles	O
)	O
,	O
patients	O
V	O
-	O
3	O
and	O
V	O
-	O
5	O
of	O
part	O
B	O
(	O
squares	O
)	O
,	O
and	O
audiogram	O
of	O
both	O
ears	O
of	O
patient	O
VI	O
-	O
1	O
(	O
circles	O
)	O
of	O
the	O
family	O
Iranian	O
3	O
.	O

Most	O
of	O
the	O
insertion	O
/	O
deletion	O
errors	O
preferentially	O
occurred	O
at	O
a	O
homonucleotide	O
region	O
(	O
yellow	O
regions	O
in	O
Fig	O
.	O

Patient	O
U1185	O
(	O
presenting	O
with	O
typical	O
USH2	B-DISEASE
clinical	O
signs	O
)	O
carries	O
three	O
pathogenic	O
mutations	O
:	O
two	O
in	O
USH2A	B-GENE
and	O
the	O
USH1C	B-GENE
c	B-VARIANT
.	I-VARIANT
496	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
splice	O
mutation	O
.	O

Thirty	O
individuals	O
with	O
hearing	B-DISEASE
impairment	I-DISEASE
were	O
recruited	O
over	O
a	O
number	O
of	O
years	O
from	O
W	O
u	O
rzburg	O
and	O
Mainz	O
,	O
Germany	O
,	O
for	O
targeted	O
deafness	B-DISEASE
gene	O
sequencing	O
after	O
genetic	O
counseling	O
was	O
initiated	O
.	O

Both	O
changes	O
were	O
predicted	O
to	O
be	O
pathogenic	O
(	O
SIFT	O
score	O
=	O
0	O
.	O
01	O
,	O
PolyPhen	O
score	O
=	O
0	O
.	O
9	O
)	O
.	O

It	O
is	O
likely	O
that	O
187delG	B-VARIANT
is	O
a	O
common	O
mutation	O
among	O
Uyghur	O
NSD	B-DISEASE
patients	O
.	O

The	O
observations	O
in	O
the	O
present	O
study	O
were	O
not	O
consistent	O
with	O
either	O
Azaiez	O
or	O
Campbell	O
'	O
s	O
findings	O
.	O

Multiplex	O
PCR	O
and	O
MLPA	O
analyses	O
of	O
the	O
affected	O
individual	O
IV	O
-	O
3	O
showed	O
that	O
he	O
has	O
a	O
deletion	O
from	O
exons	O
49	O
-	O
51	O
in	O
the	O
DMD	B-DISEASE
gene	O
(	O
Figure	O
4	O
)	O
.	O

In	O
the	O
EVA	B-DISEASE
group	O
,	O
46	O
patients	O
(	O
46	O
/	O
50	O
,	O
92	O
.	O
0	O
%	O
)	O
had	O
biallelic	O
mutations	O
and	O
three	O
patients	O
with	O
one	O
mutation	O
(	O
3	O
/	O
50	O
,	O
6	O
.	O
0	O
%	O
)	O
.	O

Two	O
patterns	O
of	O
ECochG	O
potentials	O
were	O
observed	O
in	O
the	O
OPA1	B-GENE
-	O
M	O
patients	O
.	O

Both	O
have	O
normal	O
karyotype	O
(	O
as	O
assessed	O
by	O
cytogenetic	O
analysis	O
)	O
,	O
neurological	O
,	O
and	O
cognitive	O
function	O
.	O

5a	O
,	O
b	O
)	O
.	O

The	O
mutation	O
would	O
destroy	O
that	O
splice	O
site	O
,	O
leading	O
to	O
a	O
truncated	O
protein	O
lacking	O
the	O
last	O
approximate	O
200	O
amino	O
acid	O
residues	O
.	O

Interestingly	O
,	O
in	O
a	O
recent	O
audiological	O
follow	O
-	O
up	O
after	O
the	O
finding	O
of	O
the	O
mutation	O
,	O
a	O
small	O
dip	O
in	O
mid	O
frequencies	O
in	O
her	O
audiogram	O
was	O
found	O
,	O
which	O
could	O
be	O
the	O
first	O
signs	O
of	O
an	O
effect	O
of	O
the	O
mutation	O
,	O
consistent	O
with	O
the	O
broad	O
range	O
of	O
age	O
of	O
onset	O
observed	O
in	O
the	O
family	O
for	O
the	O
trait	O
.	O

In	O
addition	O
to	O
these	O
cases	O
with	O
a	O
single	O
mutated	O
chromosome	O
,	O
there	O
were	O
11	O
patients	O
in	O
which	O
no	O
WFS1	B-GENE
mutations	O
were	O
identified	O
.	O

Numbering	O
commenced	O
with	O
the	O
A	O
of	O
the	O
ATG	O
initiation	O
codon	O
as	O
+	O
1	O
.	O

Genotype	O
confirmation	O
using	O
Sanger	O
sequencing	O
revealed	O
that	O
two	O
patients	O
,	O
II	O
-	O
2	O
and	O
III	O
-	O
1	O
,	O
were	O
heterozygous	O
for	O
this	O
mutation	O
.	O

IM	O
,	O
NL	O
and	O
CP	O
performed	O
Sanger	O
sequencing	O
and	O
analysis	O
.	O

Samples	O
were	O
prescreened	O
for	O
mutations	O
in	O
GJB2	B-GENE
(	O
MIM	O
121011	O
)	O
via	O
Sanger	O
sequencing	O
;	O
none	O
were	O
identified	O
in	O
any	O
of	O
the	O
20	O
families	O
.	O

pSTRC	O
transcripts	O
are	O
boxed	O
in	O
red	O
.	O

Affected	O
and	O
unaffected	O
individuals	O
are	O
represented	O
with	O
black	O
and	O
open	O
circles	O
,	O
respectively	O
.	O

Monozygotic	O
twin	O
pairs	O
were	O
treated	O
as	O
a	O
single	O
observation	O
in	O
the	O
analysis	O
as	O
described	O
above	O
.	O

The	O
c	B-VARIANT
.	I-VARIANT
794T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
change	O
was	O
not	O
present	O
near	O
the	O
canonical	O
splice	O
junctions	O
and	O
was	O
not	O
predicted	O
to	O
create	O
any	O
aberrant	O
splice	O
site	O
.	O

Three	O
micrograms	O
(	O
mu	O
g	O
)	O
of	O
genomic	O
DNA	O
was	O
used	O
to	O
construct	O
the	O
exome	O
library	O
.	O

Compared	O
to	O
the	O
reported	O
geographic	O
distribution	O
of	O
GSDs	B-DISEASE
(	O
Figure	O
2	O
)	O
,	O
genetic	O
testing	O
was	O
only	O
performed	O
at	O
university	O
hospitals	O
in	O
a	O
few	O
areas	O
(	O
Figure	O
4	O
)	O
.	O

A	O
detailed	O
legend	O
for	O
the	O
network	O
shapes	O
and	O
molecular	O
relationships	O
is	O
found	O
in	O
the	O
IPA	O
network	O
(	O
http	O
:	O
/	O
/	O
ingenuity	O
.	O
force	O
.	O
com	O
/	O
ipa	O
/	O
articles	O
/	O
Feature_Description	O
/	O
Legend	O
)	O
.	O

TEOAE	O
tests	O
were	O
conducted	O
on	O
the	O
same	O
day	O
as	O
the	O
pure	O
tone	O
test	O
.	O

Four	O
hours	O
following	O
cyto	O
-	O
D	O
treatment	O
(	O
i	O
.	O
e	O
.	O
,	O
the	O
recovery	O
period	O
for	O
actin	O
re	O
-	O
polymerization	O
)	O
[	O
27	O
]	O
,	O
we	O
observed	O
that	O
ELMOD3	B-GENE
re	O
-	O
accumulated	O
at	O
the	O
cell	O
membrane	O
(	O
Figure	O
6C	O
,	O
6D	O
)	O
.	O

4198delins4198	I-VARIANT
+	I-VARIANT
2_	I-VARIANT
4198	I-VARIANT
+	I-VARIANT
72	I-VARIANT
)	O
.	O

J	O
.	O

The	O
size	O
of	O
the	O
amplified	O
product	O
of	O
EYA1	B-GENE
minigene	O
transcripts	O
of	O
splice	O
site	O
mutations	O
c	B-VARIANT
.	I-VARIANT
1140	I-VARIANT
+	I-VARIANT
1	I-VARIANT
G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
A	O
)	O
,	O
c	B-VARIANT
.	I-VARIANT
1598	I-VARIANT
-	I-VARIANT
2	I-VARIANT
G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
B	O
)	O
,	O
and	O
c	B-VARIANT
.	I-VARIANT
699	I-VARIANT
+	I-VARIANT
5	I-VARIANT
G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
C	O
)	O
,	O
were	O
263	O
bp	O
which	O
is	O
smaller	O
than	O
that	O
of	O
the	O
wild	O
type	O
,	O
suggesting	O
exon	O
skipping	O
.	O

Progression	O
was	O
expressed	O
in	O
dB	O
-	O
per	O
-	O
year	O
and	O
designated	O
Annual	O
Threshold	O
Deterioration	O
(	O
ATD	O
)	O
.	O

Patients	O
carrying	O
multiple	O
mutations	O
have	O
been	O
shown	O
to	O
present	O
with	O
a	O
more	O
severe	O
phenotype	O
compared	O
to	O
patients	O
carrying	O
only	O
one	O
mutation	O
[	O
19	O
]	O
.	O

The	O
MYO7A	B-GENE
compound	O
mutations	O
c	B-VARIANT
.	I-VARIANT
73G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
G25R	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
462C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
C154X	I-VARIANT
)	O
were	O
identified	O
as	O
pathogenic	O
mutations	O
in	O
family	O
7162	O
with	O
USH1	B-DISEASE
.	O

The	O
fact	O
that	O
it	O
has	O
not	O
been	O
found	O
in	O
any	O
other	O
cohorts	O
of	O
subjects	O
with	O
HI	B-DISEASE
studied	O
so	O
far	O
might	O
be	O
just	O
the	O
consequence	O
of	O
an	O
enrolment	O
bias	O
towards	O
subjects	O
with	O
severe	O
or	O
profound	O
HI	B-DISEASE
,	O
which	O
would	O
under	O
-	O
represent	O
hypomorphic	O
alleles	O
associated	O
with	O
late	O
-	O
onset	O
mild	O
-	O
to	O
-	O
moderate	O
HI	B-DISEASE
.	O

DNA	O
sequencing	O
of	O
the	O
PCR	O
-	O
amplified	O
product	O
was	O
performed	O
bi	O
-	O
directionally	O
on	O
an	O
ABI	O
3730XL	O
automated	O
sequencer	O
(	O
Applied	O
Biosystems	O
,	O
Macrogen	O
,	O
Seoul	O
,	O
Korea	O
)	O
using	O
the	O
same	O
primers	O
for	O
amplification	O
.	O

On	O
the	O
contrary	O
,	O
patients	O
from	O
families	O
3	O
-	O
5	O
had	O
slight	O
to	O
moderate	O
thrombocytopenia	B-DISEASE
and	O
no	O
extra	B-DISEASE
-	I-DISEASE
hematological	I-DISEASE
manifestations	I-DISEASE
,	O
with	O
the	O
exception	O
of	O
a	O
very	O
mild	O
,	O
clinically	O
unnoticed	O
sensorineural	O
hearing	O
defect	O
in	O
the	O
adult	O
member	O
of	O
family	O
4	O
.	O

The	O
extreme	O
heterogeneity	O
of	O
RDs	B-DISEASE
at	O
the	O
clinical	O
and	O
genetic	O
levels	O
hinders	O
the	O
accurate	O
clinical	O
assessment	O
,	O
patient	O
management	O
,	O
and	O
genetic	O
counseling	O
.	O

All	O
the	O
data	O
used	O
for	O
the	O
graph	O
represent	O
mean	O
values	O
of	O
three	O
independent	O
samples	O
.	O

1	O
,	O
057	O
cases	O
were	O
reported	O
annually	O
in	O
recent	O
5	O
years	O
.	O

Another	O
striking	O
finding	O
in	O
our	O
study	O
was	O
the	O
occurrence	O
of	O
two	O
novel	O
mutant	O
alleles	O
in	O
the	O
TS	B-DISEASE
-	I-DISEASE
NSRAN	I-DISEASE
patient	O
,	O
thus	O
being	O
the	O
second	O
reported	O
case	O
of	O
the	O
temperature	O
-	O
sensitive	O
phenotype	O
related	O
to	O
OTOF	B-GENE
gene	O
mutations	O
in	O
the	O
literature	O
.	O

A	O
qPCR	O
assay	O
to	O
detect	O
the	O
ratio	O
between	O
wild	O
-	O
type	O
and	O
mutant	O
transcripts	O
as	O
well	O
as	O
total	O
expression	O
of	O
CD164	B-GENE
in	O
the	O
double	O
transfected	O
cell	O
lines	O
was	O
developed	O
.	O

We	O
firstly	O
selected	O
exonic	O
and	O
splicing	O
variants	O
including	O
non	O
-	O
synonymous	O
variants	O
and	O
small	O
indels	O
.	O

There	O
was	O
no	O
sign	O
of	O
hypertrophy	B-DISEASE
or	O
ischemia	B-DISEASE
in	O
the	O
ECG	O
and	O
echocardiography	O
was	O
normal	O
.	O

For	O
targeted	O
enrichment	O
of	O
deafness	B-DISEASE
genes	O
,	O
the	O
Illumina	O
library	O
DNA	O
was	O
purified	O
with	O
a	O
QIAquickMinElute	O
column	O
and	O
eluted	O
into	O
50	O
u	O
L	O
of	O
hybridization	O
buffer	O
(	O
HB	O
,	O
Roche	O
NimbleGen	O
;	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
.	O

Figure	O
4	O
Mean	O
level	O
of	O
COX	O
-	O
deficiency	O
in	O
skeletal	O
muscle	O
biopsies	O
:	O
(	O
A	O
)	O
pure	O
DOA	B-DISEASE
versus	O
DOA	O
+	O
phenotypes	O
(	O
P	O
=	O
0	O
.	O
0226	O
)	O
and	O
(	O
B	O
)	O
pure	O
DOA	B-DISEASE
versus	O
age	O
-	O
matched	O
controls	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

SIFT	O
,	O
http	O
:	O
/	O
/	O
sift	O
.	O
bii	O
.	O
a	O
-	O
star	O
.	O
edu	O
.	O
sg	O
/	O
9	O
.	O

We	O
performed	O
cycling	O
PCR	O
using	O
an	O
ABI	O
Big	O
Dye	O
Terminator	O
v	O
.	O

To	O
date	O
,	O
six	O
USH1	B-DISEASE
causative	O
genes	O
have	O
been	O
identified	O
[	O
3	O
,	O
4	O
]	O
.	O

Though	O
it	O
has	O
been	O
suggested	O
that	O
five	O
exons	O
(	O
10	O
,	O
15	O
,	O
16	O
,	O
23	O
and	O
24	O
)	O
,	O
are	O
defined	O
as	O
a	O
hot	O
spot	O
region	O
of	O
the	O
TCOF1	B-GENE
gene	O
mutations	O
[	O
14	O
]	O
,	O
a	O
distribution	O
of	O
pathogenic	O
variations	O
along	O
all	O
the	O
gene	O
was	O
reported	O
by	O
different	O
authors	O
.	O

The	O
DNA	O
-	O
binding	O
domain	O
of	O
the	O
p53	O
protein	O
(	O
black	O
)	O
bound	O
to	O
DNA	O
(	O
purple	O
)	O
[	O
84	O
]	O
.	O

The	O
188	O
NCUS	O
probands	O
and	O
48	O
CEPH	O
controls	O
underwent	O
bidirectional	O
DNA	O
sequencing	O
of	O
nine	O
Usher	B-DISEASE
genes	O
(	O
MYO7A	B-GENE
,	O
CDH23	B-GENE
,	O
PCDH15	B-GENE
,	O
USH1C	B-GENE
,	O
USH1G	B-GENE
,	O
USH2A	B-GENE
,	O
GPR98	B-GENE
,	O
WHRN	B-GENE
,	O
CLRN1	B-GENE
)	O
and	O
the	O
candidate	O
gene	O
SLC4A7	B-GENE
.	O

To	O
further	O
test	O
that	O
the	O
343G	B-VARIANT
>	I-VARIANT
A	I-VARIANT
mutation	O
in	O
Gipc3	B-GENE
causes	O
the	O
ahl5	B-DISEASE
and	O
jams1	B-DISEASE
phenotypes	O
,	O
we	O
generated	O
transgenic	O
animals	O
expressing	O
Gipc3	B-GENE
.	O

Glu340	O
also	O
forms	O
two	O
hydrogen	O
bonds	O
with	O
Arg388	O
,	O
the	O
first	O
residue	O
of	O
alpha	O
-	O
helix	O
10	O
.	O

We	O
selected	O
several	O
hundred	O
genes	O
important	O
in	O
kidney	O
development	O
and	O
glomerular	B-DISEASE
diseases	I-DISEASE
to	O
identify	O
mutations	O
that	O
may	O
provide	O
insights	O
into	O
the	O
presence	O
of	O
a	O
congenital	O
anomaly	O
(	O
VUR	B-DISEASE
,	O
hydronephrosis	B-DISEASE
)	O
and	O
proteinuria	B-DISEASE
in	O
a	O
patient	O
where	O
the	O
etiology	O
of	O
either	O
entity	O
was	O
unclear	O
since	O
FSGS	B-DISEASE
pattern	O
can	O
be	O
observed	O
in	O
obstructive	O
or	O
reflux	O
nephropathy	O
or	O
primary	O
glomerular	B-DISEASE
diseases	I-DISEASE
.	O

A	O
note	O
of	O
caution	O
regards	O
the	O
fate	O
and	O
destination	O
of	O
the	O
singly	O
transfected	O
collagen	O
chains	O
.	O

An	O
ETC	O
assay	O
,	O
performed	O
in	O
skeletal	O
muscle	O
homogenate	O
as	O
well	O
as	O
isolated	O
mitochondria	O
shows	O
significantly	O
reduced	O
COI	B-GENE
activity	O
.	O

The	O
final	O
probe	O
design	O
size	O
was	O
296	O
.	O
74	O
Kb	O
with	O
a	O
theoretical	O
coverage	O
of	O
99	O
.	O
88	O
%	O
for	O
our	O
targeted	O
regions	O
.	O

Individuals	O
may	O
see	O
many	O
different	O
eye	O
specialists	O
before	O
a	O
definitive	O
diagnosis	O
is	O
made	O
,	O
whereas	O
genetic	O
testing	O
can	O
rapidly	O
provide	O
an	O
accurate	O
diagnosis	O
.	O

Four	O
patients	O
had	O
features	O
corresponding	O
to	O
the	O
WS2	B-DISEASE
phenotype	O
(	O
figure	O
4	O
)	O
.	O

To	O
experimentally	O
explore	O
the	O
effects	O
of	O
these	O
CIB2	B-GENE
mutations	O
on	O
intracellular	O
Ca	O
2	O
+	O
signaling	O
,	O
we	O
used	O
ratiometric	O
Ca	O
2	O
+	O
imaging	O
to	O
measure	O
ATP	O
-	O
induced	O
IP	O
3	O
-	O
dependent	O
Ca	O
2	O
+	O
responses	O
10	O
in	O
transiently	O
-	O
transfected	O
COS	O
-	O
7	O
cells	O
.	O

58	O
genes	O
reported	O
to	O
be	O
causative	O
of	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O

Untagged	O
CD164	B-GENE
migrated	O
as	O
several	O
bands	O
with	O
predominant	O
species	O
around	O
80	O
-	O
100	O
kDa	O
under	O
reducing	O
conditions	O
(	O
Fig	O
5A	O
)	O
.	O

Taking	O
together	O
both	O
approaches	O
,	O
the	O
detection	O
of	O
pathogenic	O
alleles	O
was	O
62	O
.	O
5	O
%	O
.	O

We	O
identified	O
two	O
MYO7A	B-GENE
compound	O
heterozygous	O
mutations	O
,	O
c	B-VARIANT
.	I-VARIANT
73G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
462C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
as	O
disease	O
-	O
causing	O
mutations	O
through	O
multiple	O
deafness	B-DISEASE
gene	O
capture	O
,	O
NGS	O
,	O
and	O
bioinformatic	O
analysis	O
.	O

Five	O
patients	O
with	O
familial	O
congenital	O
deafness	B-DISEASE
were	O
screened	O
for	O
15	O
deafness	B-DISEASE
genes	O
on	O
the	O
454	O
Genome	O
Sequencer	O
in	O
order	O
to	O
evaluate	O
if	O
next	O
generation	O
sequencing	O
enables	O
the	O
detection	O
of	O
mutations	O
.	O

The	O
secondary	O
antibody	O
used	O
was	O
Jackson	O
ImmunoResearch	O
biotin	O
-	O
conjugated	O
donkey	O
anti	O
-	O
rabbit	O
(	O
711	O
-	O
065	O
-	O
152	O
,	O
1	O
:	O
100	O
)	O
.	O

In	O
contrast	O
,	O
we	O
did	O
not	O
neither	O
find	O
a	O
significant	O
correlations	O
between	O
RNFLs	O
at	O
the	O
posterior	O
pole	O
and	O
age	O
nor	O
between	O
RNFLs	O
at	O
the	O
posterior	O
pole	O
and	O
VA	O
in	O
our	O
group	O
.	O

According	O
to	O
a	O
number	O
of	O
previous	O
genetic	O
studies	O
,	O
hereditary	O
hearing	B-DISEASE
loss	I-DISEASE
shows	O
distinct	O
spectrums	O
and	O
prevalence	O
of	O
mutations	O
in	O
different	O
ethnic	O
groups	O
[	O
36	O
-	O
40	O
]	O
.	O

(	O
Alessandria	O
)	O
,	O
Anna	O
Paola	O
Frongia	O
M	O
.	O
D	O
.	O
,	O
Margherita	O
Chessa	O
M	O
.	O
D	O
.	O

Thus	O
,	O
the	O
EDNRB	B-GENE
isoform	O
3	O
might	O
not	O
play	O
a	O
role	O
as	O
a	O
cellular	O
receptor	O
and	O
,	O
consequently	O
,	O
nor	O
in	O
the	O
EDNRB	B-GENE
signaling	O
controlling	O
the	O
neural	O
crest	O
cells	O
fate	O
.	O

One	O
previous	O
study	O
(	O
9	O
)	O
employed	O
a	O
Sanger	O
sequence	O
approach	O
to	O
detect	O
small	O
sequence	O
changes	O
,	O
but	O
was	O
unable	O
to	O
differentiate	O
the	O
STRC	B-GENE
gene	O
from	O
the	O
pseudogene	O
,	O
which	O
is	O
a	O
drawback	O
we	O
have	O
overcome	O
.	O

Diagnosis	O
by	O
WES	O
for	O
FORGE	O
Projects	O
Presenting	O
with	O
Cerebellar	O
Ataxia	B-DISEASE
(	O
A	O
)	O
Patients	O
born	O
to	O
consanguineous	O
parents	O
;	O
(	O
B	O
)	O
Patients	O
with	O
affected	O
siblings	O
born	O
to	O
nonconsanguineous	O
parents	O
;	O
and	O
(	O
C	O
)	O
Patients	O
without	O
a	O
family	O
history	O
(	O
simplex	O
)	O
.	O

Pre	O
-	O
and	O
perinatal	O
histories	O
were	O
reviewed	O
.	O

a	O
Patient	O
II	O
-	O
2	O
was	O
unable	O
to	O
walk	O
and	O
has	O
been	O
wheelchair	O
-	O
bound	O
since	O
5	O
years	O
of	O
age	O
.	O

1	O
A	O
-	O
E	O
)	O
.	O

As	O
in	O
the	O
case	O
of	O
c	B-VARIANT
.	I-VARIANT
238	I-VARIANT
-	I-VARIANT
239insC	I-VARIANT
,	O
this	O
could	O
be	O
due	O
to	O
settlement	O
of	O
ethnic	O
groups	O
other	O
than	O
French	O
Canadians	O
.	O

Similarly	O
,	O
Fishman	O
et	O
al	O
.	O

40	O
Neither	O
family	O
was	O
known	O
to	O
be	O
consanguineous	O
.	O

Here	O
we	O
report	O
on	O
the	O
investigation	O
of	O
a	O
Chinese	O
family	O
with	O
early	O
onset	O
of	O
combined	O
blindness	B-DISEASE
and	O
deafness	B-DISEASE
,	O
key	O
features	O
of	O
USH1	B-DISEASE
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
all	O
known	O
inherited	O
retinal	B-DISEASE
dystrophy	I-DISEASE
(	O
RD	B-DISEASE
)	O
genes	O
in	O
parallel	O
by	O
targeted	O
next	O
-	O
generation	O
sequencing	O
(	O
NGS	O
)	O
in	O
a	O
cohort	O
of	O
100	O
RP	B-DISEASE
patients	O
.	O

GAPDH	O
was	O
used	O
as	O
a	O
control	O
and	O
amplified	O
under	O
the	O
same	O
conditions	O
.	O

In	O
all	O
5	O
patients	O
the	O
eye	O
with	O
generalized	O
iris	B-DISEASE
hypopigmentation	I-DISEASE
also	O
had	O
mild	O
retinal	B-DISEASE
hypopigmentation	I-DISEASE
.	O

A	O
monoallelic	O
mutation	O
in	O
FGFR1	B-GENE
underlies	O
approximately	O
10	O
%	O
of	O
KS	B-DISEASE
cases	O
[	O
16	O
]	O
.	O

germline	O
variants	O
included	O
a	O
total	O
of	O
3	O
BRCA1	B-GENE
large	O
-	O
scale	O
deletions	O
,	O
Following	O
filtering	O
of	O
variants	O
with	O
>	O
1	O
%	O
MAF	O
in	O
the	O
population	O
,	O
TCGA	O
ovarian	B-DISEASE
cancer	I-DISEASE
cases	O
,	O
and	O
WHISP	O
controls	O
,	O
a	O
total	O
of	O
3	O
,	O
635	O
truncation	O
variants	O
,	O
and	O
22	O
,	O
953	O
missense	O
variants	O
(	O
17	O
,	O
348	O
in	O
expressed	O
genes	O
)	O
remained	O
for	O
TCGA	O
cases	O
.	O

This	O
observation	O
suggests	O
that	O
exon	O
16	O
must	O
be	O
alternatively	O
spliced	O
,	O
at	O
least	O
in	O
lymphocytes	O
.	O

3D	O
modeling	O
of	O
p	B-VARIANT
.	I-VARIANT
G1734R	I-VARIANT
(	O
PDB	O
template	O
2JD4_B	O
,	O
26	O
%	O
identity	O
with	O
Lama1	O
)	O
.	O

KN	O
carried	O
out	O
molecular	O
modeling	O
of	O
gene	O
products	O
.	O

A	O
mutation	O
screening	O
strategy	O
using	O
TaqMan	O
assay	O
based	O
on	O
the	O
ethnic	O
-	O
specific	O
frequent	O
mutations	O
is	O
a	O
powerful	O
and	O
effective	O
method	O
for	O
such	O
a	O
large	O
gene	O
.	O

We	O
performed	O
whole	O
exome	O
sequencing	O
in	O
four	O
unrelated	O
Tunisian	O
patients	O
affected	O
by	O
apparently	O
isolated	O
,	O
congenital	B-DISEASE
profound	I-DISEASE
deafness	I-DISEASE
,	O
with	O
reportedly	O
normal	O
ocular	O
fundus	O
examination	O
.	O

No	O
.	O
,	O
accession	O
number	O
of	O
reference	O
sequence	O
;	O
Chr	O
,	O
chromosome	O
;	O
Ex	O
,	O
exon	O
;	O
EVS	O
,	O
exome	O
variant	O
server	O
;	O
In	O
,	O
intron	O
;	O
SNPs	O
,	O
single	O
nucleotide	O
polymorphisms	O
;	O
Ref	O
,	O
references	O
.	O

All	O
of	O
the	O
patients	O
with	O
SLC26A4	B-GENE
mutations	O
had	O
EVA	B-DISEASE
,	O
which	O
has	O
been	O
demonstrated	O
to	O
be	O
a	O
result	O
of	O
the	O
mutations	O
of	O
this	O
gene	O
.	O

We	O
analyzed	O
the	O
haplotype	O
using	O
21	O
SNPs	O
spanning	O
a	O
5	O
.	O
34Mb	O
around	O
the	O
mutation	O
c	B-VARIANT
.	I-VARIANT
1331	I-VARIANT
+	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
.	O

Other	O
neurologic	B-DISEASE
deficits	I-DISEASE
included	O
slow	O
motor	O
movements	O
in	O
three	O
(	O
17	O
%	O
)	O
and	O
increased	O
tone	O
and	O
brisk	O
deep	O
tendon	O
reflexes	O
in	O
one	O
.	O

Because	O
the	O
EVS	O
European	O
-	O
American	O
genotypic	O
distribution	O
deviated	O
from	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
(	O
A1A1	O
=	O
1	O
/	O
A1R	O
=	O
5	O
/	O
RR	O
=	O
3	O
,	O
861	O
,	O
P	O
=	O
0	O
.	O
0027	O
)	O
,	O
35	O
we	O
asked	O
the	O
Exome	O
Sequencing	O
Project	O
directly	O
about	O
this	O
EVS	O
homozygous	O
genotype	O
and	O
were	O
informed	O
that	O
the	O
homozygous	O
indel	O
genotype	O
was	O
likely	O
to	O
be	O
heterozygous	O
and	O
mistakenly	O
called	O
as	O
homozygous	O
because	O
of	O
the	O
low	O
EVS	O
sequencing	O
coverage	O
at	O
this	O
locus	O
(	O
Qian	O
Yi	O
,	O
personal	O
communication	O
)	O
.	O

In	O
this	O
regard	O
,	O
this	O
study	O
merits	O
special	O
attention	O
.	O

A	O
brilliant	O
blue	O
iris	O
was	O
present	O
in	O
five	O
patients	O
who	O
also	O
had	O
mild	O
retinal	B-DISEASE
hypopigmentation	I-DISEASE
(	O
III	O
:	O
5	O
,	O
III	O
:	O
7	O
,	O
III	O
:	O
9	O
,	O
IV	O
:	O
5	O
,	O
and	O
IV	O
:	O
6	O
;	O
Figure	O
2	O
and	O
Figure	O
3	O
)	O
.	O

(	O
b	O
)	O
The	O
average	O
coverage	O
of	O
each	O
exon	O
of	O
the	O
GJB2	B-GENE
and	O
USH2A	B-GENE
genes	O
in	O
the	O
proband	O
(	O
left	O
)	O
and	O
sequencing	O
electropherograms	O
of	O
the	O
heterozygous	O
GJB2	B-GENE
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
and	O
USH2A	B-GENE
c	B-VARIANT
.	I-VARIANT
5051C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
mutations	O
(	O
right	O
)	O
.	O

Thirty	O
-	O
six	O
Spanish	O
families	O
diagnosed	O
with	O
RP	B-DISEASE
,	O
LCA	B-DISEASE
,	O
CRD	B-DISEASE
or	O
CD	B-DISEASE
plus	O
5	O
isolated	O
Usher	B-DISEASE
'	I-DISEASE
s	I-DISEASE
syndrome	I-DISEASE
patients	O
were	O
recruited	O
for	O
this	O
study	O
.	O

There	O
are	O
several	O
parameters	O
that	O
crucially	O
influence	O
the	O
expected	O
coverage	O
in	O
a	O
wild	O
-	O
type	O
sample	O
.	O

Nevertheless	O
,	O
this	O
cohort	O
serves	O
as	O
a	O
powerful	O
resource	O
for	O
further	O
gene	O
and	O
mutation	O
discovery	O
by	O
whole	O
exome	O
as	O
well	O
as	O
genome	O
sequencing	O
.	O

Pierides	O
.	O

We	O
have	O
previously	O
reported	O
genes	O
responsible	O
for	O
deafness	B-DISEASE
in	O
Japanese	O
patients	O
and	O
observed	O
differences	O
in	O
mutation	O
spectrum	O
between	O
Japanese	O
(	O
who	O
are	O
probably	O
representative	O
of	O
other	O
Asian	O
populations	O
)	O
and	O
populations	O
with	O
European	O
ancestry	O
[	O
24	O
]	O
.	O

Moreover	O
,	O
after	O
removing	O
the	O
end	O
regions	O
of	O
the	O
read	O
sequences	O
,	O
we	O
found	O
that	O
the	O
error	O
rates	O
of	O
the	O
target	O
regions	O
for	O
each	O
category	O
were	O
0	O
.	O
20	O
,	O
0	O
.	O
134	O
,	O
0	O
.	O
023	O
,	O
and	O
0	O
.	O
014	O
%	O
,	O
respectively	O
(	O
Fig	O
.	O

In	O
10	O
,	O
features	O
other	O
than	O
DM	B-DISEASE
predated	O
OA	B-DISEASE
.	O

Siddiqi	O
MS	O
JO	O
HA	O
AB	O
M	O
.	O

These	O
findings	O
indicate	O
that	O
,	O
whereas	O
mutation	O
of	O
the	O
TJP2	B-GENE
gene	O
might	O
cause	O
ADNSHL	B-DISEASE
,	O
CLDN14	B-GENE
is	O
not	O
a	O
major	O
causative	O
gene	O
for	O
ARNSHL	B-DISEASE
in	O
the	O
Korean	O
population	O
studied	O
.	O

The	O
nonsense	O
mutation	O
rs11571833	B-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Lys3326Ter	I-VARIANT
)	O
introduces	O
a	O
stop	O
codon	O
toward	O
the	O
3	O
'	O
end	O
of	O
the	O
transcript	O
.	O

Our	O
results	O
confirmed	O
the	O
effectiveness	O
of	O
the	O
targeted	O
NGS	O
screening	O
of	O
the	O
known	O
deafness	B-DISEASE
genes	O
.	O

We	O
obtained	O
a	O
written	O
informed	O
consent	O
from	O
all	O
the	O
participants	O
in	O
this	O
study	O
.	O

T	O
.	O
H	O
.	O

'	O
ON	O
+	O
NEAR	O
BAIT	O
'	O
represents	O
the	O
percentage	O
of	O
on	O
+	O
near	O
bait	O
bases	O
against	O
bases	O
aligned	O
,	O
and	O
'	O
OFF	O
BAIT	O
'	O
represents	O
the	O
percentage	O
of	O
aligned	O
bases	O
that	O
mapped	O
neither	O
on	O
nor	O
near	O
a	O
bait	O
.	O

We	O
thank	O
Saskia	O
van	O
der	O
Velde	O
-	O
Visser	O
for	O
excellent	O
technical	O
assistance	O
.	O
Sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
affects	O
the	O
quality	O
of	O
life	O
and	O
communication	O
of	O
millions	O
of	O
people	O
,	O
but	O
the	O
underlying	O
molecular	O
mechanisms	O
remain	O
elusive	O
.	O

Because	O
the	O
silent	O
mutation	O
can	O
also	O
be	O
spliced	O
normally	O
,	O
it	O
is	O
not	O
clear	O
what	O
phenotype	O
would	O
result	O
if	O
this	O
novel	O
C	O
-	O
propeptide	O
mutation	O
had	O
been	O
inherited	O
with	O
a	O
null	O
allele	O
.	O

(	O
d	O
)	O
shows	O
the	O
family	O
tree	O
for	O
L151	O
.	O

The	O
primordium	O
of	O
the	O
cochlear	O
duct	O
evaginates	O
from	O
the	O
ventral	O
portion	O
of	O
the	O
otocyst	O
starting	O
at	O
the	O
fifth	O
week	O
.	O

In	O
addition	O
,	O
we	O
checked	O
our	O
TRS	O
-	O
204	O
data	O
to	O
see	O
if	O
there	O
was	O
any	O
deletion	O
or	O
duplication	O
of	O
targeted	O
genes	O
.	O

2	O
)	O
.	O

Identical	O
residues	O
are	O
highlighted	O
with	O
shading	O
.	O

De	O
Keulenaer	O
et	O
al	O
.	O

(	O
a	O
)	O
Family	O
pedigrees	O
showing	O
autosomal	O
dominant	O
inheritance	O
.	O

Prevalence	O
of	O
non	O
-	O
syndromic	O
RP	B-DISEASE
is	O
approximately	O
1	O
in	O
4	O
,	O
000	O
[	O
3	O
]	O
.	O

C	O
.	O

This	O
finding	O
suggests	O
that	O
the	O
mutations	O
lead	O
to	O
a	O
selective	O
defect	O
in	O
POLR3	O
assembly	O
,	O
and	O
not	O
in	O
POLR1	O
.	O

Negative	O
and	O
positive	O
controls	O
were	O
included	O
in	O
each	O
series	O
.	O

n	O
,	O
number	O
of	O
patients	O
examined	O
.	O

We	O
found	O
3	O
novel	O
variants	O
in	O
the	O
exons	O
of	O
the	O
PJVK	B-GENE
gene	O
,	O
including	O
1	O
missense	O
mutation	O
and	O
2	O
silent	O
mutations	O
,	O
which	O
are	O
as	O
follows	O
:	O
(	O
1	O
)	O
c	B-VARIANT
.	I-VARIANT
548G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
R183Q	I-VARIANT
)	O
,	O
a	O
transition	O
from	O
G	O
to	O
A	O
in	O
exon	O
4	O
caused	O
a	O
substitution	O
from	O
a	O
basic	O
amino	O
acid	O
arginine	O
to	O
a	O
neutral	O
amino	O
acid	O
glutamine	O
(	O
Figure	O
5	O
)	O
;	O
and	O
(	O
2	O
)	O
c	B-VARIANT
.	I-VARIANT
921G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
*	I-VARIANT
2	I-VARIANT
A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
were	O
silent	O
variants	O
in	O
exon	O
7	O
(	O
Table	O
2	O
)	O
.	O

Consanguineous	O
family	O
.	O

Source	O
of	O
Support	O
:	O
Nil	O
,	O
Conflict	O
of	O
Interest	O
:	O
None	O
declared	O
.	O
Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

This	O
family	O
was	O
described	O
as	O
clinically	O
compatible	O
with	O
USH2	B-DISEASE
by	O
Simsek	O
et	O
al	O
.	O

F27	O
and	O
F33	O
are	O
siblings	O
;	O
therefore	O
the	O
parents	O
of	O
F33	O
are	O
M27	O
and	O
P27	O
.	O

Serum	O
creatine	O
phosphokinase	O
was	O
3	O
,	O
218	O
IU	O
/	O
l	O
(	O
n	O
<	O
170	O
IU	O
/	O
l	O
)	O
.	O

1b	O
)	O
.	O

Ophthalmologic	O
fundus	O
examination	O
in	O
patients	O
with	O
ADOA	B-DISEASE
typically	O
discloses	O
bilateral	O
and	O
symmetric	O
temporal	O
of	O
diffuse	O
pallor	O
of	O
the	O
optic	O
disc	O
[	O
21	O
]	O
.	O

The	O
novel	O
variant	O
p	B-VARIANT
.	I-VARIANT
N174S	I-VARIANT
was	O
identified	O
in	O
one	O
allele	O
of	O
patient	O
RP	B-DISEASE
-	O
1321	O
,	O
also	O
a	O
carrier	O
of	O
variant	O
p	B-VARIANT
.	I-VARIANT
Q1496H	I-VARIANT
(	O
classified	O
as	O
pathogenic	O
)	O
located	O
in	O
the	O
CDH23	B-GENE
gene	O
[	O
12	O
]	O
.	O

Genetic	O
testing	O
is	O
a	O
new	O
method	O
helping	O
to	O
predict	O
,	O
screen	O
and	O
diagnose	O
diseases	O
.	O

Sequence	O
analysis	O
of	O
GJB2	B-GENE
in	O
the	O
current	O
cohort	O
identified	O
16	O
families	O
with	O
mutations	O
in	O
this	O
gene	O
(	O
Table	O
1	O
;	O
Table	O
2	O
)	O
segregating	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Nuclear	O
DNA	O
was	O
stained	O
with	O
DAPI	O
(	O
blue	O
)	O
.	O

Waardenburg	B-DISEASE
-	I-DISEASE
Shah	I-DISEASE
syndrome	I-DISEASE
,	O
Waardenburg	B-DISEASE
-	I-DISEASE
Hirschsprung	I-DISEASE
disease	I-DISEASE
or	O
Type	B-DISEASE
IV	I-DISEASE
Waardenburg	I-DISEASE
syndrome	I-DISEASE
(	O
WS4	B-DISEASE
;	O
MIM	O
#	O
277580	O
)	O
is	O
a	O
congenital	O
developmental	O
disorder	O
characterized	O
by	O
pigmentary	B-DISEASE
abnormalities	I-DISEASE
of	O
the	O
skin	O
,	O
eyes	O
and	O
/	O
or	O
hair	O
,	O
sensorineural	B-DISEASE
deafness	I-DISEASE
and	O
aganglionosis	O
of	O
variable	O
portions	O
of	O
the	O
colon	O
(	O
Hirschsprung	B-DISEASE
disease	I-DISEASE
)	O
[	O
1	O
]	O
.	O

Sanger	O
sequencing	O
revealed	O
that	O
the	O
other	O
subject	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
subject	O
II	O
:	O
3	O
)	O
also	O
had	O
both	O
heterozygous	O
CDH23	B-GENE
and	O
PCDH15	B-GENE
mutations	O
.	O

However	O
,	O
among	O
class	O
I	O
and	O
II	O
-	O
morphants	O
,	O
we	O
found	O
some	O
neuromasts	O
with	O
hair	O
cell	O
bundles	O
(	O
Fig	O
.	O

Furthermore	O
,	O
USH1	B-DISEASE
genes	O
may	O
be	O
responsible	O
for	O
phenotypically	O
USH2	B-DISEASE
patients	O
.	O

The	O
nonsense	O
c	B-VARIANT
.	I-VARIANT
16C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
mutation	O
was	O
previously	O
described	O
in	O
a	O
Pakistani	O
family	O
[	O
11	O
]	O
.	O

The	O
alternative	O
site	O
2	O
is	O
less	O
used	O
than	O
site	O
1	O
,	O
as	O
indicated	O
by	O
the	O
assay	O
performed	O
in	O
the	O
capillary	O
fragment	O
analyzer	O
(	O
Figure	O
3B	O
)	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
Gln277Pro	I-VARIANT
change	O
results	O
in	O
two	O
sequential	O
prolines	O
,	O
which	O
very	O
likely	O
disrupts	O
the	O
alpha	O
-	O
helical	O
structure	O
of	O
this	O
short	O
helical	O
segment	O
and	O
destabilizes	O
the	O
C	O
-	O
terminal	O
PRPS1	B-GENE
domain	O
.	O

The	O
missense	O
mutation	O
T86R	B-VARIANT
was	O
found	O
in	O
1	O
patient	O
who	O
was	O
also	O
compound	O
heterozygous	O
for	O
235delC	B-VARIANT
mutation	O
.	O

17	O
,	O
18	O
,	O
19	O
Consistent	O
with	O
several	O
studies	O
suggesting	O
digenic	O
inheritance	O
of	O
HL	B-DISEASE
,	O
20	O
,	O
21	O
the	O
concept	O
of	O
a	O
mutational	O
load	O
,	O
whereby	O
an	O
excess	O
of	O
deleterious	O
variants	O
scattered	O
across	O
multiple	O
genes	O
22	O
impedes	O
the	O
proper	O
functioning	O
of	O
auditory	O
processes	O
,	O
is	O
an	O
interesting	O
perspective	O
on	O
a	O
typically	O
Mendelian	O
disorder	O
.	O

(	O
a	O
)	O
SNP	O
linkage	O
analysis	O
maps	O
the	O
disorder	O
locus	O
to	O
chromosome	O
19	O
(	O
two	O
-	O
point	O
lod	O
scores	O
of	O
more	O
than	O
3	O
)	O
.	O

All	O
patients	O
selected	O
for	O
WES	O
had	O
undergone	O
previous	O
molecular	O
diagnostic	O
testing	O
.	O

A	O
novel	O
missense	O
mutation	O
,	O
p	B-VARIANT
.	I-VARIANT
E232K	I-VARIANT
in	O
POU4F3	B-GENE
,	O
was	O
identified	O
in	O
the	O
KNUF57	O
family	O
(	O
Figure	O
2	O
e	O
)	O
.	O

A	O
novel	O
homozygous	O
NDUFV1	B-GENE
mutation	O
(	O
c	B-VARIANT
.	I-VARIANT
1129G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
E377K	I-VARIANT
)	O
was	O
identified	O
in	O
a	O
2	O
.	O
1Mb	O
region	O
of	O
homozygosity	O
(	O
determined	O
by	O
Affymetrix	O
250K	O
Nsp	O
SNP	O
chip	O
)	O
in	O
a	O
consanguineous	O
Lebanese	O
patient	O
,	O
DT3	O
,	O
who	O
presented	O
with	O
lethal	B-DISEASE
infantile	I-DISEASE
mitochondrial	I-DISEASE
disease	I-DISEASE
(	O
LIMD	B-DISEASE
)	O
(	O
Table	O
3	O
and	O
Supplementary	O
Fig	O
.	O

The	O
frequency	O
of	O
COX	O
-	O
deficient	O
muscle	O
fibres	O
in	O
the	O
pure	O
DOA	B-DISEASE
group	O
(	O
mean	O
=	O
1	O
.	O
30	O
%	O
,	O
SD	O
=	O
1	O
.	O
20	O
%	O
,	O
range	O
=	O
0	O
-	O
3	O
.	O
00	O
%	O
)	O
was	O
significantly	O
lower	O
than	O
in	O
the	O
DOA	O
+	O
group	O
(	O
mean	O
=	O
5	O
.	O
41	O
%	O
,	O
SD	O
=	O
5	O
.	O
90	O
%	O
,	O
range	O
=	O
0	O
-	O
21	O
.	O
18	O
%	O
,	O
P	O
=	O
0	O
.	O
0226	O
,	O
Fig	O
.	O

The	O
longer	O
isoform	O
of	O
USH2A	B-GENE
encodes	O
usherin	O
,	O
a	O
transmembrane	O
protein	O
of	O
5	O
,	O
202	O
amino	O
acids	O
and	O
contains	O
68	O
additional	O
fibronectin	O
repeats	O
[	O
11	O
]	O
.	O

Dark	O
-	O
adapted	O
(	O
DA	O
)	O
mixed	O
cone	O
-	O
rod	O
a	O
and	O
b	O
-	O
wave	O
amplitudes	O
(	O
normal	O
a	O
-	O
wave	O
90	O
-	O
350	O
mu	O
V	O
,	O
normal	O
b	O
-	O
wave	O
380	O
-	O
630	O
mu	O
V	O
)	O
;	O
Dark	O
-	O
adapted	O
rod	O
response	O
b	O
-	O
wave	O
amplitude	O
(	O
normal	O
range	O
200	O
-	O
500	O
mu	O
V	O
)	O
.	O

Cell	O
cycle	O
phases	O
were	O
measured	O
by	O
flow	O
cytometry	O
using	O
a	O
cell	O
cycle	O
assay	O
kit	O
.	O

2007	O
)	O
.	O

The	O
splicing	O
alteration	O
was	O
confirmed	O
using	O
hybrid	O
minigenes	O
.	O

Detailed	O
imaging	O
studies	O
,	O
including	O
brain	O
magnetic	O
resonance	O
imaging	O
and	O
temporal	O
bone	O
computed	O
tomography	O
scans	O
,	O
did	O
not	O
reveal	O
any	O
inner	O
ear	O
abnormality	O
.	O

These	O
procedures	O
were	O
performed	O
at	O
the	O
Second	O
Hospital	O
of	O
Chifeng	O
City	O
,	O
Inner	O
Mongolia	O
and	O
hospitals	O
affiliated	O
with	O
Nantong	O
University	O
,	O
China	O
.	O

CentiMorgan	O
distances	O
were	O
obtained	O
from	O
the	O
Map	O
-	O
O	O
-	O
Mat	O
database	O
for	O
microsatellites	O
(	O
http	O
:	O
/	O
/	O
compgen	O
.	O
rutgers	O
.	O
edu	O
/	O
Mapomat	O
/	O
)	O
.	O

Evidence	O
suggests	O
that	O
WFS1	B-GENE
is	O
either	O
a	O
novel	O
endoplasmic	O
reticulum	O
calcium	O
channel	O
or	O
a	O
regulator	O
of	O
channel	O
activity	O
[	O
9	O
]	O
,	O
[	O
10	O
]	O
.	O

In	O
the	O
absence	O
of	O
integrin	O
,	O
p	O
.	O
Arg33	O
(	O
R33	O
)	O
forms	O
salt	O
bridges	O
with	O
p	O
.	O
Glu64	O
(	O
E64	O
;	O
Fig	O
.	O

We	O
also	O
identified	O
4	O
NRAS	B-GENE
mutations	O
,	O
3	O
NF2	B-GENE
mutations	O
,	O
and	O
3	O
,	O
8	O
,	O
and	O
10	O
mutations	O
in	O
the	O
known	O
tumor	O
suppressor	O
genes	O
:	O
ATR	B-GENE
,	O
ATM	B-GENE
,	O
and	O
APC	B-GENE
,	O
respectively	O
.	O

With	O
ARSNHL	O
,	O
WES	O
of	O
several	O
affected	O
and	O
healthy	O
members	O
from	O
one	O
family	O
may	O
be	O
powerful	O
for	O
quickly	O
identifying	O
new	O
susceptibility	O
genes	O
or	O
mutations	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
there	O
are	O
no	O
studies	O
looking	O
at	O
the	O
prevalence	O
of	O
rare	O
variants	O
in	O
COL4A3	B-GENE
and	O
COL4A4	B-GENE
in	O
a	O
cohort	O
of	O
patients	O
with	O
a	O
diagnosis	O
of	O
familial	O
FSGS	B-DISEASE
.	O

Ellard	O
and	O
A	O
.	O

CERKL	B-GENE
was	O
the	O
second	O
most	O
-	O
mutated	O
gene	O
in	O
Spanish	O
patients	O
affected	O
by	O
typical	O
RP	B-DISEASE
.	O

The	O
expression	O
levels	O
in	O
leucocytes	O
did	O
not	O
show	O
dependence	O
on	O
age	O
in	O
TCS	B-DISEASE
patients	O
.	O

In	O
addition	O
,	O
WES	O
will	O
allow	O
not	O
only	O
detecting	O
mutations	O
in	O
known	O
genes	O
,	O
but	O
will	O
identify	O
new	O
genes	O
responsible	O
for	O
Usher	B-DISEASE
syndrome	I-DISEASE
in	O
patients	O
who	O
are	O
negative	O
for	O
mutations	O
in	O
the	O
known	O
genes	O
.	O

This	O
study	O
followed	O
the	O
tenets	O
of	O
the	O
Declaration	O
of	O
Helsinki	O
.	O

Later	O
stages	O
of	O
disease	O
are	O
characterized	O
by	O
ophthalmoparesis	B-DISEASE
,	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
,	O
epilepsy	B-DISEASE
,	O
and	O
primary	B-DISEASE
hypogonadism	I-DISEASE
in	O
female	O
patients	O
.	O

The	O
percentage	O
of	O
C18	O
:	O
2	O
omega	O
6	O
(	O
linoleic	O
)	O
was	O
low	O
(	O
490	O
ug	O
/	O
mL	O
or	O
23	O
.	O
6	O
%	O
of	O
total	O
;	O
range	O
:	O
24	O
.	O
2	O
%	O
-	O
33	O
.	O
8	O
%	O
)	O
,	O
and	O
the	O
ratio	O
of	O
pristanic	O
acid	O
/	O
phytanic	O
acid	O
(	O
0	O
.	O
19	O
;	O
range	O
:	O
0	O
.	O
01	O
-	O
0	O
.	O
18	O
)	O
,	O
percentage	O
of	O
arachidonic	O
acid	O
(	O
208	O
ug	O
/	O
mL	O
or	O
10	O
.	O
0	O
%	O
of	O
total	O
;	O
range	O
:	O
4	O
.	O
0	O
%	O
-	O
9	O
.	O
5	O
%	O
)	O
,	O
and	O
ratio	O
of	O
arachidonic	O
/	O
docosaehexenoic	O
acid	O
(	O
5	O
.	O
6	O
;	O
range	O
:	O
0	O
.	O
43	O
-	O
5	O
.	O
4	O
)	O
were	O
mildly	O
elevated	O
.	O

Most	O
RSTS	B-DISEASE
cases	O
are	O
sporadic	O
and	O
are	O
caused	O
by	O
de	O
novo	O
mutations	O
[	O
8	O
]	O
.	O

His	O
neutrophil	O
count	O
was	O
normal	O
at	O
7490	O
/	O
mm	O
3	O
;	O
however	O
,	O
the	O
neutrophils	O
contained	O
abnormal	O
basophilic	O
inclusions	O
in	O
their	O
cytoplasm	O
.	O

Of	O
the	O
79	O
patients	O
for	O
whom	O
data	O
on	O
goiter	B-DISEASE
were	O
available	O
,	O
15	O
had	O
goiter	B-DISEASE
and	O
64	O
did	O
not	O
,	O
with	O
an	O
onset	O
age	O
from	O
12	O
to	O
33	O
years	O
.	O

We	O
believe	O
this	O
is	O
the	O
first	O
complete	O
report	O
of	O
dominant	O
inheritance	O
of	O
an	O
adult	O
-	O
onset	O
diabetes	B-DISEASE
phenotype	O
(	O
without	O
other	O
syndromic	O
features	O
of	O
WS	B-DISEASE
)	O
associated	O
with	O
a	O
missense	O
mutation	O
in	O
WFS1	B-GENE
.	O

With	O
the	O
advances	O
in	O
next	O
-	O
generation	O
sequencing	O
technologies	O
it	O
is	O
now	O
possible	O
to	O
quickly	O
screen	O
most	O
known	O
genes	O
implicated	O
in	O
NSHI	B-DISEASE
simultaneously	O
either	O
by	O
using	O
customized	O
capture	O
arrays	O
for	O
targeted	O
genes	O
or	O
exome	O
sequencing	O
[	O
3	O
,	O
4	O
]	O
for	O
the	O
benefit	O
of	O
families	O
,	O
where	O
the	O
causative	O
mutation	O
can	O
be	O
identified	O
.	O

Most	O
of	O
these	O
patients	O
were	O
selected	O
for	O
DFNB31	B-GENE
screening	O
after	O
discarding	O
the	O
presence	O
of	O
pathologic	O
mutations	O
in	O
the	O
most	O
prevalent	O
USH	B-DISEASE
genes	O
.	O

The	O
total	O
proportion	O
of	O
gene	O
variants	O
that	O
can	O
be	O
missed	O
by	O
current	O
exome	O
sequencing	O
methods	O
may	O
be	O
as	O
high	O
as	O
15	O
%	O
-	O
20	O
%	O
[	O
44	O
]	O
.	O

Band	O
A	O
is	O
the	O
normal	O
transcript	O
of	O
exon	O
21	O
(	O
CDH23	B-GENE
)	O
.	O

The	O
ratio	O
between	O
this	O
sample	O
and	O
the	O
normalized	O
data	O
was	O
altered	O
in	O
a	O
high	O
number	O
of	O
target	O
regions	O
from	O
most	O
genes	O
.	O

The	O
RefSeq	O
STRC	B-GENE
sequence	O
annotation	O
corresponds	O
to	O
NM_153700	O
.	O
2	O
and	O
Ensembl	O
ENSG00000166763	O
(	O
hg	O
18	O
)	O
.	O

We	O
also	O
note	O
that	O
such	O
relaxation	O
of	O
the	O
rules	O
to	O
define	O
"	O
qualifying	O
status	O
"	O
will	O
become	O
increasingly	O
important	O
as	O
the	O
sample	O
size	O
used	O
as	O
reference	O
controls	O
increases	O
.	O

This	O
48	O
-	O
exon	O
gene	O
can	O
encode	O
short	O
and	O
long	O
isoforms	O
by	O
means	O
of	O
alternative	O
transcription	O
start	O
and	O
splice	O
sites	O
.	O

None	O
of	O
these	O
individuals	O
displayed	O
disease	O
-	O
relevant	O
CNVs	O
elsewhere	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
S3474G	I-VARIANT
variant	O
was	O
ruled	O
out	O
because	O
it	O
was	O
reported	O
in	O
the	O
1000	O
-	O
genome	O
database	O
with	O
a	O
minor	O
allele	O
frequency	O
(	O
MAF	O
)	O
of	O
0	O
.	O
002	O
,	O
and	O
it	O
also	O
appeared	O
in	O
dbSNP137	O
(	O
rs150181830	B-VARIANT
)	O
.	O

In	O
each	O
run	O
,	O
three	O
wells	O
were	O
assayed	O
for	O
each	O
plasmid	O
,	O
and	O
the	O
experiments	O
were	O
repeated	O
three	O
times	O
independently	O
.	O

Although	O
frequency	O
estimates	O
of	O
HH	B-DISEASE
reversal	O
differed	O
significantly	O
between	O
KS	B-DISEASE
and	O
nHH	B-DISEASE
(	O
4	O
/	O
6	O
;	O
67	O
%	O
)	O
subjects	O
(	O
P	O
=	O
0	O
.	O
006	O
)	O
,	O
the	O
frequency	O
of	O
nHH	B-DISEASE
reversals	O
might	O
be	O
overestimated	O
due	O
to	O
small	O
number	O
of	O
patients	O
.	O

Although	O
consanguinity	O
had	O
not	O
been	O
reported	O
,	O
the	O
mutational	O
screening	O
of	O
PROM1	B-GENE
revealed	O
a	O
novel	O
homozygous	O
mutation	O
,	O
c	B-VARIANT
.	I-VARIANT
1984	I-VARIANT
-	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
,	O
which	O
ablates	O
the	O
consensus	O
acceptor	O
splice	O
site	O
of	O
intron	O
17	O
.	O

EVS	O
,	O
exome	O
variant	O
server	O
;	O
The	O
pathogenicity	O
of	O
this	O
mutation	O
is	O
controversial	O
.	O

However	O
,	O
significant	O
degeneration	O
is	O
observed	O
when	O
flies	O
are	O
raised	O
in	O
constant	O
light	O
for	O
5	O
days	O
,	O
indicating	O
that	O
Cib2	B-GENE
is	O
necessary	O
to	O
prevent	O
light	B-DISEASE
-	I-DISEASE
induced	I-DISEASE
retinal	I-DISEASE
degeneration	I-DISEASE
.	O
This	O
is	O
an	O
open	O
-	O
access	O
article	O
distributed	O
under	O
the	O
terms	O
of	O
the	O
Creative	O
Commons	O
Attribution	O
License	O
,	O
which	O
permits	O
unrestricted	O
use	O
,	O
distribution	O
,	O
and	O
reproduction	O
in	O
any	O
medium	O
,	O
provided	O
the	O
original	O
work	O
is	O
properly	O
cited	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
GG	O
PG	O
KPS	O
KA	O
.	O

p	B-VARIANT
.	I-VARIANT
Asp428Asn	I-VARIANT
in	O
SR	O
-	O
68	O
was	O
also	O
heterozygous	O
.	O

(	O
C	O
)	O
Mapping	O
of	O
homologs	O
of	O
the	O
p	B-VARIANT
.	I-VARIANT
Val213Phe	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
Asn381Ser	I-VARIANT
mutations	O
in	O
a	O
3D	O
structure	O
of	O
NARS2	B-GENE
.	O

The	O
PCR	O
products	O
were	O
treated	O
with	O
ExoSAP	O
-	O
IT	O
(	O
GE	O
Healthcare	O
Bio	O
,	O
Buckinghamshire	O
,	O
UK	O
)	O
and	O
by	O
incubation	O
at	O
37	O
deg	O
C	O
for	O
60	O
min	O
,	O
and	O
inactivation	O
at	O
80	O
deg	O
C	O
for	O
15	O
min	O
.	O

Electron	O
microscopy	O
(	O
EM	O
)	O
data	O
was	O
available	O
in	O
five	O
of	O
the	O
seven	O
families	O
with	O
collagen	O
(	O
IV	O
)	O
variants	O
(	O
Families	O
DUK6534	O
,	O
DUK6585	O
,	O
DUK6527	O
,	O
DUK6630	O
and	O
DUK6669	O
)	O
.	O

performed	O
the	O
bioinformatics	O
experiments	O
.	O

For	O
USH1C	B-GENE
mutations	O
,	O
affected	O
individuals	O
were	O
homozygotes	O
in	O
three	O
families	O
,	O
compound	O
heterozygotes	O
(	O
p	B-VARIANT
.	I-VARIANT
R620C	I-VARIANT
/	O
p	B-VARIANT
.	I-VARIANT
R89H	I-VARIANT
)	O
in	O
one	O
family	O
and	O
heterozygotes	O
in	O
five	O
families	O
.	O

Comparisons	O
between	O
groups	O
were	O
tested	O
using	O
the	O
chi	O
2	O
or	O
Fisher	O
'	O
s	O
exact	O
tests	O
.	O

The	O
largest	O
survey	O
,	O
including	O
2	O
,	O
500	O
consecutive	O
,	O
unrelated	O
LQTS	B-DISEASE
patients	O
,	O
presented	O
one	O
of	O
the	O
lowest	O
mutation	O
yields	O
of	O
36	O
%	O
.	O

For	O
example	O
,	O
in	O
Taiwan	O
,	O
although	O
mutations	O
in	O
certain	O
genes	O
such	O
as	O
GJB2	B-GENE
(	O
or	O
Cx26	B-GENE
)	O
(	O
Gene	O
ID	O
:	O
2706	O
)	O
,	O
SLC26A4	B-GENE
(	O
or	O
PDS	B-GENE
)	O
(	O
Gene	O
ID	O
:	O
5172	O
)	O
,	O
and	O
the	O
mitochondrial	B-GENE
12SrRNA	I-GENE
gene	O
(	O
MTRNR1	B-GENE
)	O
(	O
Gene	O
ID	O
:	O
4549	O
)	O
have	O
been	O
shown	O
to	O
be	O
much	O
more	O
prevalent	O
than	O
other	O
genes	O
,	O
a	O
definitive	O
diagnosis	O
by	O
direct	O
sequencing	O
of	O
these	O
coding	O
regions	O
could	O
only	O
be	O
established	O
in	O
approximately	O
1	O
/	O
3	O
patients	O
with	O
idiopathic	O
SNHI	B-DISEASE
[	O
8	O
]	O
and	O
1	O
/	O
4	O
patients	O
with	O
cochlear	O
implantation	O
[	O
4	O
]	O
,	O
respectively	O
.	O

However	O
,	O
it	O
would	O
also	O
be	O
a	O
huge	O
job	O
for	O
mutation	O
analysis	O
using	O
Sanger	O
sequencing	O
.	O

*	O
Three	O
cases	O
carried	O
double	O
mutations	O
(	O
cases	O
1	O
to	O
3	O
in	O
Table	O
5	O
)	O
.	O

and	O
Z	O
.	O
M	O
.	O
A	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
Pro301Leu	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
P301L	I-VARIANT
)	O
mutation	O
affects	O
the	O
structure	O
of	O
the	O
turn	O
and	O
the	O
turn	O
becomes	O
shorter	O
(	O
B	O
)	O
.	O

The	O
data	O
were	O
plotted	O
on	O
a	O
scatter	O
plot	O
(	O
S1	O
Fig	O
)	O
.	O

IGFALS	B-GENE
-	O
dependent	O
growth	O
changes	O
related	O
to	O
sex	O
-	O
specific	O
body	O
characteristics	O
and	O
bone	O
size	O
have	O
been	O
reported	O
previously	O
[	O
35	O
,	O
36	O
]	O
.	O

We	O
performed	O
exome	O
sequencing	O
of	O
175	O
ASD	B-DISEASE
probands	O
and	O
their	O
parents	O
across	O
five	O
centers	O
with	O
multiple	O
protocols	O
and	O
validation	O
techniques	O
(	O
Supplementary	O
Information	O
)	O
.	O

In	O
Tunisia	O
,	O
genetic	O
data	O
are	O
considered	O
as	O
personal	O
private	O
data	O
,	O
for	O
these	O
reasons	O
we	O
have	O
submitted	O
the	O
minimal	O
dataset	O
as	O
supporting	O
files	O
but	O
we	O
are	O
not	O
allowed	O
to	O
submit	O
the	O
full	O
raw	O
data	O
.	O

Top	O
-	O
rated	O
network	O
generated	O
by	O
Ingenuity	O
Pathway	O
Analysis	O
(	O
IPA	O
)	O
(	O
Ingenuity	O
Systems	O
www	O
.	O
ingenuity	O
.	O
com	O
)	O
using	O
89	O
known	O
NSHL	B-DISEASE
-	O
causing	O
genes	O
(	O
grey	O
shade	O
)	O
and	O
HOMER2	B-GENE
and	O
CDC42	B-GENE
as	O
seeds	O
.	O

Domains	O
of	O
the	O
usherin	B-GENE
protein	O
are	O
indicated	O
.	O

Numbering	O
of	O
GJB2	B-GENE
begins	O
with	O
the	O
nucleotide	O
A	O
of	O
the	O
ATG	O
start	O
codon	O
in	O
Exon2	O
as	O
cDNA	O
position	O
number	O
1	O
.	O

Hiroshi	O
Ogawa	O
and	O
Koichi	O
Omori	O
(	O
Fukushima	O
Medical	O
University	O
)	O
,	O
Drs	O
.	O

The	O
sigmoidal	O
regression	O
curve	O
for	O
individual	O
E10	O
takes	O
a	O
fairly	O
median	O
position	O
;	O
however	O
,	O
some	O
of	O
the	O
other	O
individuals	O
are	O
represented	O
by	O
threshold	O
values	O
that	O
indicate	O
major	O
deviations	O
from	O
that	O
position	O
(	O
Fig	O
.	O

The	O
purpose	O
of	O
our	O
study	O
is	O
to	O
identify	O
the	O
genetic	O
abnormality	O
responsible	O
for	O
ANFH	B-DISEASE
and	O
LCPD	B-DISEASE
in	O
a	O
single	O
family	O
and	O
to	O
determine	O
the	O
factors	O
responsible	O
for	O
the	O
distinct	O
phenotypes	O
manifested	O
by	O
different	O
family	O
members	O
.	O

Type	O
3	O
is	O
similar	O
to	O
type	O
2	O
but	O
without	O
a	O
cloverleaf	B-DISEASE
-	I-DISEASE
shaped	I-DISEASE
head	I-DISEASE
.	O

We	O
measured	O
the	O
fasting	O
blood	O
glucose	O
and	O
cortisol	O
(	O
08	O
.	O
00	O
h	O
)	O
,	O
free	O
thyroxin	O
and	O
insulin	O
-	O
like	O
growth	O
factor	O
1	O
of	O
all	O
patients	O
seen	O
during	O
the	O
first	O
year	O
of	O
life	O
to	O
identify	O
and	O
exclude	O
hypothalamic	B-DISEASE
-	I-DISEASE
pituitary	I-DISEASE
deficiencies	I-DISEASE
other	O
than	O
HH	B-DISEASE
.	O

Our	O
data	O
provide	O
additional	O
insights	O
into	O
the	O
clinical	O
features	O
of	O
this	O
disease	O
and	O
allow	O
a	O
better	O
understanding	O
of	O
the	O
underlying	O
genetic	O
mechanisms	O
.	O

The	O
quantification	O
of	O
the	O
library	O
was	O
performed	O
by	O
either	O
fluorometry	O
with	O
the	O
Qubit	O
dsDNA	O
HS	O
Assay	O
Kit	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
or	O
quantitative	O
PCR	O
(	O
qPCR	O
)	O
using	O
the	O
KAPA	O
Library	O
Quantification	O
Kit	O
for	O
Illumina	O
sequencing	O
platforms	O
(	O
KAPABIOSYSTEMS	O
,	O
Wilmington	O
,	O
MA	O
,	O
EUA	O
)	O
using	O
the	O
average	O
fragment	O
size	O
of	O
each	O
library	O
according	O
to	O
the	O
Bioanalyzer	O
(	O
464	O
bp	O
)	O
.	O

P12	O
and	O
P14	O
rat	O
cochlea	O
were	O
incubated	O
for	O
one	O
day	O
,	O
at	O
4	O
deg	O
C	O
,	O
in	O
0	O
.	O
25M	O
EDTA	O
.	O

Schematic	O
structure	O
of	O
Myosin	B-GENE
XVa	I-GENE
and	O
conservation	O
analysis	O
.	O

After	O
removing	O
variants	O
suspected	O
to	O
be	O
non	O
-	O
pathogenic	O
based	O
on	O
previous	O
published	O
findings	O
(	O
ATM	B-GENE
F1463C	B-VARIANT
34	O
,	O
BRCA1	B-GENE
L668F	B-VARIANT
and	O
P1637L	B-VARIANT
32	O
,	O
PALB2	B-GENE
H1170Y	B-VARIANT
35	O
,	O
SMO	B-GENE
36	O
and	O
TSC2	B-GENE
37	O
,	O
38	O
)	O
,	O
the	O
missense	O
list	O
includes	O
variants	O
from	O
several	O
genes	O
including	O
the	O
two	O
known	O
pathogenic	O
BRCA1	B-GENE
variants	O
(	O
G1788V	B-VARIANT
and	O
R1699W	B-VARIANT
)	O
,	O
four	O
BRIP1	B-GENE
variants	O
,	O
three	O
ATM	B-GENE
variants	O
,	O
four	O
NF1	B-GENE
variants	O
,	O
and	O
one	O
TP53	B-GENE
variant	O
previously	O
identified	O
in	O
breast	B-DISEASE
cancer	I-DISEASE
39	O
(	O
Table	O
2	O
)	O
.	O

Brain	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
showed	O
mild	O
pachygyria	O
.	O

Calcified	O
masses	O
,	O
which	O
are	O
similar	O
to	O
familial	O
tumoral	B-DISEASE
calcinosis	I-DISEASE
,	O
are	O
also	O
observed	O
in	O
acquired	O
conditions	O
such	O
as	O
chronic	B-DISEASE
kidney	I-DISEASE
disease	I-DISEASE
.	O

A	O
summary	O
of	O
median	O
thickness	O
values	O
of	O
all	O
subfields	O
is	O
provided	O
in	O
Table	O
2	O
.	O

Two	O
more	O
TCOF1	B-GENE
variations	O
were	O
found	O
in	O
patient	O
TCS	B-DISEASE
7	O
.	O

Mutations	O
in	O
the	O
paired	B-GENE
box	I-GENE
gene	I-GENE
3	I-GENE
(	O
PAX3	B-GENE
,	O
OMIM	O
606597	O
)	O
have	O
been	O
identified	O
to	O
be	O
responsible	O
for	O
WS1	B-DISEASE
[	O
18	O
,	O
19	O
]	O
.	O

Patient	O
P0418	O
carries	O
a	O
nonsense	O
mutation	O
in	O
USH2A	B-GENE
(	O
p	B-VARIANT
.	I-VARIANT
S5030X	I-VARIANT
)	O
and	O
a	O
missense	O
mutation	O
in	O
MYO7A	B-GENE
(	O
p	B-VARIANT
.	I-VARIANT
K268R	I-VARIANT
)	O
,	O
but	O
his	O
brother	O
,	O
who	O
is	O
also	O
clinically	O
affected	O
,	O
does	O
not	O
carry	O
the	O
MYO7A	B-GENE
mutation	O
.	O

Patient	O
consent	O
:	O
Obtained	O
.	O

Auditory	B-DISEASE
neuropathy	I-DISEASE
(	O
AN	B-DISEASE
)	O
,	O
a	O
unique	O
form	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
involves	O
absence	O
or	O
severe	O
abnormality	O
of	O
auditory	O
brainstem	O
response	O
(	O
ABR	O
)	O
,	O
but	O
presence	O
of	O
otoacoustic	O
emissions	O
(	O
OAE	O
)	O
and	O
/	O
or	O
cochlear	O
microphonic	O
(	O
CM	O
)	O
.	O

Ultra	O
-	O
thin	O
sections	O
(	O
60	O
-	O
65	O
nm	O
)	O
were	O
contrasted	O
with	O
uranyl	O
acetate	O
and	O
lead	O
citrate	O
for	O
ultrastructural	O
studies	O
(	O
H	O
-	O
7650	O
,	O
Hitachi	O
,	O
Japan	O
)	O
.	O

The	O
COL4A3	B-GENE
-	O
p	B-VARIANT
.	I-VARIANT
(	I-VARIANT
G484R	I-VARIANT
)	I-VARIANT
,	O
COL4A3	B-GENE
-	O
p	B-VARIANT
.	I-VARIANT
(	I-VARIANT
G871C	I-VARIANT
)	I-VARIANT
and	O
COL4A3	B-GENE
-	O
p	B-VARIANT
.	I-VARIANT
(	I-VARIANT
A587G	I-VARIANT
)	I-VARIANT
point	O
mutations	O
were	O
introduced	O
in	O
the	O
WT	O
COL4A3	B-GENE
by	O
PCR	O
-	O
based	O
site	O
-	O
directed	O
mutagenesis	O
(	O
QuickChange	O
Site	O
-	O
Directed	O
Mutagenesis	O
,	O
Stratagene	O
,	O
La	O
Jolla	O
,	O
CA	O
)	O
.	O

Samples	O
were	O
barcoded	O
and	O
hybridized	O
individually	O
.	O

The	O
H723D	B-VARIANT
mutation	O
is	O
caused	O
by	O
nucleotide	O
substitution	O
,	O
c	B-VARIANT
.	I-VARIANT
2167C	I-VARIANT
>	I-VARIANT
G	I-VARIANT
,	O
which	O
is	O
predicted	O
to	O
be	O
deleterious	O
since	O
a	O
milder	O
change	O
at	O
the	O
same	O
amino	O
acid	O
residue	O
,	O
H723R	B-VARIANT
that	O
has	O
been	O
found	O
to	O
be	O
the	O
most	O
common	O
pathogenic	O
mutation	O
in	O
Japanese	O
.	O

3D	O
,	O
asterisks	O
)	O
,	O
at	O
P2	O
(	O
Fig	O
.	O

Only	O
one	O
variant	O
is	O
at	O
a	O
position	O
that	O
aligns	O
with	O
a	O
murine	O
residue	O
implicated	O
in	O
binding	O
one	O
of	O
this	O
domain	O
'	O
s	O
ligands	O
,	O
single	O
-	O
stranded	O
DNA	O
,	O
double	O
-	O
stranded	O
DNA	O
,	O
or	O
the	O
DSS1	O
protein	O
.	O

The	O
median	O
maternal	O
age	O
at	O
diagnosis	O
was	O
31	O
years	O
(	O
range	O
18	O
-	O
39	O
)	O
.	O

In	O
addition	O
,	O
in	O
joint	O
cartilage	O
,	O
type	O
2	O
collagen	O
forms	O
a	O
complex	O
with	O
proteoglycan	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
aim	O
to	O
determine	O
the	O
genetic	O
etiology	O
and	O
to	O
characterize	O
the	O
correlated	O
clinical	O
phenotypes	O
for	O
three	O
Chinese	O
pedigrees	O
with	O
nonsyndromic	B-DISEASE
RP	I-DISEASE
,	O
one	O
with	O
RP	B-DISEASE
sine	I-DISEASE
pigmento	I-DISEASE
(	O
RPSP	B-DISEASE
)	O
,	O
and	O
one	O
with	O
USH2	B-DISEASE
.	O

*	O
3	O
Motor	O
milestones	O
:	O
Head	O
control	O
<	O
4	O
months	O
,	O
Walking	O
alone	O
<	O
14	O
months	O
.	O

16	O
One	O
might	O
speculate	O
that	O
altered	O
interactions	O
of	O
KCNQ1	B-GENE
and	O
calmodulin	O
,	O
in	O
the	O
presence	O
of	O
KCNQ1	B-GENE
mutations	O
,	O
could	O
perturb	O
intracellular	O
calcium	O
homeostasis	O
and	O
affect	O
the	O
contractile	O
performance	O
of	O
cardiac	O
myocytes	O
.	O

The	O
pedigree	O
of	O
this	O
Japanese	O
family	O
is	O
shown	O
in	O
Fig	O
.	O

were	O
responsible	O
for	O
the	O
collection	O
of	O
clinical	O
and	O
laboratory	O
data	O
for	O
the	O
family	O
and	O
reviewed	O
and	O
edited	O
the	O
manuscript	O
.	O

coli	O
competent	O
cells	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
)	O
using	O
standard	O
procedures	O
.	O

For	O
scanning	O
electron	O
microscopy	O
,	O
ears	O
were	O
fixed	O
in	O
4	O
%	O
glutaraldehyde	O
,	O
3	O
mM	O
CaCl	O
2	O
,	O
0	O
.	O
1M	O
HEPES	O
pH	O
7	O
.	O
4	O
,	O
dissected	O
,	O
washed	O
in	O
PBS	O
,	O
post	O
-	O
fixed	O
in	O
1	O
%	O
OsO	O
4	O
,	O
dehydrated	O
in	O
ethanol	O
,	O
critical	O
point	O
dried	O
,	O
sputter	O
coated	O
with	O
platinum	O
and	O
imaged	O
in	O
a	O
Field	O
emission	O
scanning	O
electron	O
microscope	O
(	O
Hitachi	O
,	O
S	O
-	O
4500	O
)	O
.	O

Hearing	B-DISEASE
impairment	I-DISEASE
was	O
assessed	O
by	O
audiograms	O
across	O
a	O
range	O
of	O
frequencies	O
(	O
125	O
-	O
8000	O
Hz	O
)	O
,	O
and	O
by	O
brainstem	O
auditory	O
evoked	O
potentials	O
to	O
explore	O
the	O
central	O
conduction	O
time	O
of	O
the	O
auditory	O
pathways	O
.	O

Mutations	O
in	O
three	O
genes	O
-	O
-	O
USH2A	B-GENE
(	O
USH2A	B-GENE
)	O
[	O
9	O
,	O
10	O
]	O
,	O
GPR98	B-GENE
(	O
USH2C	B-GENE
)	O
[	O
11	O
]	O
,	O
and	O
WHRN	B-GENE
(	O
USH2D	B-GENE
)	O
[	O
12	O
]	O
-	O
-	O
have	O
been	O
identified	O
as	O
disease	O
-	O
causing	O
for	O
USH2	B-DISEASE
.	O

The	O
primers	O
used	O
in	O
this	O
step	O
are	O
modified	O
at	O
their	O
5	O
'	O
end	O
with	O
a	O
universal	O
M13	O
linker	O
sequence	O
.	O

Laboratory	O
investigations	O
revealed	O
a	O
marked	O
defect	B-DISEASE
in	I-DISEASE
COX	I-DISEASE
activity	I-DISEASE
and	O
the	O
accumulation	B-DISEASE
of	I-DISEASE
mtDNA	I-DISEASE
multiple	I-DISEASE
deletions	I-DISEASE
in	O
skeletal	O
muscle	O
in	O
both	O
of	O
them	O
.	O

reported	O
p	B-VARIANT
.	I-VARIANT
T416P	I-VARIANT
and	O
IVS8	B-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
as	O
the	O
two	O
most	O
frequent	O
mutations	O
in	O
northern	O
European	O
populations	O
[	O
6	O
]	O
,	O
whereas	O
Blons	O
et	O
al	O
.	O

in	O
those	O
with	O
an	O
awareness	O
age	O
of	O
0	O
~	O
6	O
years	O
.	O

The	O
Genomes	O
Management	O
Application	O
(	O
GEM	O
.	O
app	O
)	O
,	O
University	O
of	O
Miami	O
Miller	O
School	O
of	O
Medicine	O
(	O
https	O
:	O
/	O
/	O
secureforms	O
.	O
med	O
.	O
miami	O
.	O
edu	O
/	O
hihg	O
/	O
gem	O
-	O
app	O
)	O
was	O
applied	O
for	O
data	O
filtering	O
.	O

(	O
c	O
)	O
Compound	O
heterozygosity	O
for	O
c	B-VARIANT
.	I-VARIANT
216G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
238	I-VARIANT
-	I-VARIANT
239insC	I-VARIANT
in	O
two	O
brothers	O
.	O

Patients	O
with	O
USH2	B-DISEASE
experience	O
congenital	O
moderate	O
to	O
severe	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
and	O
postpuberal	O
onset	O
of	O
RP	B-DISEASE
with	O
intact	O
vestibular	O
function	O
.	O

1	O
C	O
)	O
.	O

coli	O
LeuRS	B-GENE
amino	O
acid	O
sequences	O
(	O
UniProt	O
accession	O
numbers	O
Q15031	O
and	O
P07813	O
)	O
,	O
as	O
described	O
6	O
.	O

The	O
median	O
green	O
,	O
straight	O
line	O
presents	O
the	O
normal	O
control	O
with	O
c	B-VARIANT
.	I-VARIANT
6317T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
.	O

A	O
thorough	O
clinical	O
evaluation	O
including	O
an	O
ophthalmological	O
exam	O
and	O
high	O
resolution	O
CT	O
scans	O
of	O
the	O
temporal	O
bone	O
in	O
affected	O
family	O
members	O
were	O
normal	O
.	O

G	O
presents	O
a	O
heterozygous	O
7	O
bp	O
deletion	O
mutation	O
c	B-VARIANT
.	I-VARIANT
9492_9498del	I-VARIANT
TGATGAT	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT

The	O
deafness	O
-	O
associated	O
gene	O
mutation	O
spectrum	O
and	O
dominant	O
mutation	O
profile	O
may	O
be	O
unique	O
in	O
Uyghur	O
population	O
residing	O
in	O
Xinjiang	O
due	O
to	O
the	O
multi	O
-	O
ethnic	O
coalition	O
over	O
one	O
thousand	O
years	O
.	O

The	O
number	O
of	O
published	O
cases	O
is	O
listed	O
in	O
Table	O
1	O
.	O

We	O
observed	O
an	O
average	O
of	O
68	O
nonsynonymous	O
variants	O
per	O
individual	O
,	O
almost	O
all	O
of	O
which	O
are	O
of	O
unknown	O
clinical	O
significance	O
.	O

They	O
also	O
thank	O
audiologists	O
Fionov	O
G	O
.	O
S	O
.	O

S1	O
)	O
.	O

The	O
present	O
results	O
revealed	O
an	O
extremely	O
high	O
prevalence	O
of	O
CDH23	B-GENE
mutations	O
among	O
patients	O
with	O
congenital	O
sporadic	O
or	O
recessively	O
inherited	O
high	B-DISEASE
-	I-DISEASE
frequency	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O

That	O
guanine	O
to	O
adenine	O
substitution	O
leads	O
to	O
the	O
change	O
of	O
the	O
amino	O
acid	O
glutamine	O
to	O
lysine	O
.	O

For	O
the	O
families	O
with	O
one	O
mutated	O
allele	O
,	O
one	O
patient	O
from	O
each	O
arRP	B-DISEASE
family	O
was	O
sequenced	O
for	O
the	O
gene	O
(	O
CNGA1	B-GENE
,	O
CRB1	B-GENE
,	O
PDE6A	B-GENE
,	O
or	O
USH2A	B-GENE
)	O
that	O
cosegregated	O
with	O
the	O
disease	O
.	O

While	O
extra	O
-	O
renal	O
features	O
may	O
be	O
helpful	O
in	O
suggesting	O
a	O
likely	O
clinical	O
differential	O
diagnosis	O
,	O
they	O
cannot	O
be	O
relied	O
upon	O
to	O
make	O
a	O
firm	O
diagnosis	O
in	O
familial	B-DISEASE
kidney	I-DISEASE
diseases	I-DISEASE
.	O

All	O
listed	O
mutations	O
are	O
predicted	O
to	O
lead	O
to	O
a	O
truncated	O
protein	O
due	O
to	O
the	O
apparition	O
of	O
a	O
PTC	O
either	O
directly	O
,	O
or	O
because	O
of	O
a	O
frameshift	O
.	O

(	O
Physical	O
Therapy	O
)	O
Jerrel	O
Rutlin	O
,	O
B	O
.	O
A	O
.	O

Red	O
indicates	O
patients	O
with	O
confirmed	O
genetic	O
diagnosis	O
,	O
and	O
gray	O
indicates	O
absence	O
of	O
genetic	O
diagnosis	O
.	O

But	O
,	O
interestingly	O
,	O
in	O
one	O
patient	O
(	O
RP	B-DISEASE
-	O
259	O
)	O
,	O
the	O
sensorineural	O
hearing	B-DISEASE
loss	I-DISEASE
was	O
profound	O
,	O
RP	B-DISEASE
started	O
at	O
the	O
age	O
of	O
6	O
years	O
and	O
he	O
also	O
had	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
(	O
clinical	O
findings	O
typical	O
for	O
USH1	B-DISEASE
)	O
.	O

showed	O
that	O
in	O
patients	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
EVA	B-DISEASE
,	O
in	O
whom	O
thyroid	B-DISEASE
disorder	I-DISEASE
was	O
not	O
used	O
as	O
a	O
clinical	O
criterion	O
,	O
19	O
%	O
of	O
siblings	O
had	O
a	O
single	O
mutation	O
in	O
SLC26A4	B-GENE
and	O
42	O
%	O
had	O
zero	O
mutations	O
,	O
suggesting	O
that	O
other	O
genetic	O
factors	O
may	O
be	O
involved	O
[	O
19	O
]	O
in	O
the	O
aetiology	O
of	O
their	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

The	O
authors	O
declare	O
no	O
conflicting	O
financial	O
and	O
non	O
-	O
financial	O
(	O
e	O
.	O
g	O
.	O
,	O
political	O
,	O
personal	O
,	O
religious	O
,	O
academic	O
,	O
commercial	O
or	O
any	O
other	O
)	O
interests	O
.	O

Both	O
programs	O
implement	O
hidden	O
Markov	O
models	O
based	O
on	O
normalized	O
probe	O
intensity	O
value	O
against	O
expected	O
intensity	O
in	O
terms	O
of	O
Log	O
2	O
R	O
ratio	O
and	O
relative	O
allelic	O
copy	O
in	O
terms	O
of	O
B	O
allele	O
frequency	O
.	O

Open	O
-	O
set	O
disyllable	O
recognition	O
scores	O
were	O
evaluated	O
before	O
cochlear	O
implantation	O
and	O
after	O
1	O
year	O
of	O
cochlear	O
implant	O
use	O
.	O

These	O
include	O
the	O
genes	O
KAL1	B-GENE
,	O
FGFR1	B-GENE
,	O
FGF8	B-GENE
which	O
encodes	O
the	O
ligand	O
of	O
FGFR1	B-GENE
,	O
PROKR2	B-GENE
and	O
PROK2	B-GENE
,	O
NELF	B-GENE
(	O
nasal	O
embryonic	O
factor	O
)	O
and	O
mutations	O
in	O
CHD7	B-GENE
associated	O
with	O
the	O
CHARGE	B-DISEASE
syndrome	I-DISEASE
.	O

"	O
Each	O
of	O
the	O
variants	O
leading	O
to	O
a	O
diagnosis	O
was	O
visually	O
inspected	O
using	O
Integrative	O
Genomics	O
Viewer	O
11	O
followed	O
by	O
Sanger	O
validation	O
.	O

The	O
same	O
approach	O
was	O
used	O
for	O
testing	O
the	O
occurrence	O
of	O
the	O
c	B-VARIANT
.	I-VARIANT
595G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
1276G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
variants	O
in	O
Dutch	O
control	O
individuals	O
.	O

All	O
the	O
patients	O
had	O
bilateral	O
profound	B-DISEASE
deafness	I-DISEASE
.	O

This	O
included	O
one	O
case	O
with	O
an	O
initial	O
diagnosis	O
of	O
Sotos	B-DISEASE
syndrome	I-DISEASE
(	O
R121	O
)	O
,	O
but	O
on	O
finding	O
a	O
mutation	O
in	O
the	O
EZH2	B-GENE
gene	O
the	O
case	O
was	O
re	O
-	O
evaluated	O
and	O
determined	O
to	O
be	O
Weaver	B-DISEASE
syndrome	I-DISEASE
.	O

Despite	O
their	O
striking	O
homology	O
and	O
presence	O
in	O
all	O
cell	O
types	O
27	O
,	O
beta	O
-	O
and	O
gamma	O
-	O
actins	O
have	O
been	O
proposed	O
to	O
play	O
at	O
least	O
partially	O
distinct	O
physiological	O
functions	O
based	O
on	O
their	O
relative	O
spatial	O
and	O
temporal	O
enrichment	O
in	O
neurons	O
28	O
and	O
other	O
cell	O
types	O
29	O
,	O
30	O
,	O
and	O
on	O
different	O
phenotypes	O
observed	O
in	O
homozygous	O
mouse	O
mutants	O
.	O

Sequencing	O
of	O
the	O
normal	O
479	O
bp	O
product	O
from	O
these	O
individuals	O
showed	O
complete	O
absence	O
of	O
the	O
mutant	O
allele	O
(	O
illustrated	O
in	O
Figure	O
2	O
C	O
for	O
II	O
-	O
1	O
from	O
Family	O
1	O
)	O
,	O
indicating	O
that	O
both	O
mutations	O
abolish	O
use	O
of	O
the	O
normal	O
exon	O
IIIc	O
donor	O
splice	O
site	O
.	O

Our	O
results	O
are	O
close	O
to	O
the	O
Besnard	O
et	O
al	O
.	O

More	O
than	O
38	O
000	O
and	O
1700	O
high	O
-	O
quality	O
variants	O
were	O
called	O
for	O
III	O
-	O
4	O
and	O
III	O
-	O
13	O
,	O
respectively	O
.	O

We	O
performed	O
a	O
visual	O
inspection	O
of	O
read	O
alignments	O
using	O
the	O
Integrative	O
Genomics	O
Viewer	O
(	O
IGV	O
)	O
browser	O
,	O
and	O
then	O
removed	O
"	O
Benign	O
"	O
and	O
"	O
Likely	O
Benign	O
"	O
variants	O
after	O
classification	O
.	O

However	O
,	O
we	O
must	O
bear	O
in	O
mind	O
that	O
these	O
results	O
are	O
only	O
computing	O
predictions	O
and	O
additional	O
studies	O
are	O
necessary	O
to	O
confirm	O
the	O
effect	O
of	O
those	O
changes	O
not	O
clearly	O
classified	O
.	O

The	O
mutation	O
abolishes	O
this	O
restriction	O
site	O
,	O
thus	O
retaining	O
the	O
undigested	O
528	O
bp	O
amplicon	O
in	O
affected	O
indivuduals	O
.	O

In	O
OTOF	B-GENE
a	O
compound	O
heterozygous	O
variant	O
was	O
found	O
:	O
c	B-VARIANT
.	I-VARIANT
2317	I-VARIANT
C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Arg773Cys	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
4936	I-VARIANT
C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Pro1646Ser	I-VARIANT
)	O
.	O

Part	O
of	O
this	O
study	O
carried	O
out	O
in	O
the	O
USA	O
was	O
supported	O
by	O
intramural	O
funds	O
from	O
the	O
NIDCD	O
/	O
NIH	O
(	O
Z01	O
-	O
DC00039	O
-	O
14	O
)	O
to	O
TBF	O
.	O

Polymerase	O
chained	O
reaction	O
,	O
chip	O
hybridization	O
,	O
and	O
chip	O
scan	O
were	O
conducted	O
as	O
recommended	O
by	O
the	O
manufacturer	O
of	O
the	O
microarray	O
kit	O
(	O
CapitalBio	O
Corporation	O
,	O
Beijing	O
,	O
China	O
)	O
for	O
the	O
simultaneous	O
detection	O
of	O
nine	O
hotspot	O
mutations	O
in	O
four	O
most	O
prevalent	O
NSD	O
-	O
associated	O
genes	O
,	O
including	O
GJB2	B-GENE
(	O
35delG	B-VARIANT
,	O
176	B-VARIANT
-	I-VARIANT
191del16	I-VARIANT
,	O
235delC	B-VARIANT
,	O
and	O
299	B-VARIANT
-	I-VARIANT
300delAT	I-VARIANT
)	O
,	O
GJB3	B-GENE
(	O
538C	B-VARIANT
>	I-VARIANT
T	I-VARIANT
)	O
,	O
SLC26A4	B-GENE
(	O
IVS7	B-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
and	O
2168A	B-VARIANT
>	I-VARIANT
G	I-VARIANT
)	O
,	O
and	O
mitochondrial	B-GENE
12S	I-GENE
rRNA	I-GENE
(	O
1555A	B-VARIANT
>	I-VARIANT
G	I-VARIANT
and	O
1494C	B-VARIANT
>	I-VARIANT
T	I-VARIANT
)	O
.	O

FX	O
,	O
YY	O
,	O
and	O
XD	O
carried	O
out	O
the	O
molecular	O
genetic	O
studies	O
and	O
participated	O
in	O
sequence	O
alignment	O
.	O

With	O
congenital	O
onset	O
and	O
symmetric	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
,	O
the	O
rate	O
increased	O
to	O
48	O
%	O
(	O
p	O
<	O
0	O
.	O
005	O
)	O
,	O
and	O
if	O
the	O
physical	O
examination	O
was	O
normal	O
,	O
it	O
increased	O
further	O
to	O
51	O
%	O
(	O
p	O
<	O
0	O
.	O
005	O
)	O
.	O

In	O
the	O
absence	O
of	O
the	O
ER	O
stress	O
inducer	O
TG	O
,	O
the	O
p	B-VARIANT
.	I-VARIANT
His313Tyr	I-VARIANT
mutant	O
strongly	O
activated	O
the	O
ERSE	O
reporter	O
.	O

Data	O
was	O
analyzed	O
using	O
the	O
platform	O
provided	O
by	O
DNAnexus	O
(	O
www	O
.	O
dnanexus	O
.	O
com	O
)	O
.	O

The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O
http	O
:	O
/	O
/	O
www	O
.	O
biomedcentral	O
.	O
com	O
/	O
1471	O
-	O
2350	O
/	O
12	O
/	O
125	O
/	O
prepub	O
We	O
are	O
thankful	O
to	O
Drs	O
.	O

This	O
migratory	O
behavior	O
is	O
believed	O
to	O
be	O
due	O
to	O
extensive	O
and	O
variable	O
glycosylation	O
of	O
CD164	B-GENE
molecules	O
[	O
13	O
-	O
15	O
]	O
.	O

Clusters	O
with	O
fewer	O
than	O
20	O
subjects	O
were	O
aggregated	O
into	O
an	O
"	O
Other	O
"	O
group	O
and	O
include	O
Middle	O
Easterners	O
,	O
admixed	O
Eurasians	O
,	O
and	O
others	O
of	O
unknown	O
background	O
.	O

We	O
may	O
have	O
missed	O
a	O
mutation	O
due	O
to	O
an	O
intragenic	O
recombination	O
event	O
,	O
genetic	O
heterogeneity	O
,	O
or	O
when	O
the	O
mutation	O
is	O
present	O
in	O
deep	O
intronic	O
regions	O
or	O
cis	O
-	O
regulatory	O
regions	O
of	O
the	O
gene	O
.	O

One	O
family	O
member	O
(	O
IV	O
-	O
21	O
,	O
Fig	O
1A	O
)	O
with	O
hearing	B-DISEASE
impairment	I-DISEASE
had	O
experienced	O
severe	O
recurrent	O
otitis	O
media	O
in	O
childhood	O
.	O

Latencies	O
of	O
3	O
-	O
to	O
10	O
-	O
week	O
-	O
old	O
BLSW	O
mice	O
were	O
on	O
average	O
0	O
.	O
14	O
ms	O
higher	O
than	O
those	O
in	O
control	O
mice	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
did	O
not	O
change	O
significantly	O
over	O
the	O
test	O
period	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

This	O
work	O
was	O
supported	O
by	O
a	O
grant	O
form	O
Conselleria	O
de	O
Sanitat	O
de	O
la	O
Comunitat	O
Valenciana	O
GE039	O
/	O
09	O
and	O
grants	O
from	O
the	O
Spanish	O
Ministry	O
of	O
Science	O
and	O
Innovation	O
PI08	O
/	O
90311	O
and	O
PI07	O
/	O
0558	O
and	O
by	O
European	O
Regional	O
Development	O
Fund	O
.	O

The	O
effect	O
of	O
a	O
splice	O
site	O
mutation	O
was	O
also	O
assessed	O
by	O
RT	O
-	O
PCR	O
analysis	O
of	O
lymphoid	O
RNAs	O
obtained	O
from	O
affected	O
and	O
control	O
individuals	O
.	O

Ninety	O
-	O
three	O
that	O
consented	O
to	O
molecular	O
genetic	O
testing	O
and	O
underwent	O
at	O
least	O
one	O
molecular	O
genetic	O
test	O
were	O
included	O
.	O

Haplotype	O
analysis	O
with	O
markers	O
linked	O
to	O
all	O
known	O
USH1	B-DISEASE
loci	O
indicated	O
co	O
-	O
segregation	O
of	O
a	O
haplotype	O
of	O
two	O
polymorphic	O
marker	O
alleles	O
(	O
D11S902	O
and	O
D11S4138	O
)	O
linked	O
to	O
the	O
USH1C	B-GENE
locus	O
on	O
chromosome	O
11p15	O
.	O
1	O
with	O
USH1	B-DISEASE
in	O
this	O
family	O
(	O
Figure	O
1A	O
)	O
.	O

The	O
differences	O
in	O
thickness	O
values	O
between	O
patients	O
and	O
controls	O
were	O
not	O
only	O
found	O
in	O
adult	O
patients	O
but	O
also	O
in	O
the	O
two	O
children	O
of	O
4	O
and	O
11	O
years	O
of	O
age	O
with	O
recent	O
diagnosis	O
of	O
the	O
disease	O
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
subjects	O
(	O
including	O
the	O
control	O
individuals	O
)	O
or	O
their	O
legal	O
guardians	O
.	O

It	O
differs	O
from	O
the	O
manifestation	O
of	O
ANFH	B-DISEASE
,	O
which	O
does	O
not	O
include	O
coxa	B-DISEASE
plana	I-DISEASE
.	O

Yet	O
,	O
the	O
transmission	O
of	O
WS4	B-DISEASE
is	O
described	O
as	O
neither	O
fully	O
recessive	O
nor	O
fully	O
dominant	O
.	O

It	O
has	O
been	O
described	O
as	O
a	O
founder	O
mutation	O
restricted	O
to	O
the	O
Acadian	O
population	O
(	O
'	O
Acadian	O
allele	O
'	O
)	O
,	O
where	O
it	O
accounts	O
for	O
virtually	O
all	O
USH1	B-DISEASE
cases	O
[	O
5	O
,	O
8	O
,	O
17	O
]	O
and	O
is	O
in	O
complete	O
linkage	O
disequilibrium	O
with	O
the	O
9VNTR	O
(	O
t	O
,	O
t	O
)	O
allele	O
of	O
a	O
45	O
base	O
-	O
pair	O
(	O
bp	O
)	O
variable	O
number	O
of	O
tandem	O
repeat	O
(	O
VNTR	O
)	O
polymorphism	O
in	O
intron	O
5	O
of	O
the	O
USH1C	B-GENE
gene	O
[	O
17	O
]	O
.	O

Predicted	O
functional	O
germline	O
missense	O
variants	O
having	O
low	O
frequencies	O
were	O
detected	O
in	O
several	O
somatic	O
SMGs	O
,	O
including	O
BRCA1	B-GENE
(	O
germline	O
missense	O
n	O
=	O
27	O
)	O
,	O
BRCA2	B-GENE
(	O
n	O
=	O
13	O
)	O
,	O
NF1	B-GENE
(	O
n	O
=	O
8	O
)	O
,	O
RB1	B-GENE
(	O
n	O
=	O
3	O
)	O
,	O
and	O
TP53	B-GENE
(	O
n	O
=	O
1	O
)	O
(	O
Supplementary	O
Table	O
3	O
)	O
.	O

e	O
This	O
fetus	O
is	O
of	O
Indian	O
ancestry	O
,	O
whereas	O
the	O
majority	O
of	O
the	O
cohort	O
is	O
of	O
European	O
ancestry	O
.	O

A	O
correspondence	O
analysis	O
of	O
the	O
identified	O
variants	O
in	O
the	O
entire	O
data	O
set	O
with	O
23	O
probands	O
and	O
9	O
controls	O
did	O
not	O
reveal	O
any	O
clustering	O
;	O
in	O
particular	O
,	O
there	O
was	O
no	O
split	O
between	O
affected	O
individuals	O
and	O
controls	O
(	O
data	O
not	O
shown	O
)	O
.	O

SOLiD	O
5500	O
x	O
l	O
reads	O
were	O
aligned	O
against	O
the	O
human	O
genome	O
reference	O
(	O
hg19	O
)	O
using	O
the	O
program	O
Blat	O
-	O
like	O
Fast	O
Accurate	O
Search	O
Tool	O
(	O
BFAST	O
)	O
.	O

The	O
single	O
-	O
nucleotide	O
change	O
of	O
C	O
to	O
T	O
at	O
nucleotide	O
position	O
2971	O
(	O
c	B-VARIANT
.	I-VARIANT
2971	I-VARIANT
C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
)	O
introduced	O
a	O
stop	O
codon	O
corresponding	O
to	O
amino	O
acid	O
position	O
991	O
.	O

To	O
date	O
and	O
including	O
this	O
study	O
,	O
mutations	O
in	O
11	O
Lebanese	O
families	O
clinically	O
with	O
USH	B-DISEASE
,	O
four	O
with	O
USH1	B-DISEASE
,	O
six	O
with	O
USH2	B-DISEASE
,	O
and	O
one	O
with	O
USH3	B-DISEASE
,	O
have	O
been	O
reported	O
[	O
6	O
]	O
,	O
[	O
27	O
]	O
.	O

To	O
study	O
the	O
genetic	O
variation	O
in	O
cancer	O
-	O
susceptibility	O
genes	O
in	O
a	O
cohort	O
representative	O
of	O
a	O
general	O
,	O
ancestrally	O
diverse	O
population	O
,	O
we	O
analyzed	O
whole	O
genome	O
sequences	O
from	O
participants	O
in	O
a	O
pre	B-DISEASE
-	I-DISEASE
term	I-DISEASE
birth	I-DISEASE
research	O
study	O
.	O

Each	O
genomic	O
DNA	O
sample	O
(	O
40	O
ng	O
)	O
was	O
amplified	O
,	O
using	O
Ampli	O
Taq	O
Gold	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
,	O
for	O
5	O
min	O
at	O
95	O
deg	O
C	O
,	O
followed	O
by	O
30	O
three	O
-	O
step	O
cycles	O
of	O
95	O
deg	O
C	O
for	O
30s	O
,	O
60	O
deg	O
C	O
for	O
30s	O
,	O
and	O
72	O
deg	O
C	O
for	O
60s	O
,	O
with	O
a	O
final	O
extension	O
at	O
72	O
deg	O
C	O
for	O
7	O
min	O
,	O
ending	O
with	O
a	O
holding	O
period	O
at	O
4	O
deg	O
C	O
in	O
a	O
PCR	O
thermal	O
cycler	O
(	O
Takara	O
,	O
Shiga	O
,	O
Japan	O
)	O
.	O

We	O
did	O
not	O
find	O
another	O
CLRN1	B-GENE
sequence	O
alteration	O
in	O
this	O
patient	O
,	O
but	O
the	O
changed	O
amino	O
acid	O
leucine	O
is	O
conserved	O
in	O
evolution	O
(	O
Figure	O
1	O
)	O
.	O

To	O
further	O
confirm	O
that	O
the	O
p	B-VARIANT
.	I-VARIANT
Leu265Ser	I-VARIANT
allele	O
of	O
ELMOD3	B-GENE
is	O
the	O
only	O
mutation	O
that	O
was	O
associated	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
at	O
the	O
DFNB88	B-GENE
locus	O
,	O
we	O
sequenced	O
the	O
coding	O
,	O
non	O
-	O
coding	O
,	O
and	O
approximately	O
75	O
bp	O
flanking	O
sequences	O
of	O
the	O
exon	O
-	O
intron	O
boundaries	O
of	O
all	O
the	O
known	O
candidate	O
genes	O
present	O
within	O
the	O
linkage	O
region	O
in	O
two	O
affected	O
individuals	O
of	O
family	O
PKDF468	O
(	O
Figure	O
1C	O
)	O
.	O

Peripheral	O
blood	O
samples	O
were	O
collected	O
from	O
all	O
available	O
family	O
members	O
for	O
DNA	O
extraction	O
.	O

4C	O
-	O
E	O
)	O
.	O

N	O
/	O
A	O
:	O
Not	O
applicable	O
Dystopia	B-DISEASE
canthorum	I-DISEASE
was	O
detected	O
in	O
all	O
affected	O
patients	O
(	O
Figure	O
2	O
)	O
.	O

[	O
9	O
]	O
with	O
modifications	O
and	O
standard	O
PCR	O
conditions	O
.	O

The	O
variants	O
classified	O
as	O
benign	O
satisfied	O
one	O
or	O
more	O
of	O
the	O
following	O
criteria	O
:	O
(	O
i	O
)	O
allele	O
frequency	O
of	O
0	O
.	O
01	O
or	O
more	O
among	O
the	O
control	O
individuals	O
;	O
(	O
ii	O
)	O
lack	O
of	O
segregation	O
with	O
the	O
deafness	O
phenotype	O
;	O
(	O
iii	O
)	O
poor	O
evolutionary	O
conservation	O
and	O
(	O
iv	O
)	O
apparently	O
no	O
effect	O
on	O
transcript	O
or	O
protein	O
function	O
(	O
Table	O
S1	O
)	O
.	O

An	O
arginine	O
residue	O
at	O
position	O
177	O
is	O
evolutionarily	O
conserved	O
among	O
Wolframin	O
proteins	O
in	O
several	O
species	O
,	O
indicating	O
its	O
biologic	O
significance	O
.	O

2	O
B	O
)	O
.	O

The	O
X	O
-	O
linked	O
form	O
of	O
the	O
condition	O
,	O
AUNX1	B-GENE
,	O
has	O
been	O
mapped	O
to	O
Xq23	O
-	O
q27	O
.	O
3	O
,	O
although	O
the	O
causative	O
gene	O
has	O
yet	O
to	O
be	O
identified	O
.	O

Molecular	O
analysis	O
of	O
20	O
DNAs	O
from	O
retinal	B-DISEASE
dystrophy	I-DISEASE
patients	O
identified	O
likely	O
pathogenic	O
mutations	O
in	O
12	O
cases	O
,	O
many	O
of	O
them	O
known	O
and	O
/	O
or	O
confirmed	O
by	O
segregation	O
.	O

Table	O
S1	O
.	O

Over	O
-	O
expressed	O
wild	O
-	O
type	O
GFP	O
-	O
ELMOD3	B-GENE
localized	O
along	O
the	O
length	O
of	O
the	O
stereocilia	O
of	O
cochlear	O
hair	O
cells	O
(	O
Figure	O
5C	O
)	O
.	O

Molecular	O
Genetic	O
Testing	O
Prior	O
to	O
Exome	O
Sequencing	O
for	O
Selected	O
Projects	O
*	O
Competing	O
Interests	O
:	O
TE	O
,	O
CN	O
,	O
CD	O
,	O
AB	O
,	O
CB	O
and	O
HJB	O
are	O
employees	O
of	O
Bioscientia	O
,	O
which	O
is	O
part	O
of	O
a	O
publicly	O
traded	O
diagnostic	O
company	O
.	O

1	O
)	O
.	O

The	O
results	O
obtained	O
from	O
the	O
microarray	O
were	O
confirmed	O
with	O
direct	O
sequencing	O
.	O

The	O
cluster	O
with	O
individuals	O
of	O
13	O
-	O
75	O
%	O
African	O
ancestry	O
and	O
21	O
-	O
87	O
%	O
European	O
ancestry	O
was	O
named	O
African	O
-	O
European	O
.	O

Immunohistochemistry	O
was	O
then	O
carried	O
out	O
on	O
slides	O
using	O
the	O
Ventana	O
Discovery	O
machine	O
with	O
the	O
manufacturer	O
'	O
s	O
reagents	O
CC1	O
(	O
cat	O
.	O
no	O
950	O
-	O
124	O
)	O
,	O
EZPrep	O
(	O
cat	O
.	O
no	O
950	O
-	O
100	O
)	O
,	O
LCS	O
(	O
cat	O
.	O
no	O
650	O
-	O
010	O
)	O
,	O
RiboWash	O
(	O
cat	O
.	O
no	O
760	O
-	O
105	O
)	O
,	O
Reaction	O
Buffer	O
(	O
cat	O
.	O
no	O
95	O
-	O
300	O
)	O
,	O
and	O
RiboCC	O
(	O
cat	O
.	O
no	O
760	O
-	O
107	O
)	O
and	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

In	O
particular	O
,	O
a	O
mild	O
hearing	B-DISEASE
loss	I-DISEASE
was	O
initially	O
present	O
involving	O
medium	O
and	O
high	O
frequencies	O
.	O

The	O
eight	O
other	O
known	O
USH	B-DISEASE
gene	O
products	O
are	O
hypothesized	O
to	O
form	O
an	O
USH	B-DISEASE
interactome	O
with	O
a	O
role	O
in	O
the	O
molecular	O
transport	O
in	O
the	O
photoreceptor	O
connecting	O
cilium	O
,	O
and	O
in	O
the	O
development	O
and	O
function	O
of	O
cochlear	O
hair	O
cells	O
[	O
3	O
,	O
26	O
-	O
28	O
]	O
.	O

Sequence	O
mismatches	O
were	O
introduced	O
to	O
create	O
BstEII	O
and	O
NheI	O
restriction	O
sites	O
(	O
bold	O
letters	O
)	O
.	O

Bioinformatics	O
analysis	O
was	O
conducted	O
as	O
detailed	O
previously	O
[	O
18	O
]	O
.	O

TMPRSS3	B-GENE
mutations	O
account	O
for	O
5	O
.	O
9	O
%	O
of	O
autosomal	B-DISEASE
recessive	I-DISEASE
non	I-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
arNSHL	B-DISEASE
)	O
cases	O
and	O
8	O
.	O
3	O
of	O
postlingual	B-DISEASE
arNSHL	I-DISEASE
cases	O
in	O
Korean	O
patients	O
[	O
21	O
]	O
.	O

*	O
*	O
Total	O
effective	O
reads	O
is	O
the	O
same	O
meaning	O
as	O
the	O
unique	O
mapped	O
reads	O
which	O
was	O
stated	O
in	O
the	O
pipeline	O
above	O
.	O

Small	O
fragments	O
were	O
removed	O
using	O
Agencourt	O
AMPure	O
XP	O
beads	O
(	O
Beckman	O
Coulter	O
,	O
Agencourt	O
,	O
Beverly	O
,	O
MA	O
)	O
.	O

More	O
than	O
70	O
pathogenic	O
PAX3	B-GENE
mutations	O
including	O
missense	O
,	O
nonsense	O
,	O
and	O
frameshifts	O
mutations	O
,	O
small	O
insertions	O
or	O
deletions	O
,	O
and	O
splice	O
alterations	O
have	O
been	O
reported	O
in	O
patients	O
with	O
WS1	B-DISEASE
[	O
17	O
]	O
.	O

Fundus	O
examinations	O
showed	O
temporal	B-DISEASE
palor	I-DISEASE
of	I-DISEASE
the	I-DISEASE
optic	I-DISEASE
discs	I-DISEASE
(	O
Figure	O
3	O
(	O
a	O
)	O
)	O
.	O

Mutations	O
in	O
OTOF	B-GENE
and	O
PJVK	B-GENE
genes	O
cause	O
DFNB9	B-DISEASE
and	O
DFNB59	B-DISEASE
types	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
respectively	O
.	O

The	O
gene	O
KCNJ10	B-GENE
encodes	O
an	O
inwardly	O
rectifying	O
potassium	O
(	O
K	O
+	O
)	O
channel	O
,	O
namely	O
the	O
Kir4	O
.	O
1	O
channel	O
,	O
expressed	O
in	O
a	O
wide	O
variety	O
of	O
tissues	O
but	O
most	O
importantly	O
in	O
the	O
case	O
of	O
Pendred	B-DISEASE
syndrome	I-DISEASE
,	O
in	O
the	O
cochlear	O
stria	O
vascularis	O
which	O
maintains	O
the	O
endocochlear	O
potential	O
and	O
K	O
+	O
homeostasis	O
[	O
22	O
-	O
24	O
]	O
.	O

This	O
work	O
was	O
supported	O
by	O
the	O
Chinese	O
National	O
Nature	O
Science	O
Foundation	O
Research	O
Grant	O
30728030	O
,	O
30872862	O
,	O
and	O
Chinese	O
Capital	O
Medical	O
Development	O
Scientific	O
Funding	O
2005	O
-	O
1032	O
to	O
Dongyi	O
Han	O
.	O

To	O
improve	O
sensitivity	O
,	O
we	O
additionally	O
applied	O
an	O
ad	O
hoc	O
approach	O
to	O
identify	O
246	O
low	O
-	O
confidence	O
variants	O
supported	O
by	O
at	O
least	O
3	O
reads	O
on	O
each	O
strand	O
(	O
Table	O
2	O
)	O
.	O

,	O
2006	O
;	O
Lange	O
et	O
al	O
.	O

In	O
all	O
patients	O
,	O
visual	O
loss	O
started	O
in	O
childhood	O
or	O
adolescence	O
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
individuals	O
or	O
guardians	O
.	O

Therefore	O
,	O
as	O
a	O
preliminary	O
screening	O
of	O
deaf	O
families	O
the	O
sequencing	O
of	O
this	O
gene	O
is	O
suggested	O
in	O
Pakistan	O
.	O

He	O
was	O
in	O
a	O
wheelchair	O
by	O
the	O
age	O
of	O
14	O
years	O
.	O

Co	O
-	O
segregation	O
of	O
candidate	O
variants	O
was	O
tested	O
in	O
all	O
family	O
members	O
for	O
whom	O
DNA	O
was	O
available	O
and	O
co	O
-	O
segregating	O
candidate	O
variants	O
were	O
genotyped	O
in	O
100	O
unrelated	O
Chinese	O
healthy	O
controls	O
.	O

Genomic	O
extraction	O
of	O
DNA	O
was	O
performed	O
using	O
the	O
standard	O
salting	O
-	O
out	O
method	O
[	O
7	O
]	O
.	O

(	O
A	O
)	O
Family	O
tree	O
of	O
the	O
affected	O
proband	O
(	O
II	O
-	O
3	O
)	O
.	O

CTL	O
(	O
W	O
)	O
,	O
wild	O
type	O
;	O
CTL	O
(	O
D	O
)	O
,	O
common	O
deletion	O
in	O
adPEO	B-DISEASE
;	I-DISEASE
II	O
-	O
2	O
(	O
B	O
)	O
,	O
DNA	O
from	O
the	O
blood	O
of	O
patient	O
II	O
-	O
2	O
;	O
II	O
-	O
2	O
(	O
T	O
)	O
,	O
DNA	O
from	O
the	O
vastus	O
lateralis	O
muscle	O
;	O
and	O
M	O
(	O
1kb	O
)	O
,	O
1	O
-	O
kb	O
DNA	O
ladder	O
Pedigree	O
,	O
sequencing	O
of	O
C10orf2	B-GENE
gene	O
mutations	O
,	O
and	O
mtDNA	O
deletions	O
in	O
a	O
Korean	O
family	O
.	O

SBN	O
:	O
acquisition	O
of	O
data	O
,	O
revising	O
the	O
manuscript	O
.	O

Thus	O
,	O
we	O
believe	O
that	O
the	O
presence	O
of	O
the	O
GST	O
moiety	O
at	O
the	O
N	O
-	O
terminus	O
does	O
not	O
interfere	O
with	O
access	O
to	O
the	O
substrate	O
or	O
with	O
enzymatic	O
activity	O
in	O
our	O
assay	O
.	O

Screening	O
was	O
performed	O
for	O
GJB2	B-GENE
,	O
GJB3	B-GENE
,	O
GJB6	B-GENE
,	O
SLC26A4	B-GENE
,	O
12S	B-GENE
rRNA	I-GENE
,	O
and	O
tRNA	O
ser	O
(	O
UCN	O
)	O
genes	O
in	O
this	O
population	O
.	O

The	O
locations	O
of	O
mutations	O
are	O
boxed	O
.	O

The	O
splicing	O
variant	O
c	B-VARIANT
.	I-VARIANT
8559	I-VARIANT
-	I-VARIANT
2	I-VARIANT
A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
may	O
result	O
in	O
the	O
skipping	O
of	O
exon	O
43	O
of	O
USH2A	B-GENE
.	O

MD	O
participated	O
in	O
the	O
clinical	O
diagnosis	O
of	O
patients	O
.	O

Kazuma	O
Sugahara	O
and	O
Hiroshi	O
Yamashita	O
(	O
Yamaguchi	O
University	O
)	O
,	O
Drs	O
.	O

NS	O
,	O
not	O
significant	O
.	O

Informed	O
consent	O
was	O
obtained	O
from	O
patients	O
and	O
control	O
individuals	O
in	O
accordance	O
with	O
the	O
ethics	O
committee	O
of	O
the	O
University	O
Hospital	O
of	O
Sfax	O
.	O

Tables	O
2	O
and	O
3	O
also	O
indicate	O
the	O
expected	O
effect	O
of	O
the	O
polymorphisms	O
on	O
PEX1	B-GENE
gene	O
expression	O
levels	O
following	O
the	O
analysis	O
of	O
Maxwell	O
et	O
al	O
.	O

Therefore	O
,	O
we	O
focused	O
in	O
this	O
study	O
on	O
the	O
comparative	O
evaluation	O
of	O
the	O
coverage	O
depth	O
,	O
which	O
is	O
the	O
major	O
determinant	O
of	O
the	O
power	O
for	O
variant	O
discovery	O
.	O

We	O
characterized	O
the	O
hearing	B-DISEASE
impairment	I-DISEASE
in	O
eight	O
Dutch	O
families	O
with	O
compound	O
heterozygous	O
mutations	O
in	O
TMPRSS3	B-GENE
and	O
describe	O
genotype	O
-	O
phenotype	O
correlations	O
.	O

In	O
most	O
cases	O
,	O
the	O
individual	O
genes	O
in	O
these	O
pathways	O
are	O
altered	O
rarely	O
by	O
either	O
germline	O
or	O
somatic	O
variants	O
,	O
and	O
it	O
is	O
only	O
through	O
the	O
combined	O
analysis	O
of	O
both	O
types	O
of	O
variants	O
across	O
many	O
genes	O
that	O
the	O
alteration	O
of	O
these	O
pathways	O
becomes	O
apparent	O
.	O

Detailed	O
data	O
are	O
provided	O
in	O
Supplementary	O
Table	O
2	O
.	O

The	O
age	O
of	O
onset	O
and	O
progression	O
of	O
HL	B-DISEASE
were	O
variable	O
among	O
the	O
affected	O
members	O
of	O
this	O
family	O
[	O
30	O
]	O
.	O

Data	O
are	O
means	O
+	O
-	O
SEM	O
of	O
three	O
independent	O
experiments	O
.	O

Overall	O
,	O
many	O
of	O
the	O
CNVs	O
reported	O
in	O
DGV	O
are	O
also	O
reported	O
in	O
DECIPHER	O
patients	O
which	O
indicate	O
that	O
the	O
contribution	O
of	O
each	O
CNV	O
to	O
the	O
phenotype	O
,	O
if	O
any	O
,	O
would	O
be	O
limited	O
to	O
the	O
individual	O
bearing	O
them	O
and	O
this	O
could	O
account	O
for	O
the	O
intra	O
-	O
familial	O
variability	O
observed	O
,	O
as	O
exemplified	O
by	O
the	O
phenotype	O
presented	O
by	O
individual	O
II	O
-	O
5	O
.	O

No	O
SNPs	O
were	O
found	O
using	O
SNPCheckV3	O
(	O
https	O
:	O
/	O
/	O
ngrl	O
.	O
manchester	O
.	O
ac	O
.	O
uk	O
/	O
SNPCheckV3	O
/	O
snpcheck	O
.	O
htm	O
;	O
jsessionid	O
=	O
1D413B67748713D5A68E85D95C00D87C	O
,	O
NGRL	O
Manchester	O
)	O
.	O

The	O
association	O
of	O
OSBPL2	B-GENE
mutations	O
with	O
ADNSHL	B-DISEASE
indicates	O
a	O
role	O
of	O
lipid	O
metabolism	O
in	O
hair	O
cell	O
function	O
,	O
defining	O
another	O
functional	O
category	O
of	O
proteins	O
involved	O
in	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

The	O
Arg544	O
residue	O
in	O
the	O
motor	O
domain	O
of	O
myosin	O
1A	O
is	O
hydrophilic	O
and	O
forms	O
hydrogen	O
bonds	O
with	O
several	O
surrounding	O
residues	O
(	O
figure	O
3	O
b	O
)	O
.	O

We	O
also	O
report	O
four	O
mutations	O
in	O
the	O
ATP6V0A4	B-GENE
gene	O
:	O
one	O
single	O
nucleotide	O
deletion	O
in	O
exon	O
13	O
(	O
c	B-VARIANT
.	I-VARIANT
1221delG	I-VARIANT
;	O
p	B-VARIANT
.	I-VARIANT
Met408Cysfs	I-VARIANT
*	I-VARIANT
10	I-VARIANT
)	O
;	O
the	O
nonsense	O
c	B-VARIANT
.	I-VARIANT
16C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
;	O
p	B-VARIANT
.	I-VARIANT
Arg6	I-VARIANT
*	I-VARIANT
,	O
in	O
exon	O
3	O
;	O
and	O
the	O
missense	O
changes	O
c	B-VARIANT
.	I-VARIANT
1739	I-VARIANT
T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
;	O
p	B-VARIANT
.	I-VARIANT
Met580Thr	I-VARIANT
,	O
in	O
exon	O
17	O
and	O
c	B-VARIANT
.	I-VARIANT
2035G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
;	O
p	B-VARIANT
.	I-VARIANT
Asp679Tyr	I-VARIANT
,	O
in	O
exon	O
19	O
.	O

Furthermore	O
,	O
mutations	O
causing	O
disease	O
include	O
point	O
mutations	O
and	O
large	O
rearrangements	O
,	O
most	O
of	O
them	O
,	O
being	O
private	O
.	O

All	O
genetic	O
variants	O
were	O
evaluated	O
in	O
182	O
randomly	O
and	O
anonymously	O
collected	O
blood	O
donor	O
controls	O
(	O
364	O
alleles	O
)	O
.	O

The	O
combination	O
of	O
RP	B-DISEASE
,	O
congenital	O
profound	O
SNHL	B-DISEASE
,	O
and	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
is	O
consistent	O
with	O
a	O
diagnosis	O
of	O
USH1	B-DISEASE
[	O
3	O
]	O
.	O

The	O
significance	O
of	O
genetic	O
counseling	O
services	O
for	O
NSHI	B-DISEASE
in	O
the	O
south	O
Chinese	O
population	O
.	O

8b	O
)	O
.	O

To	O
further	O
investigate	O
the	O
effect	O
of	O
the	O
c	B-VARIANT
.	I-VARIANT
940T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
variant	O
on	O
WFS1	B-GENE
transcripts	O
and	O
protein	O
product	O
,	O
we	O
assessed	O
fibroblast	O
cell	O
lines	O
generated	O
from	O
a	O
family	O
quartet	O
of	O
c	B-VARIANT
.	I-VARIANT
940T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
carriers	O
and	O
noncarriers	O
(	O
III	O
-	O
1	O
,	O
III	O
-	O
2	O
,	O
IV	O
-	O
1	O
,	O
and	O
IV	O
-	O
2	O
)	O
for	O
differences	O
in	O
1	O
)	O
WFS1	B-GENE
transcript	O
levels	O
,	O
2	O
)	O
WFS1	B-GENE
protein	O
abundance	O
,	O
3	O
)	O
cellular	O
localization	O
of	O
the	O
WFS1	B-GENE
protein	O
,	O
and	O
4	O
)	O
cAMP	O
levels	O
,	O
which	O
are	O
regulated	O
by	O
interactions	O
between	O
WFS1	B-GENE
and	O
adenyl	O
cyclase	O
8	O
(	O
19	O
)	O
.	O

Sensorineural	O
hearing	B-DISEASE
loss	I-DISEASE
was	O
noted	O
at	O
age	O
34	O
.	O

Drs	O
.	O

Reads	O
were	O
mapped	O
against	O
the	O
hg19	O
human	O
reference	O
genome	O
using	O
BWA	O
[	O
7	O
]	O
and	O
processed	O
with	O
SAMtools	O
[	O
8	O
]	O
,	O
Picard	O
(	O
http	O
:	O
/	O
/	O
broadinstitute	O
.	O
github	O
.	O
io	O
/	O
picard	O
/	O
)	O
and	O
GATK	O
[	O
9	O
]	O
.	O

The	O
SALSA	O
MLPA	O
probemix	O
P153	O
-	O
A2	O
EYA1	B-GENE
kit	O
(	O
MRC	O
-	O
Holland	O
,	O
Amsterdam	O
,	O
The	O
Netherlands	O
)	O
that	O
was	O
used	O
includes	O
17	O
probes	O
for	O
14	O
of	O
the	O
18	O
EYA1	B-GENE
exons	O
(	O
probes	O
for	O
exons	O
1	O
,	O
8	O
,	O
13	O
,	O
16	O
are	O
not	O
included	O
whereas	O
two	O
different	O
probes	O
exist	O
for	O
exons	O
6	O
,	O
9	O
,	O
10	O
)	O
and	O
14	O
control	O
probes	O
.	O

(	O
DOCX	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Medical	O
histories	O
were	O
collected	O
including	O
age	O
at	O
onset	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
degree	O
and	O
progression	O
of	O
hearing	O
impairment	O
,	O
and	O
other	O
relevant	O
clinical	O
manifestations	O
.	O

Variants	O
that	O
did	O
not	O
change	O
the	O
open	O
reading	O
frame	O
(	O
i	O
.	O
e	O
.	O

We	O
applied	O
targeted	O
custom	O
exome	O
capture	O
and	O
next	O
-	O
generation	O
sequencing	O
and	O
identified	O
known	O
and	O
/	O
or	O
novel	O
variants	O
in	O
patients	O
with	O
complex	O
kidney	O
disease	O
or	O
where	O
clinicopathological	O
and	O
genetic	O
correlations	O
were	O
discordant	O
.	O

Approximately	O
50	O
%	O
of	O
the	O
described	O
mutations	O
of	O
PAX3	B-GENE
are	O
missense	O
;	O
the	O
remaining	O
are	O
truncating	O
variations	O
[	O
17	O
]	O
.	O

(	O
Table	O
1	O
)	O
.	O

(	O
C	O
)	O
Enlargement	O
of	O
the	O
tail	O
-	O
currents	O
normalized	O
to	O
maximum	O
current	O
amplitude	O
(	O
gray	O
:	O
I	B-GENE
Ks	I-GENE
-	O
WT	O
;	O
black	O
:	O
I	B-GENE
Ks	I-GENE
-	O
G60D	B-VARIANT
)	O
.	O

Submicroscopic	O
chromosomal	O
anomalies	O
may	O
be	O
diagnosed	O
using	O
FISH	O
,	O
but	O
this	O
is	O
highly	O
limited	O
in	O
being	O
a	O
'	O
targeted	O
'	O
approach	O
,	O
requiring	O
knowledge	O
that	O
a	O
specific	O
karyotypic	O
rearrangement	O
is	O
associated	O
with	O
a	O
specific	O
malformation	O
.	O

Patients	O
were	O
anonymized	O
and	O
the	O
corresponding	O
code	O
was	O
conserved	O
in	O
a	O
confidential	O
file	O
.	O

Eleven	O
patients	O
(	O
27	O
.	O
5	O
%	O
)	O
had	O
intact	O
WFS1	B-GENE
alleles	O
.	O

B	O
,	O
Facial	O
appearance	O
of	O
II	O
-	O
1	O
from	O
Family	O
1	O
aged	O
33	O
years	O
.	O

Calcium	O
-	O
containing	O
phosphate	O
binders	O
(	O
calcium	O
carbonate	O
)	O
were	O
used	O
to	O
reduce	O
phosphate	O
levels	O
,	O
and	O
serum	O
calcium	O
levels	O
were	O
elevated	O
to	O
7	O
.	O
5	O
-	O
9	O
.	O
3	O
mg	O
/	O
dL	O
.	O

Grades	O
2	O
to	O
4	O
are	O
classified	O
as	O
disabling	O
hearing	B-DISEASE
impairment	I-DISEASE
.	O

Although	O
OPA1	B-GENE
mutations	O
contribute	O
to	O
the	O
most	O
(	O
60	O
%	O
-	O
70	O
%	O
)	O
cases	O
with	O
DOA	B-DISEASE
[	O
19	O
]	O
,	O
the	O
genetic	O
diagnosis	O
of	O
DOA	B-DISEASE
is	O
still	O
a	O
challenge	O
.	O

Last	O
nucleotide	O
of	O
exon	O
(	O
possibly	O
affects	O
splicing	O
)	O
.	O

The	O
inconsistent	O
results	O
between	O
the	O
two	O
methods	O
were	O
due	O
to	O
this	O
mutation	O
being	O
located	O
in	O
the	O
homo	O
-	O
polymer	O
(	O
poly	O
C	O
stretch	O
)	O
region	O
,	O
which	O
is	O
difficult	O
to	O
detect	O
using	O
this	O
system	O
[	O
9	O
]	O
The	O
patient	O
(	O
5y	O
5	O
m	O
-	O
old	O
boy	O
)	O
had	O
compound	O
heterozygous	O
MYO15A	B-GENE
mutations	O
(	O
c	O
.	O
[	O
9478C	B-VARIANT
>	I-VARIANT
T	I-VARIANT
]	O
;	O
[	O
1179_1185insC	B-VARIANT
]	O
)	O
,	O
and	O
the	O
parents	O
were	O
found	O
to	O
be	O
carriers	O
for	O
these	O
mutations	O
(	O
Fig	O
.	O

Direct	O
exon	O
sequencing	O
of	O
a	O
set	O
of	O
specific	O
disease	O
genes	O
is	O
a	O
reliable	O
,	O
easy	O
set	O
-	O
up	O
method	O
,	O
which	O
remains	O
less	O
expensive	O
than	O
full	O
exome	O
sequencing	O
in	O
the	O
patients	O
.	O

Overlapping	O
audiograms	O
of	O
all	O
21	O
subjects	O
with	O
biallelic	O
CDH23	B-GENE
mutations	O
are	O
shown	O
in	O
Figure	O
2	O
.	O

Phosphoribosyl	B-GENE
pyrophosphate	I-GENE
synthetase	I-GENE
1	I-GENE
(	O
PRS	B-GENE
-	I-GENE
I	I-GENE
,	O
[	O
MIM	O
311850	O
]	O
)	O
is	O
an	O
ubiquitous	O
enzyme	O
with	O
an	O
essential	O
role	O
in	O
nucleotide	O
metabolism	O
:	O
it	O
catalyzes	O
the	O
synthesis	O
of	O
phosphoribosyl	O
pyrophosphate	O
(	O
PRPP	O
)	O
,	O
the	O
substrate	O
for	O
the	O
synthesis	O
of	O
purine	O
,	O
pyridine	O
,	O
and	O
pyrimidine	O
nucleotides	O
[	O
1	O
]	O
.	O

Their	O
studies	O
indicated	O
that	O
mutations	O
in	O
USH2A	B-GENE
may	O
cause	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
without	O
hearing	B-DISEASE
loss	I-DISEASE
[	O
24	O
,	O
29	O
,	O
33	O
]	O
.	O

S3	O
and	O
S4	O
)	O
.	O

A	O
.	O

Exons	O
2	O
-	O
19	O
of	O
MYH9	B-GENE
encode	O
the	O
NMMHC	B-GENE
-	I-GENE
IIA	I-GENE
N	O
-	O
terminal	O
or	O
motor	O
domain	O
(	O
MD	O
)	O
,	O
an	O
actin	O
-	O
binding	O
site	O
and	O
the	O
ATP	O
hydrolysis	O
region	O
.	O

Crkl	B-GENE
and	O
Tbx1	B-GENE
genetically	O
interact	O
,	O
and	O
developmental	O
defects	O
associated	O
with	O
loss	O
of	O
Crkl	B-GENE
and	O
Tbx1	B-GENE
were	O
linked	O
to	O
two	O
major	O
signalling	O
pathways	O
(	O
RA	O
and	O
Fgf8	O
)	O
during	O
embryonic	O
development	O
in	O
model	O
organisms	O
[	O
10	O
,	O
11	O
]	O
.	O

c	O
In	O
-	O
frame	O
skipping	O
of	O
exon	O
12	O
(	O
p	B-VARIANT
.	I-VARIANT
T381	I-VARIANT
-	I-VARIANT
N404del	I-VARIANT
)	O
.	O

-	I-VARIANT
22	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
IVS1	O
-	O
2A	O
>	O
C	O
)	O
.	O

These	O
variants	O
included	O
21	O
missense	O
,	O
8	O
nonsense	O
,	O
9	O
frameshifts	O
,	O
9	O
intronic	O
mutations	O
and	O
6	O
large	O
rearrangements	O
.	O

Analysis	O
of	O
c	B-VARIANT
.	I-VARIANT
2968A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
SNP	O
(	O
p	B-VARIANT
.	I-VARIANT
R990G	I-VARIANT
,	O
rs1042636	B-VARIANT
)	O
with	O
a	O
gain	O
-	O
of	O
-	O
function	O
effect	O
in	O
exon	O
7	O
of	O
CASR	B-GENE
.	O

To	O
identify	O
SNPs	O
and	O
point	O
mutations	O
,	O
data	O
were	O
aligned	O
to	O
hg19	O
using	O
Burrows	O
-	O
Wheeler	O
Aligner	O
(	O
BWA	O
)	O
[	O
37	O
]	O
and	O
MAQ	O
[	O
38	O
]	O
,	O
after	O
removal	O
of	O
reads	O
with	O
duplicate	O
start	O
and	O
end	O
sites	O
.	O

There	O
is	O
little	O
research	O
on	O
EYA4	B-GENE
and	O
GRHL2	B-GENE
in	O
the	O
Korean	O
population	O
.	O

This	O
was	O
the	O
case	O
with	O
cases	O
diagnosed	O
as	O
multiple	B-DISEASE
exostoses	I-DISEASE
(	O
exon	O
coverage	O
for	O
EXT1	B-GENE
,	O
60	O
-	O
215X	O
;	O
EXT2	B-GENE
,	O
150X	O
)	O
,	O
geleophysic	B-DISEASE
dysplasia	I-DISEASE
(	O
ADAMTSL2	B-GENE
,	O
100	O
-	O
385X	O
;	O
FBN1	B-GENE
,	O
115X	O
)	O
,	O
MOPDII	B-DISEASE
(	O
PCNT	B-GENE
95	O
-	O
690X	O
)	O
,	O
trichorhinophalangeal	B-DISEASE
syndrome	I-DISEASE
(	O
TRPS1	B-GENE
,	O
106	O
-	O
230X	O
)	O
,	O
Hajdu	B-DISEASE
-	I-DISEASE
Cheney	I-DISEASE
syndrome	I-DISEASE
(	O
NOTCH2	B-GENE
,	O
33	O
-	O
502X	O
,	O
including	O
201X	O
for	O
exon	O
34	O
)	O
,	O
and	O
occulodentodigital	B-DISEASE
syndrome	I-DISEASE
(	O
GJA1	B-GENE
,	O
80X	O
)	O
.	O

The	O
interval	O
changes	O
over	O
3	O
years	O
in	O
patient	O
II	O
-	O
2	O
revealed	O
slow	O
disease	O
progression	O
.	O

They	O
were	O
injected	O
at	O
2	O
.	O
2	O
mg	O
/	O
ml	O
along	O
with	O
1	O
mg	O
/	O
ml	O
p53	O
MO	O
(	O
5	O
'	O
-	O
GCGCCATTGCTTTGCAAGAATTG	O
-	O
3	O
'	O
)	O
.	O

2	O
It	O
encloses	O
a	O
broad	O
spectrum	O
of	O
malformations	O
,	O
from	O
shortening	O
of	O
the	O
central	O
digit	O
to	O
reduction	O
of	O
the	O
hand	O
/	O
foot	O
to	O
a	O
single	O
ray	O
,	O
and	O
may	O
be	O
variable	O
even	O
between	O
the	O
limbs	O
of	O
an	O
affected	O
individual	O
.	O

This	O
work	O
was	O
supported	O
by	O
the	O
'	O
Centre	O
Hospitalier	O
et	O
Universitaire	O
'	O
of	O
Montpellier	O
(	O
France	O
)	O
.	O

PCR	O
cycling	O
information	O
Table	O
S3	O
.	O

Thus	O
,	O
the	O
specificity	O
of	O
such	O
sensorial	O
symptoms	O
in	O
WFS	B-DISEASE
requires	O
further	O
evaluation	O
in	O
larger	O
cohorts	O
.	O

+	O
+	O
Individual	O
with	O
only	O
one	O
detectable	O
WFS1	B-GENE
mutation	O
.	O

Using	O
its	O
carboxy	O
(	O
C	O
)	O
terminal	O
domain	O
,	O
GIPC1	B-GENE
was	O
demonstrated	O
to	O
interact	O
with	O
Myosin	B-GENE
VI	I-GENE
,	O
which	O
is	O
associated	O
with	O
SNHL	B-DISEASE
in	O
both	O
mice	O
and	O
humans	O
21	O
22	O
23	O
.	O

We	O
excluded	O
known	O
variants	O
identified	O
in	O
1	O
,	O
000	O
genomes	O
project	O
,	O
HapMap	O
,	O
dbSNP132	O
,	O
and	O
YH1	O
.	O

Cardiac	O
examination	O
was	O
normal	O
.	O

The	O
patient	O
was	O
subsequently	O
diagnosed	O
and	O
found	O
to	O
be	O
a	O
heterozygote	O
for	O
an	O
insertion	O
mutation	O
c	B-VARIANT
.	I-VARIANT
255_256ins4	I-VARIANT
(	I-VARIANT
GTGC	I-VARIANT
)	I-VARIANT
in	O
exon	O
2	O
of	O
GATA3	B-GENE
.	O

1A	O
)	O
.	O

However	O
,	O
Matos	O
et	O
al	O
.	O

Deactivation	O
kinetics	O
were	O
investigated	O
by	O
recording	O
tail	O
-	O
currents	O
at	O
potentials	O
ranging	O
from	O
-	O
140	O
to	O
-	O
40	O
in	O
20	O
mV	O
increments	O
after	O
an	O
activating	O
step	O
to	O
+	O
40	O
mV	O
(	O
Figure	O
3A	O
,	O
B	O
)	O
.	O

The	O
difference	O
between	O
p	B-VARIANT
.	I-VARIANT
S647P	I-VARIANT
allele	O
frequencies	O
in	O
cases	O
and	O
controls	O
was	O
significant	O
at	O
P	O
<	O
10	O
-	O
23	O
.	O

Three	O
of	O
the	O
six	O
rearrangements	O
found	O
in	O
this	O
study	O
had	O
been	O
previously	O
described	O
.	O

In	O
three	O
patients	O
,	O
ZS	B-DISEASE
8	O
,	O
ZS	B-DISEASE
14	O
,	O
and	O
ZS	B-DISEASE
26	O
,	O
the	O
second	O
mutation	O
is	O
not	O
identified	O
.	O

It	O
is	O
observed	O
that	O
the	O
mutations	O
spread	O
over	O
the	O
whole	O
region	O
of	O
the	O
gene	O
.	O

The	O
protein	O
structure	O
of	O
the	O
chain	O
A	O
,	O
L	O
-	O
fucose	O
isomerase	O
(	O
1FUI_A	O
499	O
-	O
568	O
)	O
fragment	O
(	O
A	O
)	O
p	O
.	O
T559	O
of	O
1FUI_A	O
is	O
equivalent	O
to	O
p	O
.	O
T237	O
.	O

Purified	O
products	O
were	O
then	O
sequenced	O
with	O
BigDye	O
v3	O
.	O
1	O
(	O
Applied	O
Biosystems	O
)	O
and	O
run	O
on	O
an	O
Applied	O
Biosystems	O
3730xl	O
DNA	O
Analyzer	O
.	O

The	O
mutation	O
in	O
our	O
patient	O
occurred	O
on	O
the	O
actin	O
binding	O
site	O
of	O
the	O
head	O
domain	O
of	O
NMMHC	B-GENE
-	I-GENE
IIA	I-GENE
at	O
exon	O
1	O
.	O

The	O
ratio	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
CD164	B-GENE
transcript	O
for	O
each	O
cell	O
line	O
.	O

Each	O
stereocilium	O
is	O
composed	O
of	O
an	O
actin	O
core	O
that	O
contains	O
cross	O
-	O
linked	O
and	O
bundled	O
gamma	O
-	O
and	O
beta	O
-	O
actin	O
microfilaments	O
that	O
are	O
uniformly	O
polarized	O
,	O
with	O
the	O
barbed	O
(	O
positive	O
)	O
ends	O
localized	O
at	O
the	O
tip	O
.	O

COL4	B-GENE
alpha	I-GENE
3	I-GENE
immunostaining	O
in	O
control	O
shows	O
the	O
normal	O
tubular	O
and	O
capillary	O
loop	O
distribution	O
for	O
comparison	O
(	O
F	O
)	O
.	O

CC	O
=	O
coiled	O
-	O
coil	O
domain	O
;	O
GE	O
=	O
GTPase	O
effector	O
domain	O
;	O
UTR	O
=	O
untranslated	O
region	O
.	O

(	O
a	O
)	O
The	O
percentage	O
of	O
targeted	O
bases	O
sequenced	O
at	O
a	O
minimum	O
depth	O
of	O
2	O
,	O
10	O
,	O
20	O
and	O
30	O
reads	O
per	O
base	O
for	O
regions	O
of	O
interest	O
for	O
all	O
28	O
MODY	B-DISEASE
/	O
neonatal	B-DISEASE
diabetes	I-DISEASE
genes	O
and	O
the	O
m	B-VARIANT
.	I-VARIANT
3243	I-VARIANT
base	O
(	O
black	O
bars	O
)	O
and	O
for	O
the	O
20	O
genes	O
routinely	O
tested	O
by	O
Sanger	O
sequencing	O
in	O
our	O
laboratory	O
(	O
white	O
bars	O
)	O
.	O

Genetic	O
screening	O
through	O
traditional	O
approaches	O
,	O
such	O
as	O
direct	O
sequencing	O
is	O
therefore	O
difficult	O
.	O

Twelve	O
USH2	B-DISEASE
patients	O
remained	O
with	O
no	O
mutation	O
in	O
either	O
of	O
the	O
USH2	O
genes	O
.	O

The	O
frequency	O
of	O
AF	B-DISEASE
was	O
higher	O
during	O
periods	O
of	O
physiological	O
stress	O
.	O

The	O
data	O
for	O
previously	O
reported	O
mutations	O
as	O
well	O
as	O
the	O
mutations	O
found	O
in	O
this	O
study	O
are	O
shown	O
.	O

Considering	O
these	O
data	O
and	O
recent	O
advances	O
in	O
genetic	O
technologies	O
,	O
Sanger	O
sequencing	O
of	O
CDH23	B-GENE
is	O
not	O
likely	O
to	O
be	O
the	O
most	O
practical	O
clinical	O
test	O
currently	O
available	O
.	O

The	O
data	O
presented	O
here	O
demonstrate	O
that	O
genetic	O
counseling	O
has	O
been	O
greatly	O
improved	O
with	O
the	O
identification	O
of	O
the	O
delta	O
(	O
GJB6	B-GENE
-	O
D13S1830	O
)	O
mutation	O
and	O
a	O
total	O
of	O
30	O
families	O
could	O
benefit	O
from	O
a	O
GJB2	B-GENE
and	O
/	O
or	O
GJB6	B-GENE
unambiguous	O
molecular	O
diagnosis	O
.	O

2012	O
;	O
Redin	O
et	O
al	O
.	O

Among	O
these	O
structures	O
,	O
1XT5	O
(	O
crystal	O
structure	O
of	O
VCBP3	O
,	O
domain	O
1	O
,	O
from	O
Branchiostomafloridae	O
)	O
,	O
which	O
demonstrated	O
the	O
highest	O
alignment	O
score	O
,	O
was	O
chosen	O
as	O
the	O
template	O
structure	O
.	O

USH2	B-DISEASE
,	O
the	O
subject	O
of	O
this	O
study	O
,	O
is	O
the	O
most	O
common	O
type	O
and	O
is	O
characterized	O
by	O
moderate	O
to	O
severe	O
congenital	O
HL	B-DISEASE
and	O
normal	O
vestibular	O
function	O
[	O
5	O
]	O
.	O

COL4A3	B-GENE
c	B-VARIANT
.	I-VARIANT
G2290A	I-VARIANT
mutation	O
predicts	O
substitution	O
of	O
a	O
highly	O
conserved	O
glycine	O
by	O
glutamine	O
in	O
the	O
collagenous	O
domain	O
of	O
the	O
protein	O
(	O
Figure	O
3	O
B	O
)	O
and	O
was	O
classified	O
as	O
pathogenic	O
by	O
in	O
silico	O
software	O
(	O
Results	O
summarized	O
in	O
Table	O
1	O
)	O
.	O

This	O
is	O
probably	O
due	O
to	O
two	O
reasons	O
.	O

Three	O
dimensional	O
skull	O
CT	O
revealed	O
closure	B-DISEASE
of	I-DISEASE
the	I-DISEASE
bilateral	I-DISEASE
coronal	I-DISEASE
sutures	I-DISEASE
and	I-DISEASE
left	I-DISEASE
lambdoidal	I-DISEASE
suture	I-DISEASE
,	O
midface	B-DISEASE
hypoplasia	I-DISEASE
,	O
and	O
shallow	B-DISEASE
orbits	I-DISEASE
(	O
Fig	O
.	O

Normal	O
hearing	O
was	O
found	O
in	O
most	O
participants	O
under	O
the	O
age	O
of	O
40	O
at	O
all	O
examined	O
frequencies	O
(	O
250	O
-	O
12	O
,	O
000	O
Hz	O
;	O
see	O
an	O
example	O
in	O
Fig	O
.	O

Samtools	O
14	O
was	O
used	O
to	O
sort	O
and	O
index	O
the	O
resultant	O
bam	O
files	O
.	O

The	O
novel	O
and	O
rare	O
variants	O
were	O
analyzed	O
by	O
PolyPhen	O
2	O
(	O
http	O
:	O
/	O
/	O
genetics	O
.	O
bwh	O
.	O
harvard	O
.	O
edu	O
/	O
pph2	O
/	O
)	O
,	O
SNPs	O
&	O
GO	O
(	O
http	O
:	O
/	O
/	O
snps	O
-	O
and	O
-	O
go	O
.	O
biocomp	O
.	O
unibo	O
.	O
it	O
)	O
,	O
and	O
MutPred	O
(	O
http	O
:	O
/	O
/	O
mutpred	O
.	O
mutdb	O
.	O
org	O
)	O
to	O
predict	O
their	O
pathogenicity	O
.	O

Genomic	O
structure	O
and	O
differential	O
splicing	O
of	O
human	O
EDNRB	B-GENE
gene	O
.	O

Contributed	O
to	O
the	O
writing	O
of	O
the	O
manuscript	O
:	O
XC	O
CZ	O
.	O

The	O
hearing	O
curve	O
was	O
flat	O
and	O
showed	O
decreased	O
hearing	O
at	O
all	O
frequencies	O
.	O

P1	O
virus	O
was	O
collected	O
from	O
Sf9	O
cells	O
after	O
infection	O
with	O
P0	O
virus	O
for	O
4	O
days	O
.	O

Five	O
causative	O
genes	O
have	O
been	O
identified	O
:	O
USH1B	B-GENE
,	O
encoding	O
myosin	B-GENE
VIIa	I-GENE
;	I-GENE
USH1C	B-GENE
,	O
encoding	O
harmonin	B-GENE
(	O
USH1C	B-GENE
)	O
;	O
USH1D	B-GENE
,	O
encoding	O
cadherin	B-GENE
23	I-GENE
(	O
CDH23	B-GENE
)	O
;	O
USH1F	B-GENE
,	O
encoding	O
protocadherin	B-GENE
15	I-GENE
(	O
PCDH15	B-GENE
)	O
;	O
and	O
USH1G	O
,	O
encoding	O
SANS	O
.	O

ST	O
and	O
JR	O
prepared	O
tables	O
and	O
figures	O
.	O

(	O
C	O
)	O
Sanger	O
sequencing	O
electropherograms	O
confirming	O
the	O
heterozygous	O
missense	O
COL4A4	B-GENE
c	B-VARIANT
.	I-VARIANT
G2636A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Gly879Glu	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
C4715T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Pro1572Leu	I-VARIANT
)	O
mutations	O
,	O
and	O
multiple	O
species	O
protein	O
sequence	O
alignment	O
showing	O
conservation	O
of	O
the	O
mutated	O
Gly879	O
and	O
Pro1572	O
residues	O
.	O

Thus	O
,	O
CDH23	B-GENE
mutations	O
are	O
responsible	O
for	O
20	O
%	O
of	O
USH1	B-DISEASE
cases	O
in	O
our	O
study	O
(	O
Figure	O
1a	O
)	O
.	O

The	O
number	O
of	O
remaining	O
variants	O
was	O
then	O
further	O
reduced	O
by	O
removing	O
known	O
SNPs	O
that	O
were	O
present	O
in	O
dbSNP	O
version	O
130	O
(	O
a	O
version	O
that	O
is	O
devoid	O
of	O
data	O
from	O
large	O
-	O
scale	O
endeavors	O
)	O
and	O
having	O
an	O
allelic	O
frequency	O
higher	O
than	O
0	O
.	O
02	O
.	O

All	O
21	O
exons	O
of	O
EYA4	B-GENE
,	O
16	O
exons	O
of	O
GRHL2	B-GENE
,	O
and	O
intron	O
-	O
exon	O
boundaries	O
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
using	O
h	O
-	O
Taq	O
DNA	O
Polymerase	O
(	O
Solgent	O
,	O
Daejeon	O
,	O
Korea	O
)	O
.	O

Evidence	O
for	O
pathogenicity	O
was	O
also	O
demonstrated	O
for	O
a	O
number	O
of	O
variants	O
in	O
cancer	O
genes	O
including	O
two	O
pathogenic	O
BRCA1	B-GENE
,	O
three	O
ATM	B-GENE
,	O
and	O
four	O
BRIP1	B-GENE
missense	O
variants	O
that	O
met	O
at	O
least	O
two	O
of	O
the	O
five	O
criteria	O
for	O
classifying	O
candidate	O
pathogenic	O
missense	O
variants	O
.	O

However	O
,	O
we	O
could	O
not	O
detect	O
a	O
candidate	O
variant	O
in	O
those	O
genes	O
.	O

SIFT	O
(	O
Sort	O
Intolerant	O
From	O
Tolerant	O
,	O
)	O
Score	O
ranges	O
from	O
0	O
to	O
1	O
.	O

The	O
novel	O
identified	O
variants	O
were	O
subsequently	O
verified	O
and	O
screened	O
in	O
200	O
healthy	O
matched	O
control	O
subjects	O
with	O
Sanger	O
sequencing	O
.	O

To	O
date	O
,	O
43	O
different	O
mutations	O
of	O
the	O
MYH9	B-GENE
gene	O
in	O
more	O
than	O
200	O
families	O
have	O
been	O
identified	O
.	O

Furthermore	O
,	O
the	O
normal	O
-	O
hearing	O
parents	O
of	O
patients	O
with	O
NSEVA	B-DISEASE
having	O
two	O
SLC26A4	B-GENE
mutations	O
carried	O
the	O
KCNJ10	B-GENE
c	B-VARIANT
.	I-VARIANT
1042C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
or	O
c	B-VARIANT
.	I-VARIANT
812G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
mutation	O
and	O
a	O
SLC26A4	B-GENE
pathogenic	O
mutation	O
.	O

Purified	O
PSR	O
products	O
were	O
cycle	O
-	O
sequenced	O
on	O
an	O
ABI	O
3500	O
Genetic	O
Analyzer	O
(	O
Applied	O
Biosystems	O
,	O
CA	O
)	O
.	O

The	O
exact	O
frequency	O
of	O
such	O
mutations	O
will	O
need	O
to	O
be	O
determined	O
in	O
a	O
future	O
larger	O
cohort	O
mutation	O
analysis	O
and	O
close	O
attention	O
should	O
be	O
paid	O
to	O
this	O
gene	O
when	O
performing	O
genetic	O
testing	O
of	O
patients	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
East	O
Asia	O
.	O

Associated	O
symptoms	O
:	O
N	O
+	O
D	O
(	O
n	O
=	O
5	O
;	O
8	O
.	O
06	O
%	O
)	O
,	O
N	O
+	O
Ca	O
(	O
n	O
=	O
2	O
;	O
3	O
.	O
22	O
%	O
)	O
,	O
N	O
+	O
D	O
+	O
Ca	O
(	O
n	O
=	O
1	O
;	O
1	O
.	O
61	O
%	O
)	O
.	O

Age	O
of	O
diagnosis	O
,	O
onset	O
of	O
night	B-DISEASE
blindness	I-DISEASE
and	O
visual	B-DISEASE
field	I-DISEASE
loss	I-DISEASE
are	O
expressed	O
in	O
years	O
.	O

Performed	O
the	O
experiments	O
:	O
DLB	O
PK	O
JNM	O
.	O

S2	O
)	O
results	O
from	O
skipping	O
exon	O
30	O
,	O
in	O
other	O
words	O
,	O
a	O
new	O
transcript	O
with	O
a	O
splicing	O
of	O
exon	O
29	O
with	O
exon	O
31	O
will	O
be	O
generated	O
(	O
Fig	O
.	O

Samples	O
that	O
were	O
loaded	O
alone	O
on	O
a	O
lane	O
had	O
an	O
average	O
base	O
coverage	O
of	O
1970	O
x	O
,	O
while	O
samples	O
loaded	O
two	O
in	O
lane	O
had	O
an	O
average	O
base	O
coverage	O
of	O
937	O
x	O
.	O

Some	O
individuals	O
had	O
prelingual	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
whereas	O
other	O
individuals	O
were	O
not	O
aware	O
of	O
being	O
hearing	O
impaired	O
until	O
in	O
their	O
late	O
teens	O
,	O
which	O
indicates	O
postlingual	O
hearing	B-DISEASE
impairment	I-DISEASE
(	O
Table	O
1	O
)	O
.	O

Furthermore	O
,	O
the	O
transduction	O
with	O
mutant	O
NARS2	B-GENE
did	O
not	O
rescue	O
the	O
OCR	O
function	O
,	O
which	O
supports	O
the	O
pathogenic	O
nature	O
of	O
the	O
p	B-VARIANT
.	I-VARIANT
Val213Phe	I-VARIANT
allele	O
(	O
Fig	O
.	O

One	O
of	O
these	O
exceptions	O
are	O
the	O
multiple	O
epiphyseal	O
dysplasias	O
,	O
whose	O
frequency	O
in	O
Europe	O
is	O
5	O
/	O
100	O
,	O
000	O
,	O
while	O
only	O
a	O
total	O
of	O
122	O
cases	O
were	O
reported	O
in	O
Chinese	O
biomedical	O
literature	O
in	O
the	O
past	O
34	O
years	O
.	O

The	O
query	O
sequence	O
was	O
aligned	O
to	O
that	O
of	O
the	O
template	O
by	O
the	O
clustalx	O
software	O
.	O

After	O
verifying	O
the	O
quality	O
of	O
our	O
sequencing	O
results	O
,	O
we	O
examined	O
our	O
patients	O
for	O
pathogenic	O
mutations	O
in	O
ABCA4	B-GENE
.	O

Novel	O
DNA	O
sequence	O
variations	O
were	O
sought	O
in	O
controls	O
.	O

A	O
gain	O
of	O
either	O
<	O
0	O
.	O
23	O
in	O
test	O
or	O
time	O
constant	O
of	O
<	O
8	O
s	O
on	O
impulsive	O
rotation	O
was	O
considered	O
vestibular	O
hypofunction	O
.	O

Digital	O
slit	O
lamp	O
photography	O
was	O
used	O
to	O
document	O
the	O
bilateral	B-DISEASE
anterior	I-DISEASE
and	I-DISEASE
posterior	I-DISEASE
lenticonus	I-DISEASE
found	O
in	O
proband	O
II	O
-	O
2	O
.	O

CIB2	B-GENE
primers	O
are	O
listed	O
in	O
Supplementary	O
Table	O
7	O
.	O

This	O
variant	O
was	O
not	O
detected	O
in	O
the	O
unaffected	O
family	O
members	O
.	O

Enlarged	B-DISEASE
vestibular	I-DISEASE
aqueduct	I-DISEASE
syndrome	I-DISEASE
(	O
EVAS	B-DISEASE
)	O
and	O
MD	B-DISEASE
are	O
the	O
most	O
frequently	O
encountered	O
radiographic	B-DISEASE
anomalies	I-DISEASE
of	I-DISEASE
the	I-DISEASE
inner	I-DISEASE
ear	I-DISEASE
.	O

In	O
total	O
,	O
32	O
-	O
69	O
million	O
short	O
reads	O
(	O
90	O
-	O
bp	O
paired	O
-	O
end	O
reads	O
)	O
were	O
obtained	O
via	O
whole	O
-	O
exome	O
sequencing	O
.	O

The	O
pooled	O
sequencing	O
protocol	O
was	O
designed	O
and	O
established	O
at	O
the	O
Broad	O
Institute	O
by	O
DA	O
,	O
MJD	O
and	O
SBG	O
.	O

Other	O
microdeletions	O
have	O
already	O
been	O
described	O
in	O
this	O
region	O
[	O
8	O
,	O
11	O
,	O
16	O
-	O
18	O
]	O
.	O

All	O
coding	O
exons	O
and	O
adjacent	O
intronic	O
regions	O
of	O
PAX3	B-GENE
were	O
sequenced	O
directly	O
.	O

This	O
level	O
of	O
coverage	O
is	O
sufficient	O
for	O
high	O
-	O
quality	O
variant	O
calling	O
but	O
not	O
clinical	O
diagnosis	O
[	O
29	O
]	O
.	O

One	O
patient	O
was	O
compound	O
heterozygous	O
for	O
c	B-VARIANT
.	I-VARIANT
ins238	I-VARIANT
-	I-VARIANT
239insC	I-VARIANT
and	O
a	O
novel	O
deletion	O
in	O
exon	O
9	O
,	O
c	B-VARIANT
.	I-VARIANT
748_759	I-VARIANT
+	I-VARIANT
5del	I-VARIANT
(	O
see	O
Additional	O
data	O
file	O
1f	O
)	O
.	O

Mutation	O
c	B-VARIANT
.	I-VARIANT

Full	O
length	O
XBP1	O
requires	O
the	O
endoribonuclease	O
domain	O
of	O
activated	O
IRE1	O
for	O
processing	O
into	O
active	O
sXBP1	O
,	O
thus	O
the	O
splicing	O
of	O
XBP1	O
is	O
a	O
key	O
marker	O
for	O
UPR	O
activation	O
.	O

2002	O
)	O
.	O

The	O
purpose	O
of	O
this	O
work	O
was	O
to	O
perform	O
PCDH15	B-GENE
mutation	O
screening	O
to	O
identify	O
the	O
genetic	O
cause	O
of	O
the	O
disease	O
in	O
a	O
cohort	O
of	O
Spanish	O
patients	O
with	O
Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
I	I-DISEASE
and	O
establish	O
phenotype	O
-	O
genotype	O
correlation	O
.	O

A	O
,	O
B	O
OSBPL2	B-GENE
(	O
green	O
)	O
is	O
expressed	O
in	O
stereocilia	O
of	O
cochlear	O
outer	O
hair	O
cells	O
(	O
OHC	O
)	O
as	O
demonstrated	O
by	O
co	O
-	O
immunostaining	O
with	O
anti	O
-	O
prestin	O
antibody	O
(	O
red	O
)	O
of	O
mature	O
(	O
P20	O
)	O
mice	O
.	O

Two	O
circles	O
and	O
a	O
square	O
filled	O
in	O
black	O
indicate	O
probands	O
with	O
suspected	O
hereditary	O
optic	B-DISEASE
atrophy	I-DISEASE
.	O

SNPs	O
with	O
missing	O
genotypes	O
or	O
Mendelian	O
inconsistencies	O
identified	O
using	O
Pedstats	O
(	O
12	O
)	O
were	O
excluded	O
.	O

Several	O
observations	O
support	O
a	O
dominant	O
-	O
negative	O
or	O
gain	O
-	O
of	O
-	O
function	O
mechanism	O
for	O
the	O
disease	O
-	O
causing	O
mutations	O
.	O

B	O
Revision	O
Date	O
14	O
July	O
2012	O
)	O
.	O

A	O
Federal	O
Certificate	O
of	O
Confidentiality	O
was	O
obtained	O
.	O

Three	O
of	O
these	O
are	O
predicted	O
to	O
have	O
benign	O
effects	O
by	O
PolyPhen	O
,	O
and	O
one	O
,	O
p	B-VARIANT
.	I-VARIANT
Arg1835Gln	I-VARIANT
,	O
is	O
predicted	O
to	O
be	O
probably	O
damaging	O
.	O

There	O
are	O
many	O
reported	O
phenotypes	O
of	O
type	B-DISEASE
II	I-DISEASE
collagenopathies	I-DISEASE
,	O
avascular	B-DISEASE
necrosis	I-DISEASE
of	I-DISEASE
femoral	I-DISEASE
head	I-DISEASE
(	O
ANFH	B-DISEASE
OMIM	O
#	O
608805	O
)	O
[	O
4	O
]	O
,	O
spondyloperipheral	B-DISEASE
dysplasia	I-DISEASE
congenita	I-DISEASE
(	O
SEDC	B-DISEASE
#	O
183900	O
)	O
[	O
5	O
]	O
,	O
and	O
Legg	B-DISEASE
-	I-DISEASE
Calv	I-DISEASE
e	I-DISEASE
-	I-DISEASE
Perthes	I-DISEASE
disease	I-DISEASE
(	O
LCPD	B-DISEASE
OMIM	O
#	O
150600	O
)	O
[	O
6	O
]	O
,	O
[	O
7	O
]	O
.	O

Nine	O
family	O
members	O
with	O
profound	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
two	O
relatives	O
with	O
normal	O
hearing	O
enrolled	O
in	O
the	O
study	O
(	O
Figure	O
2	O
)	O
.	O

-	I-VARIANT
22	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
abolished	O
the	O
acceptor	O
splice	O
site	O
of	O
the	O
single	O
GJB2	B-GENE
intron	O
,	O
resulting	O
in	O
the	O
absence	O
of	O
normally	O
processed	O
transcripts	O
from	O
this	O
allele	O
.	O

To	O
assess	O
the	O
importance	O
of	O
CDH23	B-GENE
mutations	O
in	O
non	O
-	O
syndromic	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
two	O
-	O
step	O
screening	O
was	O
applied	O
and	O
clinical	O
characteristics	O
of	O
the	O
patients	O
with	O
CDH23	B-GENE
mutations	O
were	O
examined	O
in	O
this	O
study	O
.	O

Figure	O
S3	O
.	O

In	O
addition	O
to	O
the	O
patients	O
,	O
58	O
DNA	O
samples	O
of	O
family	O
members	O
with	O
normal	O
hearing	O
were	O
included	O
.	O

These	O
results	O
provide	O
a	O
foundation	O
from	O
which	O
to	O
make	O
appropriate	O
recommendations	O
for	O
the	O
use	O
of	O
comprehensive	O
genetic	O
testing	O
in	O
the	O
evaluation	O
of	O
patients	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Tomoo	O
Watanabe	O
,	O
Tsukasa	O
Ito	O
and	O
Masaru	O
Aoyagi	O
(	O
Yamagata	O
University	O
)	O
,	O
Drs	O
.	O

Of	O
these	O
seven	O
,	O
five	O
had	O
diabetes	B-DISEASE
insipidus	I-DISEASE
,	O
but	O
6	O
(	O
67	O
%	O
)	O
of	O
the	O
subjects	O
who	O
were	O
scanned	O
who	O
had	O
diagnosed	O
diabetes	B-DISEASE
insipidus	I-DISEASE
did	O
not	O
have	O
an	O
abnormal	O
pituitary	O
.	O

PhastCons	O
,	O
and	O
GERP	O
have	O
been	O
used	O
evaluate	O
the	O
conservation	O
score	O
of	O
each	O
variation	O
.	O

As	O
a	O
result	O
of	O
the	O
different	O
referral	O
patterns	O
in	O
this	O
study	O
,	O
the	O
prevalence	O
of	O
patients	O
with	O
DOA	O
+	O
phenotypes	O
is	O
difficult	O
to	O
ascertain	O
.	O

These	O
results	O
were	O
confirmed	O
by	O
RACE	O
.	O

Table	O
1	O
Test	O
group	O
:	O
patients	O
carrying	O
sequence	O
variants	O
in	O
USH	B-DISEASE
genes	O
previously	O
detected	O
Samples	O
that	O
failed	O
in	O
the	O
amplification	O
process	O
are	O
marked	O
with	O
SS	O
.	O

FOXI1	B-GENE
is	O
a	O
transcription	O
factor	O
gene	O
and	O
an	O
upstream	O
regulator	O
of	O
SCL26A4	B-GENE
[	O
19	O
,	O
29	O
]	O
.	O

Retinitis	B-DISEASE
pigmentosa	I-DISEASE
(	O
RP	B-DISEASE
)	O
is	O
a	O
group	O
of	O
hereditary	O
retinal	O
diseases	O
,	O
which	O
are	O
characterized	O
by	O
the	O
degeneration	O
of	O
rod	O
-	O
cone	O
photoreceptors	O
with	O
resultant	O
night	B-DISEASE
blindness	I-DISEASE
and	O
visual	B-DISEASE
field	I-DISEASE
loss	I-DISEASE
.	O

(	O
b	O
)	O
shows	O
a	O
mutation	O
c	B-VARIANT
.	I-VARIANT
1032G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
arrow	O
)	O
found	O
in	O
both	O
the	O
daughter	O
and	O
father	O
,	O
which	O
induced	O
a	O
splicing	O
error	O
.	O

Thus	O
,	O
a	O
set	O
of	O
18	O
genes	O
with	O
two	O
or	O
more	O
hits	O
is	O
not	O
quite	O
significant	O
(	O
p	O
=	O
0	O
.	O
063	O
)	O
.	O

A	O
mutation	O
in	O
a	O
neighboring	O
gene	O
that	O
fell	O
within	O
the	O
no	O
-	O
or	O
low	O
-	O
coverage	O
region	O
on	O
the	O
whole	O
-	O
exome	O
sequence	O
might	O
account	O
for	O
the	O
high	B-DISEASE
-	I-DISEASE
frequency	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
in	O
this	O
family	O
,	O
and	O
p	B-VARIANT
.	I-VARIANT
T237I	I-VARIANT
in	O
TECTA	B-GENE
may	O
have	O
coincidentally	O
been	O
in	O
linkage	O
disequilibrium	O
with	O
the	O
true	O
causative	O
gene	O
.	O

The	O
Ethics	O
Committee	O
of	O
the	O
Helsinki	O
University	O
Central	O
Hospital	O
approved	O
the	O
study	O
protocol	O
,	O
appropriate	O
permissions	O
were	O
provided	O
from	O
each	O
university	O
hospital	O
in	O
Finland	O
,	O
and	O
all	O
subjects	O
signed	O
the	O
written	O
informed	O
consent	O
.	O

In	O
addition	O
to	O
the	O
patients	O
'	O
DNA	O
sample	O
,	O
the	O
samples	O
of	O
their	O
relatives	O
were	O
used	O
for	O
segregation	O
analysis	O
.	O

Deaf	O
individuals	O
who	O
underwent	O
a	O
caloric	O
test	O
had	O
vestibular	B-DISEASE
areflexia	I-DISEASE
.	O

found	O
by	O
newborn	O
hearing	O
screening	O
.	O

NGS	O
allows	O
to	O
efficiently	O
sequence	O
an	O
entire	O
genome	O
,	O
an	O
exome	O
,	O
or	O
specific	O
genomic	O
regions	O
.	O

All	O
mutations	O
identified	O
are	O
predicted	O
to	O
affect	O
the	O
POU	O
-	O
specific	O
or	O
POU	O
homeo	O
domains	O
of	O
the	O
protein	O
and	O
co	O
-	O
segregated	O
with	O
deafness	B-DISEASE
in	O
all	O
families	O
.	O

(	O
c	O
)	O
Conservation	O
of	O
Gly403	O
and	O
Ile770	O
in	O
orthologs	O
and	O
paralogs	O
.	O

An	O
international	O
multicenter	O
study	O
confirmed	O
the	O
prevalence	O
and	O
spectrum	O
of	O
OTOF	B-GENE
mutation	O
in	O
Spanish	O
families	O
or	O
subjects	O
of	O
Spanish	O
ancestry	O
with	O
NSHL	B-DISEASE
[	O
17	O
]	O
.	O

However	O
,	O
nHH	B-DISEASE
subjects	O
'	O
testosterone	O
exposure	O
had	O
lasted	O
for	O
years	O
before	O
reversal	O
,	O
proband	O
#	O
3	O
was	O
later	O
restarted	O
on	O
TRT	O
due	O
to	O
a	O
decline	O
in	O
serum	O
T	O
,	O
and	O
the	O
proband	O
#	O
2	O
presented	O
with	O
unilateral	O
olfactory	O
bulb	O
aplasia	O
.	O

Consanguineous	O
marriage	O
was	O
reported	O
in	O
this	O
family	O
.	O

Results	O
are	O
the	O
means	O
of	O
at	O
least	O
three	O
independent	O
experiments	O
.	O

The	O
geographical	O
distribution	O
covered	O
six	O
provinces	O
(	O
Figure	O
1	O
)	O
.	O

Kazuhiko	O
Takeuchi	O
(	O
Mie	O
University	O
)	O
,	O
Dr	O
.	O

All	O
p	O
-	O
values	O
were	O
taken	O
to	O
be	O
significant	O
at	O
<	O
0	O
.	O
05	O
.	O

Clinical	O
characteristics	O
of	O
the	O
lone	O
AF	B-DISEASE
population	O
(	O
n	O
=	O
209	O
)	O
All	O
numbers	O
are	O
reported	O
as	O
mean	O
+	O
-	O
standard	O
-	O
deviation	O
unless	O
otherwise	O
noted	O
.	O

Activation	O
of	O
cGMP	O
-	O
PDE	O
leads	O
to	O
reduced	O
intracellular	O
concentration	O
of	O
cGMP	O
,	O
thus	O
closing	O
cGMP	O
-	O
gated	O
cation	O
channels	O
located	O
on	O
the	O
rod	O
plasma	O
membrane	O
and	O
initiating	O
a	O
neural	O
response	O
to	O
light	O
[	O
19	O
]	O
.	O

1	O
and	O
2a	O
;	O
Supplementary	O
Fig	O
.	O

For	O
MA8	O
,	O
family	O
history	O
suggested	O
dominant	O
or	O
X	O
-	O
linked	O
inheritance	O
of	O
RP	B-DISEASE
with	O
macular	O
involvement	O
.	O

Comparison	O
of	O
mtDNA	O
copy	O
number	O
in	O
homogenate	O
skeletal	O
muscle	O
DNA	O
from	O
patients	O
with	O
OPA1	B-GENE
mutations	O
(	O
mean	O
=	O
5144	O
,	O
SD	O
=	O
2843	O
,	O
n	O
=	O
24	O
)	O
with	O
age	O
-	O
matched	O
healthy	O
controls	O
(	O
mean	O
=	O
4669	O
,	O
SD	O
=	O
2640	O
,	O
n	O
=	O
20	O
,	O
P	O
=	O
0	O
.	O
5719	O
)	O
,	O
and	O
patients	O
with	O
mtDNA	B-DISEASE
depletion	I-DISEASE
syndromes	I-DISEASE
(	O
mean	O
=	O
524	O
,	O
SD	O
=	O
345	O
,	O
n	O
=	O
6	O
,	O
P	O
=	O
0	O
.	O
0005	O
)	O
.	O

Finally	O
,	O
we	O
detected	O
the	O
mutation	O
p	B-VARIANT
.	I-VARIANT
K928X	I-VARIANT
(	O
c	B-VARIANT
.	I-VARIANT
2782A	I-VARIANT
>	I-VARIANT
T	I-VARIANT
)	O
in	O
the	O
homozygous	O
state	O
in	O
patient	O
RP	B-DISEASE
-	O
576M	O
,	O
who	O
belongs	O
to	O
a	O
consanguineous	O
family	O
.	O

Success	O
in	O
identifying	O
the	O
pathogenic	O
mutation	O
has	O
,	O
to	O
date	O
varied	O
from	O
18	O
%	O
(	O
3	O
out	O
of	O
17	O
cases	O
studied	O
)	O
[	O
11	O
]	O
to	O
60	O
%	O
(	O
3	O
out	O
of	O
5	O
cases	O
studied	O
)	O
[	O
9	O
]	O
and	O
there	O
does	O
not	O
appear	O
to	O
be	O
any	O
correlation	O
between	O
successfully	O
identifying	O
the	O
pathogenic	O
mutation	O
and	O
the	O
library	O
preparation	O
method	O
or	O
machine	O
used	O
for	O
the	O
study	O
.	O

The	O
two	O
most	O
common	O
single	O
mutations	O
are	O
the	O
founder	O
mutations	O
p	B-VARIANT
.	I-VARIANT
Y176X	I-VARIANT
in	O
the	O
Finnish	O
population	O
,	O
and	O
the	O
p	B-VARIANT
.	I-VARIANT
N48K	I-VARIANT
mutation	O
among	O
Ashkenazi	O
Jews	O
[	O
22	O
,	O
23	O
,	O
32	O
]	O
.	O

Accordingly	O
,	O
WES	O
uses	O
next	O
-	O
generation	O
technologies	O
to	O
provide	O
a	O
transformational	O
approach	O
for	O
identifying	O
causative	O
mutations	O
of	O
Mendelian	O
disorders	O
.	O

Figure	O
1	O
A	O
shows	O
an	O
example	O
of	O
a	O
homozygous	O
deletion	O
of	O
the	O
exon	O
1	O
of	O
the	O
DIAPH1	B-GENE
gene	O
,	O
which	O
could	O
directly	O
disrupt	O
gene	O
function	O
.	O

M	O
.	O

External	O
software	O
and	O
databases	O
were	O
fully	O
integrated	O
in	O
the	O
third	O
step	O
,	O
which	O
focused	O
on	O
the	O
classification	O
of	O
the	O
Usher	B-DISEASE
candidate	O
variants	O
.	O

Autosomal	O
dominant	O
missense	O
mutations	O
in	O
TECTA	B-GENE
give	O
rise	O
to	O
various	O
hearing	B-DISEASE
loss	I-DISEASE
phenotypes	O
,	O
depending	O
on	O
the	O
protein	O
domains	O
in	O
which	O
the	O
mutations	O
reside	O
,	O
in	O
contrast	O
with	O
autosomal	O
recessive	O
mutations	O
that	O
show	O
similar	O
phenotypes	O
[	O
3	O
]	O
,	O
[	O
9	O
]	O
-	O
[	O
20	O
]	O
.	O

There	O
was	O
no	O
neck	O
stiffness	O
or	O
other	O
abnormalities	O
.	O

He	O
had	O
proptosis	B-DISEASE
,	O
exophthalmos	B-DISEASE
,	O
maxillary	B-DISEASE
hypoplasia	I-DISEASE
,	O
high	B-DISEASE
arched	I-DISEASE
palate	I-DISEASE
,	O
broad	B-DISEASE
thumbs	I-DISEASE
and	O
great	B-DISEASE
toes	I-DISEASE
,	O
both	O
medially	O
deviated	O
.	O

This	O
finding	O
,	O
together	O
with	O
the	O
detection	O
of	O
prolonged	O
neural	O
potentials	O
in	O
ECochG	O
recording	O
in	O
the	O
presence	O
of	O
normal	O
cochlear	O
receptor	O
activities	O
,	O
points	O
to	O
degeneration	B-DISEASE
of	I-DISEASE
auditory	I-DISEASE
nerve	I-DISEASE
fibres	I-DISEASE
as	O
the	O
primary	O
damage	O
underlying	O
hearing	B-DISEASE
dysfunction	I-DISEASE
in	O
patients	O
with	O
OPA1	B-GENE
disease	O
.	O

Descriptions	O
of	O
DNA	O
and	O
amino	O
acid	O
positions	O
in	O
the	O
literature	O
[	O
6	O
-	O
10	O
,	O
12	O
,	O
14	O
,	O
19	O
]	O
and	O
the	O
HGMD	O
database	O
were	O
reassigned	O
through	O
original	O
test	O
programs	O
to	O
present	O
the	O
information	O
in	O
a	O
consistent	O
format	O
.	O

Although	O
depths	O
of	O
those	O
targets	O
in	O
the	O
CUHK	O
-	O
HL	B-DISEASE
V1	O
kit	O
were	O
typically	O
higher	O
than	O
the	O
mean	O
coverage	O
,	O
the	O
depths	O
of	O
similar	O
targets	O
in	O
the	O
SureSelect	O
50	O
Mb	O
kit	O
tended	O
to	O
be	O
lower	O
than	O
the	O
mean	O
(	O
Figure	O
2d	O
)	O
.	O

(	O
E	O
-	O
H	O
)	O
DNA	O
sequencing	O
profiles	O
for	O
the	O
four	O
identified	O
disease	O
-	O
causing	O
mutations	O
(	O
left	O
panel	O
)	O
and	O
the	O
corresponding	O
wide	O
type	O
forms	O
(	O
right	O
panel	O
)	O
.	O

In	O
situ	O
hybridization	O
was	O
performed	O
on	O
mouse	O
cochlear	O
cryosections	O
at	O
post	O
-	O
natal	O
day	O
2	O
(	O
P2	O
)	O
.	O

The	O
girl	O
presented	O
with	O
clinical	O
features	O
of	O
Waardenburg	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
1	I-DISEASE
(	O
see	O
table	O
1	O
)	O
:	O
dystopia	B-DISEASE
canthorum	I-DISEASE
,	O
high	B-DISEASE
nasal	I-DISEASE
bridge	I-DISEASE
,	O
synophrys	B-DISEASE
,	O
eyebrow	B-DISEASE
flaring	I-DISEASE
,	O
skin	B-DISEASE
depigmentation	I-DISEASE
and	O
bilateral	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O

Kcnj10	B-GENE
is	O
a	O
membrane	O
channel	O
normally	O
expressed	O
in	O
the	O
strial	O
intermediate	O
cells	O
while	O
laminin	O
marks	O
the	O
basal	O
lamina	O
around	O
strial	O
blood	O
vessels	O
.	O

Clinically	O
,	O
it	O
is	O
subdivided	O
into	O
three	O
subclasses	O
with	O
nine	O
genes	O
identified	O
so	O
far	O
.	O

In	O
749	O
patients	O
with	O
CAKUT	B-DISEASE
from	O
650	O
families	O
,	O
disease	O
-	O
causing	O
heterogeneous	O
dominant	O
mutations	O
were	O
identified	O
in	O
41	O
unrelated	O
families	O
(	O
6	O
.	O
3	O
%	O
)	O
(	O
Table	O
1	O
)	O
.	O

The	O
speech	O
material	O
was	O
obtained	O
from	O
the	O
protocol	O
of	O
patient	O
candidacy	O
for	O
cochlear	O
implantation	O
for	O
the	O
Italian	O
language	O
(	O
Quaranta	O
et	O
al	O
.	O

Leisner	O
at	O
University	O
of	O
North	O
Carolina	O
for	O
the	O
generous	O
gift	O
of	O
CIB	O
antibodies	O
.	O

Edited	O
the	O
manuscript	O
:	O
LW	O
QS	O
XQH	O
LH	O
HWL	O
DM	O
.	O

The	O
proportion	O
of	O
our	O
patients	O
having	O
the	O
four	O
components	O
of	O
DIDMOAD	B-DISEASE
was	O
comparable	O
to	O
that	O
in	O
former	O
studies	O
using	O
similar	O
patient	O
identification	O
criteria	O
(	O
49	O
%	O
vs	O
.	O

Hs	O
:	O
Homo	O
sapiens	O
,	O
MaMu	O
:	O
Macaca	O
mulatta	O
;	O
Mm	O
:	O
Mus	O
musculus	O
;	O
Cf	O
:	O
Canis	O
familiaris	O
;	O
Ec	O
:	O
Equus	O
caballus	O
;	O
Xl	O
;	O
Xenopus	O
laevis	O
;	O
Dm	O
:	O
Drosophila	O
melanogaster	O
.	O
Perrault	B-DISEASE
syndrome	I-DISEASE
(	O
MIM	O
#	O
233400	O
)	O
is	O
a	O
rare	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
ovarian	B-DISEASE
dysgenesis	I-DISEASE
and	O
primary	B-DISEASE
ovarian	I-DISEASE
insufficiency	I-DISEASE
in	O
females	O
,	O
and	O
progressive	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
in	O
both	O
genders	O
.	O

It	O
was	O
reported	O
that	O
SLC26A4	B-GENE
mutations	O
accounted	O
for	O
approximately	O
5	O
%	O
of	O
all	O
cases	O
of	O
prelingual	O
deafness	B-DISEASE
in	O
East	O
Asia	O
,	O
5	O
%	O
of	O
cases	O
of	O
recessive	O
deafness	B-DISEASE
in	O
south	O
Asia	O
[	O
26	O
]	O
,	O
3	O
.	O
5	O
%	O
in	O
the	O
UK	O
,	O
and	O
4	O
%	O
in	O
the	O
Caucasian	O
population	O
with	O
nonsyndromic	O
hearing	B-DISEASE
loss	I-DISEASE
[	O
27	O
]	O
.	O

2	O
.	O
5	O
)	O
software	O
(	O
Applied	O
Biosystems	O
)	O
,	O
and	O
the	O
sequences	O
were	O
compared	O
with	O
the	O
corresponding	O
sequences	O
in	O
GenBank	O
(	O
accession	O
no	O
.	O

The	O
CIBER	O
de	O
Enfermedades	O
Raras	O
is	O
an	O
initiative	O
of	O
the	O
ISCIII	O
.	O

None	O
of	O
these	O
19	O
rare	O
changes	O
were	O
found	O
in	O
the	O
homozygous	O
state	O
or	O
in	O
trans	O
to	O
another	O
putatively	O
pathogenic	O
variation	O
.	O

The	O
TJP2	B-GENE
gene	O
,	O
which	O
is	O
located	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
9	O
,	O
contains	O
25	O
exons	O
and	O
1	O
,	O
190	O
amino	O
acids	O
.	O

An	O
ophthalmic	O
examination	O
and	O
an	O
audiometric	O
test	O
were	O
conducted	O
to	O
ascertain	O
the	O
phenotype	O
of	O
two	O
affected	O
siblings	O
.	O

In	O
Hungary	O
,	O
three	O
major	O
Roma	O
groups	O
,	O
the	O
Romungro	O
(	O
inhabiting	O
most	O
of	O
the	O
country	O
)	O
,	O
Valachian	O
(	O
in	O
Northern	O
Hungary	O
)	O
and	O
Boyash	O
(	O
mostly	O
in	O
Southern	O
Hungary	O
)	O
are	O
recognized	O
[	O
37	O
]	O
.	O

The	O
efficacy	O
of	O
homer2	B-GENE
knockdown	O
by	O
each	O
morpholino	O
was	O
assessed	O
by	O
RT	O
-	O
PCR	O
analysis	O
with	O
the	O
following	O
primer	O
sets	O
:	O
forward	O
(	O
5	O
'	O
-	O
GGTTCCCGCCAGTAAACAG	O
-	O
3	O
'	O
)	O
and	O
reverse	O
(	O
5	O
'	O
-	O
GTTTGAGCTCCGTCTTCAGG	O
-	O
3	O
'	O
)	O
,	O
which	O
amplified	O
the	O
region	O
between	O
exons	O
1	O
and	O
12	O
;	O
B	O
-	O
actin	O
primers	O
were	O
forward	O
(	O
5	O
'	O
-	O
GAGATGATGCCCCTCGTG	O
-	O
3	O
'	O
)	O
and	O
reverse	O
5	O
'	O
-	O
GCTCAATGGGGTATTTGAGG	O
-	O
3	O
'	O
)	O
.	O

Detailed	O
phenotypic	O
data	O
and	O
variant	O
datasets	O
will	O
need	O
to	O
be	O
shared	O
to	O
facilitate	O
the	O
validation	O
of	O
such	O
novel	O
genes	O
.	O

Temporal	O
bone	O
CT	O
was	O
taken	O
to	O
rule	O
out	O
any	O
abnormality	O
of	O
the	O
inner	O
ear	O
.	O

Very	O
recently	O
,	O
Al	O
-	O
Maawali	O
and	O
colleagues	O
expanded	O
the	O
PRPS1	B-GENE
phenotype	O
to	O
retinal	O
dystrophy	O
and	O
diabetes	O
insipidus	O
in	O
a	O
family	O
with	O
two	O
males	O
affected	O
with	O
Leber	O
'	O
s	O
congenital	O
amaurosis	O
along	O
with	O
other	O
manifestations	O
,	O
and	O
no	O
carrier	O
female	O
affected	O
[	O
37	O
]	O
.	O

DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
leukocytes	O
using	O
commercially	O
available	O
DNA	O
extraction	O
kit	O
(	O
Watson	O
Biotechnologies	O
Inc	O
,	O
Shanghai	O
,	O
China	O
)	O
.	O

Rhodamine	O
phalloidin	O
(	O
red	O
)	O
was	O
used	O
to	O
reveal	O
F	O
-	O
actin	O
and	O
highlight	O
the	O
microvilli	O
on	O
the	O
CL4	O
cell	O
surface	O
.	O

The	O
Ashkenazi	O
Jewish	O
mutation	O
(	O
p	B-VARIANT
.	I-VARIANT
N48K	I-VARIANT
)	O
was	O
detected	O
in	O
a	O
Canadian	O
USH	B-DISEASE
patient	O
in	O
homozygous	O
form	O
,	O
and	O
in	O
a	O
Finnish	O
patient	O
in	O
heterozygous	O
form	O
with	O
the	O
Finnish	O
founder	O
mutation	O
p	B-VARIANT
.	I-VARIANT
Y176X	I-VARIANT
.	O

Magnetic	O
resonance	O
imaging	O
of	O
the	O
brain	O
showed	O
normal	O
myelination	O
pattern	O
.	O

Together	O
with	O
the	O
OCR	O
measurements	O
,	O
the	O
results	O
from	O
these	O
functional	O
studies	O
revealed	O
that	O
Leigh	B-DISEASE
syndrome	I-DISEASE
and	O
DFNB94	B-DISEASE
associated	O
alleles	O
impair	O
the	O
mitochondrial	O
function	O
of	O
NARS2	B-GENE
.	O

The	O
four	O
genes	O
most	O
frequently	O
implicated	O
were	O
GJB2	B-GENE
(	O
22	O
%	O
)	O
,	O
STRC	B-GENE
(	O
16	O
%	O
)	O
,	O
SLC26A4	B-GENE
,	O
(	O
7	O
%	O
)	O
and	O
TECTA	B-GENE
(	O
5	O
%	O
)	O
,	O
although	O
this	O
list	O
varied	O
based	O
on	O
degree	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Muscle	O
specimens	O
from	O
probands	O
of	O
Family	O
2	O
were	O
not	O
available	O
,	O
since	O
diagnosis	O
was	O
performed	O
at	O
the	O
genetic	O
level	O
.	O

p	B-VARIANT
.	I-VARIANT
C759F	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
C3267R	I-VARIANT
were	O
already	O
described	O
by	O
others	O
authors	O
as	O
damaging	O
[	O
https	O
:	O
/	O
/	O
grenada	O
.	O
lumc	O
.	O
nl	O
/	O
LOVD2	O
/	O
Usher_montpellier	O
,	O
[	O
35	O
]	O
]	O
.	O

This	O
strategy	O
can	O
be	O
applied	O
in	O
principle	O
to	O
any	O
disorder	O
for	O
which	O
a	O
cellular	O
phenotype	O
exists	O
.	O

(	O
D	O
-	O
E	O
)	O
The	O
pie	O
chart	O
of	O
RNFL	O
thickness	O
in	O
the	O
left	O
eye	O
.	O

Table	O
S4	O
,	O
Per	O
-	O
gene	O
statistics	O
.	O

F	O
.	O
S	O
.	O
C	O
.	O

[	O
16	O
]	O
.	O

We	O
applied	O
DAPPLE	O
14	O
,	O
which	O
uses	O
the	O
InWeb	O
database	O
15	O
,	O
to	O
determine	O
whether	O
there	O
is	O
excess	O
protein	O
protein	O
interaction	O
across	O
the	O
genes	O
hit	O
by	O
a	O
functional	O
de	O
novo	O
event	O
.	O

23	O
Large	O
deletion	O
speculated	O
based	O
on	O
patient	O
'	O
s	O
homozygosity	O
of	O
USH2A	B-GENE
haplotypes	O
and	O
failure	O
to	O
amplify	O
exon	O
.	O

We	O
also	O
thank	O
the	O
clinicians	O
who	O
referred	O
samples	O
to	O
us	O
,	O
and	O
the	O
patients	O
and	O
their	O
families	O
for	O
their	O
participation	O
.	O
Patient	O
genetic	O
heterogeneity	O
renders	O
it	O
difficult	O
to	O
discover	O
disease	O
-	O
cause	O
genes	O
.	O

Both	O
amplitude	O
and	O
latency	O
of	O
the	O
compound	O
action	O
potential	O
peak	O
recorded	O
from	O
children	O
in	O
response	O
to	O
click	O
stimulation	O
at	O
several	O
intensities	O
were	O
comparable	O
to	O
the	O
corresponding	O
values	O
reported	O
in	O
other	O
studies	O
for	O
normally	O
-	O
hearing	O
and	O
hearing	B-DISEASE
-	I-DISEASE
impaired	I-DISEASE
adults	O
(	O
Eggermont	O
,	O
1976	O
;	O
Noguchi	O
et	O
al	O
.	O

Interestingly	O
,	O
optic	B-DISEASE
atrophy	I-DISEASE
and	O
RP	B-DISEASE
are	O
the	O
only	O
common	O
manifestations	O
to	O
all	O
three	O
females	O
and	O
the	O
only	O
phenotype	O
correlating	O
with	O
the	O
degree	O
of	O
enzyme	O
deficiency	O
.	O

Protein	O
or	O
sequence	O
alignment	O
showed	O
conservation	O
of	O
residues	O
MYO15A	B-GENE
IVS25	O
+	O
3	O
and	O
V2792	O
across	O
nine	O
species	O
.	O

Unfortunately	O
,	O
targeted	O
NGS	O
of	O
deafness	O
genes	O
or	O
exome	O
sequencing	O
does	O
not	O
reliably	O
detect	O
STRC	B-GENE
mutations	O
.	O

In	O
total	O
,	O
16	O
,	O
099	O
GSDs	B-DISEASE
have	O
been	O
reported	O
.	O

One	O
missense	O
change	O
,	O
classified	O
as	O
probably	O
pathogenic	O
,	O
was	O
identified	O
in	O
this	O
study	O
.	O

We	O
detected	O
several	O
causative	O
CNVs	O
which	O
were	O
key	O
to	O
the	O
diagnosis	O
in	O
hitherto	O
unsolved	O
constellations	O
,	O
e	O
.	O
g	O
.	O

A	O
frameshift	O
mutation	O
in	O
DFNA5	B-DISEASE
,	O
which	O
would	O
lead	O
to	O
decreased	O
expression	O
,	O
has	O
been	O
reported	O
not	O
to	O
cause	O
hearing	B-DISEASE
loss	I-DISEASE
[	O
33	O
]	O
;	O
therefore	O
,	O
the	O
cause	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
subjects	O
IV	O
:	O
2	O
and	O
IV	O
:	O
3	O
is	O
more	O
likely	O
to	O
POU4F3	B-GENE
with	O
the	O
p	B-VARIANT
.	I-VARIANT
A336Vfs	I-VARIANT
mutation	O
derived	O
from	O
subject	O
III	O
:	O
1	O
,	O
rather	O
than	O
DFNA5	B-DISEASE
with	O
p	B-VARIANT
.	I-VARIANT
R261X	I-VARIANT
mutation	O
derived	O
from	O
subject	O
III	O
:	O
2	O
.	O

Thus	O
,	O
dCib2	O
is	O
required	O
for	O
proper	O
phototransduction	O
and	O
prevention	O
of	O
light	B-DISEASE
-	I-DISEASE
dependent	I-DISEASE
retinal	I-DISEASE
degeneration	I-DISEASE
.	O

We	O
conducted	O
direct	O
sequencing	O
using	O
a	O
BigDye	O
Terminator	O
v3	O
.	O
1	O
Cycle	O
Sequencing	O
Kit	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
.	O

To	O
address	O
this	O
,	O
we	O
collected	O
~	O
1	O
million	O
sequence	O
reads	O
using	O
the	O
454	O
GS	O
-	O
FLX	O
sequencer	O
for	O
14	O
amplicons	O
of	O
NLRP3	B-GENE
exons	O
from	O
50	O
control	O
samples	O
that	O
were	O
thought	O
to	O
be	O
free	O
from	O
somatic	O
mosaicism	O
,	O
and	O
~	O
94	O
%	O
of	O
those	O
reads	O
were	O
mapped	O
to	O
one	O
of	O
the	O
reference	O
NLRP3	B-GENE
exon	O
sequences	O
.	O

Laboratory	O
testing	O
for	O
organic	O
acids	O
revealed	O
mild	O
elevation	O
in	O
TCA	O
cycle	O
metabolites	O
,	O
fumaric	O
,	O
malic	O
,	O
and	O
2	O
-	O
keto	O
-	O
glutaric	O
acids	O
;	O
suggestive	O
of	O
mitochondrial	B-DISEASE
disease	I-DISEASE
.	O

Starting	O
from	O
3	O
mu	O
g	O
of	O
genomic	O
DNA	O
,	O
the	O
exome	O
of	O
five	O
family	O
members	O
(	O
II	O
:	O
3	O
,	O
II	O
:	O
4	O
,	O
II	O
:	O
5	O
,	O
II	O
:	O
6	O
and	O
I	O
:	O
2	O
)	O
was	O
enriched	O
using	O
SureSelectXT	O
Human	O
All	O
Exon	O
V5	O
(	O
Agilent	O
Technologies	O
,	O
Inc	O
.	O
)	O
and	O
a	O
whole	O
exome	O
fragment	O
library	O
was	O
then	O
constructed	O
following	O
the	O
manufacturer	O
'	O
s	O
protocols	O
(	O
SureSelect	O
Target	O
Enrichment	O
System	O
for	O
the	O
Applied	O
Biosystems	O
SOLiD	O
System	O
-	O
Version	O
2	O
.	O
0	O
.	O
1	O
)	O
.	O

The	O
MYH14	B-GENE
gene	O
was	O
identified	O
as	O
a	O
causal	O
gene	O
of	O
DFNA4	B-DISEASE
deafness	I-DISEASE
[	O
17	O
]	O
.	O

Alternatively	O
,	O
if	O
neither	O
of	O
the	O
parents	O
with	O
normal	O
hearing	O
carries	O
this	O
mutation	O
,	O
the	O
24_49ins26bp	B-VARIANT
mutation	O
in	O
the	O
patient	O
may	O
have	O
arisen	O
de	O
novo	O
and	O
may	O
be	O
the	O
genetic	O
cause	O
or	O
at	O
least	O
one	O
of	O
the	O
factors	O
responsible	O
for	O
her	O
phenotype	O
.	O

He	O
was	O
the	O
first	O
-	O
born	O
to	O
nonconsanguineous	O
parents	O
.	O

In	O
fact	O
,	O
the	O
patients	O
reported	O
by	O
Kalay	O
et	O
al	O
.	O

Washington	O
University	O
Wolfram	O
Study	O
Group	O
Members	O
:	O
Paul	O
Austin	O
,	O
M	O
.	O
D	O
.	O

More	O
than	O
94	O
%	O
of	O
targeted	O
exon	O
regions	O
were	O
covered	O
with	O
at	O
least	O
10	O
x	O
depth	O
,	O
which	O
is	O
sufficient	O
for	O
variant	O
discovery	O
.	O

(	O
A	O
)	O
Exon	O
-	O
intron	O
structure	O
of	O
the	O
NLPR3	B-GENE
gene	O
.	O

CRB1	B-GENE
mutations	O
are	O
known	O
to	O
cause	O
severe	O
diffuse	O
retinal	B-DISEASE
degeneration	I-DISEASE
with	O
absent	O
or	O
severely	O
diminished	O
ERGs	O
including	O
LCA	B-DISEASE
,	O
juvenile	B-DISEASE
RP	I-DISEASE
,	O
and	O
CRD	B-DISEASE
.	O

(	O
b	O
)	O
ECG	O
for	O
L148	O
-	O
02	O
,	O
a	O
5	O
-	O
year	O
-	O
old	O
boy	O
:	O
The	O
left	O
one	O
showed	O
very	O
broad	O
and	O
notched	O
or	O
bifid	O
even	O
biphasic	O
T	O
waves	O
on	O
multi	O
-	O
leads	O
(	O
arrows	O
)	O
(	O
QTc	O
600	O
ms	O
)	O
before	O
he	O
had	O
received	O
left	O
cardiac	O
sympathetic	O
denervation	O
(	O
LCSD	O
)	O
;	O
the	O
right	O
one	O
showed	O
less	O
abnormal	O
ECG	O
15	O
months	O
after	O
LCSD	O
(	O
QTc	O
490	O
ms	O
)	O
.	O

Predicted	O
structures	O
were	O
displayed	O
using	O
PyMol	O
software	O
(	O
version	O
1	O
.	O
5	O
)	O
.	O

A	O
3	O
x	O
centered	O
tiling	O
design	O
was	O
chosen	O
and	O
the	O
repeat	O
masked	O
function	O
was	O
used	O
to	O
avoid	O
simple	O
repeats	O
[	O
9	O
]	O
.	O

USH2A	B-GENE
mutations	O
account	O
for	O
over	O
70	O
%	O
of	O
USH2	B-DISEASE
cases	O
in	O
multiple	O
populations	O
[	O
11	O
]	O
,	O
[	O
12	O
]	O
,	O
[	O
13	O
]	O
,	O
[	O
14	O
]	O
.	O

Our	O
data	O
confirm	O
that	O
STRC	B-GENE
biallelic	O
mutations	O
significantly	O
contribute	O
to	O
NSHL	B-DISEASE
,	O
particularly	O
in	O
children	O
with	O
mild	O
to	O
moderate	O
hearing	B-DISEASE
impairment	I-DISEASE
with	O
greater	O
affection	O
in	O
higher	O
frequencies	O
.	O

(	O
B	O
)	O
Absence	O
of	O
Homer2	B-GENE
staining	O
in	O
the	O
cochlea	O
of	O
Homer2	B-GENE
-	O
/	O
-	O
mice	O
.	O

Both	O
amino	O
acids	O
are	O
highly	O
conserved	O
across	O
species	O
(	O
Figure	O
4B	O
)	O
.	O

If	O
no	O
candidate	O
mutations	O
were	O
detected	O
among	O
these	O
genes	O
,	O
the	O
23	O
genes	O
responsible	O
for	O
syndromic	O
hearing	B-DISEASE
loss	I-DISEASE
were	O
subjected	O
to	O
sequence	O
analysis	O
.	O

Early	O
developmental	O
milestones	O
were	O
normal	O
.	O

Patients	O
'	O
clinical	O
presentation	O
was	O
consistent	O
with	O
the	O
prototypic	O
picture	O
of	O
primary	O
dRTA	B-DISEASE
,	O
and	O
every	O
patient	O
showed	O
inability	O
to	O
acidify	O
urine	O
in	O
presence	O
of	O
non	O
-	O
gap	O
metabolic	B-DISEASE
acidosis	I-DISEASE
[	O
1	O
,	O
3	O
,	O
19	O
]	O
.	O

They	O
underwent	O
the	O
following	O
clinical	O
investigations	O
and	O
audiological	O
evaluation	O
:	O
tympanometry	O
,	O
auditory	O
brainstem	O
response	O
,	O
computed	O
tomography	O
of	O
the	O
temporal	O
bones	O
,	O
magnetic	O
resonance	O
imaging	O
of	O
the	O
inner	O
ear	O
,	O
ocular	O
fundus	O
examination	O
,	O
cardiac	O
and	O
renal	O
ultrasonography	O
.	O

Myosin	B-GENE
VI	I-GENE
has	O
three	O
functional	O
domains	O
:	O
an	O
N	O
-	O
terminal	O
motor	O
domain	O
or	O
head	O
domain	O
,	O
a	O
C	O
-	O
terminal	O
tail	O
domain	O
and	O
a	O
so	O
-	O
called	O
neck	O
region	O
.	O

The	O
mutational	O
analysis	O
was	O
performed	O
in	O
26	O
cases	O
the	O
DNA	O
being	O
unavailable	O
in	O
16	O
patients	O
(	O
including	O
3	O
with	O
KS	B-DISEASE
)	O
seen	O
at	O
the	O
onset	O
of	O
the	O
study	O
.	O

NR	O
=	O
Not	O
reported	O
and	O
EBV	O
-	O
LCLs	O
=	O
Epstein	O
-	O
Barr	O
virus	O
-	O
transformed	O
lymphoblastoid	O
cell	O
lines	O
.	O

Auditory	O
function	O
of	O
affected	O
subjects	O
was	O
assessed	O
by	O
pure	O
tone	O
audiometry	O
,	O
speech	O
-	O
audiometry	O
,	O
and	O
tympanometry	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
differential	O
diagnosis	O
is	O
necessary	O
.	O

Primer	O
sequences	O
are	O
available	O
in	O
S3	O
Table	O
.	O

NM_004999	O
.	O
3	O
for	O
MYO6	B-GENE
)	O
.	O

In	O
contrast	O
to	O
these	O
findings	O
,	O
we	O
recently	O
showed	O
that	O
the	O
KCNQ1	B-GENE
p	B-VARIANT
.	I-VARIANT
Y111C	I-VARIANT
mutation	O
presents	O
with	O
a	O
low	O
incidence	O
of	O
life	O
threatening	O
events	O
in	O
a	O
Swedish	O
Y111C	O
-	O
positive	O
LQTS	B-DISEASE
population	O
[	O
29	O
]	O
.	O

Five	O
of	O
the	O
seven	O
mutations	O
predict	O
a	O
premature	O
termination	O
codon	O
,	O
leading	O
to	O
a	O
truncated	O
protein	O
.	O

At	O
the	O
time	O
of	O
their	O
last	O
ophthalmological	O
assessment	O
,	O
the	O
mean	O
visual	O
acuity	O
was	O
0	O
.	O
87	O
LogMAR	O
(	O
6	O
/	O
44	O
Snellen	O
)	O
for	O
patients	O
with	O
pure	O
DOA	B-DISEASE
,	O
and	O
1	O
.	O
07	O
LogMAR	O
(	O
6	O
/	O
70	O
Snellen	O
)	O
for	O
those	O
with	O
DOA	O
+	O
phenotypes	O
,	O
this	O
difference	O
being	O
statistically	O
significant	O
(	O
P	O
=	O
0	O
.	O
0170	O
)	O
(	O
Fig	O
.	O

Four	O
non	O
-	O
synonymous	O
nucleotide	O
changes	O
were	O
identified	O
by	O
direct	O
sequencing	O
of	O
the	O
WFS1	B-GENE
gene	O
coding	O
sequence	O
(	O
exon	O
2	O
-	O
8	O
)	O
in	O
the	O
three	O
affected	O
individuals	O
.	O

Authors	O
'	O
contributions	O
BA	O
contributed	O
to	O
the	O
design	O
of	O
the	O
study	O
,	O
performed	O
experiments	O
and	O
data	O
analysis	O
,	O
the	O
interpretation	O
of	O
results	O
,	O
and	O
wrote	O
the	O
manuscript	O
.	O

31171217	O
)	O
,	O
and	O
by	O
a	O
grant	O
from	O
the	O
Research	O
Special	O
Fund	O
for	O
Public	O
Welfare	O
Industry	O
of	O
Health	O
,	O
Ministry	O
of	O
Health	O
of	O
China	O
(	O
no	O
.	O

The	O
variant	O
list	O
derived	O
from	O
case	O
1024	O
(	O
a	O
male	O
)	O
highlighted	O
two	O
heterozygous	O
missense	O
variants	O
in	O
CDH23	B-GENE
as	O
possible	O
candidates	O
even	O
though	O
recessive	O
mutations	O
in	O
this	O
gene	O
usually	O
cause	O
Usher	B-DISEASE
syndrome	I-DISEASE
.	O

The	O
ATG	O
start	O
codon	O
appears	O
in	O
bold	O
.	O

This	O
gene	O
encodes	O
a	O
197	O
amino	O
acid	O
transmembrane	O
sialomucin	O
(	O
known	O
as	O
endolyn	B-GENE
,	O
MUC	B-GENE
-	I-GENE
24	I-GENE
or	O
CD164	B-GENE
)	O
,	O
which	O
is	O
widely	O
expressed	O
and	O
involved	O
in	O
cell	O
adhesion	O
and	O
migration	O
.	O

Previously	O
unidentified	O
mutations	O
were	O
found	O
in	O
five	O
patients	O
with	O
MODY	B-DISEASE
(	O
15	O
%	O
)	O
and	O
nine	O
with	O
neonatal	B-DISEASE
diabetes	I-DISEASE
(	O
18	O
%	O
)	O
.	O

As	O
suggested	O
by	O
genotype	O
-	O
phenotype	O
correlation	O
study	O
,	O
Usher	B-DISEASE
1D	I-DISEASE
,	O
which	O
has	O
congenital	O
profound	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
,	O
and	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
,	O
is	O
usually	O
associated	O
with	O
nonsense	O
mutations	O
,	O
whereas	O
DFNB12	B-DISEASE
,	O
which	O
has	O
a	O
milder	O
phenotype	O
,	O
is	O
associated	O
with	O
missense	O
mutations	O
[	O
1	O
]	O
,	O
[	O
2	O
]	O
,	O
[	O
5	O
]	O
-	O
[	O
8	O
]	O
.	O

The	O
expected	O
position	O
of	O
a	O
truncated	O
NARS2	B-GENE
protein	O
product	O
(	O
delta	O
154aa	O
)	O
stemming	O
from	O
the	O
p	B-VARIANT
.	I-VARIANT
Tyr323	I-VARIANT
*	I-VARIANT
allele	O
is	O
indicated	O
with	O
a	O
black	O
arrow	O
.	O

The	O
final	O
clinical	O
diagnosis	O
of	O
USH2	B-DISEASE
was	O
verified	O
based	O
on	O
typical	O
RP	B-DISEASE
symptoms	O
companied	O
with	O
sensorineural	O
hearing	B-DISEASE
impairment	I-DISEASE
and	O
normal	O
vestibular	O
function	O
.	O

Creating	O
a	O
network	O
for	O
rare	O
diseases	O
is	O
an	O
important	O
medical	O
policy	O
that	O
should	O
significantly	O
reduce	O
misdiagnosis	O
and	O
improve	O
the	O
level	O
of	O
treatment	O
.	O

1	O
,	O
2	O
It	O
has	O
been	O
estimated	O
that	O
about	O
two	O
-	O
thirds	O
of	O
these	O
cases	O
have	O
a	O
genetic	O
origin	O
,	O
most	O
of	O
which	O
are	O
monogenic	O
.	O

S2	O
)	O
.	O

The	O
SOAPsnp	O
software	O
was	O
used	O
for	O
SNP	O
genotyping	O
(	O
BGI	O
,	O
China	O
)	O
.	O

This	O
table	O
was	O
selected	O
,	O
updated	O
and	O
extended	O
from	O
de	O
Brouwer	O
et	O
al	O
.	O
,	O
2010	O
[	O
6	O
]	O
.	O

Through	O
the	O
targeted	O
resequencing	O
of	O
the	O
20	O
families	O
,	O
we	O
found	O
most	O
likely	O
responsible	O
genes	O
for	O
nine	O
out	O
of	O
thirteen	O
AD	O
families	O
and	O
four	O
genes	O
from	O
seven	O
AR	O
families	O
.	O

Sequences	O
were	O
evaluated	O
using	O
the	O
software	O
Sequencher	O
(	O
tm	O
)	O
4	O
.	O
9	O
(	O
Gene	O
Codes	O
Corporation	O
,	O
MI	O
,	O
USA	O
)	O
.	O

(	O
29	O
)	O
proposed	O
that	O
the	O
loss	O
of	O
Cys342	O
released	O
a	O
cysteine	O
at	O
position	O
278	O
,	O
possibly	O
generates	O
a	O
dimerization	O
of	O
receptor	O
molecules	O
and	O
,	O
consequently	O
,	O
constitutive	O
activation	O
(	O
gain	O
-	O
of	O
-	O
function	O
)	O
.	O

Disease	O
allele	O
frequency	O
was	O
set	O
to	O
0	O
.	O
0001	O
and	O
penetrance	O
to	O
1	O
.	O

Detailed	O
information	O
of	O
the	O
two	O
microarrays	O
has	O
been	O
previously	O
described	O
[	O
1	O
]	O
,	O
[	O
18	O
]	O
,	O
[	O
19	O
]	O
,	O
[	O
20	O
]	O
.	O

All	O
MARVELD2	B-GENE
mutations	O
so	O
far	O
described	O
are	O
located	O
within	O
the	O
coding	O
region	O
or	O
splice	O
sites	O
,	O
which	O
were	O
included	O
in	O
our	O
sequence	O
analysis	O
.	O

For	O
1D	O
electrophoresis	O
equal	O
volumes	O
of	O
reduced	O
denatured	O
samples	O
were	O
separated	O
on	O
two	O
4	O
-	O
12	O
%	O
polyacrylamide	O
gels	O
(	O
Life	O
Technologies	O
)	O
.	O

Table	O
S1	O
,	O
Variants	O
in	O
cancer	O
-	O
susceptibility	O
genes	O
observed	O
in	O
the	O
cohort	O
.	O

Red	O
indicates	O
patients	O
with	O
likely	O
pathogenic	O
variants	O
,	O
blue	O
indicates	O
patients	O
with	O
variants	O
of	O
uncertain	O
significance	O
(	O
VUS	O
)	O
,	O
and	O
gray	O
indicates	O
patients	O
without	O
'	O
likely	O
deleterious	O
'	O
variants	O
.	O

Detailed	O
funduscopic	O
examination	O
of	O
some	O
affected	O
individuals	O
ruled	O
out	O
obvious	O
signs	O
of	O
retinopathy	O
.	O

For	O
the	O
genetic	O
diagnosis	O
of	O
HL	B-DISEASE
,	O
which	O
has	O
a	O
very	O
limited	O
mutation	O
spectrum	O
at	O
mtDNA	O
,	O
28	O
a	O
dedicated	O
target	O
of	O
entire	O
mtDNA	O
may	O
not	O
be	O
necessary	O
.	O

Signal	O
-	O
to	O
-	O
noise	O
ratios	O
of	O
greater	O
than	O
6	O
dB	O
was	O
shown	O
in	O
a	O
specific	O
frequency	O
band	O
in	O
distortion	O
product	O
otoacoustic	O
emissions	O
(	O
lower	O
panel	O
)	O
.	O

The	O
remaining	O
parts	O
were	O
soaked	O
in	O
a	O
RNA	O
stabilization	O
solution	O
(	O
Ambion	O
,	O
Life	O
Technologies	O
)	O
to	O
remove	O
the	O
volute	O
.	O

However	O
,	O
we	O
note	O
that	O
a	O
review	O
of	O
this	O
biopsy	O
concluded	O
that	O
although	O
some	O
glomeruli	O
exhibited	O
mesangial	O
proliferative	O
changes	O
,	O
these	O
were	O
not	O
sufficient	O
to	O
warrant	O
a	O
histological	O
diagnosis	O
of	O
MPGN	B-DISEASE
.	O

Probands	O
of	O
each	O
family	O
were	O
pointed	O
by	O
the	O
arrows	O
.	O

For	O
instance	O
it	O
has	O
been	O
shown	O
that	O
the	O
mitochondrial	O
DNA	O
,	O
which	O
encodes	O
respiratory	O
chain	O
subunits	O
,	O
can	O
influence	O
the	O
expression	O
of	O
ADOA	B-DISEASE
[	O
35	O
]	O
.	O

Three	O
prominent	O
deafness	B-DISEASE
-	O
related	O
genes	O
,	O
GJB2	B-GENE
,	O
SLC26A4	B-GENE
and	O
mtDNA	B-GENE
12S	I-GENE
rRNA	I-GENE
,	O
were	O
analyzed	O
.	O

Our	O
patient	O
had	O
low	O
testosterone	O
levels	O
,	O
combined	O
with	O
an	O
elevated	O
FSH	O
,	O
suggesting	O
primary	O
testicular	O
failure	O
.	O

Abbreviations	O
:	O
cd	O
,	O
cochlear	O
duct	O
,	O
SG	O
,	O
spiral	O
ganglion	O
.	O

Others	O
have	O
used	O
a	O
software	O
-	O
assisted	O
image	O
analysis	O
system	O
(	O
Noris	O
et	O
al	O
.	O

SIFT	O
analysis	O
for	O
the	O
novel	O
substitutions	O
predicted	O
these	O
changes	O
would	O
affect	O
the	O
protein	O
function	O
(	O
SIFT	O
score	O
<	O
0	O
.	O
05	O
)	O
,	O
except	O
for	O
the	O
p	B-VARIANT
.	I-VARIANT
Thr153Ala	I-VARIANT
mutation	O
in	O
RPE65	B-GENE
(	O
the	O
SIFT	O
analysis	O
predicted	O
this	O
change	O
would	O
be	O
tolerated	O
)	O
.	O

DNA	O
was	O
extracted	O
from	O
the	O
index	O
patient	O
as	O
well	O
as	O
from	O
other	O
affected	O
and	O
unaffected	O
family	O
members	O
using	O
the	O
FlexiGene	O
DNA	O
kit	O
(	O
QIAGEN	O
)	O
.	O

In	O
general	O
,	O
individuals	O
with	O
USH1D	B-DISEASE
mostly	O
carry	O
a	O
truncated	O
CDH23	B-GENE
protein	O
because	O
of	O
nonsense	O
,	O
frameshift	O
,	O
or	O
splice	O
-	O
site	O
mutations	O
,	O
whereas	O
those	O
with	O
DFNB12	B-DISEASE
usually	O
carry	O
missense	O
mutations	O
[	O
7	O
,	O
10	O
,	O
13	O
]	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
nonlinear	O
compression	O
function	O
of	O
the	O
cochlea	O
was	O
impaired	O
and	O
suggest	O
that	O
the	O
lesion	O
was	O
near	O
the	O
outer	O
hair	O
cells	O
.	O

So	O
far	O
,	O
there	O
is	O
less	O
variation	O
in	O
thresholds	O
in	O
families	O
E	O
and	O
H	O
at	O
matching	O
ages	O
.	O

The	O
prevalences	O
of	O
the	O
mutation	O
in	O
implanted	O
subjects	O
seem	O
to	O
be	O
dependent	O
on	O
ethnicities	O
.	O

(	O
d	O
)	O
Montage	O
of	O
AO	O
image	O
corresponding	O
to	O
area	O
(	O
c	O
)	O
is	O
shown	O
.	O

However	O
,	O
an	O
additional	O
factor	O
here	O
is	O
that	O
for	O
most	O
genes	O
where	O
disruptive	O
genetic	O
variants	O
can	O
cause	O
developmental	O
disorders	O
,	O
our	O
understanding	O
of	O
the	O
phenotypic	O
consequences	O
of	O
this	O
variation	O
is	O
limited	O
to	O
postnatal	O
observations	O
that	O
are	O
often	O
not	O
detectable	O
by	O
prenatal	O
ultrasound	O
investigations	O
(	O
e	O
.	O
g	O
.	O

Pro88del	I-VARIANT
)	O
variant	O
co	O
-	O
segregated	O
with	O
the	O
phenotype	O
and	O
was	O
absent	O
in	O
the	O
100	O
ethnicity	O
-	O
matched	O
controls	O
.	O

One	O
case	O
carried	O
KCNQ1	B-GENE
:	O
p	B-VARIANT
.	I-VARIANT
A341V	I-VARIANT
and	O
KCNH2	B-GENE
:	O
p	B-VARIANT
.	I-VARIANT
R328C	I-VARIANT
while	O
the	O
other	O
carried	O
KCNQ1	B-GENE
:	O
p	B-VARIANT
.	I-VARIANT
A341V	I-VARIANT
and	O
KCNE1	B-GENE
:	O
p	B-VARIANT
.	I-VARIANT
D91E	I-VARIANT
.	O

Heritability	O
and	O
twin	O
studies	O
have	O
suggested	O
genetic	O
contributions	O
to	O
presbycusis	B-DISEASE
and	O
a	O
genome	O
-	O
wide	O
-	O
association	O
study	O
recently	O
identified	O
a	O
genetic	O
variant	O
in	O
the	O
metabotropic	B-GENE
glutamate	I-GENE
receptor	I-GENE
7	I-GENE
(	O
GRM7	B-GENE
)	O
gene	O
as	O
a	O
risk	O
factor	O
2	O
3	O
4	O
5	O
.	O

Individual	O
94	O
was	O
tested	O
for	O
STRC	B-GENE
CNVs	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
(	O
qPCR	O
)	O
,	O
using	O
unique	O
STRC	B-GENE
exon	O
22	O
primers	O
excluding	O
the	O
pseudogene	O
(	O
Table	O
S1	O
,	O
Supporting	O
Information	O
;	O
exon	O
22	O
primers	O
without	O
M13	O
tags	O
)	O
and	O
the	O
SensiMix	O
SYBR	O
Green	O
Kit	O
(	O
Bioline	O
,	O
Luckenwalde	O
,	O
Germany	O
)	O
.	O

(	O
left	O
)	O
Pedigree	O
of	O
the	O
family	O
under	O
study	O
.	O

High	O
-	O
resolution	O
CT	O
of	O
the	O
temporal	O
bone	O
and	O
the	O
brain	O
in	O
the	O
affected	O
subject	O
II	O
:	O
4	O
was	O
normal	O
,	O
excluding	O
inner	O
-	O
ear	O
gross	O
malformations	O
.	O

Defects	O
in	O
TECTA	B-GENE
,	O
the	O
gene	O
encodes	O
alpha	O
-	O
tectorin	O
,	O
are	O
cause	O
of	O
both	O
dominant	O
(	O
DFNA8	B-GENE
/	I-GENE
12	I-GENE
)	O
and	O
recessive	O
(	O
DFNB21	B-GENE
)	O
forms	O
of	O
deafness	B-DISEASE
.	O

The	O
diagnosis	O
of	O
CHI	B-DISEASE
was	O
carried	O
out	O
according	O
to	O
the	O
following	O
criteria	O
:	O
a	O
fasting	O
and	O
post	O
-	O
prandial	O
hypoglycemia	O
with	O
unsuppressed	O
insulin	O
secretion	O
,	O
a	O
positive	O
response	O
to	O
the	O
administration	O
of	O
glucagon	O
,	O
negative	O
ketone	O
bodies	O
in	O
urine	O
and	O
plasma	O
,	O
and	O
a	O
prolonged	O
dependence	O
to	O
treatment	O
to	O
prevent	O
hypoglycemia	O
.	O

Our	O
cell	O
-	O
based	O
in	O
vitro	O
functional	O
assays	O
study	O
also	O
indicated	O
that	O
c	B-VARIANT
.	I-VARIANT
109G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
homozygote	O
could	O
impair	O
connexin26	O
gap	O
junctional	O
coupling	O
and	O
should	O
be	O
assigned	O
to	O
pathogenic	O
mutation	O
(	O
unpublished	O
data	O
)	O
.	O

The	O
missense	O
mutation	O
p	B-VARIANT
.	I-VARIANT
I5126T	I-VARIANT
in	O
USH2A	B-GENE
has	O
been	O
reported	O
as	O
likely	O
pathogenic	O
[	O
87	O
]	O
.	O

We	O
used	O
the	O
average	O
coverage	O
of	O
targeted	O
exons	O
of	O
deafness	B-DISEASE
genes	O
as	O
the	O
basis	O
to	O
calculate	O
CNVs	O
in	O
the	O
targeted	O
regions	O
.	O

Our	O
evaluation	O
suggests	O
rooms	O
for	O
improvement	O
for	O
our	O
custom	O
TGE	O
kit	O
,	O
and	O
also	O
illustrates	O
several	O
issues	O
that	O
need	O
to	O
be	O
considered	O
in	O
the	O
kit	O
design	O
.	O

Many	O
mutations	O
(	O
5	O
out	O
of	O
10	O
possible	O
pathologic	O
mutations	O
,	O
2	O
out	O
of	O
17	O
uncertain	O
variants	O
)	O
were	O
found	O
in	O
DRE	O
,	O
DXNDN	O
,	O
and	O
DXD	O
motif	O
(	O
Table	O
1	O
and	O
2	O
)	O
.	O

d	O
Identification	O
of	O
a	O
4	O
,	O
977	O
-	O
bp	O
common	O
deletion	O
in	O
mtDNA	O
.	O

In	O
the	O
present	O
study	O
,	O
whole	O
-	O
exome	O
sequencing	O
combined	O
with	O
co	O
-	O
segregation	O
analysis	O
identified	O
a	O
novel	O
EYA4	B-GENE
mutation	O
,	O
c	B-VARIANT
.	I-VARIANT
T1301A	I-VARIANT
,	O
in	O
a	O
Chinese	O
family	O
with	O
autosomal	B-DISEASE
-	I-DISEASE
dominant	I-DISEASE
NSHL	I-DISEASE
,	O
which	O
predicts	O
an	O
isoleucine	O
-	O
to	O
-	O
lysine	O
substitution	O
(	O
p	B-VARIANT
.	I-VARIANT
I411K	I-VARIANT
)	O
.	O

To	O
determine	O
which	O
genes	O
have	O
the	O
greatest	O
impact	O
on	O
deafness	B-DISEASE
etiology	O
,	O
the	O
number	O
of	O
mutations	O
was	O
counted	O
,	O
showing	O
that	O
those	O
in	O
GJB2	B-GENE
were	O
exceptionally	O
higher	O
,	O
followed	O
by	O
mutations	O
in	O
SLC26A4	B-GENE
,	O
USH2A	B-GENE
,	O
GPR98	B-GENE
,	O
MYO15A	B-GENE
,	O
COL4A5	B-GENE
and	O
CDH23	B-GENE
.	O

The	O
protein	O
concentration	O
was	O
determined	O
using	O
a	O
Bradford	O
assay	O
.	O

Lysates	O
from	O
HEK293	O
cells	O
transfected	O
with	O
CIB2	B-GENE
-	O
GFP	O
and	O
tdTomato	O
-	O
CIB2	B-GENE
expression	O
constructs	O
were	O
co	O
-	O
immunoprecipitated	O
with	O
anti	O
-	O
GFP	O
antibody	O
.	O

Additional	O
germline	O
SNPs	O
were	O
identified	O
using	O
Samtools	O
(	O
Version	O
0	O
.	O
1	O
.	O
7a	O
(	O
revision	O
#	O
599	O
)	O
and	O
additional	O
germline	O
indels	O
were	O
identified	O
using	O
GATK	O
(	O
Version	O
1	O
.	O
0	O
(	O
revision	O
5336	O
)	O
.	O

6	O
years	O
.	O

This	O
generated	O
chromatin	O
fragments	O
of	O
500	O
bp	O
on	O
average	O
.	O

Any	O
genes	O
on	O
the	O
list	O
that	O
represented	O
common	O
fusion	O
products	O
of	O
translocation	O
or	O
any	O
gene	O
that	O
could	O
not	O
be	O
identified	O
based	O
on	O
Ensembl	O
release	O
58	O
and	O
the	O
corresponding	O
release	O
of	O
NCBI	O
Refseq	O
from	O
the	O
same	O
time	O
point	O
were	O
excluded	O
.	O

(	O
1A	O
-	O
5A	O
)	O
Anterior	O
view	O
of	O
craniofacial	O
features	O
of	O
PS	B-DISEASE
patients	O
with	O
different	O
severity	O
.	O

Electropherogram	O
of	O
the	O
partial	O
cDNA	O
sequence	O
of	O
RNA	O
derived	O
from	O
cells	O
transfected	O
with	O
the	O
pCI	O
-	O
NEO	O
with	O
either	O
the	O
mutant	O
or	O
wildtype	O
TMC1	B-GENE
exon	O
8	O
.	O

To	O
measure	O
the	O
activity	O
of	O
complex	O
V	O
,	O
we	O
first	O
disrupted	O
cells	O
by	O
freezing	O
in	O
liquid	O
nitrogen	O
,	O
followed	O
by	O
rapid	O
thawing	O
at	O
37	O
deg	O
C	O
.	O

Interactions	O
between	O
the	O
experimental	O
groups	O
(	O
HEK293	O
cells	O
expressing	O
WT	O
and	O
mutant	O
KCNQ1	B-GENE
)	O
and	O
responses	O
of	O
the	O
currents	O
to	O
changes	O
in	O
voltage	O
were	O
analyzed	O
by	O
MANOVA	O
(	O
Stata64	O
for	O
Mac	O
,	O
10	O
.	O
1	O
)	O
.	O

Direct	O
sequencing	O
revealed	O
that	O
the	O
374	O
bp	O
contains	O
exon	O
16	O
,	O
whereas	O
the	O
246	O
-	O
bp	O
PCR	O
product	O
is	O
lacking	O
the	O
exon	O
.	O

Text	O
in	O
bold	O
and	O
italicised	O
highlights	O
high	O
pathogenicity	O
of	O
missense	O
variants	O
.	O

We	O
uncovered	O
a	O
novel	O
nonsynonymous	O
variant	O
(	O
p	B-VARIANT
.	I-VARIANT
Trp314Arg	I-VARIANT
)	O
in	O
the	O
Wolfram	B-DISEASE
syndrome	I-DISEASE
1	O
(	O
WFS1	B-GENE
)	O
gene	O
that	O
segregates	O
completely	O
with	O
the	O
diabetic	B-DISEASE
phenotype	O
.	O

None	O
of	O
the	O
CNVs	O
co	O
-	O
segregated	O
with	O
affected	O
or	O
unaffected	O
family	O
members	O
.	O

The	O
intrafamilial	O
heterogeneity	O
in	O
female	O
patients	O
of	O
family	O
3	O
may	O
be	O
due	O
to	O
variable	O
X	O
-	O
chromosomal	O
inactivation	O
[	O
27	O
]	O
.	O

This	O
alteration	O
was	O
not	O
found	O
in	O
the	O
patient	O
'	O
s	O
parents	O
.	O

23	O
Our	O
observation	O
that	O
individuals	O
in	O
the	O
undiagnosed	O
group	O
harbor	O
significantly	O
more	O
damaging	O
variants	O
in	O
HL	B-DISEASE
genes	O
than	O
controls	O
supports	O
this	O
hypothesis	O
.	O

The	O
phenotype	O
of	O
the	O
AUNX1	B-GENE
family	O
has	O
been	O
reported	O
and	O
includes	O
auditory	B-DISEASE
neuropathy	I-DISEASE
and	O
delayed	B-DISEASE
peripheral	I-DISEASE
sensory	I-DISEASE
neuropathy	I-DISEASE
inherited	O
in	O
an	O
X	O
-	O
linked	O
recessive	O
pattern	O
.	O

We	O
sequenced	O
otoancorin	B-GENE
in	O
a	O
deaf	O
individual	O
and	O
identified	O
mis	O
-	O
sense	O
mutation	O
1067A	B-VARIANT
>	I-VARIANT
T	I-VARIANT
,	O
which	O
leads	O
to	O
substitution	O
of	O
valine	O
for	O
aspartic	O
acid	O
at	O
residue	O
356	O
(	O
D356V	B-VARIANT
)	O
.	O

B	O
)	O
Nucleotide	O
sequence	O
of	O
exon	O
24	O
(	O
capital	O
letter	O
)	O
,	O
where	O
three	O
deletions	O
and	O
one	O
duplication	O
(	O
c	B-VARIANT
.	I-VARIANT
3142_3162del	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
3164_3205del	I-VARIANT
,	O
and	O
c	B-VARIANT
.	I-VARIANT
3195_3215del	I-VARIANT
/	O
dup	O
)	O
so	O
far	O
identified	O
are	O
indicated	O
.	O

Mutant	O
pcDNA3	O
.	O
1	O
-	O
Gipc3	B-GENE
343A	O
was	O
generated	O
by	O
site	O
-	O
directed	O
mutagenesis	O
using	O
QuickChange	O
mutagenesis	O
kit	O
(	O
Stratagene	O
)	O
.	O

gDNA	O
quality	O
was	O
evaluated	O
using	O
the	O
optical	O
density	O
ratio	O
(	O
260	O
/	O
280	O
ratio	O
)	O
and	O
gel	O
electrophoresis	O
imaging	O
.	O

Average	O
coverage	O
of	O
consensus	O
coding	O
sequence	O
(	O
CCDS	O
)	O
exons	O
was	O
calculated	O
for	O
each	O
sample	O
using	O
GATK	O
[	O
DePristo	O
et	O
al	O
.	O
,	O
2011	O
]	O
;	O
mean	O
coverage	O
was	O
106x	O
after	O
duplicate	O
read	O
removal	O
,	O
with	O
a	O
range	O
of	O
55	O
x	O
to	O
162	O
x	O
.	O

All	O
affected	O
individuals	O
reported	O
progressive	O
bilateral	O
hearing	B-DISEASE
impairment	I-DISEASE
.	O

In	O
addition	O
,	O
it	O
has	O
been	O
reported	O
that	O
the	O
DFNB12	B-DISEASE
allele	O
is	O
phenotypically	O
dominant	O
to	O
an	O
USH1D	B-DISEASE
allele	O
[	O
29	O
]	O
.	O

Few	O
targets	O
showed	O
coverage	O
below	O
1X	O
.	O

According	O
to	O
our	O
criteria	O
3	O
,	O
208	O
Chinese	O
reports	O
were	O
qualified	O
for	O
inclusion	O
.	O

Of	O
the	O
11	O
tested	O
for	O
bladder	O
emptying	O
,	O
five	O
(	O
45	O
%	O
)	O
had	O
elevated	O
post	O
-	O
void	O
residual	O
bladder	O
volume	O
.	O

Fig	O
.	O

In	O
the	O
adult	O
kidney	O
this	O
complex	O
is	O
composed	O
of	O
subunits	O
encoded	O
by	O
the	O
genes	O
COL4A3	B-GENE
and	O
COL4A4	B-GENE
(	O
which	O
are	O
situated	O
on	O
chromosome	O
2	O
)	O
and	O
COL4A5	B-GENE
which	O
lies	O
on	O
the	O
X	O
chromosome	O
.	O

In	O
developmental	O
studies	O
,	O
the	O
expression	O
of	O
murine	O
eya1	B-GENE
in	O
the	O
sensory	O
hair	O
cells	O
continued	O
after	O
birth	O
and	O
after	O
maturation	O
(	O
P16	O
in	O
mouse	O
)	O
,	O
suggesting	O
an	O
additional	O
role	O
for	O
eya1	B-GENE
in	O
the	O
differentiation	O
and	O
/	O
or	O
survival	O
of	O
the	O
inner	O
ear	O
cell	O
populations	O
in	O
particular	O
the	O
sensory	O
cells	O
[	O
26	O
]	O
.	O

Homozygous	O
or	O
compound	O
heterozygous	O
pathogenic	O
mutations	O
were	O
found	O
in	O
21	O
subjects	O
,	O
which	O
included	O
16	O
probands	O
.	O

The	O
incidence	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
among	O
Turkish	O
patients	O
with	O
WS1	B-DISEASE
was	O
published	O
as	O
75	O
%	O
by	O
Oysu	O
et	O
al	O
.	O

The	O
deleterious	O
560_605ins46	B-VARIANT
mutation	O
was	O
found	O
in	O
1	O
Man	O
patient	O
.	O

Fig	O
.	O

JBN	O
acquired	O
clinical	O
data	O
and	O
drafted	O
the	O
manuscript	O
.	O

Vertical	O
dashed	O
black	O
lines	O
indicate	O
wave	O
I	O
,	O
III	O
and	O
V	O
peaks	O
in	O
the	O
control	O
,	O
while	O
the	O
vertical	O
red	O
line	O
refers	O
to	O
wave	O
V	O
peak	O
in	O
OPA1	B-GENE
-	O
M	O
Subject	O
1	O
.	O

Thirty	O
-	O
four	O
USH2A	B-GENE
gene	O
variants	O
were	O
detected	O
,	O
including	O
eight	O
missense	O
variants	O
,	O
nine	O
nonsense	O
variants	O
,	O
six	O
splicing	O
variants	O
,	O
and	O
11	O
duplications	O
/	O
deletions	O
;	O
19	O
patients	O
were	O
compound	O
heterozygous	O
,	O
and	O
three	O
were	O
homozygous	O
.	O

OTOF	B-GENE
gene	O
mutations	O
have	O
been	O
inferred	O
to	O
be	O
responsible	O
for	O
2	O
%	O
-	O
3	O
%	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
hearing	I-DISEASE
losses	I-DISEASE
(	O
NSHL	B-DISEASE
)	O
in	O
some	O
ethnic	O
groups	O
,	O
and	O
most	O
of	O
these	O
patients	O
meet	O
the	O
diagnostic	O
criteria	O
for	O
ANSD	B-DISEASE
[	O
16	O
]	O
,	O
[	O
17	O
]	O
.	O

In	O
five	O
of	O
these	O
cases	O
,	O
the	O
mutations	O
were	O
the	O
following	O
:	O
c	B-VARIANT
.	I-VARIANT
2680G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
E894K	I-VARIANT
)	O
,	O
n	O
=	O
1	O
,	O
c	B-VARIANT
.	I-VARIANT
2152C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
R718W	I-VARIANT
)	O
n	O
=	O
2	O
,	O
c	B-VARIANT
.	I-VARIANT
1115A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Q372R	I-VARIANT
)	O
n	O
=	O
1	O
,	O
and	O
c	B-VARIANT
.	I-VARIANT
2105G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
R702H	I-VARIANT
)	O
n	O
=	O
1	O
.	O

Four	O
MYO7A	B-GENE
and	O
17	O
USH2A	B-GENE
variants	O
have	O
already	O
been	O
described	O
in	O
the	O
literature	O
.	O

In	O
14	O
patients	O
carrying	O
a	O
single	O
mutation	O
identified	O
by	O
Sanger	O
analysis	O
,	O
no	O
additional	O
mutations	O
were	O
detected	O
by	O
NGS	O
.	O

Altogether	O
fifteen	O
affected	O
and	O
unaffected	O
members	O
(	O
II	O
:	O
1	O
,	O
II	O
:	O
2	O
,	O
II	O
:	O
5	O
,	O
II	O
:	O
6	O
,	O
II	O
:	O
7	O
,	O
II	O
:	O
9	O
,	O
II	O
:	O
10	O
,	O
III	O
:	O
2	O
,	O
III	O
:	O
3	O
,	O
III	O
:	O
7	O
,	O
III	O
:	O
9	O
,	O
III	O
:	O
10	O
,	O
III	O
:	O
11	O
,	O
III	O
:	O
12	O
,	O
III	O
:	O
13	O
)	O
from	O
the	O
second	O
and	O
third	O
generations	O
were	O
selected	O
for	O
linkage	O
analysis	O
.	O

Following	O
infiltration	O
using	O
0	O
.	O
3	O
%	O
Triton	O
X	O
-	O
100	O
and	O
blocking	O
with	O
5	O
%	O
normal	O
goat	O
serum	O
,	O
we	O
incubated	O
the	O
tissues	O
in	O
rabbit	O
HOMER2	B-GENE
polyclonal	O
primary	O
antibody	O
(	O
NB100	O
-	O
98712	O
,	O
Novus	O
Biologicals	O
,	O
Littleton	O
,	O
CO	O
)	O
diluted	O
1	O
:	O
1000	O
in	O
PBS	O
overnight	O
at	O
4	O
deg	O
C	O
.	O

A	O
Relative	O
expression	O
of	O
GJB2	B-GENE
transcript	O
generated	O
by	O
splicing	O
from	O
the	O
known	O
site	O
(	O
two	O
-	O
tailed	O
p	O
<	O
0	O
.	O
0001	O
,	O
N	O
=	O
5	O
)	O
.	O

The	O
finding	O
of	O
the	O
c	B-VARIANT
.	I-VARIANT
35delG	I-VARIANT
mutation	O
in	O
Xinjiang	O
may	O
be	O
due	O
in	O
part	O
to	O
the	O
close	O
vicinity	O
of	O
Xinjiang	O
to	O
Russia	O
and	O
Eastern	O
European	O
countries	O
,	O
and	O
possible	O
admixture	O
.	O

The	O
enamel	O
on	O
the	O
occlusal	O
and	O
lingual	O
surfaces	O
was	O
of	O
serious	O
wear	O
.	O

The	O
penetrance	O
is	O
considered	O
to	O
be	O
complete	O
,	O
but	O
there	O
is	O
a	O
high	O
inter	O
and	O
intra	O
-	O
familial	O
phenotypic	O
variation	O
,	O
ranging	O
from	O
cases	O
with	O
perinatal	O
death	O
due	O
to	O
airway	O
obstruction	O
by	O
severe	O
orofacial	O
malformations	O
to	O
those	O
that	O
are	O
not	O
clinically	O
diagnosed	O
[	O
2	O
]	O
.	O

Although	O
exons	O
27	O
,	O
8	O
,	O
and	O
15	O
were	O
suggested	O
to	O
be	O
regions	O
of	O
mutation	O
hot	O
spots	O
in	O
a	O
previous	O
study	O
by	O
Ferre	O
et	O
al	O
.	O

Myosin	B-GENE
VIIA	I-GENE
is	O
predominantly	O
monomeric	O
in	O
cells	O
,	O
but	O
can	O
be	O
induced	O
to	O
dimerize	O
via	O
the	O
predicted	O
coiled	O
-	O
coil	O
-	O
domain	O
after	O
cargo	O
binding	O
and	O
functions	O
as	O
a	O
cargo	O
transporter	O
[	O
24	O
]	O
.	O

Patients	O
carrying	O
a	O
mutation	O
in	O
the	O
DFNA1	O
locus	O
typically	O
experience	O
a	O
rapidly	O
deteriorating	O
hearing	B-DISEASE
impairment	I-DISEASE
spreading	O
from	O
low	O
to	O
all	O
higher	O
frequencies	O
[	O
10	O
]	O
.	O

HeLa	O
cells	O
were	O
washed	O
twice	O
with	O
Ca	O
2	O
+	O
/	O
Mg	O
2	O
+	O
-	O
free	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
;	O
1X	O
)	O
,	O
collected	O
by	O
trypsinization	O
,	O
and	O
centrifuged	O
.	O

Almost	O
all	O
of	O
the	O
BRCA1	B-GENE
and	O
BRCA2	B-GENE
variants	O
observed	O
in	O
our	O
cohort	O
are	O
unlikely	O
to	O
have	O
strong	O
effects	O
on	O
cancer	B-DISEASE
susceptibility	O
.	O

Beta	O
-	O
blockers	O
,	O
the	O
first	O
line	O
therapy	O
of	O
LQTS	B-DISEASE
,	O
generally	O
provide	O
limited	O
protection	O
to	O
JLNS	B-DISEASE
patients	O
.	O
[	O
9	O
]	O
Malfunction	O
,	O
or	O
complete	O
loss	B-DISEASE
of	I-DISEASE
function	I-DISEASE
of	I-DISEASE
I	I-DISEASE
Ks	I-DISEASE
in	I-DISEASE
the	I-DISEASE
inner	I-DISEASE
ear	I-DISEASE
is	O
the	O
underlying	O
cause	O
of	O
the	O
auditory	O
impairment	O
or	O
sensorineural	B-DISEASE
deafness	I-DISEASE
in	O
JLNS	B-DISEASE
.	O

NimbleGen	O
sequence	O
capture	O
array	O
was	O
designed	O
to	O
target	O
all	O
protein	O
coding	O
sequences	O
(	O
CDSs	O
)	O
and	O
100	O
bp	O
of	O
the	O
flanking	O
sequence	O
of	O
80	O
common	O
deafness	B-DISEASE
genes	O
.	O

Approval	O
for	O
the	O
study	O
was	O
obtained	O
by	O
the	O
Second	O
University	O
of	O
Naples	O
and	O
by	O
IRCCS	O
-	O
Burlo	O
Garofolo	O
of	O
Trieste	O
Ethics	O
Committees	O
.	O

Among	O
these	O
new	O
findings	O
were	O
mutations	O
in	O
seven	O
different	O
Usher	B-DISEASE
genes	O
,	O
CDH23	B-GENE
,	O
GPR98	B-GENE
,	O
MYO7A	B-GENE
,	O
PCDH15	B-GENE
,	O
USH1G	B-GENE
,	O
USH1C	B-GENE
,	O
and	O
USH2A	B-GENE
.	O

Proband	O
Z438A	O
,	O
of	O
Algerian	O
origin	O
,	O
was	O
homozygous	O
for	O
the	O
mutation	O
,	O
which	O
segregated	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
his	O
family	O
.	O

Graphic	O
output	O
of	O
haplotypes	O
was	O
generated	O
with	O
HaploPainter	O
[	O
69	O
]	O
.	O

A	O
:	O
Fundus	O
photographs	O
:	O
typical	O
form	O
of	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
.	O

RP	O
-	O
1850	O
has	O
not	O
developed	O
cataracts	O
at	O
the	O
age	O
of	O
19	O
and	O
neither	O
has	O
RP	O
-	O
1521	O
at	O
the	O
age	O
of	O
50	O
years	O
old	O
while	O
the	O
elder	O
brother	O
has	O
cataracts	O
in	O
both	O
eyes	O
.	O

Primer	O
sequences	O
are	O
available	O
upon	O
request	O
.	O

DNA	O
sequence	O
analysis	O
of	O
SLC26A4	B-GENE
was	O
performed	O
in	O
all	O
144	O
patients	O
.	O

[	O
26	O
]	O
.	O

Despite	O
these	O
medical	O
problems	O
,	O
she	O
was	O
healthy	O
and	O
she	O
had	O
an	O
active	O
life	O
.	O

The	O
arrow	O
points	O
to	O
the	O
region	O
of	O
retinal	O
thinning	O
in	O
patient	O
'	O
s	O
macula	O
.	O

The	O
mutation	O
segregated	O
with	O
the	O
hearing	B-DISEASE
loss	I-DISEASE
of	O
the	O
family	O
.	O

Here	O
we	O
report	O
our	O
studies	O
of	O
Baraitser	B-DISEASE
-	I-DISEASE
Winter	I-DISEASE
syndrome	I-DISEASE
,	O
a	O
well	O
-	O
defined	O
syndrome	O
characterized	O
by	O
distinct	O
craniofacial	O
features	O
,	O
ocular	B-DISEASE
colobomata	I-DISEASE
and	O
a	O
neuronal	B-DISEASE
migration	I-DISEASE
defect	I-DISEASE
6	O
,	O
7	O
.	O

Discussion	O
with	O
the	O
treating	O
physicians	O
followed	O
by	O
Sanger	O
validation	O
established	O
the	O
diagnoses	O
for	O
a	O
total	O
of	O
29	O
patients	O
(	O
Supplementary	O
Table	O
S6	O
online	O
)	O
.	O

YW	O
and	O
QW	O
carried	O
out	O
temporal	O
CT	O
scan	O
and	O
thyroid	O
hormone	O
assays	O
.	O

However	O
,	O
in	O
our	O
patient	O
we	O
found	O
heterozygous	O
SNPs	O
in	O
the	O
gene	O
,	O
with	O
close	O
to	O
50	O
%	O
allele	O
distribution	O
,	O
indicating	O
that	O
the	O
gene	O
is	O
not	O
deleted	O
for	O
this	O
patient	O
.	O

Syzygy	O
was	O
developed	O
and	O
run	O
by	O
MR	O
and	O
MJD	O
.	O

The	O
inhibitory	O
effect	O
of	O
CIB2	B-GENE
on	O
Ca	O
2	O
+	O
responses	O
could	O
be	O
due	O
to	O
its	O
Ca	O
2	O
+	O
buffering	O
ability	O
,	O
6	O
or	O
similar	O
to	O
CIB1	B-GENE
and	O
CaBP1	B-GENE
,	O
due	O
to	O
CIB2	B-GENE
interacting	O
with	O
IP	O
receptors	O
.	O

Informed	O
consent	O
was	O
obtained	O
from	O
all	O
adult	O
participants	O
and	O
from	O
parents	O
of	O
the	O
children	O
studied	O
.	O

On	O
one	O
hand	O
,	O
our	O
retrospective	O
study	O
approach	O
-	O
to	O
identify	O
all	O
diagnosed	O
KS	B-DISEASE
cases	O
throughout	O
Finland	O
born	O
during	O
a	O
defined	O
time	O
period	O
-	O
does	O
not	O
account	O
for	O
those	O
who	O
remain	O
undiagnosed	O
with	O
KS	B-DISEASE
due	O
to	O
partial	O
pubertal	O
development	O
or	O
unrecognized	O
hyposmia	B-DISEASE
.	O

The	O
barcoded	O
Illumina	O
gDNA	O
libraries	O
(	O
0	O
.	O
5	O
u	O
g	O
)	O
were	O
incubated	O
in	O
with	O
probes	O
to	O
enrich	O
for	O
the	O
targets	O
in	O
solution	O
.	O

C	O
,	O
Tail	O
current	O
densities	O
are	O
plotted	O
as	O
a	O
function	O
of	O
test	O
potentials	O
and	O
tail	O
current	O
-	O
voltage	O
relationships	O
are	O
shown	O
for	O
WT	O
-	O
E1	O
(	O
N	O
=	O
26	O
cells	O
)	O
and	O
R397Q	B-VARIANT
-	O
E1	O
(	O
N	O
=	O
20	O
cells	O
)	O
.	O

It	O
is	O
notable	O
that	O
in	O
our	O
strategy	O
revealed	O
genetic	O
mutations	O
in	O
several	O
extraordinary	O
cases	O
in	O
this	O
study	O
.	O

The	O
T	O
-	O
box	O
is	O
indicated	O
by	O
yellow	O
boxes	O
,	O
the	O
nuclear	O
localization	O
signal	O
(	O
NLA	O
)	O
by	O
a	O
blue	O
segment	O
,	O
and	O
the	O
transactivation	O
domain	O
(	O
TAD	O
)	O
by	O
a	O
green	O
arrow	O
.	O

The	O
PTA	O
test	O
revealed	O
slightly	O
different	O
characteristics	O
of	O
the	O
hearing	B-DISEASE
loss	I-DISEASE
observed	O
in	O
I	O
-	O
2	O
and	O
II	O
-	O
1	O
.	O

Analytical	O
sensitivity	O
of	O
targeted	O
capture	O
approach	O
.	O

Study	O
protocols	O
were	O
approved	O
by	O
the	O
Partners	O
Human	O
Research	O
Committee	O
.	O

In	O
addition	O
to	O
normally	O
-	O
hearing	O
controls	O
,	O
we	O
extracted	O
from	O
the	O
large	O
sample	O
a	O
group	O
of	O
hearing	B-DISEASE
-	I-DISEASE
impaired	I-DISEASE
subjects	O
meeting	O
specific	O
inclusion	O
criteria	O
(	O
genetic	O
aetiology	O
,	O
compound	O
action	O
potential	O
threshold	O
between	O
80	O
and	O
100	O
dB	O
SPL	O
)	O
.	O

The	O
etiology	O
is	O
located	O
within	O
the	O
cochlea	O
,	O
therefore	O
comparatively	O
better	O
outcomes	O
can	O
be	O
predicted	O
.	O

We	O
applied	O
whole	O
-	O
exome	O
sequencing	O
to	O
reveal	O
the	O
molecular	O
genetic	O
etiology	O
of	O
high	B-DISEASE
-	I-DISEASE
frequency	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
segregating	O
in	O
one	O
mid	O
-	O
sized	O
Korean	O
family	O
,	O
SNUBH18	O
(	O
Seoul	O
National	O
University	O
Bundang	O
Hospital	O
18	O
)	O
.	O

He	O
showed	O
a	O
delay	O
in	O
speech	O
acquisition	O
,	O
starting	O
to	O
speak	O
at	O
36	O
months	O
and	O
requiring	O
deaf	O
school	O
education	O
.	O

NetGene2	O
predicted	O
the	O
abolition	O
of	O
the	O
splice	O
donor	O
site	O
of	O
exon	O
5	O
as	O
a	O
result	O
of	O
the	O
c	B-VARIANT
.	I-VARIANT
3866	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
mutation	O
in	O
intron	O
5	O
of	O
MYO15A	B-GENE
.	O

The	O
patient	O
presently	O
has	O
normal	O
levels	O
of	O
calcium	O
and	O
phosphorus	O
.	O

Affected	O
subjects	O
are	O
denoted	O
in	O
black	O
.	O

Clinical	O
Characteristics	O
of	O
TCGA	O
cases	O
.	O

Summary	O
of	O
clinical	O
data	O
Using	O
ALLEGRO	O
we	O
identifed	O
two	O
genomic	O
regions	O
with	O
a	O
maximum	O
LOD	O
score	O
of	O
2	O
.	O
7	O
.	O

Both	O
pure	O
tone	O
audiometry	O
(	O
PTA	O
)	O
and	O
physical	O
examinations	O
were	O
performed	O
on	O
four	O
members	O
(	O
Fig	O
.	O

This	O
mutation	O
is	O
predicted	O
to	O
cause	O
substitution	O
of	O
a	O
highly	O
conserved	O
glycine	O
residue	O
with	O
arginine	O
(	O
p	B-VARIANT
.	I-VARIANT
G56R	I-VARIANT
)	O
,	O
18	O
amino	O
acids	O
from	O
the	O
mitochondrial	O
targeting	O
sequence	O
cleavage	O
site	O
predicted	O
by	O
TargetP	O
(	O
Supplementary	O
Fig	O
.	O

Collectively	O
,	O
mutations	O
in	O
these	O
five	O
genes	O
contribute	O
to	O
about	O
one	O
-	O
tenth	O
of	O
ARNSHL	B-DISEASE
among	O
the	O
families	O
examined	O
.	O

Since	O
the	O
age	O
of	O
six	O
years	O
,	O
he	O
developed	O
gradually	B-DISEASE
progressive	I-DISEASE
difficulty	I-DISEASE
in	I-DISEASE
walking	I-DISEASE
and	I-DISEASE
getting	I-DISEASE
up	I-DISEASE
from	I-DISEASE
sitting	I-DISEASE
position	I-DISEASE
.	O

We	O
only	O
identified	O
two	O
already	O
described	O
heterozygous	O
mutations	O
(	O
c	B-VARIANT
.	I-VARIANT
2035G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
1739	I-VARIANT
T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
)	O
in	O
the	O
ATP6V0A4	B-GENE
gene	O
.	O

(	O
b	O
)	O
Volcano	O
plots	O
of	O
the	O
log	O
2	O
-	O
transformed	O
average	O
spectral	O
count	O
ratios	O
N32I	B-VARIANT
or	O
N74S	B-VARIANT
/	O
WT	O
(	O
x	O
axis	O
)	O
and	O
the	O
-	O
log	O
10	O
-	O
transformed	O
P	O
values	O
(	O
adjusted	O
with	O
the	O
Benjamini	O
-	O
Hochberg	O
procedure	O
)	O
resulting	O
from	O
the	O
two	O
-	O
tailed	O
one	O
-	O
sample	O
t	O
-	O
tests	O
of	O
the	O
high	O
-	O
confidence	O
interactors	O
of	O
POLR1C	B-GENE
.	O

Furthermore	O
,	O
as	O
the	O
evidence	O
base	O
for	O
considering	O
mutations	O
disease	O
-	O
causing	O
is	O
not	O
always	O
clear	O
[	O
10	O
]	O
,	O
and	O
rare	O
variants	O
which	O
are	O
not	O
associated	O
with	O
disease	O
are	O
found	O
in	O
controls	O
[	O
11	O
]	O
,	O
we	O
report	O
our	O
reasoning	O
for	O
considering	O
the	O
variants	O
found	O
in	O
this	O
cohort	O
disease	O
-	O
causing	O
.	O

WES	O
yields	O
data	O
on	O
a	O
far	O
greater	O
number	O
of	O
genes	O
,	O
including	O
those	O
not	O
initially	O
considered	O
candidates	O
for	O
the	O
phenotype	O
being	O
investigated	O
.	O

This	O
is	O
the	O
largest	O
study	O
reported	O
on	O
HH	B-DISEASE
diagnosed	O
during	O
the	O
childhood	O
and	O
adolescence	O
.	O

Research	O
of	O
genes	O
involved	O
in	O
severe	O
to	O
profound	O
congenital	B-DISEASE
deafness	I-DISEASE
is	O
particularly	O
efficient	O
in	O
geographic	O
regions	O
in	O
which	O
consanguineous	O
marriages	O
are	O
frequent	O
,	O
such	O
as	O
the	O
southern	O
and	O
eastern	O
Mediterranean	O
Basin	O
,	O
including	O
North	O
Africa	O
[	O
3	O
-	O
5	O
]	O
.	O

Moreover	O
,	O
mutations	O
of	O
USH2A	B-GENE
could	O
also	O
be	O
responsible	O
for	O
atypical	O
USH	B-DISEASE
and	O
nonsyndromic	O
RP	B-DISEASE
[	O
11	O
-	O
13	O
]	O
.	O

Prolonged	B-DISEASE
QT	I-DISEASE
interval	I-DISEASE
suggests	O
Jervell	B-DISEASE
and	I-DISEASE
Lange	I-DISEASE
-	I-DISEASE
Nielsen	I-DISEASE
syndrome	I-DISEASE
and	O
mutations	O
in	O
KCNQ1	B-GENE
or	O
KCNE1	B-GENE
.	O

Blood	O
glucose	O
was	O
confirmed	O
to	O
be	O
above	O
4	O
mmol	O
/	O
l	O
prior	O
to	O
testing	O
.	O

We	O
identified	O
CDH23	B-GENE
mutations	O
in	O
two	O
of	O
13	O
families	O
with	O
ARNSHL	B-DISEASE
by	O
whole	O
-	O
exome	O
sequencing	O
.	O

(	O
d	O
)	O
Images	O
of	O
tolouidine	O
-	O
stained	O
cross	O
-	O
sections	O
of	O
the	O
organ	O
of	O
Corti	O
and	O
spiral	O
ganglion	O
are	O
shown	O
.	O

This	O
variant	O
was	O
not	O
present	O
in	O
any	O
of	O
the	O
databases	O
searched	O
(	O
NCBI	O
,	O
dbSNP137	O
,	O
1000	O
Genomes	O
Project	O
-	O
release	O
13	O
,	O
December	O
2012	O
-	O
)	O
.	O

It	O
is	O
therefore	O
interesting	O
that	O
two	O
of	O
the	O
four	O
Israeli	O
Arab	O
families	O
reported	O
here	O
have	O
mutations	O
in	O
these	O
two	O
genes	O
.	O

Two	O
normal	O
-	O
hearing	O
subjects	O
,	O
II	O
:	O
2	O
and	O
III	O
:	O
1	O
(	O
paternal	O
aunt	O
and	O
brother	O
of	O
the	O
index	O
case	O
,	O
respectively	O
)	O
were	O
carriers	O
of	O
c	B-VARIANT
.	I-VARIANT

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
YHZ	O
DYK	O
YSS	O
.	O

Table	O
S1	O
,	O
All	O
rare	O
variants	O
of	O
30	O
arRP	B-DISEASE
/	O
spRP	B-DISEASE
paients	O
of	O
this	O
study	O
,	O
focusing	O
on	O
212	O
retinal	O
disease	O
-	O
causing	O
genes	O
registered	O
in	O
the	O
Retinal	O
Information	O
Network	O
(	O
https	O
:	O
/	O
/	O
sph	O
.	O
uth	O
.	O
edu	O
/	O
retnet	O
/	O
)	O
.	O

Numbering	O
according	O
to	O
the	O
reference	O
sequence	O
NM_015340	O
.	O
3	O
The	O
mutation	O
is	O
present	O
in	O
the	O
homozygous	O
state	O
HL	B-DISEASE
:	O
Hearing	B-DISEASE
Loss	I-DISEASE
;	O
FSH	O
:	O
follicle	O
-	O
stimulating	O
hormone	O
;	O
LH	O
:	O
luteinizing	O
hormone	O
;	O
y	O
.	O
o	O
.	O
:	O
years	O
old	O
;	O
n	O
.	O
r	O
.	O
:	O
not	O
reported	O
The	O
last	O
two	O
authors	O
contributed	O
equally	O
to	O
this	O
work	O
.	O

Analyzed	O
genes	O
(	O
*	O
)	O
Homopolymer	O
repeats	O
>	O
=	O
6	O
located	O
in	O
the	O
exons	O
+	O
/	O
-	O
10	O
bp	O
.	O

Ten	O
SLC26A4	B-GENE
variants	O
were	O
cloned	O
for	O
functional	O
study	O
.	O

1	O
;	O
Table	O
1	O
)	O
.	O

Renal	O
structures	O
were	O
assessed	O
by	O
abdominal	O
ultrasound	O
scan	O
.	O

The	O
TMPRSS3	B-GENE
protein	O
contains	O
several	O
common	O
functional	O
domains	O
,	O
including	O
a	O
transmembrane	O
domain	O
,	O
a	O
low	O
density	O
lipoprotein	O
receptor	O
A	O
domain	O
(	O
LDLRA	O
)	O
,	O
a	O
scavenger	O
receptor	O
cysteine	O
rich	O
domain	O
(	O
SRCR	O
)	O
,	O
and	O
a	O
carboxyl	O
terminal	O
serine	O
protease	O
domain	O
[	O
9	O
]	O
.	O

Usher	B-DISEASE
syndrome	I-DISEASE
(	O
USH	B-DISEASE
;	O
OMIM	O
276900	O
-	O
2276905	O
,	O
605472	O
)	O
is	O
an	O
autosomal	O
recessive	O
disease	O
in	O
which	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
is	O
associated	O
with	O
photoreceptor	B-DISEASE
degeneration	I-DISEASE
with	O
the	O
clinical	O
features	O
of	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
[	O
1	O
-	O
3	O
]	O
.	O

The	O
patient	O
history	O
was	O
taken	O
and	O
ophthalmic	O
examinations	O
were	O
performed	O
.	O

For	O
fibroblast	O
lysates	O
we	O
used	O
antibody	O
GRIM19	B-GENE
(	O
Abcam	O
)	O
,	O
which	O
corresponds	O
to	O
the	O
mitochondrial	O
complex	O
I	O
subunit	O
NDUFA13	B-GENE
.	O

Phenotype	O
characteristics	O
were	O
determined	O
by	O
the	O
presence	O
or	O
absence	O
of	O
syncope	B-DISEASE
and	O
precipitating	O
factors	O
,	O
age	O
at	O
first	O
cardiac	B-DISEASE
event	I-DISEASE
,	O
and	O
changes	O
in	O
T	O
wave	O
morphology	O
before	O
and	O
after	O
therapies	O
.	O

Primers	O
for	O
B	O
-	O
actin	O
were	O
forward	O
(	O
5	O
'	O
-	O
CGCGCAGGAGATGGGAACC	O
-	O
3	O
'	O
)	O
and	O
reverse	O
(	O
5	O
'	O
-	O
CAACGGAAACGCTCATTGC	O
-	O
3	O
'	O
)	O
.	O

3	O
)	O
.	O

was	O
supported	O
by	O
the	O
University	O
Grants	O
Commission	O
Research	O
Scientist	O
Scheme	O
in	O
New	O
Delhi	O
,	O
India	O
.	O

Data	O
of	O
the	O
family	O
667	O
.	O

This	O
study	O
investigated	O
a	O
Chinese	O
family	O
with	O
non	O
-	O
syndromic	O
arRP	B-DISEASE
.	O

This	O
loss	O
of	O
nucleotides	O
creates	O
a	O
new	O
open	O
reading	O
frame	O
,	O
leading	O
to	O
a	O
premature	O
stop	O
codon	O
five	O
amino	O
acids	O
downstream	O
.	O

Wrote	O
the	O
paper	O
:	O
DL	O
PG	O
SB	O
VN	O
.	O

After	O
comparison	O
with	O
SNP	O
databases	O
,	O
including	O
dbSNP132	O
,	O
the	O
1000	O
Genome	O
Project	O
(	O
10	O
/	O
2010	O
release	O
)	O
,	O
HapMap	O
data	O
(	O
HapMap	O
8	O
/	O
2010	O
release	O
)	O
,	O
and	O
YH	O
(	O
Asian	O
)	O
,	O
we	O
identified	O
6	O
rare	O
SNPs	O
and	O
2	O
indels	O
in	O
transcribed	O
sequences	O
that	O
co	O
-	O
segregated	O
with	O
the	O
phenotype	O
in	O
these	O
4	O
subjects	O
(	O
Table	O
2	O
)	O
.	O

For	O
the	O
mismatch	O
error	O
rate	O
,	O
we	O
did	O
not	O
consider	O
the	O
type	O
of	O
base	O
substituted	O
in	O
an	O
amplicon	O
position	O
in	O
this	O
study	O
.	O

He	O
was	O
hospitalized	O
because	O
of	O
dyspepsia	O
.	O

Although	O
many	O
studies	O
have	O
dissected	O
USH2A	B-GENE
functional	O
properties	O
[	O
33	O
-	O
36	O
]	O
,	O
genotype	O
-	O
phenotype	O
correlations	O
are	O
still	O
not	O
well	O
understood	O
.	O

Medical	O
history	O
revealed	O
recurrent	O
episodes	O
of	O
epistaxis	B-DISEASE
and	O
excessive	O
bleeding	O
after	O
the	O
loss	O
of	O
one	O
milk	O
tooth	O
.	O

A	O
:	O
Overlapping	O
audiograms	O
of	O
subjects	O
with	O
homozygous	O
p	B-VARIANT
.	I-VARIANT
P240L	I-VARIANT
mutations	O
.	O

Shafique	O
S	O
.	O

There	O
were	O
no	O
false	O
-	O
positive	O
variant	O
calls	O
.	O

Concerning	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
LARS2	B-GENE
-	O
dependent	O
Perrault	B-DISEASE
syndrome	I-DISEASE
,	O
the	O
here	O
-	O
described	O
Italian	O
proband	O
shows	O
a	O
more	O
severe	O
audiological	O
phenotype	O
(	O
congenital	B-DISEASE
profound	I-DISEASE
HL	I-DISEASE
affecting	O
all	O
frequencies	O
)	O
,	O
but	O
a	O
milder	O
ovarian	O
phenotype	O
(	O
normal	O
menarche	O
at	O
age	O
13	O
and	O
primary	B-DISEASE
ovarian	I-DISEASE
insufficiency	I-DISEASE
at	O
28	O
y	O
.	O
o	O
.	O
)	O
compared	O
with	O
previously	O
-	O
reported	O
cases	O
(	O
Table	O
1	O
)	O
.	O

Although	O
this	O
specific	O
sequence	O
change	O
has	O
not	O
been	O
previously	O
published	O
,	O
a	O
c	B-VARIANT
.	I-VARIANT
148	I-VARIANT
-	I-VARIANT
2a	I-VARIANT
>	I-VARIANT
t	I-VARIANT
mutation	O
has	O
been	O
shown	O
to	O
be	O
pathogenic	O
and	O
to	O
result	O
in	O
the	O
skipping	O
of	O
exon	O
3	O
of	O
COL9A3	B-GENE
due	O
to	O
the	O
loss	O
of	O
the	O
consensus	O
"	O
a	O
"	O
at	O
the	O
-	O
2	O
position	O
of	O
a	O
splice	O
acceptor	O
site	O
[	O
Paassilta	O
et	O
al	O
.	O
,	O
1999	O
]	O
.	O

Li	O
et	O
al	O
.	O

Already	O
72	O
loci	O
have	O
been	O
described	O
to	O
be	O
involved	O
in	O
arNSHI	B-DISEASE
and	O
40	O
causative	O
genes	O
have	O
been	O
indentified	O
thus	O
far	O
,	O
indicating	O
enormous	O
genetic	O
heterogeneity	O
.	O

This	O
work	O
was	O
supported	O
by	O
a	O
Research	O
on	O
Applying	O
Health	O
Technology	O
grant	O
(	O
H23	O
-	O
013	O
)	O
from	O
the	O
Ministry	O
of	O
Health	O
and	O
Labour	O
and	O
Welfare	O
,	O
Japan	O
and	O
a	O
Grant	O
-	O
in	O
-	O
Aid	O
for	O
Clinical	O
Research	O
from	O
the	O
National	O
Hospital	O
Organization	O
.	O
Recessive	O
mutations	O
of	O
the	O
myosin	B-GENE
VIIA	I-GENE
(	O
MYO7A	B-GENE
)	O
gene	O
are	O
reported	O
to	O
be	O
responsible	O
for	O
both	O
a	O
deaf	B-DISEASE
-	I-DISEASE
blindness	I-DISEASE
syndrome	I-DISEASE
(	O
Usher	B-GENE
type	I-GENE
1B	I-GENE
[	O
USH1B	B-DISEASE
]	O
and	O
atypical	B-DISEASE
Usher	I-DISEASE
syndrome	I-DISEASE
)	O
and	O
nonsyndromic	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
HL	B-DISEASE
;	I-DISEASE
Deafness	B-DISEASE
,	O
Neurosensory	O
,	O
Autosomal	O
Recessive	O
2	O
[	O
DFNB2	B-GENE
]	O
)	O
.	O

Such	O
compounds	O
,	O
or	O
others	O
that	O
are	O
selective	O
for	O
recurrent	O
mutations	O
,	O
may	O
have	O
particular	O
promise	O
in	O
the	O
treatment	O
of	O
a	O
subset	O
of	O
patients	O
with	O
CACNA1D	B-GENE
mutations	O
.	O

Mutation	O
reported	O
in	O
Human	O
Genome	O
Mutation	O
Database	O
(	O
HGMD	O
)	O
.	O

CTDs	B-DISEASE
are	O
severe	O
malformations	O
associated	O
with	O
cyanosis	O
and	O
many	O
other	O
serious	O
manifestations	O
of	O
hypoxia	O
and	O
are	O
characterised	O
by	O
a	O
disordered	O
orchestration	O
of	O
the	O
ventricle	O
,	O
the	O
aorta	O
and	O
the	O
pulmonary	O
artery	O
.	O

There	O
is	O
statistically	O
significant	O
XBP1	O
splicing	O
when	O
either	O
WT	O
or	O
any	O
of	O
the	O
mutant	O
chains	O
is	O
overexpressed	O
in	O
AB8	O
/	O
13	O
cells	O
.	O

NM_032213	O
.	O
4	O
)	O
.	O

Moreover	O
,	O
only	O
the	O
proband	O
displayed	O
a	O
complete	O
lack	O
of	O
expression	O
of	O
the	O
wild	O
type	O
allele	O
in	O
leukocytes	O
that	O
seems	O
to	O
correlate	O
with	O
the	O
degree	O
of	O
PRS	O
deficiency	O
and	O
the	O
severity	O
of	O
the	O
phenotype	O
.	O

A	O
thorough	O
physical	O
and	O
history	O
is	O
essential	O
and	O
determine	O
the	O
expected	O
outcome	O
of	O
CGT	O
.	O

screened	O
FOXI1	B-GENE
in	O
100	O
patients	O
with	O
EVA	B-DISEASE
and	O
found	O
no	O
mutations	O
,	O
although	O
KCNJ10	B-GENE
was	O
not	O
screened	O
at	O
that	O
time	O
[	O
37	O
]	O
.	O

The	O
other	O
5	O
variants	O
,	O
at	O
codons	O
110	O
,	O
191	O
,	O
202	O
,	O
213	O
,	O
and	O
235	O
,	O
fall	O
on	O
the	O
portion	O
of	O
the	O
protein	O
distal	O
to	O
the	O
DNA	O
-	O
binding	O
site	O
,	O
and	O
are	O
likely	O
to	O
have	O
weaker	O
effects	O
on	O
protein	O
function	O
and	O
hence	O
cancer	B-DISEASE
risk	O
(	O
Figure	O
6	O
)	O
.	O

Hearing	O
-	O
impaired	O
brothers	O
homozygous	O
for	O
the	O
mutation	O
(	O
II	O
.	O
I	O
and	O
II	O
.	O
3	O
;	O
A	O
/	O
A	O
)	O
are	O
indicated	O
by	O
filled	O
black	O
boxes	O
and	O
normal	O
hearing	O
relatives	O
are	O
indicated	O
by	O
open	O
symbols	O
.	O

This	O
study	O
also	O
indicates	O
that	O
a	O
substantial	O
portion	O
of	O
unsolved	O
cases	O
after	O
applying	O
our	O
current	O
protocol	O
are	O
predicted	O
to	O
have	O
non	O
-	O
genetic	O
or	O
complex	O
etiology	O
rather	O
than	O
a	O
Mendelian	O
genetic	O
disorder	O
involving	O
new	O
genes	O
beyond	O
the	O
204	O
target	O
genes	O
.	O

This	O
hypothesis	O
will	O
be	O
addressed	O
in	O
future	O
experiments	O
.	O

Sequence	O
products	O
were	O
resolved	O
in	O
an	O
ABIPrism	O
3130	O
(	O
Applied	O
Biosystems	O
)	O
.	O

Some	O
of	O
the	O
variants	O
with	O
frequencies	O
differing	O
between	O
subpopulations	O
,	O
such	O
as	O
TP53	B-GENE
c	B-VARIANT
.	I-VARIANT
215C	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Pro72Arg	I-VARIANT
)	O
,	O
were	O
previously	O
described	O
as	O
ancestry	O
-	O
dependent	O
in	O
gene	O
-	O
specific	O
studies	O
,	O
further	O
supporting	O
the	O
generalizability	O
of	O
the	O
findings	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
probed	O
western	O
blots	O
with	O
polyclonal	O
antisera	O
raised	O
against	O
Gipc3	O
-	O
specific	O
peptides	O
.	O

To	O
examine	O
further	O
the	O
functional	O
significance	O
of	O
the	O
detected	O
mutations	O
in	O
TBX1	B-GENE
,	O
we	O
engineered	O
the	O
c	B-VARIANT
.	I-VARIANT
385G	I-VARIANT
-	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
E129K	I-VARIANT
)	O
mutation	O
in	O
the	O
human	O
TBX1	B-GENE
cDNA	O
.	O

No	O
.	O
,	O
accession	O
number	O
of	O
reference	O
sequence	O
;	O
Chr	O
,	O
chromosome	O
;	O
Ex	O
,	O
exon	O
;	O
EVS	O
,	O
exome	O
variant	O
server	O
;	O
hg19	O
,	O
human	O
genome	O
assembly	O
19	O
;	O
In	O
,	O
intron	O
;	O
NA	O
,	O
not	O
applicable	O
;	O
ND	O
,	O
not	O
determined	O
;	O
SNPs	O
,	O
single	O
nucleotide	O
polymorphisms	O
;	O
PhyloP	O
,	O
phylogenetic	O
P	O
-	O
values	O
;	O
Polyphen	O
,	O
polymorphism	O
phenotyping	O
;	O
SIFT	O
,	O
sorting	O
intolerance	O
from	O
tolerance	O
.	O

Both	O
strands	O
were	O
sequenced	O
on	O
an	O
automated	O
sequencer	O
(	O
ABI	O
3730	O
,	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
.	O

In	O
contrast	O
,	O
the	O
wild	O
type	O
threonine	O
residue	O
was	O
embedded	O
in	O
the	O
structure	O
,	O
suggesting	O
a	O
significant	O
effect	O
of	O
p	B-VARIANT
.	I-VARIANT
T237I	I-VARIANT
on	O
protein	O
structure	O
(	O
Fig	O
.	O

N	O
represents	O
the	O
normal	O
control	O
.	O

(	O
C	O
)	O
Predicted	O
protein	O
:	O
The	O
predicted	O
abnormal	O
sequence	O
p	B-VARIANT
.	I-VARIANT
R1922Rfs	I-VARIANT
*	I-VARIANT
43	I-VARIANT
is	O
shown	O
as	O
compared	O
to	O
the	O
wild	O
-	O
type	O
one	O
.	O

We	O
believed	O
that	O
the	O
R183Q	B-VARIANT
variation	O
is	O
another	O
pathogenic	O
mutation	O
in	O
the	O
PJVK	B-GENE
gene	O
.	O

The	O
segregation	O
analyses	O
support	O
the	O
damaging	O
effect	O
of	O
p	B-VARIANT
.	I-VARIANT
C3358Y	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
P4818L	I-VARIANT
,	O
so	O
we	O
have	O
considered	O
them	O
as	O
pathogenic	O
.	O

The	O
35delG	B-VARIANT
mutation	O
was	O
screened	O
in	O
a	O
total	O
of	O
6	O
,	O
293	O
newborns	O
(	O
2	O
,	O
777	O
were	O
analyzed	O
by	O
PSDM	O
and	O
3	O
,	O
516	O
by	O
PCR	O
-	O
DHPLC	O
)	O
.	O

Removal	O
of	O
all	O
types	O
of	O
N	O
-	O
linked	O
carbohydrate	O
chains	O
with	O
PNGase	O
digestion	O
reduced	O
the	O
bands	O
into	O
a	O
single	O
one	O
of	O
~	O
100	O
kDa	O
.	O

This	O
work	O
was	O
supported	O
by	O
INSERM	O
,	O
the	O
University	O
Hospital	O
of	O
Angers	O
(	O
PHRC	O
04	O
-	O
12	O
)	O
,	O
the	O
University	O
of	O
Angers	O
,	O
and	O
by	O
grants	O
from	O
the	O
following	O
associations	O
of	O
patients	O
:	O
Association	O
contre	O
les	O
Maladies	O
Mitochondriales	O
(	O
AMMi	O
)	O
,	O
Retina	O
France	O
,	O
Ouvrir	O
les	O
Yeux	O
(	O
OLY	O
)	O
,	O
and	O
Union	O
Nationale	O
des	O
Aveugles	O
et	O
D	O
e	O
ficients	O
Visuels	O
(	O
UNADEV	O
)	O
.	O
Long	B-DISEASE
QT	I-DISEASE
syndrome	I-DISEASE
(	O
LQTS	B-DISEASE
)	O
is	O
characterized	O
by	O
QT	B-DISEASE
prolongation	I-DISEASE
,	O
syncope	B-DISEASE
and	O
sudden	B-DISEASE
death	I-DISEASE
.	O

Rare	O
variants	O
are	O
also	O
prevalent	O
,	O
with	O
27	O
%	O
of	O
the	O
population	O
carrying	O
rare	O
variants	O
in	O
at	O
least	O
one	O
of	O
these	O
two	O
genes	O
.	O

m	O
,	O
mutant	O
allele	O
;	O
+	O
,	O
wt	O
allele	O
.	O

(	O
B	O
)	O
The	O
top	O
panel	O
shows	O
partial	O
DNA	O
sequences	O
of	O
the	O
TJP2	B-GENE
gene	O
that	O
indicate	O
the	O
genotypes	O
of	O
patients	O
and	O
normal	O
controls	O
.	O

One	O
patient	O
(	O
Case	O
#	O
4	O
)	O
had	O
heterozygote	O
mutations	O
in	O
two	O
USH1	B-DISEASE
genes	O
(	O
p	B-VARIANT
.	I-VARIANT
Ala771Ser	I-VARIANT
in	O
MYO7A	B-GENE
and	O
c	B-VARIANT
.	I-VARIANT
158	I-VARIANT
-	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
in	O
PCDH15	B-GENE
)	O
.	O

Large	O
scale	O
screening	O
of	O
selective	O
exons	O
in	O
30	O
RP	B-DISEASE
-	O
causing	O
genes	O
was	O
previously	O
performed	O
in	O
193	O
Japanese	O
RP	B-DISEASE
families	O
[	O
11	O
]	O
.	O

Following	O
that	O
,	O
DNA	O
sequencing	O
of	O
all	O
21	O
exons	O
,	O
their	O
adjacent	O
intronic	O
sequences	O
and	O
the	O
promoter	O
of	O
SLC26A4	B-GENE
was	O
carried	O
out	O
for	O
mutation	O
detection	O
.	O

Schematic	O
diagram	O
of	O
TBX1	B-GENE
bound	O
to	O
DNA	O
.	O

The	O
hearing	B-DISEASE
loss	I-DISEASE
is	O
characterized	O
by	O
a	O
biased	O
hearing	O
sound	O
range	O
.	O

In	O
the	O
absence	O
of	O
exposure	O
to	O
aminoglycosides	O
,	O
the	O
age	O
of	O
onset	O
associated	O
with	O
the	O
1555A	B-VARIANT
>	I-VARIANT
G	I-VARIANT
mutation	O
may	O
differ	O
considerably	O
among	O
members	O
of	O
the	O
same	O
family	O
.	O

These	O
primers	O
were	O
designed	O
to	O
avoid	O
the	O
VNTR	O
in	O
intron	O
5	O
.	O

Clinical	O
investigations	O
were	O
conducted	O
according	O
to	O
the	O
Declaration	O
of	O
Helsinki	O
,	O
and	O
the	O
study	O
was	O
approved	O
by	O
the	O
institutional	O
review	O
board	O
of	O
the	O
Ethics	O
Committee	O
of	O
the	O
University	O
Hospital	O
of	O
Cologne	O
.	O

This	O
variant	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
MFN2	B-GENE
gene	O
and	O
it	O
is	O
characterized	O
by	O
early	O
onset	O
,	O
severe	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
in	O
the	O
first	O
decade	O
of	O
life	O
,	O
followed	O
by	O
subacute	O
,	O
progressive	O
optic	B-DISEASE
atrophy	I-DISEASE
in	O
later	O
childhood	O
(	O
Zuchner	O
et	O
al	O
.	O

However	O
less	O
positive	O
results	O
will	O
be	O
obtained	O
since	O
there	O
are	O
a	O
significant	O
amount	O
of	O
deafness	B-DISEASE
cases	O
caused	O
by	O
non	O
-	O
genetic	O
factors	O
.	O

In	O
total	O
,	O
701	O
patients	O
lacked	O
GJB3	B-GENE
c	B-VARIANT
.	I-VARIANT
538C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
547G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
and	O
WFS1	B-GENE
c	B-VARIANT
.	I-VARIANT
1901A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
mutations	O
,	O
suggesting	O
that	O
these	O
variants	O
are	O
rare	O
in	O
south	O
Chinese	O
.	O

The	O
following	O
second	O
screening	O
based	O
on	O
TaqMan	O
assay	O
followed	O
by	O
Sanger	O
sequencing	O
confirmed	O
10	O
"	O
possibly	O
pathologic	O
"	O
mutations	O
(	O
Table	O
1	O
)	O
and	O
17	O
variants	O
with	O
uncertain	O
pathogenicity	O
(	O
Table	O
2	O
)	O
in	O
a	O
large	O
cohort	O
of	O
the	O
patients	O
.	O

[	O
9	O
]	O
recently	O
also	O
demonstrated	O
a	O
generalized	O
decrease	O
in	O
peripapillary	O
RNFL	B-DISEASE
thickness	I-DISEASE
on	O
Stratus	O
OCT	O
in	O
40	O
patients	O
with	O
OPA1	B-GENE
mutations	O
,	O
with	O
a	O
statistically	O
significant	O
inverse	O
correlation	O
between	O
RNFL	B-DISEASE
thickness	I-DISEASE
and	O
logMAR	O
VA	O
.	O

The	O
protein	O
product	O
of	O
WFS1	B-GENE
,	O
wolframin	B-GENE
,	O
is	O
a	O
membrane	O
glycoprotein	O
that	O
is	O
estimated	O
to	O
have	O
nine	O
helical	O
transmembrane	O
segments	O
.	O

For	O
these	O
subjects	O
,	O
we	O
additionally	O
performed	O
Sanger	O
sequencing	O
for	O
CDH23	B-GENE
mutations	O
.	O

35	O
,	O
36	O
Furushima	O
et	O
al	O
.	O

These	O
included	O
72	O
CNV	O
gains	O
and	O
25	O
CNV	O
losses	O
(	O
details	O
are	O
given	O
in	O
the	O
Table	O
2	O
and	O
Additional	O
file	O
4	O
:	O
Table	O
S5	O
)	O
.	O

The	O
pathogenicity	O
of	O
the	O
two	O
novel	O
variants	O
,	O
p	B-VARIANT
.	I-VARIANT
C584F	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
R4192C	I-VARIANT
,	O
was	O
supported	O
by	O
the	O
PolyPhen	O
and	O
SIFT	O
algorythms	O
(	O
Table	O
2	O
)	O
.	O

Hearing	B-DISEASE
loss	I-DISEASE
in	O
PS	B-DISEASE
and	O
DFNB4	O
occurs	O
either	O
congenitally	O
or	O
after	O
some	O
mild	O
head	O
injury	O
,	O
showing	O
fluctuating	O
and	O
progressive	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

One	O
of	O
these	O
genes	O
is	O
Usher	B-GENE
syndrome	I-GENE
1C	I-GENE
(	O
USH1C	B-GENE
)	O
,	O
which	O
encodes	O
a	O
protein	O
,	O
harmonin	O
,	O
containing	O
PDZ	O
domains	O
.	O

PAX3	B-GENE
mutations	O
are	O
inherited	O
dominantly	O
with	O
variable	O
expressivity	O
[	O
43	O
]	O
.	O

Fiftynanogram	O
of	O
genomic	O
DNA	O
was	O
amplified	O
in	O
30	O
mu	O
l	O
volume	O
using	O
10	O
pmol	O
of	O
each	O
primer	O
and	O
AmpliTaq	O
-	O
Gold	O
polymerase	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
,	O
with	O
initial	O
denaturation	O
for	O
5	O
minutes	O
at	O
95	O
deg	O
C	O
followed	O
by	O
40	O
cycles	O
of	O
95	O
deg	O
C	O
for	O
30	O
seconds	O
,	O
56	O
deg	O
C	O
for	O
45	O
seconds	O
and	O
72	O
deg	O
C	O
for	O
60	O
seconds	O
,	O
and	O
a	O
final	O
extension	O
at	O
72	O
deg	O
C	O
for	O
10	O
minutes	O
.	O

10	O
mu	O
l	O
of	O
cDNA	O
was	O
amplified	O
by	O
PCR	O
using	O
the	O
5	O
'	O
primer	O
(	O
TCC	O
AAC	O
AAG	O
ATC	O
TGC	O
AAC	O
CA	O
)	O
and	O
the	O
3	O
'	O
primer	O
(	O
ATC	O
CAG	O
TCC	O
AGG	O
AAG	O
GAG	O
GT	O
)	O
using	O
standard	O
conditions	O
.	O

Unsolved	O
patients	O
were	O
clinically	O
re	O
-	O
examined	O
and	O
tested	O
for	O
copy	O
number	O
variations	O
(	O
CNVs	O
)	O
as	O
well	O
as	O
intronic	O
mutations	O
.	O

1C	O
)	O
.	O

A	O
missense	O
mutation	O
in	O
the	O
ELMO	O
/	O
CED12	O
domain	O
of	O
ELMOD3	B-GENE
is	O
present	O
in	O
all	O
the	O
affected	O
individuals	O
of	O
the	O
PKDF468	O
family	O
.	O

USH2	B-DISEASE
is	O
characterized	O
by	O
moderate	O
to	O
severe	O
congenital	B-DISEASE
deafness	I-DISEASE
and	O
post	O
pubertal	O
onset	O
of	O
RP	B-DISEASE
.	O

When	O
the	O
same	O
rare	O
variants	O
had	O
been	O
previously	O
associated	O
with	O
disease	O
,	O
this	O
was	O
considered	O
strong	O
evidence	O
that	O
they	O
were	O
likely	O
to	O
be	O
involved	O
in	O
the	O
disorder	O
.	O

Fifty	O
-	O
four	O
healthy	O
unaffected	O
individuals	O
,	O
above	O
20	O
years	O
of	O
age	O
without	O
any	O
apparent	O
family	O
history	O
of	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
were	O
also	O
included	O
in	O
this	O
study	O
as	O
controls	O
to	O
estimate	O
allele	O
frequencies	O
of	O
the	O
sequence	O
variants	O
found	O
during	O
the	O
course	O
of	O
this	O
work	O
.	O

Extracted	O
DNA	O
was	O
then	O
amplified	O
by	O
ligation	O
-	O
mediated	O
PCR	O
(	O
LM	O
-	O
PCR	O
)	O
,	O
purified	O
,	O
and	O
hybridized	O
to	O
the	O
custom	O
Nimblegen	O
SeqCap	O
EZ	O
Library	O
(	O
Roche	O
/	O
NimbleGen	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
for	O
enrichment	O
.	O

X	O
:	O
frenquency	O
;	O
Y	O
:	O
intensity	O
(	O
dB	O
)	O
.	O

After	O
breaking	O
and	O
enrichment	O
,	O
about	O
276	O
million	O
enriched	O
template	O
beads	O
were	O
sequenced	O
per	O
lane	O
on	O
a	O
six	O
-	O
lane	O
SOLiD	O
5500	O
x	O
l	O
slide	O
.	O

Application	O
of	O
a	O
computational	O
algorithm	O
to	O
infer	O
copy	O
number	O
variants	O
(	O
CNVs	O
)	O
from	O
exome	O
data	O
revealed	O
a	O
heterozygous	O
12	O
kb	O
deletion	O
of	O
exons	O
10	O
-	O
13	O
of	O
HSD17B4	B-GENE
that	O
was	O
compounded	O
with	O
a	O
rare	O
missense	O
variant	O
(	O
p	B-VARIANT
.	I-VARIANT
A196V	I-VARIANT
)	O
at	O
a	O
highly	O
conserved	O
residue	O
.	O

The	O
control	O
group	O
consisted	O
of	O
105	O
matched	O
normal	O
-	O
hearing	O
subjects	O
.	O

Analyzed	O
the	O
data	O
:	O
XG	O
LPG	O
QYZ	O
JW	O
YYY	O
.	O

Sanger	O
sequencing	O
was	O
subsequently	O
performed	O
for	O
validation	O
of	O
variants	O
in	O
all	O
USH	B-DISEASE
causative	O
genes	O
and	O
prevalence	O
test	O
in	O
100	O
unrelated	O
controls	O
,	O
using	O
a	O
previously	O
defined	O
protocol	O
[	O
30	O
]	O
.	O

[	O
14	O
]	O
.	O

The	O
mutation	O
is	O
located	O
in	O
the	O
Gly	O
-	O
X	O
-	O
Y	O
repeats	O
.	O

Homozygosity	O
mapping	O
was	O
performed	O
by	O
employing	O
whole	O
genome	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
genotyping	O
in	O
the	O
families	O
that	O
did	O
not	O
carry	O
mutations	O
in	O
GJB2	B-GENE
or	O
MYO15A	B-GENE
.	O

Since	O
TMPRSS3	B-GENE
,	O
the	O
gene	O
encoding	O
transmembrane	B-GENE
protease	I-GENE
serine	I-GENE
3	I-GENE
,	O
is	O
the	O
most	O
frequently	O
detected	O
gene	O
in	O
subjects	O
with	O
ski	B-DISEASE
-	I-DISEASE
slope	I-DISEASE
type	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
in	O
the	O
Korean	O
population	O
[	O
17	O
]	O
,	O
we	O
examined	O
the	O
TMPRSS3	B-GENE
sequence	O
present	O
in	O
SH23	O
-	O
98	O
and	O
SH23	O
-	O
52	O
to	O
identify	O
any	O
mutation	O
(	O
s	O
)	O
located	O
within	O
the	O
exons	O
and	O
/	O
or	O
splice	O
junctions	O
;	O
however	O
,	O
we	O
failed	O
to	O
identify	O
any	O
mutations	O
within	O
this	O
gene	O
.	O

We	O
used	O
the	O
Xenopus	O
laevis	O
oocyte	O
system	O
as	O
it	O
allows	O
for	O
better	O
control	O
of	O
subunit	O
ratios	O
compared	O
to	O
transfection	O
of	O
mammalian	O
cell	O
lines	O
such	O
as	O
CHO	O
-	O
K1	O
.	O

Note	O
mild	O
shortening	B-DISEASE
of	I-DISEASE
the	I-DISEASE
fifth	I-DISEASE
metacarpal	I-DISEASE
of	I-DISEASE
the	I-DISEASE
hands	I-DISEASE
.	O

The	O
funders	O
had	O
no	O
role	O
in	O
study	O
design	O
,	O
data	O
collection	O
and	O
analysis	O
,	O
decision	O
to	O
publish	O
or	O
preparation	O
of	O
the	O
manuscript	O
.	O

ASSR	O
and	O
COR	O
evaluated	O
at	O
the	O
age	O
of	O
8	O
m	O
,	O
1	O
y	O
3	O
m	O
,	O
and	O
1	O
y	O
9	O
m	O
showed	O
progressive	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

GJB2	B-GENE
was	O
the	O
most	O
common	O
mutant	O
gene	O
in	O
the	O
two	O
ethnicities	O
,	O
whilst	O
the	O
two	O
ethnicities	O
differed	O
substantially	O
in	O
hotspot	O
mutations	O
.	O

and	O
2PO1	O
-	O
NS048120	O
to	O
M	O
.	O
E	O
.	O
R	O
.	O
)	O
,	O
the	O
Netherlands	O
Organization	O
for	O
Health	O
Research	O
and	O
Development	O
(	O
ZonMW	O
grants	O
917	O
-	O
66	O
-	O
363	O
and	O
911	O
-	O
08	O
-	O
025	O
to	O
J	O
.	O
A	O
.	O
V	O
.	O
)	O
,	O
the	O
EU	O
-	O
funded	O
TECHGENE	O
project	O
(	O
Health	O
-	O
F5	O
-	O
2009	O
-	O
223143	O
to	O
J	O
.	O
A	O
.	O
V	O
.	O
)	O
and	O
the	O
AnEUploidy	O
project	O
(	O
LSHG	O
-	O
CT	O
-	O
2006	O
-	O
37627	O
to	O
A	O
.	O
H	O
.	O
,	O
B	O
.	O
W	O
.	O
M	O
.	O
v	O
.	O
B	O
.	O
,	O
H	O
.	O
G	O
.	O
B	O
.	O

We	O
found	O
no	O
significant	O
differences	O
in	O
the	O
spectrum	O
or	O
prevalence	O
of	O
GJB2	B-GENE
and	O
SLC26A4	B-GENE
between	O
patients	O
from	O
Chifeng	O
City	O
and	O
those	O
from	O
Nantong	O
City	O
.	O

III	O
-	O
1	O
'	O
s	O
mother	O
(	O
II	O
-	O
2	O
)	O
also	O
developed	O
MH	B-DISEASE
and	O
proteinuria	B-DISEASE
in	O
her	O
30s	O
but	O
declined	O
renal	O
biopsy	O
.	O

TABLE	O
1	O
Overview	O
of	O
the	O
clinical	O
characteristics	O
and	O
genotypes	O
in	O
the	O
eight	O
families	O
Family	O
E	O
is	O
previously	O
described	O
by	O
Cremers	O
et	O
al	O
.	O

Additionally	O
the	O
identification	O
of	O
TNC	B-GENE
here	O
adds	O
new	O
evidence	O
for	O
the	O
importance	O
of	O
BM	O
proteins	O
in	O
hereditary	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

None	O
of	O
his	O
living	O
family	O
members	O
were	O
available	O
for	O
clinical	O
or	O
genetic	O
studies	O
.	O

The	O
average	O
quality	O
of	O
single	O
nucleotide	O
variations	O
and	O
insertions	O
or	O
deletions	O
(	O
INDELs	O
)	O
was	O
798	O
and	O
1014	O
,	O
respectively	O
.	O

Patients	O
from	O
two	O
families	O
that	O
segregated	O
mutations	O
COL4A3	B-GENE
-	O
c	B-VARIANT
.	I-VARIANT
2621	I-VARIANT
-	I-VARIANT
2622delGAinsT	I-VARIANT
and	O
COL4A3	B-GENE
-	O
p	B-VARIANT
.	I-VARIANT
(	I-VARIANT
G1077D	I-VARIANT
)	I-VARIANT
were	O
married	O
and	O
had	O
children	O
who	O
inherited	O
both	O
mutations	O
and	O
manifested	O
classical	O
autosomal	B-DISEASE
recessive	I-DISEASE
Alport	I-DISEASE
Syndrome	I-DISEASE
.	O

Of	O
these	O
variants	O
,	O
only	O
four	O
were	O
shared	O
amongst	O
the	O
three	O
sequenced	O
exomes	O
(	O
S2	O
Table	O
)	O
and	O
only	O
one	O
segregated	O
with	O
the	O
ADNSHL	B-DISEASE
phenotype	O
in	O
the	O
extended	O
family	O
(	O
Fig	O
1A	O
and	O
1C	O
)	O
.	O

It	O
was	O
unclear	O
from	O
the	O
clinical	O
course	O
if	O
the	O
patient	O
had	O
primary	O
or	O
secondary	O
FSGS	B-DISEASE
,	O
for	O
example	O
,	O
due	O
to	O
VUR	B-DISEASE
or	O
another	O
disease	O
.	O

We	O
assume	O
that	O
de	O
novo	O
variants	O
in	O
the	O
TNC	B-GENE
gene	O
are	O
related	O
to	O
the	O
neurological	O
phenotype	O
and	O
those	O
in	O
the	O
IGFALS	B-GENE
gene	O
are	O
related	O
to	O
growth	B-DISEASE
retardation	I-DISEASE
.	O

Mutations	O
in	O
almost	O
every	O
nuclear	O
-	O
encoded	O
mitochondrial	O
aminoacyl	O
-	O
tRNA	O
synthetase	O
(	O
18	O
out	O
of	O
19	O
)	O
are	O
associated	O
with	O
a	O
wide	O
variety	O
of	O
syndromes	O
and	O
diseases	O
,	O
all	O
caused	O
by	O
defective	O
aminoacylation	O
activity	O
of	O
the	O
corresponding	O
enzyme	O
25	O
,	O
26	O
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
Picard	O
with	O
the	O
module	O
'	O
CalculateHsMetrics	O
'	O
.	O

In	O
these	O
pedigrees	O
,	O
the	O
number	O
of	O
candidate	O
mutations	O
in	O
non	O
-	O
reported	O
RD	B-DISEASE
genes	O
was	O
simply	O
too	O
elevated	O
and	O
,	O
in	O
absence	O
of	O
an	O
additional	O
filtering	O
based	O
on	O
co	O
-	O
segregation	O
of	O
disease	O
and	O
DNA	O
changes	O
in	O
affected	O
relatives	O
,	O
could	O
not	O
be	O
reduced	O
.	O

Long	O
-	O
term	O
follow	O
-	O
up	O
is	O
necessary	O
in	O
the	O
2	O
controls	O
with	O
A194T	B-VARIANT
mutation	O
to	O
determine	O
whether	O
their	O
hearing	O
level	O
will	O
show	O
any	O
impairment	O
in	O
future	O
.	O

Unique	O
reads	O
were	O
aligned	O
to	O
the	O
reference	O
human	O
genome	O
(	O
build	O
hg19	O
)	O
or	O
to	O
the	O
human	O
rDNA	O
reference	O
sequence	O
(	O
rDNA	O
;	O
NCBI	O
accession	O
number	O
:	O
HSU13369	O
)	O
with	O
Bowtie	O
version	O
2	O
.	O
1	O
.	O
0	O
(	O
ref	O
.	O

Interestingly	O
,	O
in	O
our	O
study	O
family	O
with	O
visual	B-DISEASE
impairment	I-DISEASE
by	O
optic	B-DISEASE
neuropathy	I-DISEASE
,	O
there	O
were	O
no	O
signs	O
that	O
the	O
hearing	B-DISEASE
impairment	I-DISEASE
is	O
caused	O
by	O
auditory	B-DISEASE
neuropathy	I-DISEASE
.	O

As	O
expected	O
the	O
majority	O
of	O
mutations	O
where	O
an	O
electrophysiological	O
assessment	O
was	O
available	O
(	O
p	B-VARIANT
.	I-VARIANT
V254M	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
L273F	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
Y315C	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R583C	I-VARIANT
in	O
KCNQ1	B-GENE
,	O
p	B-VARIANT
.	I-VARIANT
F29L	I-VARIANT
in	O
KCNH2	B-GENE
,	O
p	B-VARIANT
.	I-VARIANT
L1785Q	I-VARIANT
in	O
SCN5A	B-GENE
,	O
p	B-VARIANT
.	I-VARIANT
D76N	I-VARIANT
in	O
KCNE1	B-GENE
,	O
p	B-VARIANT
.	I-VARIANT
I57T	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
V65M	I-VARIANT
in	O
KCNE2	B-GENE
)	O
were	O
found	O
to	O
have	O
an	O
effect	O
on	O
protein	O
function	O
.	O

1	O
)	O
.	O

This	O
mutation	O
caused	O
an	O
autosomal	O
dominant	O
clinical	O
triad	O
:	O
congenital	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
diabetes	B-DISEASE
mellitus	I-DISEASE
,	O
and	O
optic	B-DISEASE
atrophy	I-DISEASE
.	O

Three	O
programs	O
were	O
used	O
:	O
Spliceview	O
(	O
The	O
National	O
Research	O
Council	O
,	O
Institute	O
for	O
Biomedical	O
Technologies	O
,	O
Milan	O
,	O
Italy	O
)	O
,	O
NNSPLICE	O
0	O
.	O
9	O
from	O
the	O
Berkeley	O
Drosophila	O
Genome	O
Project	O
,	O
and	O
Human	O
Splicing	O
Finder	O
,	O
Version	O
2	O
.	O
4	O
(	O
French	O
Institute	O
of	O
Health	O
and	O
Medical	O
Research	O
,	O
Inserm	O
U827	O
,	O
Montpellier	O
,	O
France	O
)	O
.	O

It	O
is	O
likely	O
that	O
there	O
are	O
other	O
,	O
relatively	O
uncommon	O
,	O
genetic	O
mutations	O
that	O
contribute	O
to	O
SNHI	B-DISEASE
in	O
some	O
of	O
the	O
remaining	O
families	O
,	O
especially	O
those	O
with	O
many	O
affected	O
members	O
(	O
i	O
.	O
e	O
.	O
,	O
multiplex	O
families	O
)	O
.	O

In	O
silico	O
prediction	O
tools	O
were	O
used	O
to	O
determine	O
mutational	O
impact	O
on	O
protein	O
function	O
and	O
the	O
structure	O
of	O
the	O
identified	O
variants	O
.	O

It	O
is	O
predicted	O
that	O
cartilaginous	O
structure	O
abnormality	O
is	O
already	O
in	O
existence	O
at	O
the	O
time	O
of	O
the	O
growth	O
spurt	O
.	O

NT	O
not	O
tested	O
.	O

3	O
)	O
.	O

The	O
age	O
(	O
years	O
)	O
at	O
onset	O
was	O
significantly	O
lower	O
for	O
deafness	B-DISEASE
(	O
median	O
=	O
16	O
years	O
;	O
range	O
:	O
2	O
-	O
60	O
)	O
than	O
for	O
nephropathy	B-DISEASE
(	O
median	O
=	O
27	O
years	O
;	O
range	O
:	O
6	O
-	O
60	O
)	O
,	O
P	O
=	O
0	O
.	O
04	O
,	O
(	O
Fig	O
.	O

Patient	O
2471	O
,	O
with	O
compound	O
heterozygous	O
mutations	O
in	O
SLC26A4	B-GENE
,	O
developed	O
NSEVA	B-DISEASE
,	O
whereas	O
his	O
father	O
,	O
with	O
double	O
heterozygosity	O
in	O
both	O
SLC26A4	B-GENE
and	O
KCNJ10	B-GENE
,	O
was	O
not	O
affected	O
(	O
Table	O
3	O
)	O
.	O

BSND	B-GENE
encodes	O
the	O
barttin	O
protein	O
,	O
which	O
is	O
a	O
vital	O
subunit	O
of	O
the	O
chloride	O
and	O
voltage	O
-	O
sensitive	O
Ka	O
(	O
CLCNKA	O
)	O
and	O
Kb	O
(	O
CLCNKB	O
)	O
channels	O
in	O
the	O
inner	O
ear	O
and	O
the	O
kidney	O
.	O

Compound	O
heterozygous	O
mutations	O
,	O
c	B-VARIANT
.	I-VARIANT
605	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
a	O
splicing	O
mutation	O
and	O
c	B-VARIANT
.	I-VARIANT
815G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Gly272Asp	I-VARIANT
)	O
,	O
a	O
missense	O
mutation	O
of	O
KCNQ1	B-GENE
,	O
were	O
identified	O
in	O
these	O
two	O
siblings	O
.	O

The	O
platelet	O
count	O
was	O
decreased	O
at	O
15000	O
/	O
mm	O
3	O
with	O
giant	O
platelets	O
.	O

The	O
selection	O
of	O
samples	O
was	O
random	O
regardless	O
of	O
the	O
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
genotype	O
.	O

We	O
observed	O
a	O
wide	O
range	O
of	O
expression	O
levels	O
,	O
with	O
a	O
variance	O
that	O
was	O
very	O
similar	O
for	O
individuals	O
with	O
or	O
without	O
a	O
pathogenic	O
mutation	O
in	O
the	O
TCOF1	B-GENE
gene	O
,	O
and	O
also	O
independently	O
from	O
the	O
tissue	O
where	O
the	O
mRNA	O
was	O
obtained	O
.	O

The	O
data	O
was	O
also	O
analysed	O
for	O
reported	O
variants	O
within	O
the	O
gene	O
by	O
using	O
Alamut	O
(	O
Interactive	O
Biosoftware	O
)	O
.	O

Similarly	O
,	O
we	O
show	O
that	O
human	O
ELMOD3	B-GENE
possesses	O
Arl2	O
GAP	O
activity	O
but	O
the	O
mutant	O
has	O
at	O
least	O
a	O
10	O
-	O
fold	O
loss	O
in	O
activity	O
.	O

The	O
identification	O
of	O
the	O
Y669H	B-VARIANT
mutation	O
in	O
the	O
WFS1	B-GENE
gene	O
product	O
of	O
members	O
of	O
the	O
Taiwanese	O
family	O
with	O
symptoms	O
of	O
LFSNHL	B-DISEASE
,	O
the	O
absence	O
of	O
this	O
mutation	O
in	O
control	O
subjects	O
with	O
a	O
normal	O
hearing	O
ability	O
,	O
and	O
the	O
degree	O
of	O
conservation	O
of	O
Y669	O
in	O
the	O
WFS1	B-GENE
protein	O
of	O
human	O
,	O
mouse	O
,	O
and	O
rat	O
supports	O
our	O
interpretation	O
that	O
the	O
Y669H	B-VARIANT
mutation	O
is	O
causative	O
.	O

Variants	O
which	O
could	O
not	O
be	O
confidently	O
classified	O
as	O
either	O
pathogenic	O
or	O
neutral	O
were	O
called	O
'	O
unclassified	O
variants	O
'	O
(	O
UV1	O
-	O
UV4	O
)	O
,	O
with	O
UV4	O
being	O
probably	O
pathogenic	O
and	O
UV1	O
being	O
probably	O
neutral	O
.	O

Variants	O
classified	O
as	O
VUS	O
,	O
VLP	O
,	O
and	O
Pathogenic	O
mutation	O
were	O
also	O
confirmed	O
using	O
an	O
IGV	O
browser	O
.	O

Interestingly	O
,	O
the	O
phenotype	O
of	O
mild	O
postlingual	O
HI	B-DISEASE
was	O
associated	O
with	O
the	O
c	B-VARIANT
.	I-VARIANT
35delG	I-VARIANT
/	O
c	B-VARIANT
.	I-VARIANT
-	I-VARIANT
22	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
genotype	O
.	O

Recording	O
pipettes	O
were	O
filled	O
with	O
intracellular	O
solution	O
.	O

The	O
mean	O
age	O
-	O
related	O
typical	O
audiograms	O
for	O
DFNA6	O
/	O
14	O
,	O
adapted	O
and	O
modified	O
from	O
Pennings	O
and	O
coworkers	O
[	O
29	O
]	O
,	O
are	O
depicted	O
in	O
panel	O
B	O
.	O

Our	O
results	O
provide	O
evidence	O
that	O
these	O
two	O
mutations	O
in	O
the	O
longer	O
isoform	O
can	O
cause	O
Usher	B-DISEASE
syndrome	I-DISEASE
.	O

The	O
haplotype	O
analysis	O
of	O
the	O
family	O
with	O
microsatellite	O
markers	O
from	O
the	O
EDN3	B-GENE
candidate	O
region	O
.	O

We	O
set	O
out	O
to	O
determine	O
the	O
diagnostic	O
yield	O
of	O
exome	O
sequencing	O
in	O
pediatric	B-DISEASE
patients	O
with	O
ataxia	B-DISEASE
without	O
a	O
molecular	O
diagnosis	O
after	O
standard	O
-	O
of	O
-	O
care	O
assessment	O
in	O
Canada	O
.	O

The	O
frequency	O
of	O
GJB2	B-GENE
mutations	O
(	O
alleles	O
)	O
varies	O
from	O
4	O
%	O
to	O
30	O
.	O
4	O
%	O
among	O
different	O
regions	O
of	O
China	O
.	O

The	O
white	O
boxes	O
represent	O
healthy	O
males	O
and	O
white	O
circles	O
represent	O
healthy	O
females	O
.	O

Because	O
this	O
variation	O
showed	O
a	O
very	O
low	O
global	O
minor	O
allele	O
frequency	O
,	O
with	O
a	O
score	O
of	O
0	O
.	O
0005	O
,	O
the	O
dbSNP	O
of	O
NCBI	O
suggested	O
that	O
it	O
has	O
a	O
deleterious	O
influence	O
on	O
normal	O
hearing	B-DISEASE
.	O

For	O
functional	O
analysis	O
of	O
thyroid	O
in	O
all	O
patients	O
,	O
thyroid	O
stimulated	O
hormone	O
(	O
TSH	O
)	O
,	O
thyroxin	O
(	O
T	O
4	O
)	O
,	O
and	O
triiodothyronine	O
(	O
T	O
3	O
)	O
levels	O
were	O
measured	O
by	O
means	O
of	O
a	O
chemiluminescent	O
immunoassay	O
(	O
Berthold	O
Technology	O
-	O
CSA	O
,	O
Bad	O
Wildbad	O
,	O
Germany	O
)	O
.	O

De	O
novo	O
PARD3B	B-GENE
mutations	O
have	O
not	O
been	O
reported	O
in	O
other	O
larger	O
sequencing	O
studies	O
suggesting	O
that	O
PARD3B	B-GENE
does	O
not	O
have	O
an	O
unusually	O
high	O
mutation	O
rate	O
(	O
9	O
,	O
11	O
)	O
.	O

(	O
a	O
)	O
Green	O
,	O
arginine	O
;	O
red	O
,	O
glutamine	O
;	O
magenta	O
,	O
ATP	O
;	O
orange	O
,	O
glutamic	O
acid	O
and	O
serine	O
.	O

S2	O
)	O
[	O
20	O
]	O
.	O

van	O
Kuilenburg	O
reports	O
no	O
disclosures	O
.	O

About	O
half	O
of	O
the	O
occurrences	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
are	O
caused	O
by	O
genetic	O
factors	O
.	O

The	O
methionine	O
side	O
chain	O
is	O
longer	O
,	O
more	O
flexible	O
and	O
is	O
unbranched	O
compared	O
with	O
threonine	O
(	O
Figure	O
3	O
)	O
.	O

2004	O
;	O
Hutchin	O
et	O
al	O
.	O

Genomic	O
DNAs	O
were	O
extracted	O
from	O
peripheral	O
blood	O
as	O
described	O
previously	O
[	O
6	O
]	O
.	O

The	O
product	O
of	O
wild	O
type	O
was	O
186bp	O
in	O
length	O
,	O
while	O
the	O
mutant	O
had	O
a	O
main	O
product	O
of	O
319bp	O
(	O
Figure	O
4	O
)	O
indicating	O
the	O
non	O
-	O
splicing	O
of	O
intron	O
3	O
.	O

All	O
subjects	O
or	O
next	O
of	O
kin	O
,	O
caretakers	O
,	O
or	O
guardians	O
on	O
the	O
behalf	O
of	O
the	O
minors	O
/	O
children	O
gave	O
prior	O
written	O
informed	O
consent	O
for	O
participation	O
in	O
the	O
project	O
,	O
and	O
the	O
Shinshu	O
University	O
Ethical	O
Committee	O
as	O
well	O
as	O
the	O
respective	O
Ethical	O
Committees	O
of	O
the	O
other	O
participating	O
institutions	O
of	O
the	O
Deafness	B-DISEASE
Gene	O
Study	O
Consortium	O
(	O
Hokkaido	O
University	O
,	O
Hirosaki	O
University	O
,	O
Iwate	O
Medical	O
University	O
,	O
Tohoku	O
University	O
,	O
Yamagata	O
University	O
,	O
Fukushima	O
Medical	O
University	O
,	O
Jichi	O
Medical	O
University	O
,	O
Gunma	O
University	O
,	O
Nihon	O
University	O
,	O
Nippon	O
Medical	O
School	O
,	O
Nippon	O
Medical	O
School	O
Tama	O
Nagayama	O
Hospital	O
,	O
Jikei	O
University	O
,	O
Toranomon	O
Hospital	O
,	O
Kitasato	O
University	O
,	O
Hamamatsu	O
Medical	O
University	O
,	O
Mie	O
University	O
,	O
Shiga	O
Medical	O
Center	O
for	O
Children	O
,	O
Osaka	O
Medical	O
College	O
,	O
Hyogo	O
College	O
of	O
Medicine	O
,	O
Kobe	O
City	O
Medical	O
Center	O
General	O
Hospital	O
,	O
Wakayama	O
Medical	O
University	O
,	O
Okayama	O
University	O
,	O
Yamaguchi	O
University	O
,	O
Ehime	O
University	O
,	O
Kyushu	O
University	O
,	O
Fukuoka	O
University	O
,	O
Nagasaki	O
University	O
,	O
Kanda	O
ENT	O
Clinic	O
,	O
Miyazaki	O
Medical	O
College	O
,	O
Kagoshima	O
University	O
,	O
Ryukyus	O
University	O
)	O
approved	O
the	O
study	O
.	O

Successful	O
outcome	O
can	O
be	O
expected	O
with	O
cochlear	O
implantations	O
in	O
patients	O
with	O
BOR	B-DISEASE
/	O
BO	B-DISEASE
syndrome	O
who	O
cannot	O
benefit	O
from	O
hearing	O
aids	O
.	O

For	O
this	O
reason	O
she	O
underwent	O
diagnostic	O
screening	O
for	O
Myasthenia	B-DISEASE
Gravis	I-DISEASE
(	O
EMG	O
with	O
repetitive	O
stimulation	O
and	O
jitter	O
,	O
anti	O
-	O
acetylcholine	O
receptor	O
antibody	O
dosage	O
)	O
,	O
which	O
was	O
normal	O
.	O

In	O
this	O
study	O
we	O
characterized	O
the	O
hearing	B-DISEASE
dysfunction	I-DISEASE
in	O
OPA1	B-DISEASE
-	I-DISEASE
linked	I-DISEASE
disorders	I-DISEASE
and	O
provided	O
effective	O
rehabilitative	O
options	O
to	O
improve	O
speech	O
perception	O
.	O

The	O
PCR	O
parameters	O
were	O
optimized	O
as	O
follows	O
:	O
an	O
initial	O
denaturation	O
at	O
94	O
deg	O
C	O
for	O
7	O
min	O
,	O
35	O
cycles	O
of	O
denaturation	O
(	O
94	O
deg	O
C	O
for	O
30	O
s	O
)	O
,	O
annealing	O
(	O
58	O
deg	O
C	O
for	O
30	O
s	O
)	O
,	O
elongation	O
(	O
72	O
deg	O
C	O
for	O
45	O
s	O
)	O
,	O
and	O
a	O
final	O
elongation	O
for	O
7	O
min	O
at	O
72	O
deg	O
C	O
.	O

Genome	O
-	O
wide	O
homozygosity	O
mapping	O
was	O
performed	O
using	O
the	O
Affymetrix	O
GeneChip	O
Human	O
Mapping	O
6	O
.	O
0	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
array	O
(	O
Affymetrix	O
,	O
Santa	O
Clara	O
,	O
CA	O
)	O
.	O

Assessment	O
of	O
phenotypes	O
revealed	O
notable	O
findings	O
in	O
nine	O
patients	O
.	O

Sequences	O
were	O
compared	O
with	O
reference	O
sequence	O
from	O
GenBank	O
NG_017201	O
.	O
1	O
using	O
the	O
SeqScape	O
software	O
(	O
version	O
2	O
.	O
7	O
;	O
Life	O
Technologies	O
,	O
USA	O
)	O
.	O

Most	O
likely	O
,	O
the	O
identification	O
of	O
other	O
as	O
yet	O
unidentified	O
deafness	B-DISEASE
genes	O
will	O
follow	O
.	O

The	O
results	O
of	O
the	O
audiological	O
examination	O
tests	O
are	O
depicted	O
for	O
each	O
ear	O
separately	O
.	O

We	O
identified	O
four	O
missense	O
variants	O
(	O
p	B-VARIANT
.	I-VARIANT
Arg371Gly	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
Val932Ala	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
Ser1724Asn	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
Asp2006Tyr	I-VARIANT
)	O
and	O
four	O
synonymous	O
variants	O
(	O
p	B-VARIANT
.	I-VARIANT
Ala495Ala	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
Ile752Ile	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
Tyr935Tyr	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
Ser1878Ser	I-VARIANT
)	O
in	O
coding	O
regions	O
of	O
TECTA	B-GENE
.	O

After	O
all	O
these	O
considerations	O
,	O
we	O
set	O
out	O
to	O
investigate	O
the	O
genetic	O
lesions	O
underlying	O
this	O
variable	O
phenotype	O
.	O

Advances	O
in	O
genome	O
sequencing	O
technology	O
offer	O
a	O
new	O
opportunity	O
to	O
solve	O
the	O
genetic	O
basis	O
of	O
disease	O
even	O
beginning	O
with	O
individual	O
cases	O
.	O

Variants	O
were	O
annotated	O
using	O
Annovar	O
[	O
Wang	O
et	O
al	O
.	O
,	O
2010	O
]	O
as	O
well	O
as	O
custom	O
scripts	O
to	O
select	O
coding	O
and	O
splice	O
-	O
site	O
variants	O
,	O
and	O
to	O
exclude	O
common	O
(	O
>	O
=	O
1	O
%	O
minor	O
allele	O
frequency	O
)	O
polymorphisms	O
represented	O
in	O
the	O
1000	O
genomes	O
project	O
or	O
the	O
NHLBI	O
exome	O
sequencing	O
project	O
,	O
or	O
with	O
frequency	O
>	O
4	O
%	O
in	O
our	O
FORGE	O
control	O
exomes	O
,	O
which	O
increased	O
in	O
size	O
from	O
~	O
100	O
to	O
1	O
,	O
000	O
exomes	O
as	O
the	O
FORGE	O
project	O
progressed	O
over	O
2	O
years	O
.	O

In	O
the	O
four	O
remaining	O
patients	O
,	O
the	O
undetected	O
mutations	O
might	O
still	O
be	O
located	O
in	O
the	O
unexplored	O
promoter	O
regions	O
or	O
intragenic	O
regulatory	O
sequences	O
of	O
these	O
genes	O
,	O
but	O
may	O
also	O
be	O
located	O
in	O
other	O
,	O
still	O
unknown	O
USH	B-DISEASE
genes	O
,	O
as	O
in	O
patient	O
S1823	O
.	O

The	O
temperature	O
and	O
pressure	O
coupling	O
constants	O
were	O
set	O
to	O
2	O
.	O
0	O
ps	B-DISEASE
and	O
1	O
.	O
0	O
ps	B-DISEASE
,	O
respectively	O
[	O
14	O
]	O
.	O

Four	O
mutations	O
were	O
located	O
in	O
exon	O
5	O
and	O
exon	O
7	O
,	O
both	O
of	O
which	O
encode	O
NH2	O
-	O
terminal	O
cytosolic	O
domains	O
of	O
the	O
protein	O
(	O
Figure	O
1	O
)	O
.	O

Consanguineous	O
families	O
are	O
a	O
powerful	O
resource	O
for	O
genetic	O
linkage	O
studies	O
of	O
recessively	O
inherited	O
hearing	B-DISEASE
impairment	I-DISEASE
.	O

Neurological	O
examinations	O
revealed	O
no	O
significant	O
findings	O
and	O
there	O
were	O
no	O
obvious	O
abnormalities	O
in	O
her	O
limbs	O
.	O

(	O
d	O
)	O
Severe	O
hearing	B-DISEASE
impairment	I-DISEASE
across	O
all	O
frequencies	O
were	O
seen	O
in	O
both	O
ears	O
of	O
individual	O
III	O
:	O
1	O
.	O

The	O
proband	O
is	O
heterozygous	O
for	O
missense	O
mutation	O
WFS1	B-GENE
c	B-VARIANT
.	I-VARIANT
2765G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
E864K	I-VARIANT
)	O
(	O
Tables	O
2	O
and	O
3	O
)	O
.	O

The	O
investigation	O
of	O
skin	O
fibroblasts	O
from	O
the	O
patient	O
revealed	O
a	O
coupling	O
defect	O
of	O
oxidative	O
phosphorylation	O
and	O
a	O
larger	O
proportion	O
of	O
short	O
mitochondria	O
than	O
in	O
controls	O
.	O

The	O
array	O
incorporates	O
changes	O
of	O
an	O
unknown	O
pathologic	O
nature	O
.	O

This	O
consisted	O
of	O
46	O
,	O
287	O
RNA	O
baits	O
at	O
5	O
x	O
tiling	O
to	O
cover	O
776	O
.	O
5	O
kb	O
of	O
DNA	O
sequence	O
.	O

All	O
but	O
one	O
patient	O
from	O
the	O
OPA1	B-GENE
-	O
M	O
group	O
had	O
elevated	O
hearing	O
thresholds	O
,	O
and	O
the	O
severity	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
ranged	O
from	O
mild	O
to	O
profound	O
(	O
Table	O
1	O
)	O
.	O

Typically	O
,	O
the	O
disease	O
-	O
causing	O
mutation	O
is	O
a	O
missense	O
mutation	O
that	O
is	O
unique	O
for	O
the	O
family	O
,	O
although	O
founder	O
mutations	O
have	O
been	O
described	O
in	O
different	O
,	O
relatively	O
isolated	O
populations	O
[	O
16	O
-	O
18	O
]	O
.	O

Error	O
bars	O
display	O
one	O
standard	O
deviation	O
.	O

GAPDH	O
(	O
glyceraldehyde	O
-	O
3	O
-	O
phosphate	O
dehydrogenase	O
)	O
was	O
used	O
as	O
the	O
reference	O
.	O

USH2A	B-GENE
has	O
been	O
described	O
as	O
the	O
most	O
common	O
locus	O
for	O
syndromic	O
RP	B-DISEASE
[	O
10	O
]	O
.	O

The	O
large	O
differences	O
in	O
specific	O
activities	O
observed	O
in	O
the	O
Arl2	O
GAP	O
assay	O
may	O
be	O
due	O
to	O
differences	O
in	O
the	O
specificities	O
of	O
ELMODs	O
as	O
GAPs	O
for	O
different	O
GTPases	O
,	O
including	O
the	O
lack	O
of	O
one	O
or	O
more	O
binding	O
partners	O
(	O
e	O
.	O
g	O
.	O
,	O
one	O
that	O
is	O
perhaps	O
analogous	O
to	O
Dock180	O
binding	O
to	O
ELMO1	O
or	O
a	O
co	O
-	O
activator	O
for	O
activity	O
such	O
as	O
has	O
been	O
proposed	O
for	O
COP	O
-	O
I	O
and	O
ArfGAP1	O
[	O
34	O
]	O
)	O
,	O
and	O
/	O
or	O
the	O
lack	O
of	O
post	O
-	O
translational	O
modification	O
.	O

To	O
separate	O
the	O
mutant	O
transcripts	O
from	O
wild	O
-	O
type	O
transcripts	O
,	O
the	O
RT	O
-	O
PCR	O
products	O
were	O
cloned	O
into	O
a	O
cloning	O
vector	O
.	O

5	O
.	O
05	O
[	O
18	O
]	O
.	O

Yuki	O
Takaoka	O
at	O
the	O
Department	O
of	O
Pediatrics	O
,	O
Kyoto	O
University	O
Graduate	O
School	O
of	O
Medicine	O
and	O
Mr	O
.	O

The	O
novel	O
variant	O
c	B-VARIANT
.	I-VARIANT
1263A	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Q421H	I-VARIANT
)	O
in	O
HNF4G	B-GENE
did	O
not	O
co	O
-	O
segregate	O
with	O
the	O
phenotype	O
in	O
the	O
entire	O
family	O
but	O
variant	O
c	B-VARIANT
.	I-VARIANT
1328C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
T443M	I-VARIANT
)	O
in	O
ZNF57	B-GENE
did	O
(	O
Figure	O
1A	O
and	O
C	O
)	O
.	O

and	O
W	O
.	O
B	O
.	O
D	O
.	O

Another	O
reason	O
for	O
the	O
detection	O
failure	O
may	O
be	O
due	O
to	O
the	O
technical	O
incompleteness	O
.	O

Selection	O
of	O
four	O
short	O
tandem	O
repeat	O
(	O
STR	O
)	O
markers	O
(	O
D7S2456	O
,	O
D7S2459	O
,	O
D7S496	O
,	O
and	O
D7S2420	O
)	O
and	O
their	O
primers	O
were	O
based	O
on	O
their	O
physical	O
distance	O
,	O
available	O
at	O
NCBI	O
UniSTS	O
and	O
NCBI	O
map	O
viewer	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
mapview	O
)	O
.	O

Two	O
families	O
of	O
3	O
affected	O
individuals	O
were	O
subjected	O
to	O
LOD	O
score	O
calculation	O
by	O
linkage	O
analysis	O
and	O
the	O
remaining	O
3	O
families	O
with	O
two	O
affected	O
individuals	O
were	O
analyzed	O
by	O
homozygosity	O
mapping	O
(	O
Figure	O
1	O
)	O
.	O

GKP	O
showed	O
altitudinal	O
arched	O
vision	O
islands	O
with	O
central	O
vision	O
not	O
conserved	O
in	O
the	O
right	O
eye	O
of	O
90x20	O
degrees	O
and	O
in	O
the	O
left	O
eye	O
of	O
60x10	O
degrees	O
.	O

Of	O
the	O
20	O
,	O
239	O
genes	O
that	O
had	O
an	O
expression	O
value	O
in	O
ovarian	B-DISEASE
cancer	I-DISEASE
,	O
4	O
,	O
957	O
were	O
low	O
expressed	O
genes	O
.	O

This	O
mutation	O
,	O
absent	O
in	O
1	O
,	O
000	O
genomes	O
project	O
,	O
HapMap	O
,	O
dbSNP132	O
,	O
YH1	O
databases	O
,	O
and	O
100	O
normal	O
controls	O
,	O
cosegregated	O
with	O
patients	O
in	O
the	O
family	O
.	O

The	O
categories	O
are	O
modified	O
higher	O
order	O
HPO	O
terms	O
,	O
and	O
the	O
data	O
come	O
from	O
ultrasound	O
scans	O
,	O
postmortem	O
reports	O
or	O
pediatric	O
follow	O
-	O
up	O
.	O

Comprehensive	O
targeted	O
enrichment	O
and	O
massive	O
parallel	O
sequencing	O
have	O
been	O
employed	O
for	O
nonsyndromic	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
[	O
15	O
-	O
17	O
]	O
and	O
have	O
focused	O
only	O
on	O
the	O
exons	O
of	O
all	O
known	O
deafness	B-DISEASE
genes	O
.	O

The	O
patients	O
examined	O
in	O
this	O
study	O
underwent	O
a	O
screening	O
visit	O
at	O
the	O
diagnostic	O
centers	O
of	O
either	O
Trieste	O
or	O
Naples	O
that	O
included	O
a	O
basic	O
ophthalmic	O
consultation	O
,	O
central	O
visual	O
acuity	O
(	O
CVA	O
)	O
,	O
Goldman	O
visual	O
field	O
(	O
GVF	O
)	O
,	O
fundus	O
oculi	O
,	O
standard	O
electroretinography	O
(	O
ERG	O
)	O
,	O
and	O
a	O
series	O
of	O
periodic	O
control	O
visits	O
.	O

None	O
of	O
the	O
probands	O
with	O
reversal	O
had	O
been	O
treated	O
for	O
cryptorchidism	O
or	O
micropenis	O
in	O
infancy	O
.	O

(	O
d	O
)	O
Temporal	O
bone	O
computed	O
tomography	O
(	O
CT	O
)	O
of	O
individual	O
IV	O
:	O
4	O
.	O

Clinical	O
details	O
of	O
patients	O
with	O
c	B-VARIANT
.	I-VARIANT
983A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
mutation	O
versus	O
patients	O
with	O
c	B-VARIANT
.	I-VARIANT

Furthermore	O
,	O
this	O
study	O
provides	O
the	O
first	O
indication	O
of	O
the	O
relative	O
contribution	O
of	O
each	O
gene	O
and	O
confirms	O
that	O
they	O
account	O
for	O
the	O
majority	O
of	O
PSACH	B-DISEASE
and	O
MED	B-DISEASE
.	O

P	O
.	O
S	O
.	O
C	O
.	O

F	O
-	O
actin	O
was	O
primarily	O
recovered	O
in	O
the	O
pellet	O
fraction	O
(	O
lane	O
2	O
)	O
.	O

The	O
neck	O
region	O
contains	O
two	O
light	O
-	O
chain	O
binding	O
motifs	O
(	O
1	O
,	O
909	O
-	O
1	O
,	O
942	O
)	O
.	O

A	O
blood	O
sample	O
was	O
drawn	O
for	O
DNA	O
extraction	O
.	O

(	O
DOCX	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Based	O
on	O
these	O
data	O
,	O
hearing	B-DISEASE
loss	I-DISEASE
associated	O
with	O
MARVELD2	B-GENE
mutations	O
is	O
not	O
known	O
to	O
develop	O
in	O
children	O
older	O
than	O
2	O
-	O
3	O
years	O
,	O
and	O
may	O
be	O
considered	O
congenital	O
in	O
vast	O
majority	O
of	O
the	O
cases	O
.	O

Funduscopy	O
showed	O
that	O
RP	B-DISEASE
is	O
mild	O
in	O
adult	O
patients	O
.	O

1	O
)	O
.	O

Samples	O
of	O
mitochondrial	O
tRNA	O
were	O
deacylated	O
by	O
being	O
treated	O
at	O
pH	O
9	O
.	O

The	O
clinical	O
manifestations	O
of	O
BOR	B-DISEASE
syndrome	O
include	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
93	O
%	O
)	O
,	O
preauricular	B-DISEASE
pits	I-DISEASE
or	I-DISEASE
tags	I-DISEASE
(	O
82	O
%	O
)	O
,	O
renal	B-DISEASE
anomalies	I-DISEASE
(	O
67	O
%	O
)	O
,	O
branchial	B-DISEASE
fistulae	I-DISEASE
(	O
49	O
%	O
)	O
,	O
and	O
pinnae	B-DISEASE
deformity	I-DISEASE
(	O
36	O
%	O
)	O
[	O
2	O
]	O
.	O

Ser86Cys	I-VARIANT
;	O
p	B-VARIANT
.	I-VARIANT

Hypoglycemia	B-DISEASE
is	O
known	O
to	O
perturb	O
ER	O
function	O
(	O
5	O
)	O
.	O

(	O
a	O
)	O
Shown	O
are	O
audiogenic	B-DISEASE
seizure	I-DISEASE
latencies	O
(	O
seconds	O
)	O
after	O
white	O
noise	O
stimulation	O
at	O
90	O
,	O
100	O
and	O
110	O
dBSPL	O
(	O
dotted	O
lines	O
)	O
of	O
BLSW	O
(	O
red	O
,	O
n	O
>	O
=	O
9	O
)	O
and	O
C3HeB	O
/	O
FeJ	O
(	O
blue	O
,	O
n	O
>	O
=	O
3	O
)	O
as	O
function	O
of	O
weeks	O
of	O
age	O
.	O

All	O
patients	O
with	O
AIFM1	B-GENE
mutations	O
had	O
normal	O
serum	O
levels	O
of	O
lactate	O
dehydrogenase	O
and	O
creatine	O
kinase	O
.	O

(	O
a	O
,	O
b	O
)	O
Confocal	O
images	O
of	O
COS7	O
cells	O
expressing	O
Flag	O
-	O
tagged	O
wild	O
type	O
(	O
WT	O
,	O
a	O
)	O
and	O
G169R	B-VARIANT
mutant	O
(	O
b	O
)	O
CEACAM16	B-GENE
(	O
green	O
)	O
,	O
counterstained	O
for	O
actin	O
(	O
red	O
)	O
.	O

Only	O
index	O
patients	O
from	O
each	O
family	O
were	O
analyzed	O
by	O
WES	O
,	O
except	O
for	O
family	O
RP	B-DISEASE
-	O
0235	O
,	O
for	O
which	O
all	O
5	O
members	O
underwent	O
WES	O
analyses	O
.	O

High	O
-	O
resolution	O
single	O
-	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
genotyping	O
and	O
mutation	O
analysis	O
was	O
performed	O
as	O
described	O
46	O
.	O

+	O
DC	O
,	O
disease	O
causing	O
;	O
PO	O
,	O
polymorphism	O
.	O

#	O
HL	O
-	O
01	O
is	O
the	O
family	O
presented	O
in	O
this	O
study	O
.	O

Several	O
other	O
studies	O
have	O
also	O
found	O
a	O
variety	O
of	O
TMPRSS3	B-GENE
mutations	O
in	O
patients	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
Table	O
3	O
)	O
[	O
11	O
]	O
,	O
[	O
23	O
]	O
-	O
[	O
27	O
]	O
.	O

However	O
,	O
whether	O
p	B-VARIANT
.	I-VARIANT
Arg703Cys	I-VARIANT
is	O
the	O
causative	O
mutation	O
in	O
that	O
family	O
is	O
unclear	O
,	O
as	O
only	O
three	O
of	O
the	O
four	O
affected	O
family	O
members	O
tested	O
were	O
mutation	O
carriers	O
,	O
and	O
the	O
ages	O
of	O
diabetes	B-DISEASE
diagnoses	O
were	O
vastly	O
different	O
among	O
the	O
carriers	O
.	O

Fully	O
informed	O
written	O
consent	O
was	O
attained	O
from	O
each	O
subject	O
or	O
their	O
guardians	O
.	O

SNA	O
collected	O
the	O
oral	O
mucosa	O
samples	O
and	O
performed	O
the	O
molecular	O
analysis	O
.	O

(	O
2012	O
)	O
.	O

Genomic	O
DNA	O
were	O
extracted	O
from	O
the	O
blood	O
samples	O
using	O
the	O
Blood	O
DNA	O
kit	O
(	O
TIANGEN	O
BIOTECH	O
,	O
Beijing	O
,	O
China	O
)	O
and	O
fragmented	O
to	O
200	O
-	O
300	O
base	O
pairs	O
using	O
an	O
ultrasonoscope	O
(	O
Covaris	O
S2	O
,	O
Massachusetts	O
,	O
USA	O
)	O
.	O

Three	O
JLNS	B-DISEASE
kindreds	O
,	O
two	O
of	O
Han	O
and	O
one	O
of	O
Miao	O
descent	O
,	O
selected	O
from	O
160	O
LQTS	B-DISEASE
families	O
in	O
the	O
Chinese	O
Channelopathy	O
Registry	O
,	O
were	O
enrolled	O
into	O
this	O
study	O
.	O

Schematic	O
distribution	O
shows	O
the	O
five	O
novel	O
mutations	O
identified	O
in	O
the	O
current	O
study	O
along	O
the	O
USH2A	B-GENE
isoform	O
b	O
protein	O
domains	O
.	O

Animal	O
model	O
experimental	O
evidence	O
suggests	O
that	O
Tbx1	B-GENE
is	O
required	O
for	O
normal	O
heart	O
development	O
[	O
26	O
,	O
27	O
]	O
;	O
however	O
,	O
no	O
unequivocal	O
mutation	O
of	O
TBX1	B-GENE
has	O
been	O
discovered	O
in	O
isolated	O
CTDs	B-DISEASE
patients	O
.	O

WU	O
.	O
WOLF	O
-	O
19	O
)	O
.	O

Nevertheless	O
,	O
the	O
visual	O
acuity	O
remained	O
at	O
20	O
/	O
250	O
in	O
the	O
left	O
eye	O
,	O
with	O
resolution	O
of	O
the	O
disc	O
edema	B-DISEASE
.	O

(	O
DOCX	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

However	O
,	O
a	O
member	O
of	O
the	O
patient	O
'	O
s	O
family	O
(	O
#	O
2841	O
)	O
showed	O
normal	O
hearing	O
instead	O
of	O
being	O
homozygous	O
.	O

Indeed	O
,	O
assembly	O
of	O
nuclear	O
RNA	O
polymerases	O
has	O
previously	O
been	O
shown	O
to	O
occur	O
in	O
the	O
cell	O
'	O
s	O
cytoplasm	O
and	O
defects	O
in	O
RNA	O
polymerase	O
assembly	O
caused	O
by	O
functional	O
disruption	O
of	O
the	O
RNA	O
Polymerase	O
-	O
Associated	O
proteins	O
was	O
previously	O
shown	O
to	O
lead	O
to	O
cytoplasmic	O
accumulation	O
of	O
polymerase	O
subunits	O
15	O
16	O
17	O
18	O
19	O
20	O
21	O
.	O

In	O
case	O
of	O
children	O
participants	O
,	O
the	O
written	O
informed	O
consent	O
was	O
obtained	O
from	O
the	O
parents	O
or	O
guardians	O
on	O
behalf	O
of	O
them	O
.	O

Participating	O
subjects	O
were	O
evaluated	O
by	O
medical	O
history	O
interviews	O
.	O

The	O
detection	O
of	O
USH2A	B-GENE
mutations	O
in	O
35	O
of	O
our	O
44	O
analyzed	O
individuals	O
is	O
therefore	O
in	O
accordance	O
with	O
these	O
findings	O
.	O

Annalisa	O
Pastore	O
(	O
MRC	O
-	O
London	O
)	O
for	O
revising	O
the	O
manuscript	O
.	O

We	O
would	O
like	O
to	O
thank	O
the	O
family	O
members	O
for	O
their	O
enthusiastic	O
participation	O
in	O
the	O
present	O
study	O
.	O

Each	O
LQTS	B-DISEASE
family	O
has	O
to	O
be	O
carefully	O
examined	O
as	O
there	O
is	O
a	O
risk	O
of	O
compound	O
heterozygosity	O
or	O
digenic	O
inheritance	O
.	O

Audiograms	O
from	O
patients	O
presenting	O
with	O
NSHL	B-DISEASE
were	O
collected	O
and	O
profound	O
HL	B-DISEASE
confirmed	O
.	O

(	O
a	O
)	O
Families	O
of	O
transduction	O
currents	O
recorded	O
from	O
OHC	O
(	O
n	O
=	O
8	O
-	O
11	O
)	O
and	O
IHC	O
(	O
n	O
=	O
3	O
-	O
10	O
)	O
collected	O
from	O
the	O
apical	O
turn	O
of	O
BLSW	O
and	O
control	O
mice	O
at	O
P6	O
and	O
P12	O
are	O
shown	O
.	O

Since	O
there	O
may	O
have	O
been	O
some	O
overlap	O
between	O
the	O
two	O
conditions	O
,	O
the	O
patient	O
was	O
treated	O
with	O
intravenous	O
methylprednisolone	O
to	O
try	O
to	O
improve	O
her	O
vision	O
.	O

High	O
rates	O
of	O
the	O
V27I	B-VARIANT
and	O
[	O
V27I	B-VARIANT
;	I-VARIANT
E114G	B-VARIANT
]	O
alleles	O
were	O
detected	O
in	O
Altaian	O
patients	O
and	O
Altaian	O
controls	O
with	O
no	O
significant	O
differences	O
between	O
both	O
groups	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

2747G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
916R	I-VARIANT
>	I-VARIANT
Q	I-VARIANT
)	O
in	O
NF1	B-GENE
(	O
MIM	O
613113	O
,	O
ENST00000456735	O
)	O
.	O

To	O
this	O
is	O
added	O
the	O
further	O
potential	O
complexity	O
of	O
digenic	O
inheritance	O
which	O
has	O
been	O
proposed	O
in	O
some	O
cases	O
of	O
Usher	B-DISEASE
syndrome	I-DISEASE
and	O
described	O
in	O
other	O
retinal	B-DISEASE
diseases	I-DISEASE
.	O

His	O
elder	O
brother	O
was	O
biopsied	O
in	O
1996	O
when	O
he	O
too	O
had	O
advanced	O
renal	O
impairment	O
(	O
serum	O
creatinine	O
390	O
u	O
mol	O
/	O
L	O
)	O
,	O
demonstrating	O
advanced	O
glomerulosclerosis	B-DISEASE
with	O
mesangial	O
expansion	O
but	O
negative	O
immunofluorescence	O
.	O

Aiming	O
to	O
clinically	O
characterize	O
patients	O
with	O
the	O
c	B-VARIANT
.	I-VARIANT
1220delG	I-VARIANT
mutation	O
,	O
we	O
performed	O
full	O
ophthalmologic	O
examinations	O
and	O
audiometric	O
testing	O
in	O
most	O
of	O
the	O
patients	O
.	O

The	O
ancestry	O
-	O
based	O
subpopulations	O
differ	O
in	O
the	O
number	O
of	O
cancer	O
-	O
gene	O
variants	O
per	O
person	O
(	O
Figure	O
3	O
)	O
(	O
p	O
<	O
2	O
.	O
2e	O
-	O
16	O
by	O
ANOVA	O
)	O
.	O

Cells	O
were	O
fused	O
with	O
143B	O
rhoo	O
cells	O
as	O
previously	O
described	O
[	O
63	O
]	O
.	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Informed	O
consent	O
was	O
obtained	O
from	O
all	O
subjects	O
prior	O
to	O
blood	O
sampling	O
.	O

Homology	O
model	O
of	O
human	O
myosin	B-GENE
VIIA	I-GENE
showing	O
the	O
exon	O
16	O
-	O
encoded	O
peptide	O
in	O
green	O
in	O
the	O
middle	O
of	O
the	O
motor	O
domain	O
,	O
which	O
is	O
colored	O
in	O
orange	O
.	O

Briefly	O
,	O
PEX1	B-GENE
specific	O
reverse	O
primers	O
(	O
SP1	O
,	O
SP2	O
,	O
SP3	O
,	O
respectively	O
)	O
and	O
Reverse	O
Transcriptase	O
were	O
used	O
to	O
synthesize	O
cDNA	O
extending	O
to	O
the	O
5	O
'	O
end	O
of	O
the	O
PEX1	B-GENE
mRNA	O
.	O

Toppari	O
.	O

Hence	O
,	O
CIB2	B-GENE
is	O
one	O
of	O
the	O
major	O
causes	O
of	O
ARNSHI	B-DISEASE
within	O
the	O
Pakistani	O
population	O
(	O
Supplementary	O
Tables	O
1	O
and	O
2	O
)	O
.	O

In	O
Canada	O
,	O
physicians	O
must	O
apply	O
for	O
funding	O
from	O
the	O
provincial	O
health	O
authority	O
for	O
genetic	O
testing	O
not	O
available	O
within	O
the	O
province	O
and	O
approval	O
rates	O
vary	O
across	O
the	O
country	O
.	O

Electrochromatograms	O
showing	O
the	O
frameshift	O
mutation	O
by	O
Sanger	O
sequencing	O
.	O

Sequencing	O
of	O
those	O
exons	O
identified	O
a	O
4	O
bp	O
deletion	O
mutation	O
(	O
c	B-VARIANT
.	I-VARIANT
2983	I-VARIANT
-	I-VARIANT
1_2985del	I-VARIANT
)	O
in	O
OPA1	B-GENE
.	O

EPS8	B-GENE
-	I-GENE
3	I-GENE
F	O
forward	O
primer	O
:	O
5	O
'	O
-	O
CGTGGTGATTATAGTGCATTGG	O
-	O
3	O
'	O
and	O
EPS8	B-GENE
-	I-GENE
3R	I-GENE
reverse	O
primer	O
:	O
5	O
'	O
-	O
ATCACTGCCTCATTCCAAAC	O
-	O
3	O
'	O
were	O
used	O
to	O
amplify	O
and	O
sequence	O
EPS8	B-GENE
exon	O
3	O
.	O

That	O
change	O
was	O
included	O
in	O
the	O
genotyping	O
microarray	O
,	O
so	O
in	O
that	O
case	O
,	O
the	O
result	O
was	O
considered	O
a	O
false	O
negative	O
.	O

Transfected	O
by	O
electroporation	O
(	O
Neon	O
,	O
Invitrogen	O
)	O
COS	O
-	O
7	O
cells	O
were	O
incubated	O
overnight	O
at	O
37	O
deg	O
C	O
with	O
5	O
%	O
CO2	O
and	O
then	O
fixed	O
with	O
4	O
%	O
paraformaldehyde	O
(	O
EMS	O
)	O
for	O
20	O
min	O
,	O
permeabilized	O
for	O
15	O
min	O
in	O
0	O
.	O
2	O
%	O
Triton	O
X	O
-	O
100	O
and	O
blocked	O
by	O
incubation	O
in	O
2	O
%	O
BSA	O
and	O
5	O
%	O
normal	O
goat	O
serum	O
for	O
30	O
min	O
.	O

Noteworthy	O
,	O
one	O
of	O
the	O
two	O
eliminated	O
hydrogen	O
bonds	O
was	O
between	O
resides	O
Thr165	O
and	O
Asp437	O
,	O
the	O
latter	O
of	O
which	O
has	O
significance	O
in	O
the	O
disease	O
mechanism	O
of	O
Usher	B-DISEASE
syndrome	I-DISEASE
.	O

The	O
severity	O
of	O
hearing	B-DISEASE
impairment	I-DISEASE
was	O
defined	O
as	O
mild	O
(	O
20	O
~	O
40	O
dB	O
)	O
,	O
moderate	O
(	O
41	O
-	O
70	O
dB	O
)	O
,	O
severe	O
(	O
71	O
~	O
95	O
dB	O
)	O
and	O
profound	O
(	O
>	O
95	O
dB	O
)	O
.	O

Table	O
1	O
Clinical	O
phenotypes	O
in	O
five	O
Brazilian	O
families	O
with	O
Pfeiffer	B-DISEASE
Syndrome	I-DISEASE
and	O
genetic	O
findings	O
.	O

For	O
missense	O
mutations	O
altogether	O
six	O
criteria	O
from	O
biological	O
observations	O
and	O
in	O
silico	O
predictions	O
are	O
considered	O
to	O
compute	O
a	O
score	O
that	O
guides	O
the	O
classification	O
.	O

Even	O
in	O
familial	O
Mendelian	O
disorders	O
,	O
the	O
overall	O
success	O
rate	O
for	O
identifying	O
disease	O
-	O
causing	O
genes	O
is	O
around	O
50	O
%	O
[	O
5	O
]	O
.	O

In	O
another	O
patient	O
(	O
patient	O
9	O
)	O
,	O
a	O
congenital	O
cholesteatoma	O
filling	O
middle	O
ear	O
space	O
eroding	O
incus	O
and	O
malleus	O
was	O
identified	O
,	O
and	O
incus	O
interposition	O
was	O
performed	O
after	O
removal	O
of	O
cholesteatoma	O
.	O

The	O
proband	O
was	O
a	O
21	O
-	O
year	O
-	O
old	O
man	O
with	O
thrombocytopenia	B-DISEASE
.	O

JQL	O
performed	O
sequence	O
alignment	O
,	O
analyzed	O
and	O
summarized	O
the	O
data	O
,	O
and	O
wrote	O
part	O
of	O
the	O
paper	O
.	O

The	O
occurrence	O
of	O
COL2A1	B-GENE
gene	O
mutations	O
in	O
Chinese	O
patients	O
with	O
two	O
different	O
diseases	O
related	O
to	O
type	O
II	O
collagen	O
is	O
rare	O
.	O

The	O
other	O
was	O
a	O
novel	O
synonymous	O
variant	O
(	O
c	B-VARIANT
.	I-VARIANT
417C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
)	O
and	O
was	O
found	O
in	O
one	O
heterozygous	O
patient	O
.	O

While	O
we	O
did	O
observe	O
novel	O
variants	O
,	O
for	O
example	O
,	O
in	O
USH2A	B-GENE
in	O
patients	O
that	O
fit	O
to	O
USH2	B-DISEASE
(	O
e	O
.	O
g	O
.	O
,	O
12	O
-	O
0894	O
,	O
12	O
-	O
0654	O
)	O
and	O
novel	O
variants	O
,	O
for	O
example	O
,	O
in	O
USH1G	B-GENE
that	O
fit	O
to	O
USH1	B-DISEASE
(	O
12	O
-	O
0889	O
)	O
,	O
other	O
cases	O
cannot	O
be	O
properly	O
classified	O
into	O
these	O
subtypes	O
.	O

Western	O
Blot	O
analysis	O
of	O
beta	O
-	O
and	O
gamma	O
-	O
actin	O
isoforms	O
in	O
lymphoblastoid	O
cells	O
derived	O
from	O
an	O
unaffected	O
control	O
(	O
line	O
09	O
.	O
1359	O
)	O
and	O
two	O
patients	O
carrying	O
the	O
ACTB	B-GENE
p	B-VARIANT
.	I-VARIANT
Arg196His	I-VARIANT
(	O
LR04	O
-	O
173	O
)	O
and	O
ACTG1	B-GENE
p	B-VARIANT
.	I-VARIANT
Ser155Phe	I-VARIANT
(	O
LP98	O
-	O
096	O
)	O
recurrent	O
mutations	O
using	O
beta	O
-	O
specific	O
(	O
Sigma	O
clone	O
AC	O
-	O
15	O
)	O
and	O
gamma	O
-	O
specific	O
(	O
Sigma	O
clone	O
2	O
-	O
2	O
.	O
1	O
.	O
14	O
.	O
17	O
)	O
cytoplasmic	O
actin	O
antibodies	O
.	O

1	O
)	O
.	O

A	O
novel	O
mutation	O
of	O
GATA3	B-GENE
is	O
identified	O
in	O
this	O
patient	O
.	O

These	O
new	O
mutations	O
were	O
considered	O
pathogenic	O
because	O
they	O
are	O
a	O
nonsense	O
mutation	O
(	O
c	B-VARIANT
.	I-VARIANT
1609C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
)	O
,	O
disrupt	O
splicing	O
(	O
c	B-VARIANT
.	I-VARIANT
639	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
or	O
alter	O
the	O
reading	O
frame	O
(	O
c	B-VARIANT
.	I-VARIANT
3853delC	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
1298delC	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
218_222insAACC	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
4344dupA	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
431delC	I-VARIANT
)	O
.	O

The	O
occurrence	O
of	O
these	O
histological	O
findings	O
is	O
frequently	O
detected	O
in	O
OPA1	B-GENE
-	O
mutated	O
patients	O
with	O
a	O
4	O
-	O
to	O
-	O
1	O
ratio	O
in	O
OPA1	B-DISEASE
-	I-DISEASE
plus	I-DISEASE
patients	O
respect	O
to	O
individuals	O
with	O
pure	O
optic	O
nerve	O
involvement	O
[	O
14	O
]	O
.	O

The	O
remaining	O
variants	O
were	O
further	O
selected	O
by	O
segregating	O
from	O
the	O
unaffected	O
member	O
(	O
control	O
)	O
and	O
the	O
3	O
affected	O
members	O
.	O

Transduced	O
cell	O
were	O
sorted	O
by	O
flow	O
cytometry	O
with	O
standard	O
FITC	O
filter	O
sets	O
,	O
and	O
tdTomato	O
positive	O
cells	O
were	O
selected	O
for	O
NARS2	B-GENE
over	O
-	O
expression	O
.	O

Genome	O
-	O
wide	O
linkage	O
analysis	O
using	O
Affymetrix	O
GeneChip	O
Human	O
Mapping	O
10K	O
arrays	O
were	O
performed	O
in	O
three	O
cochlear	O
implanted	O
Saudi	O
siblings	O
born	O
from	O
a	O
consanguineous	O
marriage	O
,	O
clinically	O
diagnosed	O
with	O
USH1	B-DISEASE
by	O
comprehensive	O
clinical	O
,	O
audiological	O
,	O
and	O
ophthalmological	O
examinations	O
.	O

Low	O
-	O
quality	O
read	O
depth	O
(	O
DP	O
)	O
and	O
genotype	O
(	O
GP	O
)	O
under	O
20	O
and	O
30	O
,	O
respectively	O
,	O
or	O
variant	O
/	O
total	O
depth	O
less	O
than	O
0	O
.	O
2	O
were	O
also	O
discarded	O
.	O

2011	O
)	O
.	O

Upon	O
swapping	O
of	O
the	O
tags	O
,	O
FLAG4	O
-	O
CD164	B-GENE
R192	B-VARIANT
*	I-VARIANT
was	O
co	O
-	O
immunoprecipitated	O
with	O
HA2	O
-	O
CD164	B-GENE
(	O
Fig	O
5B	O
right	O
upper	O
panel	O
)	O
.	O

Clinical	O
data	O
of	O
family	O
RP	B-DISEASE
-	O
0482	O
and	O
primers	O
used	O
in	O
the	O
study	O
.	O

1987	O
)	O
.	O

This	O
locus	O
contains	O
the	O
two	O
Gap	O
junction	O
genes	O
GJB2	B-GENE
and	O
GJB6	B-GENE
,	O
encoding	O
,	O
respectively	O
connexin	O
26	O
(	O
CX26	O
)	O
and	O
connexin	O
30	O
(	O
CX30	O
)	O
.	O

We	O
cannot	O
exclude	O
that	O
the	O
TBX1	B-GENE
G310S	B-VARIANT
mutant	O
protein	O
might	O
have	O
an	O
effect	O
on	O
the	O
pathogenesis	O
of	O
congenital	O
malformations	O
.	O

It	O
was	O
hypothesized	O
that	O
DFNB2	B-GENE
mutations	O
cause	O
a	O
less	O
severe	O
phenotype	O
than	O
the	O
USH1B	O
-	O
associated	O
alleles	O
because	O
the	O
resulting	O
protein	O
retains	O
some	O
degree	O
of	O
normal	O
function	O
,	O
at	O
least	O
in	O
retina	O
.	O

To	O
investigate	O
the	O
genetic	O
aetiology	O
of	O
these	O
unexplained	O
cases	O
,	O
we	O
performed	O
exome	O
sequencing	O
in	O
three	O
cases	O
with	O
typical	O
clinical	O
and	O
/	O
or	O
radiological	O
features	O
of	O
POLR3	B-DISEASE
-	I-DISEASE
related	I-DISEASE
leukodystrophy	I-DISEASE
negative	O
for	O
POLR3A	B-GENE
or	O
POLR3B	B-GENE
mutation	O
.	O

NCBI	O
HomoloGene	O
-	O
generated	O
amino	O
acid	O
sequences	O
were	O
aligned	O
using	O
Clustal	O
Omega	O
software	O
.	O

For	O
family	O
11DF	O
,	O
microsatellite	O
markers	O
(	O
D9S166	O
,	O
D9S1806	O
and	O
D9S1876	O
)	O
were	O
used	O
for	O
exclusion	O
of	O
the	O
TMC1	B-GENE
region	O
.	O

Mutations	O
identified	O
in	O
7	O
families	O
a	O
Negative	O
and	O
positive	O
scores	O
indicate	O
deleterious	O
and	O
neutral	O
,	O
respectively	O
,	O
with	O
cut	O
-	O
off	O
score	O
set	O
at	O
-	O
1	O
.	O
3	O
;	O
b	O
Score	O
ranges	O
from	O
0	O
(	O
deleterious	O
)	O
to	O
1	O
(	O
neutral	O
)	O
,	O
with	O
cut	O
-	O
off	O
score	O
set	O
at	O
0	O
.	O
05	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
our	O
results	O
from	O
three	O
years	O
of	O
molecular	O
diagnostic	O
testing	O
of	O
GJB2	B-GENE
/	O
GJB6	B-GENE
including	O
the	O
clinical	O
and	O
associated	O
audiologic	O
findings	O
and	O
also	O
determine	O
the	O
prevalence	O
and	O
spectrum	O
of	O
DFNB1	B-GENE
mutations	O
in	O
the	O
southern	O
France	O
population	O
.	O

Because	O
Bohring	B-DISEASE
-	I-DISEASE
Opitz	I-DISEASE
syndrome	I-DISEASE
is	O
an	O
early	O
-	O
onset	O
severe	O
malformation	B-DISEASE
syndrome	I-DISEASE
and	O
its	O
causal	O
mutations	O
are	O
presumably	O
highly	O
penetrant	O
,	O
the	O
presence	O
of	O
p	B-VARIANT
.	I-VARIANT
Arg404Ter	I-VARIANT
in	O
two	O
African	O
-	O
American	O
EVS	O
subjects	O
leads	O
us	O
to	O
consider	O
this	O
Sanger	O
-	O
validated	O
de	O
novo	O
nonsense	O
mutation	O
as	O
a	O
very	O
good	O
candidate	O
rather	O
than	O
a	O
"	O
genetic	O
diagnosis	O
determined	O
.	O

Previous	O
medical	O
records	O
and	O
audiograms	O
were	O
traced	O
for	O
individual	O
longitudinal	O
analysis	O
.	O

Here	O
,	O
p	B-VARIANT
.	I-VARIANT
Ser6ProfsX2	I-VARIANT
denotes	O
a	O
frameshift	O
change	O
with	O
Serine	O
6	O
as	O
the	O
first	O
affected	O
amino	O
acid	O
,	O
changing	O
into	O
a	O
Proline	O
and	O
the	O
new	O
reading	O
frame	O
ending	O
with	O
stop	O
codon	O
X	O
at	O
position	O
2	O
in	O
the	O
shifted	O
reading	O
frame	O
.	O
[	O
15	O
]	O
A	O
substitution	O
of	O
either	O
the	O
first	O
or	O
the	O
last	O
two	O
nucleotides	O
of	O
a	O
particular	O
exon	O
has	O
the	O
capacity	O
to	O
alter	O
proper	O
mRNA	O
splicing	O
,	O
regardless	O
of	O
whether	O
the	O
nucleotide	O
substitution	O
codes	O
for	O
a	O
different	O
amino	O
acid	O
(	O
missense	O
mutation	O
)	O
,	O
produces	O
a	O
stop	O
codon	O
(	O
nonsense	O
mutation	O
)	O
or	O
does	O
not	O
alter	O
the	O
open	O
reading	O
frame	O
at	O
all	O
(	O
i	O
.	O
e	O
.	O
,	O
a	O
synonymous	O
or	O
silent	O
single	O
nucleotide	O
substitution	O
)	O
.	O

We	O
postulated	O
that	O
hearing	B-DISEASE
impairment	I-DISEASE
in	O
these	O
families	O
was	O
likely	O
to	O
be	O
caused	O
by	O
mutations	O
in	O
novel	O
deafness	B-DISEASE
genes	O
and	O
warranted	O
further	O
studies	O
by	O
linkage	O
analysis	O
and	O
/	O
or	O
whole	O
-	O
exome	O
sequencing	O
.	O

List	O
of	O
19	O
candidate	O
genes	O
shortlisted	O
for	O
custom	O
multiindexed	O
exome	O
sequencing	O
.	O
able	O
.	O

Unlike	O
in	O
the	O
case	O
of	O
GJB2	B-GENE
,	O
phenotype	O
cannot	O
be	O
predicted	O
from	O
the	O
genotype	O
;	O
6	O
however	O
,	O
the	O
clarification	O
of	O
clinical	O
features	O
will	O
enable	O
more	O
appropriate	O
genetic	O
counseling	O
and	O
proper	O
medical	O
management	O
for	O
these	O
patients	O
.	O

Informed	O
consent	O
has	O
been	O
obtained	O
from	O
guardians	O
of	O
all	O
patients	O
.	O

DNA	O
sequence	O
analysis	O
was	O
performed	O
using	O
Gensearch	O
software	O
(	O
Phenosystems	O
,	O
Lillois	O
Witterzee	O
,	O
Belgium	O
)	O
.	O

ESDN	O
-	O
00695	O
:	O
Radiographs	O
of	O
spine	O
,	O
pelvis	O
,	O
knee	O
,	O
and	O
hand	O
taken	O
at	O
the	O
age	O
of	O
7	O
years	O
.	O

Based	O
upon	O
previous	O
studies	O
,	O
allele	O
frequencies	O
,	O
segregation	O
analysis	O
,	O
bioinformatics	O
'	O
predictions	O
and	O
in	O
vitro	O
experiments	O
,	O
37	O
variants	O
(	O
23	O
of	O
them	O
novel	O
)	O
were	O
classified	O
as	O
pathogenic	O
mutations	O
.	O

Of	O
these	O
97	O
variants	O
,	O
all	O
variants	O
were	O
selected	O
that	O
were	O
consistent	O
with	O
the	O
known	O
inheritance	O
pattern	O
of	O
the	O
respective	O
gene	O
,	O
resulting	O
in	O
44	O
remaining	O
variants	O
,	O
including	O
16	O
of	O
the	O
known	O
variants	O
(	O
step	O
3	O
)	O
.	O

and	O
D	O
.	O
T	O
.	O

These	O
results	O
show	O
c	B-VARIANT
.	I-VARIANT
863	I-VARIANT
-	I-VARIANT
864insT	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
881	I-VARIANT
-	I-VARIANT
882delAC	I-VARIANT
would	O
most	O
probably	O
cause	O
PS	B-DISEASE
with	O
rather	O
similar	O
phenotypic	O
patterns	O
.	O

Alexa647	O
-	O
phalloidin	O
(	O
blue	O
)	O
was	O
used	O
to	O
stain	O
F	O
-	O
actin	O
,	O
and	O
a	O
ZO1	O
antibody	O
was	O
used	O
to	O
label	O
the	O
tight	O
junctions	O
(	O
red	O
)	O
.	O

Performed	O
the	O
bioinformatics	O
analyses	O
:	O
JK	O
SL	O
NK	O
.	O

In	O
clinically	O
atypical	O
presentations	O
or	O
ambiguous	O
family	O
history	O
,	O
the	O
genotype	O
may	O
specify	O
or	O
even	O
reverse	O
the	O
previous	O
diagnosis	O
or	O
the	O
assumed	O
mode	O
of	O
inheritance	O
.	O

Our	O
results	O
did	O
not	O
show	O
a	O
relationship	O
between	O
isolated	O
MD	B-DISEASE
and	O
the	O
SLC26A4	B-GENE
gene	O
in	O
this	O
Chinese	O
population	O
.	O

Watanabe	O
et	O
al	O
.	O

Arrow	O
shows	O
the	O
proband	O
(	O
IV	O
:	O
22	O
)	O
The	O
bars	O
below	O
each	O
symbol	O
indicate	O
individuals	O
involved	O
in	O
this	O
study	O
.	O

Approximately	O
half	O
of	O
cases	O
have	O
a	O
genetic	O
etiology	O
,	O
including	O
syndromic	O
and	O
non	O
-	O
syndromic	O
forms	O
,	O
with	O
extraordinary	O
genetic	O
heterogeneity	O
.	O

The	O
84	O
genes	O
that	O
were	O
targeted	O
for	O
next	O
-	O
generation	O
sequencing	O
.	O

An	O
additional	O
50	O
bp	O
of	O
flanking	O
intronic	O
sequence	O
were	O
added	O
to	O
each	O
exon	O
and	O
genomic	O
intervals	O
were	O
merged	O
using	O
Galaxy	O
software	O
(	O
http	O
:	O
/	O
/	O
galaxy	O
.	O
psu	O
.	O
edu	O
)	O
.	O

Additionally	O
SDS	O
PAGE	O
and	O
Western	O
blot	O
for	O
muscle	O
and	O
fibroblast	O
lysates	O
from	O
proband	O
II	O
.	O
1	O
were	O
performed	O
with	O
a	O
standard	O
protocol	O
(	O
29	O
)	O
.	O

The	O
work	O
was	O
funded	O
by	O
the	O
Michaelsen	O
Foundation	O
,	O
The	O
Danish	O
Eye	O
Research	O
Foundation	O
,	O
Fight	O
for	O
Sight	O
,	O
Denmark	O
and	O
The	O
A	O
.	O
P	O
.	O

The	O
predictions	O
were	O
based	O
on	O
the	O
presence	O
of	O
frameshift	O
or	O
premature	O
stop	O
codon	O
mutations	O
,	O
which	O
disrupt	O
the	O
function	O
of	O
genes	O
known	O
to	O
be	O
essential	O
for	O
hearing	O
[	O
13	O
]	O
.	O

[	O
7	O
]	O
,	O
which	O
considers	O
sRP	B-DISEASE
plus	O
consanguinity	O
to	O
be	O
arRP	O
:	O
107	O
families	O
with	O
arRP	B-DISEASE
and	O
165	O
families	O
with	O
sRP	B-DISEASE
.	O

Moreover	O
,	O
we	O
found	O
that	O
de	O
novo	O
hot	O
zone	O
mutations	O
in	O
essential	O
genes	O
occurred	O
in	O
16	O
(	O
15	O
.	O
5	O
%	O
)	O
of	O
the	O
103	O
case	O
trios	O
and	O
in	O
only	O
14	O
of	O
the	O
728	O
control	O
trios	O
(	O
1	O
.	O
9	O
%	O
)	O
(	O
P	O
=	O
3	O
.	O
4	O
x	O
10	O
-	O
8	O
,	O
Fisher	O
'	O
s	O
exact	O
test	O
)	O
.	O

Two	O
of	O
the	O
identified	O
mutations	O
are	O
novel	O
(	O
c	B-VARIANT
.	I-VARIANT
1135	I-VARIANT
-	I-VARIANT
1147dup	I-VARIANT
in	O
MYO7A	B-GENE
and	O
c	B-VARIANT
.	I-VARIANT
206	I-VARIANT
-	I-VARIANT
207insC	I-VARIANT
in	O
USH1G	B-GENE
)	O
.	O

They	O
suggested	O
that	O
CHD7	B-GENE
gene	O
analysis	O
should	O
be	O
performed	O
in	O
KS	B-DISEASE
patients	O
who	O
have	O
at	O
least	O
two	O
of	O
the	O
following	O
features	O
of	O
CHARGE	B-DISEASE
syndrome	I-DISEASE
:	O
ocular	B-DISEASE
coloboma	I-DISEASE
,	O
choanal	B-DISEASE
atresia	I-DISEASE
/	O
stenosis	B-DISEASE
,	O
characteristic	B-DISEASE
external	I-DISEASE
ear	I-DISEASE
anomaly	I-DISEASE
,	O
cranial	B-DISEASE
nerve	I-DISEASE
dysfunction	I-DISEASE
,	O
or	O
balance	B-DISEASE
disturbance	I-DISEASE
.	O

The	O
most	O
common	O
clinical	O
indication	O
was	O
speech	O
delay	O
,	O
which	O
was	O
present	O
in	O
seven	O
of	O
the	O
probands	O
(	O
D1	O
,	O
D3	O
,	O
R3	O
,	O
R5	O
,	O
U2	O
,	O
U5	O
,	O
and	O
U6	O
)	O
,	O
but	O
this	O
is	O
a	O
common	O
occurrence	O
in	O
children	O
with	O
HL	B-DISEASE
,	O
because	O
hearing	O
and	O
speaking	O
are	O
complementary	O
processes	O
.	O

The	O
red	O
line	O
indicates	O
the	O
proband	O
.	O

The	O
epiphyses	O
of	O
the	O
proximal	O
phalanges	O
are	O
fragmented	O
.	O

Takashi	O
Watanabe	O
at	O
the	O
Department	O
of	O
Human	O
Genome	O
Research	O
,	O
Kazusa	O
DNA	O
Research	O
Institute	O
for	O
their	O
technical	O
assistance	O
.	O
Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

These	O
results	O
confirmed	O
that	O
our	O
patients	O
III1	O
and	O
III2	O
with	O
USH	B-DISEASE
carry	O
both	O
mutations	O
of	O
c	B-VARIANT
.	I-VARIANT
3742G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
6501	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
.	O

Sequence	O
variants	O
of	O
interest	O
identified	O
by	O
high	O
-	O
throughput	O
sequencing	O
were	O
verified	O
by	O
Sanger	O
sequencing	O
following	O
PCR	O
amplification	O
of	O
the	O
respective	O
coding	O
exons	O
and	O
adjacent	O
intronic	O
sequences	O
by	O
standard	O
protocols	O
.	O

Nonspecific	O
DNA	O
fragments	O
were	O
removed	O
after	O
six	O
washing	O
steps	O
in	O
washing	O
buffer	O
(	O
Roche	O
NimbleGen	O
,	O
Madison	O
,	O
WI	O
)	O
.	O

Our	O
western	O
blot	O
data	O
indicate	O
that	O
the	O
Gly115Arg	B-VARIANT
substitution	O
leads	O
to	O
a	O
reduction	O
in	O
Gipc3	B-GENE
protein	O
levels	O
.	O

(	O
B	O
)	O
The	O
phenotype	O
in	O
AUNX1	B-GENE
family	O
co	O
-	O
segregates	O
with	O
the	O
c	B-VARIANT
.	I-VARIANT
1352G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
R451Q	I-VARIANT
)	O
mutation	O
in	O
AIFM1	B-GENE
.	O

All	O
the	O
reported	O
cases	O
occurred	O
sporadically	O
.	O

For	O
Figure	O
8	O
(	O
b	O
)	O
,	O
we	O
moved	O
a	O
horizontal	O
scan	O
line	O
manually	O
to	O
the	O
area	O
containing	O
the	O
MME	B-DISEASE
detected	O
by	O
AO	O
with	O
centered	O
patient	O
fixation	O
.	O

mulatta	O
,	O
NP_001181370	O
.	O
1	O
;	O
G	O
.	O

The	O
homozygous	O
mutation	O
of	O
1503	B-VARIANT
G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
was	O
an	O
unreported	O
gene	O
mutation	O
.	O

BRCA1	B-GENE
and	O
BRCA2	B-GENE
are	O
the	O
two	O
major	O
breast	B-DISEASE
cancer	I-DISEASE
susceptibility	O
genes	O
.	O

Heatmap	O
for	O
percentage	O
of	O
bases	O
>	O
=	O
depth	O
10	O
,	O
50	O
or	O
100	O
within	O
all	O
target	O
exons	O
and	O
samples	O
.	O

DNA	O
concentration	O
was	O
normalized	O
to	O
20ng	O
/	O
mu	O
L	O
based	O
on	O
two	O
rounds	O
of	O
quantification	O
and	O
dilution	O
,	O
yielding	O
mean	O
19	O
.	O
2ng	O
/	O
mu	O
l	O
concentration	O
(	O
1	O
.	O
56	O
standard	O
deviation	O
)	O
.	O

The	O
diagnosis	O
of	O
RP	B-DISEASE
is	O
usually	O
made	O
at	O
the	O
mean	O
age	O
of	O
17	O
years	O
.	O

The	O
KCNE1	B-GENE
p	B-VARIANT
.	I-VARIANT
R32H	I-VARIANT
(	O
homozygous	O
)	O
mutation	O
carrier	O
,	O
had	O
a	O
QTc	O
of	O
447	O
ms	O
,	O
is	O
being	O
treated	O
with	O
beta	O
-	O
blockers	O
and	O
has	O
not	O
experienced	O
syncope	B-DISEASE
.	O

An	O
additional	O
69	O
arRP	B-DISEASE
/	O
spRP	B-DISEASE
patients	O
were	O
analyzed	O
by	O
direct	O
sequencing	O
for	O
all	O
coding	O
exons	O
(	O
4	O
to	O
11	O
)	O
of	O
CNGA1	B-GENE
.	O

Serum	O
testosterone	O
concentrations	O
were	O
measured	O
with	O
an	O
API	O
2000	O
tandem	O
mass	O
spectrometer	O
(	O
AB	O
Sciex	O
,	O
Foster	O
City	O
,	O
California	O
,	O
USA	O
)	O
with	O
a	O
limit	O
of	O
detection	O
0	O
.	O
05	O
nmol	O
/	O
L	O
.	O

The	O
frequencies	O
of	O
common	O
missense	O
variants	O
such	O
as	O
p	B-VARIANT
.	I-VARIANT
V37I	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
V27I	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
I203T	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
T123N	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
E114G	I-VARIANT
in	O
patients	O
,	O
control	O
,	O
and	O
other	O
Asian	O
populations	O
were	O
compared	O
(	O
see	O
Supplemental	O
Table	O
4	O
and	O
Table	O
5	O
)	O
.	O

The	O
plot	O
shows	O
a	O
drop	O
-	O
out	O
of	O
two	O
amplicons	O
(	O
red	O
)	O
.	O

1B	O
)	O
.	O

D	O
,	O
H	O
)	O
OCT	O
studies	O
show	O
loss	O
of	O
the	O
IS	O
/	O
OS	O
junctions	O
,	O
a	O
disorganized	O
external	O
limiting	O
membrane	O
and	O
outer	O
nuclear	O
layer	O
,	O
thinning	O
of	O
the	O
outer	O
nuclear	O
layer	O
in	O
the	O
fovea	B-DISEASE
and	I-DISEASE
sub	I-DISEASE
-	I-DISEASE
foveal	I-DISEASE
edema	I-DISEASE
.	O

This	O
is	O
in	O
agreement	O
with	O
other	O
studies	O
in	O
Italian	O
and	O
world	O
-	O
wide	O
populations	O
[	O
15	O
]	O
.	O

For	O
the	O
sequenced	O
samples	O
,	O
we	O
typically	O
observed	O
that	O
the	O
achieved	O
coverage	O
at	O
given	O
depth	O
would	O
reach	O
a	O
plateau	O
at	O
the	O
increase	O
of	O
raw	O
sequences	O
.	O

After	O
being	O
correctly	O
diagnosed	O
at	O
the	O
17th	O
week	O
of	O
gestation	O
this	O
young	O
woman	O
was	O
faced	O
with	O
the	O
decision	O
either	O
to	O
terminate	O
or	O
to	O
carry	O
on	O
the	O
pregnancy	O
and	O
face	O
the	O
birth	O
of	O
an	O
affected	O
child	O
.	O

The	O
patient	O
is	O
now	O
four	O
years	O
old	O
and	O
has	O
not	O
undergone	O
any	O
surgical	O
intervention	O
,	O
as	O
she	O
has	O
a	O
good	O
overall	O
head	O
shape	O
with	O
no	O
major	O
midface	B-DISEASE
retrusion	I-DISEASE
,	O
is	O
making	O
good	O
developmental	O
progress	O
,	O
and	O
has	O
no	O
features	O
to	O
suggest	O
significant	O
intracranial	B-DISEASE
restriction	I-DISEASE
.	O

As	O
expected	O
,	O
we	O
have	O
found	O
recessive	O
alleles	O
responsible	O
for	O
inherited	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
such	O
families	O
.	O

In	O
pedigree	O
,	O
the	O
square	O
symbol	O
indicates	O
male	O
,	O
the	O
circle	O
symbol	O
denotes	O
female	O
and	O
black	O
symbol	O
represents	O
affected	O
individuals	O
.	O

Autosomal	O
recessive	O
inheritance	O
is	O
rare	O
in	O
nonsyndromic	O
hearing	B-DISEASE
impairment	I-DISEASE
with	O
postlingual	O
onset	O
(	O
Petersen	O
and	O
Willems	O
2006	O
)	O
.	O

All	O
coding	O
regions	O
of	O
the	O
constructs	O
were	O
sequence	O
verified	O
.	O

supervised	O
the	O
work	O
at	O
the	O
NIDCD	O
/	O
NIH	O
and	O
helped	O
with	O
data	O
interpretation	O
.	O

A	O
ConSeq	O
conservation	O
score	O
of	O
9	O
is	O
obtained	O
for	O
H170	O
showing	O
that	O
this	O
residue	O
is	O
highly	O
conserved	O
.	O

None	O
of	O
these	O
three	O
individuals	O
had	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

POU4F3	B-GENE
is	O
responsible	O
for	O
DFNA15	B-DISEASE
(	O
OMIM	O
602459	O
)	O
[	O
30	O
,	O
31	O
]	O
,	O
and	O
DFNA5	B-DISEASE
is	O
responsible	O
for	O
DFNA5	B-DISEASE
(	O
OMIM	O
600994	O
)	O
[	O
32	O
]	O
.	O

For	O
the	O
enrichment	O
we	O
used	O
customized	O
oligonucleotide	O
baits	O
in	O
solution	O
from	O
Agilent	O
(	O
SureSelect	O
)	O
.	O

The	O
skipping	O
of	O
exon	O
43	O
doesn	O
'	O
t	O
result	O
in	O
the	O
interruption	O
of	O
the	O
reading	O
frame	O
.	O

The	O
chromatograms	O
in	O
this	O
patient	O
show	O
the	O
presence	O
of	O
a	O
heterozygous	O
R289G	B-VARIANT
(	O
GGG	O
to	O
AGG	O
)	O
mutation	O
in	O
exon	O
4	O
.	O

The	O
box	O
with	O
half	O
white	O
and	O
half	O
black	O
indicate	O
the	O
status	O
of	O
carrier	O
,	O
including	O
an	O
asymptomatic	O
7	O
-	O
year	O
old	O
girl	O
(	O
IV	O
-	O
9	O
)	O
.	O

Mutations	O
in	O
the	O
autosomal	O
genes	O
TMPRSS3	B-GENE
,	O
TMC1	B-GENE
,	O
USHIC	B-GENE
,	O
CDH23	B-GENE
and	O
TMIE	B-GENE
are	O
known	O
to	O
cause	O
hereditary	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Performed	O
the	O
experiments	O
:	O
AV	O
AH	O
MP	O
AB	O
.	O

Sequence	O
alignment	O
of	O
partial	O
amino	O
acid	O
sequence	O
of	O
human	O
SLC26A4	B-GENE
and	O
its	O
homologs	O
.	O

b	O
These	O
variant	O
may	O
alter	O
normal	O
splicing	O
.	O

The	O
313	O
-	O
bp	O
product	O
suggested	O
the	O
existence	O
of	O
a	O
second	O
alternative	O
acceptor	O
site	O
(	O
see	O
below	O
)	O
.	O

CDH23	B-GENE
is	O
responsible	O
for	O
both	O
DFNB12	B-DISEASE
(	O
OMIM	O
601386	O
)	O
and	O
Usher	B-DISEASE
syndrome	I-DISEASE
1D	I-DISEASE
(	O
OMIM	O
601067	O
)	O
[	O
44	O
]	O
,	O
whereas	O
PCDH15	B-GENE
is	O
responsible	O
for	O
both	O
DFNB23	B-DISEASE
(	O
OMIM	O
609533	O
)	O
and	O
Usher	B-DISEASE
syndrome	I-DISEASE
1F	I-DISEASE
(	O
OMIM	O
602083	O
)	O
[	O
45	O
]	O
.	O

The	O
mean	O
platelet	O
count	O
(	O
x	O
10	O
9	O
/	O
L	O
)	O
was	O
53	O
with	O
a	O
range	O
between	O
under	O
10	O
and	O
136	O
,	O
the	O
highest	O
platelet	O
count	O
being	O
under	O
the	O
normal	O
range	O
(	O
150	O
-	O
400	O
x	O
10	O
9	O
/	O
L	O
)	O
(	O
Fig	O
.	O

Variants	O
were	O
also	O
recalibrated	O
using	O
GATK	O
based	O
on	O
dbSNP137	O
,	O
Mills	O
indels	O
,	O
Hap	O
Map	O
,	O
and	O
Omni	O
.	O

We	O
found	O
two	O
cases	O
(	O
SJ19	O
-	O
19	O
and	O
SH35	O
-	O
75	O
)	O
with	O
known	O
pathogenic	O
mutations	O
in	O
GJB2	B-GENE
gene	O
.	O

Exon	O
primers	O
for	O
ESRRB	B-GENE
(	O
RefSeq	O
NM_004452	O
.	O
3	O
)	O
gene	O
were	O
designed	O
using	O
Primer3	O
software	O
[	O
9	O
]	O
.	O

Individuals	O
1	O
-	O
93	O
were	O
screened	O
for	O
copy	O
number	O
variations	O
(	O
CNVs	O
)	O
using	O
the	O
Omni1	O
-	O
Quad	O
v1	O
.	O
0	O
array	O
(	O
Illumina	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
and	O
analyzed	O
using	O
GenomeStudio	O
version	O
2011	O
.	O
1	O
.	O

Complex	O
IV	O
(	O
cytochrome	O
c	O
oxidase	O
,	O
COX	O
)	O
,	O
complex	O
V	O
(	O
F1	O
-	O
ATPase	O
)	O
,	O
and	O
citrate	O
synthase	O
activities	O
were	O
recorded	O
following	O
Rustin	O
et	O
al	O
.	O

PAX3	B-GENE
encodes	O
a	O
member	O
of	O
the	O
mammalian	O
PAX	O
family	O
of	O
transcription	O
factors	O
,	O
which	O
contains	O
two	O
highly	O
conserved	O
domains	O
for	O
DNA	O
binding	O
,	O
paired	O
box	O
domain	O
and	O
paired	O
-	O
type	O
homeodomain	O
[	O
20	O
]	O
.	O

Figure	O
4	O
shows	O
the	O
available	O
single	O
-	O
snapshot	O
measurements	O
of	O
the	O
phoneme	O
scores	O
in	O
the	O
affected	O
members	O
of	O
families	O
A	O
,	O
D	O
,	O
E	O
,	O
F	O
,	O
G	O
,	O
and	O
H	O
.	O

Almost	O
all	O
known	O
MYO7A	B-GENE
mutations	O
cause	O
USH1B	B-DISEASE
.	O

Comprehensive	O
targeted	O
enrichment	O
and	O
MPS	O
has	O
been	O
employed	O
previously	O
for	O
non	O
-	O
syndromic	O
hearing	B-DISEASE
loss	I-DISEASE
[	O
25	O
]	O
.	O

Data	O
of	O
the	O
family	O
1225	O
.	O

Lymphoblastoid	O
cell	O
lines	O
were	O
established	O
by	O
standard	O
Epstein	O
-	O
Barr	O
virus	O
-	O
mediated	O
transformation	O
.	O

Proline	O
would	O
also	O
disrupt	O
the	O
hydrogen	O
bond	O
between	O
p	O
.	O
R244	O
and	O
p	O
.	O
D396	O
amino	O
acids	O
.	O

Pedigree	O
of	O
the	O
family	O
with	O
X	B-DISEASE
-	I-DISEASE
linked	I-DISEASE
Alport	I-DISEASE
syndrome	I-DISEASE
.	O

The	O
functional	O
experiments	O
mostly	O
included	O
DNA	O
-	O
binding	O
activity	O
and	O
transactivation	O
capabilities	O
.	O

Patients	O
RP1604	O
and	O
RP1611	O
diagnosed	O
as	O
USH2	B-DISEASE
,	O
and	O
patient	O
RP1024	O
classified	O
as	O
USH3	B-DISEASE
,	O
were	O
found	O
mutated	O
in	O
genes	O
(	O
CDH23	B-GENE
,	O
CLRN1	B-GENE
,	O
and	O
MYO7A	B-GENE
,	O
respectively	O
)	O
usually	O
implicated	O
in	O
a	O
different	O
clinical	O
subtype	O
.	O

Therefore	O
,	O
the	O
effect	O
of	O
the	O
second	O
mutation	O
on	O
the	O
phenotype	O
in	O
these	O
families	O
could	O
be	O
determined	O
.	O

Genotypes	O
are	O
indicated	O
below	O
each	O
symbol	O
(	O
W	O
,	O
wild	O
-	O
type	O
alleles	O
,	O
M	O
,	O
mutant	O
alleles	O
)	O
.	O

Click	O
here	O
for	O
file	O
Candidate	O
variants	O
identified	O
in	O
this	O
study	O
.	O

At	O
the	O
end	O
of	O
the	O
initial	O
filtering	O
stage	O
,	O
5	O
-	O
15	O
possible	O
pathological	O
mutation	O
candidates	O
were	O
identified	O
in	O
each	O
case	O
.	O

Molecular	O
analysis	O
of	O
HLA	O
-	O
DR	O
and	O
HLA	O
-	O
DQ	O
regions	O
revealed	O
0	O
heterodimers	O
of	O
susceptibility	O
for	O
type	B-DISEASE
1	I-DISEASE
DM	I-DISEASE
.	O

Supplementary	O
Table	O
1	O
(	O
PDF	O
86	O
kb	O
)	O
Supplementary	O
Figure	O
1	O
(	O
PDF	O
69	O
kb	O
)	O
(	O
PDF	O
86	O
kb	O
)	O
(	O
PDF	O
69	O
kb	O
)	O
Nicole	O
J	O
.	O

Both	O
patients	O
were	O
compound	O
heterozygous	O
for	O
two	O
novel	O
missense	O
variants	O
within	O
the	O
mitochondrial	B-GENE
leucyl	I-GENE
-	I-GENE
tRNA	I-GENE
synthetase	I-GENE
(	O
LARS2	B-GENE
)	O
,	O
NM_015340	O
.	O
3	O
:	O
c	B-VARIANT
.	I-VARIANT
899C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Thr300Met	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
1912G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Glu638Lys	I-VARIANT
)	O
.	O

By	O
using	O
whole	O
-	O
exome	O
sequencing	O
in	O
three	O
proband	O
-	O
parent	O
trios	O
,	O
we	O
identified	O
de	O
novo	O
missense	O
changes	O
in	O
the	O
cytoplasmic	O
actin	O
genes	O
ACTB	B-GENE
and	O
ACTG1	B-GENE
in	O
one	O
and	O
two	O
probands	O
,	O
respectively	O
.	O

1997	O
)	O
to	O
extensive	O
direct	O
sequencing	O
(	O
Aller	O
et	O
al	O
.	O

The	O
complete	O
description	O
of	O
this	O
methodology	O
can	O
be	O
found	O
at	O
the	O
AsperBio	O
website	O
,	O
and	O
has	O
been	O
previously	O
published	O
elsewhere	O
[	O
8	O
]	O
.	O

CT	O
scan	O
showed	O
no	O
adrenal	O
abnormality	O
,	O
and	O
echocardiogram	O
showed	O
mild	O
left	O
ventricular	O
hypertrophy	O
.	O

Datasets	O
of	O
NGS	O
were	O
deposited	O
in	O
National	O
Institutes	O
of	O
Health	O
(	O
NIH	O
)	O
Short	O
Read	O
Archive	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
sra	O
)	O
.	O

Despite	O
the	O
fact	O
that	O
most	O
Usher	B-DISEASE
syndrome	I-DISEASE
patients	O
can	O
be	O
reliably	O
grouped	O
into	O
one	O
of	O
the	O
three	O
main	O
clinical	O
classes	O
,	O
a	O
comprehensive	O
molecular	O
diagnostics	O
protocol	O
for	O
Usher	B-DISEASE
syndrome	I-DISEASE
has	O
been	O
hampered	O
by	O
genetic	O
heterogeneity	O
,	O
the	O
large	O
number	O
of	O
exons	O
to	O
analyze	O
and	O
by	O
the	O
high	O
costs	O
associated	O
with	O
application	O
of	O
conventional	O
techniques	O
[	O
29	O
]	O
.	O

In	O
the	O
retina	O
,	O
usherin	O
is	O
predicted	O
to	O
be	O
a	O
fi	O
brous	O
link	O
that	O
connects	O
the	O
photoreceptor	O
inner	O
segment	O
plasma	O
membrane	O
to	O
the	O
ciliary	O
surface	O
[	O
14	O
,	O
15	O
]	O
.	O

The	O
nucleotide	O
sequences	O
of	O
the	O
control	O
(	O
WT	O
/	O
WT	O
)	O
and	O
the	O
affected	O
individuals	O
(	O
WT	O
/	O
MT	O
)	O
are	O
shown	O
for	O
patients	O
5	O
(	O
A	O
)	O
,	O
6	O
(	O
B	O
)	O
,	O
and	O
7	O
(	O
C	O
)	O
.	O

The	O
variant	O
segregated	O
with	O
the	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
the	O
family	O
(	O
Figure	O
1	O
)	O
and	O
was	O
predicted	O
to	O
create	O
a	O
novel	O
splice	O
donor	O
site	O
with	O
a	O
similar	O
confidence	O
score	O
as	O
the	O
original	O
splice	O
donor	O
site	O
.	O

(	O
DOCX	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O
Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

28025	O
-	O
013	O
)	O
.	O

HotNet	O
identifies	O
a	O
list	O
of	O
subnetworks	O
,	O
each	O
containing	O
at	O
least	O
s	O
genes	O
,	O
and	O
employs	O
a	O
two	O
-	O
stage	O
statistical	O
test	O
to	O
assess	O
the	O
significance	O
of	O
the	O
list	O
of	O
subnetworks	O
.	O

Severe	O
to	O
profound	O
mixed	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
both	O
ears	O
was	O
observed	O
in	O
the	O
affected	O
individuals	O
of	O
family	O
PKDF536	O
.	O

Alexa	O
488	O
-	O
conjugated	O
donkey	O
anti	O
-	O
rat	O
IgG	O
and	O
Alexa	O
647	O
-	O
conjugated	O
donkey	O
anti	O
-	O
rabbit	O
IgG	O
Molecular	O
Probes	O
were	O
obtained	O
from	O
Life	O
Technologies	O
(	O
Eugene	O
,	O
OR	O
,	O
USA	O
)	O
.	O

Previous	O
studies	O
have	O
reported	O
findings	O
of	O
FSGS	B-DISEASE
in	O
cohort	O
of	O
patients	O
with	O
collagen	B-DISEASE
(	I-DISEASE
IV	I-DISEASE
)	I-DISEASE
related	I-DISEASE
kidney	I-DISEASE
diseases	I-DISEASE
,	O
however	O
the	O
biological	O
significance	O
of	O
these	O
findings	O
is	O
unknown	O
.	O

In	O
addition	O
some	O
of	O
these	O
genes	O
are	O
alternatively	O
spliced	O
(	O
[	O
4	O
]	O
,	O
[	O
7	O
]	O
,	O
[	O
8	O
]	O
,	O
[	O
16	O
]	O
,	O
[	O
17	O
]	O
and	O
NCBI	O
database	O
:	O
http	O
:	O
/	O
/	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
nuccore	O
/	O
)	O
.	O

A	O
total	O
of	O
5	O
.	O
1	O
gigabases	O
(	O
Gb	O
)	O
of	O
paired	O
-	O
end	O
100	O
-	O
nucleotide	O
sequence	O
reads	O
were	O
obtained	O
for	O
each	O
sample	O
,	O
90	O
%	O
of	O
which	O
were	O
mapped	O
to	O
gene	O
regions	O
following	O
alignment	O
to	O
the	O
human	O
genome	O
reference	O
sequence	O
(	O
hg19	O
)	O
using	O
the	O
DNAnexus	O
software	O
package	O
.	O

This	O
study	O
was	O
supported	O
by	O
the	O
Intramural	O
Research	O
Program	O
of	O
the	O
National	O
Human	O
Genome	O
Research	O
Institute	O
,	O
project	O
1ZIAHG000024	O
(	O
F	O
.	O
S	O
.	O
C	O
.	O
)	O
;	O
grants	O
from	O
the	O
Academy	O
of	O
Finland	O
(	O
M	O
.	O
L	O
.	O
)	O
and	O
Finnish	O
Diabetes	O
Research	O
Foundation	O
(	O
M	O
.	O
L	O
.	O
)	O
;	O
National	O
Institute	O
of	O
Diabetes	O
and	O
Digestive	O
and	O
Kidney	O
Diseases	O
grants	O
DK	O
-	O
062370	O
(	O
M	O
.	O
B	O
.	O
)	O
,	O
DK	O
-	O
067493	O
(	O
F	O
.	O
U	O
.	O
)	O
,	O
DK	O
-	O
016746	O
(	O
F	O
.	O
U	O
.	O
)	O
,	O
1K99	O
-	O
DK	O
-	O
092251	O
(	O
M	O
.	O
L	O
.	O
S	O
.	O
)	O
,	O
P30	O
-	O
DK	O
-	O
020579	O
(	O
F	O
.	O
U	O
.	O
)	O
,	O
and	O
UL1	O
-	O
TR	O
-	O
000448	O
(	O
F	O
.	O
U	O
.	O
)	O
;	O
Juvenile	O
Diabetes	O
Research	O
Foundation	O
Grant	O
47	O
-	O
2012	O
-	O
760	O
(	O
F	O
.	O
U	O
.	O
)	O
;	O
and	O
American	O
Diabetes	O
Association	O
Grant	O
1	O
-	O
12	O
-	O
CT	O
-	O
61	O
(	O
F	O
.	O
U	O
.	O
)	O
.	O

Detection	O
rate	O
was	O
elevated	O
when	O
subjects	O
were	O
restricted	O
to	O
those	O
with	O
inner	B-DISEASE
ear	I-DISEASE
anomaly	I-DISEASE
or	O
EVA	B-DISEASE
.	O

Optic	B-DISEASE
atrophy	I-DISEASE
shows	O
genetic	O
heterogeneity	O
.	O

Whether	O
the	O
missense	O
mutation	O
causes	O
a	O
dominant	O
negative	O
effect	O
and	O
/	O
or	O
specifies	O
a	O
different	O
phenotype	O
is	O
not	O
clear	O
.	O

Following	O
informed	O
consent	O
and	O
a	O
complete	O
medical	O
history	O
of	O
each	O
family	O
,	O
5	O
ml	O
of	O
peripheral	O
blood	O
was	O
taken	O
from	O
the	O
antecubital	O
vein	O
using	O
EDTA	O
-	O
containing	O
vials	O
.	O

D	O
,	O
E	O
:	O
Adult	O
II	O
:	O
1	O
from	O
family	O
E	O
showed	O
dystopia	B-DISEASE
canthorum	I-DISEASE
,	O
heterochromia	B-DISEASE
iridis	I-DISEASE
(	O
left	O
iris	O
)	O
.	O

The	O
authors	O
would	O
like	O
to	O
express	O
the	O
gratitude	O
to	O
the	O
patients	O
and	O
their	O
families	O
for	O
participation	O
in	O
this	O
study	O
.	O

However	O
,	O
in	O
EDNRB	B-GENE
isoform	O
3	O
(	O
NP_001188326	O
.	O
1	O
;	O
532	O
amino	O
acids	O
)	O
the	O
replacement	O
is	O
at	O
Met91	O
(	O
M91V	B-VARIANT
)	O
and	O
is	O
predicted	O
benign	O
by	O
PolyPhen	O
[	O
30	O
]	O
.	O

A	O
three	O
-	O
generation	O
pedigree	O
including	O
10	O
members	O
is	O
presented	O
.	O

USH1C	B-GENE
gene	O
mutation	O
screening	O
allowed	O
us	O
to	O
detect	O
47	O
additional	O
sequence	O
variants	O
,	O
25	O
of	O
which	O
had	O
previously	O
been	O
reported	O
as	O
presumably	O
non	O
-	O
pathogenic	O
(	O
see	O
Table	O
2	O
)	O
.	O

Nine	O
of	O
16	O
affected	O
individuals	O
(	O
A5	O
,	O
B3	O
,	O
C4	O
,	O
E8	O
,	O
E9	O
,	O
E10	O
,	O
E13	O
,	O
and	O
G3	O
)	O
underwent	O
vestibular	O
and	O
ocular	O
motor	O
tests	O
.	O

Due	O
to	O
the	O
low	O
number	O
of	O
characterized	O
families	O
,	O
this	O
approach	O
should	O
be	O
used	O
in	O
tandem	O
with	O
other	O
techniques	O
.	O

Their	O
targeted	O
deletion	O
in	O
mice	O
causes	O
significant	O
dysregulation	O
of	O
Ca	O
2	O
+	O
re	O
-	O
entry	O
that	O
leads	O
to	O
hearing	O
impairment	O
and	O
vestibular	O
deficits	O
[	O
37	O
]	O
.	O

The	O
genotype	O
comparison	O
between	O
GJB2	B-GENE
and	O
/	O
or	O
delta	O
(	O
GJB6	B-GENE
-	O
D13S1830	O
)	O
patients	O
with	O
GJB2	B-GENE
negative	O
subjects	O
is	O
significant	O
with	O
P	O
-	O
values	O
<	O
10	O
-	O
6	O
(	O
Table	O
3	O
)	O
.	O

(	O
b	O
,	O
c	O
)	O
shows	O
boxed	O
area	O
in	O
a	O
at	O
a	O
higher	O
magnification	O
,	O
separated	O
in	O
red	O
(	O
b	O
,	O
rhodamine	O
-	O
phalloidin	O
)	O
and	O
green	O
(	O
c	O
,	O
CIB2	B-GENE
)	O
channels	O
.	O

Hiroshi	O
Ogawa	O
and	O
Koichi	O
Omori	O
(	O
Fukushima	O
Medical	O
University	O
)	O
,	O
Drs	O
.	O

A	O
missense	O
mutation	O
,	O
p	B-VARIANT
.	I-VARIANT
L299V	I-VARIANT
,	O
was	O
predicted	O
to	O
be	O
pathologic	O
by	O
several	O
software	O
programs	O
(	O
Table	O
1	O
)	O
.	O

(	O
(	O
a	O
)	O
and	O
(	O
b	O
)	O
)	O
SD	O
-	O
OCT	O
images	O
of	O
the	O
patient	O
do	O
not	O
show	O
microcystic	B-DISEASE
macular	I-DISEASE
edema	I-DISEASE
clearly	O
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
the	O
parents	O
of	O
all	O
participants	O
to	O
the	O
study	O
.	O

To	O
date	O
,	O
more	O
than	O
150	O
mutations	O
,	O
polymorphisms	O
,	O
and	O
unclassified	O
variants	O
have	O
been	O
described	O
in	O
the	O
GJB2	B-GENE
gene	O
.	O

Macular	O
involvement	O
was	O
also	O
indicated	O
by	O
her	O
fundus	O
appearance	O
(	O
Figure	O
3A	O
)	O
.	O

In	O
brief	O
,	O
genomic	O
DNA	O
was	O
captured	O
using	O
the	O
NimblegenSeqCap	O
EZ	O
Library	O
(	O
64	O
Mb	O
for	O
I1	O
,	O
I2	O
,	O
II	O
:	O
1	O
,	O
II	O
:	O
2	O
)	O
.	O

Schematic	O
illustration	O
of	O
POU3F4	B-GENE
protein	O
labeled	O
with	O
the	O
five	O
mutations	O
identified	O
in	O
this	O
study	O
(	O
D	O
)	O
.	O

The	O
enzymatic	O
activities	O
were	O
measured	O
in	O
three	O
experiments	O
for	O
the	O
patient	O
and	O
each	O
control	O
subject	O
(	O
n	O
=	O
6	O
)	O
.	O

Arrow	O
indicates	O
the	O
proband	O
2	O
.	O

The	O
variant	O
p	B-VARIANT
.	I-VARIANT
L46F	I-VARIANT
has	O
been	O
recently	O
reported	O
in	O
NCBI	O
as	O
a	O
SNP	O
with	O
an	O
allelic	O
frequency	O
of	O
2	O
deg	O
/	O
degdeg	O
or	O
4	O
deg	O
/	O
degdeg	O
(	O
ESP	O
-	O
cohort	O
-	O
population	O
and	O
CSAgilent	O
,	O
respectively	O
)	O
,	O
S1114P	B-VARIANT
has	O
an	O
allelic	O
frequency	O
of	O
1	O
deg	O
/	O
degdeg	O
(	O
CSAgilent	O
,	O
Massy	O
,	O
France	O
)	O
but	O
no	O
frequency	O
data	O
in	O
the	O
population	O
were	O
reported	O
for	O
c	B-VARIANT
.	I-VARIANT
5766	I-VARIANT
-	I-VARIANT
3del	I-VARIANT
.	O

It	O
is	O
estimated	O
that	O
in	O
developed	O
countries	O
,	O
genetic	O
causes	O
are	O
responsible	O
in	O
at	O
least	O
two	O
-	O
thirds	O
of	O
prelingual	O
cases	O
.	O

Variant	O
filtering	O
under	O
the	O
assumption	O
of	O
a	O
dominant	O
inheritance	O
yielded	O
141	O
variants	O
in	O
126	O
genes	O
as	O
potential	O
candidates	O
(	O
Additional	O
file	O
3	O
)	O
with	O
no	O
known	O
cause	O
of	O
retinal	O
degeneration	O
amongst	O
them	O
(	O
RetNet	O
,	O
[	O
28	O
]	O
accessed	O
June	O
,	O
2013	O
)	O
.	O

Mean	O
thickness	O
values	O
for	O
the	O
ETDRS	O
grid	O
subfields	O
5	O
-	O
8	O
were	O
calculated	O
for	O
the	O
spaces	O
neurosensory	O
retina	O
,	O
retinal	O
nerve	O
fiber	O
layer	O
(	O
RNFL	O
)	O
,	O
ganglion	O
cell	O
layer	O
(	O
GCL	O
)	O
,	O
a	O
combined	O
space	O
of	O
inner	O
plexiform	O
layer	O
/	O
outer	O
plexiform	O
layer	O
/	O
inner	O
nuclear	O
layer	O
(	O
IPL	O
+	O
INL	O
+	O
OPL	O
)	O
,	O
and	O
a	O
combined	O
space	O
of	O
outer	O
nuclear	O
layer	O
/	O
photoreceptor	O
layers	O
(	O
ONL	O
+	O
PL	O
)	O
.	O

After	O
the	O
screening	O
of	O
USH2A	B-GENE
for	O
RP	O
-	O
0653	O
the	O
p	B-VARIANT
.	I-VARIANT
Arg4192His	I-VARIANT
change	O
,	O
a	O
previously	O
benign	O
variant	O
,	O
was	O
detected	O
.	O

RNA	O
analyses	O
revealed	O
that	O
exon	O
16	O
is	O
slightly	O
excluded	O
in	O
control	O
lymphocytes	O
and	O
that	O
the	O
c	B-VARIANT
.	I-VARIANT
1935G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
mutation	O
triggers	O
enhanced	O
exon	O
skipping	O
.	O

CNGA1	B-GENE
mutations	O
are	O
one	O
of	O
the	O
most	O
frequent	O
arRP	B-DISEASE
-	O
causing	O
mutations	O
in	O
Japanese	O
patients	O
.	O

The	O
MGG	O
-	O
stained	O
blood	O
smears	O
were	O
carefully	O
examined	O
for	O
the	O
presence	O
or	O
absence	O
of	O
basophilic	O
inclusions	O
(	O
D	O
o	O
hle	O
-	O
like	O
bodies	O
)	O
in	O
the	O
leukocyte	O
cytoplasm	O
.	O

Some	O
of	O
KS	B-DISEASE
genes	O
(	O
such	O
as	O
fibroblast	O
growth	O
factor	O
receptor	O
1	O
(	O
FGFR1	B-GENE
)	O
,	O
FGF8	B-GENE
,	O
PROKR2	B-GENE
and	O
PROK2	B-GENE
can	O
also	O
be	O
associated	O
with	O
a	O
normosmic	O
HH	B-DISEASE
.	O

Data	O
of	O
the	O
family	O
572	O
.	O

Mutations	O
in	O
PCDH15	B-GENE
are	O
responsible	O
for	O
USH1	B-DISEASE
and	O
for	O
autosomal	O
recessive	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
DFNB23	B-DISEASE
)	O
[	O
13	O
]	O
.	O

Direct	O
sequencing	O
was	O
performed	O
using	O
the	O
same	O
primers	O
.	O

The	O
results	O
of	O
both	O
programs	O
indicated	O
that	O
the	O
variation	O
would	O
have	O
a	O
deleterious	O
effect	O
,	O
with	O
a	O
PolyPhen2	O
score	O
of	O
1	O
.	O
000	O
and	O
a	O
SIFT	O
score	O
of	O
0	O
.	O
00	O
.	O

We	O
show	O
normal	O
flicker	O
electroretinograms	O
(	O
A	O
)	O
,	O
scotopic	O
electroretinograms	O
(	O
B	O
)	O
,	O
and	O
photopic	O
electroretinograms	O
(	O
C	O
)	O
.	O

A	O
:	O
The	O
upper	O
portion	O
presents	O
the	O
visual	O
field	O
printouts	O
of	O
the	O
Goldmann	O
perimetry	O
(	O
GP	O
)	O
test	O
,	O
and	O
the	O
lower	O
part	O
shows	O
screenshots	O
from	O
Heidelberg	O
Retina	O
Tomograph	O
II	O
(	O
HRT	O
)	O
.	O

Well	O
-	O
conserved	O
retinal	O
architecture	O
was	O
found	O
in	O
the	O
left	O
eye	O
(	O
LE	O
)	O
and	O
the	O
atrophy	B-DISEASE
is	O
restricted	O
to	O
RPE	O
and	O
external	O
layers	O
.	O

Those	O
samples	O
included	O
more	O
than	O
1000	O
patients	O
diagnosed	O
with	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
and	O
about	O
800	O
normal	O
-	O
hearing	O
control	O
samples	O
.	O

We	O
next	O
aimed	O
to	O
identify	O
low	O
frequency	O
single	O
nucleotide	O
variants	O
(	O
SNVs	O
)	O
and	O
small	O
insertion	O
/	O
deletion	O
variants	O
(	O
indels	O
)	O
in	O
the	O
pooled	O
samples	O
.	O

However	O
,	O
there	O
was	O
only	O
one	O
statistically	O
significant	O
peak	O
identified	O
by	O
testing	O
the	O
two	O
groups	O
that	O
segregated	O
with	O
the	O
disease	O
,	O
and	O
this	O
peak	O
did	O
not	O
correlate	O
with	O
disease	O
status	O
.	O

The	O
constructed	O
model	O
covered	O
the	O
target	O
sequence	O
of	O
myosin	B-GENE
XVa	I-GENE
(	O
residues	O
2685	O
-	O
2896	O
)	O
.	O

The	O
duplicate	O
-	O
removed	O
BAM	O
files	O
were	O
used	O
as	O
inputs	O
of	O
GATK	O
-	O
1	O
.	O
6	O
for	O
InDel	O
re	O
-	O
alignment	O
and	O
base	O
quality	O
recalibration	O
using	O
known	O
InDels	O
from	O
dbSNP137	O
and	O
the	O
1000	O
Genome	O
project	O
.	O

However	O
,	O
a	O
subset	O
of	O
5	O
-	O
6	O
amino	O
acids	O
showed	O
some	O
non	O
-	O
significant	O
homology	O
with	O
proteins	O
of	O
simple	O
organisms	O
such	O
as	O
Polysphondylium	O
pallidum	O
etc	O
.	O
.	O

The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O
We	O
are	O
grateful	O
to	O
the	O
families	O
,	O
patients	O
and	O
control	O
individuals	O
who	O
permitted	O
us	O
to	O
perform	O
this	O
study	O
.	O

Click	O
here	O
for	O
file	O
We	O
wish	O
to	O
thank	O
all	O
the	O
patients	O
and	O
their	O
relatives	O
for	O
participating	O
in	O
this	O
study	O
.	O

In	O
addition	O
,	O
OPA1	B-GENE
and	O
three	O
known	O
LHON	B-DISEASE
mutations	O
(	O
mtDNA	O
positions	O
m	O
.	O
11778	O
,	O
m	O
.	O
3460	O
,	O
and	O
m	O
.	O
14484	O
)	O
were	O
screened	O
by	O
a	O
combination	O
of	O
dHPLC	O
(	O
Transgenomic	O
,	O
Inc	O
.	O
,	O
Omaha	O
,	O
NE	O
)	O
and	O
direct	O
sequencing	O
analysis	O
.	O

In	O
the	O
present	O
study	O
a	O
cohort	O
of	O
30	O
ARNSHL	B-DISEASE
families	O
was	O
initially	O
screened	O
for	O
mutations	O
in	O
GJB2	B-GENE
and	O
MYO15A	B-GENE
.	O

4	O
)	O
.	O

All	O
reported	O
causative	O
mutations	O
were	O
confirmed	O
by	O
Sanger	O
sequencing	O
using	O
standard	O
techniques	O
.	O

This	O
may	O
result	O
in	O
a	O
glycine	O
-	O
to	O
-	O
serine	O
substitution	O
at	O
position	O
630	O
(	O
p	B-VARIANT
.	I-VARIANT

Type	O
2	O
genes	O
have	O
an	O
internal	O
promoter	O
composed	O
of	O
A	O
and	O
B	O
boxes	O
(	O
tRNA	O
genes	O
,	O
for	O
example	O
)	O
,	O
while	O
the	O
promoter	O
of	O
type	O
3	O
genes	O
(	O
U6	O
,	O
7SK	O
,	O
RNase	O
P	O
and	O
others	O
)	O
is	O
located	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
(	O
TSS	O
)	O
55	O
.	O

This	O
pilot	O
study	O
of	O
NGS	O
applied	O
to	O
the	O
molecular	O
diagnosis	O
of	O
an	O
heterogeneous	O
disorder	O
emphasizes	O
the	O
need	O
of	O
special	O
expertise	O
of	O
the	O
genes	O
analyzed	O
for	O
correct	O
interpretation	O
of	O
variants	O
in	O
a	O
clinical	O
context	O
.	O

S	O
.	O

Hereditary	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
can	O
be	O
subdivided	O
into	O
nonsyndromic	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
and	O
syndromic	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
according	O
to	O
the	O
clinical	O
manifestations	O
[	O
1	O
-	O
3	O
]	O
.	O

A2	O
)	O
.	O

U	O
:	O
undigested	O
control	O
,	O
M	O
:	O
DNA	O
marker	O
.	O

The	O
targeted	O
next	O
-	O
generation	O
sequencing	O
assay	O
'	O
captured	O
'	O
the	O
protein	O
coding	O
regions	O
and	O
conserved	O
splice	O
sites	O
of	O
the	O
28	O
monogenic	O
diabetes	B-DISEASE
genes	O
and	O
the	O
m	B-VARIANT
.	I-VARIANT
3243	I-VARIANT
region	O
of	O
the	O
mitochondrial	O
genome	O
from	O
the	O
patients	O
'	O
DNA	O
samples	O
by	O
hybridisation	O
.	O

Two	O
unreported	O
mutations	O
in	O
ABCA4	B-GENE
were	O
identified	O
,	O
the	O
nonsense	O
c	B-VARIANT
.	I-VARIANT
3988G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
p	B-VARIANT
.	I-VARIANT
E1330X	I-VARIANT
and	O
the	O
missense	O
c	B-VARIANT
.	I-VARIANT
6410G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
p	B-VARIANT
.	I-VARIANT
C2137Y	I-VARIANT
variants	O
.	O

However	O
,	O
screening	O
of	O
100	O
unrelated	O
individuals	O
with	O
normal	O
hearing	B-DISEASE
identified	O
an	O
individual	O
with	O
normal	O
hearing	B-DISEASE
who	O
carried	O
this	O
variation	O
in	O
heterozygous	O
state	O
.	O

05	O
)	O
,	O
respectively	O
.	O

Purified	O
PCR	O
products	O
with	O
a	O
size	O
of	O
420	O
bp	O
were	O
sent	O
for	O
Sanger	O
sequencing	O
(	O
Sangon	O
Biotech	O
,	O
Shanghai	O
,	O
China	O
)	O
.	O

Our	O
findings	O
provide	O
additional	O
information	O
regarding	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
and	O
establish	O
the	O
role	O
of	O
the	O
OPA1	B-GENE
gene	O
in	O
Greek	O
patients	O
with	O
ADOA	B-DISEASE
.	O

At	O
least	O
eight	O
loci	O
(	O
OPA1	B-GENE
to	O
OPA8	B-GENE
)	O
have	O
been	O
mapped	O
to	O
the	O
nuclear	O
genome	O
in	O
association	O
with	O
optic	B-DISEASE
atrophy	I-DISEASE
,	O
in	O
which	O
three	O
causative	O
genes	O
have	O
been	O
identified	O
,	O
including	O
the	O
optic	B-GENE
atrophy	I-GENE
1	I-GENE
(	O
OPA1	B-GENE
,	O
OMIM	O
605290	O
)	O
gene	O
,	O
the	O
optic	B-GENE
atrophy	I-GENE
3	I-GENE
(	O
OPA3	B-GENE
,	O
OMIM	O
606580	O
)	O
gene	O
,	O
and	O
the	O
transmembrane	O
protein	O
126A	B-GENE
(	O
TMEM126A	B-GENE
,	O
OMIM	O
612988	O
)	O
gene	O
[	O
1	O
]	O
.	O

(	O
b	O
)	O
shows	O
a	O
G	O
to	O
A	O
change	O
at	O
position	O
815	O
,	O
which	O
is	O
a	O
known	O
mutation	O
p	B-VARIANT
.	I-VARIANT
Gly272Asp	I-VARIANT
,	O
previously	O
reported	O
in	O
a	O
Romano	B-DISEASE
-	I-DISEASE
Ward	I-DISEASE
syndrome	I-DISEASE
European	O
patient	O
.	O

Also	O
,	O
70	O
patients	O
(	O
70	O
%	O
)	O
showed	O
progressive	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
56	O
patients	O
(	O
56	O
.	O
0	O
%	O
)	O
felt	O
fluctuation	O
of	O
hearing	O
.	O

Macular	O
degeneration	O
was	O
also	O
identified	O
in	O
this	O
patient	O
.	O

A	O
Pedigree	O
of	O
family	O
S1599	O
,	O
indicating	O
the	O
GJB2	B-GENE
genotypes	O
of	O
subjects	O
who	O
were	O
analyzed	O
.	O

Given	O
the	O
variable	O
expression	O
of	O
the	O
disease	O
in	O
the	O
family	O
it	O
is	O
very	O
possible	O
that	O
either	O
X	O
-	O
inactivation	O
is	O
skewed	O
in	O
those	O
target	O
systems	O
or	O
that	O
the	O
expression	O
of	O
PRS	B-GENE
-	I-GENE
II	I-GENE
is	O
compensating	O
PRS	O
enzymatic	O
function	O
as	O
previously	O
suggested	O
,	O
and	O
so	O
phosphoribosyl	O
pyrophosphate	O
synthesis	O
would	O
not	O
be	O
critically	O
affected	O
[	O
11	O
]	O
.	O

Scale	O
=	O
10	O
mu	O
m	O
.	O

Most	O
GSDs	B-DISEASE
have	O
been	O
reported	O
in	O
"	O
case	O
reports	O
"	O
in	O
Chinese	O
biomedical	O
literature	O
,	O
but	O
these	O
sources	O
are	O
usually	O
not	O
available	O
to	O
international	O
readers	O
.	O

The	O
asparagine	O
side	O
chain	O
forms	O
two	O
side	O
chain	O
H	O
-	O
bonds	O
with	O
two	O
main	O
chain	O
atoms	O
(	O
ASP	O
128	O
NH	O
:	O
ASN	O
170	O
OD1	O
and	O
ASN	O
170	O
OD2	O
-	O
HD22	O
:	O
THR	O
127	O
O	O
)	O
which	O
renders	O
the	O
side	O
chain	O
solvent	O
inaccessible	O
.	O

The	O
Cq	O
value	O
is	O
displayed	O
in	O
function	O
of	O
the	O
corresponding	O
amplicon	O
for	O
the	O
OTOF	B-GENE
and	O
CDH23	B-GENE
gene	O
.	O

The	O
area	O
with	O
microcystic	O
structures	O
is	O
outlined	O
in	O
dotted	O
yellow	O
line	O
.	O

(	O
J	O
)	O
Head	O
MRI	O
scan	O
of	O
individual	O
IV	O
:	O
2	O
does	O
not	O
evidence	O
any	O
sign	O
of	O
cerebellar	B-DISEASE
atrophy	I-DISEASE
.	O

Fundus	O
examination	O
of	O
the	O
father	O
showed	O
bilateral	O
disc	O
pallor	O
similar	O
to	O
his	O
son	O
while	O
OCT	B-DISEASE
and	O
PVEP	O
tests	O
revealed	O
milder	O
abnormalities	O
compared	O
with	O
the	O
son	O
.	O

Exon	O
11	O
of	O
FOXRED1	B-GENE
or	O
exon	O
10	O
of	O
NUBPL	B-GENE
was	O
PCR	O
-	O
amplified	O
(	O
Supplementary	O
Table	O
5	O
)	O
from	O
100ng	O
of	O
patient	O
gDNA	O
,	O
the	O
products	O
were	O
checked	O
by	O
gel	O
electrophoresis	O
,	O
digested	O
overnight	O
with	O
AflIII	O
or	O
NlaIV	O
respectively	O
(	O
New	O
England	O
Biolabs	O
)	O
as	O
per	O
manufacturer	O
'	O
s	O
protocol	O
,	O
then	O
resolved	O
on	O
1	O
%	O
agarose	O
gels	O
.	O

Different	O
targeted	O
genomic	O
capture	O
methods	O
and	O
massive	O
parallel	O
sequencing	O
have	O
been	O
successfully	O
applied	O
to	O
screen	O
mutations	O
in	O
hereditary	O
deafness	B-DISEASE
in	O
relatively	O
small	O
sets	O
of	O
families	O
[	O
7	O
]	O
-	O
[	O
9	O
]	O
.	O

A	O
schematic	O
of	O
a	O
rDNA	O
repeat	O
is	O
included	O
below	O
the	O
graph	O
.	O

Allele	O
sizing	O
was	O
done	O
using	O
GENEMAPPER	O
v3	O
.	O
7	O
(	O
Applied	O
Biosystems	O
)	O
.	O

Family	O
BR	O
included	O
six	O
individuals	O
with	O
prelingual	O
,	O
bilateral	O
,	O
moderate	O
to	O
severe	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Although	O
many	O
mutations	O
have	O
been	O
identified	O
in	O
Caucasians	O
,	O
several	O
cases	O
have	O
been	O
determined	O
in	O
the	O
Chinese	O
population	O
[	O
26	O
,	O
27	O
]	O
.	O

Van	O
Esch	O
et	O
al	O
.	O

The	O
sequences	O
were	O
compared	O
to	O
the	O
known	O
CLRN1	B-GENE
main	O
splice	O
variant	O
sequence	O
(	O
NM_174878	O
)	O
.	O

The	O
two	O
kits	O
showed	O
different	O
normalized	O
depths	O
for	O
low	O
GC	O
targets	O
(	O
0	O
.	O
3	O
~	O
0	O
.	O
4	O
GC	O
content	O
)	O
.	O

Our	O
data	O
points	O
towards	O
an	O
important	O
role	O
of	O
CD164	B-GENE
in	O
the	O
function	O
of	O
the	O
inner	O
ear	O
and	O
suggest	O
that	O
the	O
lack	O
of	O
the	O
YXX	O
F	O
motif	O
,	O
which	O
is	O
important	O
for	O
AP2	O
mediated	O
endocytosis	O
,	O
underlies	O
the	O
hearing	B-DISEASE
impairment	I-DISEASE
in	O
this	O
family	O
,	O
however	O
the	O
exact	O
molecular	O
disease	O
mechanism	O
needs	O
to	O
be	O
further	O
investigated	O
.	O

[	O
12	O
]	O
roughly	O
estimated	O
the	O
age	O
of	O
the	O
235delC	B-VARIANT
mutation	O
to	O
be	O
about	O
11500	O
years	O
old	O
and	O
speculated	O
that	O
the	O
235delC	B-VARIANT
mutation	O
might	O
have	O
arisen	O
in	O
the	O
Lake	O
Baikal	O
area	O
and	O
then	O
spread	O
to	O
Mongolia	O
,	O
China	O
,	O
and	O
Japan	O
through	O
subsequent	O
migrations	O
.	O

Both	O
variants	O
were	O
good	O
candidates	O
based	O
on	O
genetic	O
and	O
in	O
silico	O
data	O
.	O

The	O
age	O
of	O
onset	O
of	O
the	O
symptoms	O
(	O
usually	O
hemeralopia	O
and	O
/	O
or	O
visual	O
field	O
reduction	O
)	O
and	O
the	O
clinical	O
pictures	O
,	O
including	O
best	O
-	O
corrected	O
visual	O
acuity	O
(	O
BCVA	O
)	O
,	O
perimetry	O
,	O
and	O
ERG	O
responses	O
varied	O
.	O

Genomic	O
DNA	O
(	O
gDNA	O
)	O
was	O
extracted	O
from	O
whole	O
blood	O
using	O
standard	O
salt	O
extraction	O
methods	O
.	O

(	O
DOCX	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Other	O
associated	O
clinical	O
findings	O
in	O
WS	B-DISEASE
include	O
gastrointestinal	B-DISEASE
disorders	I-DISEASE
,	O
such	O
as	O
dismotility	B-DISEASE
(	O
constipation	B-DISEASE
as	O
well	O
as	O
chronic	B-DISEASE
diarrhea	I-DISEASE
)	O
,	O
urinary	B-DISEASE
incontinence	I-DISEASE
,	O
recurrent	B-DISEASE
urinary	I-DISEASE
infections	I-DISEASE
,	O
hidronephrosis	B-DISEASE
,	O
primary	B-DISEASE
gonadal	I-DISEASE
atrophy	I-DISEASE
(	O
males	O
)	O
,	O
and	O
menstrual	B-DISEASE
irregularities	I-DISEASE
and	O
delayed	B-DISEASE
menarche	I-DISEASE
[	O
3	O
,	O
5	O
]	O
.	O

The	O
Finnish	O
p	B-VARIANT
.	I-VARIANT
N48K	I-VARIANT
/	O
p	B-VARIANT
.	I-VARIANT
Y176X	I-VARIANT
compound	O
heterozygous	O
patient	O
was	O
diagnosed	O
with	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
at	O
age	O
7	O
;	O
testing	O
revealed	O
a	O
U	O
-	O
shaped	O
audiogram	O
.	O

B	O
:	O
The	O
c	B-VARIANT
.	I-VARIANT
700C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Q234X	I-VARIANT
)	O
mutation	O
of	O
MYO7A	B-GENE
.	O

However	O
,	O
there	O
was	O
no	O
excess	O
of	O
male	O
mutation	O
-	O
negative	O
RP	B-DISEASE
patients	O
:	O
41	O
%	O
of	O
RP	B-DISEASE
patients	O
without	O
mutations	O
were	O
male	O
which	O
corresponds	O
to	O
their	O
percentage	O
(	O
40	O
%	O
)	O
in	O
the	O
RP	B-DISEASE
cohort	O
(	O
excluding	O
the	O
three	O
proven	O
X	O
-	O
RP	B-DISEASE
patients	O
)	O
.	O

Based	O
on	O
familial	O
history	O
and	O
parental	O
consanguinity	O
,	O
we	O
hypothesized	O
that	O
the	O
causal	O
mutations	O
would	O
be	O
present	O
at	O
the	O
homozygous	O
state	O
at	O
least	O
in	O
three	O
patients	O
,	O
and	O
possibly	O
at	O
the	O
compound	O
heterozygous	O
state	O
in	O
patient	O
DF103	O
-	O
III	O
.	O
2	O
,	O
who	O
was	O
born	O
to	O
presumably	O
unrelated	O
parents	O
.	O

Bleeding	B-DISEASE
was	O
minor	O
or	O
moderate	O
in	O
most	O
cases	O
.	O

When	O
observed	O
or	O
expected	O
values	O
were	O
below	O
5	O
,	O
a	O
Fisher	O
exact	O
test	O
was	O
performed	O
.	O

Some	O
aaRSs	O
have	O
an	O
additional	O
domain	O
with	O
editing	O
functions	O
to	O
prevent	O
the	O
insertion	O
of	O
inappropriate	O
amino	O
acids	O
during	O
protein	O
synthesis	O
.	O

Table	O
1	O
Coverage	O
and	O
sequencing	O
statistics	O
of	O
7	O
probands	O
Coverage	O
and	O
sequencing	O
statistics	O
of	O
7	O
probands	O
Six	O
families	O
with	O
candidate	O
variants	O
(	O
JSNY	O
-	O
021	O
,	O
JSNY	O
-	O
027	O
,	O
JSNY	O
-	O
033	O
,	O
JSNY	O
-	O
043	O
,	O
JSNY	O
-	O
053	O
and	O
JSNY	O
-	O
056	O
)	O
showed	O
autosomal	O
dominant	O
inheritance	O
(	O
Figure	O
1	O
a	O
)	O
.	O

Sequence	O
analysis	O
was	O
based	O
on	O
remote	O
homology	O
of	O
the	O
amino	O
acid	O
regions	O
surrounding	O
the	O
identified	O
mutations	O
by	O
using	O
the	O
HHblits	O
algorithm	O
.	O

The	O
c	B-VARIANT
.	I-VARIANT
341G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
transition	O
mutation	O
was	O
absent	O
in	O
150	O
DNA	O
samples	O
from	O
normal	O
hearing	O
Pakistani	O
individuals	O
and	O
in	O
the	O
1000	O
Genomes	O
database	O
of	O
human	O
genetic	O
variation	O
.	O

Overall	O
,	O
we	O
could	O
find	O
causative	O
variants	O
in	O
51	O
(	O
54	O
.	O
8	O
%	O
)	O
of	O
the	O
93	O
cochlear	O
implantees	O
.	O

The	O
other	O
interesting	O
result	O
was	O
the	O
mutations	O
in	O
the	O
genes	O
previously	O
reported	O
to	O
be	O
syndromic	O
genes	O
such	O
as	O
EYA1	B-GENE
.	O

DFNB31	B-GENE
is	O
not	O
a	O
major	O
cause	O
of	O
USH	B-DISEASE
.	O

We	O
report	O
the	O
results	O
of	O
an	O
8	O
-	O
year	O
study	O
of	O
a	O
large	O
cohort	O
of	O
109	O
patients	O
from	O
37	O
sporadic	O
cases	O
and	O
39	O
unrelated	O
families	O
.	O

Therefore	O
,	O
regular	O
examinations	O
of	O
hearing	O
function	O
and	O
identification	O
of	O
other	O
factors	O
that	O
can	O
exacerbate	O
hearing	B-DISEASE
loss	I-DISEASE
should	O
be	O
performed	O
for	O
prevention	O
.	O

and	O
S	O
.	O
L	O
.	O

A	O
sterile	O
stainless	O
steel	O
needle	O
electrode	O
was	O
passed	O
through	O
the	O
tympanic	O
membrane	O
and	O
placed	O
on	O
the	O
promontory	O
wall	O
with	O
the	O
aid	O
of	O
an	O
operating	O
microscope	O
.	O

SDS	O
-	O
PAGE	O
was	O
performed	O
under	O
reducing	O
conditions	O
.	O

Eighty	O
genes	O
targeted	O
for	O
the	O
next	O
-	O
generation	O
sequencing	O
.	O

In	O
common	O
with	O
several	O
other	O
published	O
studies	O
,	O
panel	O
sequencing	O
was	O
found	O
to	O
be	O
a	O
rapid	O
and	O
cost	O
-	O
efficient	O
solution	O
for	O
genetically	O
heterogeneous	O
skeletal	O
conditions	O
[	O
2	O
,	O
17	O
,	O
80	O
]	O
.	O

5	O
'	O
polymorphisms	O
were	O
analysed	O
in	O
relation	O
to	O
the	O
two	O
most	O
common	O
mutations	O
in	O
PEX1	B-GENE
and	O
were	O
incorporated	O
into	O
a	O
novel	O
genotype	O
-	O
phenotype	O
analysis	O
by	O
correlation	O
of	O
three	O
classes	O
of	O
PEX1	B-GENE
mutations	O
with	O
patient	O
survival	O
.	O

To	O
further	O
confirm	O
that	O
mutated	O
POLR1C	B-GENE
variants	O
(	O
N32I	B-VARIANT
and	O
N74S	B-VARIANT
)	O
are	O
impaired	O
in	O
supporting	O
enzyme	O
assembly	O
and	O
nuclear	O
import	O
,	O
immunofluorescence	O
studies	O
were	O
performed	O
using	O
anti	O
-	O
FLAG	O
antibodies	O
.	O

The	O
mutation	O
was	O
not	O
found	O
in	O
156	O
(	O
312	O
chromosomes	O
)	O
ethnically	O
matched	O
control	O
individuals	O
.	O

B	O
:	O
Western	O
blot	O
analysis	O
of	O
WFS1	B-GENE
protein	O
abundance	O
with	O
tubulin	O
as	O
loading	O
control	O
.	O

Forty	O
-	O
five	O
pairs	O
of	O
PCR	O
primers	O
were	O
designed	O
to	O
amplify	O
all	O
of	O
the	O
exons	O
and	O
their	O
flanking	O
regions	O
of	O
the	O
OTOF	B-GENE
gene	O
.	O

Evaluated	O
according	O
to	O
the	O
Ivy	O
method	O
.	O

KCNJ10	B-GENE
encodes	O
a	O
42	O
.	O
5	O
-	O
kD	O
member	O
of	O
the	O
inward	O
rectifier	O
potassium	O
channel	O
family	O
and	O
is	O
expressed	O
mainly	O
in	O
the	O
brain	O
,	O
kidney	O
,	O
and	O
inner	O
ear	O
.	O

The	O
proband	O
'	O
s	O
parents	O
,	O
II	O
-	O
2	O
at	O
age	O
41	O
and	O
II	O
-	O
3	O
at	O
age	O
39	O
,	O
showed	O
normal	O
hearing	O
audiograms	O
,	O
while	O
the	O
affected	O
brothers	O
,	O
III	O
-	O
2	O
and	O
III	O
-	O
3	O
,	O
showed	O
severe	O
to	O
profound	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Conservation	O
of	O
STRC	B-GENE
residues	O
in	O
mutated	O
positions	O
.	O

We	O
then	O
applied	O
our	O
multistep	O
analysis	O
to	O
classify	O
these	O
49	O
variants	O
(	O
Roux	O
et	O
al	O
.	O

The	O
authors	O
are	O
indebted	O
to	O
the	O
patients	O
and	O
their	O
families	O
for	O
making	O
this	O
work	O
possible	O
.	O

All	O
samples	O
were	O
tested	O
for	O
the	O
35delG	B-VARIANT
mutation	O
,	O
the	O
non	O
coding	O
and	O
coding	O
exons	O
of	O
GJB2	B-GENE
(	O
E1	O
and	O
E2	O
respectively	O
)	O
and	O
for	O
the	O
delta	O
(	O
GJB6	B-GENE
-	O
D13S1830	O
)	O
mutation	O
.	O

For	O
diseases	O
with	O
different	O
subtypes	O
(	O
for	O
example	O
,	O
Osteogenesis	B-DISEASE
Imperfecta	I-DISEASE
,	O
types	O
I	O
-	O
V	O
)	O
,	O
only	O
the	O
main	O
term	O
(	O
"	O
Osteogenesis	B-DISEASE
Imperfecta	I-DISEASE
"	O
)	O
was	O
used	O
in	O
the	O
search	O
,	O
and	O
information	O
on	O
the	O
type	O
was	O
gleaned	O
from	O
the	O
text	O
.	O

These	O
changes	O
were	O
selected	O
according	O
to	O
their	O
nature	O
,	O
or	O
the	O
presence	O
of	O
another	O
pathogenic	O
allele	O
in	O
the	O
same	O
gene	O
in	O
the	O
same	O
patient	O
.	O

Mutations	O
are	O
color	O
-	O
coded	O
according	O
to	O
their	O
mutation	O
categories	O
:	O
group	O
1	O
(	O
red	O
)	O
,	O
group	O
2	O
(	O
blue	O
)	O
,	O
and	O
group	O
3	O
(	O
green	O
)	O
.	O

We	O
identified	O
35	O
de	O
novo	O
single	O
-	O
nucleotide	O
variants	O
(	O
SNVs	O
)	O
,	O
small	O
indels	O
,	O
deletions	O
or	O
duplications	O
,	O
of	O
which	O
three	O
(	O
accounting	O
for	O
10	O
%	O
of	O
the	O
cohort	O
)	O
are	O
highly	O
likely	O
to	O
be	O
causative	O
.	O

The	O
second	O
mutation	O
(	O
p	B-VARIANT
.	I-VARIANT
C40G	I-VARIANT
)	O
was	O
homozygously	O
found	O
in	O
a	O
possible	O
consanguineous	O
Spanish	O
USH3	B-DISEASE
family	O
by	O
Aller	O
et	O
al	O
.	O

The	O
short	O
tandem	O
repeat	O
(	O
STR	O
)	O
markers	O
,	O
their	O
relative	O
map	O
positions	O
(	O
Mb	O
)	O
according	O
to	O
UCSC	O
Genome	O
Bioinformatics	O
Build	O
GRCh37	O
(	O
hg19	O
)	O
,	O
and	O
their	O
genetic	O
positions	O
(	O
cM	O
)	O
based	O
on	O
the	O
Marshfield	O
genetic	O
map	O
are	O
shown	O
next	O
to	O
the	O
pedigree	O
.	O

Summary	O
of	O
the	O
mutations	O
of	O
OPA1	B-GENE
gene	O
.	O

We	O
thank	O
Ina	O
le	O
Roux	O
,	O
Christine	O
Bugay	O
Valdez	O
,	O
Dennis	O
Dion	O
Petersen	O
and	O
Karina	O
Liebmann	O
Madsen	O
for	O
their	O
excellent	O
technical	O
assistance	O
.	O

With	O
the	O
Illumina	O
MiSeq	O
instrument	O
,	O
the	O
average	O
coverage	O
was	O
significantly	O
higher	O
(	O
250	O
-	O
fold	O
)	O
and	O
more	O
complete	O
(	O
15	O
-	O
fold	O
for	O
more	O
than	O
99	O
%	O
of	O
target	O
sequences	O
)	O
.	O

(	O
b	O
)	O
In	O
cases	O
with	O
bulbous	O
dilatation	O
at	O
the	O
distal	O
end	O
of	O
the	O
IAC	O
and	O
basal	O
turn	O
of	O
the	O
cochlea	O
incompletely	O
separated	O
from	O
the	O
IAC	O
(	O
arrow	O
)	O
were	O
tested	O
for	O
POU3F4	B-GENE
.	O

In	O
this	O
study	O
,	O
the	O
two	O
nonsense	O
mutations	O
p	B-VARIANT
.	I-VARIANT
Q393X	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
S288X	I-VARIANT
were	O
expected	O
to	O
cause	O
hearing	B-DISEASE
loss	I-DISEASE
but	O
not	O
cardiomyopathy	B-DISEASE
,	O
because	O
they	O
retain	O
the	O
Eya	O
VR	O
domain	O
.	O

-	O
Family	O
2	O
The	O
proband	O
was	O
a	O
girl	O
,	O
aged	O
9	O
years	O
and	O
born	O
by	O
vaginal	O
delivery	O
.	O

2010	O
)	O
.	O

Reads	O
passing	O
the	O
Illumina	O
"	O
chastity	O
filter	O
"	O
were	O
aligned	O
to	O
the	O
UCSC	O
hg19	O
genome	O
assembly	O
(	O
pseudoautosomal	O
region	O
on	O
Y	O
chromosome	O
masked	O
,	O
alternative	O
haplotypes	O
removed	O
)	O
using	O
Novoalign	O
v2	O
.	O
07	O
.	O
18	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
novocraft	O
.	O
com	O
)	O
,	O
and	O
duplicate	O
read	O
pairs	O
were	O
removed	O
.	O

FLAG	O
-	O
tagged	O
versions	O
of	O
the	O
wild	O
-	O
type	O
(	O
WT	O
)	O
form	O
of	O
POLR1C	B-GENE
and	O
its	O
variants	O
having	O
the	O
p	B-VARIANT
.	I-VARIANT
Asn32Ile	I-VARIANT
(	O
N32I	B-VARIANT
)	O
or	O
p	B-VARIANT
.	I-VARIANT
Asn74Ser	I-VARIANT
(	O
N74S	B-VARIANT
)	O
substitution	O
were	O
expressed	O
in	O
HeLa	O
cells	O
.	O

Competing	O
interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Based	O
on	O
pendrin	O
structural	O
modeling	O
,	O
predicted	O
by	O
Everett	O
et	O
al	O
.	O

We	O
appreciate	O
all	O
the	O
patients	O
,	O
their	O
parents	O
,	O
the	O
clinical	O
research	O
coordinators	O
,	O
and	O
the	O
referring	O
physicians	O
for	O
participating	O
in	O
this	O
study	O
.	O

The	O
TCOF1	B-GENE
gene	O
mutations	O
include	O
missense	O
,	O
nonsense	O
,	O
small	O
deletions	O
and	O
duplications	O
.	O

To	O
investigate	O
the	O
possible	O
effect	O
of	O
the	O
mutation	O
on	O
mRNA	O
splicing	O
,	O
we	O
performed	O
an	O
RT	O
-	O
PCR	O
analysis	O
of	O
total	O
lymphocyte	O
RNA	O
obtained	O
from	O
the	O
patient	O
.	O

histolytica	O
residue	O
corresponding	O
to	O
human	O
p	O
.	O
Val213	O
is	O
p	O
.	O
Glu197	O
and	O
is	O
displayed	O
in	O
dark	O
brown	O
.	O

1	O
)	O
.	O

The	O
vestibular	O
symptom	O
,	O
vertigo	O
,	O
was	O
only	O
reported	O
by	O
III	O
-	O
8	O
(	O
Table	O
S1	O
)	O
.	O

Pure	O
-	O
tone	O
threshold	O
audiometry	O
was	O
performed	O
in	O
58	O
out	O
of	O
65	O
cases	O
and	O
confirmed	O
sensorineural	B-DISEASE
hearing	I-DISEASE
impairment	I-DISEASE
.	O

This	O
is	O
the	O
first	O
comprehensive	O
study	O
of	O
the	O
molecular	O
etiology	O
of	O
nonsyndromic	O
hearing	B-DISEASE
impairment	I-DISEASE
in	O
mainland	O
China	O
.	O

Although	O
the	O
remaining	O
region	O
(	O
64	O
base	O
positions	O
out	O
of	O
3407	O
target	O
positions	O
)	O
was	O
too	O
error	O
-	O
prone	O
(	O
the	O
error	O
rate	O
ranged	O
from	O
0	O
.	O
1	O
to	O
1	O
.	O
7	O
%	O
in	O
either	O
the	O
upper	O
or	O
lower	O
strand	O
)	O
to	O
detect	O
low	O
-	O
level	O
mosaicism	O
by	O
MPS	O
,	O
medium	O
-	O
level	O
mosaicism	O
(	O
5	O
%	O
or	O
high	O
)	O
could	O
be	O
identified	O
in	O
all	O
base	O
positions	O
in	O
the	O
target	O
region	O
with	O
the	O
same	O
significance	O
level	O
.	O

After	O
12	O
hours	O
,	O
cells	O
were	O
transiently	O
transfected	O
with	O
,	O
either	O
the	O
pcDNA3	O
.	O
1	O
-	O
wild	O
type	O
(	O
wt	O
)	O
RPGRIP1	B-GENE
minigene	O
,	O
the	O
pcDNA3	O
.	O
1	O
-	O
mut	O
RPGRIP1	B-GENE
minigene	O
(	O
containing	O
the	O
c	B-VARIANT
.	I-VARIANT
2367	I-VARIANT
+	I-VARIANT
23del	I-VARIANT
mutation	O
)	O
,	O
or	O
the	O
empty	O
vector	O
(	O
Clontech	O
-	O
BD	O
)	O
,	O
using	O
Lipofectamine	O
2000	O
(	O
Invitrogen	O
)	O
.	O

Mie	O
Mochizuki	O
in	O
the	O
Division	O
of	O
Pediatrics	O
at	O
Kofu	O
municipal	O
hospital	O
and	O
Dr	O
.	O

Mutation	O
screening	O
was	O
performed	O
by	O
direct	O
sequencing	O
of	O
the	O
coding	O
regions	O
of	O
the	O
TJP2	B-GENE
(	O
OMIM	O
607709	O
;	O
NM	O
004817	O
.	O
3	O
;	O
NP	O
004808	O
.	O
2	O
)	O
and	O
CLDN14	B-GENE
(	O
OMIM	O
605608	O
;	O
NM	O
144492	O
.	O
2	O
;	O
NP	O
652763	O
.	O
1	O
)	O
genes	O
.	O

Moreover	O
,	O
15	O
variants	O
encoding	O
polymorphic	O
changes	O
were	O
identified	O
,	O
including	O
4	O
missense	O
variants	O
,	O
namely	O
,	O
c	B-VARIANT
.	I-VARIANT
157G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
A53T	I-VARIANT
)	O
,	O
c	B-VARIANT
.	I-VARIANT
158C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
A53V	I-VARIANT
)	O
,	O
c	B-VARIANT
.	I-VARIANT
244C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
R82C	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
4936C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
P1646S	I-VARIANT
)	O
;	O
all	O
of	O
which	O
have	O
been	O
reported	O
previously	O
[	O
21	O
]	O
(	O
Table	O
S3	O
in	O
supplementary	O
document	O
)	O
.	O

The	O
gene	O
is	O
involved	O
in	O
otic	O
development	O
and	O
hearing	O
in	O
animals	O
,	O
and	O
GRHL2	B-GENE
mutations	O
are	O
correlated	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
humans	O
[	O
16	O
]	O
.	O

We	O
thank	O
Dr	O
.	O

References	O
for	O
Table	O
1	O
and	O
Table	O
S2	O
.	O

2	O
This	O
approach	O
not	O
only	O
provides	O
diagnoses	O
based	O
on	O
mutations	O
found	O
in	O
already	O
known	O
genes	O
but	O
also	O
can	O
provide	O
pointers	O
toward	O
novel	O
disease	O
genes	O
,	O
such	O
as	O
the	O
identification	O
of	O
NGLY1	B-GENE
in	O
our	O
previous	O
work	O
,	O
2	O
which	O
was	O
subsequently	O
confirmed	O
in	O
seven	O
additional	O
rare	O
cases	O
with	O
similar	O
clinical	O
presentations	O
.	O

Excluding	O
variants	O
having	O
alternative	O
allele	O
frequencies	O
>	O
0	O
.	O
01	O
in	O
any	O
one	O
of	O
the	O
populations	O
in	O
dbSNP	O
and	O
1000	O
genomes	O
.	O

Dentinogenesis	B-DISEASE
imperfecta	I-DISEASE
(	I-DISEASE
DGI	I-DISEASE
)	I-DISEASE
type	I-DISEASE
II	I-DISEASE
is	O
an	O
autosomal	O
dominant	O
disease	O
characterized	O
by	O
a	O
serious	B-DISEASE
disorders	I-DISEASE
in	I-DISEASE
teeth	I-DISEASE
.	O

These	O
findings	O
have	O
implications	O
for	O
other	O
hormone	O
-	O
secreting	O
tumors	O
and	O
endocrinopathies	O
in	O
which	O
hormone	O
secretion	O
is	O
regulated	O
by	O
Ca	O
2	O
+	O
.	O

The	O
patient	O
,	O
a	O
girl	O
aged	O
6	O
years	O
and	O
8	O
months	O
,	O
was	O
examined	O
in	O
the	O
child	O
psychiatry	O
clinic	O
of	O
the	O
Seoul	O
National	O
University	O
Bundang	O
Hospital	O
.	O

Among	O
32	O
familial	O
NSHL	B-DISEASE
cases	O
,	O
we	O
could	O
detect	O
mutations	O
in	O
25	O
probands	O
(	O
79	O
.	O
1	O
%	O
)	O
by	O
Sanger	O
and	O
targeted	O
exome	O
sequencing	O
in	O
total	O
.	O

The	O
observation	O
that	O
the	O
boy	O
'	O
s	O
audiological	O
evaluation	O
correlated	O
with	O
his	O
body	O
temperature	O
(	O
over	O
a	O
15	O
-	O
day	O
period	O
in	O
our	O
hospital	O
when	O
he	O
was	O
four	O
years	O
old	O
)	O
led	O
to	O
his	O
diagnosis	O
of	O
temperature	O
-	O
sensitive	O
AN	B-DISEASE
.	O

When	O
we	O
compared	O
two	O
Pakistani	O
families	O
,	O
each	O
containing	O
different	O
MARVELD2	B-GENE
mutations	O
,	O
we	O
only	O
found	O
9	O
shared	O
SNP	O
markers	O
(	O
Fig	O
1	O
)	O
.	O

The	O
remaining	O
variants	O
were	O
further	O
processed	O
according	O
to	O
the	O
dbSNP	O
database	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
dental	B-DISEASE
anomalies	I-DISEASE
have	O
not	O
been	O
reported	O
as	O
being	O
associated	O
with	O
WS	B-DISEASE
and	O
it	O
is	O
unknown	O
to	O
us	O
if	O
dental	B-DISEASE
anomalies	I-DISEASE
in	O
this	O
family	O
were	O
related	O
to	O
the	O
specific	O
WFS1	B-GENE
compound	O
mutation	O
.	O

After	O
addition	O
of	O
FCCP	O
,	O
rotenone	O
and	O
antimycin	O
A	O
are	O
added	O
to	O
inhibit	O
complexes	O
I	O
and	O
III	O
,	O
which	O
then	O
stop	O
all	O
mitochondrial	O
respiration	O
.	O

For	O
cases	O
with	O
a	O
defined	O
initial	O
diagnostic	O
hypothesis	O
,	O
but	O
for	O
whom	O
no	O
mutation	O
was	O
found	O
in	O
the	O
expected	O
gene	O
,	O
coverage	O
was	O
high	O
.	O

We	O
aligned	O
reads	O
to	O
the	O
human	O
reference	O
genome	O
(	O
hg19	O
)	O
with	O
the	O
Burrows	O
-	O
Wheeler	O
Aligner	O
(	O
BWA	O
)	O
42	O
and	O
removed	O
potential	O
duplicate	O
paired	O
-	O
end	O
reads	O
.	O

54	O
Therefore	O
,	O
8	O
.	O
5	O
%	O
of	O
the	O
founder	O
mutation	O
-	O
carrying	O
families	O
had	O
members	O
that	O
were	O
double	O
heterozygotes	O
.	O

Gel	O
electrophoresis	O
shows	O
the	O
different	O
splicing	O
processes	O
for	O
WT	O
minigene	O
and	O
mutants	O
constructions	O
.	O

Nucleotide	O
alterations	O
were	O
identified	O
by	O
sequence	O
alignment	O
with	O
the	O
MYO7A	B-GENE
GenBank	O
sequence	O
using	O
the	O
GeneTools	O
software	O
.	O

Pedigree	O
with	O
autosomal	O
recessive	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
showing	O
cosegregation	O
of	O
the	O
compound	O
heterozygous	O
changes	O
,	O
c	B-VARIANT
.	I-VARIANT
4325	I-VARIANT
T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
15188	I-VARIANT
T	I-VARIANT
>	I-VARIANT
G	I-VARIANT
within	O
the	O
USH2A	B-GENE
gene	O
in	O
all	O
affected	O
members	O
.	O

A	O
-	O
E	O
)	O
.	O

Hence	O
,	O
the	O
mutation	O
G60D	B-VARIANT
in	O
this	O
close	O
proximity	O
could	O
be	O
speculated	O
to	O
compromise	O
the	O
function	O
of	O
this	O
critical	O
amino	O
acid	O
and	O
thereby	O
speed	O
up	O
activation	O
[	O
30	O
-	O
33	O
]	O
.	O

troglodytes	O
)	O
,	O
XP_002689695	O
.	O
1	O
(	O
B	O
.	O

DNA	O
samples	O
of	O
40	O
unrelated	O
Canadian	O
USH	B-DISEASE
patients	O
without	O
previously	O
known	O
mutations	O
and	O
19	O
USH	B-DISEASE
patients	O
diagnosed	O
in	O
Finland	O
after	O
2001	O
were	O
sequenced	O
for	O
CLRN1	B-GENE
mutation	O
identification	O
.	O

In	O
conclusion	O
,	O
our	O
findings	O
showed	O
that	O
genetically	O
identified	O
ADOA	B-DISEASE
patients	O
without	O
any	O
sign	O
of	O
inflammation	O
can	O
have	O
MME	B-DISEASE
in	O
the	O
INL	O
of	O
the	O
retina	O
.	O

Waardenburg	O
index	O
was	O
0	O
.	O
4059	O
,	O
thus	O
ruling	O
out	O
dystopia	B-DISEASE
canthorum	I-DISEASE
.	O

The	O
GJB2	B-GENE
and	O
SLC26A4	B-GENE
genes	O
are	O
frequently	O
implicated	O
in	O
ARNSHL	B-DISEASE
,	O
and	O
screening	O
for	O
these	O
genes	O
is	O
relatively	O
easy	O
.	O

27	O
Fibrochondrogenesis	B-DISEASE
was	O
first	O
characterised	O
molecularly	O
by	O
Tompson	O
et	O
al	O
,	O
19	O
who	O
found	O
heterozygous	O
null	O
alleles	O
inherited	O
along	O
with	O
a	O
substitution	O
of	O
an	O
obligate	O
glycine	O
on	O
the	O
second	O
allele	O
.	O

No	O
potential	O
conflict	O
of	O
interest	O
relevant	O
to	O
this	O
article	O
was	O
reported	O
.	O

The	O
wild	O
type	O
linker	O
in	O
ZNF57	B-GENE
(	O
has	O
the	O
sequence	O
TQEQL	O
)	O
and	O
the	O
canonical	O
zinc	O
finger	O
linker	O
sequence	O
is	O
TGEKP	O
.	O

For	O
disorders	O
hypothesized	O
to	O
result	O
from	O
de	O
novo	O
mutations	O
,	O
a	O
potentially	O
more	O
powerful	O
alternative	O
approach	O
involves	O
exome	O
sequencing	O
in	O
parent	O
-	O
child	O
trios	O
,	O
which	O
should	O
rapidly	O
narrow	O
the	O
number	O
of	O
candidate	O
mutations	O
to	O
a	O
handful	O
in	O
view	O
of	O
the	O
rarity	O
of	O
de	O
novo	O
events	O
in	O
protein	O
coding	O
sequences	O
11	O
,	O
12	O
.	O

Decision	O
tree	O
for	O
prioritizing	O
candidate	O
genes	O
into	O
three	O
categories	O
.	O

10	O
-	O
12	O
However	O
,	O
a	O
well	O
-	O
known	O
caveat	O
of	O
MPS	O
is	O
the	O
high	O
rate	O
of	O
sequencing	O
errors	O
,	O
which	O
cannot	O
be	O
disregarded	O
when	O
identifying	O
low	O
-	O
level	O
somatic	O
mosaicism	O
.	O

It	O
is	O
possible	O
that	O
some	O
of	O
these	O
could	O
be	O
neutral	O
or	O
beneficial	O
or	O
deleterious	O
mutations	O
.	O

Of	O
36	O
cases	O
with	O
a	O
specific	O
clinical	O
hypothesis	O
with	O
a	O
known	O
genetic	O
basis	O
,	O
mutations	O
were	O
identified	O
for	O
eight	O
cases	O
(	O
22	O
%	O
)	O
.	O

b	O
At	O
17	O
years	O
of	O
age	O
,	O
no	O
high	O
-	O
intensity	O
lesions	O
were	O
found	O
in	O
the	O
middle	O
cerebellar	O
peduncle	O
of	O
patient	O
II	O
-	O
2	O
.	O

Missense	O
and	O
silent	O
changes	O
of	O
the	O
last	O
nucleotide	O
of	O
the	O
exon	O
that	O
are	O
likely	O
to	O
affect	O
splicing	O
were	O
also	O
described	O
as	O
'	O
UV3	O
'	O
if	O
they	O
were	O
found	O
in	O
the	O
same	O
gene	O
as	O
another	O
'	O
pathogenic	O
'	O
or	O
'	O
UV4	O
'	O
variant	O
.	O

Recently	O
,	O
the	O
advent	O
of	O
next	O
generation	O
sequencing	O
(	O
NGS	O
)	O
technologies	O
has	O
markedly	O
influenced	O
our	O
strategy	O
regarding	O
the	O
genetic	O
diagnosis	O
of	O
deafness	B-DISEASE
.	O

The	O
proband	O
'	O
s	O
parents	O
were	O
silent	O
single	O
-	O
gene	O
mutation	O
carriers	O
and	O
both	O
only	O
presented	O
with	O
markedly	O
prolonged	O
QT	O
intervals	O
.	O

14	O
novel	O
sequence	O
variations	O
were	O
discovered	O
.	O

Protein	O
structures	O
were	O
displayed	O
with	O
Jmol	O
[	O
27	O
]	O
.	O

These	O
effects	O
should	O
impact	O
cell	O
morphology	O
,	O
motility	O
,	O
and	O
other	O
actin	O
-	O
related	O
functions	O
.	O

We	O
diluted	O
the	O
polymerase	O
20	O
-	O
fold	O
using	O
1	O
x	O
LA	O
buffer	O
.	O

The	O
scale	O
bar	O
represents	O
50	O
u	O
m	O
.	O

For	O
example	O
,	O
F1	O
has	O
more	O
than	O
eight	O
separate	O
abnormalities	O
of	O
skeletal	O
morphology	O
.	O

This	O
carrier	O
rate	O
is	O
similar	O
to	O
the	O
one	O
observed	O
by	O
Green	O
et	O
al	O
.	O

Of	O
24	O
selected	O
splice	O
-	O
site	O
mutations	O
,	O
after	O
Sanger	O
sequencing	O
,	O
22	O
were	O
not	O
identified	O
but	O
2	O
actual	O
splice	O
-	O
site	O
mutations	O
in	O
3	O
families	O
were	O
successfully	O
identified	O
in	O
KCNQ1	B-GENE
and	O
SLC26A4	B-GENE
(	O
Table	O
S2	O
,	O
Fig	O
.	O

Quantitative	O
PCR	O
assessing	O
the	O
relative	O
quantity	O
of	O
mRNA	O
from	O
zebrafish	O
embryos	O
injected	O
with	O
WT	O
HOMER2	B-GENE
(	O
wtRNA	O
)	O
or	O
HOMER2	B-GENE
P185	O
-	O
mutant	O
RNA	O
(	O
P185RNA	O
)	O
demonstrates	O
overexpression	O
of	O
both	O
injected	O
mRNAs	O
.	O

This	O
novel	O
mutation	O
is	O
expected	O
to	O
lead	O
to	O
a	O
frameshift	O
and	O
premature	O
termination	O
of	O
translation	O
after	O
insertion	O
of	O
63	O
irrelevant	O
amino	O
acids	O
,	O
starting	O
at	O
position	O
383	O
of	O
the	O
myosin	O
VIIA	O
protein	O
(	O
p	B-VARIANT
.	I-VARIANT
S383W	I-VARIANT
fs	I-VARIANT
X63	I-VARIANT
)	O
.	O

The	O
replacement	O
of	O
Gly	O
by	O
Arg	O
may	O
induce	O
a	O
new	O
secondary	O
structure	O
that	O
includes	O
Leu1831	O
,	O
Val1832	O
,	O
and	O
Val1833	O
.	O

The	O
plots	O
are	O
the	O
average	O
of	O
the	O
fraction	O
of	O
covered	O
bases	O
(	O
Y	O
-	O
axis	O
)	O
and	O
the	O
read	O
depth	O
(	O
X	O
-	O
axis	O
)	O
in	O
the	O
20	O
families	O
included	O
in	O
the	O
study	O
.	O

C	O
,	O
D	O
OSBPL2	B-GENE
(	O
green	O
)	O
is	O
also	O
expressed	O
in	O
stereocilia	O
of	O
cochlear	O
inner	O
hair	O
cells	O
(	O
IHC	O
)	O
as	O
demonstrated	O
by	O
co	O
-	O
immunostaining	O
with	O
anti	O
-	O
otoferlin	O
antibody	O
(	O
red	O
)	O
.	O

Genetic	O
analysis	O
demonstrates	O
co	O
-	O
segregation	O
of	O
an	O
USH1C	B-GENE
-	O
linked	O
haplotype	O
and	O
mutation	O
(	O
c	B-VARIANT
.	I-VARIANT
497	I-VARIANT
-	I-VARIANT
2delA	I-VARIANT
)	O
with	O
USH1	B-DISEASE
.	O

Before	O
that	O
,	O
as	O
to	O
the	O
function	O
of	O
DSPP	B-GENE
mutations	O
,	O
only	O
a	O
skip	O
of	O
exon	O
3	O
was	O
noticed	O
by	O
in	O
vitro	O
splicing	O
analysis	O
in	O
another	O
DSPP	B-GENE
mutation	O
[	O
1	O
]	O
.	O

None	O
of	O
the	O
patients	O
with	O
SLC26A4	B-GENE
mutations	O
or	O
variants	O
showed	O
the	O
presence	O
of	O
goiter	O
.	O

This	O
finding	O
further	O
demonstrates	O
the	O
unique	O
genetic	O
structure	O
of	O
the	O
Israeli	O
population	O
in	O
general	O
,	O
and	O
the	O
Israeli	O
Arab	O
population	O
in	O
particular	O
,	O
which	O
due	O
to	O
high	O
rates	O
of	O
consanguinity	O
segregates	O
many	O
rare	O
autosomal	O
recessive	O
genetic	O
conditions	O
[	O
6	O
]	O
.	O

Depending	O
upon	O
the	O
proteolytic	O
activity	O
of	O
the	O
mutant	O
TMPRSS3	B-GENE
protein	O
[	O
17	O
,	O
30	O
]	O
,	O
two	O
discrete	O
types	O
of	O
phenotypes	O
can	O
manifest	O
.	O

OPA7	B-DISEASE
(	O
OMIM	O
612989	O
)	O
is	O
caused	O
by	O
mutations	O
in	O
TMEM126A	B-GENE
(	O
OMIM	O
612988	O
)	O
.	O

Bone	O
conduction	O
thresholds	O
were	O
determined	O
at	O
0	O
.	O
5	O
,	O
1	O
,	O
2	O
and	O
4	O
kHz	O
in	O
some	O
patient	O
to	O
exclude	O
conductive	O
hearing	O
impairment	O
.	O

Amplification	O
was	O
conducted	O
for	O
the	O
coding	O
regions	O
and	O
flanking	O
intronic	O
sequences	O
of	O
ATP6V0A4	B-GENE
using	O
a	O
set	O
of	O
newly	O
designed	O
primers	O
pairs	O
.	O

In	O
detail	O
,	O
we	O
counted	O
the	O
number	O
of	O
COX	O
-	O
positive	O
and	O
COX	O
-	O
negative	O
/	O
deficient	O
fibres	O
in	O
at	O
least	O
20	O
different	O
fields	O
of	O
about	O
100	O
fibres	O
each	O
for	O
every	O
patient	O
.	O

Based	O
on	O
the	O
pedigree	O
analysis	O
,	O
it	O
is	O
evident	O
that	O
III	O
-	O
1	O
and	O
III	O
-	O
2	O
are	O
third	O
cousins	O
and	O
that	O
the	O
FGFR2	B-GENE
mutation	O
present	O
in	O
these	O
two	O
branches	O
is	O
identical	O
by	O
descent	O
(	O
Figure	O
1	O
C	O
)	O
.	O

Therefore	O
,	O
the	O
HUGO	O
nomenclature	O
committee	O
assigned	O
the	O
designation	O
DFNB94	B-DISEASE
to	O
the	O
locus	O
defined	O
by	O
the	O
PKDF406	O
family	O
.	O

In	O
the	O
DF7	O
patients	O
,	O
a	O
missense	O
mutation	O
,	O
c	B-VARIANT
.	I-VARIANT
5417T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
L1806P	I-VARIANT
)	O
,	O
was	O
identified	O
in	O
exon	O
22	O
of	O
MYO15A	B-GENE
(	O
NM_016239	O
)	O
.	O

13	O
,	O
14	O
To	O
date	O
,	O
most	O
of	O
the	O
known	O
mutations	O
of	O
claudin	O
14	O
are	O
within	O
or	O
close	O
to	O
the	O
second	O
or	O
third	O
transmembrane	O
domains	O
(	O
Figure	O
1a	O
)	O
and	O
some	O
of	O
them	O
have	O
been	O
shown	O
to	O
affect	O
membrane	O
localization	O
.	O

Jaijo	O
et	O
al	O
.	O

In	O
this	O
study	O
,	O
we	O
performed	O
whole	O
-	O
exome	O
sequencing	O
(	O
WES	O
)	O
,	O
podocyte	O
-	O
exome	O
sequencing	O
(	O
PES	O
)	O
or	O
direct	O
sequencing	O
on	O
70	O
families	O
with	O
a	O
diagnosis	O
of	O
familial	O
FSGS	B-DISEASE
.	O

However	O
,	O
the	O
phenotype	O
of	O
the	O
heterozygous	O
c	B-VARIANT
.	I-VARIANT
5945C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
mutation	O
identified	O
in	O
this	O
study	O
,	O
is	O
more	O
similar	O
to	O
the	O
phenotype	O
of	O
a	O
homozygous	O
inactivating	O
c	B-VARIANT
.	I-VARIANT
6203	I-VARIANT
-	I-VARIANT
6218del	I-VARIANT
mutation	O
identified	O
in	O
an	O
Iranian	O
DFNB21	B-GENE
family	O
[	O
12	O
]	O
.	O

This	O
signifies	O
the	O
potential	O
role	O
of	O
the	O
UPR	O
cascade	O
in	O
modulating	O
the	O
final	O
phenotype	O
in	O
patients	O
with	O
collagen	O
IV	O
nephropathies	O
.	O

Polyphen	O
-	O
2	O
(	O
http	O
:	O
/	O
/	O
genetics	O
.	O
bwh	O
.	O
harvard	O
.	O
edu	O
/	O
pph2	O
/	O
)	O
;	O
SIFT	O
(	O
http	O
:	O
/	O
/	O
sift	O
.	O
jcvi	O
.	O
org	O
)	O
;	O
HGVB	O
=	O
Human	O
Genetic	O
Variation	O
Browser	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
genome	O
.	O
med	O
.	O
kyoto	O
-	O
u	O
.	O
ac	O
.	O
jp	O
/	O
SnpDB	O
/	O
about	O
.	O
html	O
)	O
;	O
Frequency	O
*	O
show	O
the	O
number	O
of	O
mutations	O
or	O
variants	O
found	O
in	O
1150	O
alleles	O
of	O
575	O
controls	O
.	O

OPA1	B-GENE
was	O
detected	O
using	O
a	O
mouse	O
anti	O
-	O
OPA1	B-GENE
monoclonal	O
antibody	O
(	O
Santa	O
Cruz	O
,	O
cat	O
No	O
.	O
SC323936	O
)	O
followed	O
by	O
anti	O
-	O
mouse	O
IgG	O
,	O
coupled	O
to	O
IRDye	O
800CW	O
(	O
Licor	O
Biosciences	O
,	O
cat	O
No	O
.	O

The	O
severity	O
of	O
HL	B-DISEASE
for	O
all	O
patients	O
has	O
been	O
shown	O
in	O
Table	O
2	O
.	O

Indeed	O
,	O
since	O
the	O
development	O
of	O
this	O
gene	O
panel	O
several	O
new	O
causative	O
genes	O
for	O
skeletal	B-DISEASE
disorders	I-DISEASE
have	O
been	O
characterized	O
,	O
so	O
the	O
panel	O
will	O
need	O
to	O
be	O
continuously	O
updated	O
to	O
keep	O
pace	O
with	O
new	O
developments	O
.	O

Mutations	O
in	O
the	O
GJB2	B-GENE
gene	O
,	O
encoding	O
the	O
connexin	O
26	O
gap	O
-	O
junction	O
protein	O
,	O
account	O
for	O
a	O
significant	O
proportion	O
of	O
NSHL	O
[	O
2	O
]	O
.	O

The	O
dashed	O
line	O
and	O
red	O
arrows	O
indicate	O
lower	O
coverage	O
for	O
heterozygously	O
deleted	O
regions	O
compared	O
to	O
one	O
control	O
sample	O
.	O

Based	O
on	O
the	O
recessive	O
mode	O
of	O
inheritance	O
evident	O
in	O
the	O
pedigree	O
,	O
we	O
analyzed	O
genes	O
with	O
homozygous	O
changes	O
and	O
potential	O
compound	O
heterozygous	O
changes	O
.	O

We	O
aimed	O
at	O
determining	O
the	O
relationship	O
between	O
genotype	O
and	O
phenotype	O
by	O
dividing	O
patients	O
into	O
three	O
groups	O
according	O
to	O
the	O
predicted	O
consequences	O
of	O
their	O
mutations	O
on	O
wolframin	B-GENE
function	O
and	O
assuming	O
translation	O
of	O
mutated	O
WSF1	B-GENE
transcripts	O
,	O
as	O
previously	O
shown	O
(	O
25	O
)	O
.	O

Six	O
patients	O
(	O
19	O
to	O
24	O
)	O
carry	O
one	O
SLC26A4	B-GENE
mutant	O
allele	O
,	O
and	O
two	O
patients	O
(	O
18	O
and	O
25	O
)	O
carry	O
a	O
novel	O
unclassified	O
missense	O
variant	O
,	O
I491T	B-VARIANT
and	O
L597S	B-VARIANT
,	O
respectively	O
,	O
that	O
are	O
likely	O
pathogenic	O
due	O
to	O
their	O
evolutionary	O
conservation	O
and	O
conserved	O
amino	O
acid	O
change	O
.	O

Moreover	O
,	O
we	O
hypothesized	O
that	O
the	O
p	B-VARIANT
.	I-VARIANT
A112T	I-VARIANT
variation	O
may	O
affect	O
binding	O
affinity	O
of	O
ZO2	B-GENE
protein	O
because	O
of	O
its	O
position	O
in	O
the	O
first	O
PDZ	O
domain	O
,	O
which	O
is	O
an	O
essential	O
protein	O
-	O
binding	O
domain	O
.	O

The	O
causative	O
genes	O
underlying	O
the	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
the	O
3	O
other	O
families	O
are	O
still	O
awaiting	O
discovery	O
.	O

The	O
proband	O
III	O
-	O
1	O
of	O
KNUF46	O
who	O
shows	O
low	O
-	O
to	O
-	O
mid	O
frequency	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
carries	O
a	O
missense	O
mutation	O
(	O
p	B-VARIANT
.	I-VARIANT
P678S	I-VARIANT
)	O
in	O
DIAPH1	B-GENE
gene	O
which	O
causes	O
low	O
frequency	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

We	O
identified	O
a	O
Korean	O
family	O
with	O
six	O
members	O
affected	O
by	O
NSHL	B-DISEASE
and	O
seven	O
unaffected	O
members	O
(	O
Figure	O
1	O
A	O
)	O
.	O

We	O
could	O
detect	O
not	O
only	O
point	O
mutations	O
but	O
also	O
CNVs	O
.	O

A	O
total	O
of	O
126	O
patients	O
(	O
53	O
with	O
arRP	B-DISEASE
,	O
14	O
with	O
adRP	B-DISEASE
,	O
3	O
with	O
X	O
-	O
RP	B-DISEASE
and	O
56	O
with	O
LCA	B-DISEASE
)	O
were	O
included	O
in	O
this	O
study	O
.	O

Consanguineous	O
families	O
:	O
*	O
parents	O
first	O
cousins	O
*	O
*	O
parents	O
second	O
cousins	O
.	O

The	O
massive	O
amounts	O
of	O
data	O
generated	O
by	O
NGS	O
represent	O
both	O
a	O
challenge	O
for	O
analysis	O
and	O
a	O
powerful	O
tool	O
to	O
define	O
sequence	O
variations	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
JGV	O
DLB	O
JNM	O
RKI	O
JEN	O
.	O

Their	O
glycoform	O
patterns	O
were	O
,	O
however	O
,	O
different	O
from	O
that	O
of	O
the	O
WT	O
,	O
probably	O
reflecting	O
their	O
retention	O
in	O
the	O
ER	O
.	O

Follow	O
up	O
MRI	O
showed	O
multiple	O
areas	O
of	O
hyperintensive	O
T2	O
-	O
weighted	O
and	O
Fluid	O
-	O
attenuated	O
inversion	O
recovery	O
(	O
FLAIR	O
)	O
signal	O
within	O
periventricular	O
white	O
matter	O
and	O
posterior	O
corona	O
radiata	O
with	O
extension	O
into	O
the	O
posterior	O
limbs	O
of	O
the	O
internal	O
capsule	O
.	O
There	O
was	O
also	O
a	O
hyperintensive	O
signal	O
in	O
the	O
thalami	O
and	O
dentate	O
nuclei	O
.	O

5	O
Identification	O
of	O
the	O
pathogenic	O
mutations	O
underlying	O
ADNSHL	B-DISEASE
is	O
still	O
difficult	O
because	O
of	O
the	O
incredible	O
genetic	O
heterogeneity	O
regarding	O
HL	B-DISEASE
,	O
and	O
likelihood	O
that	O
ADNSHL	B-DISEASE
is	O
not	O
entirely	O
caused	O
by	O
monogenic	O
mutations	O
(	O
also	O
known	O
as	O
Mendelian	O
disorder	O
)	O
.	O

A	O
list	O
of	O
these	O
mutations	O
is	O
highlighted	O
in	O
Table	O
4	O
and	O
the	O
sequence	O
chromatograms	O
of	O
each	O
candidate	O
variant	O
highlighted	O
in	O
Figure	O
S1	O
in	O
File	O
S1	O
.	O

Later	O
Akawi	O
et	O
al	O
20	O
characterised	O
two	O
families	O
who	O
both	O
had	O
biallelic	O
null	O
mutations	O
.	O

3	O
)	O
.	O

Louis	O
,	O
United	O
States	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
manual	O
.	O

The	O
major	O
disadvantage	O
of	O
aCGH	O
arrays	O
is	O
its	O
poor	O
resolution	O
of	O
CNVs	O
,	O
which	O
is	O
generally	O
much	O
larger	O
than	O
the	O
size	O
of	O
a	O
single	O
exon	O
as	O
achieved	O
in	O
this	O
work	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
identify	O
the	O
involved	O
region	O
inside	O
/	O
outside	O
of	O
the	O
cochlea	O
by	O
identifying	O
the	O
responsible	O
gene	O
.	O

To	O
investigate	O
the	O
cause	O
of	O
the	O
audiogenic	B-DISEASE
seizure	I-DISEASE
susceptibility	O
and	O
resistance	O
,	O
we	O
correlated	O
various	O
ABR	O
output	O
parameters	O
with	O
seizure	B-DISEASE
progression	O
.	O

Table	O
3	O
shows	O
the	O
distribution	O
of	O
these	O
polymorphisms	O
in	O
relation	O
to	O
the	O
most	O
common	O
PEX1	B-GENE
mutation	O
,	O
p	B-VARIANT
.	I-VARIANT
Gly843Asp	I-VARIANT
.	O

Since	O
the	O
majority	O
of	O
subjects	O
with	O
WFS	B-DISEASE
have	O
diabetes	B-DISEASE
mellitus	I-DISEASE
at	O
the	O
time	O
that	O
WFS	B-DISEASE
is	O
diagnosed	O
,	O
these	O
other	O
sensory	O
and	O
neurological	O
manifestations	O
may	O
be	O
important	O
for	O
following	O
the	O
natural	O
history	O
of	O
WFS	B-DISEASE
and	O
testing	O
the	O
effect	O
of	O
potential	O
interventions	O
.	O

In	O
our	O
panel	O
,	O
the	O
LCA	B-DISEASE
pedigree	O
(	O
10RE	O
)	O
carried	O
a	O
novel	O
splicing	O
mutation	O
,	O
whereas	O
the	O
RP	B-DISEASE
pedigrees	O
(	O
12ORG	O
,	O
23NCE	O
,	O
25NCE	O
,	O
T5	O
)	O
were	O
all	O
associated	O
to	O
missense	O
variants	O
(	O
Table	O
1	O
)	O
.	O

We	O
appreciate	O
professor	O
Wolfgang	O
Zimmermann	O
and	O
his	O
lab	O
(	O
Tumor	O
Immunology	O
Laboratory	O
,	O
LIFE	O
Center	O
,	O
University	O
Hospital	O
of	O
Munich	O
,	O
Ludwig	O
-	O
Maximilians	O
-	O
University	O
Munich	O
,	O
Germany	O
)	O
for	O
providing	O
the	O
pRc	O
/	O
CMV	O
-	O
hCEACAM16	B-GENE
plasmid	O
.	O

The	O
variants	O
c	B-VARIANT
.	I-VARIANT
9811del	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Met3271Cysfs	I-VARIANT
*	I-VARIANT
30	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
1663C	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Leu555Val	I-VARIANT
)	O
were	O
the	O
most	O
common	O
allelic	O
variants	O
of	O
the	O
USH2A	B-GENE
gene	O
in	O
our	O
series	O
and	O
were	O
found	O
in	O
3	O
/	O
33	O
patients	O
(	O
9	O
.	O
1	O
%	O
)	O
and	O
then	O
in	O
3	O
/	O
66	O
(	O
4	O
.	O
5	O
%	O
)	O
alleles	O
.	O

While	O
the	O
affected	O
subject	O
(	O
II	O
-	O
5	O
of	O
KNUF24	O
)	O
was	O
homozygous	O
for	O
the	O
178	O
allele	O
at	O
D6S262	O
,	O
the	O
other	O
affected	O
subjects	O
(	O
II	O
-	O
5	O
and	O
III	O
-	O
2	O
of	O
HL	O
-	O
01	O
)	O
were	O
homozygous	O
for	O
the	O
176	O
allele	O
in	O
the	O
same	O
region	O
.	O

Second	O
,	O
this	O
variant	O
was	O
undetected	O
in	O
334	O
(	O
54	O
+	O
280	O
)	O
ethnically	O
matched	O
Korean	O
control	O
subjects	O
and	O
in	O
1	O
,	O
000	O
genomes	O
.	O

The	O
sequencing	O
data	O
were	O
then	O
compared	O
with	O
the	O
reference	O
sequence	O
using	O
the	O
Basic	O
Local	O
Alignment	O
Search	O
Tool	O
(	O
BLAST	O
)	O
on	O
the	O
National	O
Center	O
for	O
Biotechnology	O
Information	O
(	O
NCBI	O
)	O
website	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
)	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
MYO15A	B-GENE
mutations	O
in	O
an	O
East	O
Asian	O
population	O
.	O

All	O
mutations	O
were	O
confirmed	O
in	O
a	O
second	O
PCR	O
reaction	O
.	O

For	O
the	O
32	O
kHz	O
stimulus	O
tg	O
+	O
A	O
/	O
A	O
mice	O
had	O
thresholds	O
that	O
were	O
elevated	O
compared	O
with	O
tg	O
(	O
+	O
/	O
-	O
)	O
G	O
/	O
A	O
heterozygotes	O
(	O
71	O
+	O
-	O
9	O
dBSPL	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
although	O
these	O
thresholds	O
were	O
still	O
lower	O
than	O
those	O
of	O
tg	O
-	O
A	O
/	O
A	O
(	O
92	O
+	O
-	O
8	O
dBSPL	O
)	O
.	O

Additional	O
frequent	O
mutations	O
found	O
in	O
this	O
study	O
together	O
with	O
TaqMan	O
procedures	O
will	O
facilitate	O
genetic	O
testing	O
for	O
deafness	B-DISEASE
patients	O
.	O

Vestibular	O
function	O
was	O
normal	O
in	O
all	O
patients	O
from	O
all	O
four	O
families	O
.	O

In	O
contrast	O
,	O
more	O
than	O
648	O
USH2A	B-GENE
variants	O
have	O
been	O
detected	O
,	O
the	O
majority	O
are	O
also	O
single	O
-	O
base	O
variants	O
.	O

Until	O
methods	O
for	O
detecting	O
changes	O
within	O
homopolymers	O
are	O
improved	O
,	O
Sanger	O
sequencing	O
should	O
be	O
performed	O
systematically	O
for	O
patients	O
in	O
whom	O
one	O
pathogenic	O
variant	O
is	O
identified	O
by	O
NGS	O
.	O

In	O
Families	O
DUK6527	O
,	O
DUK6585	O
,	O
and	O
DUK6669	O
the	O
GBMs	O
were	O
thickened	O
and	O
wrinkled	O
.	O

10b	O
-	O
c	O
)	O
.	O

Case	O
1	O
had	O
intrauterine	O
growth	O
retardation	O
.	O

[	O
12	O
]	O
suggested	O
that	O
mutations	O
in	O
the	O
USH1	B-DISEASE
and	O
USH2	B-DISEASE
genes	O
could	O
be	O
responsible	O
for	O
the	O
lower	O
ciliary	O
beat	O
frequency	O
.	O

Hence	O
,	O
the	O
prime	O
biological	O
importance	O
of	O
the	O
editing	O
domain	O
of	O
LeuRS	B-GENE
might	O
consist	O
in	O
excluding	O
from	O
protein	O
synthesis	O
a	O
range	O
of	O
non	O
-	O
proteinogenic	O
amino	O
acids	O
(	O
including	O
norvaline	O
)	O
,	O
which	O
are	O
ubiquitous	O
in	O
many	O
cellular	O
metabolic	O
pathways	O
and	O
can	O
accumulate	O
in	O
stress	O
conditions	O
or	O
can	O
be	O
taken	O
up	O
in	O
the	O
diet	O
24	O
.	O

mulatta	O
)	O
,	O
XP_528322	O
.	O
2	O
(	O
P	O
.	O

,	O
2008	O
)	O
.	O

Ophthalmic	O
examination	O
of	O
the	O
two	O
"	O
healthy	O
carriers	O
"	O
demonstrated	O
mild	O
phenotype	O
of	O
optic	O
atrophy	O
:	O
mild	O
reduced	O
visual	O
acuity	O
,	O
attenuated	O
retinal	O
vessels	O
,	O
temporal	O
disc	O
pallor	O
,	O
and	O
thinning	O
RNFL	O
on	O
the	O
OCT	B-DISEASE
scan	O
(	O
Table	O
4	O
)	O
.	O

for	O
individual	O
II	O
:	O
4	O
,	O
4	O
y	O
.	O
o	O
.	O

The	O
sample	O
included	O
33	O
male	O
and	O
54	O
female	O
patients	O
,	O
with	O
an	O
average	O
age	O
of	O
40	O
.	O
439	O
ranging	O
from	O
3	O
months	O
to	O
73	O
years	O
.	O

(	O
D	O
)	O
Immunoblot	O
analysis	O
of	O
transfected	O
GFP	O
-	O
tagged	O
NARS2	B-GENE
constructs	O
.	O

5b	O
)	O
.	O

Studies	O
investigating	O
heterogeneous	O
sensorineural	O
disorders	O
such	O
as	O
intellectual	O
disability	O
and	O
macular	O
degeneration	O
have	O
uncovered	O
the	O
complex	O
variation	O
landscape	O
underlying	O
these	O
phenotypes	O
and	O
detected	O
an	O
accumulation	O
of	O
rare	O
deleterious	O
variants	O
in	O
probands	O
versus	O
controls	O
.	O

(	O
D	O
)	O
DNA	O
sequencing	O
chromatograms	O
showing	O
the	O
mutation	O
(	O
arrow	O
)	O
.	O

In	O
some	O
cases	O
,	O
we	O
could	O
observe	O
that	O
the	O
CNV	O
analysis	O
displayed	O
doubtful	O
results	O
in	O
the	O
targeted	O
regions	O
.	O

Wrote	O
the	O
paper	O
:	O
LC	O
EHMW	O
MMGB	O
.	O

(	O
The	O
variant	O
data	O
other	O
than	O
those	O
described	O
in	O
Supplemental	O
Tables	O
may	O
be	O
available	O
on	O
request	O
after	O
discussion	O
with	O
the	O
family	O
members	O
and	O
approval	O
by	O
our	O
IRBs	O
,	O
because	O
they	O
contain	O
a	O
huge	O
amount	O
of	O
individual	O
genetic	O
information	O
.	O
)	O
The	O
results	O
are	O
summarized	O
in	O
Table	O
S1	O
.	O

The	O
sporadic	O
case	O
from	O
family	O
USH03	O
was	O
found	O
to	O
carry	O
a	O
recurrent	O
homozygous	O
variants	O
in	O
MYO7A	B-GENE
,	O
c	B-VARIANT
.	I-VARIANT
494C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
[	O
34	O
]	O
,	O
which	O
would	O
lead	O
to	O
the	O
amino	O
acid	O
change	O
from	O
threonine	O
to	O
methionine	O
at	O
condon	O
165	O
(	O
p	B-VARIANT
.	I-VARIANT
Thr165Met	I-VARIANT
)	O
(	O
Figure	O
1H	O
)	O
.	O

Variants	O
were	O
filtered	O
if	O
they	O
either	O
could	O
not	O
be	O
mapped	O
uniquely	O
from	O
NCBI	O
build	O
36	O
to	O
GRCh37	O
,	O
were	O
protein	O
altering	O
in	O
a	O
rare	O
transcript	O
that	O
was	O
exclusive	O
to	O
either	O
the	O
NCBI	O
or	O
Ensembl	O
database	O
,	O
or	O
if	O
they	O
were	O
nonsynonymous	O
only	O
in	O
transcripts	O
that	O
lacked	O
a	O
valid	O
open	O
reading	O
frame	O
due	O
to	O
internal	O
frame	O
shifts	O
,	O
missing	O
start	O
codons	O
,	O
and	O
/	O
or	O
missing	O
stop	O
codons	O
.	O

The	O
ancestry	O
-	O
based	O
groupings	O
are	O
strengthened	O
by	O
using	O
genomic	O
data	O
for	O
clustering	O
rather	O
than	O
relying	O
on	O
self	O
-	O
reported	O
data	O
.	O

Genetic	O
analysis	O
for	O
WFS1	B-GENE
was	O
performed	O
by	O
direct	O
sequencing	O
.	O

Elijah	O
Behr	O
;	O
Dr	O
.	O

1	O
)	O
.	O

Further	O
analysis	O
of	O
535	O
missense	O
variants	O
from	O
cancer	O
genes	O
,	O
using	O
the	O
same	O
criteria	O
applied	O
for	O
truncations	O
,	O
identified	O
35	O
and	O
14	O
missense	O
events	O
in	O
COSMIC	O
and	O
OMIM	O
,	O
respectively	O
(	O
Supplementary	O
Data	O
11	O
)	O
.	O

who	O
detected	O
one	O
or	O
two	O
mutations	O
in	O
41	O
out	O
of	O
47	O
(	O
87	O
.	O
2	O
%	O
)	O
USH1	B-DISEASE
patients	O
[	O
12	O
]	O
.	O

The	O
results	O
identified	O
two	O
novel	O
compound	O
heterozygous	O
disease	O
-	O
segregating	O
mutations	O
,	O
c	B-VARIANT
.	I-VARIANT
IVS25	I-VARIANT
+	I-VARIANT
3G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
8375	I-VARIANT
T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
V2792A	I-VARIANT
)	O
,	O
in	O
the	O
MYO15A	B-GENE
gene	O
.	O

We	O
also	O
observed	O
decreased	O
mt	B-GENE
-	I-GENE
tRNA	I-GENE
Asn	I-GENE
levels	O
in	O
our	O
patient	O
fibroblasts	O
,	O
which	O
may	O
have	O
further	O
increased	O
severity	O
of	O
the	O
mitochondrial	B-DISEASE
dysfunction	I-DISEASE
,	O
particularly	O
in	O
CNS	O
tissue	O
.	O

For	O
the	O
three	O
USH2	B-DISEASE
families	O
(	O
F6	O
,	O
F7	O
,	O
and	O
F8	O
)	O
,	O
one	O
allele	O
carried	O
nonsense	O
mutations	O
,	O
c	B-VARIANT
.	I-VARIANT
1876C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
R626X	I-VARIANT
)	O
,	O
c	B-VARIANT
.	I-VARIANT
3788G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
W1263X	I-VARIANT
)	O
,	O
and	O
c	B-VARIANT
.	I-VARIANT
14403C	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT

beta	O
-	O
tubulin	O
was	O
used	O
as	O
a	O
loading	O
control	O
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
.	O

Central	O
causes	O
of	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
were	O
excluded	O
by	O
ASSR	O
testing	O
,	O
which	O
revealed	O
normal	O
function	O
of	O
the	O
auditory	O
nerve	O
.	O

All	O
affected	O
members	O
presented	O
prelingual	O
profound	O
HL	B-DISEASE
and	O
were	O
using	O
sign	O
language	O
to	O
communicate	O
.	O

The	O
arrow	O
indicates	O
the	O
proband	O
.	O

for	O
individual	O
II	O
:	O
4	O
,	O
16	O
y	O
.	O
o	O
.	O

After	O
applying	O
filtering	O
criteria	O
,	O
the	O
number	O
of	O
remaining	O
variants	O
(	O
in	O
parenthesis	O
)	O
were	O
as	O
follows	O
:	O
1	O
)	O
minor	O
variant	O
frequency	O
<	O
10	O
%	O
(	O
56	O
,	O
410	O
)	O
,	O
2	O
)	O
dbSNP135	O
with	O
minor	O
allele	O
frequency	O
(	O
MAF	O
)	O
<	O
1	O
%	O
(	O
23	O
,	O
491	O
)	O
,	O
3	O
)	O
non	O
-	O
synonymous	O
changes	O
and	O
splice	O
variants	O
(	O
7	O
,	O
252	O
)	O
,	O
4	O
)	O
variant	O
with	O
minor	O
variant	O
frequency	O
>	O
30	O
%	O
(	O
2	O
,	O
511	O
)	O
,	O
5	O
)	O
same	O
variant	O
presents	O
in	O
<	O
5	O
%	O
of	O
the	O
study	O
cohort	O
(	O
341	O
)	O
.	O

Therefore	O
,	O
we	O
compared	O
the	O
audiograms	O
among	O
the	O
three	O
affected	O
SB18	O
subjects	O
with	O
their	O
ages	O
being	O
roughly	O
three	O
decades	O
apart	O
.	O

The	O
hypoparathyroidism	B-DISEASE
is	O
characterized	O
by	O
symptomatic	O
or	O
asymptomatic	O
hypocalcemia	B-DISEASE
with	O
low	O
or	O
undetectable	O
serum	O
levels	O
of	O
parathyroid	O
hormone	O
(	O
PTH	O
)	O
.	O

The	O
severity	O
of	O
hearing	B-DISEASE
impairment	I-DISEASE
was	O
moderate	O
(	O
8	O
cases	O
)	O
to	O
severe	O
(	O
2	O
cases	O
)	O
and	O
progressed	O
slowly	O
with	O
increasing	O
patient	O
age	O
.	O

The	O
majority	O
of	O
off	O
-	O
target	O
sequences	O
reflected	O
sequences	O
adjacent	O
to	O
genes	O
in	O
the	O
ROI	O
and	O
homologous	O
genes	O
.	O

In	O
selected	O
patients	O
we	O
performed	O
ISCEV	O
standard	O
ERGs	O
and	O
multifocal	O
ERGs	O
(	O
Diagnosys	O
,	O
Boston	O
USA	O
)	O
.	O

This	O
is	O
in	O
agreement	O
with	O
the	O
low	O
transcript	O
levels	O
of	O
the	O
long	O
isoform	O
in	O
the	O
cochlea	O
[	O
14	O
]	O
.	O

Click	O
here	O
for	O
file	O
Supplemental	O
Figures	O
.	O

The	O
arginine	O
at	O
residue	O
702	O
is	O
also	O
a	O
conserved	O
amino	O
acid	O
,	O
as	O
previously	O
reported	O
for	O
other	O
two	O
mutations	O
hitting	O
the	O
same	O
residue	O
,	O
p	B-VARIANT
.	I-VARIANT
Arg702Cys	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
Arg702His	I-VARIANT
[	O
2	O
,	O
7	O
]	O
.	O

Assessment	O
of	O
her	O
medical	O
history	O
revealed	O
easy	O
bruising	B-DISEASE
,	O
menorrhagia	B-DISEASE
,	O
prolonged	B-DISEASE
bleeding	I-DISEASE
after	O
minor	O
wounds	O
,	O
and	O
occasional	B-DISEASE
epistaxis	I-DISEASE
.	O

Chromatograms	O
of	O
the	O
patients	O
with	O
MYO7A	B-GENE
,	O
GPR98	B-GENE
,	O
USH2A	B-GENE
and	O
CDH23	B-GENE
mutations	O
.	O

Interestingly	O
,	O
several	O
patients	O
with	O
a	O
single	O
GPR98	B-GENE
mutation	O
have	O
been	O
identified	O
in	O
other	O
studies	O
[	O
11	O
,	O
12	O
]	O
.	O

Therefore	O
,	O
it	O
could	O
be	O
possible	O
that	O
HH	B-DISEASE
patients	O
with	O
an	O
R262Q	B-VARIANT
mutation	O
in	O
GNRHR	B-GENE
are	O
especially	O
prone	O
to	O
reversal	O
of	O
HH	B-DISEASE
.	O

34	O
KCNQ1	B-GENE
:	O
p	B-VARIANT
.	I-VARIANT
T587M	I-VARIANT
was	O
found	O
to	O
result	O
in	O
haplo	O
-	O
insufficiency	O
as	O
a	O
consequence	O
of	O
being	O
transport	O
deficient	O
.	O

Alternatively	O
,	O
CHD7	B-GENE
is	O
one	O
of	O
the	O
key	O
genes	O
for	O
the	O
formation	O
of	O
cranial	O
neural	O
crest	O
[	O
38	O
]	O
,	O
which	O
has	O
been	O
suggested	O
to	O
be	O
the	O
source	O
of	O
~	O
30	O
%	O
of	O
GnRH	O
neurons	O
in	O
mice	O
[	O
39	O
]	O
.	O

As	O
shown	O
in	O
Figure	O
4C	O
,	O
for	O
homozygous	O
normal	O
individuals	O
II1	O
,	O
II3	O
,	O
and	O
II4	O
,	O
the	O
restrictive	O
digestion	O
by	O
BstXI	O
resulted	O
in	O
two	O
bands	O
of	O
282	O
bp	O
and	O
172	O
bp	O
.	O

S2	O
)	O
.	O

However	O
,	O
the	O
ultimate	O
effect	O
of	O
these	O
deletions	O
cannot	O
be	O
anticipated	O
yet	O
.	O

Dr	O
.	O

Thus	O
,	O
mutation	O
analysis	O
was	O
performed	O
for	O
all	O
coding	O
exons	O
and	O
exon	O
-	O
intron	O
boundaries	O
of	O
TMPRSS3	B-GENE
.	O

Fifty	O
-	O
three	O
different	O
mutations	O
were	O
detected	O
.	O

rerio	O
(	O
3	O
)	O
allele	O
is	O
present	O
in	O
the	O
Exome	O
Variant	O
Server	O
(	O
EVS	O
)	O
database	O
.	O

A	O
PCR	O
amplification	O
of	O
the	O
captured	O
target	O
libraries	O
was	O
performed	O
following	O
the	O
manufacturer	O
'	O
s	O
instructions	O
and	O
,	O
after	O
its	O
purification	O
with	O
the	O
"	O
AMPure	O
XP	O
beads	O
"	O
(	O
BECKMAN	O
CULTER	O
Inc	O
)	O
,	O
the	O
validation	O
and	O
quantification	O
of	O
the	O
enriched	O
target	O
DNA	O
in	O
each	O
library	O
was	O
performed	O
using	O
the	O
2100	O
Bioanalyzer	O
system	O
with	O
the	O
High	O
Sensitivity	O
DNA	O
Kit	O
and	O
the	O
2100	O
Expert	O
Software	O
(	O
Agilent	O
Technologies	O
Inc	O
,	O
CA	O
,	O
USA	O
)	O
.	O

For	O
endoglycosidase	O
digestions	O
,	O
sub	O
-	O
confluent	O
COS	O
-	O
1	O
cells	O
were	O
transiently	O
transfected	O
.	O

We	O
are	O
indebted	O
to	O
all	O
the	O
subjects	O
who	O
participated	O
in	O
the	O
study	O
.	O

List	O
of	O
the	O
participants	O
in	O
the	O
appendix	O
.	O

The	O
extracellular	O
solution	O
contained	O
(	O
in	O
mmol	O
/	O
L	O
)	O
140	O
NaCl	O
,	O
5	O
.	O
4	O
KCl	O
,	O
1	O
.	O
8	O
CaCl	O
2	O
,	O
0	O
.	O
5	O
MgCl	O
2	O
,	O
0	O
.	O
33	O
NaH	O
2	O
PO	O
4	O
,	O
5	O
.	O
5	O
glucose	O
,	O
and	O
5	O
.	O
0	O
HEPES	O
(	O
pH	O
adjusted	O
to	O
7	O
.	O
4	O
with	O
NaOH	O
)	O
.	O

Malfunction	O
of	O
pendrin	O
leads	O
to	O
Pendred	B-DISEASE
syndrome	I-DISEASE
(	O
PS	B-DISEASE
)	O
and	O
non	O
-	O
syndromic	O
DFNB4	O
deafness	B-DISEASE
with	O
EVA	B-DISEASE
[	O
6	O
]	O
.	O

Missense	O
changes	O
,	O
which	O
were	O
absent	O
from	O
the	O
Single	O
Nucleotide	O
Polymorphism	O
database	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
projects	O
/	O
SNP	O
/	O
)	O
and	O
from	O
at	O
least	O
100	O
controls	O
from	O
the	O
same	O
geographical	O
region	O
,	O
were	O
identified	O
as	O
possibly	O
pathogenic	O
mutations	O
,	O
and	O
characterized	O
further	O
by	O
functional	O
in	O
vitro	O
studies	O
.	O

Neither	O
abnormality	O
was	O
found	O
in	O
140	O
and	O
100	O
healty	O
chromosomes	O
,	O
respectively	O
,	O
indicating	O
that	O
they	O
were	O
not	O
common	O
polymorphisms	O
.	O

Recombination	O
events	O
delimited	O
the	O
ahl5	B-DISEASE
interval	O
to	O
a	O
2	O
.	O
19	O
Mbp	O
region	O
(	O
Fig	O
.	O

Of	O
the	O
60	O
unrelated	O
Altaian	O
patient	O
alleles	O
,	O
only	O
8	O
.	O
3	O
%	O
were	O
carrying	O
GJB2	B-GENE
mutations	O
with	O
the	O
235delC	B-VARIANT
representing	O
6	O
.	O
67	O
%	O
of	O
the	O
alleles	O
and	O
the	O
W172C	B-VARIANT
,	O
1	O
.	O
67	O
%	O
.	O

All	O
subjects	O
had	O
moderate	O
to	O
profound	O
bilateral	O
sensorineural	O
hearing	B-DISEASE
impairment	I-DISEASE
on	O
audiograms	O
.	O

We	O
report	O
the	O
genetic	O
analysis	O
of	O
autosomal	O
dominant	O
,	O
nonsyndromic	O
,	O
progressive	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
in	O
a	O
Chinese	O
family	O
.	O

The	O
high	O
-	O
to	O
-	O
low	O
frequency	O
progression	O
of	O
the	O
hearing	B-DISEASE
loss	I-DISEASE
suggested	O
a	O
histopathology	O
in	O
the	O
organ	O
of	O
Corti	O
.	O

Over	O
200	O
different	O
mutations	O
have	O
been	O
found	O
in	O
the	O
COL2A1	B-GENE
gene	O
;	O
the	O
most	O
common	O
type	O
is	O
the	O
substitution	O
of	O
the	O
triple	O
-	O
helical	O
glycine	O
residues	O
.	O

Eighteen	O
of	O
these	O
correspond	O
to	O
high	O
GC	O
content	O
(	O
>	O
60	O
%	O
)	O
.	O

5C	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
Arg257Stop	I-VARIANT
mutation	O
is	O
the	O
only	O
one	O
found	O
in	O
the	O
Spanish	O
arRP	B-DISEASE
population	O
to	O
date	O
.	O

The	O
third	O
proband	O
also	O
had	O
cup	B-DISEASE
-	I-DISEASE
shaped	I-DISEASE
ears	I-DISEASE
and	O
upper	O
body	O
muscular	B-DISEASE
atrophy	I-DISEASE
;	I-DISEASE
unfortunately	O
,	O
MRI	O
scan	O
was	O
not	O
available	O
.	O

A	O
.	O

In	O
addition	O
,	O
diagnostic	O
investigations	O
usually	O
include	O
MRI	O
,	O
and	O
may	O
include	O
lumbar	O
puncture	O
,	O
muscle	O
or	O
skin	O
biopsy	O
,	O
and	O
other	O
invasive	O
investigations	O
as	O
indicated	O
.	O

For	O
the	O
screening	O
of	O
mutations	O
in	O
patients	O
with	O
proteinuria	B-DISEASE
or	O
AS	B-DISEASE
multiplexed	O
targeted	O
exome	O
capture	O
and	O
NGS	O
was	O
done	O
on	O
a	O
set	O
of	O
19	O
genes	O
(	O
Supplemental	O
Table	O
S3	O
)	O
known	O
or	O
predicted	O
to	O
be	O
associated	O
with	O
AS	B-DISEASE
or	O
proteinuria	B-DISEASE
.	O

The	O
hearing	B-DISEASE
loss	I-DISEASE
range	O
was	O
described	O
as	O
follows	O
,	O
depending	O
on	O
the	O
pure	O
-	O
tone	O
audiometry	O
results	O
:	O
low	O
frequency	O
,	O
250	O
-	O
500	O
Hz	O
;	O
mid	O
frequency	O
,	O
1	O
-	O
2	O
kHz	O
;	O
and	O
high	O
frequency	O
,	O
4	O
-	O
8	O
kHz	O
[	O
34	O
]	O
.	O

We	O
began	O
to	O
address	O
this	O
need	O
by	O
characterizing	O
the	O
genetic	O
variation	O
in	O
cancer	O
-	O
susceptibility	O
genes	O
present	O
in	O
healthy	O
individuals	O
,	O
information	O
that	O
is	O
critical	O
for	O
interpreting	O
cancer	O
-	O
susceptibility	O
risk	O
from	O
personal	O
genome	O
sequences	O
[	O
62	O
]	O
.	O

In	O
our	O
cohort	O
of	O
patients	O
,	O
RDH12	B-GENE
accounted	O
for	O
3	O
.	O
4	O
%	O
(	O
3	O
out	O
of	O
86	O
)	O
of	O
the	O
families	O
.	O

Temporal	O
bone	O
computed	O
tomography	O
was	O
obtained	O
from	O
subjects	O
II	O
-	O
4	O
and	O
III	O
-	O
1	O
to	O
identify	O
any	O
inner	O
ear	O
anomalies	O
related	O
to	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
this	O
family	O
.	O

No	O
pigmentations	O
are	O
indicated	O
.	O

In	O
some	O
cases	O
,	O
the	O
disease	O
causing	O
nature	O
of	O
the	O
variant	O
will	O
not	O
be	O
convincing	O
and	O
additional	O
investigations	O
as	O
segregation	O
in	O
the	O
family	O
or	O
functional	O
analysis	O
will	O
be	O
essential	O
.	O

A	O
similar	O
pattern	O
of	O
distribution	O
was	O
observed	O
when	O
both	O
WT	O
and	O
mutant	O
constructs	O
were	O
cotransfected	O
.	O

Probands	O
from	O
each	O
family	O
were	O
found	O
to	O
be	O
negative	O
for	O
GJB2	B-GENE
and	O
SLC26A4	B-GENE
mutations	O
based	O
on	O
Sanger	O
sequencing	O
.	O

(	O
XLS	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

The	O
high	O
carrier	O
frequency	O
of	O
the	O
235delC	B-VARIANT
mutation	O
in	O
normal	O
hearing	O
Altaians	O
(	O
4	O
.	O
6	O
%	O
)	O
is	O
probably	O
defined	O
by	O
gene	O
drift	O
/	O
founder	O
effect	O
in	O
a	O
particular	O
Altaian	O
group	O
.	O

In	O
contrast	O
,	O
HEK293	O
cells	O
expressing	O
wild	O
-	O
type	O
MCM2	B-GENE
(	O
WT	O
group	O
)	O
contained	O
18	O
.	O
66	O
+	O
-	O
0	O
.	O
470	O
%	O
apoptotic	O
cells	O
.	O

This	O
rare	O
ocular	O
phenotype	O
may	O
also	O
be	O
due	O
,	O
in	O
part	O
,	O
to	O
the	O
X	O
-	O
inactivation	O
pattern	O
,	O
a	O
process	O
ensuring	O
only	O
a	O
single	O
X	O
is	O
active	O
in	O
both	O
the	O
XX	O
female	O
and	O
the	O
XY	O
male	O
.	O

The	O
voltage	O
dependence	O
of	O
activation	O
is	O
shifted	O
to	O
more	O
hyperpolarized	O
potentials	O
in	O
Gly403Asp	B-VARIANT
,	O
Gly403Arg	B-VARIANT
and	O
Ile770Met	B-VARIANT
channels	O
.	O

Severe	O
functional	O
impact	O
of	O
this	O
variant	O
was	O
indicated	O
by	O
all	O
three	O
online	O
prediction	O
software	O
.	O

From	O
the	O
variant	O
list	O
of	O
patient	O
3347	O
(	O
a	O
male	O
)	O
,	O
no	O
obvious	O
candidates	O
could	O
be	O
identified	O
.	O

Kunst	O
contributed	O
equally	O
.	O

Genotypes	O
were	O
transferred	O
into	O
Excel	O
files	O
and	O
sorted	O
according	O
to	O
genomic	O
positions	O
along	O
with	O
all	O
40	O
previously	O
identified	O
autosomal	O
recessive	O
nonsyndromic	O
deafness	B-DISEASE
genes	O
.	O

(	O
TIF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Predicted	O
models	O
were	O
found	O
to	O
satisfy	O
with	O
quality	O
criteria	O
,	O
such	O
as	O
C	O
-	O
score	O
and	O
TM	O
-	O
score	O
.	O

-	I-VARIANT
22	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
allele	O
:	O
770	O
bp	O
+	O
137	O
bp	O
.	O

Of	O
the	O
remaining	O
eight	O
variants	O
,	O
two	O
variants	O
were	O
also	O
detected	O
in	O
disease	O
-	O
related	O
genes	O
:	O
p	B-VARIANT
.	I-VARIANT
G204R	I-VARIANT
in	O
HDAC4	B-GENE
for	O
brachydactyly	B-DISEASE
-	I-DISEASE
mental	I-DISEASE
retardation	I-DISEASE
syndrome	I-DISEASE
[	O
15	O
]	O
,	O
and	O
p	B-VARIANT
.	I-VARIANT
276del	I-VARIANT
in	O
CCND1	B-GENE
constituting	O
a	O
susceptibility	O
factor	O
for	O
colorectal	O
cancer	O
and	O
a	O
modifier	O
for	O
von	B-DISEASE
Hippel	I-DISEASE
-	I-DISEASE
Lindau	I-DISEASE
disease	I-DISEASE
[	O
16	O
]	O
,	O
[	O
17	O
]	O
.	O

Nucleotide	O
sequences	O
were	O
compared	O
with	O
the	O
published	O
cDNA	O
sequence	O
of	O
the	O
USH2A	B-GENE
gene	O
(	O
GenBank	O
NM_206933	O
.	O
2	O
)	O
.	O

Usher	B-DISEASE
syndrome	I-DISEASE
is	O
an	O
autosomal	O
recessive	O
disorder	O
recognized	O
as	O
the	O
most	O
frequent	O
cause	O
of	O
deaf	B-DISEASE
-	I-DISEASE
blindness	I-DISEASE
.	O

One	O
or	O
two	O
pathogenic	O
/	O
likely	O
pathogenic	O
variants	O
were	O
identified	O
in	O
86	O
%	O
of	O
cases	O
.	O

Very	O
few	O
subjects	O
in	O
our	O
cohort	O
were	O
found	O
to	O
have	O
mutations	O
in	O
CLRN1	B-GENE
.	O

Rather	O
,	O
we	O
found	O
a	O
potentially	O
pathogenic	O
variant	O
(	O
c	B-VARIANT
.	I-VARIANT
G5054A	I-VARIANT
:	O
p	B-VARIANT
.	I-VARIANT
R1685Q	I-VARIANT
)	O
in	O
the	O
MYH14	B-GENE
gene	O
,	O
a	O
known	O
deafness	B-DISEASE
gene	O
in	O
DFNA4	B-GENE
locus	O
from	O
this	O
proband	O
.	O

A	O
schematic	O
representation	O
of	O
the	O
coverage	O
of	O
all	O
target	O
regions	O
is	O
showed	O
in	O
Figure	O
2	O
.	O

A	O
participant	O
identification	O
number	O
is	O
given	O
above	O
each	O
lane	O
.	O

Chromatograms	O
showing	O
wild	O
type	O
(	O
4A	O
)	O
,	O
hemizygous	O
NM_000307	O
.	O
4	O
:	O
c	B-VARIANT
.	I-VARIANT
902C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
(	I-VARIANT
Pro301Leu	I-VARIANT
)	I-VARIANT
)	O
mutation	O
in	O
the	O
affected	O
male	O
(	O
4B	O
)	O
and	O
c	B-VARIANT
.	I-VARIANT
902C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
(	I-VARIANT
Pro301Leu	I-VARIANT
)	I-VARIANT
)	O
mutation	O
in	O
the	O
female	O
carrier	O
(	O
4C	O
)	O
.	O

Therefore	O
the	O
inserted	O
sequence	O
represented	O
a	O
pseudoexon	O
which	O
was	O
activated	O
by	O
the	O
c	B-VARIANT
.	I-VARIANT
2607A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
variant	O
.	O

The	O
proband	O
of	O
Miao	O
descent	O
family	O
L151	O
was	O
a	O
46	O
-	O
year	O
-	O
old	O
man	O
with	O
congenital	O
deafness	B-DISEASE
,	O
a	O
history	O
of	O
recurrent	O
syncope	B-DISEASE
and	O
borderline	O
QTc	B-DISEASE
prolongation	I-DISEASE
(	O
460	O
ms	O
)	O
.	O

Seven	O
novel	O
mutations	O
were	O
identified	O
.	O

Duchenne	B-DISEASE
muscular	I-DISEASE
dystrophy	I-DISEASE
(	O
DMD	B-DISEASE
)	O
is	O
the	O
most	O
common	O
X	B-DISEASE
-	I-DISEASE
linked	I-DISEASE
recessive	I-DISEASE
disease	I-DISEASE
.	O

The	O
long	O
variant	O
is	O
the	O
predominant	O
form	O
in	O
the	O
retina	O
[	O
15	O
]	O
.	O

SLC26A5	B-GENE
encodes	O
prestin	O
,	O
a	O
member	O
of	O
the	O
SLC26A	O
/	O
SulP	O
transporter	O
family	O
,	O
and	O
is	O
responsible	O
for	O
DFNB61	B-DISEASE
(	O
OMIM	O
613865	O
)	O
[	O
34	O
]	O
.	O

This	O
may	O
be	O
surprising	O
,	O
however	O
,	O
in	O
other	O
fibrillar	O
collagens	O
the	O
substitution	O
of	O
obligate	O
glycines	O
can	O
result	O
in	O
a	O
wide	O
range	O
of	O
phenotypic	O
severity	O
from	O
lethal	O
to	O
mild	O
,	O
with	O
the	O
genes	O
for	O
type	O
I	O
collagen	O
and	O
osteogenesis	O
imperfecta	O
being	O
the	O
most	O
studied	O
.	O

NARS2	B-GENE
lentiviral	O
constructs	O
were	O
made	O
by	O
cloning	O
human	O
NARS2	B-GENE
cDNA	O
into	O
pLVX	O
-	O
IRES	O
-	O
tdTomato	O
vector	O
and	O
then	O
packaged	O
into	O
pseudoviral	O
particles	O
.	O

Prior	O
to	O
lysis	O
at	O
24	O
h	O
after	O
transfection	O
,	O
cells	O
were	O
treated	O
with	O
or	O
without	O
10	O
nmol	O
/	O
L	O
of	O
thapsigargin	O
(	O
TG	O
)	O
for	O
6	O
h	O
.	O

1	O
In	O
a	O
subset	O
of	O
patients	O
with	O
hereditary	B-DISEASE
cardiomyopathies	I-DISEASE
,	O
the	O
cardinal	O
features	O
are	O
early	O
manifestations	O
of	O
ventricular	B-DISEASE
arrhythmia	I-DISEASE
and	O
sudden	B-DISEASE
cardiac	I-DISEASE
death	I-DISEASE
,	O
typically	O
in	O
the	O
context	O
of	O
normal	O
cardiac	O
structure	O
and	O
function	O
or	O
disproportionate	O
to	O
structural	O
and	O
functional	O
abnormalities	O
.	O

Because	O
of	O
the	O
aminoglycoside	O
exposures	O
of	O
some	O
patients	O
in	O
this	O
family	O
,	O
we	O
firstly	O
conducted	O
the	O
Sanger	O
sequence	O
to	O
detect	O
the	O
mitochondrial	B-GENE
12S	I-GENE
rRNA	I-GENE
A1555G	B-VARIANT
mutation	O
in	O
all	O
patients	O
of	O
this	O
family	O
.	O

WFS1	B-GENE
regions	O
potentially	O
harboring	O
the	O
promoter	O
(	O
upstream	O
of	O
the	O
5	O
'	O
untranslated	O
region	O
[	O
UTR	O
]	O
)	O
or	O
regulatory	O
elements	O
such	O
as	O
enhancers	O
/	O
insulators	O
(	O
5	O
'	O
UTR	O
/	O
exon	O
1	O
and	O
intron	O
1	O
)	O
were	O
Sanger	O
sequenced	O
(	O
ACGT	O
)	O
.	O

In	O
TMC1	B-GENE
,	O
two	O
mutations	O
,	O
c	B-VARIANT
.	I-VARIANT
237	I-VARIANT
-	I-VARIANT
6T	I-VARIANT
>	I-VARIANT
G	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
453	I-VARIANT
+	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
,	O
are	O
likely	O
to	O
affect	O
splicing	O
.	O

The	O
identification	O
of	O
SALL1	B-GENE
mutations	O
>	O
1	O
%	O
of	O
our	O
cohort	O
,	O
suggests	O
that	O
this	O
gene	O
may	O
be	O
more	O
common	O
cause	O
of	O
CAKUT	B-DISEASE
than	O
previously	O
believed	O
35	O
.	O

8e	O
)	O
.	O

Otherwise	O
,	O
they	O
could	O
be	O
located	O
in	O
other	O
USH	B-DISEASE
genes	O
,	O
already	O
known	O
or	O
yet	O
to	O
be	O
identified	O
.	O

Gene	O
and	O
protein	O
reference	O
sequences	O
are	O
listed	O
in	O
Table	O
S2	O
of	O
the	O
online	O
Supporting	O
Information	O
.	O

Gema	O
Garc	O
i	O
a	O
-	O
Garc	O
i	O
a	O
and	O
Mar	O
i	O
a	O
Jos	O
e	O
Aparisi	O
are	O
recipient	O
of	O
a	O
fellowship	O
from	O
the	O
Spanish	O
Ministry	O
of	O
Education	O
(	O
REF	O
:	O
AP2008	O
-	O
02760	O
and	O
AP2009	O
-	O
3344	O
,	O
respectively	O
)	O
.	O

573	O
/	O
618	O
for	O
wild	O
-	O
type	O
;	O
p	O
=	O
7	O
.	O
34	O
x	O
10	O
-	O
65	O
)	O
(	O
Fig	O
.	O

This	O
is	O
a	O
pilot	O
study	O
aiming	O
to	O
develop	O
an	O
approach	O
based	O
on	O
next	O
-	O
generation	O
sequencing	O
to	O
determine	O
the	O
genetic	O
defects	O
in	O
patients	O
with	O
USH	B-DISEASE
or	O
allied	O
diseases	O
precisely	O
and	O
effectively	O
.	O

The	O
fifty	O
affected	O
individuals	O
were	O
from	O
families	O
presenting	O
with	O
ARNSHL	B-DISEASE
and	O
in	O
whom	O
mutations	O
of	O
GJB2	B-GENE
and	O
SLC26A4	B-GENE
had	O
been	O
excluded	O
previously	O
.	O

The	O
following	O
primary	O
antibodies	O
were	O
used	O
:	O
monoclonal	O
Anti	O
-	O
FLAG	O
and	O
Anti	O
-	O
c	O
-	O
MYC	O
antibodies	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
.	O

So	O
far	O
,	O
more	O
than	O
90	O
pathologic	O
mutations	O
have	O
been	O
reported	O
in	O
OTOF	B-GENE
[	O
25	O
]	O
.	O

The	O
protocol	O
was	O
approved	O
by	O
the	O
ethics	O
committee	O
of	O
The	O
Eye	O
Hospital	O
of	O
Wenzhou	O
Medical	O
College	O
and	O
written	O
informed	O
consent	O
has	O
been	O
obtained	O
from	O
all	O
study	O
subjects	O
.	O

Large	O
deletions	O
are	O
not	O
detected	O
and	O
variants	O
such	O
as	O
branch	O
site	O
mutations	O
may	O
be	O
missed	O
or	O
overlooked	O
.	O

Wrote	O
the	O
paper	O
:	O
SK	O
TI	O
.	O

The	O
nonsense	O
mutations	O
,	O
W4X	B-VARIANT
and	O
R609X	B-VARIANT
,	O
and	O
the	O
frameshift	O
mutations	O
(	O
E84GfsX26	B-VARIANT
,	O
K321RfsX13	B-VARIANT
,	O
S436YfsX3	B-VARIANT
)	O
,	O
all	O
lead	O
to	O
premature	O
stop	O
codons	O
.	O

They	O
revealed	O
a	O
broad	O
Nars2	B-GENE
expression	O
pattern	O
in	O
the	O
spiral	O
ganglion	O
(	O
Fig	O
.	O

Here	O
we	O
report	O
that	O
mutations	O
in	O
CIB2	B-GENE
,	O
encoding	O
a	O
Ca	O
2	O
+	O
-	O
and	O
integrin	O
-	O
binding	O
protein	O
,	O
are	O
associated	O
with	O
nonsyndromic	O
deafness	B-DISEASE
(	O
DFNB48	B-DISEASE
)	O
and	O
Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
1J	I-DISEASE
(	O
USH1J	B-DISEASE
)	O
.	O

Identical	O
residues	O
are	O
boxed	O
in	O
gray	O
.	O

In	O
WES	O
analyses	O
,	O
we	O
observed	O
de	O
novo	O
variants	O
in	O
the	O
CREBBP	B-GENE
,	O
TNC	B-GENE
,	O
and	O
IGFALS	B-GENE
genes	O
.	O

The	O
Grantham	O
score	O
evaluates	O
the	O
effect	O
of	O
an	O
amino	O
acid	O
substitution	O
on	O
a	O
protein	O
sequence	O
,	O
based	O
on	O
the	O
natural	O
physicochemical	O
properties	O
of	O
amino	O
acids	O
.	O

Novel	O
pathogenic	O
mutations	O
described	O
in	O
this	O
study	O
are	O
in	O
bold	O
.	O

2	O
A	O
)	O
.	O

Macular	O
region	O
was	O
relatively	O
preserved	O
according	O
to	O
his	O
fundus	O
appearance	O
and	O
OCT	O
results	O
.	O

To	O
process	O
sam	O
/	O
bam	O
files	O
and	O
mark	O
duplicates	O
,	O
Samtools	O
and	O
Picards	O
were	O
used	O
.	O

Proof	O
of	O
principle	O
of	O
prenatal	O
NGS	O
for	O
diagnosis	O
of	O
aneuploidy	O
and	O
chromosomal	O
rearrangements	O
has	O
been	O
established	O
(	O
6	O
,	O
7	O
)	O
.	O

A	O
group	O
of	O
216	O
ethnically	O
matched	O
healthy	O
controls	O
was	O
screened	O
employing	O
high	O
resolution	O
melting	O
curve	O
analysis	O
(	O
Light	O
Scanner	O
,	O
Idaho	O
technology	O
,	O
Salt	O
Lake	O
City	O
,	O
USA	O
)	O
,	O
and	O
bidirectional	O
sequencing	O
of	O
genes	O
previously	O
associated	O
with	O
AF	B-DISEASE
was	O
performed	O
(	O
Additional	O
file	O
1	O
)	O
.	O

It	O
has	O
been	O
established	O
that	O
the	O
common	O
deafness	B-DISEASE
mutations	O
for	O
the	O
Chinese	O
population	O
are	O
GJB2	B-GENE
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
299	I-VARIANT
-	I-VARIANT
300delAT	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
176	I-VARIANT
-	I-VARIANT
191del16	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
35delG	I-VARIANT
;	O
GJB3	B-GENE
c	B-VARIANT
.	I-VARIANT
538C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
;	O
SLC26A4	B-GENE
c	B-VARIANT
.	I-VARIANT
IVS7	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
2168A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
;	O
and	O
mitochondrial	O
m	B-VARIANT
.	I-VARIANT
1555A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
and	O
m	B-VARIANT
.	I-VARIANT
1494C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
[	O
8	O
,	O
10	O
]	O
,	O
whereas	O
the	O
major	O
mutations	O
in	O
the	O
south	O
Chinese	O
population	O
consist	O
of	O
GJB2	B-GENE
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
109G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
299	I-VARIANT
-	I-VARIANT
300delAT	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
176	I-VARIANT
-	I-VARIANT
191del16	I-VARIANT
;	O
SLC26A4	B-GENE
c	B-VARIANT
.	I-VARIANT
IVS7	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
1229	I-VARIANT
T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
;	O
and	O
mitochondrial	O
m	B-VARIANT
.	I-VARIANT
1555A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
.	O

By	O
Sanger	O
sequencing	O
and	O
subsequent	O
MLPA	O
in	O
seven	O
patients	O
with	O
pedigrees	O
suggesting	O
incomplete	O
penetrance	O
,	O
we	O
identified	O
point	O
mutations	O
in	O
two	O
patients	O
,	O
and	O
three	O
had	O
multiple	O
exon	O
to	O
whole	O
-	O
gene	O
deletions	O
(	O
these	O
patients	O
were	O
not	O
part	O
of	O
this	O
study	O
)	O
,	O
compatible	O
with	O
a	O
previous	O
study	O
suggesting	O
that	O
the	O
RP11	O
locus	O
is	O
prone	O
to	O
genomic	O
rearrangements	O
[	O
22	O
]	O
.	O

The	O
patients	O
in	O
whom	O
we	O
did	O
not	O
identify	O
deleterious	O
COL4A	O
mutations	O
suggest	O
either	O
that	O
these	O
patients	O
need	O
reevaluation	O
of	O
clinical	O
diagnosis	O
or	O
there	O
are	O
changes	O
in	O
COL4A	O
gene	O
structures	O
that	O
were	O
not	O
identified	O
here	O
.	O

The	O
syndrome	O
is	O
characterized	O
by	O
a	O
group	O
of	O
well	O
-	O
defined	O
clinical	O
features	O
including	O
characteristic	O
facial	B-DISEASE
,	I-DISEASE
dental	I-DISEASE
,	I-DISEASE
and	I-DISEASE
limb	I-DISEASE
dysmorphology	I-DISEASE
,	O
and	O
growth	B-DISEASE
retardation	I-DISEASE
[	O
3	O
]	O
.	O

Wrote	O
the	O
paper	O
:	O
MHS	O
HRK	O
U	O
-	O
KK	O
JYC	O
.	O

These	O
findings	O
indicate	O
that	O
APAs	B-DISEASE
are	O
commonly	O
caused	O
by	O
single	O
mutations	O
and	O
have	O
implications	O
for	O
other	O
hormone	O
-	O
producing	O
tumors	O
.	O

In	O
addition	O
,	O
while	O
p	B-VARIANT
.	I-VARIANT
G204R	I-VARIANT
on	O
HDAC4	B-GENE
for	O
brachydactyly	B-DISEASE
-	I-DISEASE
mental	I-DISEASE
retardation	I-DISEASE
syndrome	I-DISEASE
was	O
assessed	O
as	O
non	O
-	O
pathologic	O
by	O
in	O
silico	O
analysis	O
,	O
it	O
may	O
have	O
played	O
a	O
certain	O
role	O
in	O
the	O
occurrence	O
of	O
developmental	O
delay	O
in	O
groups	O
1	O
+	O
2	O
.	O

Wild	O
-	O
type	O
and	O
mutated	O
sequences	O
were	O
compared	O
manually	O
.	O

There	O
were	O
only	O
two	O
affected	O
individuals	O
:	O
the	O
proband	O
and	O
his	O
mother	O
suffered	O
diabetes	B-DISEASE
mellitus	I-DISEASE
with	O
congenital	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O

Molecular	O
genetic	O
testing	O
allows	O
a	O
definitive	O
diagnosis	O
to	O
be	O
made	O
in	O
index	O
patients	O
and	O
at	O
-	O
risk	O
family	O
members	O
.	O

Sanger	O
sequencing	O
confirmed	O
that	O
each	O
parent	O
contributes	O
one	O
heterozygous	O
allele	O
,	O
and	O
only	O
patients	O
in	O
Branch	O
A	O
carried	O
compound	O
heterozygotes	O
of	O
CDH23	B-GENE
mutations	O
(	O
Figure	O
1a	O
)	O
.	O

Both	O
of	O
these	O
changes	O
are	O
novel	O
and	O
were	O
absent	O
from	O
the	O
dbSNP	O
variation	O
database	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
snp	O
)	O
.	O

KCNJ10	B-GENE
c	B-VARIANT
.	I-VARIANT
1042C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
was	O
not	O
found	O
in	O
ESP	O
6500	O
and	O
was	O
regarded	O
as	O
a	O
pathogenic	O
SNV	O
by	O
1000	O
Genomes	O
.	O

These	O
genes	O
are	O
involved	O
in	O
a	O
wide	O
variety	O
of	O
molecular	O
processes	O
such	O
as	O
gene	O
regulation	O
,	O
cytoskeleton	O
dynamics	O
,	O
cell	O
-	O
cell	O
junction	O
formation	O
,	O
endocytosis	O
and	O
membrane	O
transport	O
[	O
2	O
]	O
.	O

JBC	O
,	O
LC	O
,	O
AHK	O
,	O
GA	O
conceived	O
the	O
study	O
,	O
analyzed	O
and	O
interpreted	O
the	O
data	O
and	O
introduce	O
major	O
corrections	O
to	O
the	O
manuscript	O
.	O

Unfortunately	O
,	O
it	O
was	O
impossible	O
to	O
get	O
a	O
new	O
DNA	O
sample	O
for	O
this	O
patient	O
to	O
repeat	O
the	O
experiment	O
.	O

In	O
addition	O
,	O
we	O
filtered	O
out	O
missense	O
variants	O
at	O
sites	O
with	O
low	O
evolutionary	O
conservation	O
,	O
as	O
these	O
sites	O
had	O
a	O
reduced	O
frequency	O
of	O
pathogenic	O
mutations	O
based	O
on	O
training	O
data	O
(	O
Figure	O
2c	O
)	O
.	O

We	O
have	O
finally	O
prioritized	O
the	O
variants	O
based	O
on	O
the	O
inheritance	O
pattern	O
of	O
deafness	B-DISEASE
.	O

Indicated	O
figures	O
are	O
related	O
to	O
the	O
average	O
of	O
the	O
control	O
group	O
.	O

All	O
genetically	O
affected	O
probands	O
were	O
heterozygous	O
carriers	O
.	O

3	O
C	O
,	O
D	O
)	O
.	O

As	O
regards	O
the	O
Qatari	O
population	O
,	O
a	O
recent	O
study	O
using	O
high	O
-	O
density	O
SNP	O
arrays	O
revealed	O
three	O
clusters	O
consistent	O
with	O
Arabian	O
origin	O
,	O
an	O
eastern	O
or	O
Persian	O
origin	O
and	O
individuals	O
with	O
African	O
admixture	O
[	O
6	O
]	O
.	O

Kinetic	O
fields	O
were	O
measured	O
by	O
Goldmann	O
perimetry	O
.	O

The	O
reconstructed	O
RPGRIP1	B-GENE
minigene	O
encompassed	O
exons	O
12	O
to	O
18	O
,	O
plus	O
at	O
least	O
200	O
bp	O
of	O
each	O
intron	O
-	O
exon	O
boundary	O
,	O
after	O
amplification	O
of	O
genomic	O
DNA	O
from	O
patient	O
1	O
of	O
the	O
59RE	O
pedigree	O
(	O
heterozygote	O
for	O
the	O
c	B-VARIANT
.	I-VARIANT
2367	I-VARIANT
+	I-VARIANT
23del	I-VARIANT
mutation	O
)	O
.	O

As	O
a	O
result	O
,	O
a	O
total	O
of	O
144	O
DNA	O
sequence	O
variants	O
were	O
identified	O
.	O

2011	O
)	O
.	O

1c	O
,	O
d	O
)	O
.	O

The	O
enrichment	O
libraries	O
were	O
sequenced	O
on	O
an	O
Illumina	O
HiSeq	O
2000	O
sequencer	O
for	O
100	O
bp	O
paired	O
reads	O
.	O

A	O
strict	O
criterion	O
was	O
applied	O
to	O
identify	O
the	O
possible	O
pathogenic	O
mutations	O
including	O
limiting	O
the	O
candidate	O
mutations	O
only	O
to	O
those	O
with	O
allele	O
frequencies	O
of	O
0	O
.	O
0025	O
or	O
lower	O
(	O
based	O
on	O
our	O
in	O
-	O
house	O
sequencing	O
data	O
of	O
200	O
ethnically	O
-	O
matched	O
normal	O
hearing	O
controls	O
)	O
,	O
recognizing	O
only	O
the	O
bi	O
-	O
allelic	O
variants	O
as	O
candidate	O
recessive	O
mutations	O
,	O
confirming	O
the	O
genotype	O
-	O
phenotype	O
co	O
-	O
segregation	O
with	O
extended	O
family	O
members	O
of	O
the	O
multiplex	O
probands	O
,	O
and	O
using	O
a	O
variety	O
of	O
analysis	O
programs	O
to	O
predict	O
the	O
effects	O
of	O
the	O
candidate	O
mutations	O
.	O

1888	I-VARIANT
G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
in	O
the	O
COL2A1	B-GENE
gene	O
.	O

a	O
These	O
two	O
mutations	O
are	O
allelic	O
.	O

At	O
least	O
eight	O
members	O
of	O
this	O
family	O
presented	O
with	O
diabetes	B-DISEASE
with	O
age	O
of	O
diagnosis	O
ranging	O
from	O
18	O
to	O
51	O
years	O
and	O
a	O
pattern	O
suggesting	O
autosomal	O
dominant	O
inheritance	O
.	O

The	O
NARS2	B-GENE
mutations	O
described	O
in	O
this	O
report	O
may	O
therefore	O
affect	O
NARS2	B-GENE
protein	O
stability	O
compensatory	O
gene	O
expression	O
in	O
a	O
tissue	O
specific	O
manner	O
.	O

Brown	O
;	O
and	O
S	O
.	O

Synonymous	O
and	O
non	O
-	O
coding	O
variants	O
(	O
with	O
exception	O
of	O
intronic	O
variants	O
within	O
10	O
bp	O
flanking	O
exons	O
)	O
were	O
further	O
removed	O
.	O

Furthermore	O
,	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
ocular	O
abnormality	O
happened	O
in	O
90	O
%	O
and	O
35	O
%	O
of	O
male	O
patients	O
,	O
respectively	O
[	O
10	O
]	O
.	O

As	O
OPA1	B-GENE
contributes	O
to	O
mitochondrial	O
structure	O
and	O
biogenesis	O
,	O
it	O
would	O
not	O
be	O
surprising	O
if	O
a	O
mutation	O
in	O
this	O
gene	O
alters	O
mitochondrion	O
morphology	O
,	O
and	O
therefore	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
ADOA	B-DISEASE
.	O

Progression	O
of	O
their	O
hearing	B-DISEASE
loss	I-DISEASE
may	O
have	O
occurred	O
before	O
these	O
ages	O
.	O

Their	O
hearing	B-DISEASE
loss	I-DISEASE
was	O
further	O
aggravated	O
and	O
became	O
profound	O
in	O
their	O
late	O
forties	O
.	O

We	O
previously	O
mapped	O
to	O
chromosome	O
15q23	O
-	O
q25	O
.	O
1	O
a	O
type	B-DISEASE
I	I-DISEASE
Usher	I-DISEASE
syndrome	I-DISEASE
locus	O
(	O
USH1H	B-GENE
)	O
segregating	O
in	O
two	O
families	O
and	O
an	O
autosomal	B-DISEASE
recessive	I-DISEASE
nonsyndromic	I-DISEASE
hearing	I-DISEASE
impairment	I-DISEASE
(	O
ARNSHI	B-DISEASE
)	O
locus	O
(	O
DFNB48	B-DISEASE
)	O
segregating	O
in	O
five	O
families	O
.	O

The	O
protein	O
nomenclature	O
was	O
that	O
used	O
in	O
the	O
recent	O
mutation	O
update	O
on	O
LQTS	B-DISEASE
[	O
2	O
]	O
.	O

Since	O
variants	O
within	O
the	O
ESRRB	B-GENE
gene	O
are	O
known	O
to	O
be	O
involved	O
in	O
NSHI	B-DISEASE
[	O
2	O
]	O
,	O
the	O
exon	O
regions	O
of	O
ESRRB	B-GENE
gene	O
were	O
sequenced	O
.	O

2A	O
)	O
,	O
resulting	O
in	O
a	O
technical	O
mutation	O
detection	O
rate	O
of	O
87	O
.	O
5	O
%	O
.	O

EVA	B-DISEASE
was	O
defined	O
as	O
the	O
diameter	O
at	O
the	O
midway	O
between	O
the	O
common	O
crus	O
and	O
the	O
external	O
aperture	O
being	O
equal	O
or	O
more	O
than	O
1	O
.	O
5	O
mm	O
[	O
16	O
]	O
.	O

Amino	O
acid	O
conservation	O
within	O
the	O
NIDO	O
domain	O
indicated	O
that	O
the	O
p	O
.	O
T237	O
residue	O
was	O
well	O
-	O
conserved	O
among	O
vertebrate	O
species	O
,	O
with	O
threonine	O
(	O
TECTA	B-GENE
and	O
SNED1	B-GENE
proteins	O
)	O
and	O
serine	O
(	O
NID1	B-GENE
and	O
NID2	B-GENE
proteins	O
)	O
polar	O
,	O
uncharged	O
side	O
chains	O
(	O
Fig	O
.	O

[	O
?	O
]	O
Dot	B-DISEASE
-	I-DISEASE
and	I-DISEASE
-	I-DISEASE
fleck	I-DISEASE
retinopathy	I-DISEASE
,	O
anterior	B-DISEASE
lenticonus	I-DISEASE
and	O
posterior	B-DISEASE
polymorphous	I-DISEASE
corneal	I-DISEASE
dystrophy	I-DISEASE
;	I-DISEASE
COL4A5	B-GENE
,	O
the	O
collagen	B-GENE
type	I-GENE
IV	I-GENE
alpha	I-GENE
-	I-GENE
5	I-GENE
gene	I-GENE
;	I-GENE
F	O
,	O
female	O
;	O
M	O
,	O
male	O
;	O
ESRD	B-DISEASE
,	O
end	B-DISEASE
-	I-DISEASE
stage	I-DISEASE
renal	I-DISEASE
disease	I-DISEASE
.	O
Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Moreover	O
,	O
most	O
rare	O
nonpathogenic	O
variants	O
in	O
exome	O
sequences	O
reside	O
outside	O
of	O
coding	O
sequences	O
owing	O
to	O
the	O
efficiency	O
of	O
microarray	O
cross	O
-	O
hybridization	O
.	O

None	O
of	O
the	O
patients	O
hosting	O
double	O
mutations	O
displayed	O
the	O
phenotype	O
of	O
Jervell	B-DISEASE
and	I-DISEASE
Lange	I-DISEASE
-	I-DISEASE
Nielsen	I-DISEASE
syndrome	I-DISEASE
with	O
clinical	O
deafness	O
,	O
even	O
though	O
the	O
mutations	O
resided	O
on	O
different	O
alleles	O
.	O

GW	O
,	O
QL	O
,	O
YY	O
,	O
XL	O
,	O
KY	O
,	O
JH	O
,	O
JH	O
,	O
YH	O
,	O
YW	O
,	O
QY	O
,	O
YY	O
,	O
HL	O
,	O
LL	O
,	O
WD	O
,	O
XZ	O
,	O
YY	O
,	O
JC	O
,	O
NH	O
,	O
XX	O
,	O
JZ	O
,	O
LT	O
,	O
RS	O
,	O
YL	O
,	O
SS	O
,	O
RZ	O
,	O
HW	O
and	O
YM	O
carried	O
out	O
epidemiological	O
survey	O
.	O

However	O
,	O
not	O
all	O
patients	O
with	O
NSEVA	B-DISEASE
carry	O
biallelic	O
mutations	O
in	O
SLC26A4	B-GENE
.	O

Evaluation	O
of	O
previous	O
Chinese	O
domestic	O
studies	O
indicates	O
that	O
the	O
incidence	O
of	O
the	O
SLC26A4	B-GENE
mutation	O
may	O
be	O
between	O
12	O
-	O
14	O
%	O
in	O
patients	O
with	O
NSHI	B-DISEASE
[	O
19	O
,	O
20	O
]	O
.	O

Mouse	O
mutations	O
of	O
the	O
otoferlin	O
gene	O
have	O
yielded	O
valuable	O
insights	O
into	O
the	O
molecular	O
function	O
of	O
this	O
gene	O
[	O
17	O
,	O
18	O
]	O
.	O

These	O
results	O
suggest	O
that	O
in	O
most	O
families	O
with	O
heterozygous	O
COL4A3	B-GENE
/	I-GENE
A4	I-GENE
mutations	O
and	O
MH	B-DISEASE
due	O
to	O
TBMN	B-DISEASE
,	O
some	O
patients	O
will	O
progress	O
to	O
a	O
more	O
severe	O
clinical	O
outcome	O
with	O
age	O
-	O
dependent	O
penetrance	O
.	O

In	O
a	O
recent	O
study	O
on	O
USH1	B-DISEASE
patients	O
from	O
the	O
US	O
and	O
the	O
UK	O
,	O
39	O
%	O
of	O
patients	O
had	O
mutations	O
in	O
myosin	B-GENE
-	I-GENE
7A	I-GENE
(	O
MYO7A	B-GENE
/	O
USH1B	B-GENE
)	O
or	O
cadherin	B-GENE
-	I-GENE
23	I-GENE
(	O
CDH23	B-GENE
/	O
USH1D	B-GENE
)	O
,	O
11	O
%	O
had	O
mutations	O
in	O
protocadherin	B-GENE
-	I-GENE
15	I-GENE
(	O
PCDH15	B-GENE
/	O
USH1F	B-GENE
)	O
,	O
7	O
%	O
had	O
mutations	O
in	O
SANS	B-GENE
(	O
USH1G	B-GENE
)	O
,	O
and	O
7	O
%	O
had	O
mutations	O
in	O
USH1C	B-GENE
(	O
non	O
-	O
Acadians	O
)	O
[	O
11	O
]	O
.	O

We	O
thank	O
the	O
patients	O
and	O
their	O
families	O
for	O
their	O
participation	O
in	O
the	O
study	O
.	O

A	O
:	O
Coupling	O
efficiency	O
(	O
ATP	O
/	O
O	O
)	O
:	O
Reduced	O
efficiency	O
of	O
ATP	O
synthesis	O
was	O
found	O
in	O
the	O
patient	O
'	O
s	O
fibroblasts	O
in	O
comparison	O
to	O
controls	O
.	O

Given	O
advances	O
in	O
cochlear	O
implantation	O
(	O
CI	O
)	O
and	O
the	O
extension	O
of	O
indications	O
for	O
the	O
procedure	O
,	O
more	O
attention	O
has	O
been	O
focused	O
on	O
the	O
etiology	O
of	O
deafness	B-DISEASE
and	O
its	O
potential	O
impact	O
on	O
CI	O
outcomes	O
[	O
1	O
-	O
3	O
]	O
.	O

Further	O
analyses	O
showed	O
that	O
the	O
proband	O
III	O
-	O
2	O
had	O
a	O
homozygous	O
mutation	O
in	O
exon	O
6	O
of	O
TMPRSS3	B-GENE
(	O
TMPRSS3	B-GENE
:	O
c	B-VARIANT
.	I-VARIANT
535G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
(	O
Table	O
1	O
and	O
Figure	O
2	O
)	O
.	O

By	O
contrast	O
,	O
the	O
PTA	O
from	O
control	O
subjects	O
with	O
normal	O
hearing	O
was	O
in	O
the	O
range	O
of	O
0	O
-	O
40	O
dB	O
(	O
Figure	O
2	O
)	O
.	O

As	O
a	O
result	O
,	O
the	O
causal	O
variant	O
for	O
these	O
hearing	B-DISEASE
-	I-DISEASE
impaired	I-DISEASE
patients	O
has	O
remained	O
elusive	O
and	O
the	O
genes	O
for	O
many	O
human	O
deafness	B-DISEASE
associated	O
loci	O
have	O
not	O
been	O
identified	O
.	O

Consenting	O
deaf	O
adults	O
and	O
children	O
,	O
hearing	O
adults	O
and	O
hearing	O
children	O
older	O
than	O
the	O
oldest	O
age	O
of	O
onset	O
of	O
inherited	O
deafness	B-DISEASE
in	O
their	O
family	O
were	O
enrolled	O
.	O

Amplification	O
of	O
all	O
coding	O
exons	O
and	O
flanking	O
intronic	O
sequences	O
by	O
PCR	O
was	O
performed	O
on	O
40	O
ng	O
of	O
genomic	O
DNA	O
with	O
Taq	O
DNA	O
polymerase	O
(	O
Roche	O
)	O
.	O

Double	O
horizontal	O
bars	O
above	O
a	O
symbol	O
indicate	O
individuals	O
who	O
underwent	O
genetic	O
analysis	O
by	O
targeted	O
next	O
-	O
generation	O
sequencing	O
.	O

This	O
report	O
provide	O
a	O
wide	O
spectrum	O
of	O
USH2A	B-GENE
mutations	O
and	O
clinical	O
features	O
,	O
including	O
atypical	B-DISEASE
Usher	I-DISEASE
syndrome	I-DISEASE
phenotypes	O
resembling	O
Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
I	I-DISEASE
.	O

Eighty	O
percent	O
of	O
NSHL	B-DISEASE
is	O
autosomal	B-DISEASE
recessive	I-DISEASE
nonsyndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
ARNSHL	B-DISEASE
)	O
.	O

Performed	O
the	O
experiments	O
:	O
CMW	O
ME	O
-	O
A	O
DAP	O
JEM	O
CVL	O
.	O

They	O
were	O
born	O
between	O
1976	O
and	O
1987	O
,	O
when	O
altogether	O
767	O
778	O
infants	O
were	O
born	O
alive	O
in	O
Finland	O
.	O

Band	O
C	O
is	O
the	O
transcript	O
corresponding	O
to	O
the	O
new	O
donor	O
splice	O
site	O
from	O
exon	O
27	O
plus	O
the	O
first	O
52	O
nucleotides	O
of	O
the	O
intron	O
27	O
.	O

All	O
annotated	O
transcripts	O
were	O
included	O
(	O
Table	O
S2	O
)	O
.	O

SIFT	O
prediction	O
is	O
based	O
on	O
the	O
degree	O
of	O
conservation	O
of	O
amino	O
acid	O
residues	O
in	O
multiple	O
alignment	O
information	O
.	O

Chung	O
carried	O
out	O
the	O
molecular	O
genetic	O
studies	O
.	O

of	O
alleles	O
:	O
Number	O
of	O
alleles	O
identified	O
in	O
patients	O
.	O

This	O
study	O
was	O
approved	O
by	O
the	O
Institutional	O
Review	O
Board	O
of	O
PUMCH	O
and	O
adhered	O
to	O
the	O
tenets	O
of	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
the	O
Guidance	O
on	O
Sample	O
Collection	O
of	O
Human	O
Genetic	O
Diseases	O
by	O
the	O
Ministry	O
of	O
Public	O
Health	O
of	O
China	O
.	O

25	O
)	O
a	O
pathogenic	O
mutation	O
in	O
conjunction	O
with	O
the	O
homozygous	O
c	B-VARIANT
.	I-VARIANT
3893A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
variant	O
,	O
and	O
3	O
(	O
nos	O
.	O

In	O
this	O
study	O
using	O
WES	O
,	O
we	O
identified	O
novel	O
and	O
rare	O
type	O
IV	O
collagen	O
gene	O
mutations	O
in	O
3	O
unrelated	O
Chinese	O
families	O
with	O
glomerulonephritis	B-DISEASE
and	O
no	O
extra	O
-	O
renal	O
involvement	O
,	O
in	O
whom	O
diagnosis	O
had	O
been	O
difficult	O
to	O
make	O
because	O
of	O
atypical	O
clinical	O
presentation	O
and	O
complex	O
or	O
incomplete	O
histological	O
findings	O
.	O

In	O
this	O
study	O
,	O
none	O
of	O
the	O
results	O
from	O
the	O
exome	O
sequencing	O
were	O
relayed	O
to	O
patients	O
.	O

The	O
newly	O
introduced	O
COL4A3	B-GENE
-	O
p	B-VARIANT
.	I-VARIANT
(	I-VARIANT
A587G	I-VARIANT
)	I-VARIANT
for	O
restoring	O
the	O
Gly	O
-	O
X	O
-	O
Y	O
motif	O
,	O
although	O
not	O
reaching	O
statistical	O
significance	O
,	O
showed	O
evidence	O
for	O
BiP	O
and	O
p	O
-	O
PERK	O
induction	O
,	O
thus	O
supporting	O
the	O
notion	O
that	O
naturally	O
existing	O
interruptions	O
of	O
the	O
collagenous	O
domain	O
exert	O
important	O
functions	O
.	O

In	O
summary	O
,	O
we	O
have	O
identified	O
MCM2	B-GENE
as	O
a	O
novel	O
gene	O
responsible	O
for	O
nonsyndromic	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
of	O
autosomal	O
dominant	O
inheritance	O
in	O
a	O
Chinese	O
family	O
.	O

At	O
least	O
11	O
splice	O
variants	O
have	O
been	O
reported	O
[	O
8	O
]	O
.	O

GC	O
performed	O
pooling	O
.	O

Among	O
101	O
patients	O
available	O
,	O
41	O
(	O
40	O
.	O
6	O
%	O
)	O
presented	O
at	O
least	O
one	O
extrahematological	O
symptom	O
.	O

2b	O
-	O
c	O
)	O
.	O

(	O
b	O
)	O
Region	O
of	O
low	O
coverage	O
(	O
<	O
30	O
reads	O
per	O
base	O
)	O
within	O
GATA6	B-GENE
exon	O
2	O
.	O

This	O
study	O
was	O
approved	O
by	O
the	O
Ethnic	O
Committee	O
of	O
Chinese	O
PLA	O
General	O
Hospital	O
.	O

Thus	O
,	O
it	O
is	O
tempting	O
to	O
speculate	O
that	O
the	O
transmission	O
of	O
the	O
trait	O
results	O
from	O
two	O
independent	O
mutations	O
in	O
two	O
different	O
genes	O
of	O
the	O
same	O
pathway	O
.	O

The	O
combination	O
of	O
autosomal	O
dominant	O
optic	B-DISEASE
neuropathy	I-DISEASE
and	O
deafness	B-DISEASE
has	O
been	O
reported	O
in	O
families	O
and	O
in	O
isolated	O
cases	O
with	O
a	O
heterozygous	O
missense	O
mutation	O
in	O
Optic	B-GENE
atrophy	I-GENE
-	I-GENE
1	I-GENE
gene	O
(	O
OPA1	B-GENE
;	O
OMIM	O
605290	O
)	O
[	O
3	O
-	O
6	O
]	O
.	O

B	O
:	O
Electropherogram	O
corresponding	O
to	O
the	O
healthy	O
mother	O
,	O
carrying	O
the	O
mutation	O
in	O
heterozygous	O
state	O
(	O
c	B-VARIANT
.	I-VARIANT
672C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
.	O

A	O
sampling	O
of	O
the	O
allele	O
frequencies	O
in	O
this	O
cohort	O
agrees	O
well	O
with	O
genotyping	O
results	O
from	O
the	O
Human	O
Genome	O
Diversity	O
Project	O
[	O
73	O
]	O
,	O
supporting	O
the	O
relevance	O
of	O
our	O
estimates	O
.	O

The	O
oblique	O
plane	O
sagittal	O
image	O
(	O
3D	O
-	O
fast	O
-	O
spin	O
echo	O
sequence	O
,	O
middle	O
panel	O
)	O
obtained	O
on	O
the	O
left	O
side	O
demonstrates	O
an	O
abnormally	O
small	O
cochlea	O
nerve	O
(	O
Cn	O
,	O
white	O
arrow	O
)	O
but	O
a	O
normal	O
size	O
IAC	O
with	O
normal	O
facial	O
(	O
Fn	O
)	O
,	O
superior	O
(	O
Vsn	O
)	O
and	O
inferior	O
(	O
Vin	O
)	O
vestibular	O
nerves	O
(	O
green	O
arrows	O
)	O
.	O

No	O
differences	O
were	O
seen	O
following	O
cytochrome	O
oxidase	O
(	O
Fig	O
.	O

For	O
the	O
mutations	O
present	O
in	O
patients	O
originating	O
from	O
Maghreb	O
,	O
the	O
DNAs	O
from	O
95	O
Moroccan	O
and	O
91	O
Algerian	O
healthy	O
unrelated	O
individuals	O
were	O
used	O
as	O
controls	O
.	O

These	O
traces	O
confirm	O
the	O
evidence	O
of	O
a	O
significant	O
bilateral	B-DISEASE
global	I-DISEASE
retinal	I-DISEASE
degeneration	I-DISEASE
.	O

Other	O
genes	O
reported	O
to	O
be	O
relatively	O
important	O
for	O
arNSHI	B-DISEASE
in	O
populations	O
of	O
western	O
European	O
origin	O
are	O
TMC1	B-GENE
,	O
OTOF	B-GENE
,	O
and	O
CDH23	B-GENE
(	O
Hilgert	O
et	O
al	O
.	O

The	O
full	O
raw	O
data	O
may	O
be	O
made	O
available	O
upon	O
request	O
by	O
other	O
investigators	O
and	O
after	O
approval	O
of	O
our	O
IRB	O
.	O

Shuntaro	O
Shigihara	O
,	O
Yasuyuki	O
Nomura	O
and	O
Minoru	O
Ikeda	O
(	O
Nihon	O
University	O
School	O
)	O
,	O
Drs	O
.	O

At	O
this	O
time	O
point	O
the	O
current	O
amplitude	O
had	O
reached	O
a	O
steady	O
-	O
state	O
for	O
all	O
pacing	O
frequencies	O
tested	O
.	O

Affected	O
individuals	O
are	O
shaded	O
.	O

Stickler	B-DISEASE
syndrome	I-DISEASE
is	O
usually	O
a	O
dominant	O
disorder	O
due	O
to	O
mutations	O
in	O
the	O
collagen	O
genes	O
COL2A1	B-GENE
,	O
COL11A1	B-GENE
and	O
COL11A2	B-GENE
.	O

Together	O
these	O
cases	O
illustrate	O
the	O
diagnostic	O
power	O
that	O
the	O
application	O
of	O
molecular	O
genetics	O
to	O
clinical	O
practice	O
can	O
bring	O
to	O
the	O
diagnosis	O
of	O
patients	O
with	O
kidney	B-DISEASE
disease	I-DISEASE
.	O

Likewise	O
,	O
full	O
-	O
length	O
KCNE1	B-GENE
cDNA	O
encoding	O
human	O
KCNE1	B-GENE
protein	O
subcloned	O
into	O
the	O
pDSRed	O
-	O
Monomer	O
-	O
N1	O
expression	O
vector	O
.	O

Others	O
may	O
be	O
due	O
,	O
in	O
part	O
,	O
to	O
the	O
limitations	O
of	O
WES	O
which	O
can	O
include	O
poor	O
coverage	O
of	O
certain	O
regions	O
,	O
and	O
an	O
inability	O
to	O
detect	O
noncoding	O
mutations	O
,	O
trinucleotide	O
repeats	O
in	O
known	O
[	O
Sailer	O
et	O
al	O
.	O
,	O
2012	O
]	O
and	O
unknown	O
genes	O
,	O
and	O
large	O
chromosomal	O
rearrangements	O
.	O

The	O
other	O
gel	O
was	O
transferred	O
onto	O
0	O
.	O
2	O
mu	O
m	O
nitrocellulose	O
membrane	O
(	O
Pall	O
)	O
and	O
processed	O
for	O
Western	O
Blotting	O
.	O

These	O
variants	O
were	O
detected	O
when	O
filter	O
for	O
read	O
depth	O
was	O
>	O
=	O
8	O
x	O
.	O

In	O
two	O
other	O
patients	O
(	O
RP	O
-	O
1847	O
and	O
RP	O
-	O
1923	O
)	O
with	O
biallelic	O
mutations	O
in	O
USH	B-GENE
2A	I-GENE
,	O
we	O
were	O
able	O
to	O
detect	O
additional	O
mutations	O
in	O
USH1G	B-GENE
and	O
DFNB31	O
,	O
respectively	O
.	O

Both	O
of	O
the	O
novel	O
mutations	O
are	O
located	O
in	O
exons	O
22	O
-	O
72	O
.	O

(	O
f	O
)	O
ClustalW	O
alignment	O
of	O
the	O
amino	O
-	O
acid	O
sequence	O
of	O
Gipc3	B-GENE
homologues	O
and	O
the	O
location	O
of	O
the	O
Gly115Arg	B-VARIANT
relative	O
to	O
the	O
secondary	O
structure	O
,	O
obtained	O
from	O
the	O
GIPC2	B-GENE
crystal	O
structure	O
(	O
DOI	O
:	O
10	O
.	O
2210	O
/	O
pdb3gge	O
/	O
pdb	O
)	O
is	O
shown	O
.	O

This	O
cohort	O
of	O
patients	O
consisted	O
of	O
133	O
males	O
and	O
102	O
females	O
from	O
17	O
to	O
23	O
years	O
old	O
,	O
with	O
an	O
average	O
age	O
of	O
17	O
.	O
26	O
+	O
-	O
2	O
.	O
12	O
years	O
.	O

Band	O
A	O
is	O
the	O
correct	O
splicing	O
process	O
of	O
exon	O
60	O
(	O
CDH23	B-GENE
)	O
.	O

ratio	O
tests	O
to	O
confirm	O
its	O
purity	O
and	O
concentration	O
prior	O
to	O
Covaris	O
fragmentation	O
(	O
Covaris	O
,	O
Inc	O
.	O
,	O
Woburn	O
,	O
MA	O
,	O
USA	O
)	O
.	O

Our	O
in	O
vitro	O
experiment	O
revealed	O
that	O
ELMOD3	B-GENE
harboring	O
the	O
p	B-VARIANT
.	I-VARIANT
Leu265Ser	I-VARIANT
mutation	O
,	O
unlike	O
ELMOD3	B-GENE
,	O
has	O
no	O
or	O
few	O
GAP	O
activity	O
against	O
Arl2	O
.	O

1	O
,	O
2	O
To	O
date	O
,	O
five	O
loci	O
for	O
nonsyndromic	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
DFN2	B-GENE
,	O
DFN3	B-GENE
,	O
DFN4	B-GENE
,	O
DFN6	B-GENE
,	O
AUNX	O
)	O
have	O
been	O
reported	O
and	O
genes	O
for	O
two	O
of	O
them	O
,	O
PRPS1	B-GENE
(	O
DFN2	B-GENE
)	O
and	O
POU3F4	B-GENE
(	O
DFN3	B-GENE
)	O
,	O
have	O
been	O
identified	O
.	O

A	O
heterozygous	O
mutation	O
(	O
G289R	B-VARIANT
)	O
(	O
Fig	O
.	O

Therefore	O
,	O
it	O
is	O
anticipated	O
that	O
the	O
p	B-VARIANT
.	I-VARIANT
R205Q	I-VARIANT
mutation	O
in	O
human	O
myosin	B-GENE
VI	I-GENE
disrupts	O
this	O
salt	O
bridge	O
,	O
which	O
will	O
hamper	O
motor	O
activity	O
.	O

The	O
PhyloP	O
scores	O
that	O
determines	O
the	O
grade	O
of	O
conservation	O
showed	O
-	O
0	O
.	O
27	O
,	O
which	O
means	O
that	O
this	O
site	O
predicted	O
to	O
be	O
fast	O
-	O
evolving	O
.	O

Twenty	O
-	O
four	O
subjects	O
were	O
classified	O
as	O
having	O
normal	O
hearing	O
due	O
to	O
a	O
specific	O
audiogram	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
only	O
in	O
the	O
high	O
or	O
low	O
frequency	O
portions	O
.	O

Mutations	O
in	O
other	O
tight	O
junction	O
proteins	O
are	O
also	O
known	O
to	O
cause	O
deafness	B-DISEASE
in	O
humans	O
and	O
mice	O
.	O

However	O
,	O
it	O
is	O
hard	O
to	O
explain	O
the	O
existence	O
of	O
USH1	B-DISEASE
and	O
nonsyndromic	B-DISEASE
RP	I-DISEASE
in	O
three	O
siblings	O
by	O
a	O
single	O
mutation	O
.	O

We	O
did	O
not	O
detect	O
this	O
mutation	O
in	O
the	O
204	O
other	O
patient	O
chromosomes	O
or	O
84	O
HapMap	O
control	O
chromosomes	O
sequenced	O
.	O

ATPase	O
reactions	O
revealed	O
groupings	O
of	O
both	O
type	O
1	O
and	O
type	O
2	O
myofibers	O
across	O
multiple	O
pH	O
concentrations	O
(	O
Fig	O
.	O

The	O
affected	O
subjects	O
had	O
very	O
similar	O
phenotypes	O
,	O
characterized	O
by	O
bilateral	O
,	O
postlingual	O
,	O
sensorineural	O
,	O
progressive	O
HL	B-DISEASE
(	O
except	O
III	O
:	O
12	O
)	O
.	O

All	O
but	O
one	O
were	O
previously	O
recorded	O
in	O
the	O
public	O
databases	O
with	O
frequencies	O
suggestive	O
of	O
a	O
benign	O
interpretation	O
.	O

The	O
variant	O
list	O
of	O
case	O
472	O
(	O
a	O
male	O
)	O
identified	O
a	O
single	O
homozygous	O
missense	O
variant	O
in	O
TRPM1	B-GENE
as	O
well	O
as	O
compound	O
heterozygous	O
variants	O
in	O
CEP290	B-GENE
and	O
a	O
variant	O
in	O
CA4	B-GENE
,	O
though	O
none	O
of	O
these	O
candidates	O
appeared	O
to	O
exactly	O
fit	O
the	O
observed	O
phenotype	O
.	O

We	O
further	O
identified	O
a	O
deleterious	O
mutation	O
in	O
SALL2	B-GENE
,	O
a	O
gene	O
important	O
in	O
early	O
kidney	O
development	O
.	O

An	O
alternative	O
splice	O
site	O
is	O
predicted	O
at	O
position	O
+	O
99	O
in	O
intron	O
5	O
,	O
if	O
this	O
alternative	O
site	O
is	O
used	O
it	O
would	O
lead	O
to	O
a	O
frameshift	O
and	O
a	O
premature	O
stop	O
codon	O
(	O
encoded	O
by	O
nucleotide	O
2	O
-	O
4	O
of	O
intron	O
5	O
)	O
.	O

However	O
,	O
we	O
have	O
observed	O
a	O
lower	O
frequency	O
of	O
the	O
35delG	B-VARIANT
mutant	O
allele	O
and	O
a	O
higher	O
heterogeneity	O
of	O
other	O
mutations	O
than	O
in	O
previous	O
studies	O
[	O
28	O
-	O
30	O
]	O
.	O

MITF	B-GENE
3	O
-	O
bp	O
deletions	O
at	O
amino	O
acid	O
position	O
217	O
have	O
previously	O
been	O
described	O
in	O
patients	O
with	O
Tietz	B-DISEASE
syndrome	I-DISEASE
(	O
TS	B-DISEASE
)	O
,	O
a	O
clinical	O
entity	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
generalised	O
hypopigmentation	B-DISEASE
.	O

Pure	O
tone	O
audiometry	O
revealed	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
in	O
both	O
ears	O
(	O
Fig	O
.	O

Twenty	O
-	O
three	O
TCGA	O
cases	O
had	O
unknown	O
ethnicity	O
information	O
;	O
we	O
were	O
able	O
to	O
assign	O
ethnicity	O
for	O
19	O
of	O
these	O
as	O
Caucasian	O
(	O
n	O
=	O
17	O
)	O
and	O
African	O
American	O
(	O
n	O
=	O
2	O
)	O
,	O
respectively	O
,	O
using	O
principal	O
components	O
analysis	O
(	O
Supplementary	O
Fig	O
.	O

This	O
does	O
not	O
alter	O
the	O
authors	O
'	O
adherence	O
to	O
all	O
the	O
PLOS	O
ONE	O
policies	O
on	O
sharing	O
data	O
and	O
materials	O
,	O
as	O
detailed	O
online	O
in	O
the	O
guide	O
for	O
authors	O
.	O

The	O
stereocilia	O
have	O
a	O
cytoskeletal	O
core	O
composed	O
of	O
tightly	O
packed	O
actin	O
filaments	O
.	O

A	O
recent	O
study	O
with	O
HEK	O
-	O
293	O
cells	O
shows	O
that	O
disruption	O
of	O
glycosylation	O
site	O
by	O
p	B-VARIANT
.	I-VARIANT
N48K	I-VARIANT
mutation	O
as	O
well	O
as	O
removal	O
of	O
the	O
N	O
-	O
linked	O
sugar	O
residue	O
from	O
the	O
WT	O
-	O
CLRN1	O
both	O
cause	O
protein	O
degradation	O
,	O
suggesting	O
that	O
the	O
incorrect	O
glycosylation	O
is	O
the	O
cause	O
for	O
p	B-VARIANT
.	I-VARIANT
N48K	I-VARIANT
mutated	O
CLRN1	B-GENE
degradation	O
[	O
28	O
]	O
.	O

Left	O
Humphrey	O
30	O
-	O
2	O
visual	O
field	O
showing	O
a	O
cecocentral	B-DISEASE
scotoma	I-DISEASE
of	O
the	O
proband	O
F1	O
II	O
:	O
5	O
.	O

The	O
FH1	O
domain	O
is	O
characterized	O
by	O
consecutive	O
proline	O
residues	O
.	O

In	O
healthy	O
controls	O
subfield	O
8	O
(	O
temporal	O
)	O
showed	O
the	O
thinnest	O
retinal	O
thickness	O
,	O
INL	O
+	O
IPL	O
+	O
OPL	O
and	O
RNFL	O
values	O
compared	O
to	O
the	O
other	O
subfields	O
.	O

B	O
:	O
sense	O
strand	O
of	O
812G	B-VARIANT
>	I-VARIANT
A	I-VARIANT
mutation	O
:	O
wild	O
type	O
of	O
KCNJ10	B-GENE
in	O
the	O
1042	O
locus	O
.	O

There	O
were	O
six	O
heterozygous	O
variants	O
in	O
15	O
normal	O
hearing	O
individuals	O
.	O

MYO7A	B-GENE
is	O
the	O
major	O
gene	O
responsible	O
for	O
USH1	B-DISEASE
and	O
mutations	O
in	O
MYO7A	B-GENE
alone	O
account	O
for	O
70	O
%	O
of	O
USH1	B-DISEASE
.	O

Kemperman	O
et	O
al	O
.	O

Scores	O
for	O
splice	O
sites	O
are	O
obtained	O
by	O
NetGene2	O
software	O
program	O
.	O

Cells	O
were	O
grown	O
on	O
Poly	O
-	O
L	O
-	O
Lysine	O
Coated	O
coverslips	O
(	O
Corning	O
,	O
Tewksbury	O
,	O
MA	O
,	O
USA	O
)	O
.	O

This	O
carrier	O
rate	O
of	O
22	O
%	O
is	O
roughly	O
8	O
times	O
higher	O
than	O
that	O
reported	O
in	O
hearing	O
control	O
populations	O
and	O
suggests	O
that	O
many	O
of	O
these	O
patients	O
have	O
yet	O
-	O
to	O
-	O
be	O
-	O
identified	O
non	O
-	O
coding	O
mutations	O
(	O
Green	O
et	O
al	O
.	O

Tails	O
added	O
at	O
the	O
beginning	O
of	O
the	O
primer	O
are	O
indicated	O
in	O
bold	O
.	O

[	O
22	O
]	O
,	O
who	O
found	O
a	O
significant	O
fraction	O
of	O
patients	O
with	O
a	O
diffuse	B-DISEASE
disc	I-DISEASE
atrophy	I-DISEASE
.	O

Retinal	O
imaging	O
of	O
BE	O
of	O
III	O
:	O
2	O
at	O
age	O
70	O
.	O

Known	O
protein	O
contaminants	O
such	O
as	O
keratins	O
,	O
which	O
are	O
not	O
expressed	O
in	O
HeLa	O
cells	O
,	O
were	O
excluded	O
from	O
the	O
data	O
set	O
.	O

Wrote	O
the	O
paper	O
:	O
CA	O
AS	O
RL	O
GDA	O
.	O

Otoancorin	B-GENE
D356V	B-VARIANT
is	O
likely	O
to	O
be	O
the	O
second	O
deafness	O
-	O
associated	O
mutation	O
and	O
the	O
first	O
deafness	O
-	O
associated	O
mis	O
-	O
sense	O
mutation	O
in	O
this	O
gene	O
.	O

Homozygous	O
mutations	O
in	O
KARS	B-GENE
,	O
an	O
aaRS	O
which	O
functions	O
in	O
the	O
cytoplasm	O
as	O
well	O
as	O
the	O
mitochondria	O
,	O
have	O
been	O
shown	O
to	O
cause	O
nonsyndromic	B-DISEASE
hearing	I-DISEASE
impairment	I-DISEASE
(	O
DFNB89	B-DISEASE
)	O
[	O
14	O
]	O
.	O

This	O
caveat	O
is	O
common	O
and	O
unconquerable	O
in	O
the	O
study	O
of	O
hereditary	O
hearing	B-DISEASE
loss	I-DISEASE
because	O
of	O
the	O
intrinsic	O
defect	O
of	O
traditional	O
method	O
.	O

(	O
C	O
)	O
This	O
schematic	O
representation	O
of	O
myosin	B-GENE
VIIA	I-GENE
functional	O
regions	O
indicates	O
the	O
location	O
of	O
the	O
eight	O
mutations	O
associated	O
with	O
DFNA11	B-DISEASE
.	O

Human	O
.	O

(	O
b	O
)	O
Pure	O
-	O
tone	O
audiograms	O
of	O
affected	O
members	O
in	O
each	O
family	O
.	O

Genotypes	O
of	O
patients	O
and	O
controls	O
with	O
variants	O
in	O
GJB3	B-GENE
gene	O
TM	O
,	O
transmembrane	O
domain	O
;	O
EC	O
,	O
extracellular	O
domain	O
;	O
IC	O
,	O
intracellular	O
domain	O
.	O

At	O
least	O
23	O
animals	O
were	O
tested	O
at	O
each	O
time	O
point	O
.	O

The	O
allele	O
frequency	O
of	O
adenine	O
in	O
the	O
NCBI	O
database	O
(	O
dbSNP	O
)	O
was	O
39	O
%	O
in	O
the	O
European	O
and	O
Asian	O
populations	O
.	O

It	O
has	O
been	O
considered	O
probable	O
pathogenic	O
because	O
it	O
was	O
not	O
detected	O
in	O
control	O
samples	O
and	O
because	O
it	O
was	O
found	O
in	O
trans	O
together	O
with	O
a	O
large	O
PCDH15	B-GENE
duplication	O
.	O

4	O
)	O
.	O

Because	O
of	O
the	O
association	O
of	O
profound	B-DISEASE
congenital	I-DISEASE
deafness	I-DISEASE
and	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
,	O
suggesting	O
USH	B-DISEASE
,	O
ocular	O
fundus	O
examination	O
was	O
carried	O
out	O
in	O
the	O
patients	O
,	O
but	O
abnormal	O
findings	O
were	O
not	O
reported	O
.	O

Each	O
variant	O
'	O
s	O
interpretation	O
included	O
consideration	O
of	O
quality	O
/	O
coverage	O
depth	O
(	O
QD	O
>	O
=	O
5	O
)	O
,	O
minor	O
allele	O
frequency	O
(	O
MAF	O
)	O
from	O
1000	O
Genomes	O
Project	O
Database	O
and	O
the	O
National	O
Heart	O
,	O
Lung	O
,	O
and	O
Blood	O
Institute	O
(	O
NHLBI	O
)	O
Exome	O
Sequencing	O
Project	O
Exome	O
Variant	O
Server	O
[	O
thresholds	O
for	O
recessive	O
and	O
dominant	O
NSHL	B-DISEASE
were	O
<	O
0	O
.	O
005	O
(	O
excluding	O
GJB2	B-GENE
variants	O
)	O
and	O
<	O
0	O
.	O
0005	O
,	O
respectively	O
]	O
(	O
Shearer	O
et	O
al	O
.	O

A	O
,	O
disease	O
causing	O
automatic	O
;	O
C	O
,	O
conserved	O
;	O
D	O
,	O
damaging	O
or	O
disease	O
causing	O
;	O
N	O
,	O
not	O
conserved	O
;	O
NA	O
,	O
not	O
applicable	O
;	O
P	O
,	O
possibly	O
damaging	O
;	O
T	O
,	O
tolerated	O
;	O
P2	O
D	O
.	O
S	O
.	O
,	O
Polyphen	O
-	O
2	O
damaging	O
score	O
.	O

A	O
4	O
-	O
year	O
-	O
old	O
boy	O
harbored	O
two	O
OPA1	B-GENE
mutations	O
,	O
c	B-VARIANT
.	I-VARIANT
190_194del	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
S64fs	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
1129G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
V377I	I-VARIANT
)	O
.	O

M	O
o	O
llerogHustruChastine	O
Mc	O
-	O
Kinney	O
M	O
o	O
ller	O
Foundation	O
.	O

Each	O
genomic	O
DNA	O
sample	O
(	O
40	O
ng	O
)	O
was	O
amplified	O
using	O
Ampli	O
Taq	O
Gold	O
(	O
Life	O
Technologies	O
)	O
for	O
5	O
min	O
at	O
94	O
deg	O
C	O
,	O
followed	O
by	O
30	O
three	O
-	O
step	O
cycles	O
of	O
94	O
deg	O
C	O
for	O
30	O
sec	O
,	O
60	O
deg	O
C	O
for	O
30	O
sec	O
,	O
and	O
72	O
deg	O
C	O
for	O
30	O
sec	O
,	O
with	O
a	O
final	O
extension	O
at	O
72	O
deg	O
C	O
for	O
5	O
min	O
,	O
ending	O
with	O
a	O
holding	O
period	O
at	O
4	O
deg	O
C	O
in	O
a	O
PCR	O
thermal	O
cycler	O
(	O
Takara	O
,	O
Shiga	O
,	O
Japan	O
)	O
.	O

Molecular	O
diagnosis	O
of	O
ATP6V1B1	B-GENE
and	O
ATP6V0A4	B-GENE
genes	O
was	O
performed	O
in	O
a	O
large	O
Tunisian	O
cohort	O
with	O
dRTA	B-DISEASE
.	O

The	O
clinical	O
phenotype	O
and	O
plasma	O
biochemical	O
abnormalities	O
pointed	O
towards	O
a	O
peroxisome	B-DISEASE
biogenesis	I-DISEASE
disorder	I-DISEASE
and	O
PEX1	B-GENE
gene	O
mutations	O
were	O
identified	O
by	O
direct	O
sequencing	O
.	O

Scale	O
bar	O
represents	O
10	O
mu	O
m	O
.	O

(	O
B	O
)	O
Sanger	O
sequencing	O
electropherograms	O
confirming	O
the	O
COL4A5	B-GENE
donor	O
splice	O
site	O
mutation	O
(	O
c	B-VARIANT
.	I-VARIANT
687	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
,	O
and	O
multiple	O
species	O
sequence	O
alignment	O
showing	O
conserved	O
GT	O
in	O
the	O
donor	O
splice	O
site	O
.	O

Identical	O
audiometric	O
curves	O
were	O
obtained	O
for	O
both	O
ears	O
in	O
both	O
patients	O
.	O

Information	O
on	O
isoforms	O
was	O
accessed	O
from	O
the	O
GTEx	O
Portal	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
gtexportal	O
.	O
org	O
/	O
home	O
/	O
)	O
.	O

After	O
uploading	O
the	O
VCF	O
file	O
to	O
Ingenuity	O
Variant	O
Analysis	O
,	O
an	O
initial	O
filtering	O
based	O
on	O
mapping	O
quality	O
and	O
chromosomal	O
position	O
identified	O
28	O
,	O
200	O
variations	O
across	O
the	O
entire	O
locus	O
.	O

Mutations	O
in	O
COL4A3	B-GENE
/	I-GENE
A4	I-GENE
/	I-GENE
A5	I-GENE
,	O
coding	O
for	O
the	O
alpha	O
chains	O
of	O
the	O
trimeric	O
collagen	O
IV	O
,	O
the	O
most	O
important	O
structural	O
component	O
of	O
the	O
glomerular	O
basement	O
membrane	O
(	O
GBM	O
)	O
[	O
2	O
]	O
,	O
[	O
3	O
]	O
appear	O
to	O
be	O
responsible	O
for	O
the	O
two	O
most	O
frequent	O
causes	O
of	O
FMH	B-DISEASE
.	O

After	O
incubation	O
for	O
3	O
min	O
,	O
the	O
reaction	O
was	O
started	O
by	O
adding	O
0	O
.	O
1	O
mM	O
NADH	O
and	O
the	O
rate	O
of	O
disappearance	O
of	O
NADH	O
was	O
monitored	O
at	O
340	O
nm	O
.	O

GJB2	B-GENE
mutations	O
are	O
the	O
most	O
common	O
cause	O
of	O
childhood	O
hearing	B-DISEASE
loss	I-DISEASE
worldwide	O
[	O
1	O
]	O
,	O
followed	O
by	O
SLC26A4	B-GENE
mutations	O
[	O
4	O
]	O
.	O

The	O
T	O
-	O
box	O
is	O
highlighted	O
in	O
yellow	O
,	O
and	O
the	O
nuclear	O
localization	O
signal	O
in	O
light	O
blue	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
version	O
.	O

538C	B-VARIANT
>	I-VARIANT
T	I-VARIANT
mutation	O
of	O
GJB3	B-GENE
is	O
detected	O
in	O
two	O
of	O
Han	O
Chinese	O
patients	O
,	O
but	O
not	O
in	O
Uyghur	O
patients	O
or	O
control	O
subjects	O
,	O
showing	O
a	O
insignificant	O
difference	O
in	O
the	O
frequency	O
of	O
GJB3	B-GENE
mutation	O
between	O
the	O
two	O
ethnicities	O
though	O
.	O

Probes	O
targeting	O
all	O
coding	O
exons	O
,	O
noncoding	O
exons	O
,	O
and	O
untranslated	O
regions	O
of	O
111	O
known	O
blindness	O
genes	O
were	O
included	O
on	O
these	O
arrays	O
,	O
as	O
well	O
as	O
probes	O
for	O
a	O
fragment	O
of	O
intron	O
26	O
of	O
CEP290	B-GENE
(	O
MIM	O
#	O
610	O
,	O
142	O
)	O
that	O
harbors	O
a	O
frequent	O
mutation	O
causing	O
Leber	B-DISEASE
congenital	I-DISEASE
amaurosis	I-DISEASE
(	O
MIM	O
#	O
204	O
,	O
000	O
;	O
Supp	O
.	O

This	O
novel	O
mutation	O
causes	O
the	O
aspartate	O
to	O
tyrosine	O
substitution	O
(	O
Asp2006Tyr	B-VARIANT
)	O
in	O
the	O
highly	O
conserved	O
ZP	O
domain	O
of	O
alpha	B-GENE
-	I-GENE
tectorin	I-GENE
.	O

USH	B-DISEASE
occurs	O
in	O
~	O
1	O
/	O
20	O
000	O
individuals	O
,	O
and	O
represents	O
50	O
%	O
of	O
all	O
monogenic	O
deaf	B-DISEASE
-	I-DISEASE
blindness	I-DISEASE
cases	O
.	O

2004	O
;	O
Chen	O
et	O
al	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
mutation	O
distribution	O
between	O
isolated	O
MD	B-DISEASE
patients	O
and	O
Yuan	O
'	O
s	O
research	O
(	O
P	O
>	O
0	O
.	O
5	O
)	O
.	O

Subsequent	O
examination	O
revealed	O
borderline	O
low	O
serum	O
intact	O
PTH	O
value	O
.	O

We	O
also	O
thank	O
AC	O
Apple	O
-	O
Mathews	O
for	O
help	O
in	O
preparing	O
the	O
manuscript	O
.	O

SLC26A4	B-GENE
is	O
the	O
major	O
genetic	O
cause	O
in	O
Chinese	O
NSEVA	B-DISEASE
patients	O
,	O
accounting	O
for	O
87	O
.	O
59	O
%	O
.	O

A	O
standard	O
caloric	O
test	O
(	O
30	O
deg	O
C	O
and	O
44	O
deg	O
C	O
)	O
was	O
performed	O
using	O
an	O
ICS	O
caloric	O
irrigation	O
system	O
and	O
observation	O
of	O
the	O
nystagmus	B-DISEASE
using	O
Frenzel	O
'	O
s	O
glasses	O
.	O

